FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Feng, YY Torres, E Li, N Wang, L Bowman, D Xiao, LH AF Feng, Yaoyu Torres, Eucaris Li, Na Wang, Lin Bowman, Dwight Xiao, Lihua TI Population genetic characterisation of dominant Cryptosporidium parvum subtype IIaA15G2R1 SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Cryptosporidium; Cryptosporidiosis; Cryptosporidium parvum; IIaA15G2R1; Virulence; Population genetics ID DAIRY CALVES; MOLECULAR CHARACTERIZATION; ZOONOTIC TRANSMISSION; UNITED-STATES; SPAIN; LAMBS; RUMINANTS; GENOTYPE; HUMANS; EPIDEMIOLOGY AB The subtype IIaA15G2R1 at the 60 kDa glycoprotein (gp60) gene locus is the most dominant Cryptosporidium parvum infecting dairy cattle and humans in industrialised nations. The reasons for its high transmissibility are not clear, and it remains to be determined whether this subtype represents a homogeneous parasite population. In this study, we sequence-characterised 26 IIaA15G2R subtype specimens and 26 non-IIaA15G2R subtype specimens from the United States, Canada, United Kingdom and Spain at seven other known polymorphic loci, including CP47, CP56, DZ-HRGP, MSC6-5, MSC6-7, RPGR and ZPT. Extensive heterogeneity within IIaA15G2R1 and discordance in typing results between gp60 and other genetic markers were observed. Results of inter-locus and intra-ZPT linkage disequilibrium and recombination analyses indicated that the heterogeneity within IIaA15G2R1 and discordance in typing results among genetic loci were largely due to the occurrence of genetic recombination, mostly within the gp60 subtype IIaA15G2R1. Although there was no clear population diversion between IIaA15G2R and non-IIaA15G2R subtypes, results of STRUCTURE and F-ST analyses suggested the presence of at least two subpopulations; subpopulation 1 had an epidemic population structure and was widely distributed, whereas subpopulation 2 had a clonal population structure and consisted of geographically segregated multilocus subtypes. Genetic recombination between epidemic and geographically segregated C. parvum populations appeared to be a driving force in the emergence of a hyper-transmissible IIaA15G2R1 subtype. Genetic recombination was observed even between the zoonotic IIa subtype family and anthroponotic subtype family IIc at CP56, MSC6-7 and ZPT. Thus, the IIaA15G2R1 subtype at gp60 is likely a fitness marker for C. parvum and the wide spread of IIaA15G2R1 subtype around the world is probably independent of the sequence characteristics at other genetic loci. (C) 2013 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved. C1 [Feng, Yaoyu; Li, Na; Wang, Lin] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. [Torres, Eucaris; Li, Na; Wang, Lin; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Bowman, Dwight] Cornell Univ, Dept Microbiol & Immunol, Coll Vet Med, Ithaca, NY 14853 USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31229005, 31110103901]; National Special Fund for State Key Laboratory of Bioreactor Engineering, China [2060204]; Fundamental Research Funds for the Central Universities, China; Centers for Disease Control and Prevention, USA FX This work was supported by the National Natural Science Foundation of China (31229005 and 31110103901.), National Special Fund for State Key Laboratory of Bioreactor Engineering, China (No. 2060204), Fundamental Research Funds for the Central Universities, China, and Centers for Disease Control and Prevention, USA. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 37 TC 16 Z9 16 U1 1 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 EI 1879-0135 J9 INT J PARASITOL JI Int. J. Parasit. PD DEC PY 2013 VL 43 IS 14 BP 1141 EP 1147 DI 10.1016/j.ijpara.2013.09.002 PG 7 WC Parasitology SC Parasitology GA 278YB UT WOS:000328924700006 PM 24126186 ER PT J AU Saxby, DJ Matthews, G Warm, JS Hitchcock, EM Neubauer, C AF Saxby, Dyani J. Matthews, Gerald Warm, Joel S. Hitchcock, Edward M. Neubauer, Catherine TI Active and Passive Fatigue in Simulated Driving: Discriminating Styles of Workload Regulation and Their Safety Impacts SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-APPLIED LA English DT Article DE fatigue; automation; driving scenarios; simulated driving; performance ID ADAPTIVE CRUISE CONTROL; INDIVIDUAL-DIFFERENCES; SUSTAINED ATTENTION; DRIVER FATIGUE; TASK ENGAGEMENT; PERFORMANCE; STRESS; AUTOMATION; DURATION; STATES AB Despite the known dangers of driver fatigue, it is a difficult construct to study empirically. Different forms of task-induced fatigue may differ in their effects on driver performance and safety. Desmond and Hancock (2001) defined active and passive fatigue states that reflect different styles of workload regulation. In 2 driving simulator studies we investigated the multidimensional subjective states and safety outcomes associated with active and passive fatigue. Wind gusts were used to induce active fatigue, and full vehicle automation to induce passive fatigue. Drive duration was independently manipulated to track the development of fatigue states over time. Participants were undergraduate students. Study 1 (N = 108) focused on subjective response and associated cognitive stress processes, while Study 2 (N = 168) tested fatigue effects on vehicle control and alertness. In both studies the 2 fatigue manipulations produced different patterns of subjective response reflecting different styles of workload regulation, appraisal, and coping. Active fatigue was associated with distress, overload, and heightened coping efforts, whereas passive fatigue corresponded to large-magnitude declines in task engagement, cognitive underload, and reduced challenge appraisal. Study 2 showed that only passive fatigue reduced alertness, operationalized as speed of braking and steering responses to an emergency event. Passive fatigue also increased crash probability, but did not affect a measure of vehicle control. Findings support theories that see fatigue as an outcome of strategies for managing workload. The distinction between active and passive fatigue is important for assessment of fatigue and for evaluating automated driving systems which may induce dangerous levels of passive fatigue. C1 [Saxby, Dyani J.; Neubauer, Catherine] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA. [Matthews, Gerald] Univ Cent Florida, Inst Simulat & Training, Orlando, FL 32826 USA. [Warm, Joel S.] Air Force Res Lab, Wright Patterson AFB, OH USA. [Warm, Joel S.] Univ Dayton, Res Inst, Human Factors Grp, Dayton, OH 45469 USA. [Hitchcock, Edward M.] NIOSH, Cincinnati, OH 45226 USA. RP Matthews, G (reprint author), Univ Cent Florida, Inst Simulat & Training, ACT Lab, 3100 Technol Pkwy, Orlando, FL 32826 USA. EM gmatthews@ist.ucf.edu FU Intramural CDC HHS [CC999999] NR 68 TC 18 Z9 18 U1 8 U2 27 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1076-898X EI 1939-2192 J9 J EXP PSYCHOL-APPL JI J. Exp. Psychol.-Appl. PD DEC PY 2013 VL 19 IS 4 BP 287 EP 300 DI 10.1037/a0034386 PG 14 WC Psychology, Applied SC Psychology GA 277KH UT WOS:000328817200002 PM 24041288 ER PT J AU Shega, JW Andrew, M Kotwal, A Lau, DT Herr, K Ersek, M Weiner, DK Chin, MH Dale, W AF Shega, Joseph W. Andrew, Melissa Kotwal, Ashwin Lau, Denys T. Herr, Keela Ersek, Mary Weiner, Debra K. Chin, Marshall H. Dale, William TI Relationship Between Persistent Pain and 5-Year Mortality: A Population-Based Prospective Cohort Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; mortality; older adult ID DWELLING OLDER-ADULTS; LOW-BACK-PAIN; HEALTH-CARE UTILIZATION; COGNITIVE IMPAIRMENT; PHYSICAL FUNCTION; MANAGEMENT; PREVALENCE; FRAILTY; PEOPLE; OSTEOARTHRITIS AB ObjectivesTo assess the association between self-reported noncancer pain and 5-year mortality. DesignCohort. SettingCommunity-dwelling older adults. ParticipantsCanadian Study of Health and Aging 1996 wave. MeasurementsRegistrar of Vital Statistics-established 5-year mortality. Noncancer pain was assessed using the 5-point verbal descriptor scale, dichotomized into no or very mild versus moderate, severe, or very severe pain. Frailty was the accumulation of health deficits. Cognitive status (Modified Mini-Mental State Examination) and depressed mood (five-item mental health screening questionnaire) were also assessed. Multivariable logistic regression and Cox proportional hazards were used to analyze the relationship between pain and 5-year mortality. ResultsOf 5,703 participants, 4,694 (82.3%) had complete data for analysis; 1,663 of these (35.4%) reported moderate, severe, or very severe pain, and 1,343 (28.6%) had died at 5-year follow-up. Four hundred ninety-six of those who died (29.8%) reported moderate, severe, or very severe pain and 847 (27.9%) no or very mild pain. Multivariate logistic analysis found that individuals with moderate, severe, or very severe pain had lower odds of 5-year mortality than those with no or very mild pain (odds ratio=0.78, 95% confidence interval (CI)=0.66-0.92; P<.001). The risk of death was lower in persons reporting moderate or greater pain than in those with no or very mild pain (HR=0.85, 95% CI=0.75-0.96; P=.01). An interaction between pain and sex explained this effect. Men with pain were not significantly more likely than men without pain to die (HR=1.00, 95% CI=0.84-1.19; P=.99), whereas women without pain (HR=0.54, 95% CI=0.47-0.63; P<0.01) and women with pain (HR=0.40; CI=0.33-0.47; P<.01) had less risk of death than men without and with pain, respectively. ConclusionOlder women with pain were less likely to die within 5years than older women without pain, men in pain, or men without pain. C1 [Shega, Joseph W.; Kotwal, Ashwin; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Andrew, Melissa] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada. [Lau, Denys T.] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Atlanta, GA USA. [Lau, Denys T.] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA. [Herr, Keela] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Weiner, Debra K.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Chin, Marshall H.] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. [Dale, William] Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA. RP Shega, JW (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, MC 6098,5841 S Maryland Ave, Chicago, IL 60637 USA. EM jshega@gmail.com FU National Health Research Development Program [6606-3954-MC(S)]; National Institute on Aging [K23AG029815]; Canadian Institutes of Health Research [MOP-62823]; National Institute of Diabetes and Digestive and Kidney Diseases Midcareer Investigator Award in Patient-Oriented Research [K24 DK071933]; Chicago Center for Diabetes Translation Research [P30 DK092949] FX All the data reported here were gathered using public funding from the National Health Research Development Program, which administrated a grant from the Seniors' Independence Research program (6606-3954-MC(S)). Funding for these analyses came from a career development award from the National Institute on Aging (K23AG029815) and from the Canadian Institutes of Health Research through an operating grant (MOP-62823). Dr. Chin was supported by a National Institute of Diabetes and Digestive and Kidney Diseases Midcareer Investigator Award in Patient-Oriented Research (K24 DK071933) and the Chicago Center for Diabetes Translation Research (P30 DK092949). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute on Aging, the Centers for Disease Control and Prevention, or the National Center for Health Statistics. NR 41 TC 4 Z9 4 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2013 VL 61 IS 12 BP 2135 EP 2141 DI 10.1111/jgs.12554 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271UB UT WOS:000328416000010 PM 24320761 ER PT J AU Li, FZ Harmer, P Stock, R Fitzgerald, K Stevens, J Gladieux, M Chou, LS Carp, K Voit, J AF Li, Fuzhong Harmer, Peter Stock, Ronald Fitzgerald, Kathleen Stevens, Judy Gladieux, Michele Chou, Li-Shan Carp, Kenji Voit, Jan TI Implementing an Evidence-Based Fall Prevention Program in an Outpatient Clinical Setting SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dissemination; RE-AIM; older adults; falls; Tai Ji Quan ID RANDOMIZED CONTROLLED-TRIAL; TAI-CHI; OLDER-ADULTS; RECOMMENDATION; INTERVENTION; METAANALYSIS; TRANSLATION; EXERCISE AB ObjectivesTo investigate the dissemination potential of a Tai Ji Quan-based program, previously shown to be efficacious for reducing risk of falls in older adults, through outpatient clinical settings. DesignA single-group pre/post design in which participants attended a twice-weekly Tai Ji Quan training program for 24weeks. SettingCommunities in Lane County, Oregon. ParticipantsIndependently living individuals (N= 379) aged 65 and older. MeasurementsUsing the Reach, Effectiveness, Adoption, Implementation and Maintenance framework, the primary outcome was the proportion of participating healthcare providers who made referrals. Secondary outcomes were the proportion of referred individuals agreeing to participate and enrolling in the program, and measures of program implementation, maintenance, and effectiveness (on measures of falls, balance, gait, physical performance, and balance efficacy). ResultsOf the 252 providers invited to participate, 157 made referrals (62% adoption rate). Of 564 individuals referred, 379 (67% reach) enrolled in the program, which was successfully implemented in senior and community centers with good fidelity, 283 completed the program (75% retention), and 212 of these attended 75% or more of the 48 sessions. Participants reported a reduction in falls, with an incidence rate of 0.13 falls per person-month, and showed significant improvement from baseline in all outcome measures. A 3-month postintervention follow-up indicated encouraging levels of program maintenance among providers, participants, and community centers. ConclusionHealthcare providers successfully implemented a protocol to refer individuals at risk of falling to a Tai Ji Quan-based program. The evidence-based program appears readily scalable and exportable, with potential for substantial clinical and public health effect. C1 [Li, Fuzhong] Oregon Res Inst, Eugene, OR 97403 USA. [Harmer, Peter] Willamette Univ, Dept Exercise Sci, Salem, OR 97301 USA. [Stock, Ronald] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Fitzgerald, Kathleen] Oregon Med Grp, Eugene, OR USA. [Stevens, Judy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gladieux, Michele] Peace Hlth, Sacred Heart Med Ctr, Outpatient Rehabil Serv, Eugene, OR USA. [Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA. [Carp, Kenji] Cooperat Performance & Rehabil, Eugene, OR USA. [Voit, Jan] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. RP Li, FZ (reprint author), Oregon Res Inst, 1776 Millrace Dr, Eugene, OR 97403 USA. EM fuzhongl@ori.org OI Li, Fuzhong/0000-0001-6644-4702 FU Centers for Disease Control and Prevention [5R18CE001723] FX The project reported in this manuscript was supported through a cooperative agreement with the Centers for Disease Control and Prevention (5R18CE001723). The opinions expressed are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. The authors of this paper reported no financial conflicts of interest. NR 38 TC 12 Z9 12 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2013 VL 61 IS 12 BP 2142 EP 2149 DI 10.1111/jgs.12509 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271UB UT WOS:000328416000011 PM 24164465 ER PT J AU Zhao, H Wilkins, K Damon, IK Li, Y AF Zhao, Hui Wilkins, Kimberly Damon, Inger K. Li, Yu TI Specific qPCR assays for the detection of orf virus, pseudocowpox virus and bovine papular stomatitis virus SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Parapoxviruses; Orf virus; Pseudocowpox virus; Bovine papular stomatitis virus; qPCR; Droplet digital PCR ID POLYMERASE-CHAIN-REACTION; PCR ASSAYS; PARAPOXVIRUS; INFECTION; QUANTIFICATION; DIAGNOSIS; DEER; DNA AB The genus Parapoxvirus (PAPV) is comprised traditionally of orf virus (ORFV), pseudocowpox virus (PCPV) and bovine papular stomatitis virus (BPSV), which cause infections of ruminants and their handlers in the U.S. and worldwide. Unlike orthopoxvirus infections, which can cause systemic or localized infections, PAPV infections present normally as benign, self-limited and localized skin lesions; infections do not confer lifelong immunity. In recent years, related potentially to enhanced awareness and the availability of diagnostic methods, there has been an observed increase in reported cases of PAPV in animals and humans. This study describes TaqMan based real-time PCR assays for both generic and specific detection of PAPV species for surveillance and outbreak investigations. These assays target highly conserved PAPV RNA polymerase gene sequences and are capable of detecting three known species of PAPVs (ORFV, PCPV, and BPSV). The assays were evaluated using a panel of PAPV DNA derived from human infections or animal specimen remainders. The sensitivities of all four assays were determined using droplet digital PCR; fewer than 10 copies of clinical PAPV DNA can be detected consistently. These assays provide a reliable and sensitive method for rapid confirmation and characterization PAPV infections with varying clinical presentations. Published by Elsevier B.V. C1 [Zhao, Hui; Wilkins, Kimberly; Damon, Inger K.; Li, Yu] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Li, Y (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Mail Stop G-43,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM yuli@cdc.gov NR 24 TC 9 Z9 9 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD DEC PY 2013 VL 194 IS 1-2 BP 229 EP 234 DI 10.1016/j.jviromet.2013.08.027 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 273FV UT WOS:000328521600037 PM 24035807 ER PT J AU Esona, MD McDonald, S Kamili, S Kerin, T Gautam, R Bowen, MD AF Esona, Mathew D. McDonald, Sharla Kamili, Shifaq Kerin, Tara Gautam, Rashi Bowen, Michael D. TI Comparative evaluation of commercially available manual and automated nucleic acid extraction methods for rotavirus RNA detection in stools SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rotavirus; Stool; Extraction methods; Quantitative real-time RT-PCR ID POLYMERASE-CHAIN-REACTION; GROUP-A ROTAVIRUS; RT-PCR DETECTION; UNITED-STATES; VACCINE-INTRODUCTION; HELICOBACTER-PYLORI; FECAL SPECIMENS; STRAINS; GASTROENTERITIS; IDENTIFICATION AB Rotaviruses are a major cause of viral gastroenteritis in children. For accurate and sensitive detection of rotavirus RNA from stool samples by reverse transcription-polymerase chain reaction (RT-PCR), the extraction process must be robust. However, some extraction methods may not remove the strong RT-PCR inhibitors known to be present in stool samples. The objective of this study was to evaluate and compare the performance of six extraction methods used commonly for extraction of rotavirus RNA from stool, which have never been formally evaluated: the MagNA Pure Compact, KingFisher Flex and NucliSENS (R) easyMAG (R) instruments, the NucliSENS (R) miniMAG (R) semi-automated system, and two manual purification kits, the QIAamp Viral RNA kit and a modified RNaid (R) kit. Using each method, total nucleic acid or RNA was extracted from eight rotavirus-positive stool samples with enzyme immunoassay optical density (EIA OD) values ranging from 0.176 to 3.098. Extracts prepared using the MagNA Pure Compact instrument yielded the most consistent results by qRT-PCR and conventional RT-PCR. When extracts prepared from a dilution series were extracted by the 6 methods and tested, rotavirus RNA was detected in all samples by qRT-PCR but by conventional RT-PCR testing, only the MagNA Pure Compact and KingFisher Flex extracts were positive in all cases. RT-PCR inhibitors were detected in extracts produced with the QIAamp Viral RNA Mini kit. The findings of this study should prove useful for selection of extraction methods to be incorporated into future rotavirus detection and genotyping protocols. Published by Elsevier B.V. C1 [Esona, Mathew D.; McDonald, Sharla; Kamili, Shifaq; Kerin, Tara; Gautam, Rashi; Bowen, Michael D.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Kamili, Shifaq; Gautam, Rashi] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, DVD, NCIRD, Mailstop G04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM MKB6@CDC.GOV FU Intramural CDC HHS [CC999999] NR 53 TC 12 Z9 12 U1 1 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD DEC PY 2013 VL 194 IS 1-2 BP 242 EP 249 DI 10.1016/j.jviromet.2013.08.023 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 273FV UT WOS:000328521600039 PM 24036075 ER PT J AU Iqbal, S Barile, JP Thompson, WW DeStefano, F AF Iqbal, Shahed Barile, John P. Thompson, William W. DeStefano, Frank TI Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7-10 years SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE antigens; pediatrics; neuropsychology; epidemiology; child health; pharmacoepidemiology ID THIMEROSAL EXPOSURE; EARLY-LIFE; PARENTS; CHILDREN; SAFETY AB PurposeConcerns have been raised that children may be receiving too many immunizations under the recommended schedule in the USA. We used a publicly available dataset to evaluate the association between antibody-stimulating proteins and polysaccharides from early childhood vaccines and neuropsychological outcomes at age 7-10years. MethodsChildren aged 7-10years from four managed care organizations underwent standardized tests for domain-specific neuropsychological outcomes: general intellectual function, speech and language, verbal memory, attention and executive function, tics, achievement, visual spatial ability, and behavior regulation. Vaccination histories up to 24months of age were obtained from medical charts, electronic records, and parents' records. Logistic regressions and structural equation modeling (SEM) were used to determine associations between total antigens up to 7, 12, and 24months and domain-specific outcomes. ResultsOn average, children (N=1047) received 7266, 8127, and 10341 antigens by ages 7, 12, and 24months, respectively. For adjusted analyses, increase (per 1000) in the number of antigens was not associated with any neuropsychological outcomes. Antigen counts above the 10th percentile, compared with lower counts, were also not associated with any adverse outcomes. However, children with higher antigen counts up to 24months performed better on attention and executive function tests (odds ratio for lower scores=0.51, 95% confidence interval=0.26, 0.99). Similar results were found with SEM analysis (b=0.08, p=0.02). ConclusionsWe did not find any adverse associations between antigens received through vaccines in the first two years of life and neuropsychological outcomes in later childhood. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Iqbal, Shahed; DeStefano, Frank] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA USA. [Barile, John P.] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. [Thompson, William W.] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Div Behav Surveillance, Atlanta, GA USA. RP Iqbal, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot & Infect Dis, Div Healthcare Qual & Promot, Immunizat Safety Off, Atlanta, GA 30333 USA. EM siqbal@cdc.gov RI Barile, John/F-9456-2015 OI Barile, John/0000-0003-4098-0640 NR 29 TC 2 Z9 2 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD DEC PY 2013 VL 22 IS 12 BP 1263 EP 1270 DI 10.1002/pds.3482 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 258GG UT WOS:000327446700003 PM 23847024 ER PT J AU Carter, MW Kraft, JM Hatfield-Timajchy, K Snead, MC Ozeryansky, L Fasula, AM Koenig, L Kourtis, AP AF Carter, Marion W. Kraft, Joan M. Hatfield-Timajchy, Kendra Snead, Margaret C. Ozeryansky, Larisa Fasula, Amy M. Koenig, Linda Kourtis, Athena P. TI The Reproductive Health Behaviors of HIV-Infected Young Women in the United States: A Literature Review SO AIDS PATIENT CARE AND STDS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATALLY ACQUIRED HIV; SEXUAL RISK BEHAVIOR; POSITIVE WOMEN; REVISED RECOMMENDATIONS; HORMONAL CONTRACEPTION; SEROSTATUS DISCLOSURE; ADOLESCENT FEMALES; MENTAL-HEALTH; CONDOM USE AB HIV-infected young women in the United States have important reproductive health needs that are made more complex by their HIV status. We searched Pubmed and relevant bibliographies to identify 32 articles published from 2001 to July 2012 that described the prevalence, correlates, and characteristics of the sexual activity, relationships, pregnancy intentions, HIV status disclosure, and contraceptive and condom use among US HIV-infected adolescents and young women. Our synthesis of those articles found that, like youth not infected with HIV, substantial proportions of HIV-infected youth were sexually active, and most sought romantic or sexual relationships, though their serostatus may have affected the pace of physical and emotional intimacy. Disclosure was difficult, and large proportions of HIV-infected youth had not disclosed their serostatus to recent partners. A few studies suggest that most HIV-infected young women hoped to have children in the future, but many wanted to avoid pregnancy until later. Only one study described contraceptive use among this population in detail and found that condoms were a primary method of contraception. The results point to substantial gaps in published research, particularly in the areas of pregnancy intentions and contraceptive use. Much more needs to be done in research and health services to better understand and meet the complex health needs of HIV-infected young women. C1 [Carter, Marion W.; Kraft, Joan M.; Hatfield-Timajchy, Kendra; Snead, Margaret C.; Ozeryansky, Larisa; Fasula, Amy M.; Koenig, Linda; Kourtis, Athena P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Carter, MW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-80, Atlanta, GA 30333 USA. EM acq0@cdc.gov NR 75 TC 4 Z9 5 U1 1 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD DEC 1 PY 2013 VL 27 IS 12 BP 669 EP 680 DI 10.1089/apc.2013.0208 PG 12 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 266BV UT WOS:000327998200003 PM 24320012 ER PT J AU Iyer, SS Latner, DR Zilliox, MJ McCausland, M Akondy, RS Penaloza-MacMaster, P Hale, JS Ye, LL Mohammed, AUR Yamaguchi, T Sakaguchi, S Amara, RR Ahmed, R AF Iyer, Smita S. Latner, Donald R. Zilliox, Michael J. McCausland, Megan Akondy, Rama S. Penaloza-MacMaster, Pablo Hale, Jeffrey Scott Ye, Lilin Mohammed, Ata-Ur-Rasheed Yamaguchi, Tomoyuki Sakaguchi, Shimon Amara, Rama R. Ahmed, Rafi TI Identification of novel markers for mouse CD4(+) T follicular helper cells SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE B cells; CD4(+) T cells; CD73; Folate R 4; Viral infection ID CXC CHEMOKINE RECEPTOR-5; IMMUNE-RESPONSES; FOLATE RECEPTOR; VIRAL-INFECTION; CUTTING EDGE; DIFFERENTIATION; EXPRESSION; EFFECTOR; CD73; DEFICIENCY AB CD4(+) T follicular helper (T-FH) cells are central for generation of long-term B-cell immunity. A defining phenotypic attribute of T-FH cells is the expression of the chemokine R CXCR5, and T-FH cells are typically identified by co-expression of CXCR5 together with other markers such as PD-1, ICOS, and Bcl-6. Herein, we report high-level expression of the nutrient transporter folate R 4 (FR4) on T-FH cells in acute viral infection. Distinct from the expression profile of conventional T-FH markers, FR4 was highly expressed by naive CD4(+) T cells, was downregulated after activation and subsequently re-expressed on T-FH cells. Furthermore, FR4 expression was maintained, albeit at lower levels, on memory T-FH cells. Comparative gene expression profiling of FR4(hi) versus FR4(lo) Ag-specific CD4(+) effector T cells revealed a molecular signature consistent with T-FH and T(H)1 subsets, respectively. Interestingly, genes involved in the purine metabolic pathway, including the ecto-enzyme CD73, were enriched in T-FH cells compared with T(H)1 cells, and phenotypic analysis confirmed expression of CD73 on T-FH cells. As there is now considerable interest in developing vaccines that would induce optimal T-FH cell responses, the identification of two novel cell surface markers should be useful in characterization and identification of T-FH cells following vaccination and infection. C1 [Iyer, Smita S.; Latner, Donald R.; Zilliox, Michael J.; McCausland, Megan; Akondy, Rama S.; Penaloza-MacMaster, Pablo; Hale, Jeffrey Scott; Ye, Lilin; Mohammed, Ata-Ur-Rasheed; Amara, Rama R.; Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Iyer, Smita S.; McCausland, Megan; Akondy, Rama S.; Hale, Jeffrey Scott; Mohammed, Ata-Ur-Rasheed; Amara, Rama R.; Ahmed, Rafi] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Latner, Donald R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Zilliox, Michael J.] Loyola Univ Chicago, Stritch Sch Med, Loyola Univ Ctr Biomed Informat, Maywood, IL USA. [Penaloza-MacMaster, Pablo] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA. [Ye, Lilin] Third Mil Med Univ, Dept Immunol, Chongqing, Peoples R China. [Yamaguchi, Tomoyuki; Sakaguchi, Shimon] Osaka Univ, Immunol Frontier Res Ctr, Osaka, Japan. RP Ahmed, R (reprint author), Emory Univ, Sch Med, Emory Vaccine Ctr, Rollins Res Bldg,1500 Clifton Rd,Room G211, Atlanta, GA 30322 USA. EM rahmed@emory.edu RI Rasheed, Mohammed/N-2749-2013; Sakaguchi, Shimon/C-9535-2009; OI Akondy, Rama/0000-0003-4737-5240 FU National Institutes of Health (NIH) [R01 A1030048]; European Union's Seventh Framework Program (FP7) under Advanced Immunization Technologies (ADITEC) [280873]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Center [P30 DK58404]; Vanderbilt Vision Center [P30 EY08126] FX This work was supported by the National Institutes of Health (NIH) grant R01 A1030048 and the European Union's Seventh Framework Program (FP7/2007-2013) under Grant Agreement No: 280873 Advanced Immunization Technologies (ADITEC). We thank R. Karaffa and S. Durham for FACS sorting at the Emory University School of Medicine Flow Cytometry Core Facility. We thank the NIH Tetramer Core Facility at Emory University for providing class II tetramer IAb-GP66-77 for LCMV. All microarray experiments were performed in the Vanderbilt Genome Sciences Resource. The Vanderbilt Genome Sciences Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Digestive Disease Center (P30 DK58404), and the Vanderbilt Vision Center (P30 EY08126). We thank Carl Davis, Benjamin Youngblood, Andreas Wieland, and Reben Rahman for helpful suggestions. We are grateful to Bougmila Konieczny, Hong Wu, and Marilyn Clayton for assistance. NR 49 TC 15 Z9 16 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD DEC PY 2013 VL 43 IS 12 BP 3219 EP 3232 DI 10.1002/eji.201343469 PG 14 WC Immunology SC Immunology GA 266YX UT WOS:000328061600020 PM 24030473 ER PT J AU Coleman, E Delea, K Everstine, K Reimann, D Ripley, D AF Coleman, Erik Delea, Kristin Everstine, Karen Reimann, David Ripley, Danny CA Environm Hlth Specialists Network TI Handling Practices of Fresh Leafy Greens in Restaurants: Receiving and Training SO JOURNAL OF FOOD PROTECTION LA English DT Article ID COLI; OUTBREAK; LETTUCE; SPINACH AB Multiple foodborne illness outbreaks have been associated with the consumption of fresh produce. Investigations have indicated that microbial contamination throughout the farm-to-fork continuum often contributed to these outbreaks. Researchers have hypothesized that handling practices for leafy greens in restaurants may support contamination by and proliferation and amplification of pathogens that cause foodborne illness outbreaks. However, limited data are available on how workers handle leafy greens in restaurants. The purpose of this study was to collect descriptive data on handling practices of leafy greens in restaurants, including restaurant characteristics, types of leafy greens used, produce receipt, and food safety training and certification. As a federal collaborative partner with the Environmental Health Specialists Network (EHS-Net) of the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration (FDA) recommended that EHS-Net participants survey handling practices for leafy greens in restaurants. The recommendations in the FDA's Guide to Minimize Microbial Food Safety Hazards of Leafy Greens are significant to this study for comparison of the results. The survey revealed that appropriate handling procedures assist in the mitigation of other unsafe handling practices for leafy greens. These results are significant because the FDA guidance for the safe handling of leafy greens was not available until 2009, after the survey had been completed. The information provided from this study can be used to promote additional efforts that will assist in developing interventions to prevent future foodborne illness outbreaks associated with leafy greens. C1 [Coleman, Erik; Delea, Kristin; Environm Hlth Specialists Network] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Everstine, Karen] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Reimann, David] Minnesota Dept Hlth, Environm Hlth Serv, Mankato, MN 56001 USA. [Ripley, Danny] Metro Publ Hlth Dept, Food Div, Nashville, TN 37203 USA. RP Delea, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, MS F60,4770 Buford Highway, Atlanta, GA 30341 USA. EM kdelea@cdc.gov FU CDC [CDC-RFA-EH10-001] FX Special thanks is due to EHS-Net site participants for their involvement in data collection and data interpretation and to Cecilia Crowley, Glenda Lewis, and Laurie Williams (FDA) for their assistance with this manuscript. This study was supported by sites receiving CDC grant awards funded under CDC-RFA-EH10-001. NR 12 TC 3 Z9 3 U1 3 U2 4 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD DEC PY 2013 VL 76 IS 12 BP 2126 EP 2131 DI 10.4315/0362-028X.JFP-13-127 PG 6 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 270EH UT WOS:000328301200019 PM 24290691 ER PT J AU Bogard, AK Fuller, CC Radke, V Selman, CA Smith, KE AF Bogard, April K. Fuller, Candace C. Radke, Vincent Selman, Carol A. Smith, Kirk E. TI Ground Beef Handling and Cooking Practices in Restaurants in Eight States SO JOURNAL OF FOOD PROTECTION LA English DT Article ID ESCHERICHIA-COLI O157-H7; UNITED-STATES; FOOD SAFETY; INFECTIONS; HAMBURGERS; OUTBREAKS; PATTIES; ILLNESS AB Eating in table-service restaurants has been implicated as a risk factor for Escherichia coli O157:H7 infection. To explore this association and learn about the prevalence of risky ground beef preparation practices in restaurants, the Environmental Health Specialists Network (EHS-Net) assessed ground beef handling policies and practices in restaurants in California, Colorado, Connecticut, Georgia, Minnesota, New York, Oregon, and Tennessee. Eligible restaurants prepared and served hamburgers. EHS-Net specialists interviewed a restaurant employee with authority over the kitchen (defined as the manager) using a standard questionnaire about food safety policies, hamburger preparation policies, and use of irradiated ground beef. Interviews were followed by observations of ground beef preparation. Data from 385 restaurants were analyzed: 67% of the restaurants were independently owned and 33% were chain restaurants; 75% of the restaurants were sit down, 19% were quick service or fast food, and 6% were cafeteria or buffet restaurants. Eighty-one percent of restaurants reported determining doneness of hamburgers by one or more subjective measures, and 49% reported that they never measure the final cook temperatures of hamburgers. At least two risky ground beef handling practices were observed in 53% of restaurants. Only 1% of restaurants reported purchasing irradiated ground beef, and 29% were unfamiliar with irradiated ground beef. Differences in risky ground beef handling policies and practices were noted for type of restaurant ownership (independently owned versus chain) and type of food service style (sit down versus quick service or fast food). This study revealed the pervasiveness of risky ground beef handling policies and practices in restaurants and the need for educational campaigns targeting food workers and managers. These results highlight the importance of continued efforts to reduce the prevalence of E. coli O157:H7 in ground beef. C1 [Bogard, April K.] Minnesota Dept Hlth, Div Environm Hlth, St Paul, MN 55164 USA. [Fuller, Candace C.; Smith, Kirk E.] Minnesota Dept Hlth, Acute Dis Invest & Control Sect, St Paul, MN 55164 USA. [Radke, Vincent; Selman, Carol A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Bogard, AK (reprint author), Minnesota Dept Hlth, Div Environm Hlth, POB 64975, St Paul, MN 55164 USA. EM april.bogard@state.mn.us FU CDC [CDC-RFA-EH05-013] FX This article is based on data collected and provided by the Centers for Disease Control and Prevention (CDC) Environmental Health Specialists Network, which is supported by a CDC grant award funded under CDC-RFA-EH05-013. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC or the Agency for Toxic Substances and Disease Registry. NR 22 TC 8 Z9 9 U1 4 U2 8 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD DEC PY 2013 VL 76 IS 12 BP 2132 EP 2140 DI 10.4315/0362-028X.JFP-13-126 PG 9 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 270EH UT WOS:000328301200020 PM 24290692 ER PT J AU Brown, LG Khargonekar, S Bushnell, L AF Brown, Laura Green Khargonekar, Shivangi Bushnell, Lisa CA Environm Hlth Specialists Network TI Frequency of Inadequate Chicken Cross-Contamination Prevention and Cooking Practices in Restaurants SO JOURNAL OF FOOD PROTECTION LA English DT Article ID SEROTYPE ENTERITIDIS INFECTIONS; UNITED-STATES; FOODNET SITES; RISK-FACTORS; OUTBREAK AB This study was conducted by the Environmental Health Specialists Network (EHS-Net) of the Centers for Disease Control and Prevention. The purpose was to examine restaurant chicken preparation and cooking practices and kitchen managers' food safety knowledge concerning chicken. EHS-Net members interviewed managers about chicken preparation practices in 448 restaurants. The study revealed that many restaurants were not following U.S. Food and Drug Administration Food Code guidance concerning cross-contamination prevention and proper cooking and that managers lacked basic food safety knowledge about chicken. Forty percent of managers said that they never, rarely, or only sometimes designated certain cutting boards for raw meat (including chicken). One-third of managers said that they did not wash and rinse surfaces before sanitizing them. Over half of managers said that thermometers were not used to determine the final cook temperature of chicken. Only 43% of managers knew the temperature to which raw chicken needed to be cooked for it to be safe to eat. These findings indicate that restaurant chicken preparation and cooking practices and manager food safety knowledge need improvement. Findings from this study could be used by food safety programs and the restaurant industry to target training and intervention efforts to improve chicken preparation and cooking practices and knowledge concerning safe chicken preparation. C1 [Brown, Laura Green; Khargonekar, Shivangi; Environm Hlth Specialists Network] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Bushnell, Lisa] Connecticut Dept Publ Hlth, Div Environm Hlth, Hartford, CT 06134 USA. RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, MS F60,4770 Buford Highway, Atlanta, GA 30341 USA. EM lrgreen@cdc.gov FU CDC [CDC-RFA-EH10-001] FX This study was conducted by states receiving CDC grant awards funded under CDC-RFA-EH10-001. We thank Kristin Holt, Scott Seys, and Patsy White (USDA), Glenda Lewis and Laurie Williams (FDA), and Kristin De lea and Brenda Le (CDC) for helpful comments on drafts of the manuscript. We also thank the restaurant managers who agreed to participate in this study and the EHS-Net environmental health specialists who assisted with study design and data collection. NR 9 TC 2 Z9 2 U1 1 U2 8 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD DEC PY 2013 VL 76 IS 12 BP 2141 EP 2145 DI 10.4315/0362-028X.JFP-13-129 PG 5 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 270EH UT WOS:000328301200021 ER PT J AU Carpenter, LR Green, AL Norton, DM Frick, R Tobin-D'Angelo, M Reimann, DW Blade, H Nicholas, DC Egan, JS Everstine, K Brown, LG Le, B AF Carpenter, L. Rand Green, Alice L. Norton, Dawn M. Frick, Roberta Tobin-D'Angelo, Melissa Reimann, David W. Blade, Henry Nicholas, David C. Egan, Jessica S. Everstine, Karen Brown, Laura G. Le, Brenda TI Food Worker Experiences with and Beliefs about Working While Ill SO JOURNAL OF FOOD PROTECTION LA English DT Article ID FOODBORNE DISEASE; OUTBREAKS; SPREAD; TRANSMISSION; RESTAURANTS; NOROVIRUS AB Transmission of foodborne pathogens from ill food workers to diners in restaurants. is an important cause of foodborne illness outbreaks. The U.S. Food and Drug Administration recommends that food workers with vomiting or diarrhea (symptoms of foodborne illness) be excluded from work. To understand the experiences and characteristics of workers who work while ill, workplace interviews were conducted with 491 food workers from 391 randomly selected restaurants in nine states that participated in the Environmental Health Specialists Network of the Centers for Disease Control and Prevention. Almost 60% of workers recalled working while ill at some time. Twenty percent of workers said that they had worked while ill with vomiting or diarrhea for at least one shift in the previous year. Factors significantly related to workers having said that they had worked while ill with vomiting or diarrhea were worker sex, job responsibilities, years of work experience, concerns about leaving coworkers short staffed, and concerns about job loss. These findings suggest that the decision to work while ill with vomiting or diarrhea is complex and multifactorial. C1 [Carpenter, L. Rand; Green, Alice L.] Tennessee Dept Hlth, Nashville, TN 37243 USA. [Norton, Dawn M.] Calif Emerging Infect Program, Oakland, CA 94612 USA. [Frick, Roberta] Publ Hlth Fdn Enterprises, Calif Environm Hlth Specialists Network, Richmond, CA 91746 USA. [Tobin-D'Angelo, Melissa] Georgia Dept Publ Hlth, Atlanta, GA 30303 USA. [Reimann, David W.] Minnesota Dept Hlth, Mankato, MN 56001 USA. [Blade, Henry] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Nicholas, David C.; Egan, Jessica S.] New York State Dept Hlth, Albany, NY 12180 USA. [Everstine, Karen] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Brown, Laura G.; Le, Brenda] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM lrg0@cdc.gov FU CDC [CDC-RFA-EH05-013] FX This study was conducted in states receiving CDC grant awards funded under CDC-RFA-EH05-013. The authors thank the restaurant managers and workers who participated in this study and the EHS-Net environmental health specialists who assisted with study design and data collection. NR 9 TC 9 Z9 9 U1 0 U2 2 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD DEC PY 2013 VL 76 IS 12 BP 2146 EP 2154 DI 10.4315/0362-028X.JFP-13-128 PG 9 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 270EH UT WOS:000328301200022 PM 24290694 ER PT J AU Fleming, EB LeBlanc, TT Reid, LC AF Fleming, Eleanor B. LeBlanc, Tanya Telfair Reid, Laurie C. TI The Status of HIV Prevention Efforts for Women in Correctional Facilities SO JOURNAL OF WOMENS HEALTH LA English DT Article ID INTERVENTION; INFECTION; SETTINGS; ADAPT AB In the United States, women are a significant proportion of the correctional population. Women also account for an increasing proportion of newly diagnosed human immunodeficiency virus (HIV) cases. When compared with white women, black women have higher incarceration rates and represent more of the newly diagnosed HIV cases. Correctional facilities offer an opportunity to provide women with HIV testing and prevention services so that they will know their status and receive HIV/sexually transmitted disease (STD) risk-reduction counseling and other preventive services. In this report, we describe incarcerated population statistics and HIV surveillance epidemiology for women. We also describe HIV prevention activities undertaken by the Centers for Disease Control and Prevention's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Additional research, program development, and implementation are needed to improve HIV prevention efforts for high-risk women. C1 [Fleming, Eleanor B.; LeBlanc, Tanya Telfair; Reid, Laurie C.] Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Fleming, Eleanor B.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Fleming, EB (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,Mailstop E07, Atlanta, GA 30333 USA. EM efleming@cdc.gov NR 30 TC 0 Z9 0 U1 1 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD DEC 1 PY 2013 VL 22 IS 12 BP 1005 EP 1008 DI 10.1089/jwh.2013.4522 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 258CF UT WOS:000327435500003 PM 24116966 ER PT J AU Satlin, MJ Graham, JK Visvesvara, GS Mena, H Marks, KM Saal, SD Soave, R AF Satlin, M. J. Graham, J. K. Visvesvara, G. S. Mena, H. Marks, K. M. Saal, S. D. Soave, R. TI Fulminant and fatal encephalitis caused by Acanthamoeba in a kidney transplant recipient: case report and literature review SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Acanthamoeba; encephalitis; solid organ transplantation ID GRANULOMATOUS AMEBIC ENCEPHALITIS; FREE-LIVING AMEBAS; BALAMUTHIA-MANDRILLARIS; NAEGLERIA-FOWLERI; INFECTION; PATIENT; SPP.; IMMUNOSUPPRESSION; DISEASE; ANTIGEN AB Acanthamoeba is the most common cause of granulomatous amebic encephalitis, a typically fatal condition that is classically described as indolent and slowly progressive. We report a case of Acanthamoeba encephalitis in a kidney transplant recipient that progressed to death within 3days of symptom onset and was diagnosed at autopsy. We also review clinical characteristics, treatments, and outcomes of all published cases of Acanthamoeba encephalitis in solid organ transplant (SOT) recipients. Ten cases were identified, and the infection was fatal in 9 of these cases. In 6 patients, Acanthamoeba presented in a fulminant manner and death occurred within 2weeks after the onset of neurologic symptoms. These acute presentations are likely related to immunodeficiencies associated with solid organ transplantation that result in an inability to control Acanthamoeba proliferation. Skin lesions may predate neurologic involvement and provide an opportunity for early diagnosis and treatment. Acanthamoeba is an under-recognized cause of encephalitis in SOT recipients and often presents in a fulminant manner in this population. Increased awareness of this disease and its clinical manifestations is essential to attain an early diagnosis and provide the best chance of cure. C1 [Satlin, M. J.; Marks, K. M.; Soave, R.] Weill Cornell Med Coll, Div Infect Dis, Dept Med, New York, NY USA. [Satlin, M. J.; Soave, R.] Weill Cornell Med Coll, Dept Med, Transplantat Oncol Infect Dis Program, New York, NY USA. [Graham, J. K.; Mena, H.] Off Chief Med Examiner, New York, NY USA. [Visvesvara, G. S.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Saal, S. D.] Rogosin Inst, New York, NY USA. RP Satlin, MJ (reprint author), 1300 York Ave,A-421, New York, NY 10021 USA. EM mjs9012@med.cornell.edu NR 29 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD DEC PY 2013 VL 15 IS 6 BP 619 EP 626 DI 10.1111/tid.12131 PG 8 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 262JS UT WOS:000327731600021 PM 24010955 ER PT J AU Guiang, KMU Cantey, P Montgomery, SP Ailawadhi, S Qvarnstrom, Y Price, T Blodget, E AF Guiang, K. M. U. Cantey, P. Montgomery, S. P. Ailawadhi, S. Qvarnstrom, Y. Price, T. Blodget, E. TI Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Chagas disease; Trypanosoma cruzi; transplant; parasites; stem cell transplant; reactivation Chagas ID UNITED-STATES; CRUZI; PCR AB We report a patient with an autologous stem cell transplant and history of residence in a Chagas disease (CD) endemic area who developed Chagas reactivation after induction for transplantation. We recommend that patients at risk for CD be screened before transplantation, and patients found to have chronic infection be monitored for reactivation post transplant. C1 [Guiang, K. M. U.; Blodget, E.] Univ So Calif, Keck Sch Med, Div Infect Dis, Los Angeles, CA 90033 USA. [Cantey, P.; Montgomery, S. P.; Qvarnstrom, Y.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Ailawadhi, S.; Price, T.] Univ So Calif, Norris Comprehens Canc Ctr, Div Hematol & Oncol, Los Angeles, CA USA. RP Blodget, E (reprint author), LA Cty USC Med Ctr, 2020 Zonal Ave Room 436, Los Angeles, CA 90033 USA. EM eblodget@usc.edu NR 12 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD DEC PY 2013 VL 15 IS 6 BP E264 EP E267 DI 10.1111/tid.12157 PG 4 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 262JS UT WOS:000327731600010 PM 24147999 ER PT J AU Freedman, DS Horlick, M Berenson, GS AF Freedman, David S. Horlick, Mary Berenson, Gerald S. TI A comparison of the Slaughter skinfold-thickness equations and BMI in predicting body fatness and cardiovascular disease risk factor levels in children SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID X-RAY ABSORPTIOMETRY; INDEX-FOR-AGE; MASS INDEX; METABOLIC RISK; BLOOD-PRESSURE; FAT MASS; ADOLESCENTS; ADIPOSITY; OBESITY; YOUTH AB Background: Although estimation of percentage body fat with the Slaughter skinfold-thickness equations (PBFSlaughter) is widely used, the accuracy of this method has not been well studied. Objective: The objective was to determine the accuracy of the Slaughter skinfold-thickness equations. Design: We compared agreement between PBFSlaughter and estimations derived from dual-energy X-ray absorptiometry (PBFDXA) in 1169 children in the Pediatric Rosetta Body Composition Project and the relation to cardiovascular disease risk factors, as compared with body mass index (BMI), in 6725 children in the Bogalusa Heart Study. Results: PBFSlaughter was highly correlated (r = 0.90) with PBFDXA, but it markedly overestimated levels of PBFDXA in children with large skinfold thicknesses. In the 65 boys with a sum of skinfold thicknesses (subscapular- plus triceps-skinfold thicknesses) >= 50 mm, PBFSlaughter overestimated PBFDXA by 12 percentage points. The comparable overestimation in girls with a high skinfold sum was 6 percentage points. We also found that, after adjustment for sex and age, BMI showed slightly stronger associations with lipid, lipoprotein, insulin, and blood pressure values than did PBFSlaughter. Conclusions: These results indicate that PBFSlaughter which was developed among a group of much thinner children and adolescents, is fairly accurate among nonobese children, but markedly overestimates the body fatness of children who have thick skinfold thicknesses. Furthermore, PBFSlaughter has no advantage over sex- and age-adjusted BMIs at identifying children who are at increased risk of cardiovascular disease based on lipid, lipoprotein, insulin, and blood pressure values. C1 [Freedman, David S.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Horlick, Mary] NIDDK, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA. [Berenson, Gerald S.] Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA USA. RP Freedman, DS (reprint author), CDC F77,4770 Buford Highway, Atlanta, GA 30341 USA. EM dxf1@cdc.gov FU NIH [DK37352, AG16592] FX Supported by grants DK37352 and AG16592 from the NIH. NR 49 TC 18 Z9 20 U1 3 U2 10 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD DEC PY 2013 VL 98 IS 6 BP 1417 EP 1424 DI 10.3945/ajcn.113.065961 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 266DG UT WOS:000328002000008 PM 24153344 ER PT J AU Cogswell, ME Wang, CY Chen, TC Pfeiffer, CM Elliott, P Gillespie, CD Carriquiry, AL Sempos, CT Liu, K Perrine, CG Swanson, CA Caldwell, KL Loria, CM AF Cogswell, Mary E. Wang, Chia-Yih Chen, Te-Ching Pfeiffer, Christine M. Elliott, Paul Gillespie, Cathleen D. Carriquiry, Alicia L. Sempos, Christopher T. Liu, Kiang Perrine, Cria G. Swanson, Christine A. Caldwell, Kathleen L. Loria, Catherine M. TI Validity of predictive equations for 24-h urinary sodium excretion in adults aged 18-39 y SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID DAILY SALT INTAKE; POTASSIUM EXCRETION; BLOOD-PRESSURE; CREATININE; COLLECTIONS; VARIABILITY; SPECIMEN; CALCIUM; OUTPUT; MEN AB Background: Collecting a 24-h urine sample is recommended for monitoring the mean population sodium intake, but implementation can be difficult. Objective: The objective was to assess the validity of published equations by using spot urinary sodium concentrations to predict 24-h sodium excretion. Design: This was a cross-sectional study, conducted from June to August 2011 in metropolitan Washington, DC, of 407 adults aged 18-39 y, 48% black, who collected each urine void in a separate container for 24 h. Four timed voids (morning, afternoon, evening, and overnight) were selected from each 24-h collection. Published equations were used to predict 24-h sodium excretion with spot urine by specimen timing and race-sex subgroups. We examined mean differences with measured 24-h sodium excretion (bias) and individual differences with the use of Bland-Altman plots. Results: Across equations and specimens, mean bias in predicting 24-h sodium excretion for all participants ranged from -267 to 1300 mg (Kawasaki equation). Bias was least with International Cooperative Study on Salt, Other Factors, and Blood Pressure (INTERSALT) equations with morning (-165 mg; 95% CI: -295, 36 mg), afternoon (-90 mg; -208, 28 mg), and evening (-120 mg; -230, -11 mg) specimens. With overnight specimens, mean bias was least when the Tanaka (-23 mg; 95% CI: -141, 95 mg) or Mage (-145 mg; -314, 25 mg) equations were used but was statistically significant when using the Tanaka equations among females (216 to 243 mg) and the Mage equations among races other than black (-554 to -372 mg). Significant over- and underprediction occurred across individual sodium excretion concentrations. Conclusions: Using a single spot urine, INTERSALT equations may provide the least biased information about population mean sodium intakes among young US adults. None of the equations evaluated provided unbiased estimates of individual 24-h sodium excretion. C1 [Cogswell, Mary E.; Gillespie, Cathleen D.] CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Perrine, Cria G.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Pfeiffer, Christine M.; Caldwell, Kathleen L.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Pfeiffer, Christine M.; Caldwell, Kathleen L.] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Wang, Chia-Yih; Chen, Te-Ching] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Loria, Catherine M.] NHLBI, NIH, Bethesda, MD 20892 USA. [Sempos, Christopher T.; Swanson, Christine A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA USA. [Liu, Kiang] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England. [Elliott, Paul] MRC, Hlth Protect Agcy, Ctr Environm & Hlth, London, England. RP Cogswell, ME (reprint author), CDC, Mailstop F-72,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM mcogswell@cdc.gov FU National Institute for Health Research Biomedical Research Centre; Imperial College Healthcare National Health Service Trust; Imperial College FX The authors' responsibilities were as follows-MEC, C-YW, T-CC, CMP, PE, CDG, ALC, CTS, KL, COP, CAS, KLC, and CML: designed the analysis; MEC, C-YW, T-CC, and CDG: analyzed the data; MEC: wrote the initial draft, which was modified based on critical review from all coauthors, and had primary responsibility for all of the content. All authors read and approved the final manuscript. PE acknowledges support from the National Institute for Health Research Biomedical Research Centre, Imperial College Healthcare National Health Service Trust and Imperial College. PE is a Senior Investigator at the National Institute for Health Research. None of the authors had any conflicts of interest. NR 46 TC 37 Z9 39 U1 1 U2 2 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD DEC PY 2013 VL 98 IS 6 BP 1502 EP 1513 DI 10.3945/ajcn.113.059436 PG 12 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 266DG UT WOS:000328002000018 PM 24047921 ER PT J AU Grant, AM AF Grant, Althea M. TI NATIONAL ESTIMATES OF SICKLE CELL DISEASE WITH PEDIATRIC STROKE AMONG AFRICAN-AMERICANS-UNITED STATES, 1997-2009 SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Grant, Althea M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD DEC PY 2013 VL 88 IS 12 BP E55 EP E55 PG 1 WC Hematology SC Hematology GA 255FE UT WOS:000327224000080 ER PT J AU Tuntevski, K Durney, BC Snyder, AK LaSala, PR Nayak, AP Green, BJ Beezhold, DH Rio, RVM Holland, LA Lukomski, S AF Tuntevski, Kiril Durney, Brandon C. Snyder, Anna K. LaSala, P. Rocco Nayak, Ajay P. Green, Brett J. Beezhold, Donald H. Rio, Rita V. M. Holland, Lisa A. Lukomski, Slawomir TI Aspergillus Collagen-Like Genes (acl): Identification, Sequence Polymorphism, and Assessment for PCR-Based Pathogen Detection SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID REAL-TIME PCR; GALACTOMANNAN ENZYME-IMMUNOASSAY; INVASIVE FUNGAL-INFECTIONS; CAPILLARY-ELECTROPHORESIS; PULMONARY ASPERGILLOSIS; DNA; FUMIGATUS; DIAGNOSIS; FLAVUS; RESISTANCE AB The genus Aspergillus is a burden to public health due to its ubiquitous presence in the environment, its production of allergens, and wide demographic susceptibility among cystic fibrosis, asthmatic, and immunosuppressed patients. Current methods of detection of Aspergillus colonization and infection rely on lengthy morphological characterization or nonstandardized serological assays that are restricted to identifying a fungal etiology. Collagen-like genes have been shown to exhibit species-specific conservation across the noncollagenous regions as well as strain-specific polymorphism in the collagen-like regions. Here we assess the conserved region of the Aspergillus collagen-like (acl) genes and explore the application of PCR amplicon size-based discrimination among the five most common etiologic species of the Aspergillus genus, including Aspergillus fumigatus, A. flavus, A. nidulans, A. niger, and A. terreus. Genetic polymorphism and phylogenetic analysis of the aclF1 gene were additionally examined among the available strains. Furthermore, the applicability of the PCR-based assay to identification of these five species in cultures derived from sputum and bronchoalveolar fluid from 19 clinical samples was explored. Application of capillary electrophoresis on nanogels was additionally demonstrated to improve the discrimination between Aspergillus species. Overall, this study demonstrated that Aspergillus acl genes could be used as PCR targets to discriminate between clinically relevant Aspergillus species. Future studies aim to utilize the detection of Aspergillus acl genes in PCR and microfluidic applications to determine the sensitivity and specificity for the identification of Aspergillus colonization and invasive aspergillosis in immunocompromised subjects. C1 [Tuntevski, Kiril; Lukomski, Slawomir] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. [Durney, Brandon C.; Holland, Lisa A.] W Virginia Univ, Dept Chem, Morgantown, WV 26506 USA. [Snyder, Anna K.; Rio, Rita V. M.] W Virginia Univ, Dept Biol, Morgantown, WV 26506 USA. [LaSala, P. Rocco] W Virginia Univ, Dept Pathol, Morgantown, WV 26506 USA. [LaSala, P. Rocco] West Virginia Univ Healthcare, Clin Lab, Morgantown, WV USA. [Nayak, Ajay P.; Green, Brett J.; Beezhold, Donald H.] Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth NIOSH, Morgantown, WV USA. RP Lukomski, S (reprint author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. EM slukomski@hsc.wvu.edu OI Holland, Lisa/0000-0002-7534-6810 FU National Science Foundation [EPS-1003907, CHE1212537]; NSF-IOS [1025274]; NIH [5P20RR016477]; NSF-EPSCoR [1003907] FX This work was supported in part by National Science Foundation Cooperative Agreement EPS-1003907 (to S.L.). L.A.H. acknowledges support for capillary nanogel separations by the National Science Foundation under grant no. CHE1212537. R.V.M.R. is supported by NSF-IOS 1025274. K.T. was supported by NIH grant 5P20RR016477 to the West Virginia IDeA Network for Biomedical Research Excellence. B.C.D. was supported by the NSF-EPSCoR Graduate Fellowship Program (under Cooperative Agreement 1003907). NR 80 TC 8 Z9 8 U1 3 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD DEC PY 2013 VL 79 IS 24 BP 7882 EP 7895 DI 10.1128/AEM.02835-13 PG 14 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 263NF UT WOS:000327814600038 PM 24123732 ER PT J AU Liang, MS Keener, TC Birch, ME Baldauf, R Neal, J Yang, YJ AF Liang, Marissa S. Keener, Timothy C. Birch, M. Eileen Baldauf, Richard Neal, Jill Yang, Y. Jeffrey TI Low-wind and other microclimatic factors in near-road black carbon variability: A case study and assessment implications SO ATMOSPHERIC ENVIRONMENT LA English DT Article DE Black carbon; On-road traffic emission; Gaussian dispersion; Near-road transport; Climate change ID SULFATE DISPERSION EXPERIMENT; AEROSOL-PARTICLES; AIR-QUALITY; ULTRAFINE PARTICLES; OPTICAL-ABSORPTION; BOUNDARY-LAYER; MODEL; PLUME; ATMOSPHERE; HIGHWAY AB Airborne black carbon from urban traffic is a climate forcing agent and has been associated with health risks to near-road populations. In this paper, we describe a case study of black carbon concentration and compositional variability at and near a traffic-laden multi-lane highway in Cincinnati, Ohio, using an onsite aethalometer and filter-based NIOSH Method 5040 measurements; the former measured 1-min average black carbon concentrations and the latter determined the levels of organic and elemental carbon (OC and EC) averaged over an approximately 2-h time interval. The results show significant wind and temperature effects on black carbon concentration and composition in a way more complex than predicted by Gaussian dispersion models. Under oblique low winds, namely u(x)[= u x sin(theta)] similar to (0, -0.5 m s(-1)), which mostly occurred during morning hours, black carbon concentrations per unit traffic flow were highest and had large variation. The variability did not always follow Gaussian dispersion but was characteristic of a uniform distribution at a near-road distance. Under all other wind conditions, the near-road black carbon variation met Gaussian dispersion characteristics. Significant differences in roadside dispersion are observed between DC and EC fractions, between PM2.5 and PM10-2.5, and between the morning period and rest of the day. In a general case, the overall black carbon variability at the multi-lane highway can be stated as bimodal consisting of Gaussian dispersion and non-Gaussian uniform distribution. Transition between the two types depends on wind velocity and wind angle to the traffic flow. In the order of decreasing importance, the microclimatic controlling factors over the black carbon variability are: 1) wind velocity and the angle with traffic; 2) diurnal temperature variations due to thermal buoyancy; and 3) downwind Gaussian dispersion. Combinations of these factors may have created various traffic-microclimate interactions that have significant impact on near-road black carbon transport. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Liang, Marissa S.; Keener, Timothy C.] Univ Cincinnati, Dept Biomed Chem & Environm Engn, Coll Engn & Appl Sci, Cincinnati, OH 45221 USA. [Birch, M. Eileen] NIOSH, US Ctr Dis Control, Cincinnati, OH 45213 USA. [Baldauf, Richard] US EPA, Off Res & Dev, Natl Risk Management Res Lab, Res Triangle Pk, NC 27711 USA. [Neal, Jill; Yang, Y. Jeffrey] US EPA, Off Res & Dev, Natl Risk Management Res Lab, Cincinnati, OH 45268 USA. RP Keener, TC (reprint author), Univ Cincinnati, Dept Biomed Chem & Environm Engn, Coll Engn & Appl Sci, POB 210012, Cincinnati, OH 45221 USA. EM liangsg@mail.uc.edu; tim.keener@uc.edu FU EPA [EP-006-011] FX The authors sincerely thank Zhuo Yao, Hao Liu, Jiangchuan Hu and Beizhao for their generous support in field investigation and data processing and are grateful to Dr. Vlad Isakov of EPA, Drs. Pratim Biswas of Washington University in St. Louis, and Drs. Heng Wei, Mingming Lu, and Xinhao Wang of the University of Cincinnati, for their technical review and constructive comments. Field sampling and characterization of this research were funded and conducted under EPA contract EP-006-011. The authors acknowledge the use of NIOSH laboratories, Cincinnati, Ohio, for OC-EC analyses. The research described herein has been subjected to technical and administrative review by US EPA and CDC/NIOSH, and has been approved for external publication. Any opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the Agencies; therefore, no official endorsement should be inferred. Mention of company name or product does not constitute endorsement by EPA or CDC/NIOSH. NR 46 TC 4 Z9 4 U1 1 U2 28 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1352-2310 EI 1873-2844 J9 ATMOS ENVIRON JI Atmos. Environ. PD DEC PY 2013 VL 80 BP 204 EP 215 DI 10.1016/j.atmosenv.2013.07.057 PG 12 WC Environmental Sciences; Meteorology & Atmospheric Sciences SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 267JV UT WOS:000328094800022 PM 26561363 ER PT J AU Berry, SA Kenney, MK Harris, KB Singh, RH Cameron, CA Kraszewski, JN Levy-Fisch, J Shuger, JF Greene, CL Lloyd-Puryear, MA Boyle, CA AF Berry, Susan A. Kenney, Mary Kay Harris, Katharine B. Singh, Rani H. Cameron, Cynthia A. Kraszewski, Jennifer N. Levy-Fisch, Jill Shuger, Jill F. Greene, Carol L. Lloyd-Puryear, Michele A. Boyle, Coleen A. TI Insurance coverage of medical foods for treatment of inherited metabolic disorders SO GENETICS IN MEDICINE LA English DT Article DE diet therapy; inborn errors of metabolism; insurance coverage; neonatal screening AB Purpose: Treatment of inherited metabolic disorders is accomplished by use of specialized diets employing medical foods and medically necessary supplements. Families seeking insurance coverage for these products express concern that coverage is often limited; the extent of this challenge is not well defined. Methods: To learn about limitations in insurance coverage, parents of 305 children with inherited metabolic disorders completed a paper survey providing information about their use of medical foods, modified low-protein foods, prescribed dietary supplements, and medical feeding equipment and supplies for treatment of their child's disorder as well as details about payment sources for these products. Results: Although nearly all children with inherited metabolic disorders had medical coverage of some type, families paid "out of pocket" for all types of products. Uncovered spending was reported for 11% of families purchasing medical foods, 26% purchasing supplements, 33% of those needing medical feeding supplies, and 59% of families requiring modified low-protein foods. Forty-two percent of families using modified low-protein foods and 21% of families using medical foods reported additional treatment-related expenses of $ 100 or more per month for these products. Conclusion: Costs of medical foods used to treat inherited metabolic disorders are not completely covered by insurance or other resources. C1 [Berry, Susan A.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. [Kenney, Mary Kay] US Hlth Resources & Serv Adm, Off Epidemiol Policy & Evaluat, Rockville, MD 20857 USA. [Harris, Katharine B.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Singh, Rani H.] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. [Cameron, Cynthia A.] Michigan Publ Hlth Inst, Okemos, MI USA. [Kraszewski, Jennifer N.] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA. [Levy-Fisch, Jill] Save Babies Screening Fdn Inc, Cincinnati, OH USA. [Shuger, Jill F.] US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Greene, Carol L.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA. [Lloyd-Puryear, Michele A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Boyle, Coleen A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Berry, SA (reprint author), Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. EM berry002@umn.edu OI Berry, Susan/0000-0001-7970-688X FU Cooperative Agreement between the Maternal and Child Health Bureau (MCHB); Genetic Services Branch, and the University of Texas Health Science Center at San Antonio; National Newborn Screening and Genetics Resource Center; Health Resources and Services Administration (HRSA) [U32MC00148]; HRSA-MCHB Regional Genetic and Newborn Screening Services Collaboratives; Heritable Disorders Program: Region 2 New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services [U22MC03956]; Region 3 Southeast Newborn Screening and Genetics Collaborative [U22MC10979]; Region 4 Midwest Genetics Collaborative [U22MC03963] FX The project was supported through a Cooperative Agreement between the Maternal and Child Health Bureau (MCHB), Genetic Services Branch, and the University of Texas Health Science Center at San Antonio, National Newborn Screening and Genetics Resource Center, Health Resources and Services Administration (HRSA) grant no. U32MC00148 and by HRSA-MCHB Regional Genetic and Newborn Screening Services Collaboratives, Heritable Disorders Program: Region 2 New York-Mid-AtlantiConsortium for Genetic and Newborn Screening Services, Cooperative Agreement No. U22MC03956; Region 3 Southeast Newborn Screening and Genetics Collaborative, Cooperative Agreement No. U22MC10979; and Region 4 Midwest Genetics Collaborative, Cooperative Agreement No. U22MC03963. The authors thank the investigators at the following institutions: - University of - Minnesota Amplatz Children's Hospital (Kristi Bentler); - Cincinnati Children's Hospital Medical Center (Nancy Leslie); Emory - University (Mary Brauchla); Greenwood Genetics Center (Melinda Whetsell and Neena Champaigne); University of Florida (Helen McCune and Robert Zori); University of North - Carolina-Chapel Hill (Dianne - Frazier); University of Tennessee (Darla Henderson Smith); Vanderbilt University Medical Center (Gina Wey); Mount Sinai Medical Center (Roberta Salveson); Children's Hospital at Albany Medical Center (Katherine Marra); Children's Hospital of Pittsburgh (Judith Henry); Golisano Children's Hospital at Strong (Eileen Blakely); Maria Fareri Children's Hospital at Westchester Medical Center (Shideh Mofidi); University of Maryland Hospital for Children (Megan Skinner). NR 8 TC 5 Z9 5 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD DEC PY 2013 VL 15 IS 12 BP 978 EP 982 DI 10.1038/gim.2013.46 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 266XI UT WOS:000328056900011 PM 23598714 ER PT J AU Findlay, F Proudfoot, L Svoboda, P Pohl, J Barlow, PG AF Findlay, F. Proudfoot, L. Svoboda, P. Pohl, J. Barlow, P. G. TI The antimicrobial activity of the cationic host defence peptide, LL-37, is inhibited by exposure to nanomaterials SO IMMUNOLOGY LA English DT Meeting Abstract CT Annual Congress of the British-Society-for-Immunology CY DEC 02-05, 2013 CL Liverpool, ENGLAND SP British Soc Immunol C1 [Findlay, F.; Proudfoot, L.; Barlow, P. G.] Edinburgh Napier Univ, Sch Life Sport & Social Sci, Edinburgh, Midlothian, Scotland. [Svoboda, P.; Pohl, J.] US Ctr Dis Control & Prevent, Peptide Core Facil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 EI 1365-2567 J9 IMMUNOLOGY JI Immunology PD DEC PY 2013 VL 140 SU 1 SI SI BP 83 EP 83 PG 1 WC Immunology SC Immunology GA 258VV UT WOS:000327487700199 ER PT J AU Gore, S Bangert, M Rajam, G Ades, EW Gordon, SB Kadioglu, A AF Gore, S. Bangert, M. Rajam, G. Ades, E. W. Gordon, S. B. Kadioglu, A. TI Novel treatment for bacterial sepsis - augmented passive immunotherapy SO IMMUNOLOGY LA English DT Meeting Abstract CT Annual Congress of the British-Society-for-Immunology CY DEC 02-05, 2013 CL Liverpool, ENGLAND SP British Soc Immunol C1 [Gore, S.; Bangert, M.; Kadioglu, A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Bangert, M.; Gordon, S. B.] Univ Liverpool, Liverpool Sch Trop Med, Resp Infect Grp, Liverpool L3 5QA, Merseyside, England. [Rajam, G.; Ades, E. W.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0019-2805 EI 1365-2567 J9 IMMUNOLOGY JI Immunology PD DEC PY 2013 VL 140 SU 1 SI SI BP 201 EP 201 PG 1 WC Immunology SC Immunology GA 258VV UT WOS:000327487700529 ER PT J AU Chenet, SM Pacheco, MA Bacon, DJ Collins, WE Barnwell, JW Escalante, AA AF Chenet, Stella M. Pacheco, M. Andreina Bacon, David J. Collins, William E. Barnwell, John W. Escalante, Ananias A. TI The evolution and diversity of a low complexity vaccine candidate, merozoite surface protein 9 (MSP-9), in Plasmodium vivax and closely related species SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE ABRA; Binding sites; Genetic diversity; Merozoite surface proteins; MSP-9; Plasmodium ID BASIC REPEAT ANTIGEN; RED-BLOOD-CELLS; MALARIA PARASITES; NATURAL-SELECTION; ERYTHROCYTE-BINDING; I-TASSER; FALCIPARUM; IMMUNOGENICITY; RESPONSES; EPITOPES AB The merozoite surface protein-9 (MSP-9) has been considered a target for an anti-malarial vaccine since it is one of many proteins involved in the erythrocyte invasion, a critical step in the parasite life cycle. Orthologs encoding this antigen have been found in all known species of Plasmodium parasitic to primates. In order to characterize and investigate the extent and maintenance of MSP-9 genetic diversity, we analyzed DNA sequences of the following malaria parasite species: Plasmodium falciparum, Plasmodium reichenowi, Plasmodium chabaudi, Plasmodium yoelii, Plasmodium berghei, Plasmodium coatneyi, Plasmodium gonderi, Plasmodium knowlesi, Plasmodium inui, Plasmodium simiovale, Plasmodium fieldi, Plasmodium cynomolgi and Plasmodium vivax and evaluated the signature of natural selection in all MSP-9 orthologs. Our findings suggest that the gene encoding MSP-9 is under purifying selection in P. vivax and closely related species. We further explored how selection affected different regions of MSP-9 by comparing the polymorphisms in P. vivax and P. falciparum, and found contrasting patterns between these two species that suggest differences in functional constraints. This observation implies that the MSP-9 orthologs in human parasites may interact differently with the host immune response. Thus, studies carried out in one species cannot be directly translated into the other. (C) 2013 Elsevier B. V. All rights reserved. C1 [Chenet, Stella M.; Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA. [Chenet, Stella M.; Pacheco, M. Andreina; Escalante, Ananias A.] Arizona State Univ, Biodesign Inst, Ctr Evolutionary Med & Informat, Tempe, AZ USA. [Bacon, David J.] Naval Res Lab, Washington, DC USA. [Collins, William E.; Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Escalante, AA (reprint author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA. EM schenet@asu.edu; Maria.Pacheco@asu.edu; david.bacon@nrl.navy.mil; wec1@cdc.gov; wzb3@cdc.gov; Ananias.Escalante@asu.edu FU US National Institutes of Health [R01 GM080586] FX This work was supported by the US National Institutes of Health (R01 GM080586 to A. A. E.). We thank the DNA laboratory at the School of Life Sciences for their technical support. We also thank Jane Carlton for providing access to 454 preliminary data from P. inui and P. gonderi. The content is solely the responsibility of the authors and does not represent the official views of the NIH, the Centers for Disease Control and Prevention, Department of the Navy, Department of Defense, or the US Government. NR 52 TC 5 Z9 5 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD DEC PY 2013 VL 20 BP 239 EP 248 DI 10.1016/j.meegid.2013.09.011 PG 10 WC Infectious Diseases SC Infectious Diseases GA 261YQ UT WOS:000327701200031 PM 24044894 ER PT J AU Gomez-Palacio, A Triana, O Jaramillo, N Dotson, EM Marcet, PL AF Gomez-Palacio, Andres Triana, Omar Jaramillo-O, Nicolas Dotson, Ellen M. Marcet, Paula L. TI Eco-geographical differentiation among Colombian populations of the Chagas disease vector Triatoma dimidiata (Hemiptera: Reduviidae) SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Triatominae; Chagas disease; Triatoma dimidiata; Multilocus microsatellite analysis; Cytochrome c oxidase subunit 1; Population genetics ID RHODNIUS-PROLIXUS HEMIPTERA; MULTILOCUS GENOTYPE DATA; MICROSATELLITE MARKERS; GENETIC-STRUCTURE; MITOCHONDRIAL-DNA; PHYLOGENETIC-RELATIONSHIPS; INFESTANS POPULATIONS; TRYPANOSOMA-CRUZI; CENTRAL-AMERICA; SOFTWARE AB Triatoma dimidiata is currently the main vector of Chagas disease in Mexico, most Central American countries and several zones of Ecuador and Colombia. Although this species has been the subject of several recent phylogeographic studies, the relationship among different populations within the species remains unclear. To elucidate the population genetic structure of T. dimidiata in Colombia, we analyzed individuals from distinct geographical locations using the cytochrome c oxidase subunit 1 gene and 7 microsatellite loci. A clear genetic differentiation was observed among specimens from three Colombian eco-geographical regions: Inter Andean Valleys, Caribbean Plains and Sierra Nevada de Santa Marta mountain (SNSM). Additionally, evidence of genetic subdivision was found within the Caribbean Plains region as well as moderate gene flow between the populations from the Caribbean Plains and SNSM regions. The genetic differentiation found among Colombian populations correlates, albeit weakly, with an isolation-by-distance model (IBD). The genetic heterogeneity among Colombian populations correlates with the eco-epidemiological and morphological traits observed in this species across regions within the country. Such genetic and epidemiological diversity should be taken into consideration for the development of vector control strategies and entomological surveillance. (C) 2013 Published by Elsevier B. V. C1 [Gomez-Palacio, Andres; Triana, Omar; Jaramillo-O, Nicolas] Univ Antioquia UdeA, Grp BCEI, Medellin, Colombia. [Dotson, Ellen M.; Marcet, Paula L.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. RP Gomez-Palacio, A (reprint author), Univ Antioquia, Lab 620, Grp Biol & Control Enfermedades Infecciosas BCEI, Sede Invest Univ, Calle 62 52-59, Medellin, Colombia. EM amgomezpa@gmail.com OI Triana, Omar/0000-0001-8031-0225; Marcet, Paula/0000-0002-0676-3020; Gomez-Palacio, Andres/0000-0002-1069-9199 FU Estrategia de sostenibilidad; CODI-Universidad de Antioquia; COLCIENCIAS [111545921460, 111549326149] FX This work was funded by Estrategia de sostenibilidad 2013-2014, CODI-Universidad de Antioquia, and by COLCIENCIAS projects # 111545921460 and 111549326149. We would like to thank to researchers Gabriel Parra-Henao (Instituto Colombiano de Medicina Tropical, Universidad CES, Medellin) and Victor Angulo (Centro de Investigaciones en Enfermedades Tropicales-CINTROP, Universidad Industrial de Santander, Bucaramanga) for providing some specimens. To Instituto Nacional de Salud de Colombia, and its entomologists staff from Boyaca, Norte de Santander and Cesar departments for their assistance in fieldwork. Oligonucleotides for microsatellite loci were synthetized by the CDC core facilities. NR 57 TC 8 Z9 8 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD DEC PY 2013 VL 20 BP 352 EP 361 DI 10.1016/j.meegid.2013.09.003 PG 10 WC Infectious Diseases SC Infectious Diseases GA 261YQ UT WOS:000327701200044 PM 24035810 ER PT J AU Arvelo, W Hall, AJ Estevez, A Lopez, B Gregoricus, N Vinje, J Gentsch, JR Parashar, U Lindblade, KA AF Arvelo, Wences Hall, Aron J. Estevez, Alejandra Lopez, Beatriz Gregoricus, Nicole Vinje, Jan Gentsch, Jon R. Parashar, Umesh Lindblade, Kim A. TI Diagnostic performance of rectal swab versus bulk stool specimens for the detection of rotavirus and norovirus: Implications for outbreak investigations SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Norovirus; Rotavirus; Diagnosis; Concordance; Surveillance; Guatemala ID CHILDREN; ASSAY; GASTROENTERITIS; SURVEILLANCE; DISEASE; PCR AB Background: In January of 2008, during the peak of the rotavirus season in Guatemala, a gastroenteritis outbreak with high mortality among infants was reported in Guatemala. Despite extensive efforts, the investigation was limited by the lack of bulk stool specimens collected, particularly from the more severely dehydrated or deceased children. Objectives: We evaluated the diagnostic performance of rectal swab specimens compared with bulk stool for the detection of rotavirus and norovirus. Study design: Patients with diarrhea (>3 loose stools in 24 h) were enrolled through an ongoing surveillance system in Guatemala. From January through March 2009, we attempted to enroll 100 patients <5 years old captured by the diarrhea surveillance, and collected paired bulk stool and rectal swabs specimens from them. Specimens were tested for norovirus using real-time reverse transcription-polymerase chain reaction and for rotavirus via enzyme immunoassay. Results: We enrolled 102 patients with paired specimens; 91% of 100 paired specimens tested for rotavirus yielded concordant results positive for rotavirus with a negativity rate of 83%. Among 100 paired specimens tested for norovirus, 86% were concordant norovirus detection and the negativity rate was 85%. The diagnostic performance for rotavirus and norovirus detection did not differ significantly between the two specimen types. Conclusions: Testing of properly collected fecal specimens using rectal swabs may be a viable alternative to bulk stool for detection of rotavirus and norovirus, particularly during outbreaks where collection of bulk stool may be difficult. Published by Elsevier B.V. C1 [Arvelo, Wences; Lindblade, Kim A.] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Reg Off Cent Amer & Panama, Guatemala City, Guatemala. [Hall, Aron J.; Gregoricus, Nicole; Vinje, Jan; Gentsch, Jon R.; Parashar, Umesh] US Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Estevez, Alejandra; Lopez, Beatriz] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. RP Arvelo, W (reprint author), US Ctr Dis Control & Prevent, Int Emerging Infect Program, Reg Off Cent Amer & Panama, Guatemala City, Guatemala. EM dwi4@cdc.gov OI Lopez, Beatriz/0000-0003-1353-9948; Vinje, Jan/0000-0002-1530-3675 FU U.S. Centers for Disease Control and Prevention [UO1 GH000028-02] FX Cooperative Agreement Number UO1 GH000028-02 from the U.S. Centers for Disease Control and Prevention. NR 13 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 EI 1873-5967 J9 J CLIN VIROL JI J. Clin. Virol. PD DEC PY 2013 VL 58 IS 4 BP 678 EP 682 DI 10.1016/j.jcv.2013.09.019 PG 5 WC Virology SC Virology GA 263PN UT WOS:000327820600014 PM 24139675 ER PT J AU Ford, ES Choi, HK AF Ford, Earl S. Choi, Hyon K. TI Associations between concentrations of uric acid with concentrations of vitamin A and beta-carotene among adults in the United States SO NUTRITION RESEARCH LA English DT Article DE Beta-carotene; Health surveys; Nutrition surveys; Uric acid; Vitamin A ID CARDIOVASCULAR-DISEASE; ALL-CAUSE; SUPPLEMENTATION; METAANALYSIS; MORTALITY; MARKERS; TRIALS; COHORT; RISK; GOUT AB Our objective was to examine the cross-sectional associations between concentrations of vitamin A and beta-carotene, a major source of vitamin A, with concentrations of uric acid in a nationally representative sample of adults from the United States. We conducted a cross-sectional study using data from up to 10893 participants aged >= 20 years of National Health and Nutrition Examination Survey from 2001 to 2006. Concentrations of uric acid adjusted for numerous covariates increased from 305.8 mu mol/L in the lowest quintile of vitamin A to 335.3 mu mol/L in the highest quintile (p for linear trend <0.001). The prevalence ratio for hyperuricemia also increased progressively across quintiles of serum vitamin A reaching 1.82 (95% confidence interval [CI]: 1.52, 2.16; p for linear trend <0.001) in the top quintile in the maximally adjusted model. Adjusted mean concentrations of uric acid decreased progressively from quintile 1 (333.8 mu mol/L) through quintile 4 of concentrations of beta-carotene and were similar for quintiles 4 (313.5 mu mol/L) and 5 (313.8 mu mol/L). Concentrations of beta-carotene were inversely associated with hyperuricemia (adjusted prevalence ratio comparing highest with lowest quintile = 0.61; 95% CI: 0.52, 0.72; p for linear trend <0.001). Concentrations of uric acid were significantly and positively associated with concentrations of vitamin A and inversely with concentrations of beta-carotene. These cross-sectional findings require confirmation with experimental studies of vitamin A and beta-carotene supplementation. Published by Elsevier Inc. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Choi, Hyon K.] Boston Univ, Sch Med, Rheumatol Sect, Boston, MA 02118 USA. [Choi, Hyon K.] Boston Univ, Sch Med, Clin Epidemiol Unit, Boston, MA 02118 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 3 Z9 3 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0271-5317 J9 NUTR RES JI Nutr. Res. PD DEC PY 2013 VL 33 IS 12 BP 995 EP 1002 DI 10.1016/j.nutres.2013.08.008 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 266GW UT WOS:000328013100002 PM 24267038 ER PT J AU Dudeck, MA Weiner, LM Allen-Bridson, K Malpiedi, PJ Peterson, KD Pollock, DA Sievert, DM Edwards, JR AF Dudeck, Margaret A. Weiner, Lindsey M. Allen-Bridson, Katherine Malpiedi, Paul J. Peterson, Kelly D. Pollock, Daniel A. Sievert, Dawn M. Edwards, Jonathan R. TI National Healthcare Safety Network (NHSN) report, data summary for 2012, Device-associated module SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article ID INFECTION C1 [Dudeck, Margaret A.; Weiner, Lindsey M.; Allen-Bridson, Katherine; Malpiedi, Paul J.; Peterson, Kelly D.; Pollock, Daniel A.; Sievert, Dawn M.; Edwards, Jonathan R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Publ Hlth Serv,US Dept Hlth & Human Serv, Atlanta, GA 30329 USA. RP Dudeck, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, 1600 Clifton Rd NE MS A-24, Atlanta, GA 30329 USA. EM mdudeck@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 93 Z9 97 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD DEC PY 2013 VL 41 IS 12 BP 1148 EP 1166 DI 10.1016/j.ajic.2013.09.002 PG 19 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 259QA UT WOS:000327540200004 PM 24274911 ER PT J AU Peterson, AE Chitnis, AS Xiang, N Scaletta, JM Geist, R Schwartz, J DeMent, J Lawlor, E LiPuma, JJ O'Connell, H Noble-Wang, J Kallen, AJ Hunt, DC AF Peterson, Amy E. Chitnis, Amit S. Xiang, Nan Scaletta, Joseph M. Geist, Robert Schwartz, Jennifer DeMent, Jamie Lawlor, Elizabeth LiPuma, John J. O'Connell, Heather Noble-Wang, Judith Kallen, Alexander J. Hunt, D. Charles TI Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Burkholderia cepacia complex; Infection control; Ventilation; Mechanical ID CEPACIA COMPLEX; OUTBREAK AB We investigated a cluster of 10 Burkholderia cepacia complex-positive cultures among ventilated patients and those with a tracheostomy in an acute care hospital. Isolates from 5 patients had outbreak-strain-related Burkholderia contaminans. Isolates of B. cepacia complex unrelated to the outbreak strain were cultured from a sink drain. The investigation identified practices that might have led to contamination of patient respiratory care supplies with tap water, which might have contributed to the cluster. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Peterson, Amy E.; Chitnis, Amit S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Peterson, Amy E.; Scaletta, Joseph M.; Geist, Robert; Schwartz, Jennifer; DeMent, Jamie; Lawlor, Elizabeth; Hunt, D. Charles] Kansas Dept Hlth & Environm, Topeka, KS USA. [Chitnis, Amit S.; Xiang, Nan; O'Connell, Heather; Noble-Wang, Judith; Kallen, Alexander J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [LiPuma, John J.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI USA. RP Peterson, AE (reprint author), 11800 Tech Rd,Suite 220, Silver Spring, MD 20904 USA. EM apeterson@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD DEC PY 2013 VL 41 IS 12 BP 1298 EP 1300 DI 10.1016/j.ajic.2013.05.015 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 259QA UT WOS:000327540200035 PM 23973426 ER PT J AU Simon, AE Uddin, SG AF Simon, Alan E. Uddin, Sayeedha G. TI National trends in primary cesarean delivery, labor attempts, and labor success, 1990-2010 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE attempted labor; labor success; primary cesarean delivery ID UNITED-STATES; IDENTIFY INDICATIONS; RATES; RECORDS; BIRTH AB OBJECTIVE: The national primary cesarean delivery rate increased until 2004, but after 2004, this rate cannot be tracked using Vital Statistics data. Additionally, it is unknown whether changes in the primary cesarean delivery rate reflect changes in the rate of labor attempts, labor success, or both. Here, using hospital discharge data, we examined national trends in primary cesarean deliveries, labor attempts, and labor success among women without prior cesarean delivery between 1990 and 2010. STUDY DESIGN: This analysis of serial cross-sectional data from the National Hospital Discharge Survey used Joinpoint regression to assess trends over time and logistic regression with marginal effects to identify rates of change over time and adjust for demographic and clinical factors. RESULTS: The primary cesarean delivery rate declined 0.2 percentage points per year (95% confidence interval [CI], 0.1-0.3) between 1990 and 1999, increased 1.0 percentage point per year (95% CI, 0.8-1.2) between 1999 and 2004, and increased 0.3 percentage points (95% CI, 0.1-0.6) per year from 2004 until 2010. Between 1998 and 2005, the rate of labor attempts declined 0.4 percentage points (95% CI, 0.3-0.5) per year. No changes in the labor attempt rate occurred between 2005 and 2010. Labor success rates increased 0.2 percentage points (95% CI, 0.1-0.3) per year between 1990 and 1998 but then declined 0.5 (95% CI, 0.5-0.8) percentage points per year from 1998 to 2010. Adjusted results were similar. CONCLUSION: The primary cesarean delivery rate continued to increase after 2004. Increases in the primary cesarean delivery rate after 2005 were driven by declines in labor success rates. C1 [Simon, Alan E.; Uddin, Sayeedha G.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Simon, AE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 29 TC 1 Z9 1 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD DEC PY 2013 VL 209 IS 6 AR 554.e1 DI 10.1016/j.ajog.2013.08.012 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 259PN UT WOS:000327538900014 PM 23954531 ER PT J AU Portnoy, J Miller, JD Williams, PB Chew, GL Miller, JD Zaitoun, F Phipatanakul, W Kennedy, K Barnes, C Grimes, C Larenas-Linnemann, D Sublett, J Bernstein, D Blessing-Moore, J Khan, D Lang, D Nicklas, R Oppenheimer, J Randolph, C Schuller, D Spector, S Tilles, SA Wallace, D AF Portnoy, Jay Miller, Jeffrey D. Williams, P. Brock Chew, Ginger L. Miller, J. David Zaitoun, Fares Phipatanakul, Wanda Kennedy, Kevin Barnes, Charles Grimes, Carl Larenas-Linnemann, Desiree Sublett, James Bernstein, David Blessing-Moore, Joann Khan, David Lang, David Nicklas, Richard Oppenheimer, John Randolph, Christopher Schuller, Diane Spector, Sheldon Tilles, Stephen A. Wallace, Dana TI Environmental assessment and exposure control of dust mites: a practice parameter SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID IN-HOUSE DUST; DER-P-I; DERMATOPHAGOIDES-PTERONYSSINUS ACARI; RANDOMIZED CONTROLLED-TRIAL; NORTHEASTERN UNITED-STATES; IMMUNOTHERAPY PRACTICE PATTERNS; REDUCING RELATIVE-HUMIDITY; LINKED-IMMUNOSORBENT-ASSAY; ATOPIC ASTHMATIC SUBJECTS; IMPERMEABLE BED COVERS C1 [Kennedy, Kevin; Barnes, Charles] Childrens Mercy Hosp & Clin, Ctr Environm Hlth, Kansas City, MO USA. [Portnoy, Jay] Univ Missouri, Sch Med, Childrens Mercy Hosp & Clin, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA. [Bernstein, David] Univ Cincinnati, Coll Med, Div Allergy Immunol, Cincinnati, OH USA. [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Palo Alto, CA 94304 USA. [Khan, David] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Lang, David] Cleveland Clin Fdn, Div Med, Allergy Immunol Sect, Cleveland, OH 44195 USA. [Nicklas, Richard] George Washington Med Ctr, Washington, DC USA. [Oppenheimer, John] Univ Med & Dent New Jersey, Pulm & Allergy Associates, Dept Internal Med, Morristown, NJ USA. [Randolph, Christopher] Yale Affiliated Hosp, Ctr Allergy Asthma & Immunol, Waterbury, CT USA. [Schuller, Diane] Penn State Univ, Milton S Hershey Med Coll, Hershey, PA USA. [Spector, Sheldon] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Tilles, Stephen A.] Univ Washington, Sch Med, Redmond, WA USA. [Wallace, Dana] Nova SE Univ, Coll Osteopath Med, Davie, FL USA. [Chew, Ginger L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Atlanta, GA USA. [Grimes, Carl] Hlth Habitats LLC, Denver, CO USA. [Larenas-Linnemann, Desiree] Hosp Medica Sur, Fac Allergy, Mexico City, DF, Mexico. [Miller, Jeffrey D.] New York Med Coll, Valhalla, NY 10595 USA. [Miller, J. David] Carleton Univ, Ottawa, ON K1S 5B6, Canada. [Phipatanakul, Wanda] Harvard Univ, Childrens Hosp, Sch Med, Div Allergy & Immunol, Boston, MA 02115 USA. [Zaitoun, Fares] Amer Univ Hosp Med Ctr, Allergy Immunol Clin Fac, Beirut, Lebanon. OI SUBLETT, JAMES L/0000-0003-4696-4609 FU National Institutes of Health; Department of Housing and Urban Development; UCB; MSD; Senosian; Almirall; Hollister Stier; AstraZeneca; GlaxoSmithKline; Greer Laboratories; ALK Abbott; TEVA; Genetech; Aventis; Boehringer; Novartis; Amphistar; Astellos FX Disclosures: Dr Barnes received research grants from the National Institutes of Health and the Department of Housing and Urban Development. Dr Larenas-Linnemann received travel grants from UCB, MSD, Senosian, Almirall, and Hollister Stier and speaker's fees from MSD, AstraZeneca, and GlaxoSmithKline; served on the advisory board of Almirall and Hollister Stier; received grants from Greer Laboratories and ALK Abbott; and led immunotherapy committees for the AAAI and CMICA. Dr Blessing-Moore served on committees of the AAAI, ATS, and ACCP and consulted for BJB Pharmaceuticals, Pfizer, and Stanford University Hospital. Dr Tilles consulted for Istra, Hycor, and Sunonon and received from grants from TEVA, Genetech, Aventis, Boehringer, the National Institutes of Health, Novartis, Amphistar, and Astellos. The Joint Task Force has made a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the Task Force will ensure that appropriate recognition of such contributions is made subsequently. NR 355 TC 24 Z9 25 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD DEC PY 2013 VL 111 IS 6 BP 465 EP 507 DI 10.1016/j.anai.2013.09.018 PG 43 WC Allergy; Immunology SC Allergy; Immunology GA 259PL UT WOS:000327538700009 PM 24267359 ER PT J AU Haigh, F Harris, E Chok, HNG Baum, F Harris-Roxas, B Kemp, L Spickett, J Keleher, H Morgan, R Harris, M Wendel, AM Dannenberg, AL AF Haigh, Fiona Harris, Elizabeth Chok, Harrison N. G. Baum, Fran Harris-Roxas, Ben Kemp, Lynn Spickett, Jeff Keleher, Helen Morgan, Richard Harris, Mark Wendel, Arthur M. Dannenberg, Andrew L. TI Characteristics of health impact assessments reported in Australia and New Zealand 2005-2009 SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH LA English DT Article DE Health Impact Assessment; Australia; New Zealand; audit AB Objective: To describe the use and reporting of Health Impact Assessment (HIA) in Australia and New Zealand between 2005 and 2009. Methods: We identified 115 HIAs undertaken in Australia and New Zealand between 2005 and 2009. We reviewed 55 HIAs meeting the study's inclusion criteria to identify characteristics and appraise the quality of the reports. Results: Of the 55 HIAs, 31 were undertaken in Australia and 24 in New Zealand. The HIAs were undertaken on plans (31), projects (12), programs (6) and policies (6). Compared to Australia, a higher proportion of New Zealand HIAs were on policies and plans and were rapid assessments done voluntarily to support decision-making. In both countries, most HIAs were on land use planning proposals. Overall, 65% of HIA reports were judged to be adequate. Conclusion: This study is the first attempt to empirically investigate the nature of the broad range of HIAs done in Australia and New Zealand and has highlighted the emergence of HIA as a growing area of public health practice. It identifies areas where current practice could be improved and provides a baseline against which future HIA developments can be assessed. Implications: There is evidence that HIA is becoming a part of public health practice in Australia and New Zealand across a wide range of policies, plans and projects. The assessment of quality of reports allows the development of practical suggestions on ways current practice may be improved. The growth of HIA will depend on ongoing organisation and workforce development in both countries. C1 [Haigh, Fiona; Harris, Elizabeth; Chok, Harrison N. G.; Kemp, Lynn] Univ New S Wales, Ctr Primary Hlth Care & Equ, CHETRE, Liverpool Bc, NSW 1871, Australia. [Haigh, Fiona; Harris, Elizabeth; Chok, Harrison N. G.; Kemp, Lynn] NSW Hlth, South Western Sydney & Sydney Local Hlth Dist, Sydney, NSW, Australia. [Baum, Fran] Flinders Univ S Australia, SACHRU, Adelaide, SA, Australia. [Spickett, Jeff] Curtin Univ, Sch Publ Hlth, Bentley, WA, Australia. [Keleher, Helen] Monash Univ, Sch Publ Hlth & Prevent Med, Clayton, Vic 3800, Australia. [Morgan, Richard] Univ Otago, Dept Geog, CIART, Christchurch, New Zealand. [Wendel, Arthur M.; Dannenberg, Andrew L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Dannenberg, Andrew L.] Carter Consulting Inc, Atlanta, GA USA. [Dannenberg, Andrew L.] Univ Washington, Seattle, WA 98195 USA. RP Harris, E (reprint author), Univ New S Wales, Liverpool Hosp, Ctr Primary Hlth Care & Equ, CHETRE, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia. EM e.harris@unsw.edu.au RI Harris-Roxas, Ben/A-3925-2015 OI Harris-Roxas, Ben/0000-0003-1716-2009 NR 46 TC 8 Z9 8 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1326-0200 EI 1753-6405 J9 AUST NZ J PUBL HEAL JI Aust. N. Z. Publ. Health PD DEC PY 2013 VL 37 IS 6 BP 534 EP 546 DI 10.1111/1753-6405.12102 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 262NQ UT WOS:000327742700007 PM 24892152 ER PT J AU Mechanic, L Mendez, A Merrill, L Rogers, J Layton, M Todd, D Varanasi, A O'Brien, B Meyer, WA Zhang, M Schleicher, RL Moye, J AF Mechanic, Leah Mendez, Armando Merrill, Lori Rogers, John Layton, Marnie Todd, Deborah Varanasi, Arti O'Brien, Barbara Meyer, William A., III Zhang, Ming Schleicher, Rosemary L. Moye, Jack, Jr. TI Planned variation in preanalytical conditions to evaluate biospecimen stability in the National Children's Study (NCS) SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE LA English DT Article DE adrenocorticotropic hormone (ACTH); biospecimen stability; carbohydrate-deficient transferrin (CDT); estradiol; free T-4; IGF-1; IL-6; insulin; preanalytical variation; vitamin C ID INSULIN-RESISTANCE; SAMPLE COLLECTION; ASCORBIC-ACID; WHOLE-BLOOD; PLASMA; SERUM; STORAGE; GLUCOSE; ANTICOAGULANTS; INTERLEUKIN-6 AB Background: Preanalytical conditions encountered during collection, processing, and storage of biospecimens may influence laboratory results. The National Children's Study (NCS) is a planned prospective cohort study of 100,000 families to examine the influence of a wide variety of exposures on child health. In developing biospecimen collection, processing, and storage procedures for the NCS, we identified several analytes of different biochemical categories for which it was unclear to what extent deviations from NCS procedures could influence measurement results. Methods: A pilot study was performed to examine effects of preanalytic sample handling conditions (delays in centrifugation, freezing delays, delays in separation from cells, additive delay, and tube type) on concentrations of eight different analytes. A total of 2825 measurements were made to assess 15 unique combinations of analyte and handling conditions in blood collected from 151 women of childbearing age (>= 20 individuals per handling condition). Results: The majority of analytes were stable under the conditions evaluated. However, levels of plasma -interleukin-6 and serum insulin were decreased in response to sample centrifugation delays of up to 5.5 h post-collection (p<0.0001). In addition, delays in freezing centrifuged plasma samples (comparing 24, 48 and 72 h to immediate freezing) resulted in increased levels of adrenocorticotropic hormone (p=0.0014). Conclusions: Determining stability of proposed analytes in response to preanalytical conditions and handling helps to ensure high-quality specimens for study now and in the future. The results inform development of procedures, plans for measurement of analytes, and interpretation of laboratory results. C1 [Moye, Jack, Jr.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Childrens Study, NIH, Bethesda, MD 20892 USA. [Mechanic, Leah] NCI, Host Susceptibil Factors Branch, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci,NIH, Bethesda, MD 20892 USA. [Mendez, Armando] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA. [Merrill, Lori; Rogers, John; Layton, Marnie; Todd, Deborah; O'Brien, Barbara] Westat Corp, Rockville, MD USA. [Varanasi, Arti] Adv Synergy LLC, Baltimore, MD USA. [Meyer, William A., III] Quest Diagnost, Baltimore, MD USA. [Zhang, Ming; Schleicher, Rosemary L.] Ctr Dis Control & Prevent CDC, Nutr Biomarkers Branch, Atlanta, GA USA. RP Moye, J (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Childrens Study, NIH, 6100 Execut Blvd,Room 5C01D,MSC 7510, Bethesda, MD 20892 USA. EM moyej@mail.nih.gov OI moye, john/0000-0001-9976-8586 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of the Director of the National Institutes of Health; NICHD [HHSN275200503395C, HHSN275201000107U, HHSN275200900010C, HHSN275201000121U] FX Research funding: This analysis was conducted as part of the National Children's Study, supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and funded, through its appropriation, by the Office of the Director of the National Institutes of Health. Supported by NICHD Contracts HHSN275200503395C, HHSN275201000107U, HHSN275200900010C, and HHSN275201000121U. The manuscript was developed by a Writing Team identified by the National Children's Study Publications Committee for the purpose of timely sharing of NCS data. NR 35 TC 4 Z9 4 U1 1 U2 9 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 1434-6621 EI 1437-4331 J9 CLIN CHEM LAB MED JI Clin. Chem. Lab. Med. PD DEC PY 2013 VL 51 IS 12 BP 2287 EP 2294 DI 10.1515/cclm-2013-0454 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 262MH UT WOS:000327739000024 PM 23924524 ER PT J AU Rubin, C Myers, T Stokes, W Dunham, B Harris, S Lautner, B Annelli, J AF Rubin, Carol Myers, Tanya Stokes, William Dunham, Bernadette Harris, Stic Lautner, Beth Annelli, Joseph TI Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Human health is inextricably linked to the health of animals and the viability of ecosystems; this is a concept commonly known as One Health. Over the last 2 decades, the Institute of Medicine (IOM) and the National Research Council (NRC) have published consensus reports and workshop summaries addressing a variety of threats to animal, human, and ecosystem health. We reviewed a selection of these publications and identified recommendations from NRC and IOM/NRC consensus reports and from opinions expressed in workshop summaries that are relevant to implementation of the One Health paradigm shift. We grouped these recommendations and opinions into thematic categories to determine if sufficient attention has been given to various aspects of One Health. We conclude that although One Health themes have been included throughout numerous IOM and NRC publications, identified gaps remain that may warrant targeted studies related to the One Health approach. C1 [Rubin, Carol; Myers, Tanya] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Stokes, William] NIEHS, Res Triangle Pk, NC 27709 USA. [Dunham, Bernadette] US FDA, Rockville, MD 20857 USA. [Harris, Stic] Dept Homeland Secur, Washington, DC USA. [Lautner, Beth] USDA, Des Moines, IA USA. [Annelli, Joseph] USDA, Riverdale, MD USA. RP Rubin, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A30, Atlanta, GA 30333 USA. EM crubin@cdc.gov NR 29 TC 6 Z9 6 U1 1 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 1913 EP 1917 DI 10.3201/eid1912.121659 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600001 PM 24274461 ER PT J AU Knust, B Rollin, PE AF Knust, Barbara Rollin, Pierre E. TI Twenty-Year Summary of Surveillance for Human Hantavirus Infections, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SIN-NOMBRE VIRUS; PULMONARY SYNDROME; CARDIOPULMONARY SYNDROME; PEROMYSCUS-MANICULATUS; GENETIC IDENTIFICATION; HEMORRHAGIC-FEVER; DISEASE; EPIDEMIOLOGY; DIAGNOSIS; OUTBREAK AB In the past 20 years of surveillance for hantavirus in humans in the United States, 624 cases of hantavirus pulmonary syndrome (HPS) have been reported, 96% of which occurred in states west of the Mississippi River. Most hantavirus infections are caused by Sin Nombre virus, but cases of HPS caused by Bayou, Black Creek Canal, Monongahela, and New York viruses have been reported, and cases of domestically acquired hemorrhagic fever and renal syndrome caused by Seoul virus have also occurred. Rarely, hantavirus infections result in mild illness that does not progress to HPS. Continued testing and surveillance of clinical cases in humans will improve our understanding of the etiologic agents involved and the spectrum of diseases. C1 [Knust, Barbara; Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Knust, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM bknust@cdc.gov NR 38 TC 15 Z9 18 U1 3 U2 24 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 1934 EP 1937 DI 10.3201/eid1912.131217 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600004 PM 24274585 ER PT J AU Nguyen, HT Nguyen, T Mishin, VP Sleeman, K Balish, A Jones, J Creanga, A Marjuki, H Uyeki, TM Nguyen, DH Nguyen, DT Do, HT Klimov, AI Davis, CT Gubareva, LV AF Nguyen, Ha T. Tung Nguyen Mishin, Vasiliy P. Sleeman, Katrina Balish, Amanda Jones, Joyce Creanga, Adrian Marjuki, Henju Uyeki, Timothy M. Nguyen, Dang H. Nguyen, Diep T. Do, Hoa T. Klimov, Alexander I. Davis, Charles T. Gubareva, Larisa V. TI Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Isolated from Poultry, Vietnam, 2009-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H5N1; NEURAMINIDASE INHIBITORS; OSELTAMIVIR RESISTANCE; MULTIPLE SUBLINEAGES; REDUCED SENSITIVITY; IN-VITRO; EVOLUTION; ASIA AB We assessed drug susceptibilities of 125 avian influenza A(H5N1) viruses isolated from poultry in Vietnam during 2009-2011. Of 25 clade 1.1. viruses, all possessed a marker of resistance to M2 blockers amantadine and rimantadine; 24 were inhibited by neuraminidase inhibitors. One clade 1.1 virus contained the R430W neuraminidase gene and reduced inhibition by oseltamivir, zanamivir, and laninamivir 12-, 73-, and 29-fold, respectively. Three of 30 clade 2.3.4 viruses contained a I223T mutation and showed 7-fold reduced inhibition by oseltamivir. One of 70 clade 2.3.2.1 viruses had the H275Y marker of oseltamivir resistance and exhibited highly reduced inhibition by oseltamivir and peramivir; antiviral agents DAS181 and favipiravir inhibited H275Y mutant virus replication in MDCK-SIAT1 cells. Replicative fitness of the H275Y mutant virus was comparable to that of wildtype virus'. These findings highlight the role of drug susceptibility monitoring of H5N1 subtype viruses circulating among birds to inform antiviral stockpiling decisions for pandemic preparedness. C1 [Nguyen, Ha T.; Mishin, Vasiliy P.; Sleeman, Katrina; Balish, Amanda; Jones, Joyce; Marjuki, Henju; Uyeki, Timothy M.; Klimov, Alexander I.; Davis, Charles T.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Nguyen, Ha T.; Creanga, Adrian] Battelle Mem Inst, Atlanta, GA USA. [Tung Nguyen; Nguyen, Dang H.; Nguyen, Diep T.] Natl Ctr Vet Diagnost, Hanoi, Vietnam. [Jones, Joyce] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop G16, Atlanta, GA 30333 USA. EM LGubareva@cdc.gov NR 37 TC 8 Z9 8 U1 0 U2 19 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 1963 EP 1971 DI 10.3201/eid1912.130705 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600008 PM 24274711 ER PT J AU Visvesvara, GS Arrowood, MJ Qvarnstrom, Y Sriram, R Bandea, R Wilkins, PR Farnon, E Weitzman, G AF Visvesvara, Govinda S. Arrowood, Michael J. Qvarnstrom, Yvonne Sriram, Rama Bandea, Rebecca Wilkins, Patricia R. Farnon, Eileen Weitzman, Gill TI Concurrent Parasitic Infections in a Renal Transplant Patient SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID CYCLOSPORA-CAYETANENSIS; PCR C1 [Visvesvara, Govinda S.; Arrowood, Michael J.; Qvarnstrom, Yvonne; Sriram, Rama; Bandea, Rebecca; Wilkins, Patricia R.; Farnon, Eileen] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Weitzman, Gill] NewYork Presbyterian Weill Cornell Med Ctr, New York, NY USA. RP Arrowood, MJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,Mailstop F36, Atlanta, GA 30341 USA. EM mja0@cdc.gov NR 5 TC 2 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 2044 EP 2045 DI 10.3201/eid1912.120926 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600029 PM 24274742 ER PT J AU Knauf, S Liu, H Harper, KN AF Knauf, Sascha Liu, Hsi Harper, Kristin N. TI Treponemal Infection in Nonhuman Primates as Possible Reservoir for Human Yaws SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Knauf, Sascha] German Primate Ctr, D-37077 Gottingen, Germany. [Liu, Hsi] Ctr Dis Control & Prevent, Atlanta, GA USA. [Harper, Kristin N.] Columbia Univ, Med Ctr, New York, NY USA. RP Knauf, S (reprint author), German Primate Ctr, Pathol Unit, Kellnerweg 4, D-37077 Gottingen, Germany. EM sknauf@dpz.eu RI Knauf, Sascha/F-1661-2017 OI Knauf, Sascha/0000-0001-5744-4946 NR 10 TC 13 Z9 13 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 2058 EP 2060 DI 10.3201/eid1912.130863 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600037 PM 24274094 ER PT J AU Potter, P AF Potter, Polyxeni TI Savage Nature and Ecologic Exchange SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Potter, Polyxeni] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD DEC PY 2013 VL 19 IS 12 BP 2068 EP 2069 DI 10.3201/eid1912.AC1912 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 263RV UT WOS:000327826600041 ER PT J AU Paxton, LA AF Paxton, Lynn A. TI Tenofovir-based HIV pre-exposure prophylaxis SO FUTURE VIROLOGY LA English DT Review DE emtricitabine; HIV; HIV prevention; PrEP; tenofovir ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL DRUG EXPOSURE; TRANSCRIPTASE MUTATION K65R; FEMALE GENITAL-TRACT; HUMANIZED BLT MICE; REVERSE-TRANSCRIPTASE; DISOPROXIL FUMARATE; ORAL PREEXPOSURE; RHESUS MACAQUES; PRECLINICAL INTERVENTIONS AB HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF) or TDF-emtricitabine (FTC) has been shown to be effective against sexual and injection-drug related HIV acquisition in four out of six large clinical trials. This article reviews the pharmacology of TDF and FTC as it relates both to PrEP efficacy and the emergence of viral resistance, summarizes the six trials and the inherent challenges to PrEP they highlighted, and proposes some future areas for further exploration. C1 [Paxton, Lynn A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Paxton, Lynn A.] USAID, Dar Es Salaam, Tanzania. RP Paxton, LA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM paxtonl@tz.cdc.gov NR 87 TC 0 Z9 0 U1 3 U2 6 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0794 EI 1746-0808 J9 FUTURE VIROL JI Future Virol. PD DEC PY 2013 VL 8 IS 12 BP 1207 EP 1218 DI 10.2217/fvl.13.111 PG 12 WC Virology SC Virology GA 258PE UT WOS:000327470400011 ER PT J AU Roberts, SS Jones, JK Miller, RK Kwo, PY Greene, MF Thorpe, PG Maddrey, WC AF Roberts, Susan Sinclair Jones, Judith K. Miller, Richard K. Kwo, Paul Y. Greene, Micheal F. Thorpe, Phoebe G. Maddrey, Willis C. TI An Update from the Ribavirin Pregnancy Registry after Nine Years of Enrollment SO HEPATOLOGY LA English DT Meeting Abstract C1 [Roberts, Susan Sinclair] Univ N Carolina, Clin Res Program, Wilmington, NC 28401 USA. [Roberts, Susan Sinclair] INC Res, Post Approval & Strateg Serv, Wilmington, NC USA. [Jones, Judith K.] Degge Grp, Alexandria, VA USA. [Miller, Richard K.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Kwo, Paul Y.] Indiana Univ, Sch Med, Indianapolis, IN USA. [Greene, Micheal F.] Harvard Univ, Sch Med, Boston, MA USA. [Thorpe, Phoebe G.] Ctr Dis Control & Prevent, Div Birth Defect & Dev Disabil, Atlanta, GA USA. [Maddrey, Willis C.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 1 Z9 1 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD DEC PY 2013 VL 58 IS 6 MA LB30 BP 1394A EP 1395A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 257LH UT WOS:000327385000031 ER PT J AU Nickeleit, V Singh, HK Goldsmith, CS Miller, SE Kenan, DJ AF Nickeleit, Volker Singh, Harsharan K. Goldsmith, Cynthia S. Miller, Sara E. Kenan, Daniel J. TI BK virus-associated urinary bladder carcinoma in transplant recipients: productive or nonproductive polyomavirus infections in tumor cells? SO HUMAN PATHOLOGY LA English DT Letter ID ELECTRON-MICROSCOPY C1 [Nickeleit, Volker; Singh, Harsharan K.] Univ N Carolina, Div Nephropathol Chapel Hill, Chapel Hill, NC 27599 USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. [Miller, Sara E.] Duke Univ, Dept Pathol, Durham, NC 27710 USA. [Kenan, Daniel J.] Univ N Carolina, Div Nephropathol, Chapel Hill, NC 27599 USA. RP Nickeleit, V (reprint author), Univ N Carolina, Div Nephropathol Chapel Hill, Chapel Hill, NC 27599 USA. EM volker_nickeleit@med.unc.edu FU Intramural CDC HHS [CC999999] NR 6 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 EI 1532-8392 J9 HUM PATHOL JI Hum. Pathol. PD DEC PY 2013 VL 44 IS 12 BP 2870 EP 2871 DI 10.1016/j.humpath.2013.08.017 PG 2 WC Pathology SC Pathology GA 262QJ UT WOS:000327752400038 PM 24262020 ER PT J AU Turk, MW Elci, OU Wang, J Sereika, SM Ewing, LJ Acharya, SD Glanz, K Burke, LE AF Turk, Melanie Warziski Elci, Okan U. Wang, Jing Sereika, Susan M. Ewing, Linda J. Acharya, Sushama D. Glanz, Karen Burke, Lora E. TI Self-Monitoring as a Mediator of Weight Loss in the SMART Randomized Clinical Trial SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Self-monitoring; Mediation; Adherence; Feedback; Weight loss; Obesity ID LIFE-STYLE MODIFICATION; MOBILE PHONE; BEHAVIORAL TREATMENT; PHYSICAL-ACTIVITY; LOSS MAINTENANCE; LOSS PROGRAM; INTERNET; OBESITY; TECHNOLOGY; DELIVER AB Integral components of behavioral weight-loss treatment include self-monitoring of diet and physical activity along with feedback to participants regarding their behaviors. While providing feedback has been associated with weight loss, no studies have examined the impact of feedback frequency on weight loss or the mediating role of self-monitoring adherence in this relationship. This study examined the effect of participant feedback frequency on weight loss and determined if this effect was mediated by adherence to self-monitoring in a behavioral weight-loss trial conducted in the USA. Participants (N = 210) were randomly assigned to one of three self-monitoring methods with either no-daily feedback messages or daily feedback messages: (1) paper diary (PD), no-daily feedback; (2) personal digital assistant (PDA), no-daily feedback; and (3) PDA, daily tailored feedback messages (PDA + FB). The Sobel test via bootstrapping examined the direct effect of feedback frequency on weight loss and the indirect effect through self-monitoring adherence. Receiving daily feedback messages significantly increased participants' self-monitoring adherence. A significant effect of feedback frequency on weight loss was noted; however, after adjusting for self-monitoring adherence, the effect of feedback frequency on weight loss was no longer significant. Feedback frequency had a significant indirect effect on weight loss through self-monitoring adherence. Self-monitoring adherence mediated the effect of feedback frequency on weight loss. Increasing the frequency with which participants receive feedback could enhance self-monitoring adherence, a critical component of behavioral weight-loss treatment. C1 [Turk, Melanie Warziski] Duquesne Univ, Sch Nursing, Pittsburgh, PA 15282 USA. [Elci, Okan U.] Univ Mississippi, Ctr Biostat & Bioinformat, Med Ctr, Jackson, MS 39216 USA. [Wang, Jing] Univ Texas Hlth Sci Ctr Houston, Sch Nursing, Houston, TX 77030 USA. [Sereika, Susan M.; Burke, Lora E.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Sereika, Susan M.; Burke, Lora E.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Ewing, Linda J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Acharya, Sushama D.] Ctr Dis Control & Prevent, Community Guide Branch, Off Surveillance Epidemiol & Lab Serv, Epidemiol & Anal Program Off, Atlanta, GA 30329 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. RP Turk, MW (reprint author), Duquesne Univ, Sch Nursing, 524 Fisher Hall,600 Forbes Ave, Pittsburgh, PA 15282 USA. EM turkm@duq.edu RI Emchi, Karma/Q-1952-2016 FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [5MO1-RR00056, M01 RR000056, UL1 RR024153]; NIDDK NIH HHS [R01 DK071817, R01-DK71817]; NINR NIH HHS [K24 NR010742, P30 NR003924, P30-NR03924] NR 31 TC 8 Z9 8 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 EI 1532-7558 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD DEC PY 2013 VL 20 IS 4 BP 556 EP 561 DI 10.1007/s12529-012-9259-9 PG 6 WC Psychology, Clinical SC Psychology GA 258YP UT WOS:000327494900009 PM 22936524 ER PT J AU Fowler, KB Gupta, V Sullender, W Broor, S Widdowson, MA Lal, RB Krishnan, A AF Fowler, Karen B. Gupta, Vivek Sullender, Wayne Broor, Shobha Widdowson, Marc-Alain Lal, Renu B. Krishnan, Anand TI Incidence of symptomatic A(H1N1)pdm09 influenza during the pandemic and post-pandemic periods in a rural Indian community SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Incidence; Influenza A(H1N1)pdm09; Epidemiology; Cohort; Rural India ID INFECTION; CHILDREN; VIRUS AB Background: Data on influenza illness rates with population denominators are needed to quantify overall morbidity and to prioritize public health intervention strategies. Methods: The rates of influenza A(H1N1)pdm09 infection during pandemic phases were determined in a longitudinal community cohort study as part of an influenza vaccine study in a rural community of North India. Results: During the 711 731 person-weeks of surveillance, a total of 1410/7571 (19%) febrile acute respiratory illness cases were positive for influenza. Of these, 749 (53%) were influenza A(H1N1) pdm09, 643 (46%) influenza B, and 18 (1%) influenza A (H3N2). The overall incidence rate of influenza-associated febrile acute respiratory illness was 128/1000 person-years. The incidence rates of influenza A(H1N1) pdm09 were high during both the pandemic phase (179/1000 person-years; November 2009 to January 2010) and post-pandemic phase (156/1000 person-years; August to October 2010), with children <18 years of age being at the greatest risk of influenza infection in the community. Conclusions: These findings provide important information for planning clinical and public health intervention strategies to mitigate the impact of influenza epidemics. (C) 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. C1 [Fowler, Karen B.; Sullender, Wayne] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35233 USA. [Gupta, Vivek; Broor, Shobha; Krishnan, Anand] All India Inst Med Sci, Delhi, India. [Widdowson, Marc-Alain; Lal, Renu B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Fowler, KB (reprint author), Univ Alabama Birmingham, Dept Pediat, 1600 7th Ave So CHB 304, Birmingham, AL 35233 USA. EM kfowler@uab.edu RI Mashamba-Thompson, Tivani /B-6087-2014; OI Gupta, Vivek/0000-0002-6157-3705; Krishnan, Anand/0000-0002-9173-7811 FU Centers for Disease Control and Prevention, Atlanta, USA [U01 IP000177] FX The study was supported by cooperative agreements U01 IP000177 from the Centers for Disease Control and Prevention, Atlanta, USA. NR 15 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD DEC PY 2013 VL 17 IS 12 BP E1182 EP E1185 DI 10.1016/j.ijid.2013.08.005 PG 4 WC Infectious Diseases SC Infectious Diseases GA 259SO UT WOS:000327546800017 PM 24103331 ER PT J AU Wu, LA Kanitz, E Crumly, J D'Ancona, F Strikas, RA AF Wu, Lauren A. Kanitz, Elisabeth Crumly, Julie D'Ancona, Fortunato Strikas, Raymond A. TI Adult immunization policies in advanced economies: vaccination recommendations, financing, and vaccination coverage SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH LA English DT Article DE Adult immunization; Vaccination policy; Vaccination coverage; Vaccine financing; Developed country; Advanced economy ID PNEUMOCOCCAL POLYSACCHARIDE VACCINE; EUROPEAN-UNION; OLDER; INFLUENZA; PROGRAM; ENGLAND AB While many countries have robust child immunization programs and high child vaccination coverage, vaccination of adults has received less attention. The objective of this study was to describe the adult vaccination policies in developed countries. From 2010 to 2011, we conducted a survey of 33 advanced economies as defined by the International Monetary Fund. The survey asked about national recommendations for adults for 16 vaccines or vaccine components, funding mechanisms for recommended adult vaccines, and the availability of adult vaccination coverage estimates. Thirty-one of 33 (93.9 %) advanced economies responded to the survey. Twelve of 31 (38.7 %) reported having a comprehensive adult immunization schedule. The total number of vaccines or vaccine components recommended for adults ranged from one to 15 with a median of 10. Seasonal influenza (n = 30), tetanus (n = 28), pneumococcal polysaccharide (n = 27), and hepatitis B (n = 27) were the most frequently recommended vaccines or components. Approximately two-thirds of survey respondents do not have a comprehensive adult vaccine schedule, and most do not measure vaccination coverage. We found that a funding mechanism is available for most recommended adult vaccines. C1 [Wu, Lauren A.] US Dept HHS, Natl Vaccine Program Off, Washington, DC 20201 USA. [Kanitz, Elisabeth; D'Ancona, Fortunato] Ctr Nazl Epidemiol Sorveglianza & Promoz, Reparto Malattie Infett, Ist Super Sanita, Rome, Italy. [Crumly, Julie] Oak Ridge Inst Sci & Educ, Hlth Commun & Mkt Grp, Hlth Commun & Tech Training Program, Oak Ridge, TN USA. [Strikas, Raymond A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA. RP Wu, LA (reprint author), US Dept HHS, Natl Vaccine Program Off, Washington, DC 20201 USA. EM lauren.wu@hhs.gov RI D'Ancona, Fortunato/B-2139-2013 OI D'Ancona, Fortunato/0000-0002-9855-2924 FU U.S. Department of Energy and Oak Ridge Associated Universities [DE-AC05-06OR23100] FX The authors would like to thank the VENICE gatekeepers, contact persons, and survey respondents for their assistance with this research. This research was partially performed under an appointment to the U.S. Department of Health and Human Services, administered by the Oak Ridge Institute for Science and Education under contract number DE-AC05-06OR23100 between the U.S. Department of Energy and Oak Ridge Associated Universities. NR 46 TC 7 Z9 8 U1 0 U2 1 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1661-8556 EI 1661-8564 J9 INT J PUBLIC HEALTH JI Int. J. Public Health PD DEC PY 2013 VL 58 IS 6 BP 865 EP 874 DI 10.1007/s00038-012-0438-x PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 264DU UT WOS:000327858000009 PM 23354183 ER PT J AU Shepardson, D Marks, SM Chesson, H Kerrigan, A Holland, DP Scott, N Tian, X Borisov, AS Shang, N Heilig, CM Sterling, TR Villarino, ME Mac Kenzie, WR AF Shepardson, D. Marks, S. M. Chesson, H. Kerrigan, A. Holland, D. P. Scott, N. Tian, X. Borisov, A. S. Shang, N. Heilig, C. M. Sterling, T. R. Villarino, M. E. Mac Kenzie, W. R. TI Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE rifapentine; cost-effectiveness; LTBI; model; computer simulation ID TRANSMISSION; RIFAPENTINE; THERAPY AB SETTING: A large randomized controlled trial recently showed that for treating latent tuberculous infection (LTBI) in persons at high risk of progression to tuberculosis (TB) disease, a 12-dose regimen of weekly rifapentine plus isoniazid (3HP) administered as directly observed treatment (DOT) can be as effective as 9 months of daily self-administered isoniazid (9H). OBJECTIVES: To assess the cost-effectiveness of 3HP compared to 9H. DESIGN: A computational model was designed to simulate individuals with LTBI treated with 9H or 3HP. Costs and health outcomes were estimated to determine the incremental costs per active TB case prevented and per quality-adjusted life year (QALY) gained by 3HP compared to 9H. RESULTS: Over a 20-year period, treatment of LTBI with 3HP rather than 9H resulted in 5.2 fewer cases of TB and 25 fewer lost QALYs per 1000 individuals treated. From the health system and societal perspectives, 3HP would cost respectively US$21525 and $4294 more per TB case prevented, and respectively $4565 and $911 more per QALY gained. CONCLUSIONS: 3HP may be a cost-effective alternative to 9H, particularly if the cost of rifapentine decreases, the effectiveness of 3HP can be maintained without DOT, and 3HP treatment is limited to those with a high risk of progression to TB disease. C1 [Shepardson, D.; Marks, S. M.; Scott, N.; Borisov, A. S.; Shang, N.; Heilig, C. M.; Villarino, M. E.; Mac Kenzie, W. R.] Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA USA. [Shepardson, D.] Off Surveillance Epidemiol & Lab Sci, CDC, Atlanta, GA USA. [Shepardson, D.; Tian, X.] Mt Holyoke Coll, Dept Math & Stat, S Hadley, MA 01075 USA. [Chesson, H.] Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, CDC, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Kerrigan, A.; Sterling, T. R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Holland, D. P.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Shepardson, D (reprint author), Mt Holyoke Coll, Dept Math & Stat, 50 Coll St, S Hadley, MA 01075 USA. EM dshepard@mtholyoke.edu RI Heilig, Charles/C-2753-2008 OI Heilig, Charles/0000-0003-1075-1310 FU DTBE; National Center for HIV/AIDS; Viral Hepatitis; STD; TB Prevention; CDC, Atlanta, GA, USA FX Funding for this study was provided by the DTBE, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, GA, USA. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 24 Z9 24 U1 2 U2 7 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD DEC PY 2013 VL 17 IS 12 BP 1531 EP 1537 DI 10.5588/ijtld.13.0423 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 261OH UT WOS:000327674000006 PM 24200264 ER PT J AU Zhao, GX Li, CY Okoro, CA Li, J Wen, XJ White, A Balluz, LS AF Zhao, Guixiang Li, Chaoyang Okoro, Catherine A. Li, Jun Wen, Xiao Jun White, Arica Balluz, Lina S. TI Trends in modifiable lifestyle-related risk factors following diagnosis in breast cancer survivors SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Breast cancer; Cancer duration; Health-related behaviors; Lifestyles; BRFSS ID FACTOR SURVEILLANCE SYSTEM; ALL-CAUSE MORTALITY; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; HEALTH BEHAVIORS; PROSPECTIVE COHORT; NATIONAL-HEALTH; COMBINED IMPACT; WOMEN; NUTRITION AB Evidence suggests that high-risk lifestyle behaviors exacerbate the health of cancer survivors and increase cancer mortality. This study examined the prevalence of lifestyle-related risk factors among female breast cancer survivors by duration of survivorship in the United States. We analyzed data from 7,443 women aged a parts per thousand yen18 years who participated in the 2009 Behavioral Risk Factor Surveillance System and reported having ever-diagnosed breast cancer. Adjusted prevalence with 95 % confidence interval for lifestyle-related risk factors (including current smoking, excessive alcohol drinking, obesity, engaging in physical activity a parts per thousand yen150 min/week, and consuming fruits and vegetables a parts per thousand yen5 times/day) was estimated using log-linear regression while controlling for confounders. Overall, the prevalence estimates for lifestyle-related risk factors were 10.2 % for current smoking, 6.8 % for excessive alcohol drinking, 24.7 % for obesity, 53.8 % for engaging in physical activity a parts per thousand yen150 min/week, and 33.9 % for consuming fruits and vegetables a parts per thousand yen5 times/day among female breast cancer survivors. After adjustment for covariates, with increasing years of survivorship, a linearly increasing trend was observed for current smoking (P = 0.038), and quadratic trends were observed for excessive alcohol drinking (P < 0.001) and obesity (P = 0.048). The adjusted prevalence estimates for engaging in physical activity a parts per thousand yen150 min/week and consuming fruits and vegetables a parts per thousand yen5 times/day did not vary significantly by duration of survivorship. Continuing efforts on counseling and encouraging breast cancer survivors to adopt healthy lifestyles are needed to improve their health. Understanding the trends of modifiable lifestyle-related risk factors among breast cancer survivors with varying duration of survivorship may assist health care providers to provide appropriate counseling for breast cancer patients to improve their health. Clinical and public health intervention programs should seek to maximize the number of recommended healthy behaviors especially in those women who are at high risk for failing to comply with the healthy lifestyle guidelines. C1 [Zhao, Guixiang; Li, Chaoyang; Okoro, Catherine A.; Wen, Xiao Jun; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30345 USA. [Li, Jun; White, Arica] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Zhao, GX (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, 2500 Century Pkwy,Mailstop E-97, Atlanta, GA 30345 USA. EM fwj4@cdc.gov NR 40 TC 7 Z9 7 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 EI 1932-2267 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD DEC PY 2013 VL 7 IS 4 BP 563 EP 569 DI 10.1007/s11764-013-0295-5 PG 7 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 259CK UT WOS:000327504800006 PM 23793468 ER PT J AU Ramsey, SD Zeliadt, SB Blough, DK Moinpour, CM Hall, IJ Smith, JL Ekwueme, DU Fedorenko, CR Fairweather, ME Koepl, LM Thompson, IM Keane, TE Penson, DF AF Ramsey, Scott D. Zeliadt, Steven B. Blough, David K. Moinpour, Carol M. Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Fedorenko, Catherine R. Fairweather, Megan E. Koepl, Lisel M. Thompson, Ian M. Keane, Thomas E. Penson, David F. TI Impact of Prostate Cancer on Sexual Relationships: A Longitudinal Perspective on Intimate Partners' Experiences SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Prostate Cancer; Partner; Sexual Function ID QUALITY-OF-LIFE; DECISION-MAKING; OUTCOMES; COUPLES; MEN; INTERVENTION; VALIDATION; ADJUSTMENT; CARCINOMA AB IntroductionIn this prospective study of localized prostate cancer patients and their partners, we analyzed how partner issues evolve over time, focusing on satisfaction with care, influence of cancer treatment, and its impact on relationship with patient, cancer worry, and personal activities. AimsOur study aims were twofold: (i) to determine whether the impact of treatment on patients and partners moderate over time and (ii) if receiving surgery (i.e., radical prostatectomy) influences partner issues more than other treatments. MethodsPatients newly diagnosed with localized prostate cancer and their female partners were recruited from three states to complete surveys by mail at three time points over 12 months. Main Outcome MeasuresThe four primary outcomes assessed in the partner analysis included satisfaction with treatment, cancer worry, and the influence of cancer and its treatment on their relationship (both general relationship and sexual relationship). ResultsThis analysis included 88 patient-partner pairs. At 6 months, partners reported that cancer had a negative impact on their sexual relationship (39%somewhat negative and 12%very negative). At 12 months, this proportion increased substantially (42%somewhat negative and 29%very negative). Partners were significantly more likely to report that their sexual relationship was worse when the patient reported having surgery (P=0.0045, odds ratio=9.8025, 95% confidence interval 2.076-46.296). A minority of partners reported significant negative impacts in other areas involving their personal activities (16% at 6 months and 25% at 12 months) or work life (6% at 6 months, which increased to 12% at 12 months). ConclusionFrom partners' perspectives, prostate cancer therapy has negative impact on sexual relationships and appears to worsen over time. Ramsey SD, Zeliadt SB, Blough DK, Moinpour CM, Hall IJ, Smith JL, Ekwueme DU, Fedorenko CR, Fairweather ME, Koepl LM, Thompson IM, Keane TE, and Penson DF. Impact of prostate cancer on sexual relationships: A longitudinal perspective on intimate partners' experiences. J Sex Med 2013;10:3135-3143. C1 [Ramsey, Scott D.; Moinpour, Carol M.; Fedorenko, Catherine R.; Fairweather, Megan E.; Koepl, Lisel M.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Zeliadt, Steven B.; Blough, David K.] Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs Med Ctr, Seattle, WA USA. [Blough, David K.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Keane, Thomas E.] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA. [Penson, David F.] Univ So Calif, Dept Urol, Norris Canc Ctr, Los Angeles, CA 90033 USA. [Penson, David F.] Univ So Calif, Dept Prevent Med, Norris Canc Ctr, Los Angeles, CA 90089 USA. [Penson, David F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. RP Koepl, LM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,MS M3-B232, Seattle, WA 98109 USA. EM lkoepl@fhcrc.org FU Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Center [U48-DP-000050]; UTHSCSA; National Cancer Institute Cancer Center [CA054174]; Cancer Surveillance System of the Fred Hutchinson Cancer Research Center from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute [N01-PC-35142]; Fred Hutchinson Cancer Research Center; State of Washington FX This publication was supported by Cooperative Agreement Number 1-U48-DP-000050 from the Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.; Additional support for the UTHSCSA program was provided by funding from the National Cancer Institute Cancer Center Support Grant (CA054174).; Case ascertainment for the developmental focus group research was supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by Contract No. N01-PC-35142 from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington. NR 26 TC 11 Z9 11 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD DEC PY 2013 VL 10 IS 12 BP 3135 EP 3143 DI 10.1111/jsm.12295 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 260GS UT WOS:000327583600025 PM 24118980 ER PT J AU Klevens, RM Moorman, AC AF Klevens, R. Monina Moorman, Anne C. TI Hepatitis C virus An overview for dental health care providers SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Hepatitis C; Centers for Disease Control and Prevention; infections ID UNITED-STATES; INFECTION; TRANSMISSION; GUIDELINE; UPDATE; LIVER; HCV; ASSOCIATION; MANAGEMENT; PROSPECTS AB Background and Overview. Changes in the science of hepatitis C virus (HCV) infection and transmission in a private dental practice provide an opportunity to update dental health care providers about this pathogen. The authors' aims in this review were to create awareness of health care-associated transmission of hepatitis C and provide an update on the changes in testing and treatment. The authors include data from population-based epidemiologic surveys, clinical practice guidelines, surveillance reports and practice protocols. Results. In the United States, the elevated prevalence of chronic HCV infection among baby boomers-people born during the period from 1945 through 1965-led the Centers for Disease Control and Prevention to release new national screening guidelines. The authors summarize information about the natural history and epidemiology of hepatitis C and describe the new guidelines and novel treatment options. In addition, the authors provide an overview of how outbreaks of health care-associated HCV are detected and prevented. Practical Implications. Because dental health care professionals likely will treat people with current infection, education in the current science of HCV infection is useful. C1 [Klevens, R. Monina; Moorman, Anne C.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Klevens, RM (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Mailstop G-37,1600 Clifton Rd, Atlanta, GA 30333 USA. EM rmk2@cdc.gov NR 55 TC 3 Z9 3 U1 0 U2 5 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD DEC PY 2013 VL 144 IS 12 BP 1340 EP 1347 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 262JV UT WOS:000327731900007 PM 24282263 ER PT J AU Rudd, S Gemelas, J Reilley, B Leston, J Tulloch, S AF Rudd, Stephen Gemelas, Jim Reilley, Brigg Leston, Jessica Tulloch, Scott TI Integrating clinical decision support to increase HIV and chlamydia screening SO PREVENTIVE MEDICINE LA English DT Letter DE American Indian/Alaska Native; HIV; Chlamydia; STDs; Screening; Public health; Clinical; Decision support; Rural ID ELECTRONIC HEALTH RECORDS C1 [Rudd, Stephen; Gemelas, Jim] IHS, Portland, OR USA. [Reilley, Brigg] IHS, Albuquerque, NM USA. [Leston, Jessica] NPAIHB, Portland, OR USA. [Tulloch, Scott] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Reilley, B (reprint author), IHS, Albuquerque, NM USA. EM Brigg.Reilley@ihs.gov NR 12 TC 3 Z9 3 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD DEC PY 2013 VL 57 IS 6 BP 908 EP 909 DI 10.1016/j.ypmed.2013.09.017 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 260BR UT WOS:000327570500032 PM 24120454 ER PT J AU Ingber, SZ Buser, MC Pohl, HR Abadin, HG Murray, HE Scinicariello, F AF Ingber, Susan Z. Buser, Melanie C. Pohl, Hana R. Abadin, Henry G. Murray, H. Edward Scinicariello, Franco TI DDT/DDE and breast cancer: A meta-analysis SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE DDT; DDE; Breast cancer; Systematic review; Meta-analysis ID PLASMA ORGANOCHLORINE LEVELS; ADIPOSE-TISSUE CONCENTRATIONS; NESTED CASE-CONTROL; POLYCHLORINATED-BIPHENYLS; SERUM ORGANOCHLORINES; AFRICAN-AMERICAN; PESTICIDE LEVELS; BLOOD-LEVELS; LONG-ISLAND; NEW-YORK AB The biological basis for investigating dichlorodiphenyltrichloroethane (DDT) exposure and breast cancer risk stems from in vitro and animal studies indicating that DDT has estrogenic properties. The objective of this study was to update a meta-analysis from 2004 which found no association between dichlorodiphenyldichloroethylene (DDE) and breast cancer. We searched PubMed and Web of Science for studies published through June 2012 assessing DDT/DDE exposure and breast cancer. Summary Odds Ratios (ORs) with 95% confidence intervals (CIs) were calculated for the prevalence of breast cancer in the highest versus the lowest exposed groups for DDT and DDE. Difference of means of exposure for cases versus controls was analyzed for DDT and DDE. From the 500 studies screened, 46 were included in the meta-analysis. Slightly elevated, but not statistically significant summary ORs were found for DDE (1.05; 95% CI: 0.93-1.18) and DDT (1.02; 95% CI: 0.92-1.13). Lipid adjusted difference of means analysis found a significantly higher DDE concentration in cases versus controls (11.30 ng/g lipid; p = 0.01). No other difference of means analysis found significant relationships. The existing information does not support the hypothesis that exposure to DDT/DDE increases the risk of breast cancer in humans. Published by Elsevier Inc. C1 [Ingber, Susan Z.; Buser, Melanie C.; Pohl, Hana R.; Abadin, Henry G.; Murray, H. Edward; Scinicariello, Franco] ATSDR, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Scinicariello, F (reprint author), Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy,MS F57, Atlanta, GA 30341 USA. EM fes6@cdc.gov OI Ingber, Susan/0000-0002-5290-8884 FU Research Participation Program at the Centers for Disease Control and Prevention FX We would like to thank Dr. Christopher Portier for his methodological insight and guidance. We thank Kirsten Bandyopadhyay for critical comments and continuous encouragement. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC (SZI, MCB). NR 66 TC 9 Z9 9 U1 2 U2 28 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD DEC PY 2013 VL 67 IS 3 BP 421 EP 433 DI 10.1016/j.yrtph.2013.08.021 PG 13 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA 257VG UT WOS:000327415300013 PM 24021539 ER PT J AU Ehrlich, S Williams, PL Hauser, R Missmer, SA Peretz, J Calafat, AM Flaws, JA AF Ehrlich, Shelley Williams, Paige L. Hauser, Russ Missmer, Stacey A. Peretz, Jackye Calafat, Antonia M. Flaws, Jodi A. TI Urinary bisphenol A concentrations and cytochrome P450 19 A1 (Cyp19) gene expression in ovarian granulosa cells: An in vivo human study SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Bisphenol A; Follicular fluid; Ovary, granulosa cells; Cyp19; P450 aromatase; Gene expression; Fertility; Human ID STEROID-HORMONE PRODUCTION; FOLLICLE GROWTH; EXPOSURE; WOMEN; ESTRADIOL; DIMETHACRYLATE; STIMULATION; INFERTILITY; AROMATASE; PATHWAY AB Background: Exposure to bisphenol A (BPA), a chemical widely used in consumer products, has been associated with in vitro Cyp19 gene expression. Objective: To evaluate an in vivo human model of Cyp19 gene expression in granulosa cells. Study Design: A subset of an ongoing prospective cohort study of women undergoing in vitro fertilization (IVF) at Massachusetts General Hospital. Methods: Mixed effect models were used to evaluate the association of urinary BPA concentrations with granulosa cell Cyp19 mRNA expression. Results: In 61 women undergoing 76 IVF cycles, adjusted changes in mean Cyp19 expression (beta estimate (95% CI)) for quartiles 2, 3 and 4 as compared to the lowest quartile were: -0.97 (-2.22, 0.28); -0.97 (-2.18, 0.24) and -0.38 (-1.58, 0.82). Conclusions: An in vivo model for evaluation of Cyp19 gene expression was developed for use in epidemilogic studies. In this pilot study, we found no statistically significant linear association between urinary BPA concentrations and Cyp19 expression. (C) 2013 Elsevier Inc. All rights reserved. C1 [Ehrlich, Shelley; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Hauser, Russ; Missmer, Stacey A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA. [Missmer, Stacey A.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Missmer, Stacey A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Peretz, Jackye; Flaws, Jodi A.] Univ Illinois, Urbana, IL USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hauser, R (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave,Bldg 1,14th Floor, Boston, MA 02115 USA. EM rhauser@hsph.harvard.edu RI Ehrlich , Shelley/L-6991-2015 FU National Institute of Environmental Health Sciences [ES009718, ES000002, ES019178]; National Institute for Occupational Safety and Health [OH008578] FX This work was supported by grant ES009718, ES000002, ES019178 from the National Institute of Environmental Health Sciences and grant OH008578 from the National Institute for Occupational Safety and Health. NR 37 TC 13 Z9 13 U1 0 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD DEC PY 2013 VL 42 BP 18 EP 23 DI 10.1016/j.reprotox.2013.06.071 PG 6 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA 260BD UT WOS:000327569100002 PM 23850856 ER PT J AU Souter, I Smith, KW Dimitriadis, I Ehrlich, S Williams, PL Calafat, AM Hauser, R AF Souter, Irene Smith, Kristen W. Dimitriadis, Irene Ehrlich, Shelley Williams, Paige L. Calafat, Antonia M. Hauser, Russ TI The association of bisphenol-A urinary concentrations with antral follicle counts and other measures of ovarian reserve in women undergoing infertility treatments SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Bisphenol-A; Antral follicle count; Day-3 follicle stimulating hormone; Ovarian volume; Ovarian reserve ID STEROID-HORMONE PRODUCTION; IN-VITRO; GRANULOSA-CELLS; ENDOCRINE DISRUPTORS; NEONATAL EXPOSURE; CIGARETTE-SMOKING; MAMMARY-GLAND; ER-ALPHA; ESTROGEN; MOUSE AB In this prospective cohort of women undergoing infertility treatments, we measured specific-gravity adjusted urinary BPA (SG-BPA) concentrations and used regression models to evaluate the association of BPA with antral follicle count (AFC), day-3 serum follicle stimulating hormone levels (FSH), and ovarian volume (OV). BPA, detected in >80% of women, had a geometric mean (+/- GSD) of 1.6 +/- 2.0, 1.7 +/- 2.1, and 1.5 +/- 1.8 mu g/L for the women contributing to the AFC (n = 154), day-3 FSH (n = 120), and OV (n = 114) analyses, respectively. There was an average decrease in AFC of 12% (95% CI: -23%, -0.6%), -22% (95% CI: -31%, -11%), and 17% (95% CI: -27%, -6%), in the 2nd, 3rd, and 4th SG-BPA quartile compared to the 1st quartile, respectively (p-trend: <0.001). No association of SG-BPA with FSH or OV was observed. Among women from an infertility clinic, higher urinary BPA concentrations were associated with lower AFC, raising concern for possible accelerated follicle loss and reproductive aging. (C) 2013 Elsevier Inc. All rights reserved. C1 [Souter, Irene; Dimitriadis, Irene; Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol,Fertil Ctr,Sch Med, Boston, MA 02114 USA. [Smith, Kristen W.; Ehrlich, Shelley; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Souter, I (reprint author), Massachusetts Gen Hosp, Fertil Ctr, Yawkey 10-A,55 Fruit St, Boston, MA 02114 USA. EM isouter@partners.org; ksmith@hsph.harvard.edu; idimitriadis@tuftsmedicalcenter.org; sehrlich@hsph.harvard.edu; paige@sdac.harvard.edu; aic7@cdc.gov; rhauser@hsph.harvard.edu RI Ehrlich , Shelley/L-6991-2015 FU National Institute for Environmental Health Sciences (NIEHS) [ES009718, ES000002, T32ES007069]; National Institute for Occupational Safety and Health (NIOSH) [OH008578] FX Supported by grants: ES009718, ES000002, and T32ES007069 from the National Institute for Environmental Health Sciences (NIEHS) and OH008578 from the National Institute for Occupational Safety and Health (NIOSH). NR 66 TC 15 Z9 15 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD DEC PY 2013 VL 42 BP 224 EP 231 DI 10.1016/j.reprotox.2013.09.008 PG 8 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA 260BD UT WOS:000327569100024 PM 24100206 ER PT J AU Noe, RS Choudhary, E Cheng-Dobson, J Wolkin, AF Newman, SB AF Noe, Rebecca S. Choudhary, Ekta Cheng-Dobson, Jennifer Wolkin, Amy F. Newman, Sara B. TI Exertional Heat-Related Illnesses at the Grand Canyon National Park, 2004-2009 SO WILDERNESS & ENVIRONMENTAL MEDICINE LA English DT Article DE heat illness; hiking; National Park; Grand Canyon; wilderness; emergency medical services AB Background.-The Grand Canyon National Park has approximately 4 million visitors between April and September each year. During this period, outdoor activity such as hiking is potentially hazardous owing to extreme heat, limited shade, and steep, long ascents. Given the high visitation and the public health interest in the effects of extreme heat, this study calculated morbidity rates and described heatrelated illness (URI) among visitors. Methods.-We conducted a retrospective cross-sectional study from April 1 through September 30, during 2004-2009. From a review of Ranger Emergency Medical Services (EMS) incident report files, we extracted information on those that met the case definition of greater than 1 hour of outdoor heat exposure with an BR' assessment or diagnosis, HRI self-report, or signs or symptoms of HRI without another etiology noted. Visitor and temperature data were obtained from respective official sources. Results.-Grand Canyon EMS responded to 474 nonfatal and 6 fatal HRI cases, with the majority (84%) being US residents, 29% from Western states. Of the nonfatal cases, 51% were women, the median age was 43 years (range, 11-83 years), and 18% reported a cardiovascular condition. Clinical BRI assessments included dehydration (25%), heat exhaustion (23%), and suspected hyponatremia (19%). Almost all (90%) were hiking; 40% required helicopter evacuation. The highest HRI rates were seen in May. Conclusions.-HRI remains a public health concern at the Grand Canyon. High-risk evacuations and life-threatening conditions were found. Majority were hikers, middle-aged adults, and US residents. These findings support the park's hiker HRI prevention efforts and use of park EMS data to measure HRI. C1 [Noe, Rebecca S.; Choudhary, Ekta; Wolkin, Amy F.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Cheng-Dobson, Jennifer; Newman, Sara B.] Natl Pk Serv, Off Risk Management, Washington, DC 20240 USA. RP Noe, RS (reprint author), Ctr Dis Control & Prevent, US PHS, Natl Ctr Environm Hlth, 4770 Buford Hwy,NE, Chamblee, GA 30341 USA. EM rhn9@cdc.gov FU National Center for Environmental Health, Division of Environmental Hazards and Health Effects FX The authors thank the Grand Canyon EMS leadership: Rangers Ken Phillips, C.J. Malcolm, and Bonnie Taylor for all their assistance on this study. Funding support for this study was provided by the National Center for Environmental Health, Division of Environmental Hazards and Health Effects. NR 10 TC 10 Z9 10 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1080-6032 EI 1545-1534 J9 WILD ENVIRON MED JI Wildern. Environ. Med. PD WIN PY 2013 VL 24 IS 4 BP 422 EP 428 PG 7 WC Public, Environmental & Occupational Health; Sport Sciences SC Public, Environmental & Occupational Health; Sport Sciences GA 266HO UT WOS:000328014900019 PM 24119571 ER PT J AU Powell, KE Zimmerman, RK Ahern, DK Lewis, AL Ramirez, AG Atienza, A Ayala, GX Elder, JP Calonge, N Chin, M Clymer, J Fielding, J Glanz, K Goetzel, R Green, LW Grossman, D Johnson, RL Kumanyika, S Orleans, T Pronk, N Ramirez, G Remington, PL Rimer, B Hesse, BW Frumkin, H Jones, BH Canham-Chervak, M Kohatsu, ND Harris, JR Koo, D Michener, L Kottke, TE Dickey, LL Maibach, E Mays, GP Halverson, PK McGinnis, JM Barry, MA Owen, N Pronk, N Sallis, JF Stokols, D Hall, KL Felitti, VJ Anda, RF Butchart, A Sethi, D Pratt, M Gruner, L AF Powell, Kenneth E. Zimmerman, Richard K. Ahern, David K. Lewis, Allison L. Ramirez, Amelie G. Atienza, Audie Ayala, Guadalupe X. Elder, John P. Calonge, Ned Chin, Marshall Clymer, John Fielding, Jonathan Glanz, Karen Goetzel, Ron Green, Lawrence W. Grossman, David Johnson, Robert L. Kumanyika, Shiriki Orleans, Tracy Pronk, Nico Ramirez, Gilbert Remington, Patrick L. Rimer, Barbara Hesse, Bradford W. Frumkin, Howard Jones, Bruce H. Canham-Chervak, Michelle Kohatsu, Neal D. Harris, Jeffrey R. Koo, Denise Michener, Lloyd Kottke, Thomas E. Dickey, Larry L. Maibach, Edward Mays, Glen P. Halverson, Paul K. McGinnis, J. Michael Barry, Michael A. Owen, Neville Pronk, Nico Sallis, James F. Stokols, Daniel Hall, Kara L. Felitti, Vincent J. Anda, Robert F. Butchart, Alexander Sethi, Dinesh Pratt, Michael Gruner, Linda TI Notes from the Field: Planting, Nurturing, and Watching Things Grow SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID ADVERSE CHILDHOOD EXPERIENCES; HEALTH COMMUNICATION APPLICATIONS; UNDERGRADUATE PUBLIC-HEALTH; PHYSICAL-ACTIVITY INTERVENTIONS; COMMUNITY-PREVENTIVE-SERVICES; BUILT ENVIRONMENT; POPULATION HEALTH; HOUSEHOLD DYSFUNCTION; CLINICAL PREVENTION; NEIGHBORHOOD WALKABILITY C1 [Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med & Clin Epidemiol, Pittsburgh, PA 15260 USA. [Ahern, David K.] Brigham & Womens Hosp, Psychiat Hlth e Technol Initiat, Boston, MA 02115 USA. [Lewis, Allison L.] Assoc Prevent Teaching & Res, Washington, DC USA. [Ramirez, Amelie G.] Univ Texas Hlth Sci Ctr San Antonio, Inst Hlth Promot Res, San Antonio, TX USA. [Atienza, Audie] NIH, Hlth Promot Res Branch, Bethesda, MD 20892 USA. [Ayala, Guadalupe X.; Elder, John P.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Hesse, Bradford W.] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA. [Frumkin, Howard] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Jones, Bruce H.; Canham-Chervak, Michelle] US Army Inst Publ Hlth, Injury Prevent Program, Aberdeen Proving Ground, MD USA. [Harris, Jeffrey R.] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. [Koo, Denise] Ctr Dis Control & Prevent, Off Director, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA. [Michener, Lloyd] Duke Univ, Med Ctr, Dept Community & Family Med, Duke Ctr Community Res, Durham, NC 27706 USA. [Kottke, Thomas E.] HealthPartners, Populat Hlth, Minneapolis, MN USA. [Maibach, Edward] George Mason Univ, Ctr Climate Change Commun, Fairfax, VA 22030 USA. [Mays, Glen P.] Univ Kentucky, Lexington, KY 40506 USA. [Halverson, Paul K.] Indiana Univ Purdue Univ Indianapolis, Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [Barry, Michael A.] Amer Coll Prevent Med, Washington, DC USA. [Owen, Neville] Monash Univ, Baker IDI Heart & Diabet Inst, Clayton, Vic 3800, Australia. [Owen, Neville] Univ Melbourne, Melbourne, Vic 3010, Australia. [Owen, Neville] Univ Queensland, Brisbane, Qld 4072, Australia. [Pronk, Nico] Harvard Univ, Sch Publ Hlth, HealthPartners, Cambridge, MA 02138 USA. [Sallis, James F.] Univ Calif San Diego, San Diego, CA 92103 USA. [Stokols, Daniel] Univ Calif Irvine, Sch Sociol Ecol, Irvine, CA USA. [Hall, Kara L.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Anda, Robert F.] ACE Interface, Fayetteville, GA USA. [Butchart, Alexander] WHO, Dept Violence & Injury Prevent & Disabil, Geneva, Switzerland. [Pratt, Michael] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Powell, KE (reprint author), Care of Seidman C, UCSD, AJPM Editorial Off, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM nekllewop@hotmail.com; zimmer@pitt.edu; dahern@partners.org; ALL@aptrweb.org; ramirezag@uthscsa.edu; AtienzaA@mail.nih.gov; ayala@mail.sdsu.edu; lwgreen@comcast.net; hesseb@mail.nih.gov; frumkin@uw.edu; michelle.c.chervak.civ@mail.mil; Neal.Kohatsu@dhcs.ca.gov; dkoo@cdc.gov; tkottke@comcast.net; emaibach@gmu.edu; MMcGinnis@nas.edu; mbarry@acpm.org; neville.owen@bakeridi.edu.au; nico.p.pronk@healthpartners.com; jsallis@ucsd.edu; dstokols@uci.edu; VJFMDSDCA@mac.com; butcharta@who.int NR 123 TC 0 Z9 0 U1 3 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2013 VL 45 IS 6 BP 687 EP 702 DI 10.1016/j.amepre.2013.09.006 PG 16 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 258SG UT WOS:000327478400007 ER PT J AU Luo, HB Sotnikov, S Shah, G AF Luo, Huabin Sotnikov, Sergey Shah, Gulzar TI Local Health Department Activities to Ensure Access to Care SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PUBLIC-HEALTH; CORE FUNCTIONS; DEPARTMENTS; DISPARITIES; PRIVATIZATION; AVAILABILITY; DETERMINANTS; PERFORMANCE; RECESSION; COVERAGE AB Background: Local health departments (LHDs) can play an important role in linking people to personal health services and ensuring the provision of health care when it is otherwise unavailable. However, the extent to which LHDs are involved in ensuring access to health care in its jurisdictions is not well known. Purpose: To provide nationally representative estimates of LHD involvement in specific activities to ensure access to healthcare services and to assess their association with macro-environment/community and LHD capacity and process characteristics. Methods: Data used were from the 2010 National Profile of Local Health Departments Study, Area Resource Files, and the Association of State and Territorial Health Officials' 2010 Profile of State Public Health Agencies Survey. Data were analyzed in 2012. Results: Approximately 66.0% of LHDs conducted activities to ensure access to medical care, 45.9% to dental care, and 32.0% to behavioral health care. About 28% of LHDs had not conducted activities to ensure access to health care in their jurisdictions in 2010. LHDs with higher per capita expenditures and larger jurisdiction population sizes were more likely to provide access to care services (p < 0.05). Conclusions: There is substantial variation in LHD engagement in activities to ensure access to care. Differences in LHD capacity and the needs of the communities in which they are located may account for this variation. Further research is needed to determine whether this variation is associated with adverse population health outcomes. (C) 2013 American Journal of Preventive Medicine. All rights reserved. C1 [Luo, Huabin; Sotnikov, Sergey] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. [Shah, Gulzar] Georgia So Univ, Dept Hlth Policy & Management, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA. [Luo, Huabin] CDC, Atlanta, GA 30333 USA. RP Luo, HB (reprint author), E Carolina Univ, Brody Sch Med, Dept Publ Hlth, Greenville, NC 27834 USA. EM luoh@ecu.edu FU Intramural CDC HHS [CC999999] NR 36 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2013 VL 45 IS 6 BP 720 EP 727 DI 10.1016/j.amepre.2013.07.010 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 258SG UT WOS:000327478400010 PM 24237913 ER PT J AU Rossen, LM Khan, D Warner, M AF Rossen, Lauren M. Khan, Diba Warner, Margaret TI Trends and Geographic Patterns in Drug-Poisoning Death Rates in the US, 1999-2009 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID INFLATED COUNT DATA; DOUBLE-HURDLE MODEL; UNITED-STATES; OVERDOSE DEATHS; MIXTURE MODEL; CONSUMPTION; PREVALENCE; FATALITIES; MORTALITY; DEMAND AB Background: Drug poisoning mortality has increased substantially in the U. S. over the past 3 decades. Previous studies have described state-level variation and urban-rural differences in drug-poisoning deaths, but variation at the county level has largely not been explored in part because crude county-level death rates are often highly unstable. Purpose: The goal of the study was to use small-area estimation techniques to produce stable county-level estimates of age-adjusted death rates (AADR) associated with drug poisoning for the U. S., 1999-2009, in order to examine geographic and temporal variation. Methods: Population-based observational study using data on 304,087 drug-poisoning deaths in the U. S. from the 1999-2009 National Vital Statistics Multiple Cause of Death Files (analyzed in 2012). Because of the zero-inflated and right-skewed distribution of drug-poisoning death rates, a two-stage modeling procedure was used in which the first stage modeled the probability of observing a death for a given county and year, and the second stage modeled the log-transformed drug-poisoning death rate given that a death occurred. Empirical Bayes estimates of county-level drug-poisoning death rates were mapped to explore temporal and geographic variation. Results: Only 3% of counties had drug-poisoning AADRs greater than ten per 100,000 per year in 1999-2000, compared to 54% in 2008-2009. Drug-poisoning AADRs grew by 394% in rural areas compared to 279% for large central metropolitan counties, but the highest drug-poisoning AADRs were observed in central metropolitan areas from 1999 to 2009. Conclusions: There was substantial geographic variation in drug-poisoning mortality across the U.S. (C) 2013 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Rossen, Lauren M.] CDC, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Khan, Diba] CDC, Off Res Methodol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Warner, Margaret] CDC, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Rossen, LM (reprint author), 3311 Toledo Rd,Room 6114, Hyattsville, MD 20910 USA. EM lrossen@cdc.gov FU Intramural CDC HHS [CC999999] NR 54 TC 14 Z9 14 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2013 VL 45 IS 6 BP E19 EP E25 DI 10.1016/j.amepre.2013.07.012 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 258SG UT WOS:000327478400001 PM 24237925 ER PT J AU Kransdorf, EP Czer, LSC Luthringer, DJ Patel, JK Montgomery, SP Velleca, A Mirocha, J Zakowski, PC Zabner, R Gaultier, CR Qvarnstrom, Y Benedict, T Steurer, F Bosserman, E Paddock, CD Rafiei, M Kobashigawa, JA AF Kransdorf, E. P. Czer, L. S. C. Luthringer, D. J. Patel, J. K. Montgomery, S. P. Velleca, A. Mirocha, J. Zakowski, P. C. Zabner, R. Gaultier, C. R. Qvarnstrom, Y. Benedict, T. Steurer, F. Bosserman, E. Paddock, C. D. Rafiei, M. Kobashigawa, J. A. TI Heart Transplantation for Chagas Cardiomyopathy in the United States SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Cardiomyopathy; Chagas disease; heart transplantation; Trypanosoma cruzi ID TRYPANOSOMA-CRUZI INFECTION; DISEASE REACTIVATION; BLOOD-DONORS; TRANSMISSION; RISK AB Since an initial case in 2006, we noted multiple patients undergoing heart transplantation (HTx) for Chagas cardiomyopathy (CC) at our transplant program. The clinical characteristics, laboratory results and outcomes of patients with CC undergoing HTx in the United States have not been reported previously. In 2010, we implemented a systematic screening and management program for patients undergoing HTx for CC. Before HTx, all patients with idiopathic dilated cardiomyopathy who were born in a Chagas disease endemic country were screened for Trypanosoma cruzi (TC) infection with serology. After HTx, monitoring for TC reactivation was performed using clinical visits, echocardiography, endomyocardial biopsy and serial whole blood polymerase chain reaction (PCR) testing. Between June 2006 and January 2012, 11 patients underwent HTx for CC. One patient was empirically treated due to the presence of TC amastigotes in explanted cardiac tissue. Two patients experienced allograft dysfunction due to TC reactivation and three patients experienced subclinical reactivation (positive PCR results), which were treated. Chagas disease is a common cause of dilated cardiomyopathy in patients from endemic countries undergoing HTx at a transplant program in the United States. Reactivation is common after transplantation and can cause adverse outcomes. The authors describe the clinical characteristics, laboratory testing results, and outcomes of 11 patients with Chagas cardiomyopathy who underwent heart transplantation between 2006 and 2012 at a transplant center in the United States. C1 [Kransdorf, E. P.; Czer, L. S. C.; Patel, J. K.; Velleca, A.; Mirocha, J.; Rafiei, M.; Kobashigawa, J. A.] Cedars Sinai Heart Inst, Los Angeles, CA USA. [Luthringer, D. J.] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA. [Montgomery, S. P.; Qvarnstrom, Y.; Benedict, T.; Steurer, F.; Bosserman, E.] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA USA. [Zakowski, P. C.; Zabner, R.; Gaultier, C. R.] Tower Infect Dis Med Associates, Los Angeles, CA USA. [Paddock, C. D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Kobashigawa, JA (reprint author), Cedars Sinai Heart Inst, Los Angeles, CA USA. EM jon.kobashigawa@cshs.org NR 25 TC 10 Z9 10 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD DEC PY 2013 VL 13 IS 12 BP 3262 EP 3268 DI 10.1111/ajt.12507 PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA 255JN UT WOS:000327235300030 PM 24165397 ER PT J AU Jamshidi, R Penman-Aguilar, A Wiener, J Gallo, MF Zenilman, JM Melendez, JH Snead, M Black, CM Jamieson, DJ Macaluso, M AF Jamshidi, Roxanne Penman-Aguilar, Ana Wiener, Jeffrey Gallo, Maria F. Zenilman, Jonathan M. Melendez, J. H. Snead, Margaret Black, Carolyn M. Jamieson, Denise J. Macaluso, Maurizio TI Detection of two biological markers of intercourse: prostate-specific antigen and Y-chromosomal DNA SO CONTRACEPTION LA English DT Article DE Clearance; Prostate-specific antigen; Semen biomarkers; Y-chromosome DNA ID CHAIN-REACTION DETECTION; VAGINAL FLUID; SEXUAL-BEHAVIOR; CONDOM FAILURE; SEMEN; SEQUENCES; FEMALE; BIOMARKER; EFFICACY; PROTEIN AB Background: Although biological markers of women's exposure to semen from vaginal intercourse have been developed as surrogates for risk of infection or probability of pregnancy, data on their persistence time and clearance are limited. Study Design: During 2006-2008, 52 couples were enrolled for three 14-day cycles of abstinence from vaginal sex during which women were exposed in the clinic to a specific quantity (10, 100 or 1000 ILL) of their partner's semen. Vaginal swabs were collected before and at 1, 6, 12, 24, 48, 72 and 144 h after exposure for testing for prostate-specific antigen (PSA) and Y-chromosome DNA (Ye DNA). Results: Immediately after exposure to 1000 ILL of semen, the predicted sensitivity of being PSA positive was 0.96; this decreased to 0.65, 0.44, 0.21 and 0.07 at 6, 12, 24 and 48 h, respectively. Corresponding predicted sensitivity of being Yc DNA positive was 0.72 immediately postexposure; this increased to 0.76 at 1 h postexposure and then decreased to 0.60 (at 6 h), 0.63 (at 12 h), 0.49 (at 24 h), 0.21 (at 48 h), 0.17 (at 72 h) and 0.12 (at 144 h). Conclusions: Overall findings suggest that PSA may be more consistent as a marker of very recent exposure and that Ye DNA is more likely to be detected in the vagina after 12 h postexposure compared to PSA. (C) 2013 Elsevier Inc. All rights reserved. C1 [Jamshidi, Roxanne] Johns Hopkins Sch Med, Dept Obstet & Gynecol, Baltimore, MD USA. [Penman-Aguilar, Ana] Ctr Dis Control & Prevent, Off Director, Off Minor Hlth & Hlth Equ, Atlanta, GA USA. [Wiener, Jeffrey; Gallo, Maria F.; Snead, Margaret; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30332 USA. [Zenilman, Jonathan M.; Melendez, J. H.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Black, Carolyn M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Sci Resources, Atlanta, GA USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. RP Gallo, MF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30332 USA. EM mgalllo@cph.osu.edu RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU CDC [TS-1327]; Association of Teachers of Preventive Medicine (ATPM) [TS-1327] FX This publication/project was made possible through a Cooperative Agreement between the CDC and the Association of Teachers of Preventive Medicine (ATPM), award number TS-1327. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or ATPM. The authors express gratitude to Dr. Marcia Hobbs for her valuable scientific review of the manuscript. NR 21 TC 11 Z9 11 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD DEC PY 2013 VL 88 IS 6 BP 749 EP 757 DI 10.1016/j.contraception.2013.08.003 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 257VP UT WOS:000327416200014 PM 24028752 ER PT J AU Jaiswal, M Lauer, A Martin, CL Bell, RA Divers, J Dabelea, D Pettitt, DJ Saydah, S Pihoker, C Standiford, DA Rodriguez, BL Pop-Busui, R Feldman, EL AF Jaiswal, Mamta Lauer, Abigail Martin, Catherine L. Bell, Ronny A. Divers, Jasmin Dabelea, Dana Pettitt, David J. Saydah, Sharon Pihoker, Catherine Standiford, Debra A. Rodriguez, Beatriz L. Pop-Busui, Rodica Feldman, Eva L. CA Search For Diabetes In Youth Study TI Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort A pilot study SO DIABETES CARE LA English DT Article ID MICROVASCULAR COMPLICATIONS; SCREENING INSTRUMENT; MICHIGAN NEUROPATHY; GLYCEMIC CONTROL; RISK-FACTORS; PREVALENCE; MELLITUS; INTERVENTIONS; TRIAL/EPIDEMIOLOGY; POLYNEUROPATHY AB OBJECTIVETo estimate the prevalence of and risk factors for diabetic peripheral neuropathy (DPN) in a pilot study among youth participating in the SEARCH for Diabetes in Youth study.RESEARCH DESIGN AND METHODSDPN was assessed using the Michigan Neuropathy Screening Instrument (MNSI) (examination for foot abnormalities, distal vibration perception, and ankle reflexes). An MNSI exam (MNSIE) score >2 is diagnostic for DPN.RESULTSThe MNSIE was completed in 399 subjects, including 329 youth with type 1 diabetes (mean age 15.7 4.3 years, duration 6.2 +/- 0.9 years) and 70 with type 2 diabetes (mean age 21.6 +/- 4.1 years, duration 7.6 +/- 1.8 years). Glycated hemoglobin (A1C) was similar in both groups (8.8 +/- 1.8% for type 1 vs. 8.5 +/- 2.9% for type 2). The prevalence of DPN was significantly higher in youth with type 2 compared with those with type 1 diabetes (25.7 vs. 8.2%; P < 0.0001). In unadjusted analyses, diabetes type, older age, longer duration of diabetes, increased waist circumference, elevated blood pressure, lower HDL cholesterol, and presence of microalbuminuria (urinary albumin-to-creatinine ratio >30 mg/g) were associated with DPN. The association between diabetes type and DPN remained significant after adjustment for age and sex (odds ratio 2.29 [95% CI 1.05-5.02], P = 0.03).CONCLUSIONSDPN prevalence among youth with type 2 diabetes approached rates reported in adult populations with diabetes. Our findings suggest not only that youth with diabetes are at risk for DPN but also that many already show measurable signs of DPN. C1 [Jaiswal, Mamta; Feldman, Eva L.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. [Lauer, Abigail; Divers, Jasmin] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Martin, Catherine L.; Pop-Busui, Rodica] Univ Michigan, Div Endocrinol Diabet & Metab, Ann Arbor, MI USA. [Bell, Ronny A.] Wake Forest Sch Med, Dept Epidemiol Prevent, Winston Salem, NC USA. [Dabelea, Dana] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Pettitt, David J.] Sansum Diabet Res Inst, Santa Barbara, CA USA. [Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Standiford, Debra A.] Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH USA. [Rodriguez, Beatriz L.] Univ Hawaii, Sch Med, Kuakini Med Ctr, Honolulu, HI USA. RP Feldman, EL (reprint author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA. EM efeldman@umich.edu OI Jaiswal, Mamta/0000-0003-1727-6225 FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU0192354, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; General Clinical Research Centers at the South Carolina Clinical & Translational Research Institute, at the Medical University of South Carolina (National Institutes of Health [NIH]/National Center for Research Resources [NCRR] [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; Institutional Clinical and Translational Science Award, NIH/NCRR at the University of Cincinnati [1UL1RR026314-01] FX SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA no. 00097, DP-05-069 and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site contract numbers are as follows: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU0192354, U01 DP000244, and U18DP002710-01), and Wake Forest University School of Medicine (U48/ CU919219, U01 DP000250, and 200-2010-35171). The authors acknowledge the involvement of General Clinical Research Centers at the South Carolina Clinical & Translational Research Institute, at the Medical University of South Carolina (National Institutes of Health [NIH]/National Center for Research Resources [NCRR] grant UL1RR029882), Children's Hospital and Regional Medical Center (grant M01RR00037), Colorado Pediatric General Clinical Research Center (grant M01 RR00069), the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516), the Institutional Clinical and Translational Science Award, NIH/NCRR at the University of Cincinnati (grant 1UL1RR026314-01), and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 24 TC 20 Z9 23 U1 1 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2013 VL 36 IS 12 BP 3903 EP 3908 DI 10.2337/dc13-1213 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255AL UT WOS:000327211500036 PM 24144652 ER PT J AU Yau, RK Strotmeyer, ES Resnick, HE Sellmeyer, DE Feingold, KR Cauley, JA Vittinghoff, E De Rekeneire, N Harris, TB Nevitt, MC Cummings, SR Shorr, RI Schwartz, AV AF Yau, Rebecca K. Strotmeyer, Elsa S. Resnick, Helaine E. Sellmeyer, Deborah E. Feingold, Kenneth R. Cauley, Jane A. Vittinghoff, Eric De Rekeneire, Nathalie Harris, Tamara B. Nevitt, Michael C. Cummings, Steven R. Shorr, Ronald I. Schwartz, Ann V. TI Diabetes and Risk of Hospitalized Fall Injury Among Older Adults SO DIABETES CARE LA English DT Article ID BODY-COMPOSITION; ELDERLY RESIDENTS; GLYCEMIC CONTROL; FRACTURE RISK; HEALTH ABC; WOMEN; MELLITUS; PREDICTORS; PEOPLE; TYPE-1 AB OBJECTIVETo determine whether older adults with diabetes are at increased risk of an injurious fall requiring hospitalization.RESEARCH DESIGN AND METHODSThe longitudinal Health, Aging, and Body Composition Study included 3,075 adults aged 70-79 years at baseline. Hospitalizations that included ICD-9-Clinical Modification codes for a fall and an injury were identified. The effect of diabetes with and without insulin use on the rate of first fall-related injury hospitalization was assessed using proportional hazards models.RESULTSAt baseline, 719 participants had diabetes, and 117 of them were using insulin. Of the 293 participants who were hospitalized for a fall-related injury, 71 had diabetes, and 16 were using insulin. Diabetes was associated with a higher rate of injurious fall requiring hospitalization (hazard ratio [HR] 1.48 [95% CI 1.12-1.95]) in models adjusted for age, race, sex, BMI, and education. In those participants using insulin, compared with participants without diabetes, the HR was 3.00 (1.78-5.07). Additional adjustment for potential intermediaries, such as fainting in the past year, standing balance score, cystatin C level, and number of prescription medications, accounted for some of the increased risk associated with diabetes (1.41 [1.05-1.88]) and insulin-treated diabetes (2.24 [1.24-4.03]). Among participants with diabetes, a history of falling, poor standing balance score, and A1C level 8% were risk factors for an injurious fall requiring hospitalization.CONCLUSIONSOlder adults with diabetes, in particular those using insulin, are at greater risk of an injurious fall requiring hospitalization than those without diabetes. Among those with diabetes, poor glycemic control may increase the risk of an injurious fall. C1 [Yau, Rebecca K.] Ctr Dis Control & Prevent, Council State & Terr Epidemiologists Appl Epidemi, Atlanta, GA 30333 USA. [Yau, Rebecca K.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA. [Strotmeyer, Elsa S.; Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Resnick, Helaine E.] Univ Maryland, Sch Med, Dept Geriatr, Baltimore, MD 21201 USA. [Resnick, Helaine E.] Gerontol Res Educ & Training Ctr, Baltimore, MD USA. [Resnick, Helaine E.] Resnick Chodorow & Associates, Silver Spring, MD USA. [Sellmeyer, Deborah E.] Johns Hopkins Sch Med, Div Endocrinol, Baltimore, MD USA. [Feingold, Kenneth R.] Univ Calif San Francisco, Dept Med, Div Endocrinol, San Francisco, CA USA. [Vittinghoff, Eric; Nevitt, Michael C.; Schwartz, Ann V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [De Rekeneire, Nathalie] Yale Univ, Sch Med, Dept Internal Med, Geriatr Sect, New Haven, CT 06510 USA. [Harris, Tamara B.] NIA, Lab Epidemiol, Bethesda, MD 20892 USA. [Cummings, Steven R.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA. [Shorr, Ronald I.] North Florida South Georgia Vet Hlth Syst, Ctr Geriatr Res Educ & Clin, Gainesville, FL USA. [Shorr, Ronald I.] Univ Florida, Dept Aging & Geriatr, Gainesville, FL USA. RP Yau, RK (reprint author), Ctr Dis Control & Prevent, Council State & Terr Epidemiologists Appl Epidemi, Atlanta, GA 30333 USA. EM rebeccayau@unc.edu RI Strotmeyer, Elsa/F-3015-2014; OI Strotmeyer, Elsa/0000-0002-4093-6036; Cauley, Jane A/0000-0003-0752-4408 FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research [R01-NR012459]; Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention [5U38HM000414]; Intramural Research Program of the National Institutes of Health, National Institute on Aging FX This research was supported by National Institute on Aging contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; National Institute on Aging grant R01-AG028050; and National Institute of Nursing Research grant R01-NR012459. This research was also supported by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by Centers for Disease Control and Prevention Cooperative Agreement number 5U38HM000414. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute on Aging. NR 39 TC 16 Z9 17 U1 1 U2 19 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2013 VL 36 IS 12 BP 3985 EP 3991 DI 10.2337/dc13-0429 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255AL UT WOS:000327211500047 PM 24130352 ER PT J AU Zhuo, XH Zhang, P Kahn, HS Gregg, EW AF Zhuo, Xiaohui Zhang, Ping Kahn, Henry S. Gregg, Edward W. TI Cost-Effectiveness of Alternative Thresholds of the Fasting Plasma Glucose Test to Identify the Target Population for Type 2 Diabetes Prevention in Adults Aged >= 45 Years SO DIABETES CARE LA English DT Article ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE; BLOOD-GLUCOSE; WEIGHT-LOSS; US ADULTS; RISK; PROGRAM; HYPERTENSION; TOLERANCE; METFORMIN AB OBJECTIVEThe study objective was to evaluate the cost-effectiveness of alternative fasting plasma glucose (FPG) thresholds to identify adults at high risk for type 2 diabetes for diabetes preventive intervention.RESEARCH DESIGN AND METHODSWe used a validated simulation model to examine the change in lifetime quality-adjusted life years (QALYs) and medical costs when the FPG threshold was progressively lowered in 5-mg/dL decrements from 120 to 90 mg/dL. The study sample includes nondiabetic adults aged 45 years in the United States using 2006-2010 data from the National Health and Nutrition Examination Survey. High-risk individuals were assumed to receive a lifestyle intervention, as that used in the Diabetes Prevention Program. We calculated cost per QALY by dividing the incremental cost by incremental QALY when lowering the threshold to the next consecutive level. Medical costs were assessed from a health care system perspective. We conducted univariate and probabilistic sensitivity analyses to assess the robustness of the results using different simulation scenarios and parameters.RESULTSProgressively lowering the FPG threshold would monotonically increase QALYs, cost, and cost per QALY. Reducing (in 5-mg/dL decrements) the threshold from 120 to 90 mg/dL cost $30,100, $32,900, $42,300, $60,700, $81,800, and $115,800 per QALY gained, respectively. The costs per QALY gained were lower for all thresholds under a lower-cost and less-effective intervention scenario.CONCLUSIONSLowering the FPG threshold leads to a greater health benefit of diabetes prevention but reduces the cost-effectiveness. Using the conventional benchmark of $50,000 per QALY, a threshold of 105 mg/dL or higher would be cost effective. A lower threshold could be selected if the intervention cost could be lowered. C1 [Zhuo, Xiaohui; Zhang, Ping; Kahn, Henry S.; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zhuo, XH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM xzhuo@cdc.gov OI Kahn, Henry/0000-0003-2533-1562 FU National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC55019, N01-HC-55020, N01-HC-55021, N01-HC-55022] FX This research uses data from the Atherosclerosis Risk in Communities (ARIC) study and the National Health and Nutrition Examination Survey (NHANES). The ARIC study is carried out as a collaboration supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. NR 45 TC 4 Z9 4 U1 1 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2013 VL 36 IS 12 BP 3992 EP 3998 DI 10.2337/dc13-0497 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255AL UT WOS:000327211500048 PM 24135386 ER PT J AU Pennotti, R Scallan, E Backer, L Thomas, J Angulo, FJ AF Pennotti, Radha Scallan, Elaine Backer, Lorraine Thomas, Jerry Angulo, Frederick J. TI Ciguatera and Scombroid Fish Poisoning in the United States SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID DATA-SYSTEM NPDS; AMERICAN-ASSOCIATION; MARINE TOXINS; SURVEILLANCE; CAROLINA; DISEASES AB Background: Ciguatera and scombroid fish poisonings are common causes of fish-related foodborne illness in the United States; however, existing surveillance systems underestimate the overall human health impact. Objectives: This study aimed to describe existing data on ciguatera and scombroid fish poisonings from outbreak and poison control center reports and to estimate the overall number of ciguatera and scombroid fish-poisoning illnesses, hospitalizations, and deaths in the United States. Methods: We analyzed outbreak data from the Foodborne Disease Outbreak Surveillance Systems (FDOSS) from 2000 to 2007 and poison control center call data from the National Poison Data System (NPDS) from 2005 to 2009 for reports of ciguatera and scombroid fish poisonings. Using a statistical model with many inputs, we adjusted the outbreak data for undercounting due to underreporting and underdiagnosis to generate estimates. Underreporting and underdiagnosis multipliers were derived from the poison control call data and the published literature. Results: Annually, an average of 15 ciguatera and 28 scombroid fish-poisoning outbreaks, involving a total of 60 and 108 ill persons, respectively, were reported to FDOSS (2000-2007). NPDS reported an average of 173 exposure calls for ciguatoxin and 200 exposure calls for scombroid fish poisoning annually (2005-2009). After adjusting for undercounting, we estimated 15,910 (90% credible interval [CrI] 4140-37,408) ciguatera fish-poisoning illnesses annually, resulting in 343 (90% CrI 69-851) hospitalizations and three deaths (90% CrI 1-7). We estimated 35,142 (90% CrI: 10,496-78,128) scombroid fish-poisoning illnesses, resulting in 162 (90% CrI 0-558) hospitalizations and 0 deaths. Conclusions: Ciguatera and scombroid fish poisonings affect more Americans than reported in surveillance systems. Although additional data can improve these assessments, the estimated number of illnesses caused by seafood intoxication illuminates this public health problem. Efforts, including education, can reduce ciguatera and scombroid fish poisonings. C1 [Pennotti, Radha; Backer, Lorraine; Thomas, Jerry] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Scallan, Elaine] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Angulo, Frederick J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Scallan, E (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, 13001 East 17th Pl,Mail Stop B119, Aurora, CO 80045 USA. EM Elaine.Scallan@ucdenver.edu NR 28 TC 15 Z9 15 U1 0 U2 17 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD DEC 1 PY 2013 VL 10 IS 12 BP 1059 EP 1066 DI 10.1089/fpd.2013.1514 PG 8 WC Food Science & Technology SC Food Science & Technology GA 255DR UT WOS:000327220100010 PM 24093307 ER PT J AU Groenewold, MR Baron, SL AF Groenewold, Matthew R. Baron, Sherry L. TI The Proportion of Work-Related Emergency Department Visits Not Expected to Be Paid by Workers' Compensation: Implications for Occupational Health Surveillance, Research, Policy, and Health Equity SO HEALTH SERVICES RESEARCH LA English DT Article DE Workers' compensation; occupational injuries; occupational diseases ID UNITED-STATES; INJURY; ILLNESS; BENEFITS; CLAIMS; RATES; PERSPECTIVE; DISPARITIES; DISORDERS; ECONOMY AB ObjectiveTo examine trends in the proportion of work-related emergency department visits not expected to be paid by workers' compensation during 2003-2006, and to identify demographic and clinical correlates of such visits. Data SourceA total of 3,881 work-related emergency department visit records drawn from the 2003-2006 National Hospital Ambulatory Medical Care Surveys. Study DesignSecondary, cross-sectional analyses of work-related emergency department visit data were performed. Odds ratios and 95 percent confidence intervals were modeled using logistic regression. Principal FindingsA substantial and increasing proportion of work-related emergency department visits in the United States were not expected to be paid by workers' compensation. Private insurance, Medicaid, Medicare, and workers themselves were expected to pay for 40 percent of the work-related emergency department visits with this percentage increasing annually. Work-related visits by blacks, in the South, to for-profit hospitals and for work-related illnesses were all more likely not to be paid by workers' compensation. ConclusionsEmergency department-based surveillance and research that determine work-relatedness on the basis of expected payment by workers' compensation systematically underestimate the occurrence of occupational illness and injury. This has important methodological and policy implications. C1 [Groenewold, Matthew R.; Baron, Sherry L.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Groenewold, MR (reprint author), NIOSH, Ctr Dis Control & Prevent, 7646 Columbia Pkwy MS R-17, Cincinnati, OH 45226 USA. EM gyr5@cdc.gov NR 45 TC 10 Z9 10 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2013 VL 48 IS 6 BP 1939 EP 1959 DI 10.1111/1475-6773.12066 PN 1 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 257NT UT WOS:000327392300009 PM 23662682 ER PT J AU Chipman, RB Cozzens, TW Shwiff, SA Biswas, R Plumley, J O'Quin, J Algeo, TP Rupprecht, CE Slate, D AF Chipman, Richard B. Cozzens, Tyler W. Shwiff, Stephanie A. Biswas, Rita Plumley, Jewell O'Quin, Jeanette Algeo, Timothy P. Rupprecht, Charles E. Slate, Dennis TI Costs of raccoon rabies incidents in cattle herds in Hampshire County, West Virginia, and Guernsey County, Ohio SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID UNITED-STATES; HEALTH; VACCINATION; WILDLIFE; PREVENTION; ECONOMICS; BENEFITS; EXPOSURE; DISEASES; IMPACT AB Objective To determine direct and indirect costs associated with raccoon rabies incidents involving cattle herds in Hampshire County, WV, in 2008 and Guernsey County, Ohio, in 2010. Design-Ex post cost analysis. Animals-1 cattle herd in Hampshire County, WV, in 2008 and 1 cattle herd in Guernsey County, Ohio, in 2010. Procedures-Data were collected for each incident through telephone and email interviews with 16 federal, state, and county agency personnel involved in the case investigations and coordinated responses for rabies in the cattle herds. To characterize the economic impact associated with rabies in the 2 cattle herds, cost analysis was conducted with 7 cost variables (salary and benefits for personnel involved in the response, human postexposure prophylaxis, indirect patient costs, rabies diagnostic testing, cattle carcass disposal, market value of euthanized cattle, and enhanced rabies surveillance). Estimates of direct costs were determined on the basis of agency records and other relevant data obtained from notes and reports made by agency staff at the time of the incident and from a review of the literature. Results-Primary costs included the market value of euthanized cattle ($51,461 in West Virginia; $12,561 in Ohio), human postexposure prophylaxis ($17959 in West Virginia; $11,297 in Ohio), and salary and benefits for personnel involved in the response ($19,792 in West Virginia; $14,496 in Ohio). Conclusions and Clinical Relevance-These results should provide a basis for better characterization of the economic impact of wildlife rabies in cattle in the United States. C1 [Chipman, Richard B.; Algeo, Timothy P.; Slate, Dennis] Wildlife Serv, USDA, APHIS, Natl Rabies Management Program, Concord, NH 03301 USA. [Cozzens, Tyler W.; Shwiff, Stephanie A.] Wildlife Serv, USDA, APHIS, Natl Wildlife Res Ctr, Ft Collins, CO 80521 USA. [Biswas, Rita] SUNY Albany, Sch Business, Albany, NY 12222 USA. [Plumley, Jewell] West Virginia Dept Agr, Moorefield, WV 26835 USA. [O'Quin, Jeanette] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA. [Rupprecht, Charles E.] CDC, Rabies Program, NCEZID DHCPP Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. RP Chipman, RB (reprint author), Wildlife Serv, USDA, APHIS, Natl Rabies Management Program, 59 Chenell Dr,Ste 2, Concord, NH 03301 USA. EM richard.b.chipman@aphis.usda.gov NR 37 TC 2 Z9 2 U1 1 U2 12 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD DEC 1 PY 2013 VL 243 IS 11 BP 1561 EP 1567 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 259XY UT WOS:000327560800014 PM 24261805 ER PT J AU Hariri, S Markowitz, LE Dunne, EF Unger, ER AF Hariri, Susan Markowitz, Lauri E. Dunne, Eileen F. Unger, Elizabeth R. TI Population Impact of HPV Vaccines: Summary of Early Evidence SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material DE HPV vaccine; Cervical cancer; Prevention ID HUMAN-PAPILLOMAVIRUS VACCINATION; GENITAL WARTS; UNITED-STATES; PROGRAM; PREVALENCE; WOMEN; REDUCTION; DANISH; CANCER; RISK AB Human papillomavirus (HPV) vaccines are available in the United States and around the world to prevent HPV-associated diseases including cervical cancer and genital warts. HPV vaccination is currently recommended for adolescents: target ages for routine and catch-up vaccinations vary by country. Because the time from vaccination to cancer development can be several decades, many studies are evaluating more immediate outcomes. In the 4 years since the vaccine was introduced, reductions in HPV vaccine type prevalence and genital warts have been reported in young females in the United States and other countries. Many questions remain about the long-term impact, but the initial studies show promising results for the relatively new HPV vaccine. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Hariri, Susan; Markowitz, Lauri E.; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Hariri, S (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clinton Rd,MS E-02, Atlanta, GA 30333 USA. EM bse4@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 NR 24 TC 30 Z9 30 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD DEC PY 2013 VL 53 IS 6 BP 679 EP 682 DI 10.1016/j.jadohealth.2013.09.018 PG 4 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 258TJ UT WOS:000327481300002 PM 24263069 ER PT J AU Hester, LL Wilce, MA Gill, SA Disler, SL Collins, P Crawford, G AF Hester, Laura L. Wilce, Maureen A. Gill, Sarah A. Disler, Sheri L. Collins, Pamela Crawford, Gregory TI Roles of the State Asthma Program in Implementing Multicomponent, School-Based Asthma Interventions SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE asthma; school-based interventions; evaluability assessment ID MANAGING ASTHMA; HEALTH CENTERS; MANAGEMENT AB BACKGROUNDAsthma is a leading chronic childhood disease in the United States and a major contributor to school absenteeism. Evidence suggests that multicomponent, school-based asthma interventions are a strategic way to address asthma among school-aged children. The Centers for Disease Control and Prevention (CDC) encourages the 36 health departments (34 states, District of Columbia, and Puerto Rico) in the National Asthma Control Program (NACP) to implement multicomponent, school-based asthma interventions on a larger scale. METHODSTo gain a better understanding of replicable best practices for state-coordinated asthma interventions in schools, an NACP evaluation team conducted evaluability assessments of promising interventions run by state asthma programs in Louisiana, Indiana, and Utah. RESULTSThe team found that state asthma programs play a critical role in implementing school-based asthma interventions due to their ability to (1) use statewide surveillance data to identify asthma trends and address disparities; (2) facilitate connections between schools, school systems, and school-related community stakeholders; (3) form state-level connections; (4) translate policies into action; (5) provide resources and public health practice information to schools and school systems; (6) monitor and evaluate implementation. CONCLUSIONSThis article presents evaluability assessment findings and illustrates state roles using examples from the 3 participating state asthma programs. C1 [Hester, Laura L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, ORISE,CDC Res Program, Atlanta, GA 30341 USA. [Wilce, Maureen A.; Gill, Sarah A.; Disler, Sheri L.; Collins, Pamela; Crawford, Gregory] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Atlanta, GA 30341 USA. RP Wilce, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, 4770 BufordHwy,Mailstop F60, Atlanta, GA 30341 USA. EM llhester@live.unc.edu; muw9@cdc.gov; iqv2@cdc.gov; sjd9@cdc.gov; jng4@cdc.gov; glc8@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 3 Z9 3 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD DEC PY 2013 VL 83 IS 12 BP 833 EP 841 DI 10.1111/josh.12101 PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 255PD UT WOS:000327251400001 PM 24261517 ER PT J AU Al-Hello, H Jorba, J Blomqvist, S Raud, R Kew, O Roivainen, M AF Al-Hello, Haider Jorba, Jaume Blomqvist, Soile Raud, Riina Kew, Olen Roivainen, Merja TI Highly Divergent Type 2 and 3 Vaccine-Derived Polioviruses Isolated from Sewage in Tallinn, Estonia SO JOURNAL OF VIROLOGY LA English DT Article ID GLOBAL POLIO ERADICATION; IMMUNODEFICIENT PATIENT; NUCLEOTIDE-SEQUENCES; GENETIC-BASIS; POLIOMYELITIS; SURVEILLANCE; WORLDWIDE; RECOMBINATION; DETERMINANTS; REPLICATION AB Highly divergent vaccine-derived polioviruses (VDPVs) have been isolated from sewage in Tallinn, Estonia, since 2002. Sequence analysis of VDPVs of serotypes 2 and 3 showed that they shared common noncapsid region recombination sites, indicating origination from a single trivalent oral polio vaccine dose, estimated to have been given between 1986 and 1998. The sewage isolates closely resemble VDPVs chronically excreted by persons with common variable immunodeficiency, but no chronic excretors have yet been identified in Estonia. C1 [Al-Hello, Haider; Blomqvist, Soile; Roivainen, Merja] Natl Inst Hlth & Welf THL, Helsinki, Finland. [Raud, Riina] Hlth Protect Inspectorate, Cent Lab Virol, Tallinn, Estonia. [Jorba, Jaume; Kew, Olen] Ctr Dis Control & Prevent CDC, Div Viral Dis, Atlanta, GA USA. RP Roivainen, M (reprint author), Natl Inst Hlth & Welf THL, Helsinki, Finland. EM merja.roivainen@thl.fi FU World Health Organization [18-TSA-005] FX This work was supported by the World Health Organization (18-TSA-005). NR 35 TC 9 Z9 9 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD DEC PY 2013 VL 87 IS 23 BP 13076 EP 13080 DI 10.1128/JVI.01174-13 PG 5 WC Virology SC Virology GA 254RG UT WOS:000327183800056 PM 24049178 ER PT J AU Houser, KV Pearce, MB Katz, JM Tumpey, TM AF Houser, Katherine V. Pearce, Melissa B. Katz, Jacqueline M. Tumpey, Terrence M. TI Impact of Prior Seasonal H3N2 Influenza Vaccination or Infection on Protection and Transmission of Emerging Variants of Influenza A(H3N2)v Virus in Ferrets SO JOURNAL OF VIROLOGY LA English DT Article ID UNITED-STATES; SWINE; VACCINES; H5N1; ANTIBODIES; CHILDREN; EFFICACY; MODEL; IMMUNOGENICITY; HEMAGGLUTININ AB Influenza H3N2 A viruses continue to circulate in swine and occasionally infect humans, resulting in outbreaks of variant influenza H3N2 [A(H3N2) v] virus. It has been previously demonstrated in ferrets that A(H3N2) v viruses transmit as efficiently as seasonal influenza viruses, raising concern over the pandemic potential of these viruses. However, A(H3N2) v viruses have not acquired the ability to transmit efficiently among humans, which may be due in part to existing cross-reactive immunity to A(H3N2) v viruses. Although current seasonal H3N2 and A(H3N2) v viruses are antigenically distinct from one another, historical H3N2 viruses have some antigenic similarity to A(H3N2) v viruses and previous exposure to these viruses may provide a measure of immune protection sufficient to dampen A(H3N2) v virus transmission. Here, we evaluated whether prior seasonal H3N2 influenza virus vaccination or infection affects virus replication and transmission of A(H3N2) v virus in the ferret animal model. We found that the seasonal trivalent inactivated influenza virus vaccine (TIV) or a monovalent vaccine prepared from an antigenically related 1992 seasonal influenza H3N2 (A/Beijing/32/1992) virus failed to substantially reduce A(H3N2) v (A/Indiana/08/2011) virus shedding and subsequent transmission to naive hosts. Conversely, ferrets primed by seasonal H3N2 virus infection displayed reduced A(H3N2) v virus shedding following challenge, which blunted transmission to naive ferrets. A higher level of specific IgG and IgA antibody titers detected among infected versus vaccinated ferrets was associated with the degree of protection offered by seasonal H3N2 virus infection. The data demonstrate in ferrets that the efficiency of A(H3N2) v transmission is disrupted by preexisting immunity induced by seasonal H3N2 virus infection. C1 [Houser, Katherine V.; Pearce, Melissa B.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Houser, Katherine V.] Emory Univ, Grad Div Biol & Biomed Sci, Grad Program Immunol & Mol Pathogenesis, Atlanta, GA 30322 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM tft9@cdc.gov FU Oak Ridge Institute for Science and Education, Oak Ridge, TN FX K.V.H. received financial support for this work from the Oak Ridge Institute for Science and Education, Oak Ridge, TN. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. NR 37 TC 18 Z9 18 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD DEC PY 2013 VL 87 IS 24 BP 13480 EP 13489 DI 10.1128/JVI.02434-13 PG 10 WC Virology SC Virology GA 258EZ UT WOS:000327443300037 PM 24089569 ER PT J AU Earnshaw, S Mendez, A Monnet, DL Hicks, L Cruickshank, M Weekes, L Njoo, H Ross, S AF Earnshaw, Sarah Mendez, Andrea Monnet, Dominique L. Hicks, Lauri Cruickshank, Marilyn Weekes, Lynn Njoo, Howard Ross, Stacie TI Global collaboration to encourage prudent antibiotic use SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material C1 [Earnshaw, Sarah; Mendez, Andrea; Monnet, Dominique L.] European Ctr Dis Prevent & Control, Stockholm, Sweden. [Hicks, Lauri] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Cruickshank, Marilyn] Australian Commiss Safety & Qual Hlth Care, Sydney, NSW, Australia. [Weekes, Lynn] NPS MedicineWise, Sydney, NSW, Australia. [Njoo, Howard] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Ross, Stacie] Commun & Educ Task Grp Antimicrobial Resistance, Winnipeg, MB, Canada. RP Earnshaw, S (reprint author), European Ctr Dis Prevent & Control, Stockholm, Sweden. EM Sarah.Earnshaw@ecdc.europa.eu NR 1 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD DEC PY 2013 VL 13 IS 12 BP 1003 EP 1004 DI 10.1016/S1473-3099(13)70315-3 PG 2 WC Infectious Diseases SC Infectious Diseases GA 256AZ UT WOS:000327283400007 PM 24252477 ER PT J AU Marshall, C Gavin, L Bish, C Winter, A Williams, L Wesley, M Zhang, L AF Marshall, Cassondra Gavin, Loretta Bish, Connie Winter, Amy Williams, Letitia Wesley, Mary Zhang, Lei TI WIC Participation and Breastfeeding Among White and Black Mothers: Data from Mississippi SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Breastfeeding; WIC; Race; PRAMS ID SUPPLEMENTAL NUTRITION PROGRAM; CHILDREN PARTICIPANTS; HUMAN-MILK; WOMEN; INFANTS; RATES; RISK; INTENTIONS; SUPPORT AB Participation in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) has been associated with lower rates of breastfeeding; studies have suggested this relationship may be modified by race. The purpose of this study is to examine the association between WIC participation and breastfeeding behaviors among white and black women in Mississippi. Using data from the 2004-2008 Mississippi Pregnancy Risk Assessment Monitoring System, we calculated multivariable prevalence and hazard ratios to assess the relationships among WIC participation during pregnancy and breastfeeding initiation and duration through 10 weeks postpartum. Stratified analyses were performed for white and black women. 52.2 % of white and 82.1 % of black women participated in WIC. 60.4 % of white and 39.7 % of black women initiated breastfeeding, and 26.5 % and 21.9 %, respectively, were breastfeeding at 10 weeks postpartum. WIC participation was negatively associated with breastfeeding initiation among whites (APR: 0.87; 95 % CI 0.77-0.99), but not blacks (APR: 0.99; 95 % CI 0.28-1.21). WIC participation was not associated with breastfeeding duration for women of either race (white: AHR: 1.05, 95 % CI 0.80-1.38; black: AHR: 0.91, 95 % CI 0.65-1.26). The results among white women suggest that Mississippi WIC might benefit from an in depth evaluation of the program's breastfeeding promotional activities to determine if aspects of the program are undermining breastfeeding initiation. High rates of participation in the WIC program among black women, and the overall low rates of breastfeeding in this population point to the potential the program has to increase breastfeeding rates among blacks. C1 [Marshall, Cassondra] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Marshall, Cassondra; Gavin, Loretta; Bish, Connie; Williams, Letitia] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Winter, Amy] Mississippi Dept Hlth, Mississippi WIC Program, Jackson, MS USA. [Wesley, Mary; Zhang, Lei] Mississippi Dept Hlth, Hlth Serv Off Hlth Data & Res, Jackson, MS USA. RP Marshall, C (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM cassiejm@berkeley.edu; LGavin1@cdc.gov; connie.bish@msdh.state.ms.us; amy.winter@msdh.state.ms.us; LMWilliams@cdc.gov; Mary.Wesley@msdh.state.ms.us; lei.zhang@msdh.state.ms.us NR 32 TC 2 Z9 2 U1 1 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD DEC PY 2013 VL 17 IS 10 BP 1784 EP 1792 DI 10.1007/s10995-012-1198-1 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 253LQ UT WOS:000327088500007 PM 23203317 ER PT J AU Alberts, MJ Wechsler, LR Jensen, MEL Latchaw, RE Crocco, TJ George, MG Baranski, J Bass, RR Ruff, RL Huang, J Mancini, B Gregory, T Gress, D Emr, M Warren, M Walker, MD AF Alberts, Mark J. Wechsler, Lawrence R. Jensen, Mary E. Lee Latchaw, Richard E. Crocco, Todd J. George, Mary G. Baranski, James Bass, Robert R. Ruff, Robert L. Huang, Judy Mancini, Barbara Gregory, Tammy Gress, Daryl Emr, Marian Warren, Margo Walker, Michael D. TI Formation and Function of Acute Stroke-Ready Hospitals Within a Stroke System of Care Recommendations From the Brain Attack Coalition SO STROKE LA English DT Article DE acute stroke; cerebrovascular disease; stroke ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; EMERGENCY MEDICAL-SERVICES; NORTH-CAROLINA STROKE; POLICY STATEMENT; GUIDELINES-STROKE; PILOT PROJECT; UNITED-STATES; ASSOCIATION; CENTERS AB Background and Purpose Many patients with an acute stroke live in areas without ready access to a Primary or Comprehensive Stroke Center. The formation of care facilities that meet the needs of these patients might improve their care and outcomes and guide them and emergency responders to such centers within a stroke system of care. Methods The Brain Attack Coalition conducted an electronic search of the English medical literature from January 2000 to December 2012 to identify care elements and processes shown to be beneficial for acute stroke care. We used evidence grading and consensus paradigms to synthesize recommendations for Acute Stroke-Ready Hospitals (ASRHs). Results Several key elements for an ASRH were identified, including acute stroke teams, written care protocols, involvement of emergency medical services and emergency department, and rapid laboratory and neuroimaging testing. Unique aspects include the use of telemedicine, hospital transfer protocols, and drip and ship therapies. Emergent therapies include the use of intravenous tissue-type plasminogen activator and the reversal of coagulopathies. Although many of the care elements are similar to those of a Primary Stroke Center, compliance rates of 67% are suggested in recognition of the staffing, logistical, and financial challenges faced by rural facilities. Conclusions ASRHs will form the foundation for acute stroke care in many settings. Recommended elements of an ASRH build on those proven to improve care and outcomes at Primary Stroke Centers. The ASRH will be a key component for patient care within an evolving stroke system of care. C1 [Alberts, Mark J.] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX USA. [Wechsler, Lawrence R.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Jensen, Mary E. Lee] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA. [Gress, Daryl] Univ Virginia, Dept Neurol, Charlottesville, VA USA. [Latchaw, Richard E.] UC Davis Med Ctr, Dept Radiol, Davis, CA USA. [Crocco, Todd J.] W Virginia Univ, Dept Emergency Med, Morgantown, WV 26506 USA. [George, Mary G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Baranski, James] Natl Stroke Assoc, Englewood, CO USA. [Bass, Robert R.] Natl Assoc EMS Officials, Falls Church, VA USA. [Ruff, Robert L.] VA Med Ctr, Dept Neurol, Cleveland, OH USA. [Huang, Judy] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA. [Mancini, Barbara] Inova Inc, San Diego, CA USA. [Gregory, Tammy] Amer Heart Assoc, Dallas, TX USA. [Emr, Marian; Warren, Margo; Walker, Michael D.] NINDS, Bethesda, MD 20892 USA. RP Alberts, MJ (reprint author), Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM Mark.Alberts@UTSouthwestern.edu NR 58 TC 14 Z9 15 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD DEC PY 2013 VL 44 IS 12 BP 3382 EP 3393 DI 10.1161/STROKEAHA.113.002285 PG 12 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 257LR UT WOS:000327386300309 PM 24222046 ER PT J AU Reithinger, R Ngondi, JM Graves, PM Hwang, J Getachew, A Jima, D AF Reithinger, R. Ngondi, J. M. Graves, P. M. Hwang, J. Getachew, A. Jima, D. CA Ethiopia Malaria Indicator Survey TI Risk factors for anemia in children under 6 years of age in Ethiopia: analysis of the data from the cross-sectional Malaria Indicator Survey, 2007 SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE Anemia; Risk factors; Malaria; Ethiopia ID OROMIA REGIONAL STATE; SUB-SAHARAN AFRICA; PLASMODIUM-FALCIPARUM; YOUNG-CHILDREN; PREVALENCE; INFECTION; HOUSEHOLD; COVERAGE; GHANA AB Malaria is a leading cause of morbidity in Ethiopia. However, its transmission varies in both space and time, and large areas of the country are hypoendemic and epidemic-prone. The Ethiopia National Malaria Indicator Survey 2007 is a cross-sectional, nationally-representative household survey. The objective of the analyses presented here were to use the surveys data to identify factors associated with anemia presence in children under 6 years of age (U6); specifically, investigate the association between malaria and anemia; and discuss using anemia as a malaria proxy biomarker in the Ethiopian hypo-endemic transmission setting. The survey sampled 4185 households in 347 enumeration areas 2500 m above sea level. Primary outcome was increasing anemia severity in sampled children: no anemia (Hb: 11g/dl); mild anemia (Hb: 8g/dl and 11g/dl); and moderatesevere anemia (Hb: 8g/dl). Secondary outcomes were positive malaria rapid diagnostic test (RDT) or blood slide microscopy. The analysis included 6054 (92.0) children U6 in 3962 households. The proportion of children with no anemia, mild anemia, and moderate-severe anemia was 63.6, 31.3, and 5.1, respectively. The overall prevalence of anemia (Hb 11g/dl) was 36.4 (95 CI 34.438.4). Factors independently associated with reduced relative odds of anemia categories were age (OR0.7, 95 CI 0.70.7) and female sex (OR0.9, 95 CI 0.81.0); malaria RDT positivity was associated with increased relative odds of a more severe anemia category (OR5.8, 95 CI 3.79.2). We conclude that at altitudes 2500 m malaria appears to be a significant risk factor for anemia; potentially anemia could be used as a useful proxy biomarker for malaria and its control in Ethiopia. C1 [Reithinger, R.] US Agcy Int Dev, Addis Ababa, Ethiopia. [Reithinger, R.] RTI Int, Washington, DC 20005 USA. [Ngondi, J. M.] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England. [Ngondi, J. M.] RTI Int, Dar Es Salaam, Tanzania. [Ngondi, J. M.; Graves, P. M.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Graves, P. M.] James Cook Univ, Sch Publ Hlth Trop Med & Rehabil Sci, Townsville, Qld, Australia. [Hwang, J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hwang, J.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Getachew, A.] PATH, Malaria Control & Evaluat Partnership Africa MACE, Addis Ababa, Ethiopia. [Jima, D.] Fed Minist Hlth, Addis Ababa, Ethiopia. RP Reithinger, R (reprint author), RTI Int, Int Dev Grp, Global Hlth Div, Suite 750,701 13th St NW, Washington, DC 20005 USA. EM rreithinger@yahoo.co.uk RI Graves, Patricia/J-8691-2014 OI Graves, Patricia/0000-0002-5215-3901 FU U.S. Agency for International Development, the Government of Ethiopia Federal Ministry of Health FX The MIS was supported by the U.S. Agency for International Development, the Government of Ethiopia Federal Ministry of Health, as well as in-kind contributions from participating organizations. NR 40 TC 7 Z9 7 U1 0 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0035-9203 EI 1878-3503 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD DEC PY 2013 VL 107 IS 12 BP 769 EP 776 DI 10.1093/trstmh/trt096 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 258LS UT WOS:000327461400004 PM 24218415 ER PT J AU Louis, FJ Anselme, R Ndongmo, C Buteau, J Boncy, J Dahourou, G Vertefeuille, J Marston, B Balajee, SA AF Louis, Frantz Jean Anselme, Renette Ndongmo, Clement Buteau, Josiane Boncy, Jacques Dahourou, Georges Vertefeuille, John Marston, Barbara Balajee, S. Arunmozhi TI Evaluation of an External Quality Assessment Program for HIV Testing in Haiti, 2006-2011 SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE HIV rapid tests; External quality assessment; Proficiency testing ID DEVELOPING-COUNTRIES; PROFICIENCY; SETTINGS AB Objectives: To evaluate an external quality assessment (EQA) program for human immunodeficiency virus (HIV) rapid diagnostics testing by the Haitian National Public Health Laboratory (French acronym: LNSP). Acceptable performance was defined as any proficiency testing (PT) score more than 80%. Methods: The PT database was reviewed and analyzed to assess the testing performance of the participating laboratories and the impact of the program over time. A total of 242 laboratories participated in the EQA program from 2006 through 2011; participation increased from 70 laboratories in 2006 to 159 in 2011. Results: In 2006, 49 (70%) laboratories had a PT score of 80% or above; by 2011, 145 (97.5%) laboratories were proficient (P < .05). Conclusions: The EQA program for HIV testing ensures quality of testing and allowed the LNSP to document improvements in the quality of HIV rapid testing over time. (C) American Society for Clinical Pathology C1 [Louis, Frantz Jean; Vertefeuille, John] Amer Embassy, Ctr Dis Control & Prevent, Haiti Country Off, Port Au Prince, Haiti. [Anselme, Renette; Buteau, Josiane; Boncy, Jacques] Govt Haiti, Lab Natl Sante Publ, Minist Hlth, Port Au Prince, Haiti. [Ndongmo, Clement] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Dahourou, Georges] Ctr Dis Control & Prevent, Kigali, Rwanda. [Marston, Barbara; Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Louis, FJ (reprint author), Amer Embassy, Ctr Dis Control & Prevent, Tabarre 41, Port Au Prince, Haiti. EM yjeanlouis@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 3 Z9 3 U1 2 U2 2 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD DEC PY 2013 VL 140 IS 6 BP 867 EP 871 DI 10.1309/AJCPYWX49IZSQKFS PG 5 WC Pathology SC Pathology GA 255ZX UT WOS:000327280400014 PM 24225755 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Univ, Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Balk, Robert; Burns, Suzanne M.; Deutschman, Clifford S.; Gutterman, David; Hammer, Beth; Hill, Nicholas S.; Kollef, Marin; Levy, Mitchell; Lipsett, Pamela] Amer Thorac Soc, Soc Crit Care Med, Amer Coll Chest Phys, Crit Care Soc Collaborat Amer Assoc Crit Care Nur, Philadelphia, PA USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Surveillance Working Grp, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Div Pulm Crit Care & Sleep, Providence, RI 02912 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Assoc Infect, Albany, NY USA. [VanAntwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX Financial support. The work described herein was supported by the Centers for Disease Control and Prevention (CDC). NR 2 TC 4 Z9 5 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC 1 PY 2013 VL 34 IS 12 BP 1239 EP 1243 DI 10.1086/673463 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 252AJ UT WOS:000326976300001 PM 24225607 ER PT J AU Belay, ED Blase, J Sehulster, LM Maddox, RA Schonberger, LB AF Belay, Ermias D. Blase, Jennifer Sehulster, Lynne M. Maddox, Ryan A. Schonberger, Lawrence B. TI Management of Neurosurgical Instruments and Patients Exposed to Creutzfeldt-Jakob Disease SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CONTAMINATED MEDICAL INSTRUMENTS; SODIUM DODECYL-SULFATE; CEREBROSPINAL-FLUID; PRION DISEASES; SCRAPIE AGENT; DECONTAMINATION; STERILIZATION; DISINFECTION; TRANSMISSION; INACTIVATION AB Objective.To summarize the approaches used to manage exposure of patients to inadequately sterilized neurosurgical instruments contaminated as a result of Creutzfeldt-Jakob disease (CJD). Methods.Information on past CJD exposure incidents reported to the Centers for Disease Control and Prevention (CDC) was aggregated and summarized. In addition, inactivation studies were reviewed, and data from selected publications were provided for reference. Results.Nineteen incidents of patient exposure to potentially CJD-contaminated instruments were reported to the CDC, including 17 that involved intracranial procedures and 2 that involved ophthalmologic procedures. In more than 50% of incidents, the neurosurgical procedures were performed for diagnostic work up of the index patients. At least 12 of the hospitals had multiple neurosurgical sets, and the CJD-contaminated instruments could not be identified in 11 of 19 hospitals. In 12 of 15 hospitals with neurosurgical incidents, a decision was made to notify patients of their potential exposure. Conclusions.Neurosurgical instruments used for treatment of patients with suspected or diagnosed CJD or patients whose diagnosis is unclear should be promptly identified and sterilized using recommended CJD decontamination protocols. Inability to trace instruments complicates appropriate management of exposure incidents. The feasibility of instituting instrument tracking procedures should be considered. C1 [Belay, Ermias D.; Blase, Jennifer; Maddox, Ryan A.; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Sehulster, Lynne M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Belay, ED (reprint author), 1600 Clifton Rd,Mailstop A 30, Atlanta, GA 30333 USA. EM ebelay@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 5 Z9 5 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC 1 PY 2013 VL 34 IS 12 BP 1272 EP 1280 DI 10.1086/673986 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 252AJ UT WOS:000326976300006 PM 24225612 ER PT J AU See, I Lessa, FC ElAta, OA Hafez, S Samy, K El-Kholy, A El Anani, MG Ismail, G Kandeel, A Galal, R Ellingson, K Talaat, M AF See, Isaac Lessa, Fernanda C. ElAta, Omar Abo Hafez, Soad Samy, Karim El-Kholy, Amani El Anani, Mervat Gaber Ismail, Ghada Kandeel, Amr Galal, Ramy Ellingson, Katherine Talaat, Maha TI Incidence and Pathogen Distribution of Healthcare-Associated Infections in Pilot Hospitals in Egypt SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; NOSOCOMIAL INFECTIONS; UNIVERSITY HOSPITALS; UNITED-STATES; SURVEILLANCE; PROGRAMS AB Objective.To report type and rates of healthcare-associated infections (HAIs) as well as pathogen distribution and antimicrobial resistance patterns from a pilot HAI surveillance system in Egypt. Methods.Prospective surveillance was conducted from April 2011 through March 2012 in 46 intensive care units (ICUs) in Egypt. Definitions were adapted from the Centers for Disease Control and Prevention''s National Healthcare Safety Network. Trained healthcare workers identified HAIs and recorded data on clinical symptoms and up to 4 pathogens. A convenience sample of clinical isolates was tested for antimicrobial resistance at a central reference laboratory. Multidrug resistance was defined by international consensus criteria. Results.ICUs from 11 hospitals collected 90,515 patient-days of surveillance data. Of 472 HAIs identified, 47% were pneumonia, 22% were bloodstream infections, and 15% were urinary tract infections; case fatality among HAI case patients was 43%. The highest rate of device-associated infections was reported for ventilator-associated pneumonia (pooled mean rate, 7.47 cases per 1,000 ventilator-days). The most common pathogens reported were Acinetobacter species (21.8%) and Klebsiella species (18.4%). All Acinetobacter isolates tested (31/31) were multidrug resistant, and 71% (17/24) of Klebsiella pneumoniae isolates were extended-spectrum -lactamase producers. Conclusions.Infection control priorities in Egypt should include preventing pneumonia and preventing infections due to antimicrobial-resistant pathogens. C1 [See, Isaac; Lessa, Fernanda C.; Ellingson, Katherine] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [See, Isaac] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [ElAta, Omar Abo; Samy, Karim; Talaat, Maha] US Naval Med Res Unit 3, Infect Control Unit, Global Dis Detect & Response Program, Cairo, Egypt. [Hafez, Soad] Alexandria Univ Hosp, Dept Infect Control, Alexandria, Egypt. [El-Kholy, Amani; El Anani, Mervat Gaber] Cairo Univ, Fac Med, Dept Clin Pathol, Infect Control Unit, Cairo, Egypt. [El-Kholy, Amani; El Anani, Mervat Gaber] Cairo Univ, Fac Med, Dept Pediat, Cairo, Egypt. [Ismail, Ghada] Ain Shams Univ Hosp, Dept Clin Pathol, Cairo, Egypt. [Kandeel, Amr; Galal, Ramy] Minist Hlth & Populat, Cairo, Egypt. RP See, I (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-24, Atlanta, GA 30333 USA. EM isee@cdc.gov FU US Agency for International Development [263-P-00-10-00005-00] FX Financial support. This work was supported by the US Agency for International Development (work unit 263-P-00-10-00005-00). We thank Drs Randy Kolstadt and Akmal El-Erian for their support during the conduct of this work. NR 23 TC 4 Z9 5 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC 1 PY 2013 VL 34 IS 12 BP 1281 EP 1288 DI 10.1086/673985 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 252AJ UT WOS:000326976300007 PM 24225613 ER PT J AU Greenbaum, AH Wong, K Nguyen, D Smith, E Torso, L Chen, G Wise, M Casey, M Ostroff, S Nambiar, A Nalluswami, K Miller, J Lute, J Klimov, A Emery, S Green, M Giampa, P Moll, M Finelli, L Jhung, M AF Greenbaum, Adena H. Wong, K. Nguyen, D. Smith, E. Torso, L. Chen, G. Wise, M. Casey, M. Ostroff, S. Nambiar, A. Nalluswami, K. Miller, J. Lute, J. Klimov, A. Emery, S. Green, M. Giampa, P. Moll, M. Finelli, L. Jhung, M. TI Assessment for Possible Healthcare-Associated Transmission of a New Variant Influenza Virus-Pennsylvania, August 2011 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID A H1N1 VIRUS; PANDEMIC H1N1; PERSONNEL; DURATION; OUTBREAK AB In August 2011, one of the earliest cases of influenza A(H3N2) variant [A(H3N2)v] virus infection was hospitalized with severe illness. To investigate the potential for healthcare-associated transmission of influenza A(H3N2)v, we evaluated both healthcare providers and patient contacts of the case. We found that healthcare-associated transmission was unlikely. C1 [Greenbaum, Adena H.; Wong, K.; Chen, G.] Ctr Dis Control & Prevent CDC, Influenza Div, Epidem Intelligence Serv, Atlanta, GA USA. [Nguyen, D.] CDC, Div Healthcare & Qual Promot, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Smith, E.; Torso, L.; Ostroff, S.; Nambiar, A.; Nalluswami, K.; Miller, J.; Lute, J.; Moll, M.] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Wise, M.] CDC, Div Healthcare & Qual Promot, Atlanta, GA 30333 USA. [Casey, M.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA. [Klimov, A.; Emery, S.; Finelli, L.; Jhung, M.] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Green, M.; Giampa, P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Greenbaum, AH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM agreenbaum@jhmi.edu NR 10 TC 0 Z9 0 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC 1 PY 2013 VL 34 IS 12 BP 1306 EP 1309 DI 10.1086/673980 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 252AJ UT WOS:000326976300010 PM 24225616 ER PT J AU Bitsko, RH Danielson, M King, M Visser, SN Scahill, L Perou, R AF Bitsko, Rebecca H. Danielson, Melissa King, Michael Visser, Susanna N. Scahill, Lawrence Perou, Ruth TI Health Care Needs of Children With Tourette Syndrome SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE Tourette syndrome; mental disorders; health care; care coordination; behavioral health; tics ID QUALITY-OF-LIFE; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; TIC DISORDERS; PSYCHIATRIC-DISORDERS; CHILDHOOD ASTHMA; BEHAVIOR-THERAPY; CHRONIC ILLNESS; UNITED-STATES; PREVALENCE AB To document the impact of Tourette syndrome on the health care needs of children and access to health care among youth with Tourette syndrome, parent-reported data from the 2007-2008 National Survey of Children's Health were analyzed. Children with Tourette syndrome had more co-occurring mental disorders than children with asthma or children without Tourette syndrome or asthma and had health care needs that were equal to or greater than children with asthma (no Tourette syndrome) or children with neither asthma nor Tourette syndrome. Health care needs were greatest among children with Tourette syndrome and co-occurring mental disorders, and these children were least likely to receive effective care coordination. Addressing co-occurring conditions may improve the health and well-being of children with Tourette syndrome. Strategies such as integration of behavioral health and primary care may be needed to improve care coordination. C1 [Bitsko, Rebecca H.; Danielson, Melissa; Visser, Susanna N.; Perou, Ruth] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [King, Michael] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Scahill, Lawrence] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Scahill, Lawrence] Marcus Ctr, Atlanta, GA USA. RP Bitsko, RH (reprint author), NCBDDD CDC, Child Dev Studies Team, Div Human Dev & Disabil, MS E-88,1600 Clifton Rd, Atlanta, GA 30333 USA. EM dvk2@cdc.gov OI Scahill, Lawrence/0000-0001-5073-1707; Danielson, Melissa/0000-0001-9461-0341 FU Shire Pharmaceuticals; Roche Pharmaceuticals; Pfizer; National Institutes of Mental Health; Tourette Syndrome Association FX The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Dr Scahill receives research funding from Shire Pharmaceuticals (ongoing), Roche Pharmaceuticals (ongoing), Pfizer (program terminated), the National Institutes of Mental Health, and the Tourette Syndrome Association. He has served as a consultant (past 2 years) for Roche, Pfizer, BioMarin, and Brackett. All other authors are employees of the US Centers for Disease Control and Prevention. NR 59 TC 5 Z9 5 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 EI 1708-8283 J9 J CHILD NEUROL JI J. Child Neurol. PD DEC PY 2013 VL 28 IS 12 BP 1626 EP 1636 DI 10.1177/0883073812465121 PG 11 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 250NQ UT WOS:000326859900011 PM 23143730 ER PT J AU Denison, AM DeLeon-Carnes, M Blau, DM Shattuck, EC McDougal, LK Rasheed, JK Limbago, BM Zaki, SR Paddock, CD AF Denison, Amy M. DeLeon-Carnes, Marlene Blau, Dianna M. Shattuck, Eric C. McDougal, Linda K. Rasheed, James K. Limbago, Brandi M. Zaki, Sherif R. Paddock, Christopher D. TI Molecular Characterization of Staphylococcus aureus and Influenza Virus Coinfections in Patients with Fatal Pneumonia SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; PANTON-VALENTINE LEUKOCIDIN; METHICILLIN-RESISTANT; UNITED-STATES; PANDEMIC INFLUENZA; BACTERIAL PNEUMONIA; A H1N1; INFECTIONS; CHILDREN; DISEASE AB Molecular techniques were used to characterize genetic features of Staphylococcus aureus in 66 fatal cases of pneumonia caused by S. aureus and influenza A or B viruses. Nucleic acids were extracted from formalin-fixed, paraffin-embedded tissues. The majority of cases revealed genetic markers for Panton-Valentine leukocidin, mecA, and spa type t008. C1 [Denison, Amy M.; DeLeon-Carnes, Marlene; Blau, Dianna M.; Shattuck, Eric C.; Zaki, Sherif R.; Paddock, Christopher D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [McDougal, Linda K.; Rasheed, James K.; Limbago, Brandi M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Denison, AM (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM crk6@cdc.gov NR 31 TC 4 Z9 4 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2013 VL 51 IS 12 BP 4223 EP 4225 DI 10.1128/JCM.02503-13 PG 3 WC Microbiology SC Microbiology GA 254EL UT WOS:000327147100057 PM 24068016 ER PT J AU Zhuo, XH AF Zhuo, Xiaohui TI Capsule Commentary on Ritzwoller et al., Economic Analyses of the Be Fit Be Well Program: A Weight Loss Program for Community Health Centers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID DIABETES PREVENTION PROGRAM C1 Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Zhuo, XH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K10, Atlanta, GA 30341 USA. EM xzhuo@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2013 VL 28 IS 12 BP 1643 EP 1643 DI 10.1007/s11606-013-2504-3 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 253YY UT WOS:000327127700020 PM 23739812 ER PT J AU Panella, NA Young, G Komar, N AF Panella, Nicholas A. Young, Ginger Komar, Nicholas TI Experimental infection of Eurasian collared-dove (Streptopelia decaocto) with West Nile virus SO JOURNAL OF VECTOR ECOLOGY LA English DT Article DE Eurasian collared-dove; West Nile virus; amplification host; virus titer; reservoir competence index ID DIPTERA-CULICIDAE; VECTOR COMPETENCE; TRANSMISSION; COLORADO; SPREAD; BIRDS AB The Eurasian collared-dove (Streptopelia decaocto) has recently experienced a population explosion in North America. It is frequently infected with West Nile virus (WNV). To test the hypothesis that the Eurasian collared-dove is competent to transmit WNV, we experimentally infected two cohorts of doves with two different strains of WNV, CO08, and NY99, respectively. Both virus strains induced a low-level viremia, capable of infecting a small fraction of vector mosquitoes. We suggest that the Eurasian collared-dove plays a relatively insignificant role as an amplifying host for WNV, but it may be important where it is locally abundant. C1 [Panella, Nicholas A.; Young, Ginger; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. RP Panella, NA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. EM nap4@cdc.gov NR 26 TC 5 Z9 6 U1 0 U2 4 PU SOC VECTOR ECOLOGY PI CORONA PA 1966 COMPTON AVE, CORONA, CA 92881 USA SN 1081-1710 EI 1948-7134 J9 J VECTOR ECOL JI J. Vector Ecol. PD DEC PY 2013 VL 38 IS 2 BP 210 EP 214 PG 5 WC Entomology SC Entomology GA 251JC UT WOS:000326923500002 PM 24581347 ER PT J AU Lobo, SA Patil, K Jain, S Marks, S Visvesvara, GS Tenner, M Braun, A Wang, GQ El Khoury, MY AF Lobo, Stephen A. Patil, Kiran Jain, Shilpa Marks, Stephen Visvesvara, Govinda S. Tenner, Michael Braun, Alex Wang, Guiqing El Khoury, Marc Y. TI Diagnostic challenges in Balamuthia mandrillaris infections SO PARASITOLOGY RESEARCH LA English DT Article ID AMEBIC ENCEPHALITIS; MENINGOENCEPHALITIS; IMMUNOCOMPETENT; PCR AB Balamuthia mandrillaris is an emerging cause of subacute granulomatous amebic encephalitis (GAE). The diagnosis of this infection has proven to be difficult and is usually made postmortem. Early recognition and treatment may offer some benefit. This report describes a previously healthy woman who died from GAE due to B. mandrillaris. C1 [Lobo, Stephen A.; El Khoury, Marc Y.] New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA. [Patil, Kiran; Marks, Stephen] New York Med Coll, Dept Neurol, Valhalla, NY 10595 USA. [Jain, Shilpa; Braun, Alex; Wang, Guiqing] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA. [Tenner, Michael] New York Med Coll, Dept Radiol, Valhalla, NY 10595 USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP El Khoury, MY (reprint author), New York Med Coll, Dept Med, Div Infect Dis, Munger Pavil,Room 245, Valhalla, NY 10595 USA. EM marc_khoury@nymc.edu NR 16 TC 5 Z9 5 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 EI 1432-1955 J9 PARASITOL RES JI Parasitol. Res. PD DEC PY 2013 VL 112 IS 12 BP 4015 EP 4019 DI 10.1007/s00436-013-3592-z PG 5 WC Parasitology SC Parasitology GA 254CS UT WOS:000327141300005 PM 24022127 ER PT J AU Payne, AB Link-Gelles, R Azonobi, I Hooper, WC Beall, BW Jorgensen, JH Juni, B Moore, M AF Payne, Amanda B. Link-Gelles, Ruth Azonobi, Ijeoma Hooper, W. Craig Beall, Bernard W. Jorgensen, James H. Juni, Billie Moore, Matthew CA Active Bacterial Core Surveillance TI Invasive Pneumococcal Disease Among Children With and Without Sickle Cell Disease in the United States, 1998 to 2009 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pneumococcal conjugate vaccine; sickle cell disease; Streptococcus pneumoniae ID CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; BACTERIAL-INFECTIONS; SEROTYPE 19A; RECOMMENDATIONS; PROPHYLAXIS; ERA; 6C; US AB Background: Children with sickle cell disease (SCD) are at increased risk of illness and death from invasive pneumococcal disease (IPD). The introduction in 2000 of the 7-valent pneumococcal conjugate vaccine and penicillin prophylaxis for children with SCD has greatly reduced the incidence of IPD in this population. However, a recent report suggested an increase in cases of IPD in children with SCD. Methods: Using data from Active Bacterial Core surveillance, we analyzed trends in hospitalizations, mortality and serotype among children with SCD compared with other children. We used neonatal screening data to estimate SCD population denominators for each Active Bacterial Core surveillance site. Results: From 1998 to 2009, 3069 cases of IPD occurred among African-American children less than 18 years of age in the Active Bacterial Core surveillance catchment area. Of these, 127 (4.1%) had SCD identified by medical chart review and 185 (6.0%) had 1 or more IPD risk factors, excluding SCD. Rates of IPD among children with SCD declined by 53% (1118 vs. 530 per 100,000) whereas the overall rates among African-American children declined by 74% (54 to 14 per 100,000). For all time periods, children with SCD and IPD were more likely to be hospitalized (84%-92% vs. 31%-56%) and more likely to die (6%-17% vs. 1%-2%) than children with no risk factors. Conclusions: Although the rate of IPD in children with SCD has dropped dramatically since 7-valent pneumococcal conjugate vaccine introduction, the rate of IPD in children with SCD remains higher than that of the general population of African-American children, pointing to the need for more effective prevention efforts to prevent IPD in children with SCD. C1 [Payne, Amanda B.; Azonobi, Ijeoma; Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA 30333 USA. [Link-Gelles, Ruth; Beall, Bernard W.; Moore, Matthew] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Juni, Billie] Minnesota Dept Hlth, Minneapolis, MN USA. RP Payne, AB (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, 1600 Clifton Rd,Mailstop D02, Atlanta, GA 30333 USA. EM bvx2@cdc.gov FU Centers for Disease Control and Prevention (CDC); Merck and bioMerieux FX This work was supported by the Centers for Disease Control and Prevention (CDC), which provides funding for the Active Bacterial Core surveillance system, a collaboration of state health departments, academic institutions, local partners, and the CDC. J.J. has served on an advisory board for Beckton Dickinson, has served as a consultant for Accelerate Diagnostics and Merck, and has received grant funding from Merck and bioMerieux. NR 32 TC 16 Z9 16 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD DEC PY 2013 VL 32 IS 12 BP 1308 EP 1312 DI 10.1097/INF.0b013e3182a11808 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 254UH UT WOS:000327192800013 PM 23811745 ER PT J AU Msimang, VMY Page, N Groome, MJ Moyes, J Cortese, MM Seheri, M Kahn, K Chagan, M Madhi, SA Cohen, C AF Msimang, Veerle M. Y. Page, Nicola Groome, Michelle J. Moyes, Jocelyn Cortese, Margaret M. Seheri, Mapaseka Kahn, Kathleen Chagan, Meera Madhi, Shabir A. Cohen, Cheryl TI Impact of Rotavirus Vaccine on Childhood Diarrheal Hospitalization After Introduction Into the South African Public Immunization Program SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rotavirus vaccine; childhood diarrhea; hospitalization ID AGED LESS-THAN-5 YEARS; US CHILDREN; REDUCTION; DISEASE; GASTROENTERITIS; SURVEILLANCE; EPIDEMIOLOGY; SEASONS; BURDEN AB Background: Oral rotavirus vaccine was introduced into the South African routine immunization program in August 2009 administered at 6 and 14 weeks with no catch-up. We described the change in rotavirus-associated diarrheal hospitalizations among children <5 years at 3 sentinel sites from 2009 through 2011. Methods: During 2009 through 2011, we compared the proportion of enrolled children aged <5 years hospitalized with acute gastroenteritis and testing rotavirus positive. We used hospital data to determine the change in diarrhea hospitalizations and estimated total numbers of rotavirus hospitalizations by adjusting for nonenrolled patients. Stool samples were tested for rotavirus using enzyme immunoassay. Results: In 2009 (May-December), 46% (404/883) of samples among children <5 years tested rotavirus positive, decreasing to 33% (192/580) (P < 0.001) in 2010 and 29% (113/396) (P < 0.001) in 2011. Compared with May-December 2009, total diarrhea hospitalizations among children aged <5 years was one-third lower in May-December of 2010 and 2011. Among infants, adjusted rotavirus hospitalizations were 61% (n = 267) and 69% (n = 214) lower, respectively, in 2010 and 2011 when compared with 2009 (n = 689), and 45 and 50 percentage points greater than the reduction in rotavirus-negative cases. Among children <5 years, rotavirus hospitalizations were 54% and 58% lower in 2010 and 2011, compared with 2009 (40 and 44 percentage points greater than reduction in rotavirus-negative cases). Rotavirus reductions occurred in rural and urban settings. Conclusion: Using published estimates of rotavirus hospitalization burden, we estimate that at least 13,000 to 20,000 hospitalizations in children <2 years were prevented in the 2 years after rotavirus vaccine introduction. C1 [Msimang, Veerle M. Y.; Page, Nicola; Moyes, Jocelyn; Madhi, Shabir A.; Cohen, Cheryl] Univ Witwatersrand, Natl Hlth Lab Serv, Natl Inst Commun Dis, Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Cortese, Margaret M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Seheri, Mapaseka] S African MRC, Diarrhoeal Pathogens Res Unit, Pretoria, South Africa. [Kahn, Kathleen] Univ Witwatersrand, Fac Hlth Sci, MRC, Wits Rural Publ Hlth & Hlth Transit Res Unit Agin, Johannesburg, South Africa. [Kahn, Kathleen] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. [Chagan, Meera] Univ Kwazulu Natal, Dept Paediat, Durban, South Africa. RP Msimang, VMY (reprint author), Natl Inst Communicable Dis, 1 Modderfontein Rd,Private Bag X4, ZA-3121 Johannesburg, South Africa. EM veerlem@nicd.ac.za OI Page, Nicola/0000-0001-5845-4417 FU GlaxoSmithKline (GSK); GSK; Merck (MSD) Pty (Ltd). FX This surveillance work was supported by an unconditional grant for the conduct of Sentinel Site Rotavirus Surveillance from GlaxoSmithKline (GSK).; N.P. reports receiving fees for speaking engagements by GSK and Merck (MSD) Pty (Ltd). S. A. M. has received honorarium from GSK and MERCK. All authors have submitted the PIDJ Form for Disclosure of Potential Conflict of Interest. Conflicts that the editors consider relevant to the content of the article have been disclosed in the Acknowledgment section. NR 33 TC 22 Z9 24 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD DEC PY 2013 VL 32 IS 12 BP 1359 EP 1364 DI 10.1097/INF.0b013e3182a72fc0 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 254UH UT WOS:000327192800023 PM 24569308 ER PT J AU Li, CY Zeliadt, SB Hall, IJ Smith, JL Ekwueme, DU Moinpour, CM Penson, DF Thompson, IM Keane, TE Ramsey, SD AF Li, Chunyu Zeliadt, Steven B. Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Moinpour, Carol M. Penson, David F. Thompson, Ian M. Keane, Thomas E. Ramsey, Scott D. TI Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Informal caregiving; Prostate cancer; Local stage; Time cost; Household chores; Productivity ID QUALITY-OF-LIFE; EMPLOYMENT; TIME; MEN; SURVIVORS; CARE; ILLNESS; STATES; BREAST; WORK AB Informal care plays an important role in the overall care for people with cancer. This study estimates lost productivity and informal caregiving and associated costs among partner caregivers of localized prostate cancer patients within 1 year after diagnosis. We applied data from the Family and Cancer Therapy Selection study, a three-wave self-administered survey among patients diagnosed with localized prostate cancer and their partner caregivers in multiple clinics in the USA. Time spent was measured by the sum of working hours lost, informal caregiving hours performed, and hours spent on household chores. The national median income for women 55 years or older was used to calculate costs associated with the time spent using the opportunity cost method. Descriptive and bivariate analyses were conducted. The average working hours decreased from 14.0 h/week (SD = 17.6) to 10.9 h/week (SD = 15.9), without a significant change in responsibility/intensity at work. The mean annual time spent on informal caregiving and household chores was 65.9 h/year (SD = 172.4) and 76.2 h/year (SD = 193.3), respectively. The mean annual economic burden among partner caregivers was US$6,063 (range US$571-US$47,105) in 2009 dollars accounted for by a mean of 276.2 h (range 26-2,146) in the study sample. The time spent on informal caregiving and household chores varied by patient and caregiver characteristics. Pilot estimates on non-medical economic burden among partner caregivers (spouses) during the initial phase of the treatment provide important information for comprehensive estimation of disease burden and can be used in cost-effectiveness analyses of prostate cancer interventions. C1 [Li, Chunyu; Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Zeliadt, Steven B.; Moinpour, Carol M.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Publ Hlth Serv Div, Seattle, WA 98104 USA. [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Penson, David F.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Med & Publ Hlth, Nashville, TN USA. [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Keane, Thomas E.] Med Univ S Carolina, Urol Serv, Charleston, SC 29425 USA. RP Li, CY (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA. EM Cli11@cdc.gov FU Centers for Disease Control and Prevention (CDC), Prevention Research Centers Program, through the University of Washington Health Promotion Research Center [SIP 25-04 1-U48-DP-000050] FX This study was supported by the Cooperative Agreement Number SIP 25-04 1-U48-DP-000050 from the Centers for Disease Control and Prevention (CDC), Prevention Research Centers Program, through the University of Washington Health Promotion Research Center. There is no conflict of interest. The corresponding author has full access to all primary data and agree to allow the journal to review their data if requested. NR 32 TC 4 Z9 5 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2013 VL 21 IS 12 BP 3461 EP 3469 DI 10.1007/s00520-013-1931-3 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 250YE UT WOS:000326892100028 PM 23955026 ER PT J AU Roess, AA McCollum, AM Gruszynski, K Zhao, H Davidson, W Lafon, N Engelmeyer, T Moyer, B Godfrey, C Kilpatrick, H Labonte, A Murphy, J Carroll, DS Li, Y Damon, IK AF Roess, A. A. McCollum, A. M. Gruszynski, K. Zhao, H. Davidson, W. Lafon, N. Engelmeyer, T. Moyer, B. Godfrey, C. Kilpatrick, H. Labonte, A. Murphy, J. Carroll, D. S. Li, Y. Damon, I. K. TI Surveillance of Parapoxvirus Among Ruminants in Virginia and Connecticut SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Parapoxvirus; pseudopoxvirus; white-tailed deer; cow ID BOVINE PAPULAR STOMATITIS; ORF-VIRUS-INFECTION; RANGIFER-TARANDUS-TARANDUS; MILKERS NODULES; SEALPOX VIRUS; RED DEER; TRANSMISSION; PSEUDOCOWPOX; CALIFORNIA; CATTLE AB In 2008, two deer hunters in Virginia and Connecticut were infected with a unique strain of pseudocowpox virus, a parapoxvirus. To estimate the prevalence of this virus, and in an attempt to define the reservoir, Parapoxvirus surveillance was undertaken between November 2009 and January 2010. 125 samples from four ruminant species (cows, goat, sheep and white-tailed deer) were collected in Virginia, and nine samples from white-tailed deer were collected in Connecticut. We found no evidence that the parapoxvirus species that infected the deer hunters is circulating among domesticated ruminants or white-tailed deer. However, parapoxvirus DNA of a different parapoxvirus species, bovine papular stomatitis virus (BPSV), was detected in 31 samples obtained from asymptomatic cattle in Virginia. Parapoxvirus DNA-positive cattle originated from the same counties indicating probable transmission among animals. Molecular analysis identified BPSV as the parapoxvirus affecting animals. Asymptomatic parapoxvirus infections in livestock, particularly young animals, may be common, and further investigation will inform our knowledge of virus transmission. C1 [Roess, A. A.; McCollum, A. M.; Zhao, H.; Davidson, W.; Carroll, D. S.; Li, Y.; Damon, I. K.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Roess, A. A.; McCollum, A. M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Gruszynski, K.; Murphy, J.] Virginia Dept Hlth, Richmond, VA USA. [Lafon, N.; Engelmeyer, T.; Moyer, B.; Godfrey, C.] Virginia Dept Game & Inland Fisheries, Richmond, VA USA. [Kilpatrick, H.; Labonte, A.] Connecticut Dept Energy & Environm Protect, Wildlife Div, North Franklin, CT USA. RP Roess, AA (reprint author), George Washington Univ, Dept Global Hlth, 2175 K St,NW Suite 200, Washington, DC 20037 USA. EM aroess@gwu.edu NR 39 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD DEC PY 2013 VL 60 IS 8 BP 543 EP 548 DI 10.1111/zph.12036 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 255QR UT WOS:000327255400004 PM 23398718 ER PT J AU Dooling, KL Crist, MB Nguyen, DB Bass, J Lorentzson, L Toews, KA Pondo, T Stone, ND Beall, B Van Beneden, C AF Dooling, Kathleen L. Crist, Matthew B. Nguyen, Duc B. Bass, Jennifer Lorentzson, Lauren Toews, Karrie-Ann Pondo, Tracy Stone, Nimalie D. Beall, Bernard Van Beneden, Chris TI Investigation of a Prolonged Group A Streptococcal Outbreak Among Residents of a Skilled Nursing Facility, Georgia, 2009-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE group A Streptococcus; emm type; Active Bacterial Core surveillance; skilled nursing facility; infection control ID TERM-CARE FACILITIES; UNITED-STATES; DISEASE; EPIDEMIOLOGY; INFECTION AB Background. Group A Streptococcus (GAS) is an important bacterial cause of life-threatening illness among the elderly. Public health officials investigated a protracted GAS outbreak in a skilled nursing facility in Georgia housing patients requiring 24-hour nursing or rehabilitation, to prevent additional cases. Methods. We defined a case as illness in a skilled nursing facility resident with onset after January 2009 with GAS isolated from a usually sterile (invasive) or nonsterile site (noninvasive). Cases were "recurrent" if >1 month elapsed between episodes. We evaluated infection control practices, performed a GAS carriage study, emm-typed available GAS isolates, and conducted a case-control study of risk factors for infection. Results. Three investigations, spanning 36 months, identified 19 residents with a total of 24 GAS infections: 15 invasive (3 recurrent) and 9 noninvasive (2 recurrent) episodes. All invasive cases required hospitalization; 4 patients died. Seven residents were GAS carriers. All invasive cases and resident carrier isolates were type emm 11.0. We observed hand hygiene lapses, inadequate infection documentation, and more frequent wound care staff turnover on wing A versus wing B. Risk factors associated with infection in multivariable analysis included living on wing A (odds ratio [OR], 3.4; 95% confidence interval [CI], .9-16.4) and having an indwelling line (OR, 5.6; 95% CI, 1.2-36.4). Cases ceased following facility-wide chemoprophylaxis in July 2012. Conclusions. Staff turnover, compromised skin integrity in residents, a suboptimal infection control program, and lack of awareness of infections likely contributed to continued GAS transmission. In widespread, prolonged GAS outbreaks in skilled nursing facilities, facility-wide chemoprophylaxis may be necessary to prevent sustained person-to-person transmission. C1 [Dooling, Kathleen L.; Toews, Karrie-Ann; Pondo, Tracy; Beall, Bernard; Van Beneden, Chris] Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA USA. [Dooling, Kathleen L.; Nguyen, Duc B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Crist, Matthew B.; Lorentzson, Lauren] Georgia Dept Publ Hlth, Atlanta, GA USA. [Nguyen, Duc B.; Stone, Nimalie D.] Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. [Bass, Jennifer] Ctr Dis Control & Prevent, Appl Epidemiol Fellowship, Atlanta, GA 30333 USA. RP Dooling, KL (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30333 USA. EM vic9@cdc.gov FU Respiratory Diseases Branch, CDC; Division of Healthcare Quality Promotion, CDC; Georgia Department of Public Health FX This work was supported by the Respiratory Diseases Branch, CDC; Division of Healthcare Quality Promotion, CDC; and the Georgia Department of Public Health. NR 13 TC 5 Z9 5 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2013 VL 57 IS 11 BP 1562 EP 1567 DI 10.1093/cid/cit558 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 247XK UT WOS:000326657000013 PM 24021484 ER PT J AU Thompson, MG Sokolow, LZ Almendares, O Openo, K Farley, MM Meek, J Ray, J Kirley, PD Reingold, A Aragon, D Hancock, E Baumbach, J Schaffner, W Lynfield, R Ryan, P Monroe, M Cheng, PY Fry, AM Shay, DK AF Thompson, Mark G. Sokolow, Leslie Z. Almendares, Olivia Openo, Kyle Farley, Monica M. Meek, James Ray, Julie Kirley, Pamala Daily Reingold, Arthur Aragon, Deborah Hancock, Emily Baumbach, Joan Schaffner, William Lynfield, Ruth Ryan, Pat Monroe, Maya Cheng, Po-Yung Fry, Alicia M. Shay, David K. TI Effectiveness of Nonadjuvanted Monovalent Influenza A(H1N1) pdm09 Vaccines for Preventing Reverse Transcription Polymerase Chain Reaction-Confirmed Pandemic Influenza Hospitalizations: Case-Control Study of Children and Adults at 10 US Influenza Surveillance Network Sites SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; influenza vaccines; vaccine effectiveness; hospitalization; pandemic/prevention & control ID A H1N1; UNITED-STATES AB During 2009-2010, we examined 217 patients hospitalized with laboratory-confirmed pandemic influenza in 9 Influenza Hospitalization Surveillance Network sites and 413 age- and community-matched controls and found that a single dose of monovalent nonadjuvanted influenza A(H1N1)pdm09 vaccine was 50% (95% confidence interval, 13%-71%) effective in preventing hospitalization associated with A(H1N1) pdm09 virus infection. C1 [Thompson, Mark G.; Sokolow, Leslie Z.; Cheng, Po-Yung; Fry, Alicia M.; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Sokolow, Leslie Z.; Cheng, Po-Yung] Battelle Mem Inst, Atlanta, GA USA. [Almendares, Olivia; Openo, Kyle; Farley, Monica M.] Atlanta VA Med Ctr, Atlanta, GA USA. [Almendares, Olivia; Openo, Kyle] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Meek, James; Ray, Julie] Connecticut Emerging Infect Program, New Haven, CT USA. [Kirley, Pamala Daily] Calif Emerging Infect Program, Oakland, CA USA. [Reingold, Arthur] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Hancock, Emily; Baumbach, Joan] New Mexico Emerging Infect Program, Santa Fe, NM USA. [Schaffner, William] Tennessee Dept Hlth, Nashville, TN USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37235 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Ryan, Pat; Monroe, Maya] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS-A32, Atlanta, GA 30333 USA. EM isq8@cdc.gov FU Centers for Disease Control and Prevention; Influenza Hospitalization Surveillance Network (FluSurv-NET), California [U01CI000309]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Colorado [U01CI000305]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Connecticut [U01CI000307]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Georgia [U01CI000312]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Maryland [U01CI000310]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Minnesota [U01CI000313]; Influenza Hospitalization Surveillance Network (FluSurv-NET), New Mexico [U01CI622221]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Oregon [U01CI000306]; Influenza Hospitalization Surveillance Network (FluSurv-NET), Tennessee [U01CI000304] FX This study was funded by the Centers for Disease Control and Prevention through cooperative agreements with the Influenza Hospitalization Surveillance Network (FluSurv-NET) by state: California (U01CI000309), Colorado (U01CI000305), Connecticut (U01CI000307), Georgia (U01CI000312), Maryland (U01CI000310), Minnesota (U01CI000313), New Mexico (U01CI622221), Oregon (U01CI000306), and Tennessee (U01CI000304). NR 12 TC 8 Z9 8 U1 0 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2013 VL 57 IS 11 BP 1587 EP 1592 DI 10.1093/cid/cit551 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 247XK UT WOS:000326657000016 PM 23956169 ER PT J AU Mirambeau, AM Wang, GJ Ruggles, L Dunet, DO AF Mirambeau, Alberta M. Wang, Guijing Ruggles, Laural Dunet, Diane O. TI A Cost Analysis of a Community Health Worker Program in Rural Vermont SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Community health worker; Program cost; Health care system ID CARE UTILIZATION; OUTREACH; INTERVENTION; ASTHMA AB Studies have shown that community health workers (CHWs) can improve the effectiveness of health care systems; however, little has been reported about CHW program costs. We examined the costs of a program staffed by three CHWs associated with a small, rural hospital in Vermont. We used a standardized data collection tool to compile cost information from administrative data and personal interviews. We analyzed personnel and operational costs from October 2010 to September 2011. The estimated total program cost was $420,348, a figure comprised of $281,063 (67 %) for personnel and $139,285 (33 %) for operations. CHW salaries and office space were the major cost components. Our cost analysis approach may be adapted by others to conduct cost analyses of their CHW program. Our cost estimates can help inform future economic studies of CHW programs and resource allocation decisions. C1 [Mirambeau, Alberta M.; Wang, Guijing; Dunet, Diane O.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Ruggles, Laural] Northeastern Vermont Reg Hosp, St Johnsbury, VT 05819 USA. RP Mirambeau, AM (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway,MS F-72, Atlanta, GA 30341 USA. EM amirambeau@cdc.gov RI Mashamba-Thompson, Tivani /B-6087-2014 FU Intramural CDC HHS [CC999999]; PHS HHS [200-2008-27957] NR 31 TC 1 Z9 1 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD DEC PY 2013 VL 38 IS 6 BP 1050 EP 1057 DI 10.1007/s10900-013-9713-x PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 248IW UT WOS:000326693600009 PM 23794072 ER PT J AU Weinmann, S Chun, C Schmid, DS Roberts, M Vandermeer, M Riedlinger, K Bialek, SR Marin, M AF Weinmann, Sheila Chun, Colleen Schmid, D. Scott Roberts, Michelle Vandermeer, Meredith Riedlinger, Karen Bialek, Stephanie R. Marin, Mona TI Incidence and Clinical Characteristics of Herpes Zoster Among Children in the Varicella Vaccine Era, 2005-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE herpes zoster; shingles; incidence; epidemiology; varicella zoster virus; varicella vaccine; children ID VIRUS; ADOLESCENTS; EPIDEMIOLOGY; SURVEILLANCE AB Background. Vaccine-strain herpes zoster (HZ) can occur after varicella vaccination. This study determined the number and proportion of HZ cases caused by vaccine-strain varicella zoster virus (VZV), assessed the positive predictive value of provider diagnosis of HZ, and computed HZ incidence rates in vaccinated and unvaccinated children. Methods. We used electronic medical records to identify all office visits with an HZ diagnosis for children aged <18 years in a managed care plan. Providers collected skin specimens and completed a questionnaire. Specimens were tested by polymerase chain reaction to identify wild-type or vaccine-strain VZV. Results. From May 2005 to September 2009, we enrolled 322 subjects. VZV was detected in 82% of specimens (84% wild-type, 15% vaccine-strain, 1% possible vaccine-wild-type recombinant). Among the 118 vaccinated subjects, VZV was detected in 70% (52% wild-type). The positive predictive value for provider diagnosis of "definite HZ" was 93% for unvaccinated and 79% for vaccinated children. The incidence of laboratory-confirmed HZ was 48 per 100 000 person-years in vaccinated children (both wild-type and vaccine-strain) and 230 per 100 000 person-years in unvaccinated children (wild-type only). Conclusions. HZ incidence in vaccinated children was 79% lower than in unvaccinated children. Among vaccinated children, half of HZ cases were due to wild-type VZV. C1 [Weinmann, Sheila; Chun, Colleen; Roberts, Michelle; Vandermeer, Meredith; Riedlinger, Karen] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Chun, Colleen] Northwest Permanente, Dept Pediat, Portland, OR USA. [Schmid, D. Scott; Bialek, Stephanie R.; Marin, Mona] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Weinmann, S (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM sheila.weinmann@kpchr.org FU CDC [5U01/P00027-05] FX This work was supported by the CDC (contract number 5U01/P00027-05). NR 24 TC 31 Z9 31 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2013 VL 208 IS 11 BP 1859 EP 1868 DI 10.1093/infdis/jit405 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 247WQ UT WOS:000326654300017 PM 23922376 ER PT J AU Debbink, K Lindesmith, LC Donaldson, EF Costantini, V Beltramello, M Corti, D Swanstrom, J Lanzavecchia, A Vinje, J Baric, RS AF Debbink, Kari Lindesmith, Lisa C. Donaldson, Eric F. Costantini, Veronica Beltramello, Martina Corti, Davide Swanstrom, Jesica Lanzavecchia, Antonio Vinje, Jan Baric, Ralph S. TI Emergence of New Pandemic GII.4 Sydney Norovirus Strain Correlates With Escape From Herd Immunity SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE norovirus; GII.4 Sydney; virus-like particles; viral evolution; virus emergence ID BLOOD GROUP ANTIGENS; NORWALK-LIKE VIRUSES; UNITED-STATES; GII-4 NOROVIRUS; EPOCHAL EVOLUTION; HUMAN-POPULATIONS; P2 DOMAIN; GASTROENTERITIS; OUTBREAKS; BINDING AB Background. GII.4 noroviruses are a significant source of acute gastroenteritis worldwide, causing the majority of human norovirus outbreaks. Evolution of the GII.4 major capsid protein occurs rapidly, resulting in the emergence of new strains that produce successive waves of pandemic disease. A new pandemic isolate, GII.4 2012 Sydney, largely replaced previously circulating strains in late 2012. We compare the antigenic properties of GII.4 2012 Sydney with previously circulating strains. Methods. To determine whether GII.4-2012 Sydney is antigenically different from recently circulating strains GII.4-2006 Minerva and GII.4-2009 New Orleans in previously identified blockade epitopes, we compared reactivity and blockade profiles of GII.4-2006, GII.4-2009, and GII.4-2012 virus-like particles in surrogate neutralization/blockade assays using monoclonal antibodies and human polyclonal sera. Results. Using monoclonal antibodies that map to known blockade epitopes in GII.4-2006 and GII.4-2009 and human outbreak polyclonal sera, we demonstrate either complete loss or significantly reduced reactivity and blockade of GII.4.2012 compared to GII.4-2006 and GII.4-2009. Conclusions. GII.4-2012 Sydney is antigenically different from GII.4-2006 Minerva and GII.4-2009 New Orleans in at least 2 key blockade epitopes. Viral evolution in key potential neutralization epitopes likely allowed GII.4-2012 to escape from human herd immunity and emerge as the new predominant strain. C1 [Debbink, Kari; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. [Lindesmith, Lisa C.; Donaldson, Eric F.; Swanstrom, Jesica; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Costantini, Veronica; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Beltramello, Martina; Corti, Davide; Lanzavecchia, Antonio] Inst Res Biomed, Bellinzona, Switzerland. [Corti, Davide] Humabs Biomed SA, Bellinzona, Switzerland. RP Baric, RS (reprint author), 2107 McGavran Greenberg,CB 7435, Chapel Hill, NC 27599 USA. EM rbaric@email.unc.edu OI Costantini, Veronica/0000-0002-1532-4345; Vinje, Jan/0000-0002-1530-3675 FU National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) [AI056351]; NIH [T32-AI007419]; Career Guidance for Trainees grant from the Burroughs Wellcome Fund; NIH, NIAID; Food and Drug Administration; Burroughs Wellcome Fund FX This work was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID; grant AI056351), and by NIH institutional training grant T32-AI007419. K. D. is supported in part by a Career Guidance for Trainees grant from the Burroughs Wellcome Fund. R. S. B. received grant support for research and travel to meetings from the NIH, NIAID. E. F. D. was paid salary by the Food and Drug Administration and grant funding from the NIH. A. L. received grant support from the NIH. Salaries of L. C. L. and J. S. were paid by grant funds from the NIH, NIAID. Salary of K. D. was paid by grant funds from the NIH and Burroughs Wellcome Fund. D. C. was paid by grant funds from the NIH. NR 45 TC 58 Z9 60 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2013 VL 208 IS 11 BP 1877 EP 1887 DI 10.1093/infdis/jit370 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 247WQ UT WOS:000326654300019 PM 23908476 ER PT J AU Othumpangat, S Noti, JD Blachere, FM Beezhold, DH AF Othumpangat, Sreekumar Noti, John D. Blachere, Francoise M. Beezhold, Donald H. TI Expression of non-structural-1A binding protein in lung epithelial cells is modulated by miRNA-548an on exposure to influenza A virus SO VIROLOGY LA English DT Article DE miRNA; NS1A binding protein; Influenza virus; Lung epithelial cells; Apoptosis ID NONSTRUCTURAL NS1 PROTEIN; MESSENGER-RNAS; MICRORNAS; REPLICATION; INFECTION; PATHWAY; TRANSLATION; SUPPRESSION; COMPONENTS; MECHANISM AB Understanding the host response to influenza A virus infection is essential for developing intervention approaches. We show that infection of human alveolar epithelial cells and human bronchial epithelial cells with influenza A for 3 h resulted in down-regulation of host hsa-miRNA-548an (miRNA-548an) which triggered the overexpression of influenza non-structural-1A binding protein (IVNS1ABP, herein referred to as NS1ABP). Reduced NS1ABP mRNA and NS1ABP protein expression after transfection of miRNA-548an mimic or increased NS1ABP mRNA and NS1ABP protein expression after transfection of miRNA-548an inhibitor provided evidence that miRNA-548an is involved in the regulation of NS1ABP. Transfection of cells with inhibitor led to reduced apoptosis of infected cells while transfection of mimic led to increased apoptosis and reduced influenza copy number suggesting that NS1ABP has a role in viral maintenance. Thus, miRNA-548an may be an important target in controlling the early stage infection of influenza A. Published by Elsevier Inc. C1 [Othumpangat, Sreekumar; Noti, John D.; Blachere, Francoise M.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Noti, JD (reprint author), NIOSH, 1095 Willowdale Rd,MS 4020, Morgantown, WV 26505 USA. EM ivr2@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 6 Z9 6 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD DEC PY 2013 VL 447 IS 1-2 BP 84 EP 94 DI 10.1016/j.virol.2013.08.031 PG 11 WC Virology SC Virology GA 246QF UT WOS:000326553500009 PM 24210102 ER PT J AU Looker, AC AF Looker, Anne C. TI Femur neck bone mineral density and fracture risk by age, sex, and race or Hispanic origin in older US adults from NHANES III SO ARCHIVES OF OSTEOPOROSIS LA English DT Article DE Epidemiology; Femur neck; Bone density; Osteoporosis; Fracture AB Differences in the relationship between femur neck bone mineral density (FNBMD) and fracture risk were examined by age, sex, and race/ethnicity in the third National Health and Nutrition Examination Survey (NHANES III) cohort. FNBMD had similar, significant predictive utility for fracture in the different subgroups, but it did not completely account for subgroup differences in risk. Purpose Few previous studies of FNBMD and fracture risk examined the relationship by age, sex, and race within the same cohort. The present study examined the relationship between FNBMD and risk of incident major osteoporotic fracture (hip, spine, radius, and humerus) in older US adults from NHANES III (1988-1994). Methods Incident fractures were identified using linked mortality and Medicare records obtained through 2007 for 2,743 men and women ages 65 years and older. FNBMD was measured by dual-energy X-ray absorptiometry. Cox proportional hazards models were used to estimate the hazards ratio (HR) of fracture for FNBMD and femur neck T score and risk of major osteoporotic fracture. Results The sample included 380 incident major osteoporotic fractures. Fracture risk approximately doubled for each SD decrease in FNBMD. HR's for FNBMD were similar within age, sex, or race/Hispanic origin subgroups, and also for T scores calculated with either white female or sex-and race/ethnic-specific reference data. Adding FNBMD to Cox models slightly attenuated HR for age, sex, or race/Hispanic origin, but all three variables remained significant predictors of fracture risk. Conclusions FNBMD had similar, significant predictive utility within age, sex, and race/Hispanic origin subgroups. However, FNBMD did not appear to completely account for fracture risk differences in these subgroups. Similarity of HR's for T scores calculated with two different reference databases support use of a uniform reference database to calculate these scores. C1 [Looker, Anne C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Room 4310,3311 Toledo Rd, Hyattsville, MD USA. RP Looker, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Room 4310,3311 Toledo Rd, Hyattsville, MD USA. EM ALooker@cdc.gov NR 38 TC 7 Z9 7 U1 1 U2 33 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 1862-3522 EI 1862-3514 J9 ARCH OSTEOPOROS JI Arch. Osteoporos. PD DEC PY 2013 VL 8 IS 1-2 AR 141 DI 10.1007/s11657-013-0141-4 PG 11 WC Endocrinology & Metabolism; Orthopedics SC Endocrinology & Metabolism; Orthopedics GA V42WW UT WOS:000209644900055 PM 23715737 ER PT J AU Wethington, H Sherry, B Park, S Blanck, HM Fulton, JE AF Wethington, Holly Sherry, Bettylou Park, Sohyun Blanck, Heidi M. Fulton, Janet E. TI Active Screen Time Among U.S. Youth Aged 9-18 Years, 2009 SO GAMES FOR HEALTH JOURNAL LA English DT Article AB Objective: This study documented the prevalence of active screen time (i.e., screen time that includes active games, exercise or dance videos, or TV exercise programs) and identified characteristics associated with it among youth 9-18 years of age. Subjects and Methods: This cross-sectional study was conducted on a convenience sample of 1,165 youth using the 2009 Styles Surveys; data were weighted to approximate the Current Population Survey. We calculated descriptive statistics and conducted multivariable logistic regression to identify characteristics associated with active screen time by estimating adjusted odds ratio (aOR) and 95 percent confidence intervals (CIs). Results: The sample comprised 51.4 percent boys, and almost 60 percent were non-Hispanic white. The prevalence of active screen time >= 1 hour/day was 31.2 percent on a typical school day and 41.6 percent on a typical weekend day. Logistic regression revealed youth with physical activity of 3-5 days/week had higher odds of active screen time >= 1 hour/day compared with youth with no physical activity (aOR school day = 2.8, 95 percent CI 1.5-5.2; aOR weekend day = 2.3, 95 percent CI 1.4-3.9). Certain characteristics (i.e., sex, age group, race/ethnicity, income, and sedentary screen time) were significantly associated with active screen time >= 1 hour/day, but associations were inconsistent for school and weekend days. Conclusions: Three in 10 youth are engaging in at least 1 hour of active screen time on school days, and about 4 in 10 youth are engaging in at least one hour on weekend days. Understanding the use of active screen time and associated characteristics are important for developing interventions addressing screen time and physical activity. C1 [Wethington, Holly; Sherry, Bettylou; Park, Sohyun; Blanck, Heidi M.; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Wethington, H (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE Mail Stop K-26, Atlanta, GA 30341 USA. EM HWethington@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 4 Z9 4 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2161-783X EI 2161-7856 J9 GAMES HEALTH J JI Games Health J. PD DEC PY 2013 VL 2 IS 6 BP 362 EP + DI 10.1089/g4h.2013.0055 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA V40ZC UT WOS:000209515500008 PM 26197078 ER PT J AU Cleveland, JL Robison, VA AF Cleveland, Jennifer L. Robison, Valerie A. TI Clinical Oral Examinations May Not Be Predictive of Dysplasia or Oral Squamous Cell Carcinoma SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE LA English DT Editorial Material C1 [Cleveland, Jennifer L.; Robison, Valerie A.] Ctr Dis Control & Prevent, Surveillance Invest & Res Team, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Cleveland, JL (reprint author), Ctr Dis Control & Prevent, Surveillance Invest & Res Team, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM JLCleveland@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-3382 J9 J EVID-BASED DENT PR JI J. Evid.-Based Dent. Pract. PD DEC PY 2013 VL 13 IS 4 BP 151 EP 154 DI 10.1016/j.jebdp.2013.10.006 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA V37RY UT WOS:000209294100005 PM 24237736 ER PT J AU Hudson, H Hall, J AF Hudson, Heidi Hall, Jennifer TI Value of Social Media in Reaching and Engaging Employers in Total Worker Health SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article AB Objective: To describe the initial use of social media by the National Institute for Occupational Safety and Health (NIOSH) Total Worker Health (TM) (TWH) Program and the University of Iowa Healthier Workforce Center for Excellence (HWCE) Outreach Program. Methods: Social media analytics tools and process evaluation methods were used to derive initial insights on the social media strategies used by the NIOSH and the HWCE. Results: The on-line community size for the NIOSH TWH Program indicated 100% growth in 6 months; however, social media platforms have been slow to gain participation among employers. Conclusion: The NIOSH TWH Program and the HWCE Outreach Program have found social media tools as an effective way to expand reach, foster engagement, and gain understanding of audience interests around TWH concepts. More needs to be known about how to best use social media to reach and engage target audiences on issues relevant to TWH. C1 [Hudson, Heidi] NIOSH, Total Worker Hlth, 4676 Columbia Pkwy,MS C-27, Cincinnati, OH 45226 USA. [Hall, Jennifer] Univ Iowa, Healthier Workforce Ctr Excellence, Iowa City, IA USA. RP Hudson, H (reprint author), NIOSH, Total Worker Hlth, 4676 Columbia Pkwy,MS C-27, Cincinnati, OH 45226 USA. EM hlhudson@cdc.gov FU NCATS NIH HHS [UL1 TR000077] NR 13 TC 1 Z9 1 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD DEC PY 2013 VL 55 IS 12 SU S BP S78 EP S81 DI 10.1097/JOM.0000000000000035 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V44HY UT WOS:000209741300013 PM 24284750 ER PT J AU Luckhaupt, SE Sestito, JP AF Luckhaupt, Sara E. Sestito, John P. TI Examining National Trends in Worker Health With the National Health Interview Survey SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article AB Objective: To describe data from the National Health Interview Survey (NHIS), both the annual core survey and periodic occupational health supplements (OHSs), available for examining national trends in worker health. Methods: The NHIS is an annual in-person household survey with a cross-sectional multistage clustered sample design to produce nationally representative health data. The 2010 NHIS included an OHS. Results: Prevalence rates of various health conditions and health behaviors among workers based on multiple years of NHIS core data are available. In addition, the 2010 NHIS-OHS data provide prevalence rates of selected health conditions, work organization factors, and occupational exposures among US workers by industry and occupation. Conclusions: The publicly available NHIS data can be used to identify areas of concern for various industries and for benchmarking data from specific worker groups against national averages. C1 [Luckhaupt, Sara E.; Sestito, John P.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Luckhaupt, SE (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM pks8@cdc.gov FU US government FX Both the authors are federal government employees, and the National Health Interview Survey and the preparation of this manuscript were completely funded by the US government. NR 14 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD DEC PY 2013 VL 55 IS 12 SU S BP S58 EP S62 DI 10.1097/JOM.0000000000000034 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V44HY UT WOS:000209741300009 PM 24284753 ER PT J AU Osborn, LV Snawder, JE Kriech, AJ Cavallari, JM McClean, MD Herrick, RF Blackburn, GR Olsen, LD AF Osborn, Linda V. Snawder, John E. Kriech, Anthony J. Cavallari, Jennifer M. McClean, Michael D. Herrick, Robert F. Blackburn, Gary R. Olsen, Larry D. TI Personal Breathing Zone Exposures among Hot-Mix Asphalt Paving Workers; Preliminary Analysis for Trends and Analysis of Work Practices That Resulted in the Highest Exposure Concentrations SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE asphalt paving emissions; personal-breathing zone; total organic matter; polycyclic aromatic compounds; diesel; biodiesel ID POLYCYCLIC AROMATIC-COMPOUNDS; DERMAL EXPOSURE; URINARY 1-HYDROXYPYRENE; INDUSTRY; FUMES; METABOLITES; PREDICTORS; INHALATION; BITUMEN AB An exposure assessment of hot-mix asphalt (HMA) paving workers was conducted to determine which of four exposure scenarios impacted worker exposure and dose. Goals of this report are to present the personal-breathing zone (PBZ) data, discuss the impact of substituting the releasing/cleaning agent, and discuss work practices that resulted in the highest exposure concentration for each analyte. One-hundred-seven PBZ samples were collected from HMA paving workers on days when diesel oil was used as a releasing/cleaning agent. An additional 36 PBZ samples were collected on days when B-100 (100% biodiesel, containing no petroleum-derived products) was used as a substitute releasing/cleaning agent. Twenty-four PBZ samples were collected from a reference group of concrete workers, who also worked in outdoor construction but had no exposure to asphalt emissions. Background and field blank samples were also collected daily. Total particulates and the benzene soluble fraction were determined gravimetrically. Total organic matter was determined using gas chromatography (GC) with flame ionization detection and provided qualitative information about other exposure sources contributing to worker exposure besides asphalt emissions. Thirty-three individual polycyclic aromatic compounds (PACs) were determined using GC with time-of-flight mass spectrometry; results were presented as either the concentration of an individual PAC or a summation of the individual PACs containing either 2- to 3-rings or 4- to 6-rings. Samples were also screened for PACs containing 4- to 6-rings using fluorescence spectroscopy. Arithmetic means, medians, and box plots of the PBZ data were used to evaluate trends in the data. Box plots illustrating the diesel oil results were more variable than the B-100. Also, the highest diesel oil results were much higher in concentration than the highest B-100 results. An analysis of the highest exposure results and field notes revealed a probable association between these exposures and the use of diesel oil, use of a diesel-powered screed, elevated HMA paving application temperatures, lubricating and working on broken-down equipment, and operation of a broom machine. [Supplementary materials are available for this article. Go to the publisher's online edition of Journal of Occupational and Environmental Hygiene for the following free supplemental resource: a file containing tables summarizing statistical data and individual analyte results.] C1 [Osborn, Linda V.; Kriech, Anthony J.] Heritage Res Grp, Indianapolis, IN 46231 USA. [Snawder, John E.; Olsen, Larry D.] NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Div Appl Res & Technol,Biomonitoring Hlth Assessm, Cincinnati, OH 45226 USA. [Cavallari, Jennifer M.] Univ Connecticut, Ctr Hlth, Div Occupat & Environm Med, Farmington, CT USA. [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Herrick, Robert F.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Blackburn, Gary R.] PetroLabs Inc, Ivyland, PA USA. RP Osborn, LV (reprint author), Heritage Res Grp, 7901 West Morris St, Indianapolis, IN 46231 USA. EM linda.osborn@heritage-enviro.com RI McClean, Michael/J-2934-2015 FU National Asphalt Pavement Association (NAPA); State Asphalt Pavement Associations (SAPA) FX This study was sponsored by the National Asphalt Pavement Association (NAPA) and the State Asphalt Pavement Associations (SAPA). The partnership, including the National Institute for Occupational Safety and Health, the Centers for Disease Control and Prevention, the Harvard School of Public Health, the Boston University School of Public Health, PetroLabs Inc., and Heritage Research Group, appreciates the involvement of E & B Paving (Indianapolis, Ind.), Mathy Construction LC (Onalaska, Wisc.), and Milestone Contractors LP (Indianapolis, Ind.) and would like to extend a special thanks to all the workers for their cooperation with this study. NR 25 TC 1 Z9 1 U1 6 U2 20 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD DEC 1 PY 2013 VL 10 IS 12 BP 663 EP 673 DI 10.1080/15459624.2013.831981 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 247KH UT WOS:000326615800003 PM 24195533 ER PT J AU Noll, JD Janisko, S AF Noll, J. D. Janisko, S. TI Evaluation of a Wearable Monitor for Measuring Real-Time Diesel Particulate Matter Concentrations in Several Underground Mines SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE diesel; measurement; real-time ID LUNG-CANCER; EXHAUST; MORTALITY; OVEREXPOSURE; COHORT AB The standard method for determining diesel particulate matter (DPM) exposures in underground metal/nonmetal mines provides the average exposure concentration for an entire working shift, and it can take weeks to obtain results. This approach is problematic because, although it reports that an overexposure has occurred, it fails to provide critical information about cause or prevention. Conversely, real-time measurement would provide miners with timely information to identify the major factors contributing to overexposures and would allow engineering controls to be deployed immediately. Due to these potential benefits, the National Institute for Occupational Safety and Health (NIOSH) developed a wearable instrument that measures real-time elemental carbon (EC) concentrations (EC is a DPM surrogate) via laser extinction. This instrument was later constructed into a commercial version (Airtec). This article evaluates the Airtec's performance in several underground metal/nonmetal mines by comparing it to the standard method for determining DPM exposures (NIOSH method 5040). The instrument was found to meet the NIOSH accuracy criteria and to show no statistical difference from NIOSH method 5040 results. In addition, the instrument's measurements were found to be unaffected by dust and humidity. C1 [Noll, J. D.; Janisko, S.] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Pittsburgh Res Lab, Pittsburgh, PA 15236 USA. RP Noll, JD (reprint author), NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Pittsburgh Res Lab, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM JIN1@cdc.gov NR 28 TC 0 Z9 0 U1 4 U2 18 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD DEC 1 PY 2013 VL 10 IS 12 BP 716 EP 722 DI 10.1080/15459624.2013.821575 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 247KH UT WOS:000326615800008 PM 24195538 ER PT J AU Hines, CJ Roberts, JL Andrews, RN Jackson, MV Deddens, JA AF Hines, Cynthia J. Roberts, Jennifer L. Andrews, Ronnee N. Jackson, Matthew V. Deddens, James A. TI Use of and Occupational Exposure to Indium in the United States SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE thin films; photovoltaics; semiconductor; indium tin oxide; copper indium gallium diselenide; indium phosphide ID PULMONARY ALVEOLAR PROTEINOSIS; COPPER GALLIUM DISELENIDE; TIN-OXIDE; INTRATRACHEAL INSTILLATIONS; OPTOELECTRONIC INDUSTRY; DEVELOPMENTAL TOXICITY; CADMIUM TELLURIDE; FISCHER-344 RATS; IN-VIVO; WORKERS AB Indium use has increased greatly in the past decade in parallel with the growth of flat-panel displays, touchscreens, optoelectronic devices, and photovoltaic cells. Much of this growth has been in the use of indium tin oxide (ITO). This increased use has resulted in more frequent and intense exposure of workers to indium. Starting with case reports and followed by epidemiological studies, exposure to ITO has been linked to serious and sometimes fatal lung disease in workers. Much of this research was conducted in facilities that process sintered ITO, including manufacture, grinding, and indium reclamation from waste material. Little has been known about indium exposure to workers in downstream applications. In 2009-2011, the National Institute for Occupational Safety and Health (NIOSH) contacted 89 potential indium-using companies; 65 (73%) responded, and 43 of the 65 responders used an indium material. Our objective was to identify current workplace applications of indium materials, tasks with potential indium exposure, and exposure controls being used. Air sampling for indium was either conducted by NIOSH or companies provided their data for a total of 63 air samples (41 personal, 22 area) across 10 companies. Indium exposure exceeded the NIOSH recommended exposure limit (REL) of 0.1mg/m(3) for certain methods of resurfacing ITO sputter targets, cleaning sputter chamber interiors, and in manufacturing some inorganic indium compounds. Indium air concentrations were low in sputter target bonding with indium solder, backside thinning and polishing of fabricated indium phosphide-based semiconductor devices, metal alloy production, and in making indium-based solder pastes. Exposure controls such as containment, local exhaust ventilation (LEV), and tool-mounted LEV can be effective at reducing exposure. In conclusion, occupational hygienists should be aware that the manufacture and use of indium materials can result in indium air concentrations that exceed the NIOSH REL. Given recent findings of adverse health effects in workers, research is needed to determine if the current REL sufficiently protects workers against indium-related diseases. C1 [Hines, Cynthia J.; Roberts, Jennifer L.; Andrews, Ronnee N.; Deddens, James A.] NIOSH, Cincinnati, OH 45226 USA. [Jackson, Matthew V.] RCS Corp, URS Profess Solut, Aiken, SC USA. [Deddens, James A.] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. RP Hines, CJ (reprint author), NIOSH, 4676 Columbia Pkwy,R-14, Cincinnati, OH 45226 USA. EM chines@cdc.gov FU National Institute of Environmental Health Sciences [Y1-ES-9018-04]; Centers for Disease Control and Prevention [11-NS09-28-M02] FX This research was supported by an Interagency Agreement between the National Institute of Environmental Health Sciences (Y1-ES-9018-04) and the Centers for Disease Control and Prevention (11-NS09-28-M02). NR 82 TC 5 Z9 6 U1 4 U2 36 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD DEC 1 PY 2013 VL 10 IS 12 BP 723 EP 733 DI 10.1080/15459624.2013.836279 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 247KH UT WOS:000326615800009 PM 24195539 ER PT J AU Gurbaxani, B Dostalek, M Gardner, I AF Gurbaxani, Brian Dostalek, Miroslav Gardner, Iain TI Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? SO MOLECULAR IMMUNOLOGY LA English DT Review DE Monoclonal antibody; Half-life; Pharmacokinetics; Neonatal Fc receptor; Endosome; Trafficking; Modelling ID I-RELATED RECEPTOR; SERUM HALF-LIFE; EPIDERMAL-GROWTH-FACTOR; PH-DEPENDENT BINDING; IMMUNOGLOBULIN-G; MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; HUMAN IGG1; NEONATAL-RAT; PBPK MODEL AB F.W.R. Brambell deduced the existence of a protective receptor for IgG, the neonatal Fc receptor (FcRn), long before its discovery in the early to mid-1990s. With the coincident, explosive development of IgG-based drugs, FcRn became a popular target for tuning the pharmacokinetics of monoclonal antibodies (mAbs). One aspect of Brambell's initial observation, however, that is seldom discussed since the discovery of the receptor, is the compliance in the mechanism that Brambell observed (saturating at 10s-100s of mu M concentration), vs. the comparative stiffness of the receptor kinetics (saturating in the nM range for most species). Although some studies reported that increasing the already very high Fc-FcRn affinity at pH 6.0 further improved mAb half-life, in fact the results were mixed, with later studies increasingly implicating non-FcRn-dependent mechanisms as determinants of mAb pharmacokinetics. Mathematical modelling of the FcRn system has also indicated that the processes determining the pharmacokinetics of mAbs have more nuances than had at first been hypothesised. We propose, in keeping with the latest modelling and experimental evidence reviewed here, that the dynamics of endosomal sorting and trafficking have important roles in the compliant salvage mechanism that Brambell first observed nearly 50 years ago, and therefore also in the pharmacokinetics of mAbs. These ideas lead to many open questions regarding the endosomal trafficking of both FcRn and mAbs and also to what properties of a mAb can be altered to achieve an improvement in pharmacokinetics. Published by Elsevier Ltd. C1 [Gurbaxani, Brian] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Dostalek, Miroslav] F Hoffmann La Roche & Cie AG, pRED, Nonclin Safety, Basel, Switzerland. [Gardner, Iain] Simcyp Ltd, Sheffield, S Yorkshire, England. RP Gurbaxani, B (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. EM brian.gurbaxani@cdc.hhs.gov NR 115 TC 19 Z9 19 U1 3 U2 29 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2013 VL 56 IS 4 BP 660 EP 674 DI 10.1016/j.molimm.2013.05.008 PG 15 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 241XZ UT WOS:000326203300041 PM 23917469 ER PT J AU Van Doren, JM Neil, KP Parish, M Gieraltowski, L Gould, LH Gombas, KL AF Van Doren, Jane M. Neil, Karen P. Parish, Mickey Gieraltowski, Laura Gould, L. Hannah Gombas, Kathy L. TI Foodborne illness outbreaks from microbial contaminants in spices, 1973-2010 SO FOOD MICROBIOLOGY LA English DT Review DE Foodborne illness; Spice; Salmonella; Food safety; Microbial contaminants ID UNITED-STATES; MICROBIOLOGICAL QUALITY; HUMAN SALMONELLOSIS; BLACK PEPPER; FOOD; INFECTIONS; PATHOGENS; PREVALENCE; RESISTANCE; PRODUCTS AB This review identified fourteen reported illness outbreaks attributed to consumption of pathogen-contaminated spice during the period 1973-2010. Countries reporting outbreaks included Canada, Denmark, England and Wales, France, Germany, New Zealand, Norway, Serbia, and the United States. Together, these outbreaks resulted in 1946 reported human illnesses, 128 hospitalizations and two deaths. Infants/children were the primary population segments impacted by 36% (5/14) of spice-attributed outbreaks. Four outbreaks were associated with multiple organisms. Salmonella enterica subspecies enterica was identified as the causative agent in 71% (10/14) of outbreaks, accounting for 87% of reported illnesses. Bacillus spp. was identified as the causative agent in 29% (4/10) of outbreaks, accounting for 13% of illnesses. 71% (10/14) of outbreaks were associated with spices classified as fruits or seeds of the source plant. Consumption of ready-to-eat foods prepared with spices applied after the final food manufacturing pathogen reduction step accounted for 70% of illnesses. Pathogen growth in spiced food is suspected to have played a role in some outbreaks, but it was not likely a contributing factor in three of the larger Salmonella outbreaks, which involved low-moisture foods. Root causes of spice contamination included contributions from both early and late stages of the farm-to-table continuum. Published by Elsevier Ltd. C1 [Van Doren, Jane M.; Parish, Mickey; Gombas, Kathy L.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA. [Neil, Karen P.; Gieraltowski, Laura; Gould, L. Hannah] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Van Doren, JM (reprint author), US FDA, Ctr Food Safety & Appl Nutr, 5100 Paint Branch Pkwy, College Pk, MD 20740 USA. EM jane.vandoren@fda.hhs.gov FU United States FDA; CDC FX The authors thank the many federal, state and international scientists who discussed the outbreak investigations with the authors and in some cases, provided additional information about the outbreak investigations that were incorporated into this manuscript, especially C. L Little (Health Protection Agency, United Kingdom.), G. Delmas (Institut de Veille Sanitaire, France), J. Higa (California Department of Public Health), R. Ireland and D. Quilliam (Rhode Island Department of Public Health), and M. Allard, T. DuVernoy, E. Pomeroy, S. Gordon, and E. Strain (FDA). We also thank S. Mettee for her assistance in reviewing CDC's Foodborne Disease Outbreak and Surveillance System, and I. Williams (CDC), for his feedback on this manuscript throughout its development. The results of this study will be incorporated into the risk profile on pathogens and filth in spices being developed by FDA and we thank the following risk profile team members who reviewed and commented on this manuscript: V. Gill, D. Kleinmeier, M. Muckenfuss, O. Nsofor, A. Westerman, and G. C. Ziobro (FDA). Additional scientists from CDC and FDA also provided helpful comments. This work was funded by the United States FDA and CDC. NR 71 TC 16 Z9 17 U1 1 U2 88 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0740-0020 J9 FOOD MICROBIOL JI Food Microbiol. PD DEC PY 2013 VL 36 IS 2 BP 456 EP 464 DI 10.1016/j.fm.2013.04.014 PG 9 WC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology SC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology GA 226MF UT WOS:000325039700041 PM 24010629 ER PT J AU Khan, D Bell, KL AF Khan, Diba Bell, Kristine L. TI Explicit Ziv-Zakai bound for analysis of DOA estimation performance of sparse linear arrays SO SIGNAL PROCESSING LA English DT Article DE DOA estimation; Sparse linear array; Ziv-Zakai bound ID TIME-DELAY ESTIMATION; SIGNAL PARAMETER-ESTIMATION; OF-ARRIVAL ESTIMATION; FUNDAMENTAL LIMITATIONS; SOURCE LOCALIZATION; ESTIMATION ERROR; SENSOR ARRAYS; SYSTEMS; ALGORITHM; GEOMETRY AB Sparse linear arrays (SLAs) provide similar direction-of-arrival estimation performance to filled linear arrays in terms of angular accuracy and resolution with reduced size, weight, power consumption, and cost. However, they are subject to significant ambiguities due to high sidelobes in the array beampattern, which give rise to large estimation errors. In this paper, we develop an explicit closed-form expression for the Ziv-Zakai bound on the mean square estimation error in order to quantify the degradation in estimation performance due to the sidelobe ambiguities. The bound consists of three terms which correspond to the three types of estimation errors: small mainlobe errors, errors due to sidelobe ambiguities, and random errors. The bound is used to analyze the performance of different SLA configurations. Maximum likelihood estimation simulations confirm the contribution of the different types of estimation errors predicted by the bound. The analysis shows that much of the performance degradation due to ambiguities are from random errors that cannot be controlled by array design, while additional degradation due to sidelobe errors depends strongly on the array configuration. Isolating the contributions of the three types of errors provides greater understanding of the behavior of sparse arrays, allowing for more effective system design and analysis. (C) 2013 Elsevier B.V. All rights reserved. C1 [Khan, Diba; Bell, Kristine L.] George Mason Univ, Dept Stat, Fairfax, VA 22030 USA. RP Bell, KL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM ild1@cdc.gov; kbell@gmu.edu NR 57 TC 2 Z9 2 U1 0 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-1684 J9 SIGNAL PROCESS JI Signal Process. PD DEC PY 2013 VL 93 IS 12 SI SI BP 3449 EP 3458 DI 10.1016/j.sigpro.2013.03.023 PG 10 WC Engineering, Electrical & Electronic SC Engineering GA 217JD UT WOS:000324354900019 ER PT J AU Matjasko, JL Niolon, PH Valle, LA AF Matjasko, Jennifer L. Niolon, Phyllis Holditch Valle, Linda Anne TI The Role of Economic Factors and Economic Support in Preventing and Escaping from Intimate Partner Violence SO JOURNAL OF POLICY ANALYSIS AND MANAGEMENT LA English DT Editorial Material ID DOMESTIC VIOLENCE; EMPLOYMENT; INTERVENTION; SURVIVORS; PROGRAM; GENDER; FAMILY; TRIAL; ABUSE; RISK C1 [Matjasko, Jennifer L.; Niolon, Phyllis Holditch; Valle, Linda Anne] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Matjasko, JL (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F64, Atlanta, GA 30341 USA. NR 28 TC 4 Z9 5 U1 4 U2 126 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0276-8739 EI 1520-6688 J9 J POLICY ANAL MANAG JI J. Policy Anal. Manage. PD WIN PY 2013 VL 32 IS 1 BP 122 EP 128 DI 10.1002/pam.21666 PG 7 WC Economics; Public Administration SC Business & Economics; Public Administration GA 063KB UT WOS:000312995700008 ER PT J AU Matjasko, JL Niolon, PH Valle, LA AF Matjasko, Jennifer L. Niolon, Phyllis Holditch Valle, Linda Anne TI Different Types of Intimate Partner Violence Likely Require Different Types of Approaches to Prevention: A Response to Buzawa and Buzawa SO JOURNAL OF POLICY ANALYSIS AND MANAGEMENT LA English DT Editorial Material ID COORDINATED COMMUNITY RESPONSES C1 [Matjasko, Jennifer L.; Niolon, Phyllis Holditch; Valle, Linda Anne] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Matjasko, JL (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F64, Atlanta, GA 30341 USA. NR 6 TC 1 Z9 1 U1 0 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0276-8739 EI 1520-6688 J9 J POLICY ANAL MANAG JI J. Policy Anal. Manage. PD WIN PY 2013 VL 32 IS 1 BP 137 EP 139 DI 10.1002/pam.21667 PG 3 WC Economics; Public Administration SC Business & Economics; Public Administration GA 063KB UT WOS:000312995700010 ER PT J AU Pazol, K Creanga, AA Burley, KD Hayes, B Jamieson, DJ AF Pazol, Karen Creanga, Andreea A. Burley, Kim D. Hayes, Brenda Jamieson, Denise J. TI Abortion Surveillance - United States, 2010 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID UNINTENDED PREGNANCY; CONTRACEPTIVE USE; SURGICAL ABORTION; RISK-FACTORS; SERVICES; RATES; COMPLICATIONS; ACCESS; TRENDS; DISPARITIES AB Problem/Condition: Since 1969, CDC has conducted abortion surveillance to document the number and characteristics of women obtaining legal induced abortions in the United States. Reporting Period Covered: 2010. Description of System: Each year, CDC requests abortion data from the central health agencies of 52 reporting areas (the 50 states, the District of Columbia, and New York City). The reporting areas provide this information voluntarily. For 2010, data were received from 49 reporting areas. For the purpose of trend analysis, abortion data were evaluated from the 46 areas that reported data every year during 2001-2010. Census and natality data, respectively, were used to calculate abortion rates (number of abortions per 1,000 women) and ratios (number of abortions per 1,000 live births). Results: A total of 765,651 abortions were reported to CDC for 2010. Of these abortions, 753,065 (98.4%) were from the 46 reporting areas that provided data every year during 2001-2010. Among these same 46 reporting areas, the abortion rate for 2010 was 14.6 abortions per 1,000 women aged 15-44 years, and the abortion ratio was 228 abortions per 1,000 live births. Compared with 2009, the total number and rate of reported abortions for 2010 decreased 3% and reached the lowest levels for the entire period of analysis (2001-2010); the abortion ratio was stable, changing only 0.4%. From 2001 to 2010, the total number, rate, and ratio of reported abortions decreased 9%, 10%, and 8%, respectively. Given the 3% decrease from 2009 to 2010 in the total number and rate of reported abortions, in combination with the 5% decrease that had occurred in the previous year from 2008 to 2009, the overall decrease for both measures was greater during 2006-2010 than during 2001-2005, despite the annual variations that resulted in no net decrease during 2006-2008. In 2010 and throughout the period of analysis, women in their 20s accounted for the majority of abortions and had the highest abortion rates, whereas women in their 30s and older accounted for a much smaller percentage of abortions and had lower abortion rates. In 2010, women aged 20-24 and 25-29 years accounted for 32.9% and 24.5% of all abortions, respectively, and had abortion rates of 26.7 and 20.2 abortions per 1,000 women aged 20-24 and 25-29 years, respectively. In contrast, women aged 30-34, 35-39, and >= 40 years accounted for 15.3%, 8.9%, and 3.4% of all abortions, respectively, and had abortion rates of 13.2, 7.6, and 2.8 abortions per 1,000 women aged 30-34 years, 35-39 years, >= 40 years, respectively. Throughout the period of analysis, abortion rates decreased among women aged 20-24 and 25-29 years, whereas they increased among women aged >= 40 years. In 2010, adolescents aged 15-19 years accounted for 14.6% of all abortions and had an abortion rate of 11.7 abortions per 1,000 adolescents aged 15-19 years. Throughout the period of analysis, the percentage of all abortions accounted for by adolescents and the adolescent abortion rate decreased. In contrast to the percentage distribution of abortions and abortion rates by age, abortion ratios in 2010 and throughout the entire period of analysis were highest among adolescents and lowest among women aged 30-39 years. Abortion ratios decreased from 2001 to 2010 for women in all age groups except for those aged <15 years, for whom they increased. In 2010, most (65.9%) abortions were performed at <= 8 weeks' gestation, and 91.9% were performed at <= 13 weeks' gestation. Few abortions (6.9%) were performed at 14-20 weeks' gestation, and even fewer (1.2%) were performed at >= 21 weeks' gestation. From 2001 to 2010, the percentage of all abortions performed at <= 8 weeks' gestation increased 10%, whereas the percentage performed at >13 weeks' decreased 10%. Moreover, among abortions performed at <= 13 weeks' gestation, the distribution shifted toward earlier gestational ages, with the percentage of these abortions performed at <= 6 weeks' gestation increasing 36%. In 2010, a total of 72.4% of abortions were performed by curettage at <= 13 weeks' gestation, 17.7% were performed by early medical abortion (a nonsurgical abortion at <= 8 weeks' gestation), and 8.3% were performed by curettage at >13 weeks' gestation. Among abortions that were performed at <= 8 weeks' gestation, and thus were eligible for early medical abortion on the basis of gestational age, 26.5% were completed by this method. From 2009 to 2010, the use of early medical abortion increased 13%. Deaths of women associated with complications from abortions for 2010 are being investigated under CDC's Pregnancy Mortality Surveillance System. In 2009, the most recent year for which data were available, eight women were identified to have died as a result of complications from known legal induced abortions. No reported deaths were associated with illegal induced abortions. Interpretation: Among the 46 areas that reported data every year during 2001-2010, the gradual decrease that had occurred during previous decades in the total number and rate of reported abortions continued through 2005, whereas year-to-year variation from 2006 to 2008 resulted in no net change during this later period. However, the large decreases that occurred both from 2008 to 2009 and from 2009 to 2010 resulted in a greater overall decrease during 2006-2010 as compared with 2001-2005 and the lowest number and rate of reported abortions for the entire period of analysis. Public Health Actions: Unintended pregnancy is the major contributor to abortion. Because unintended pregnancies are rare among women who use the most effective methods of reversible contraception, increasing access to and use of these methods can help further reduce the number of abortions performed in the United States. The data in this report can help program planners and policy makers identify groups of women at greatest risk for unintended pregnancy and help guide and evaluate prevention efforts. C1 [Pazol, Karen; Creanga, Andreea A.; Burley, Kim D.; Hayes, Brenda; Jamieson, Denise J.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Pazol, K (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 84 TC 32 Z9 32 U1 0 U2 10 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD NOV 29 PY 2013 VL 62 IS 8 BP 1 EP 44 PG 44 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 263OA UT WOS:000327816700001 PM 24280963 ER PT J AU Seretse, MD Cherutich, P Nkhata, A Come, J Anyolo, E Bonnecwe, GC Lija, GJI Opio, A Chapula, BT Manda, R Mwalili, S Barr, BAT Cummings, B Mutandi, G Toledo, C Kazaura, KJ Dea, M Mwale, J Grund, J Bock, N AF Seretse, Mpho Dorothy Cherutich, Peter Nkhata, Amon Come, Jotamo Anyolo, Epafras Bonnecwe, Goitsemodimo Collen Lija, Gissenge J. I. Opio, Alex Chapula, Bushimbwa Tambatamba Manda, Robert Mwalili, Samuel Barr, Beth A. Tippett Cummings, Beverley Mutandi, Gram Toledo, Carlos Kazaura, Kokuhumbya J. Dea, Monica Mwale, Jonas Grund, Jonathan Bock, Naomi TI Voluntary Medical Male Circumcision - Southern and Eastern Africa, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HIV PREVENTION; TRIAL; RISK; INFECTION; MEN C1 [Seretse, Mpho Dorothy] Minist Hlth, Gaborone, Botswana. [Cherutich, Peter] Natl AIDS & STI Control Programme, Nairobi, Kenya. [Nkhata, Amon] Minist Hlth, HIV & AIDS Dept, Lilongwe, Malawi. [Come, Jotamo] Minist Hlth, Maputo, Mozambique. [Anyolo, Epafras] Minist Hlth & Social Svcs, Khomas, Namibia. [Bonnecwe, Goitsemodimo Collen] Natl Dept Hlth, Pretoria, South Africa. [Lija, Gissenge J. I.] Minist Hlth & Social Welf, Natl AIDS Control Program, Dar Es Salaam, Tanzania. [Opio, Alex] Minist Hlth, Kampala, Uganda. [Chapula, Bushimbwa Tambatamba] Minist Community Dev Mother & Child Hlth, Lusaka, Zambia. [Manda, Robert] CDC Botswana, Gaborone, Botswana. [Mwalili, Samuel] CDC Kenya, Nairobi, Kenya. [Barr, Beth A. Tippett] CDC Malawi, Lilongwe, Malawi. [Cummings, Beverley] CDC Mozambique, Maputo, Mozambique. [Mutandi, Gram] CDC Namibia, Windhoek, Namibia. [Toledo, Carlos] CDC South Africa, Pretoria, South Africa. [Kazaura, Kokuhumbya J.] CDC Tanzania, Dar Es Salaam, Tanzania. [Dea, Monica] CDC Uganda, Kampala, Uganda. [Mwale, Jonas] CDC Zambia, Lusaka, Zambia. [Grund, Jonathan; Bock, Naomi] CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Grund, J (reprint author), CDC, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM jgrund@cdc.gov NR 10 TC 10 Z9 10 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 29 PY 2013 VL 62 IS 47 BP 953 EP 957 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NU UT WOS:000327534400002 ER PT J AU Paz-Bailey, G Hall, HI Wolitski, RJ Prejean, J Van Handel, MM Le, B LaFlam, M Koenig, LJ Mendoza, MCB Rose, C Valleroy, LA AF Paz-Bailey, Gabriela Hall, H. Irene Wolitski, Richard J. Prejean, Joseph Van Handel, Michelle M. Le, Binh LaFlam, Michael Koenig, Linda J. Mendoza, Maria Corazon Bueno Rose, Charles Valleroy, Linda A. TI HIV Testing and Risk Behaviors Among Gay, Bisexual, and Other Men Who Have Sex with Men - United States SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Paz-Bailey, Gabriela; Hall, H. Irene; Wolitski, Richard J.; Prejean, Joseph; Van Handel, Michelle M.; Le, Binh; LaFlam, Michael; Koenig, Linda J.; Mendoza, Maria Corazon Bueno; Rose, Charles; Valleroy, Linda A.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Paz-Bailey, G (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM gmb5@cdc.gov NR 9 TC 64 Z9 64 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 29 PY 2013 VL 62 IS 47 BP 958 EP 962 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NU UT WOS:000327534400003 ER PT J AU Nelson, C Kugeler, K Petersen, J Mead, P AF Nelson, Christina Kugeler, Kiersten Petersen, Jeannine Mead, Paul TI Tularemia - United States, 2001-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID EPIDEMIOLOGY; MANAGEMENT C1 [Nelson, Christina; Kugeler, Kiersten; Petersen, Jeannine; Mead, Paul] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. RP Nelson, C (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. EM wje1@cdc.gov NR 10 TC 13 Z9 13 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 29 PY 2013 VL 62 IS 47 BP 963 EP 966 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NU UT WOS:000327534400004 ER PT J AU Kirschner, K Leinenkugel, K Makowski, M Fletcher, AM Braun, CR Alarcon, WA Sweeney, MH Calvert, GM AF Kirschner, Kathryn Leinenkugel, Kathy Makowski, Mike Fletcher, Alicia M. Braun, Carol R. Alarcon, Walter A. Sweeney, Marie H. Calvert, Geoffrey M. TI Very High Blood Lead Levels Among Adults - United States, 2002-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID EXPOSURE C1 [Kirschner, Kathryn] Indiana Univ, Bloomington, IN 47405 USA. [Leinenkugel, Kathy] Iowa Dept Publ Hlth, Div Environm Hlth, Des Moines, IA 50319 USA. [Makowski, Mike] Penn Dept Hlth, Div Environm Hlth Epidemiol, Harrisburg, PA 17108 USA. [Fletcher, Alicia M.] New York State Dept Hlth, Bur Occupat Hlth & Injury Prevent, Albany, NY 12237 USA. [Braun, Carol R.] Missouri Dept Hlth & Senior Svcs, Bur Environm Epidemiol, Jefferson City, MO USA. [Alarcon, Walter A.; Sweeney, Marie H.; Calvert, Geoffrey M.] CDC, Natl Inst Occupat Safety & Hlth, Div Surveillance Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. RP Alarcon, WA (reprint author), CDC, Natl Inst Occupat Safety & Hlth, Div Surveillance Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. EM wda7@cdc.gov RI Alarcon, Walter/C-4470-2008 OI Alarcon, Walter/0000-0002-4907-4380 NR 9 TC 8 Z9 8 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 29 PY 2013 VL 62 IS 47 BP 967 EP 971 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NU UT WOS:000327534400005 ER PT J AU Lemons, AR Bledsoe, TA Siegel, PD Beezhold, DH Green, BJ AF Lemons, Angela R. Bledsoe, Toni A. Siegel, Paul D. Beezhold, Donald H. Green, Brett J. TI Development of sandwich ELISAs for the detection of aromatic diisocyanate adducts SO JOURNAL OF IMMUNOLOGICAL METHODS LA English DT Article DE Diisocyanate; Monoclonal antibody; Immunoassay; Occupational asthma ID 4,4'-METHYLENEDIPHENYL DIISOCYANATE; HEMOGLOBIN; PROTEINS; ALBUMIN AB Diisocyanates (dNCOs) are highly reactive low molecular weight chemicals commonly used in the manufacturing industry. Occupational exposures to dNCOs have been shown to elicit allergic sensitization and occupational asthma. Among the most commonly used dNCOs in industry are the aromatic dNCOs, toluene diisocyanate (TDI) and methylene diphenyl diisocyanate (MDI). This study aimed to develop enzyme linked immunosorbent assays (ELISA) utilizing aromatic dNCO-specific monoclonal antibodies (mAbs) for the detection of aromatic dNCO adducts. Two sandwich ELISAs were developed. The first sandwich ELISA utilized mAb 60G2 along with an anti-human serum albumin (HSA) polydonal antibody. This assay detected MDI-, 2,4- and 2,6-TDI-HSA adducts with limits of detection (LOD) of 2.67, <0.10, and 1.70 ng/mL, respectively. When spiked into human serum, the LOD of this ELISA increased to 34.37, 7.64 and 24.06 ng/mL, respectively. The second ELISA utilized mAbs 62G5 and 60G2 for capture and detection. This assay was capable of detecting 2,4- and 2,6-TDI-HSA adducts with LODs of <4.90 and 26.92 ng/mL, respectively, and when spiked in human serum, <4.90 and 95.93 ng/mL, respectively. This 62G5-60G2 sandwich assay was also able to detect dNCO adducted transferrin, hemoglobin, keratin and actin, but with less sensitivity than dNCO-HSA. The results of this study demonstrate potential application of these ELISAs in the identification and characterization of aromatic dNCO adducts as well as in biomonitoring occupational and environmental dNCO exposures. Published by Elsevier B.V. C1 [Lemons, Angela R.; Bledsoe, Toni A.; Siegel, Paul D.; Beezhold, Donald H.; Green, Brett J.] Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Branch, Natl Inst Occupat Safety & Hlth, Morgantown, WV 26505 USA. RP Green, BJ (reprint author), Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Branch, Natl Inst Occupat Safety & Hlth, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM wrw0@cdc.gov; tab4@cdc.gov; pds3@cdc.gov; zec1@cdc.gov; dox6@cdc.gov OI Lemons, Angela/0000-0003-3057-9888 FU NIEHS IAA [AES 12007-00100000] FX The findings and the conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. The authors declare no conflict of interest. This study was supported in part by an interagency agreement with NIEHS IAA# AES 12007-00100000. NR 10 TC 2 Z9 3 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-1759 EI 1872-7905 J9 J IMMUNOL METHODS JI J. Immunol. Methods PD NOV 29 PY 2013 VL 397 IS 1-2 BP 66 EP 70 DI 10.1016/j.jim.2013.08.015 PG 5 WC Biochemical Research Methods; Immunology SC Biochemistry & Molecular Biology; Immunology GA 254MB UT WOS:000327168700009 PM 24012971 ER PT J AU Zeremski, M Zibbell, JE Martinez, AD Kritz, S Smith, BD Talal, AH AF Zeremski, Marija Zibbell, Jon E. Martinez, Anthony D. Kritz, Steven Smith, Bryce D. Talal, Andrew H. TI Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Treatment of hepatitis C; Viral infection; Human immunodeficiency virus; Hepatitis C virus coinfection; Persons who inject drugs; Obstacles to treatment ID ABUSE TREATMENT PROGRAMS; UNITED-STATES; MAINTENANCE TREATMENT; HCV INFECTION; MEDICAL-CARE; USERS; SERVICES; PREVALENCE; MANAGEMENT; EFFICACY AB Despite a high prevalence of hepatitis C virus (HCV) infection, the vast majority of persons who inject drugs (PWID) have not engaged in HCV care due to a large number of obstacles. Education about the infection among both PWID and providers remains an important challenge as does discrimination faced by PWID in conventional health care settings. Many providers also remain hesitant to prescribe antiviral therapy due to concerns about adherence and relapse to drug use resulting in reinfection. Presently, however, as a result of improvements in treatment efficacy combined with professional society and government endorsement of HCV treatment for PWID, a pressing need exists to develop strategies to engage these individuals into HCV care. In this article, we propose several strategies that can be pursued in an attempt to engage PWID into HCV management. We advocate that multidisciplinary approaches that utilize health care practitioners from a wide range of specialties, as well as co-localization of medical services, are strategies likely to result in increased numbers of PWID entering into HCV management. Pursuit of HCV therapy after stabilization through drug treatment is an additional strategy likely to increase PWID engagement into HCV care. The full impact of direct acting antivirals for HCV will only be realized if innovative approaches are pursued to engage all HCV infected individuals into treatment. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved. C1 [Zeremski, Marija; Talal, Andrew H.] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY 10065 USA. [Zibbell, Jon E.; Smith, Bryce D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Martinez, Anthony D.; Talal, Andrew H.] SUNY Buffalo, Div Gastroenterol Hepatol & Nutr, Buffalo, NY 14203 USA. [Kritz, Steven] Addict Res & Treatment Corp, Brooklyn, NY 11201 USA. RP Talal, AH (reprint author), SUNY Buffalo, Div Gastroenterol Hepatol & Nutr, UB CTRC, 875 Ellicott St,Suite 6090, Buffalo, NY 14203 USA. EM ahtalal@buffalo.edu NR 52 TC 19 Z9 19 U1 3 U2 4 PU BAISHIDENG PUBL GRP CO LTD PI WANCHAI PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG 100025, PEOPLES R CHINA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD NOV 28 PY 2013 VL 19 IS 44 BP 7846 EP 7851 DI 10.3748/wjg.v19.i44.7846 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 259HZ UT WOS:000327519300004 PM 24307778 ER PT J AU Ghasemzadeh, N Hritani, AW Khayata, M Al Kassem, H Aznaouridis, K Kamineni, T Forghani, Z Reddy, PK De Staercke, C Hooper, C Mavromatis, K Quyyumi, AA AF Ghasemzadeh, Nima Hritani, Abdul Wahab Khayata, Mohamed Al Kassem, Hatem Aznaouridis, Konstantinos Kamineni, Tanuj Forghani, Zohreh Reddy, Padi K. De Staercke, Christine Hooper, Craig Mavromatis, Kreton Quyyumi, Arshad A. TI Plasma Monocyte Chemoattractant Protein Level Predicts Long-Term Adverse Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Coronay artery disease; Outcomes; Biomarkers C1 [Ghasemzadeh, Nima; Hritani, Abdul Wahab; Khayata, Mohamed; Al Kassem, Hatem; Aznaouridis, Konstantinos; Kamineni, Tanuj; Reddy, Padi K.; Quyyumi, Arshad A.] Emory Univ, Atlanta, GA 30322 USA. [Forghani, Zohreh; Mavromatis, Kreton] Atlanta VA Med Cntr, Atlanta, GA USA. [De Staercke, Christine] Cntr Dis Control & Prevent, Div Hereditary Blood Disorders, Natl Cntr Birth, Atlanta, GA USA. [Hooper, Craig] Cntr Dis Control & Prevent, CDC, Atlanta, GA USA. RI Khayata, Mohamed /I-5288-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 13941 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162903369 ER PT J AU Hong, YL Ritchey, M Loustalot, F Bowman, BA AF Hong, Yuling Ritchey, Matthew Loustalot, Fleetwood Bowman, Barbara A. TI Heart Disease Mortality Trends During the 21st Century, United States, 2000-2010 SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Epidemiology; Coronary heart disease; Heart failure; Hypertension; Prevention C1 [Hong, Yuling; Ritchey, Matthew; Loustalot, Fleetwood; Bowman, Barbara A.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 13132 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162903006 ER PT J AU Hritani, AW Ghasemzadeh, N Khayata, M Aznaouridis, K Kamineni, T Forghani, Z Reddy, PK De Staercke, C Hooper, C Kumar, S Niaz, A Mavromatis, K Quyyumi, AA AF Hritani, Abdul Wahah Ghasemzadeh, Nima Khayata, Mohamed Aznaouridis, Konstantinos Kamineni, Tanuj Forghani, Zohreh Reddy, Padi K. De Staercke, Christine Hooper, Craig Kumar, Saket Niaz, Adil Mavromatis, Kreton Quyyumi, Arshad A. TI Stromal Derived Factor-1 Level Predicts Long-Term Adverse Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Coronary artery disease; Outcomes; Biomarkers C1 [Hritani, Abdul Wahah; Ghasemzadeh, Nima; Khayata, Mohamed; Aznaouridis, Konstantinos; Kamineni, Tanuj; Reddy, Padi K.; Kumar, Saket; Niaz, Adil; Quyyumi, Arshad A.] Emory Univ, Atlanta, GA 30322 USA. [Forghani, Zohreh; Mavromatis, Kreton] Atlanta VA Med Cntr, Atlanta, GA USA. [De Staercke, Christine] Ctr Dis Control & Prevent, Div Hereditary Blood Disorders, Natl Cntr Birth, Atlanta, GA USA. [Hooper, Craig] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. RI Khayata, Mohamed /I-5288-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 13960 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162903376 ER PT J AU Yang, QH Yuan, KM Gregg, E Loustalot, F Fang, J Hong, YL Merritt, R AF Yang, Quanhe Yuan, Keming Gregg, Edward Loustalot, Fleetwood Fang, Jing Hong, Yuling Merritt, Robert TI Trends and Clustering of Cardiovascular Health Metrics Among US Adolescents 1988-2010 SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Children; Cardiovascular disease prevention; Risk factors; Epidemiology; Disparities C1 [Yang, Quanhe; Yuan, Keming; Loustalot, Fleetwood; Fang, Jing; Hong, Yuling; Merritt, Robert] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Gregg, Edward] Ctr Dis Control & Prevent CDC, Div Diabet Control, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 13067 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162902509 ER PT J AU Dantes, R Mu, Y Belflower, R Aragon, D Dumyati, G Harrison, LH Lessa, FC Lynfield, R Nadle, J Petit, S Ray, SM Schaffner, W Townes, J Fridkin, S AF Dantes, Raymund Mu, Yi Belflower, Ruth Aragon, Deborah Dumyati, Ghinwa Harrison, Lee H. Lessa, Fernanda C. Lynfield, Ruth Nadle, Joelle Petit, Susan Ray, Susan M. Schaffner, William Townes, John Fridkin, Scott CA Emerging Infections Program-Active TI National Burden of Invasive Methicillin-Resistant Staphylococcus aureus Infections, United States, 2011 SO JAMA INTERNAL MEDICINE LA English DT Article ID SOFT-TISSUE INFECTIONS; HOSPITALIZATIONS; CENTERS; BLOOD; SKIN AB IMPORTANCE Estimating the US burden of methicillin-resistant Staphylococcus aureus (MRSA) infections is important for planning and tracking success of prevention strategies. OBJECTIVE To describe updated national estimates and characteristics of health care-and community-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in 2011. DESIGN, SETTING, AND PARTICIPANTS Active laboratory-based case finding identified MRSA cultures in 9 US metropolitan areas from 2005 through 2011. Invasive infections (MRSA cultured from normally sterile body sites) were classified as health care-associated community-onset (HACO) infections (cultured <= 3 days after admission and/or prior year dialysis, hospitalization, surgery, long-term care residence, or central vascular catheter presence <= 2 days before culture); hospital-onset infections (cultured >3 days after admission); or community-associated infections if no other criteria were met. National estimates were adjusted using US census and US Renal Data System data. MAIN OUTCOMES AND MEASURES National estimates of invasive HACO, hospital-onset, and community-associated MRSA infections using US census and US Renal Data System data as the denominator. RESULTS An estimated 80 461 (95% CI, 69 515-93 914) invasive MRSA infections occurred nationally in 2011. Of these, 48 353 (95% CI, 40 195-58 642) were HACO infections; 14156 (95% CI, 10 096-20 440) were hospital-onset infections; and 16 560 (95% CI, 12 806-21 811) were community-associated infections. Since 2005, adjusted national estimated incidence rates decreased among HACO infections by 27.7% and hospital-onset infections decreased by 54.2%; community-associated infections decreased by only 5.0%. Among recently hospitalized community-onset (nondialysis) infections, 64% occurred 3 months or less after discharge, and 32% of these were admitted from long-term care facilities. CONCLUSIONS AND RELEVANCE An estimated 30 800 fewer invasive MRSA infections occurred in the United States in 2011 compared with 2005; in 2011 fewer infections occurred among patients during hospitalization than among persons in the community without recent health care exposures. Effective strategies for preventing infections outside acute care settings will have the greatest impact on further reducing invasive MRSA infections nationally. C1 [Dantes, Raymund] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Dantes, Raymund; Mu, Yi; Belflower, Ruth; Lessa, Fernanda C.; Fridkin, Scott] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Belflower, Ruth] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Dumyati, Ghinwa] Univ Rochester, Div Infect Dis, Dept Med, Rochester, NY USA. [Harrison, Lee H.] Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Ray, Susan M.] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA. [Ray, Susan M.] Georgia Emerging Infect Program, Atlanta, GA 30322 USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Townes, John] Oregon Hlth & Sci Univ, Div Infect Dis, Dept Med, Portland, OR USA. RP Dantes, R (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Epidem Intelligence Serv Officer, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM raydantes@gmail.com FU Emerging Infections Program at the Centers for Disease Control and Prevention (CDC); National Center for Emerging and Zoonotic Infectious Diseases FX This work was supported by the Emerging Infections Program at the Centers for Disease Control and Prevention (CDC) and the National Center for Emerging and Zoonotic Infectious Diseases. NR 27 TC 142 Z9 149 U1 3 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 25 PY 2013 VL 173 IS 21 BP 1970 EP 1978 DI 10.1001/jamainternmed.2013.10423 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AA2WG UT WOS:000330954300006 PM 24043270 ER PT J AU Bosch, FX Broker, TR Forman, D Moscicki, AB Gillison, ML Doorbar, J Stern, PL Stanley, M Arbyn, M Poljak, M Cuzick, J Castle, PE Schiller, JT Markowitz, LE Fisher, WA Canfell, K Denny, LA Franco, EL Steben, M Kane, MA Schiffman, M Meijer, CJLM Sankaranarayanan, R Castellsague, X Kim, JJ Brotons, M Alemany, L Albero, G Diaz, M de Sanjose, S AF Xavier Bosch, F. Broker, Thomas R. Forman, David Moscicki, Anna-Barbara Gillison, Maura L. Doorbar, John Stern, Peter L. Stanley, Margaret Arbyn, Marc Poljak, Mario Cuzick, Jack Castle, Philip E. Schiller, John T. Markowitz, Lauri E. Fisher, William A. Canfell, Karen Denny, Lynette A. Franco, Eduardo L. Steben, Marc Kane, Mark A. Schiffman, Mark Meijer, Chris J. L. M. Sankaranarayanan, Rengaswamy Castellsague, Xavier Kim, Jane J. Brotons, Maria Alemany, Laia Albero, Ginesa Diaz, Mireia de Sanjose, Silvia CA ICO Monograph Comprehensive TI Comprehensive Control of Human Papillomavirus Infections and Related Diseases SO VACCINE LA English DT Review DE HPV; Cervical cancer; Anal cancer; Penile cancer; Vaginal cancer; Vulvar cancer; Oropharyngeal cancer; Screening; HPV vaccination; HPV testing; Prevention ID CERVICAL-CANCER; PREVENTION; COUNTRIES; VACCINES; WORLD AB Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread optimally universal implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Xavier Bosch, F.; Castellsague, Xavier; Brotons, Maria; Alemany, Laia; Albero, Ginesa; Diaz, Mireia; de Sanjose, Silvia] IDIBELL, Catalan Inst Oncol ICO, Inst Catala Oncol, CERP, Lhospitalet De Llobregat, Barcelona, Spain. [Broker, Thomas R.] Univ Alabama Birmingham, Birmingham, AL USA. [Forman, David] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France. [Moscicki, Anna-Barbara] Univ Calif San Francisco, Dept Pediat, Div Adolescent Med, San Francisco, CA USA. [Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Doorbar, John] Natl Inst Med Res, Div Virol, London NW7 1AA, England. [Stern, Peter L.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England. [Stanley, Margaret] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium. [Arbyn, Marc] Univ Antwerp, Lab Cell Biol & Histol, B-2020 Antwerp, Belgium. [Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia. [Cuzick, Jack] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England. [Castle, Philip E.] Global Canc Initiat, Chestertown, MD USA. [Schiller, John T.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Fisher, William A.] Univ Western Ontario, Dept Psychol, Social Sci Ctr 7428, London, ON, Canada. [Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynaecol, Social Sci Ctr 7428, London, ON, Canada. [Canfell, Karen] Univ NSW, Prince Wales Clin Sch, Lowy Canc Res Ctr, Kensington, NSW, Australia. [Canfell, Karen] NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia. [Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Dept Obstet & Gynaecol, ZA-7925 Cape Town, South Africa. [Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa. [Franco, Eduardo L.] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada. [Steben, Marc] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada. [Kane, Mark A.] Consultant Immunizat Policy, Mercer Isl, WA USA. [Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Meijer, Chris J. L. M.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France. [Castellsague, Xavier; Alemany, Laia; Albero, Ginesa; de Sanjose, Silvia] CIBERESP, Madrid, Spain. [Kim, Jane J.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA. RP Bosch, FX (reprint author), IDIBELL, Catalan Inst Oncol ICO, Inst Catala Oncol, CERP, Lhospitalet De Llobregat, Barcelona, Spain. EM admincerp@iconcologia.net RI de Sanjose Llongueras, Silvia/H-6339-2014; Bruni, Laia/N-5816-2014; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012; Castellsague Pique, Xavier/N-5795-2014; Brotons, Maria/F-5383-2016; DIAZ SANCHIS, MIREIA/H-6335-2014; Albero, Ginesa/G-7248-2015; OI BOSCH JOSE, FRANCESC XAVIER/0000-0002-7172-3412; Castellsague Pique, Xavier/0000-0002-0802-3595; Brotons, Maria/0000-0002-3057-0616; Bruni, Laia/0000-0003-3943-0326; Kjaer, Susanne/0000-0002-8347-1398; Albero, Ginesa/0000-0002-9400-1914; Franco, Eduardo/0000-0002-4409-8084; Qiao, You-Lin/0000-0001-6380-0871 FU European Commission [HEALTH-F3-2010-242061, PREHDICT, HEALTH-F2-2011-282562, HPV AHEAD, 242061]; Instituto de Salud Carlos III (Spanish Government) [FIS PI08/1535, FIS PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056, CIBERESP]; Agencia de Gestio d'Ajuts Universitaris i de Recerca - Generalitat de Catalunya (Catalonian Government) [AGAUR 2005SGR00695, AGAUR 2009SGR126]; USPHS/NIH/National Cancer Institute (grant "Human Papillomavirus Gene Expression") [CA36200]; USPHS/NIH/National Cancer Institute (grant "Mechanisms of Human Papillomavirus DNA Replication") [CA83679]; US Public Health Service (National Cancer Institute, National Institutes of Health, Department of Health and Human Services) [R37 CA51323]; National Institute of AIDS and Infectious Disease [RC1 AI86051]; UK Medical Research Council [MC_U117584278]; Vrije Universiteit Amsterdam, the Netherlands [FP7-HEALTH-2011-282562]; Belgian Foundation Against Cancer (Brussels, Belgium); International Agency for Research on Cancer (Lyon, France); Cancer Research UK programme [A10404]; National Health and Medical Research Council, Australia [CDF APP1007994, 1007518]; non-commercial government and academic consulting agreement in Australia; non-commercial government and academic consulting agreement in New Zealand; non-commercial government and academic consulting agreement in the UK; Cancer Council NSW, Australia; Bill and Melinda Gates Foundation, USA [35537]; U.S. National Cancer Institute [U54 CA164336, R01 CA160744-01A1]; Bill and Melinda Gates Foundation [30505] FX The work was partially supported by public grants from the European Commission (7th Framework Programme grants HEALTH-F3-2010-242061, PREHDICT and HEALTH-F2-2011-282562, HPV AHEAD), from the Instituto de Salud Carlos III (Spanish Government) (grants FIS PI08/1535, FIS PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056 and CIBERESP) and from the Agencia de Gestio d'Ajuts Universitaris i de Recerca - Generalitat de Catalunya (Catalonian Government) (grants AGAUR 2005SGR00695 and AGAUR 2009SGR126), who had no role in data collection, analysis or interpretation of results. Thomas R. Broker receives research support from the USPHS/NIH/National Cancer Institute (grants "Human Papillomavirus Gene Expression" CA36200 and "Mechanisms of Human Papillomavirus DNA Replication" CA83679). Anna-Barbara Moscicki's work is supported by US Public Health Service grant R37 CA51323 (National Cancer Institute, National Institutes of Health, Department of Health and Human Services) and National Institute of AIDS and Infectious Disease RC1 AI86051. John Doorbar is funded by the UK Medical Research Council through program grant MC_U117584278 (Molecular Biology of Human Papillomavirus Infection). Marc Arbyn received financial support from: (1) the 7th Framework Programme of DG Research of the European Commission through the PREHDICT project (grant No. 242061, coordinated by the Vrije Universiteit Amsterdam, the Netherlands) and through the HPV AHEAD Network (FP7-HEALTH-2011-282562); (2) the Belgian Foundation Against Cancer (Brussels, Belgium); and (3) the International Agency for Research on Cancer (Lyon, France). Jack Cuzick was supported in part by Cancer Research UK programme grant A10404. Karen Canfell is supported by grants from the National Health and Medical Research Council, Australia (CDF APP1007994 and Project Grant #1007518), by non-commercial government and academic consulting agreements in Australia, New Zealand and the UK, and by Cancer Council NSW, Australia. Lynette A. Denny was partially supported by Bill and Melinda Gates Foundation, USA (35537). The work of Chris J.L.M. Meijer received support via the 7th Framework Programme of DG Research of the European commission through the PREHDICT project (grant 242061, coordinated via the Vrije Universiteit Amsterdam). Jane J. Kim is supported in part by grants from the U.S. National Cancer Institute (U54 CA164336, R01 CA160744-01A1) and the Bill and Melinda Gates Foundation (30505) for modeling of HPV and cervical cancer in developing countries. NR 20 TC 89 Z9 90 U1 3 U2 27 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 22 PY 2013 VL 31 SU 8 BP 1 EP 31 DI 10.1016/j.vaccine.2013.07.026 PG 31 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 269IW UT WOS:000328236000003 PM 24229716 ER PT J AU Alexander, JP AF Alexander, James P. TI Progress Toward Poliomyelitis Eradication - Pakistan, January 2012-September 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AFGHANISTAN; WORLDWIDE; POLIO C1 [Alexander, James P.] WHO, Country Off, Islamabad, Pakistan. [Alexander, James P.] WHO, Polio Eradicat Dept, Eastern Mediterranean Reg Off, Cairo, Egypt. [Alexander, James P.] WHO, Polio Eradicat Dept, Geneva, Switzerland. [Alexander, James P.] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. RP Alexander, JP (reprint author), WHO, Country Off, Islamabad, Pakistan. EM axj1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 46 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NQ UT WOS:000327534000006 ER PT J AU Alexander, JP AF Alexander, James P. TI Progress Toward Poliomyelitis Eradication - Afghanistan, January 2012-September 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID WORLDWIDE; PAKISTAN; POLIO C1 [Alexander, James P.] World Hlth Org, Country Off, Kabul, Afghanistan. [Alexander, James P.] WHO Eastern Mediterranean Reg Off, Polio Eradicat Dept, Cairo, Egypt. [Alexander, James P.] WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland. [Alexander, James P.] CDC, Natl Ctr Immunizat & Resp Dis, Ctr Global Hlth, Global Immunizat Div,Div Viral Dis, Atlanta, GA 30333 USA. RP Alexander, JP (reprint author), World Hlth Org, Country Off, Kabul, Afghanistan. EM axj1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 46 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NQ UT WOS:000327534000005 ER PT J AU Caixeta, RB Sinha, DN Khoury, RN Rarick, J Fouad, H d'Espaignet, ET Kosen, S Xiao, L Kruger, J Zhao, LH Asma, S AF Caixeta, Roberta B. Sinha, Dhirendra N. Khoury, Rula N. Rarick, James Fouad, Heba d'Espaignet, Edouard Tursan Kosen, Soewarta Xiao, Lin Kruger, Judy Zhao, Luhua Asma, Samira TI Health-Care Provider Screening for Tobacco Smoking and Advice to Quit-17 Countries, 2008-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kruger, Judy; Zhao, Luhua; Asma, Samira] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. RP Kruger, J (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM jkruger@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 46 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NQ UT WOS:000327534000004 ER PT J AU Drenzek, C Geller, RJ Steck, A Arnold, J Lopez, G Gerona, R Edison, L AF Drenzek, Cherie Geller, Robert J. Steck, Alaina Arnold, Justin Lopez, Gaylord Gerona, Roy Edison, Laura TI Severe Illness Associated with Synthetic Cannabinoid Use - Brunswick, Georgia, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Drenzek, Cherie] Georgia Dept Publ Hlth, Atlanta, GA USA. [Geller, Robert J.; Steck, Alaina; Arnold, Justin; Lopez, Gaylord] Georgia Poison Center, Atlanta, GA USA. [Gerona, Roy] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Edison, Laura] CDC, Atlanta, GA 30333 USA. RP Edison, L (reprint author), CDC, Atlanta, GA 30333 USA. EM laedison@dhr.state.ga.us NR 4 TC 0 Z9 0 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 46 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NQ UT WOS:000327534000007 ER PT J AU Ibrahim, S Scott, M Bixler, D Pedersen, R Tripp, J Carter, K Erdman, D Schneider, E Britton, C AF Ibrahim, Sherif Scott, Melissa Bixler, Danae Pedersen, Randi Tripp, Jennifer Carter, Kris Erdman, Dean Schneider, Eileen Britton, Carla TI Outbreaks of Human Metapneumovirus in Two Skilled Nursing Facilities - West Virginia and Idaho, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TERM-CARE FACILITY; INFECTION C1 [Carter, Kris] CDC, Atlanta, GA 30333 USA. EM carterk1@dhw.idaho.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 46 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259NQ UT WOS:000327534000001 ER PT J AU Frieden, TR AF Frieden, Thomas R. TI Foreword SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 CDC, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), CDC, Atlanta, GA 30333 USA. NR 10 TC 24 Z9 24 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 1 EP 2 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300001 PM 24264482 ER PT J AU Meyer, PA Yoon, PW Kaufmann, RB AF Meyer, Pamela A. Yoon, Paula W. Kaufmann, Rachel B. TI Introduction: CDC Health Disparities and Inequalities Report - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material AB This supplement is the second CDC Health Disparities and Inequalities Report (CHDIR). The 2011 CHDIR was the first CDC report to assess disparities across a wide range of diseases, behavioral risk factors, environmental exposures, social determinants, and health-care access (CDC. CDC Health Disparities and Inequalities Report-United States, 2011. MMWR 2011; 60[Suppl; January 14, 2011]). The 2013 CHDIR provides new data for 19 of the topics published in 2011 and 10 new topics. When data were available and suitable analyses were possible for the topic area, disparities were examined for population characteristics that included race and ethnicity, sex, sexual orientation, age, disability, socioeconomic status, and geographic location. The purpose of this supplement is to raise awareness of differences among groups regarding selected health outcomes and health determinants and to prompt actions to reduce disparities. The findings in this supplement can be used by practitioners in public health, academia and clinical medicine; the media; the general public; policymakers; program managers; and researchers to address disparities and help all persons in the United States live longer, healthier, and more productive lives. C1 [Meyer, Pamela A.] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. [Yoon, Paula W.; Kaufmann, Rachel B.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Meyer, PA (reprint author), CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. NR 8 TC 18 Z9 18 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 3 EP 5 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300002 PM 24264483 ER PT J AU Beckles, GL Truman, BI AF Beckles, Gloria L. Truman, Benedict I. TI Education and Income - United States, 2009 and 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Beckles, Gloria L.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Truman, Benedict I.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Beckles, GL (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM glb4@cdc.gov NR 30 TC 9 Z9 9 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 9 EP 19 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300003 PM 24264484 ER PT J AU Grimm, KA Moore, LV Scanlon, KS AF Grimm, Kirsten A. Moore, Latetia V. Scanlon, Kelley S. TI Access to Healthier Food Retailers - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Grimm, Kirsten A.; Moore, Latetia V.; Scanlon, Kelley S.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Grimm, KA (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM KGrimm@cdc.gov NR 36 TC 4 Z9 4 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 20 EP 26 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300004 PM 24264485 ER PT J AU Athar, HM Chang, MH Hahn, RA Walker, E Yoon, P AF Athar, Heba M. Chang, Man-Huei Hahn, Robert A. Walker, Eric Yoon, Paula TI Unemployment - United States, 2006 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Athar, Heba M.; Chang, Man-Huei; Hahn, Robert A.; Walker, Eric; Yoon, Paula] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Athar, HM (reprint author), CDC, Div Epidemiol Anal & Lib Serv, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM viv8@cdc.gov NR 27 TC 4 Z9 4 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 27 EP 32 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300005 PM 24264486 ER PT J AU Baron, SL Steege, AL Marsh, SM Menendez, CC Myers, JR AF Baron, Sherry L. Steege, Andrea L. Marsh, Suzanne M. Menendez, Cammie Chaumont Myers, John R. TI Nonfatal Work-Related Injuries and Illnesses - United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Baron, Sherry L.; Steege, Andrea L.; Marsh, Suzanne M.; Menendez, Cammie Chaumont; Myers, John R.] NIOSH, Washington, DC USA. RP Baron, SL (reprint author), NIOSH, CDC, Washington, DC 96433 USA. EM slb8@cdc.gov NR 13 TC 4 Z9 4 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 35 EP 40 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300006 PM 24264487 ER PT J AU Marsh, SM Menendez, CC Baron, SL Steege, AL Myers, JR AF Marsh, Suzanne M. Menendez, Cammie Chaumont Baron, Sherry L. Steege, Andrea L. Myers, John R. TI Fatal Work-Related Injuries - United States, 2005-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Marsh, Suzanne M.; Menendez, Cammie Chaumont; Baron, Sherry L.; Steege, Andrea L.; Myers, John R.] NIOSH, CDC, Washington, DC 96433 USA. RP Marsh, SM (reprint author), NIOSH, CDC, Washington, DC 96433 USA. EM smm2@cdc.gov NR 9 TC 5 Z9 6 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 41 EP 45 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300007 PM 24264488 ER PT J AU Boehmer, TK Foster, SL Henry, JR Woghiren-Akinnifesi, EL Yip, FYY AF Boehmer, Tegan K. Foster, Stephanie L. Henry, Jeffrey R. Woghiren-Akinnifesi, Efomo L. Yip, Fuyuen Y. TI Residential Proximity to Major Highways - United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Boehmer, Tegan K.; Yip, Fuyuen Y.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Boehmer, TK (reprint author), CDC, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. EM tboehmer@cdc.gov NR 41 TC 3 Z9 3 U1 4 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 46 EP 50 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300008 PM 24264489 ER PT J AU Steele, CB Rim, SH Joseph, DA King, JB Seeff, LC AF Steele, C. Brooke Rim, Sun Hee Joseph, Djenaba A. King, Jessica B. Seeff, Laura C. TI Colorectal Cancer Incidence and Screening - United States, 2008 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Steele, C. Brooke; Rim, Sun Hee; Joseph, Djenaba A.; King, Jessica B.; Seeff, Laura C.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Steele, CB (reprint author), CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM BSteele1@cdc.gov NR 34 TC 28 Z9 28 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 53 EP 60 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300009 PM 24264490 ER PT J AU Moonesinghe, R Chang, MH Truman, BI AF Moonesinghe, Ramal Chang, Man-huei Truman, Benedict I. TI Health Insurance Coverage - United States, 2008 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Moonesinghe, Ramal] CDC, Off Minor Hlth & Hlth Equ, Off Director, Atlanta, GA 30333 USA. [Chang, Man-huei] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Truman, Benedict I.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Moonesinghe, R (reprint author), CDC, Off Minor Hlth & Hlth Equ, Off Director, Atlanta, GA 30333 USA. EM zor7@cdc.gov NR 8 TC 6 Z9 6 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 61 EP 64 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300010 PM 24264491 ER PT J AU McIntyre, AF Gonzalez-Feliciano, AG Bryan, LN Santibanez, TA Williams, WW Singleton, JA AF McIntyre, Anne F. Gonzalez-Feliciano, Amparo G. Bryan, Leah N. Santibanez, Tammy A. Williams, Walter W. Singleton, James A. TI Seasonal Influenza Vaccination Coverage - United States, 2009-10 and 2010-11 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [McIntyre, Anne F.; Gonzalez-Feliciano, Amparo G.; Bryan, Leah N.; Santibanez, Tammy A.; Williams, Walter W.; Singleton, James A.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP McIntyre, AF (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM AMcIntyre@cdc.gov NR 21 TC 8 Z9 9 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 65 EP 68 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300011 PM 24264492 ER PT J AU Ventura, SJ Hamilton, BE Mathews, TJ AF Ventura, Stephanie J. Hamilton, Brady E. Mathews, T. J. TI Pregnancy and Childbirth Among Females Aged 10-19 Years - United States, 2007-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ventura, Stephanie J.; Hamilton, Brady E.; Mathews, T. J.] CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP Ventura, SJ (reprint author), CDC, Div Vital Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM sventura@cdc.gov NR 27 TC 5 Z9 5 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 71 EP 76 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300012 PM 24264493 ER PT J AU Kanny, D Liu, Y Brewer, RD Lu, H AF Kanny, Dafna Liu, Yong Brewer, Robert D. Lu, Hua TI Binge Drinking - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kanny, Dafna; Liu, Yong; Brewer, Robert D.; Lu, Hua] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Kanny, D (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM dkk3@cdc.gov NR 14 TC 31 Z9 31 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 77 EP 80 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300013 PM 24264494 ER PT J AU Garrett, BE Dube, SR Winder, C Caraballo, RS AF Garrett, Bridgette E. Dube, Shanta R. Winder, Cherie Caraballo, Ralph S. TI Cigarette Smoking - United States, 2006-2008 and 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Garrett, Bridgette E.; Dube, Shanta R.; Winder, Cherie; Caraballo, Ralph S.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Garrett, BE (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM bgarrett@cdc.gov NR 12 TC 18 Z9 18 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 81 EP 84 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300014 PM 24264495 ER PT J AU Molla, MT AF Molla, Michael T. TI Expected Years of Life Free of Chronic Condition-Induced Activity Limitations - United States, 1999-2008 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP Molla, MT (reprint author), CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM MMolla@cdc.gov NR 21 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 87 EP 92 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300015 PM 24264496 ER PT J AU Moorman, JE Person, CJ Zahran, HS AF Moorman, Jeanne E. Person, Cara J. Zahran, Hatice S. TI Asthma Attacks Among Persons with Current Asthma - United States, 2001-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Moorman, Jeanne E.; Person, Cara J.; Zahran, Hatice S.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Moorman, JE (reprint author), CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM zva9@cdc.gov NR 15 TC 8 Z9 8 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 93 EP 98 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300016 PM 24264497 ER PT J AU Beckles, GL Chou, CF AF Beckles, Gloria L. Chou, Chiu-Fang TI Diabetes - United States, 2006 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Beckles, Gloria L.; Chou, Chiu-Fang] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA USA. RP Beckles, GL (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM glb4@cdc.gov NR 23 TC 21 Z9 21 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 99 EP 104 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300017 PM 24264498 ER PT J AU Zack, MM AF Zack, Matthew M. TI Health-Related Quality of Life - United States, 2006 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zack, MM (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM mmz1@cdc.gov NR 23 TC 7 Z9 8 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 105 EP 111 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300018 PM 24264499 ER PT J AU Johnson, AS Beer, L Sionean, C Hu, XH Furlow-Parmley, C Le, B Skarbinski, J Hall, HI Dean, HD AF Johnson, Anna Satcher Beer, Linda Sionean, Catlainn Hu, Xiaohong Furlow-Parmley, Carolyn Le, Binh Skarbinski, Jacek Hall, H. Irene Dean, Hazel D. TI HIV Infection - United States, 2008 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Johnson, Anna Satcher; Beer, Linda; Sionean, Catlainn; Hu, Xiaohong; Furlow-Parmley, Carolyn; Le, Binh; Skarbinski, Jacek; Hall, H. Irene; Dean, Hazel D.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Johnson, AS (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ats5@cdc.gov NR 16 TC 14 Z9 14 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 112 EP 119 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300019 PM 24264500 ER PT J AU May, AL Freedman, D Sherry, B Blanck, HM AF May, Ashleigh L. Freedman, David Sherry, Bettylou Blanck, Heidi M. TI Obesity - United States, 1999-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [May, Ashleigh L.; Freedman, David; Sherry, Bettylou; Blanck, Heidi M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP May, AL (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM amay@cdc.gov NR 41 TC 36 Z9 38 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 120 EP 128 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300020 PM 24264501 ER PT J AU Thornton-Evans, G Eke, P Wei, L Palmer, A Moeti, R Hutchins, S Borrell, LN AF Thornton-Evans, Gina Eke, Paul Wei, Liang Palmer, Astrid Moeti, Refilwe Hutchins, Sonja Borrell, Luisa N. TI Periodontitis Among Adults Aged >= 30 Years - United States, 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Thornton-Evans, Gina; Palmer, Astrid] CDC, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Eke, Paul] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Moeti, Refilwe] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hutchins, Sonja] CDC, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. [Borrell, Luisa N.] CUNY Herbert H Lehman Coll, Dept Hlth Sci, Bronx, NY 10468 USA. RP Eke, P (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM peke@cdc.gov NR 22 TC 23 Z9 24 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 129 EP 135 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300021 PM 24264502 ER PT J AU Martin, JA Osterman, MJK AF Martin, Joyce A. Osterman, Michelle J. K. TI Preterm Births - United States, 2006 and 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Martin, Joyce A.; Osterman, Michelle J. K.] CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP Martin, JA (reprint author), CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM JAMartin@cdc.gov NR 11 TC 18 Z9 18 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 136 EP 138 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300022 PM 24264503 ER PT J AU Gillespie, CD Hurvitz, KA AF Gillespie, Cathleen D. Hurvitz, Kimberly A. TI Prevalence of Hypertension and Controlled Hypertension - United States, 2007-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Gillespie, Cathleen D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hurvitz, Kimberly A.] CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP Gillespie, CD (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM ckg2@cdc.gov NR 12 TC 51 Z9 53 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 144 EP 148 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300024 PM 24264505 ER PT J AU Khan, AD Magee, E Grant, G AF Khan, Awal D. Magee, Elvin Grant, Gail TI Tuberculosis - United States, 1993-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Khan, Awal D.; Magee, Elvin; Grant, Gail] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Khan, AD (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM AKhan2@cdc.gov NR 17 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 149 EP 154 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300025 PM 24264506 ER PT J AU Gillespie, CD Wigington, C Hong, YL AF Gillespie, Cathleen D. Wigington, Charles Hong, Yuling TI Coronary Heart Disease and Stroke Deaths - United States, 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Gillespie, Cathleen D.; Wigington, Charles; Hong, Yuling] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Gillespie, CD (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ckg2@cdc.gov NR 13 TC 24 Z9 24 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 157 EP 160 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300026 PM 24264507 ER PT J AU Mack, KA AF Mack, Karin A. TI Drug-Induced Deaths - United States, 1999-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Mack, Karin A.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Mack, KA (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM kim9@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 NR 9 TC 12 Z9 12 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 161 EP 163 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300027 PM 24264508 ER PT J AU Logan, JE Hall, J McDaniel, D Stevens, MR AF Logan, Joseph E. Hall, Jeffrey McDaniel, Dawn Stevens, Mark R. TI Homicides - United States, 2007 and 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Logan, Joseph E.; Hall, Jeffrey; McDaniel, Dawn; Stevens, Mark R.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Logan, JE (reprint author), CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM ffa3@cdc.gov NR 32 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 164 EP 170 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300028 PM 24264509 ER PT J AU MacDorman, MF Mathews, TJ AF MacDorman, Marian F. Mathews, T. J. TI Infant Deaths - United States, 2005-2008 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [MacDorman, Marian F.; Mathews, T. J.] CDC, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP MacDorman, MF (reprint author), CDC, Div Vital Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. EM mfm1@cdc.gov NR 21 TC 2 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 171 EP 175 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300029 PM 24264510 ER PT J AU West, BA Naumann, RB AF West, Bethany A. Naumann, Rebecca B. TI Motor Vehicle-Related Deaths - United States, 2005 and 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [West, Bethany A.; Naumann, Rebecca B.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP West, BA (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM bwest2@cdc.gov NR 7 TC 4 Z9 5 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 176 EP 178 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300030 PM 24264511 ER PT J AU Crosby, AE Ortega, L Stevens, MR AF Crosby, Alex E. Ortega, LaVonne Stevens, Mark R. TI Suicides - United States, 2005-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Crosby, Alex E.; Stevens, Mark R.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Ortega, LaVonne] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Crosby, AE (reprint author), CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM aec1@cdc.gov NR 26 TC 5 Z9 5 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 179 EP 183 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300031 PM 24264512 ER PT J AU Meyer, PA Penman-Aguilar, A Campbell, VA Graffunder, C O'Connor, AE Yoon, PW AF Meyer, Pamela A. Penman-Aguilar, Ana Campbell, Vincent A. Graffunder, Corinne O'Connor, Ann E. Yoon, Paula W. TI Conclusion and Future Directions: CDC Health Disparities and Inequalities Report - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Meyer, Pamela A.] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. [Penman-Aguilar, Ana] CDC, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. [Campbell, Vincent A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Graffunder, Corinne] CDC, Off Associate Director Policy, Atlanta, GA 30333 USA. [O'Connor, Ann E.] CDC, Off Associate Director Program, Atlanta, GA 30333 USA. [Yoon, Paula W.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Meyer, PA (reprint author), CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. NR 7 TC 15 Z9 15 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 22 PY 2013 VL 62 IS 3 SU S BP 184 EP 186 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40KA UT WOS:000209476300032 PM 24264513 ER PT J AU Bai, Y Malania, L Castillo, DA Moran, D Boonmar, S Chanlun, A Suksawat, F Maruyama, S Knobel, D Kosoy, M AF Bai, Ying Malania, Lile Alvarez Castillo, Danilo Moran, David Boonmar, Sumalee Chanlun, Aran Suksawat, Fanan Maruyama, Soichi Knobel, Darryn Kosoy, Michael TI Global Distribution of Bartonella Infections in Domestic Bovine and Characterization of Bartonella bovis Strains Using Multi-Locus Sequence Typing SO PLOS ONE LA English DT Article ID CAT-SCRATCH DISEASE; SP-NOV; BORRELIA-BURGDORFERI; HENSELAE; ENDOCARDITIS; VINSONII; PATIENT; BLOOD; RUMINANTS; THAILAND AB Bartonella bovis is commonly detected in cattle. One B. bovis strain was recently isolated from a cow with endocarditis in the USA, suggesting its role as an animal pathogen. In the present study, we investigated bartonella infections in 893 cattle from five countries (Kenya, Thailand, Japan, Georgia, and Guatemala) and 103 water buffaloes from Thailand to compare the prevalence of the infection among different regions and different bovid hosts. We developed a multi-locus sequence typing (MLST) scheme based on nine loci (16S rRNA, gltA, ftsZ, groEL, nuoG, ribC, rpoB, ssrA, and ITS) to compare genetic divergence of B. bovis strains, including 26 representatives from the present study and two previously described reference strains (one from French cows and another from a cow with endocarditis in the USA). Bartonella bacteria were cultured in 6.8% (7/103) of water buffaloes from Thailand; all were B. bovis. The prevalence of bartonella infections in cattle varied tremendously across the investigated regions. In Japan, Kenya, and the Mestia district of Georgia, cattle were free from the infection; in Thailand, Guatemala, and the Dusheti and Marneuli districts of Georgia, cattle were infected with prevalences of 10-90%. The Bartonella isolates from cattle belonged to three species: B. bovis (n=165), B. chomelii (n=9), and B. schoenbuchensis (n=1), with the latter two species found in Georgia only. MLST analysis suggested genetic variations among the 28 analyzed B. bovis strains, which fall into 3 lineages (I, II, and III). Lineages I and II were found in cattle while lineage III was restricted to water buffaloes. The majority of strains (17/28), together with the strain causing endocarditis in a cow in the USA, belonged to lineage I. Further investigations are needed to determine whether B. bovis causes disease in bovids. C1 [Bai, Ying; Kosoy, Michael] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Malania, Lile] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Alvarez Castillo, Danilo; Moran, David] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Boonmar, Sumalee] Thailand MOPH US CDC Collaborat, Int Emerging Infect Program, Nonthaburi, Thailand. [Chanlun, Aran; Suksawat, Fanan] Khon Kaen Univ, Khon Kaen, Thailand. [Maruyama, Soichi] Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Kanagawa, Japan. [Knobel, Darryn] Univ Pretoria, Dept Vet Trop Dis, ZA-0002 Pretoria, South Africa. [Knobel, Darryn] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent, Publ Hlth Collaborat, Kisumu, Kenya. RP Bai, Y (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. EM bby5@cdc.gov FU Wellcome Trust, UK [081828/B/06/Z] FX Specimens from cattle in Kenya were collected under a project supported by the Wellcome Trust, UK (grant number 081828/B/06/Z). The funders had no role to publish, or preparation of the manuscript. NR 33 TC 19 Z9 19 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 21 PY 2013 VL 8 IS 11 AR e80894 DI 10.1371/journal.pone.0080894 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 259PW UT WOS:000327539800089 PM 24278342 ER PT J AU Pell, C Menaca, A Afrah, NA Manda-Taylor, L Chatio, S Were, F Hodgson, A Hamel, MJ Kalilani, L Tagbor, H Pool, R AF Pell, Christopher Menaca, Arantza Afrah, Nana A. Manda-Taylor, Lucinda Chatio, Samuel Were, Florence Hodgson, Abraham Hamel, Mary J. Kalilani, Linda Tagbor, Harry Pool, Robert TI Prevention and management of malaria during pregnancy: findings from a comparative qualitative study in Ghana, Kenya and Malawi SO MALARIA JOURNAL LA English DT Article DE Malaria; Pregnancy; IPTp; Insecticide-treated bed nets; ITNs; Malaria case management ID DEMOGRAPHIC SURVEILLANCE; POLICY IMPLICATIONS; HEALTH; GUIDELINES; BURDEN; UGANDA; WOMEN AB Background: In endemic regions of sub-Saharan Africa, malaria during pregnancy (MiP) is a major preventable cause of maternal and infant morbidity and mortality. Current recommended MiP prevention and control includes intermittent preventive treatment (IPTp), distribution of insecticide-treated bed nets (ITNs) and appropriate case management. This article explores the social and cultural context to the uptake of these interventions at four sites across Africa. Methods: A comparative qualitative study was conducted at four sites in three countries: Ghana, Malawi and Kenya. Individual and group interviews were conducted with pregnant women, their relatives, opinion leaders, other community members and health providers. Observations, which focused on behaviours linked to MiP prevention and treatment, were also undertaken at health facilities and in local communities. Results: ITNs were generally recognized as important for malaria prevention. However, their availability and use differed across the sites. In Malawi and Kenya, ITNs were sought-after items, but there were complaints about availability. In central Ghana, women saved ITNs until the birth of the child and they were used seasonally in northern Ghana. In Kenya and central Ghana, pregnant women did not associate IPTp with malaria, whereas, in Malawi and northern Ghana, IPTp was linked to malaria, but not always with prevention. Although IPTp adherence was common at all sites, whether delivered with directly observed treatment or not, a few women did not comply with IPTp often citing previous side effects. Although generally viewed as positive, experiences of malaria testing varied across the four sites: treatment was sometimes administered in spite of a negative diagnosis in Ghana (observed) and Malawi (reported). Despite generally following the advice of healthcare staff, particularly in Kenya, personal experience, and the availability and accessibility of medication - including anti-malarials - influenced MiP treatment. Conclusion: Although ITNs were valued as malaria prevention, health messages could address issues that reduce their use during pregnancy in particular contexts. The impact of previous side effects on adherence to IPTp and anti-malarial treatment regimens during pregnancy also requires attention. Overtreatment of MiP highlights the need to monitor the implementation of MiP case management guidelines. C1 [Pell, Christopher; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands. [Pell, Christopher; Menaca, Arantza; Pool, Robert] Hosp Clin Univ Barcelona, CRESIB, Ctr Recerca Salut Int Barcelona, Barcelona, Spain. [Menaca, Arantza] Univ Complutense Madrid, Dept Antropol Social, Madrid, Spain. [Afrah, Nana A.; Tagbor, Harry] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Community Hlth, Kumasi, Ghana. [Manda-Taylor, Lucinda; Kalilani, Linda] Univ Malawi, Coll Med, Blantyre, Malawi. [Chatio, Samuel] Navrongo Hlth Res Ctr, Navrongo, Ghana. [Were, Florence] CDC Res & Publ Hlth Collaborat, Kenya Med Res Inst KEMRI, Kisumu, Kenya. [Were, Florence] CDC Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent, Kisumu, Kenya. [Hodgson, Abraham] Ghana Hlth Serv, Res & Dev Div, Accra, Ghana. [Hamel, Mary J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Pell, C (reprint author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands. EM c.l.pell@uva.nl OI Pell, Christopher/0000-0001-9405-5851 FU MiP Consortium; Bill and Melinda Gates Foundation [OPP46099] FX The publication is supported and endorsed by the MiP Consortium, which is funded through a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine (www.gatesfoundation.org), Grant OPP46099. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 7 Z9 7 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD NOV 20 PY 2013 VL 12 AR 427 DI 10.1186/1475-2875-12-427 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 281MS UT WOS:000329106300001 PM 24257105 ER PT J AU Carter, MD Crow, BS Pantazides, BG Watson, CM Thomas, JD Blake, TA Johnson, RC AF Carter, Melissa D. Crow, Brian S. Pantazides, Brooke G. Watson, Caroline M. Thomas, Jerry D. Blake, Thomas A. Johnson, Rudolph C. TI Direct Quantitation of Methyl Phosphonate Adducts to Human Serum Butyrylcholinesterase by Immunomagnetic-UHPLC-MS/MS SO ANALYTICAL CHEMISTRY LA English DT Article ID ORGANOPHOSPHORUS NERVE AGENTS; REACTIVATION; EXPOSURE; ACETYLCHOLINESTERASE; SAMPLES; OXIMES AB Hydrolysis of G- and V-series organophosphorus nerve agents (OPNAs) containing a phosphorus methyl bond yields a methylphosphonic acid (MeP) product when adducted to human butyrylcholinesterase (BChE). The MeP adduct is considered a sign of "aging" and results in loss of the o-alkyl identifier specific to each nerve agent. After aging has occurred, common therapeutics such as mimes cannot reactivate the cholinesterase enzyme and relieve cholinergic inhibition. Until now, a direct, quantitative method for determination of the MeP adduct to BChE was unavailable. Aged adducts in serum samples were processed by immunomagnetic separation of BChE by antibody conjugated bead, isotope-dilution, pepsin digestion, followed by UHPLC separation and detection by conventional electrospray ionization tandem mass spectrometry (ESI-MS/MS). Ions were detected in selected reaction monitoring (SRM) mode, and transition m/z 874.3 -> 778.3 was used for quantitation. The analytical response ratio was linearly proportional to the serum concentration of MeP-adducted peptide (MeP-P) over the nominal concentration range of 2.0-250 ng/mL, with a coefficient of determination of R-2 >= 0.997. Intrarun accuracy, expressed as %Relative Error (%RE), was <= 13.5%, 16.3%, and 3.20% at 2.0, 16, and 250 ng/mL, respectively; the corresponding precision expressed as %RSD was <= 11.9%, 6.15%, and 3.39%. Interday %RSD was <= 7.13%, 5.69%, and 1.91%. Recovery of MeP-P from serum was >= 68% across the validated concentration range, and contributions from matrix effects were minimal. The method provides a direct, quantitative measurement of MeP-P found in clinical samples suspected of nerve agent exposure and subjected to such post-sampling stresses as elevated temperature and extended shipping. C1 [Carter, Melissa D.; Crow, Brian S.; Pantazides, Brooke G.; Watson, Caroline M.; Thomas, Jerry D.; Blake, Thomas A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Carter, MD (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM vsm8@cdc.gov OI Blake, Thomas/0000-0001-8536-9998 FU Defense Threat Reduction Agency FX This work was supported by Defense Threat Reduction Agency. The authors would like to thank Ms. Chariety Sapp of the CDC's Incident Response Laboratory (IRL) for dispensing convenience set serum samples prior to analysis. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, or the U.S. Department of Health and Human Services. NR 23 TC 16 Z9 16 U1 1 U2 30 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD NOV 19 PY 2013 VL 85 IS 22 BP 11106 EP 11111 DI 10.1021/ac4029714 PG 6 WC Chemistry, Analytical SC Chemistry GA 257CK UT WOS:000327360900068 PM 24205842 ER PT J AU Hanna, DB Buchacz, K Gebo, KA Hessol, NA Horberg, MA Jacobson, LP Kirk, GD Kitahata, MM Korthuis, PT Moore, RD Napravnik, S Patel, P Silverberg, MJ Sterling, TR Willig, JH Collier, A Samji, H Thorne, JE Althoff, KN Martin, JN Rodriguez, B Stuart, EA Gange, SJ AF Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Collier, Ann Samji, Hasina Thorne, Jennifer E. Althoff, Keri N. Martin, Jeffrey N. Rodriguez, Benigno Stuart, Elizabeth A. Gange, Stephen J. CA Int Epidemiologic Databases TI Association between US State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009 SO PLOS ONE LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; UNITED-STATES; SERVICES UTILIZATION; VIRAL LOAD; CARE; HEALTH; DISPARITIES; TRENDS; SUPPRESSION; PREVENTION AB Background: U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV treatment outcomes. Methods: We analyzed data from HIV-infected individuals who were clinically-eligible for ART between 2001 and 2009 (i.e., a first reported CD4+ < 350 cells/uL or AIDS-defining illness) from 14 U. S. cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Using propensity score matching and Cox regression, we assessed ART initiation (within 6 months following eligibility) and virologic suppression (within 1 year) based on differences in two state ADAP features: the amount of state funding in annual ADAP budgets and the implementation of waiting lists. We performed an a priori subgroup analysis in persons with a history of injection drug use (IDU). Results: Among 8,874 persons, 56% initiated ART within six months following eligibility. Persons living in states with no additional state contribution to the ADAP budget initiated ART on a less timely basis (hazard ratio [HR] 0.73, 95% CI 0.600.88). Living in a state with an ADAP waiting list was not associated with less timely initiation (HR 1.12, 95% CI 0.87-1.45). Neither additional state contributions nor waiting lists were significantly associated with virologic suppression. Persons with an IDU history initiated ART on a less timely basis (HR 0.67, 95% CI 0.47-0.95). Conclusions: We found that living in states that did not contribute additionally to the ADAP budget was associated with delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued assessment of the role of ADAPs and their features that facilitate prompt treatment is needed. C1 [Hanna, David B.; Gebo, Kelly A.; Jacobson, Lisa P.; Kirk, Gregory D.; Moore, Richard D.; Thorne, Jennifer E.; Althoff, Keri N.; Stuart, Elizabeth A.; Gange, Stephen J.] Johns Hopkins Univ, Baltimore, MD USA. [Hanna, David B.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Buchacz, Kate; Patel, Pragna] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hessol, Nancy A.; Collier, Ann; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Horberg, Michael A.] Midatlantic Permanente Res Inst, Rockville, MD USA. [Kitahata, Mari M.] Univ Washington, Seattle, WA 98195 USA. [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Napravnik, Sonia] Univ N Carolina, Chapel Hill, NC USA. [Silverberg, Michael J.] Kaiser Permanente Northern Calif, Oakland, CA USA. [Sterling, Timothy R.] Vanderbilt Univ, Nashville, TN 37235 USA. [Willig, James H.] Univ Alabama Birmingham, Birmingham, AL USA. [Samji, Hasina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Rodriguez, Benigno] Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Hanna, DB (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. EM david.hanna@einstein.yu.edu; sgange@jhsph.edu RI Rodriguez, Benigno/C-3365-2009; OI Rodriguez, Benigno/0000-0001-9736-7957; Stuart, Elizabeth/0000-0002-9042-8611; Gange, Stephen/0000-0001-7842-512X; Mayor, Angel M./0000-0002-7705-837X FU National Institutes of Health [F31-DA30254, U01-AI069918, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI42590, U01-HD32632, UL1-RR024131, M01-RR-00052, M01-RR00071, M01-RR00079, M01-RR00083, M01-RR00722, M01-RR025747, P30-AI27757, P30-AI27767, P30-AI27763, P30-AI50410, P30-AI54999, P30-AI036219, R01-DA04334, R01-DA12568, R01-DA11602, R01-AA16893, R24-AI067039, AHQ290-01-0012, N02-CP55504, K01-AI071725, K01-AI071754, K01-AI093197, K23-AI610320, K24-DA00432, K24-AI1065298]; CDC [CDC200-2006-18797]; Canadian Institutes of Health Research [TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, 169621]; Canadian HIV Trials Network [24]; government of British Columbia FX This work was supported by grants F31-DA30254, U01-AI069918, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI42590, U01-HD32632, UL1-RR024131, UL1-RR024131, M01-RR-00052, M01-RR00071, M01-RR00079, M01-RR00083, M01-RR00722, M01-RR025747, P30-AI27757, P30-AI27767, P30-AI27763, P30-AI50410, P30-AI54999, P30-AI036219, R01-DA04334, R01-DA12568, R01-DA11602, R01-AA16893, R24-AI067039, AHQ290-01-0012, N02-CP55504, K01-AI071725, K01-AI071754, K01-AI093197, K23-AI610320, K24-DA00432, and K24-AI1065298 from the National Institutes of Health; contract CDC200-2006-18797 from the CDC; grants TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, and 169621 from the Canadian Institutes of Health Research; the Canadian HIV Trials Network, project 24; and the government of British Columbia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 4 Z9 4 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 18 PY 2013 VL 8 IS 11 AR e78952 DI 10.1371/journal.pone.0078952 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 256KH UT WOS:000327308500014 PM 24260137 ER PT J AU Bennett, JS Jones, BW Hosni, MH Zhang, YH Topmiller, JL Dietrich, WL AF Bennett, James S. Jones, Byron W. Hosni, Mohammad H. Zhang, Yuanhui Topmiller, Jennifer L. Dietrich, Watts L. TI Airborne exposure patterns from a passenger source in aircraft cabins SO HVAC&R RESEARCH LA English DT Article ID COMPUTATIONAL FLUID-DYNAMICS; FLIGHT ATTENDANTS; AIR-FLOW; NUMERICAL-SIMULATION; PATHOGEN TRANSPORT; INDOOR AIR; PART II; TRANSMISSION; AIRLINER AB Airflow is a critical factor that influences air quality, airborne contaminant distribution, and disease transmission in commercial airliner cabins. The general aircraft-cabin air-contaminant transport effect model seeks to build exposure-spatial relationships between contaminant sources and receptors, quantify the uncertainty, and provide a platform for incorporation of data from a variety of studies. Knowledge of infection risk to flight crews and passengers is needed to form a coherent response to an unfolding epidemic, and infection risk may have an airborne pathogen exposure component. The general aircraft-cabin air-contaminant transport effect model was applied to datasets from the University of Illinois and Kansas State University and also to case study information from a flight with probable severe acute respiratory syndrome transmission. Data were fit to regression curves, where the dependent variable was contaminant concentration (normalized for source strength and ventilation rate), and the independent variable was distance between source and measurement locations. The data-driven model showed exposure to viable small droplets and post-evaporation nuclei at a source distance of several rows in a mock-up of a twin-aisle airliner with seven seats per row. Similar behavior was observed in tracer gas, particle experiments, and flight infection data for severe acute respiratory syndrome. The study supports the airborne pathway as part of the matrix of possible disease transmission modes in aircraft cabins. C1 [Bennett, James S.; Topmiller, Jennifer L.; Dietrich, Watts L.] NIOSH, Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Cincinnati, OH 45226 USA. [Jones, Byron W.; Hosni, Mohammad H.] Kansas State Univ, Dept Mech & Nucl Engn, Manhattan, KS 66506 USA. [Zhang, Yuanhui] Univ Illinois, Dept Agr & Biol Engn, Urbana, IL 61801 USA. RP Bennett, JS (reprint author), NIOSH, Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, 4676 Columbia Pkwy,MS R5, Cincinnati, OH 45226 USA. EM jbennett@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 2 Z9 2 U1 1 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1078-9669 EI 1938-5587 J9 HVAC&R RES JI HVAC&R Res. PD NOV 17 PY 2013 VL 19 IS 8 BP 962 EP 973 DI 10.1080/10789669.2013.838990 PG 12 WC Thermodynamics; Construction & Building Technology; Engineering, Mechanical SC Thermodynamics; Construction & Building Technology; Engineering GA 258RS UT WOS:000327477000004 PM 26526769 ER PT J AU Arrazola, RA Dube, SR King, BA AF Arrazola, Rene A. Dube, Shanta R. King, Brian A. TI Tobacco Product Use Among Middle and High School Students - United States, 2011 and 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Arrazola, Rene A.; Dube, Shanta R.; King, Brian A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Arrazola, RA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM rarrazola@cdc.gov NR 10 TC 99 Z9 99 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 15 PY 2013 VL 62 IS 45 BP 893 EP 897 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NY UT WOS:000326937700001 ER PT J AU Bocchini, JA Rubin, L Fischer, M Hills, SL Staples, JE AF Bocchini, Joseph A., Jr. Rubin, Lorry Fischer, Marc Hills, Susan L. Staples, J. Erin TI Use of Japanese Encephalitis Vaccine in Children: Recommendations of the Advisory Committee on Immunization Practices, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SAFETY; IXIARO(R); POINTS; TRIAL; IC51 C1 [Bocchini, Joseph A., Jr.; Rubin, Lorry; Fischer, Marc; Hills, Susan L.; Staples, J. Erin] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Fischer, M (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM mfischer@cdc.gov NR 17 TC 10 Z9 10 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 15 PY 2013 VL 62 IS 45 BP 898 EP 900 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NY UT WOS:000326937700002 ER PT J AU Warren, M Miller, A Traylor, J Sidonio, R Morad, A Goodman, A Christensen, D Grant, A Odom, E Okoroh, E Clayton, J Maenner, M Marcewicz, L AF Warren, Michael Miller, Angela Traylor, Julie Sidonio, Robert Morad, Anna Goodman, Alyson Christensen, Deborah Grant, Althea Odom, Erika Okoroh, Ekwutosi Clayton, Joshua Maenner, Matthew Marcewicz, Lauren TI Late Vitamin K Deficiency Bleeding in Infants Whose Parents Declined Vitamin K Prophylaxis - Tennessee, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NEWBORN C1 [Warren, Michael; Miller, Angela; Traylor, Julie] Tennessee Dept Hlth, Chattanooga, TN 37403 USA. [Sidonio, Robert; Morad, Anna] Vanderbilt Univ, Nashville, TN USA. [Goodman, Alyson; Christensen, Deborah] CDC, Div Dev Disabil & Birth Defects, Atlanta, GA 30333 USA. [Grant, Althea; Odom, Erika; Okoroh, Ekwutosi] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Clayton, Joshua; Maenner, Matthew; Marcewicz, Lauren] CDC, EIS Officers, Atlanta, GA 30333 USA. RP Marcewicz, L (reprint author), CDC, EIS Officers, Atlanta, GA 30333 USA. EM lmarcewicz@cdc.gov NR 5 TC 15 Z9 15 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 15 PY 2013 VL 62 IS 45 BP 901 EP 902 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NY UT WOS:000326937700003 ER PT J AU Hunte, T Morris, T da Silva, A Nuriddin, A Visvesvara, G Hill, V Mull, B Xiao, LH Roellig, D Gargano, J Beach, M Yoder, J Cope, J Morris, J AF Hunte, Tai Morris, Thomas da Silva, Alexandre Nuriddin, Azizeh Visvesvara, Govinda Hill, Vincent Mull, Bonnie Xiao, Lihua Roellig, Dawn Gargano, Julia Beach, Michael Yoder, Jonathan Cope, Jennifer Morris, Jamae TI Primary Amebic Meningoencephalitis Associated with Ritual Nasal Rinsing - St. Thomas, US Virgin Islands, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hunte, Tai; Morris, Thomas] CDC, US Virgin Isl Dept Hlth, Atlanta, GA 30333 USA. [da Silva, Alexandre] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Nuriddin, Azizeh; Visvesvara, Govinda; Hill, Vincent; Mull, Bonnie; Xiao, Lihua; Roellig, Dawn; Gargano, Julia; Beach, Michael; Yoder, Jonathan; Cope, Jennifer] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Morris, Jamae] CDC, EIS Officer, Atlanta, GA 30333 USA. RP Morris, J (reprint author), CDC, EIS Officer, Atlanta, GA 30333 USA. EM jfmorris@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 2 TC 7 Z9 7 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 15 PY 2013 VL 62 IS 45 BP 903 EP 903 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NY UT WOS:000326937700004 ER PT J AU Nguyen, DB Lessa, FC Belflower, R Mu, Y Wise, M Nadle, J Bamberg, WM Petit, S Ray, SM Harrison, LH Lynfield, R Dumyati, G Thompson, J Schaffner, W Patel, PR AF Nguyen, Duc B. Lessa, Fernanda C. Belflower, Ruth Mu, Yi Wise, Matthew Nadle, Joelle Bamberg, Wendy M. Petit, Susan Ray, Susan M. Harrison, Lee H. Lynfield, Ruth Dumyati, Ghinwa Thompson, Jamie Schaffner, William Patel, Priti R. CA Emerging Infections Program TI Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Patients on Chronic Dialysis in the United States, 2005-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE invasive MRSA; dialysis; methicillin-resistant S. aureus ID BLOOD-STREAM INFECTIONS; VASCULAR ACCESS TYPE; HEMODIALYSIS-PATIENTS; CLINICAL-OUTCOMES; COMORBIDITY INDEX; RISK-FACTORS; BACTEREMIA; SURVEILLANCE; VALIDATION; SEPTICEMIA AB Background. Approximately 15 700 invasive methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in US dialysis patients in 2010. Frequent hospital visits and prolonged bloodstream access, especially via central venous catheters (CVCs), are risk factors among hemodialysis patients. We describe the epidemiology of and recent trends in invasive MRSA infections among dialysis patients. Methods. We analyzed population-based data from 9 US metropolitan areas from 2005 to 2011. Cases were defined as MRSA isolated from a normally sterile body site in a surveillance area resident who received dialysis, and were classified as hospital-onset (HO; culture collected >3 days after hospital admission) or healthcare-associated community-onset (HACO; all others). Incidence was calculated using denominators from the US Renal Data System. Temporal trends in incidence and national estimates were calculated controlling for age, sex, and race. Results. From 2005 to 2011, 7489 cases were identified; 85.7% were HACO infections, and 93.2% were bloodstream infections. Incidence of invasive MRSA infections decreased from 6.5 to 4.2 per 100 dialysis patients (annual decrease, 7.3%) with annual decreases of 6.7% for HACO and 10.5% for HO cases. Among cases identified during 2009-2011, 70% of patients were hospitalized in the year prior to infection. Among hemodialysis cases, 60.4% of patients were dialyzed through a CVC. The 2011 national estimated number of MRSA infections was 15 169. Conclusions. There has been a substantial decrease in invasive MRSA infection incidence among dialysis patients. Most cases had previous hospitalizations, suggesting that efforts to control MRSA in hospitals might have contributed to the declines. Infection prevention measures should include improved vascular access and CVC care. C1 [Nguyen, Duc B.; Lessa, Fernanda C.; Belflower, Ruth; Mu, Yi; Wise, Matthew; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Nguyen, Duc B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Belflower, Ruth] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA. [Bamberg, Wendy M.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Ray, Susan M.] Emory Univ, Sch Med, Atlanta, GA USA. [Ray, Susan M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Harrison, Lee H.] Maryland Emerging Infect Program, Baltimore, MD USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Dumyati, Ghinwa] Univ Rochester, New York, NY USA. [Thompson, Jamie] Oregon Publ Hlth Div, Portland, OR USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Nguyen, DB (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS A35, Atlanta, GA 30333 USA. EM vif8@cdc.gov FU Center for Disease Control FX This work was supported by the Center for Disease Control's Emerging Infections Program Cooperative Agreement. NR 38 TC 21 Z9 21 U1 1 U2 25 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2013 VL 57 IS 10 BP 1393 EP 1400 DI 10.1093/cid/cit546 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 243BW UT WOS:000326292400004 PM 23964088 ER PT J AU Parashar, UD Orenstein, WA AF Parashar, Umesh D. Orenstein, Walter A. TI Intussusception and Rotavirus Vaccination-Balancing Risk Against Benefit SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID US INFANTS; HOSPITALIZATIONS; EFFICACY; VACCINES; MEXICO; SAFETY C1 [Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Orenstein, Walter A.] Emory Univ, Sch Med, Atlanta, GA 30338 USA. RP Orenstein, WA (reprint author), Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30338 USA. EM dmill06@emory.edu NR 19 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2013 VL 57 IS 10 BP 1435 EP 1437 DI 10.1093/cid/cit532 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 243BW UT WOS:000326292400010 PM 23964087 ER PT J AU Haque, F Kundu, SK Islam, MS Hasan, SMM Khatun, A Gope, PS Mahmud, ZH Alamgir, ASM Islam, MS Rahman, M Luby, SP AF Haque, Farhana Kundu, Subodh Kumar Islam, Md Saiful Hasan, S. M. Murshid Khatun, Asma Gope, Partha Sarathi Mahmud, Zahid Hayat Alamgir, A. S. M. Islam, M. Sirajul Rahman, Mahmudur Luby, Stephen P. TI Outbreak of Mass Sociogenic Illness in a School Feeding Program in Northwest Bangladesh, 2010 SO PLOS ONE LA English DT Article ID PSYCHOGENIC ILLNESS; EPIDEMIC HYSTERIA; MIXED METHODS; FOOD; VACCINATION AB Background: In 2010, an acute illness outbreak was reported in school students eating high-energy biscuits supplied by the school feeding programme in northwest Bangladesh. We investigated this outbreak to describe the illness in terms of person, place and time, develop the timeline of events, and determine the cause and community perceptions regarding the outbreak. Methods: We defined case-patients as students from affected schools reporting any two symptoms including abdominal pain, heartburn, bitter taste, and headache after eating biscuits on the day of illness. We conducted in-depth interviews and group discussions with students, teachers, parents and community members to explore symptoms, exposures, and community perceptions. We conducted a questionnaire survey among case-patients to determine the symptoms and ascertain food items eaten 12 hours before illness onset, and microbiological and environmental investigations. Results: Among 142 students seeking hospital care, 44 students from four schools qualified as case-patients. Of these, we surveyed 30 who had a mean age of 9 years; 70% (21/30) were females. Predominant symptoms included abdominal pain (93%), heartburn (90%), and bitter taste (57%). All students recovered within a few hours. No pathogenic Vibrio cholerae, Shigella or Salmonella spp. were isolated from collected stool samples. We found no rancid biscuits in schools and storage sites. The female index case perceived the unusually darker packet label as a "devil's deed" that made the biscuits poisonous. Many students, parents and community members reported concerns about rumors of students dying from biscuit poisoning. Conclusions: Rapid onset, followed by rapid recovery of symptoms; female preponderance; inconsistent physical, microbiological and environmental findings suggested mass sociogenic illness rather than a foodborne or toxic cause. Rumours of student deaths heightening community anxiety apparently propagated this outbreak. Sharing investigation results and reassuring students and parents through health communication campaigns could limit similar future outbreaks and help retain beneficiaries' trust on nutrition supplementation initiatives. C1 [Haque, Farhana; Islam, Md Saiful; Hasan, S. M. Murshid; Luby, Stephen P.] CCD, Icddr b, Dhaka, Bangladesh. [Haque, Farhana; Kundu, Subodh Kumar; Khatun, Asma; Alamgir, A. S. M.; Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh. [Gope, Partha Sarathi; Mahmud, Zahid Hayat; Islam, M. Sirajul] Ctr Food & Waterborne Dis, Icddr b, Dhaka, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Global Dis Detect Program, Atlanta, GA USA. RP Haque, F (reprint author), CCD, Icddr b, Dhaka, Bangladesh. EM drfarhana2007@gmail.com FU Government of the People's Republic of Bangladesh; Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA FX This investigation was funded by the Government of the People's Republic of Bangladesh and the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. icddr,b acknowledges with gratitude the commitment of the Government of Bangladesh and the CDC to its research efforts. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 0 Z9 1 U1 0 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 14 PY 2013 VL 8 IS 11 AR UNSP e80420 DI 10.1371/journal.pone.0080420 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 254DJ UT WOS:000327143800145 PM 24244685 ER PT J AU Mason, L Nyothach, E Alexander, K Odhiambo, FO Eleveld, A Vulule, J Rheingans, R Laserson, KF Mohammed, A Phillips-Howard, PA AF Mason, Linda Nyothach, Elizabeth Alexander, Kelly Odhiambo, Frank O. Eleveld, Alie Vulule, John Rheingans, Richard Laserson, Kayla F. Mohammed, Aisha Phillips-Howard, Penelope A. TI 'We Keep It Secret So No One Should Know' - A Qualitative Study to Explore Young Schoolgirls Attitudes and Experiences with Menstruation in Rural Western Kenya SO PLOS ONE LA English DT Article ID TREATED BED NETS; ADOLESCENT GIRLS; DEMOGRAPHIC SURVEILLANCE; HYGIENE PRACTICES; SEXUAL-BEHAVIOR; PREMARITAL SEX; HIV-INFECTION; UNITED-STATES; MENARCHE; HEALTH AB Background: Keeping girls in school offers them protection against early marriage, teen pregnancy, and sexual harms, and enhances social and economic equity. Studies report menstruation exacerbates school-drop out and poor attendance, although evidence is sparse. This study qualitatively examines the menstrual experiences of young adolescent schoolgirls. Methods and Findings: The study was conducted in Siaya County in rural western Kenya. A sample of 120 girls aged 14-16 years took part in 11 focus group discussions, which were analysed thematically. The data gathered were supplemented by information from six FGDs with parents and community members. Emergent themes were: lack of preparation for menarche; maturation and sexual vulnerability; menstruation as an illness; secrecy, fear and shame of leaking; coping with inadequate alternatives; paying for pads with sex; and problems with menstrual hygiene. Girls were unprepared and demonstrated poor reproductive knowledge, but devised practical methods to cope with menstrual difficulties, often alone. Parental and school support of menstrual needs is limited, and information sparse or inaccurate. Girls' physical changes prompt boys and adults to target and brand girls as ripe for sexual activity including coercion and marriage. Girls admitted 'others' rather than themselves were absent from school during menstruation, due to physical symptoms or inadequate sanitary protection. They described difficulties engaging in class, due to fear of smelling and leakage, and subsequent teasing. Sanitary pads were valued but resource and time constraints result in prolonged use causing chafing. Improvised alternatives, including rags and grass, were prone to leak, caused soreness, and were perceived as harmful. Girls reported 'other girls' but not themselves participated in transactional sex to buy pads, and received pads from boyfriends. Conclusions: In the absence of parental and school support, girls cope, sometimes alone, with menarche in practical and sometimes hazardous ways. Emotional and physical support mechanisms need to be included within a package of measures to enable adolescent girls to reach their potential. C1 [Mason, Linda; Alexander, Kelly; Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Nyothach, Elizabeth; Odhiambo, Frank O.; Vulule, John; Laserson, Kayla F.] Kenya Med Res Inst Ctr Dis Control Res & Publ Hlt, Kisumu, Nyanza Province, Kenya. [Eleveld, Alie] Safe Water & AIDS Project, Kisumu, Nyanza Province, Kenya. [Rheingans, Richard] Univ Florida, Ctr African Studies, Gainesville, FL USA. [Laserson, Kayla F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Mohammed, Aisha] Minist Publ Hlth & Sanit, Div Reprod Hlth, Nairobi, Kenya. RP Mason, L (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. EM Linda.Mason@liverpool.ac.uk RI Mashamba-Thompson, Tivani /B-6087-2014; OI Phillips-Howard, Penelope A/0000-0003-1018-116X FU UK Medical Research Council/Department for International Development/Wellcome Trust [G1100677/1]; British Council through the Prime Ministers Initiative FX This study is part of the baseline phase of a proof of concept feasibility study on menstrual solutions for schoolgirls in western Kenya funded by the UK Medical Research Council/Department for International Development/Wellcome Trust Project Protect (G1100677/1). The British Council provided funding through the Prime Ministers Initiative (2) for workshops on water and sanitation and sexual and reproductive health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 68 TC 13 Z9 13 U1 0 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 14 PY 2013 VL 8 IS 11 AR e79132 DI 10.1371/journal.pone.0079132 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 254DJ UT WOS:000327143800033 PM 24244435 ER PT J AU Dellicour, S Desai, M Mason, L Odidi, B Aol, G Phillips-Howard, PA Laserson, KF ter Kuile, FO AF Dellicour, Stephanie Desai, Meghna Mason, Linda Odidi, Beatrice Aol, George Phillips-Howard, Penelope A. Laserson, Kayla F. ter Kuile, Feiko O. TI Exploring Risk Perception and Attitudes to Miscarriage and Congenital Anomaly in Rural Western Kenya SO PLOS ONE LA English DT Article ID DEMOGRAPHIC SURVEILLANCE; HEALTH; PREVALENCE; COUNTRIES; MORTALITY; CHILDREN; RATES; WOMEN AB Background: Understanding the socio-cultural context and perceptions of adverse pregnancy outcomes is important for informing the best approaches for public health programs. This article describes the perceptions, beliefs and health-seeking behaviours of women from rural western Kenya regarding congenital anomalies and miscarriages. Methods: Ten focus group discussions (FGDs) were undertaken in a rural district in western Kenya in September 2010. The FGDs included separate groups consisting of adult women of childbearing age, adolescent girls, recently pregnant women, traditional birth attendants and mothers of children with a birth defect. Participants were selected purposively. A deductive thematic framework approach using the questions from the FGD guides was used to analyse the transcripts. Results: There was substantial overlap between perceived causes of miscarriages and congenital anomalies and these were broadly categorized into two groups: biomedical and cultural. The biomedical causes included medications, illnesses, physical and emotional stresses, as well as hereditary causes. Cultural beliefs mostly related to the breaking of a taboo or not following cultural norms. Mothers were often stigmatised and blamed following miscarriage, or the birth of a child with a congenital anomaly. Often, women did not seek care following miscarriage unless there was a complication. Most reported that children with a congenital anomaly were neglected either because of lack of knowledge of where care could be sought or because these children brought shame to the family and were hidden from society. Conclusion: The local explanatory model of miscarriage and congenital anomalies covered many perceived causes within biomedical and cultural beliefs. Some of these fuelled stigmatisation and blame of the mother. Understanding of these beliefs, improving access to information about the possible causes of adverse outcomes, and greater collaboration between traditional healers and healthcare providers may help to reduce stigma and increase access to formal healthcare providers. C1 [Dellicour, Stephanie; Desai, Meghna; Odidi, Beatrice] Ctr Dis Control & Prevent CDC Res & Publ Hlth Col, Malaria Branch, Kenya Med Res Inst, Kisumu, Nyanza Province, Kenya. [Dellicour, Stephanie; Mason, Linda; Phillips-Howard, Penelope A.; ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Desai, Meghna; Laserson, Kayla F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Aol, George] Ctr Dis Control & Prevent Res & Publ Hlth Collabo, Int Emerging Infect Branch, Kenya Med Res Inst, Kisumu, Nyanza Province, Kenya. [Aol, George] Kenya Res & Publ Hlth Collaborat, Kisumu, Nyanza Province, Kenya. [Laserson, Kayla F.] Ctr Dis Control & Prevent Res & Publ Hlth Col, Kenya Med Res Inst, Hlth & Demog Surveillance Syst Branch, Kisumu, Nyanza Province, Kenya. RP Dellicour, S (reprint author), Ctr Dis Control & Prevent CDC Res & Publ Hlth Col, Malaria Branch, Kenya Med Res Inst, Kisumu, Nyanza Province, Kenya. EM s.dellicour@liverpool.ac.uk OI Phillips-Howard, Penelope A/0000-0003-1018-116X; ter Kuile, Feiko/0000-0003-3663-5617 FU US Centers for Disease Control and Prevention (CDC), Division of Parasitic Diseases and Malaria through Kenya Medical Research Institute (KEMRI), Center for Global Health Research (CGHR), Kisumu, Kenya; Malaria in Pregnancy Consortium; Bill & Melinda Gates Foundation; US CDC FX The funding source was the US Centers for Disease Control and Prevention (CDC), Division of Parasitic Diseases and Malaria through a cooperative agreement with Kenya Medical Research Institute (KEMRI), Center for Global Health Research (CGHR), Kisumu, Kenya. SD is partly funded by the Malaria in Pregnancy Consortium which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine. SD is also grateful to the US CDC for salary support through a cooperative agreement between the Division of Parasitic Diseases and Malaria (Centers for Disease Control and Prevention, USA) and the Malaria Epidemiology Unit of the Child and Reproductive Health group, Liverpool School of Tropical Medicine held by FOtK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 2 Z9 2 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 13 PY 2013 VL 8 IS 11 AR e80551 DI 10.1371/journal.pone.0080551 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255QK UT WOS:000327254700186 PM 24236185 ER PT J AU Eriksen, HLF Kesmodel, US Underbjerg, M Kilburn, TR Bertrand, J Mortensen, EL AF Eriksen, Hanne-Lise Falgreen Kesmodel, Ulrik Schioler Underbjerg, Mette Kilburn, Tina Rondrup Bertrand, Jacquelyn Mortensen, Erik Lykke TI Predictors of Intelligence at the Age of 5: Family, Pregnancy and Birth Characteristics, Postnatal Influences, and Postnatal Growth SO PLOS ONE LA English DT Article ID BODY-MASS INDEX; HOME-ENVIRONMENT; COGNITIVE-ABILITY; MATERNAL IQ; EARLY-CHILDHOOD; EARLY-LIFE; WEIGHT; CHILDREN; COHORT; ASSOCIATION AB Parental education and maternal intelligence are well-known predictors of child IQ. However, the literature regarding other factors that may contribute to individual differences in IQ is inconclusive. The aim of this study was to examine the contribution of a number of variables whose predictive status remain unclarified, in a sample of basically healthy children with a low rate of pre- and postnatal complications. 1,782 5-year-old children sampled from the Danish National Birth Cohort (2003-2007) were assessed with a short form of the Wechsler Preschool and Primary Scale of Intelligence - Revised. Information on parental characteristics, pregnancy and birth factors, postnatal influences, and postnatal growth was collected during pregnancy and at follow-up. A model including study design variables and child's sex explained 7% of the variance in IQ, while parental education and maternal IQ increased the explained variance to 24%. Other predictors were parity, maternal BMI, birth weight, breastfeeding, and the child's head circumference and height at follow-up. These variables, however, only increased the explained variance to 29%. The results suggest that parental education and maternal IQ are major predictors of IQ and should be included routinely in studies of cognitive development. Obstetrical and postnatal factors also predict IQ, but their contribution may be of comparatively limited magnitude. C1 [Eriksen, Hanne-Lise Falgreen; Kesmodel, Ulrik Schioler; Underbjerg, Mette; Kilburn, Tina Rondrup] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark. [Kesmodel, Ulrik Schioler] Aarhus Univ Hosp, Dept Obstet & Gynaecol, DK-8000 Aarhus, Denmark. [Underbjerg, Mette] Vejlefjord Rehabil Ctr, Childrens Neuroctr, Stouby, Denmark. [Bertrand, Jacquelyn] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Mortensen, Erik Lykke] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark. [Mortensen, Erik Lykke] Univ Copenhagen, Ctr Healthy Ageing, Copenhagen, Denmark. RP Eriksen, HLF (reprint author), Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark. EM hfe@soci.au.dk FU Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA; Pharmacy Foundation; Egmont Foundation; March of Dimes Birth Defects Foundation; Augustinus Foundation; Health Foundation FX This study was supported by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. The Danish National Research Foundation has established the Danish Epidemiology Science Centre that initiated and created the Danish National Birth Cohort. The cohort is furthermore a result of a major grant from this Foundation. Additional support for the Danish National Birth Cohort was obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus Foundation and the Health Foundation. The funders provided financial support for the data collection, but had no role in the decision to conduct and publish the analyses presented in this paper. NR 39 TC 22 Z9 22 U1 4 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 13 PY 2013 VL 8 IS 11 AR e79200 DI 10.1371/journal.pone.0079200 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255QK UT WOS:000327254700108 PM 24236109 ER PT J AU Verdijk, P Rots, NY van Oijen, MGCT Oberste, MS Boog, CJ Okayasu, H Sutter, RW Bakker, WAM AF Verdijk, Pauline Rots, Nynke Y. van Oijen, Monique G. C. T. Oberste, M. Steven Boog, Claire J. Okayasu, Hiromasa Sutter, Roland W. Bakker, Wilfried A. M. TI Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults SO VACCINE LA English DT Article DE Inactivated poliovirus vaccine; Sabin strains; Aluminum hydroxide; Adjuvant; Phase I trial; Safety; Immunogenicity ID TECHNOLOGY-TRANSFER; POLIOMYELITIS; ERADICATION; IPV AB Background: An inactivated poliovirus vaccine (IPV) based on attenuated poliovirus strains (Sabin-1, -2 and -3) was developed for technology transfer to manufacturers in low- and middle income countries in the context of the Global Polio Eradication Initiative. Method: Safety and immunogenicity of the Sabin-IPV was evaluated in a double-blind, randomized, controlled, phase I 'proof-of-concept' trial. Healthy male adults received a single intramuscular injection with Sabin-IPV, Sabin-IPV adjuvanted with aluminum hydroxide or conventional IPV. Virus-neutralizing titers against both Sabin and wild poliovirus strains were determined before and 28 days after vaccination. Results: No vaccine-related serious adverse events were observed, and all local and systemic reactions were mild or moderate and transient. In all subjects, an increase in antibody titer for all types of poliovirus (both Sabin and wild strains) was observed 28 days after vaccination. Conclusion: Sabin-IPV and Sabin-IPV adjuvanted with aluminum hydroxide administered as a booster dose were equally immunogenic and safe as conventional IPV. EudraCTnr: 2010-024581-22, NCT01708720. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Verdijk, Pauline; van Oijen, Monique G. C. T.; Boog, Claire J.; Bakker, Wilfried A. M.] Inst Translat Vaccinol Intravacc, NL-3720 AL Bilthoven, Netherlands. [Rots, Nynke Y.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Okayasu, Hiromasa; Sutter, Roland W.] World Hlth Org, CH-1211 Geneva 27, Switzerland. RP Verdijk, P (reprint author), Inst Translat Vaccinol Intravacc, POB 450, NL-3720 AL Bilthoven, Netherlands. EM pauline.verdijk@intravacc.nl; Nynke.rots@rivm.nl; Monique.van.oijen@intravacc.nl; Mbo2@cdc.gov; Claire.boog@intravacc.nl; okayasuhi@who.int; sutterr@who.int; Wilfried.bakker@intravacc.nl OI Verdijk, Pauline/0000-0003-2272-2736 FU World Health Organization; Bill and Melinda Gates Foundation FX The authors would like to thank Katarzyna Kowalska, Hanna Miatkowski and Mariola Zimolag Miroslaw Necki from Monipol Clinical Research & Medical Consultants for the conduct of the trial, Deborah Kleijne of the RIVM for her assistance during the study and Henriet Nienhuis of Nienhuis Medistat for performing the statistical analysis. We would like to thank Deborah Moore, Yiting Zhang, Sharla McDonald, William Hendley, and William Weldon of the Centers for Disease Control and Prevention (CDC), USA for performing the virus neutralization assays. Conflict of interests: The authors have no conflict of interests. Funding: This work was supported by the World Health Organization using funds provided by a Grant from the Bill and Melinda Gates Foundation. The World Health Organization was involved in the design of the clinical trial. NR 30 TC 13 Z9 14 U1 2 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 12 PY 2013 VL 31 IS 47 BP 5531 EP 5536 DI 10.1016/j.vaccine.2013.09.021 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 257WZ UT WOS:000327419800006 PM 24063976 ER PT J AU Bonhoeffer, J Imoukhuede, EB Aldrovandi, G Bachtiar, NS Chan, ES Chang, S Chen, RT Fernandopulleh, R Goldenthal, KL Heffelfinger, JD Hossain, S Jevaji, I Khamesipour, A Kochhar, S Makhene, M Malkin, E Nalin, D Prevots, R Ramasamy, R Sellers, S Vekemans, J Walker, KB Wilson, P Wong, V Zaman, K Heininger, U AF Bonhoeffer, Jan Imoukhuede, Egeruan B. Aldrovandi, Grace Bachtiar, Novilia S. Chan, Eng-Soon Chang, Soju Chen, Robert T. Fernandopulleh, Rohini Goldenthal, Karen L. Heffelfinger, James D. Hossain, Shah Jevaji, Indira Khamesipour, Ali Kochhar, Sonali Makhene, Mamodikoe Malkin, Elissa Nalin, David Prevots, Rebecca Ramasamy, Ranjan Sellers, Sarah Vekemans, Johan Walker, Kenneth B. Wilson, Pam Wong, Virginia Zaman, Khalequz Heininger, Ulrich CA Brighton Collaboration Clinical TI Template protocol for clinical trials investigating vaccines Focus on safety elements SO VACCINE LA English DT Article DE Vaccine; Immunization; Safety; Protocol; Clinical trial ID EVENT FOLLOWING IMMUNIZATION; CASE-DEFINITION; DATA-COLLECTION; INJECTION SITE; GUIDELINES; EXPOSURE; VIRUS; CHILDREN; INFANTS AB This document is intended as a guide to the protocol development for trials of prophylactic vaccines. The template may serve phases I-IV clinical trials protocol development to include safety relevant information as required by the regulatory authorities and as deemed useful by the investigators. This document may also be helpful for future site strengthening efforts. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Bonhoeffer, Jan; Heininger, Ulrich] Univ Basel, Univ Childrens Hosp UKBB, CH-4056 Basel, Switzerland. [Imoukhuede, Egeruan B.] European Vaccine Initiat, Heidelberg, Germany. [Aldrovandi, Grace] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA USA. [Chang, Soju; Jevaji, Indira; Makhene, Mamodikoe] NIH, Bethesda, MD USA. [Chen, Robert T.; Heffelfinger, James D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Fernandopulleh, Rohini] Univ Colombo, Colombo, Sri Lanka. [Khamesipour, Ali] Univ Tehran Med Sci, Tehran, Iran. [Ramasamy, Ranjan] Univ Brunei Darussalam, Inst Hlth Sci, Darussalam, Brunei. [Wilson, Pam] Harvard Clin Res Inst, Boston, MA USA. [Wong, Virginia] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China. RP Bonhoeffer, J (reprint author), Univ Basel, Univ Childrens Hosp UKBB, Spitalstr 33, CH-4056 Basel, Switzerland. EM contact@brightoncollaboration.org RI Bonhoeffer, Jan/E-5903-2014; Chiappini, Elena/D-1118-2012; OI Chiappini, Elena/0000-0002-1476-4752; McConkey, Samuel/0000-0001-9085-7793; Imoukhuede, Egeruan Babatunde/0000-0001-6679-0904; Ramasamy, Ranjan/0000-0003-0246-7053 FU European Commission [223532] FX The INYVAX project is funded by the European Commission under the Framework programme 7, project number 223532. This document does not necessarily reflect the opinion of the European Commission. Conflict of interest statement: None of the authors has claimed conflict of interest. NR 31 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 12 PY 2013 VL 31 IS 47 BP 5602 EP 5620 DI 10.1016/j.vaccine.2013.02.041 PG 19 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 257WZ UT WOS:000327419800016 PM 23499603 ER PT J AU Guy, GP Berkowitz, Z Watson, M Holman, DM Richardson, LC AF Guy, Gery P., Jr. Berkowitz, Zahava Watson, Meg Holman, Dawn M. Richardson, Lisa C. TI Indoor Tanning Among Young Non-Hispanic White Females SO JAMA INTERNAL MEDICINE LA English DT Letter ID UNITED-STATES; METAANALYSIS C1 [Guy, Gery P., Jr.; Berkowitz, Zahava; Watson, Meg; Holman, Dawn M.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mail Stop K-55, Atlanta, GA 30341 USA. EM irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 31 Z9 31 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 11 PY 2013 VL 173 IS 20 BP 1920 EP 1922 DI 10.1001/jamainternmed.2013.10013 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 302FD UT WOS:000330586600017 PM 23959651 ER PT J AU Auld, SC Click, ES Heilig, CM Miramontes, R Cain, KP Bisson, GP Mac Kenzie, WR AF Auld, Sara C. Click, Eleanor S. Heilig, Charles M. Miramontes, Roque Cain, Kevin P. Bisson, Gregory P. Mac Kenzie, William R. TI Tuberculin Skin Test Result and Risk of Death among Persons with Active TB SO PLOS ONE LA English DT Article ID PULMONARY TUBERCULOSIS; ANERGY; CHILDREN; HIV; ADULTS; IMPACT; PERU AB Background: Although the tuberculin skin test (TST) is frequently used to aid in the diagnosis of tuberculosis (TB) disease and to identify persons with latent TB infection, it is an imperfect test and approximately 10-25% of persons with microbiologically confirmed TB disease have a negative TST. Previous studies have suggested that persons with a negative TST are more likely to present with severe TB disease and have an increased rate of TB-related death. Methods: We analyzed culture-confirmed TB cases captured in US TB surveillance data from 1993 to 2008 and performed multivariate logistic regression analysis to determine the association between TST result and death. Results: Of 284,866 cases of TB reported in the US, 58,180 persons were eligible for inclusion in the analysis and 3,270 of those persons died after initiating TB treatment. Persons with a negative TST accounted for only 14% of the eligible cases but accounted for 42% of the deaths. Persons with a TST >= 15 mm had 67% lower odds of death than persons with a negative TST (adjusted odds ratio 0.33, 95% confidence interval 0.30-0.36). Conclusions: A negative TST is associated with an increased risk of death among persons with culture-confirmed TB disease, even after adjustment for HIV status, site of TB disease, sputum smear AFB status, drug susceptibility, age, sex, and origin of birth. In addition to indicating risk of developing disease, the TST may also be a marker for increased risk of death. C1 [Auld, Sara C.; Click, Eleanor S.; Heilig, Charles M.; Miramontes, Roque; Mac Kenzie, William R.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Auld, Sara C.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Cain, Kevin P.] US Ctr Dis Control & Prevent, Kisumu, Kenya. [Bisson, Gregory P.] Univ Penn, Dept Med, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Auld, SC (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM via1@cdc.gov RI Mac Kenzie, William /F-1528-2013; Heilig, Charles/C-2753-2008; OI Mac Kenzie, William /0000-0001-7723-0339; Heilig, Charles/0000-0003-1075-1310; Miramontes, Roque/0000-0001-9535-460X FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. No direct funding was received for this study. No funding bodies had any role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. NR 28 TC 1 Z9 1 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 11 PY 2013 VL 8 IS 11 AR e78779 DI 10.1371/journal.pone.0078779 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255EG UT WOS:000327221600058 PM 24244358 ER PT J AU Liu, Y Huang, PW Jiang, BM Tan, M Morrow, AL Jiang, X AF Liu, Yang Huang, Pengwei Jiang, Baoming Tan, Ming Morrow, Ardythe L. Jiang, Xi TI Poly-LacNAc as an Age-Specific Ligand for Rotavirus P[11] in Neonates and Infants SO PLOS ONE LA English DT Article ID BLOOD GROUP ANTIGENS; N-ACETYLLACTOSAMINE; NOROVIRUS; STRAIN; SUSCEPTIBILITY; VP8(STAR); PROTEIN; GLYCOSYLATION; GENOTYPE; PATTERNS AB Rotavirus (RV) P[11] is an unique genotype that infects neonates. The mechanism of such age-specific host restriction remains unknown. In this study, we explored host mucosal glycans as a potential age-specific factor for attachment of P[11] RVs. Using in vitro binding assays, we demonstrated that VP8* of a P[11] RV (N155) could bind saliva of infants (60.3%, N = 151) but not of adults (0%, N = 48), with a significantly negative correlation between binding of VP8* and ages of infants (P<0.01). Recognition to the infant saliva did not correlate with the ABO, secretor and Lewis histo-blood group antigens (HBGAs) but with the binding of the lectin Lycopersicon esculentum (LEA) that is known to recognize the oligomers of N-acetyllactosamine (LacNAc), a precursor of human HBGAs. Direct evidence of LacNAc involvement in P[11] binding was obtained from specific binding of VP8* with homopolymers of LacNAc in variable lengths through a glycan array analysis of 611 glycans. These results were confirmed by strong binding of VP8* to the Lec2 cell line that expresses LacNAc oligomers but not to the Lec8 cell line lacking the LacNAc. In addition, N155 VP8* and authentic P[11] RVs (human 116E and bovine B223) hemagglutinated human red blood cells that are known to express poly-LacNAc. The potential role of poly-LacNAc in host attachment and infection of RVs has been obtained by abrogation of 116E replication by the PAA-conjugated poly-LacNAc, human milk, and LEA positive infant saliva. Overall, our results suggested that the poly-LacNAc could serve as an age-specific receptor for P[11] RVs and well explained the epidemiology that P[11] RVs mainly infect neonates and young children. C1 [Liu, Yang; Huang, Pengwei; Tan, Ming; Jiang, Xi] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA. [Morrow, Ardythe L.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Morrow, Ardythe L.] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Cincinnati, OH 45229 USA. [Tan, Ming; Morrow, Ardythe L.; Jiang, Xi] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA. [Jiang, Baoming] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA USA. RP Jiang, X (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA. EM jason.jiang@cchmc.org FU National Institute of Health, the National Institute of Allergy and Infectious Diseases [R01 AI37093, R01 AI055649]; National Institute of Child Health and Human Development [P01 HD13021]; NIGMS - The Consortium for Functional Glycomics [GM62116, GM098791] FX This work was supported by grants from the National Institute of Health, the National Institute of Allergy and Infectious Diseases (R01 AI37093 and R01 AI055649) to XJ, National Institute of Child Health and Human Development (P01 HD13021) to ALM and XJ, and in part by NIGMS - The Consortium for Functional Glycomics GM62116 and GM098791. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 11 Z9 13 U1 3 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 11 PY 2013 VL 8 IS 11 AR e78113 DI 10.1371/journal.pone.0078113 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255EG UT WOS:000327221600017 PM 24244290 ER PT J AU Ye, JB Xiao, LH Wang, YF Wang, L Amer, S Roellig, DM Guo, YQ Feng, YY AF Ye, Jianbin Xiao, Lihua Wang, Yuanfei Wang, Lin Amer, Said Roellig, Dawn M. Guo, Yaqiong Feng, Yaoyu TI Periparturient transmission of Cryptosporidium xiaoi from ewes to lambs SO VETERINARY PARASITOLOGY LA English DT Article DE Cryptosporidium; Periparturient rise; Sheep; Genotyping; Epidemiology ID GALICIA NW SPAIN; MOLECULAR CHARACTERIZATION; GIARDIA-DUODENALIS; ENTEROCYTOZOON-BIENEUSI; CERVINE GENOTYPE; SUBTYPE ANALYSIS; UNITED-KINGDOM; OVIS-ARIES; GOAT KIDS; SHEEP AB The mechanism for the maintenance of Cryptosporidium infection in sheep between yearly lambing periods is not clear. Previously, periparturient shedding of oocysts as the result of stress from lambing was suspected to be a mechanism for the initiation of Cryptosporidium infection in lambs, but this has never been verified by genotyping studies. In this study, fecal specimens from four age groups of sheep in Inner Mongolia, China were examined for Cryptosporidium spp. by PCR-restricted fragment length polymorphism and sequence analyses of the small subunit (SSU) rRNA gene, including 59 ewes 1 week before parturition, 154 ewes at parturition, 87 lambs of 3-4 weeks, and 75 lambs of 15-16 weeks. The Cryptosporidium infection rate in ewes at parturition (7.8%) was significantly higher than at 1 week before parturition (1.7%). Higher infection rates were found in lambs (18.4% and 26.7% for 3-4-week-old and 15-16-week-old lambs, respectively). Most (10/13)Cryptosporidium-positive ewes were shedding Cryptosporidium xiaoi, which was also the dominant species (15/16) in neonatal lambs of 3-4 weeks in age (15/16). The less common species in ewes, Cryptosporidium ubiquitum, was not found in lambs of 3-4 weeks but was the dominant species (14/20) in lambs of 15-16 weeks. The major zoonotic Cryptosporidium species, C. parvum (of the IIaA15G2R1 subtype), was only found in one lamb. These data support the occurrence of periparturient transmission of Cryptosporidium spp., especially C xiaoi, from ewes to lambs. Published by Elsevier B.V. C1 [Ye, Jianbin; Wang, Yuanfei; Wang, Lin; Guo, Yaqiong; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Ye, Jianbin; Xiao, Lihua; Amer, Said; Roellig, Dawn M.; Guo, Yaqiong] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Amer, Said] Kafr El Sheikh Univ, Fac Sci, Dept Zool, Kafe El Sheikh 33516, Egypt. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; Yaqiong, Guo/N-4927-2015 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31229005, 31110103901]; Fundamental Research Funds for the Central Universities, China; National Special Fund for State Key Laboratory of Bioreactor Engineering [2060204]; Centers for Disease Control and Prevention FX This work was supported by the National Natural Science Foundation of China (31229005, 31110103901); Fundamental Research Funds for the Central Universities, China; and the National Special Fund for State Key Laboratory of Bioreactor Engineering (No. 2060204); and Centers for Disease Control and Prevention. NR 51 TC 10 Z9 11 U1 0 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 EI 1873-2550 J9 VET PARASITOL JI Vet. Parasitol. PD NOV 8 PY 2013 VL 197 IS 3-4 BP 627 EP 633 DI 10.1016/j.vetpar.2013.07.021 PG 7 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 266GD UT WOS:000328010500028 PM 23953146 ER PT J AU Barbour, KE Helmick, CG Theis, KA Murphy, LB Hootman, JM Brady, TJ Cheng, YLJ AF Barbour, Kamil E. Helmick, Charles G. Theis, Kristina A. Murphy, Louise B. Hootman, Jennifer M. Brady, Teresa J. Cheng, Yiling J. TI Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POTENTIAL BARRIER; PHYSICAL-ACTIVITY; ADULTS; OBESITY C1 [Barbour, Kamil E.; Helmick, Charles G.; Theis, Kristina A.; Murphy, Louise B.; Hootman, Jennifer M.; Brady, Teresa J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. [Cheng, Yiling J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30333 USA. RP Barbour, KE (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. EM kbarbour@cdc.gov NR 10 TC 92 Z9 93 U1 0 U2 8 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 8 PY 2013 VL 62 IS 44 BP 869 EP 873 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NW UT WOS:000326937500001 ER PT J AU Tompkins, BJ Wirsing, E Devlin, V Kamhi, L Temple, B Weening, K Cavallo, S Allen, L Brinig, P Goode, B Fitzgerald, C Heiman, K Stroika, S Mahon, B AF Tompkins, Bradley J. Wirsing, Elisabeth Devlin, Valarie Kamhi, Laura Temple, Becky Weening, Keeley Cavallo, Steffany Allen, Latasha Brinig, Paul Goode, Brant Fitzgerald, Collette Heiman, Katherine Stroika, Steven Mahon, Barbara TI Multistate Outbreak of Campylobacter jejuni Infections Associated with Undercooked Chicken Livers - Northeastern United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PATHOGENS; PATE C1 [Tompkins, Bradley J.] Vermont Dept Hlth, Infect Dis Sect, Burlington, VT 05402 USA. [Wirsing, Elisabeth] Vermont Dept Hlth, Div Environm Hlth, Burlington, VT 05402 USA. [Devlin, Valarie; Kamhi, Laura; Temple, Becky; Weening, Keeley] Vermont Dept Hlth, Publ Hlth Lab, Burlington, VT 05402 USA. [Cavallo, Steffany] New Hampshire Dept Hlth & Human Svcs, Bur Infect Dis Control, Concord, NH USA. [Fitzgerald, Collette; Heiman, Katherine; Stroika, Steven; Mahon, Barbara] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Tompkins, BJ (reprint author), Vermont Dept Hlth, Infect Dis Sect, Burlington, VT 05402 USA. EM bradley.tompkins@state.vt.us NR 10 TC 14 Z9 14 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 8 PY 2013 VL 62 IS 44 BP 874 EP 876 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NW UT WOS:000326937500002 ER PT J AU Jernigan, DH Ross, CS Ostroff, J McKnight-Eily, LR Brewer, RD AF Jernigan, David H. Ross, Craig S. Ostroff, Joshua McKnight-Eily, Lela R. Brewer, Robert D. TI Youth Exposure to Alcohol Advertising on Television 25 Markets, United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Jernigan, David H.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Ross, Craig S.; Ostroff, Joshua] Virtual Media Resources, Natick, MA USA. [McKnight-Eily, Lela R.; Brewer, Robert D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Jernigan, DH (reprint author), Johns Hopkins Univ, Baltimore, MD 21218 USA. EM djernigan@jhsph.edu NR 9 TC 13 Z9 13 U1 2 U2 9 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 8 PY 2013 VL 62 IS 44 BP 877 EP 880 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NW UT WOS:000326937500003 ER PT J AU Klabunde, CN Joseph, DA King, JB White, A Plescia, M AF Klabunde, Carrie N. Joseph, Djenaba A. King, Jessica B. White, Arica Plescia, Marcus TI Vital Signs: Colorectal Cancer Screening Test Use - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH; CARE; PREFERENCES; STRATEGIES; SYSTEM AB Background: Strong evidence exists that screening with fecal occult blood testing (FOBT), sigmoidoscopy, or colonoscopy reduces the number of deaths from colorectal cancer (CRC). The percentage of the population up-to-date with recommended CRC screening increased from 54% in 2002 to 65% in 2010, primarily through increased use of colonoscopy. Methods: Data from the 2012 Behavioral Risk Factor Surveillance System survey were analyzed to estimate percentages of adults aged 50-75 years who reported CRC screening participation consistent with United States Preventive Services Task Force recommendations. Results: In 2012, 65.1% of U. S. adults were up-to-date with CRC screening, and 27.7% had never been screened. The proportion of respondents who had never been screened was greater among those without insurance (55.0%) and without a regular care provider (61.0%) than among those with health insurance (24.0%) and a regular care provider (23.5%). Colonoscopy was the most commonly used screening test (61.7%), followed by FOBT (10.4%). Colonoscopy was used by more than 53% of the population in every state. The percentages of blacks and whites up-to-date with CRC screening were equivalent. Compared with whites, a higher percentage of blacks across all income and education levels used FOBT. Conclusions: Many age-eligible adults did not use any type of CRC screening test as recommended. Organized, population-based approaches might increase CRC screening among those who have never been screened. Promoting both FOBT and colonoscopy as viable screening test options might increase CRC screening rates and reduce health disparities. C1 [Klabunde, Carrie N.] NCI, Bethesda, MD 20892 USA. [Joseph, Djenaba A.; King, Jessica B.; White, Arica; Plescia, Marcus] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30333 USA. RP Joseph, DA (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM dajoseph@cdc.gov NR 18 TC 106 Z9 107 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 8 PY 2013 VL 62 IS 44 BP 881 EP 888 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 251NW UT WOS:000326937500004 ER PT J AU Odhiambo, FO Beynon, CM Ogwang, S Hamel, MJ Howland, O van Eijk, AM Norton, R Amek, N Slutsker, L Laserson, KF De Cock, KM Phillips-Howard, PA AF Odhiambo, Frank O. Beynon, Caryl M. Ogwang, Sheila Hamel, Mary J. Howland, Olivia van Eijk, Anne M. Norton, Robyn Amek, Nyaguara Slutsker, Laurence Laserson, Kayla F. De Cock, Kevin M. Phillips-Howard, Penelope A. TI Trauma-Related Mortality among Adults in Rural Western Kenya: Characterising Deaths Using Data from a Health and Demographic Surveillance System SO PLOS ONE LA English DT Article ID GLOBAL BURDEN; INTERPERSONAL VIOLENCE; WOMENS HEALTH; SOUTH-AFRICA; DISEASE; INJURY; PEOPLE; ADOLESCENTS; ALCOHOL; QUALITY AB Background: Information on trauma-related deaths in low and middle income countries is limited but needed to target public health interventions. Data from a health and demographic surveillance system (HDSS) were examined to characterise such deaths in rural western Kenya. Methods And Findings: Verbal autopsy data were analysed. Of 11,147 adult deaths between 2003 and 2008, 447 (4%) were attributed to trauma; 71% of these were in males. Trauma contributed 17% of all deaths in males 15 to 24 years; on a population basis mortality rates were greatest in persons over 65 years. Intentional causes accounted for a higher proportion of male than female deaths (RR 2.04, 1.37-3.04) and a higher proportion of deaths of those aged 15 to 65 than older people. Main causes in males were assaults (n=79, 25%) and road traffic injuries (n=47, 15%); and falls for females (n=17, 13%). A significantly greater proportion of deaths from poisoning (RR 5.0, 2.7-9.4) and assault (RR 1.8, 1.2-2.6) occurred among regular consumers of alcohol than among non-regular drinkers. In multivariate analysis, males had a 4-fold higher risk of death from trauma than females (Adjusted Relative Risk; ARR 4.0; 95% CI 1.7-9.4); risk of a trauma death rose with age, with the elderly at 7-fold higher risk (ARR 7.3, 1.1-49.2). Absence of care was the strongest predictor of trauma death (ARR 12.2, 9.4-15.8). Trauma-related deaths were higher among regular alcohol drinkers (ARR 1.5, 1.1-1.9) compared with non-regular drinkers. Conclusions: While trauma accounts for a small proportion of deaths in this rural area with a high prevalence of HIV, TB and malaria, preventive interventions such as improved road safety, home safety strategies for the elderly, and curbing harmful use of alcohol, are available and could help diminish this burden. Improvements in systems to record underlying causes of death from trauma are required. C1 [Odhiambo, Frank O.; Ogwang, Sheila; Amek, Nyaguara; Laserson, Kayla F.; De Cock, Kevin M.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Beynon, Caryl M.; Howland, Olivia] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 5UX, Merseyside, England. [Hamel, Mary J.; Slutsker, Laurence] Ctr Dis Control & Prevent, Dept Parasit Dis, Atlanta, GA USA. [van Eijk, Anne M.; Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Norton, Robyn] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia. [Norton, Robyn] Univ Oxford, Oxford, England. [Laserson, Kayla F.] Ctr Dis Control & Prevent, India Epidem Intelligence Serv Programme, New Delhi, India. [De Cock, Kevin M.] Ctr Dis Control & Prevent, Nairobi, Kenya. RP Odhiambo, FO (reprint author), KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. EM FOdhiambo@kemricdc.org OI Phillips-Howard, Penelope A/0000-0003-1018-116X FU KEMRI/CDC Cooperative Agreement grant FX The HDSS and field staff support has been funded through the KEMRI/CDC Cooperative Agreement grant, with supplemental support from project-specific grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 3 Z9 3 U1 2 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2013 VL 8 IS 11 AR e79840 DI 10.1371/journal.pone.0079840 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 254KD UT WOS:000327162900055 PM 24244569 ER PT J AU Vaughan, G Xia, GL Forbi, JC Purdy, MA Rossi, LMG Spradling, PR Khudyakov, YE AF Vaughan, Gilberto Xia, Guoliang Forbi, Joseph C. Purdy, Michael A. Rossi, Livia Maria Goncalves Spradling, Philip R. Khudyakov, Yury E. TI Genetic Relatedness among Hepatitis A Virus Strains Associated with Food-Borne Outbreaks SO PLOS ONE LA English DT Article ID MOLECULAR EPIDEMIOLOGY; UNITED-STATES; MULTISTATE OUTBREAK; C VIRUS; VACCINATION; INFECTION; SOFTWARE; OYSTERS; PROTEIN; GENOME AB The genetic characterization of hepatitis A virus (HAV) strains is commonly accomplished by sequencing subgenomic regions, such as the VP1/P2B junction. HAV genome is not extensively variable, thus presenting opportunity for sharing sequences of subgenomic regions among genetically unrelated isolates. The degree of misrepresentation of phylogenetic relationships by subgenomic regions is especially important for tracking transmissions. Here, we analyzed whole-genome (WG) sequences of 101 HAV strains identified from 4 major multi-state, food-borne outbreaks of hepatitis A in the Unites States and from 14 non-outbreak-related HAV strains that shared identical VP1/P2B sequences with the outbreak strains. Although HAV strains with an identical VP1/P2B sequence were specific to each outbreak, WG were different, with genetic diversity reaching 0.31% (mean 0.09%). Evaluation of different subgenomic regions did not identify any other section of the HAV genome that could accurately represent phylogenetic relationships observed using WG sequences. The identification of 2-3 dominant HAV strains in 3 out of 4 outbreaks indicates contamination of the implicated food items with a heterogeneous HAV population. However, analysis of intra-host HAV variants from eight patients involved in one outbreak showed that only a single sequence variant established infection in each patient. Four non-outbreak strains were found closely related to strains from 2 outbreaks, whereas ten were genetically different from the outbreak strains. Thus, accurate tracking of HAV strains can be accomplished using HAV WG sequences, while short subgenomic regions are useful for identification of transmissions only among cases with known epidemiological association. C1 [Vaughan, Gilberto; Xia, Guoliang; Forbi, Joseph C.; Purdy, Michael A.; Rossi, Livia Maria Goncalves; Spradling, Philip R.; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. RP Vaughan, G (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. EM GVaughan@cdc.gov FU Division of Viral Hepatitis FX This work was supported by Division of Viral Hepatitis Intramural funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 9 Z9 10 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 6 PY 2013 VL 8 IS 11 AR e74546 DI 10.1371/journal.pone.0074546 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247XD UT WOS:000326656200004 PM 24223112 ER PT J AU Hall, HI Halverson, J Wilson, DP Suligoi, B Diez, M Le Vu, S Tang, T McDonald, A Camoni, L Semaille, C Archibald, C AF Hall, H. Irene Halverson, Jessica Wilson, David P. Suligoi, Barbara Diez, Mercedes Le Vu, Stephane Tang, Tian McDonald, Ann Camoni, Laura Semaille, Caroline Archibald, Chris TI Late Diagnosis and Entry to Care after Diagnosis of Human Immunodeficiency Virus Infection: A Country Comparison SO PLOS ONE LA English DT Article ID SOCIETY-USA PANEL; HIV-INFECTION; ANTIRETROVIRAL THERAPY; EARLY RETENTION; VIRAL LOAD; TRANSMISSION; RECOMMENDATIONS; AUSTRALIA; MORTALITY; PREVENTION AB Background: Testing for HIV infection and entry to care are the first steps in the continuum of care that benefit individual health and may reduce onward transmission of HIV. We determined the percentage of people with HIV who were diagnosed late and the percentage linked into care overall and by demographic and risk characteristics by country. Methods: Data were analyzed from national HIV surveillance systems. Six countries, where available, provided data on two late diagnosis indicators (AIDS diagnosis within 3 months of HIV diagnosis, and AIDS diagnosis within 12 months before HIV diagnosis) and linkage to care (>= 1 CD4 or viral load test result within 3 months of HIV diagnosis) for people diagnosed with HIV in 2009 or 2010 (most recent year data were available). Principal Findings: The percentage of people presenting with late stage disease at HIV diagnosis varied by country, overall with a range from 28.7% (United States) to 8.8% (Canada), and by transmission categories. The percentage of people diagnosed with AIDS who had their initial HIV diagnosis within 12 months before AIDS diagnosis varied little among countries, except the percentages were somewhat lower in Spain and the United States. Overall, the majority of people diagnosed with HIV were linked to HIV care within 3 months of diagnosis (more than 70%), but varied by age and transmission category. Conclusions: Differences in patterns of late presentation at HIV diagnosis among countries may reflect differences in screening practices by providers, public health agencies, and people with HIV. The percentage of people who received assessments of immune status and viral load within 3 months of diagnosis was generally high. C1 [Hall, H. Irene] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Halverson, Jessica; Archibald, Chris] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Wilson, David P.; McDonald, Ann] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia. [Suligoi, Barbara; Camoni, Laura] Ist Super Sanita, I-00161 Rome, Italy. [Diez, Mercedes] Ctr Nacl Epidemiol, Secretaria Plan Nacl Sida, Madrid, Spain. [Le Vu, Stephane; Semaille, Caroline] Inst Veille Sanit, St Maurice, France. [Tang, Tian] ICF Marcro Int, Atlanta, GA USA. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ixh1@cdc.gov RI SULIGOI, BARBARA/C-6494-2016 NR 40 TC 18 Z9 18 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 5 PY 2013 VL 8 IS 11 AR e77763 DI 10.1371/journal.pone.0077763 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247EE UT WOS:000326597400012 PM 24223724 ER PT J AU Domingo, GJ Satyagraha, AW Anvikar, A Baird, K Bancone, G Bansil, P Carter, N Cheng, Q Culpepper, J Eziefula, C Fukuda, M Green, J Hwang, JM Lacerda, M McGray, S Menard, D Nosten, F Nuchprayoon, I Oo, NN Bualombai, P Pumpradit, W Qian, K Recht, J Roca, A Satimai, W Sovannaroth, S Vestergaard, LS Von Seidlein, L AF Domingo, Gonzalo J. Satyagraha, Ari Winasti Anvikar, Anup Baird, Kevin Bancone, Germana Bansil, Pooja Carter, Nick Cheng, Qin Culpepper, Janice Eziefula, Chi Fukuda, Mark Green, Justin Hwang, Jimee Lacerda, Marcus McGray, Sarah Menard, Didier Nosten, Francois Nuchprayoon, Issarang Oo, Nwe Nwe Bualombai, Pongwit Pumpradit, Wadchara Qian, Kun Recht, Judith Roca, Arantxa Satimai, Wichai Sovannaroth, Siv Vestergaard, Lasse S. Von Seidlein, Lorenz TI G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests SO MALARIA JOURNAL LA English DT Article ID GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; ENZYME ASSAY; PRIMAQUINE; DEHYDROGENASE; SUSCEPTIBILITY; ERYTHROCYTES; ASSOCIATION; RATIONALE; DIAGNOSIS; HEMOLYSIS AB Malaria elimination will be possible only with serious attempts to address asymptomatic infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax. Currently available drugs that can completely clear a human of P. vivax (known as "radical cure"), and that can reduce transmission of malaria parasites, are those in the 8-aminoquinoline drug family, such as primaquine. Unfortunately, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency risk having severe adverse reactions if exposed to these drugs at certain doses. G6PD deficiency is the most common human enzyme defect, affecting approximately 400 million people worldwide. Scaling up radical cure regimens will require testing for G6PD deficiency, at two levels: 1) the individual level to ensure safe case management, and 2) the population level to understand the risk in the local population to guide Plasmodium vivax treatment policy. Several technical and operational knowledge gaps must be addressed to expand access to G6PD deficiency testing and to ensure that a patient's G6PD status is known before deciding to administer an 8-aminoquinoline-based drug. In this report from a stakeholder meeting held in Thailand on October 4 and 5, 2012, G6PD testing in support of radical cure is discussed in detail. The focus is on challenges to the development and evaluation of G6PD diagnostic tests, and on challenges related to the operational aspects of implementing G6PD testing in support of radical cure. The report also describes recommendations for evaluation of diagnostic tests for G6PD deficiency in support of radical cure. C1 [Domingo, Gonzalo J.; Bansil, Pooja; McGray, Sarah; Qian, Kun] PATH, Seattle, WA 98121 USA. [Satyagraha, Ari Winasti] Eijkman Inst Mol Biol, Jakarta, Indonesia. [Anvikar, Anup] Natl Inst Malaria Res, New Delhi, India. [Baird, Kevin] Eijkman Oxford Clin Res Unit, Jakarta, Indonesia. [Bancone, Germana; Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Thailand. [Carter, Nick; Green, Justin] GlaxoSmithKline, Stockley Pk, Uxbridge, Middx, England. [Cheng, Qin] Australian Army Malaria Inst, Enoggera, Australia. [Culpepper, Janice] Bill & Melinda Gates Fdn, Seattle, WA USA. [Eziefula, Chi] Univ London London Sch Hyg & Trop Med, London, England. [Fukuda, Mark] Presidents Malaria Initiat, Bangkok, Thailand. [Hwang, Jimee] Ctr Dis Control & Prevent, San Francisco, CA USA. [Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Lacerda, Marcus] Univ State Amazonas, Manaus, Amazonas, Brazil. [Menard, Didier] Inst Pasteur Cambodge, Phnom Penh, Cambodia. [Nosten, Francois] Mahidol Oxford Res Unit, Bangkok, Thailand. [Nuchprayoon, Issarang] Chulalongkorn Univ, Bangkok, Thailand. [Oo, Nwe Nwe] Dept Med Res, Yangon, Myanmar. [Bualombai, Pongwit] Bur Vector Borne Dis, Bangkok, Thailand. [Pumpradit, Wadchara] PATH, Bangkok, Thailand. [Roca, Arantxa] Malaria Consortium, Phnom Penh, Cambodia. [Satimai, Wichai] Thailand Minist Publ Hlth, Bangkok, Thailand. [Sovannaroth, Siv] Natl Malaria Control Programme, Phnom Penh, Cambodia. [Vestergaard, Lasse S.] WHO, WPRO, Manila, Philippines. [Von Seidlein, Lorenz] Menzies Sch Hlth Res, Darwin, NT, Australia. RP Domingo, GJ (reprint author), PATH, 2201 Westlake Ave, Seattle, WA 98121 USA. EM gdomingo@path.org OI Nosten, Francois/0000-0002-7951-0745; Bancone, Germana/0000-0003-4550-0431 FU Bill & Melinda Gates Foundation FX The authors would like to thank Molly Boettcher and Amanda Vilbrandt for organization and management of meeting logistics, and John Ballenot and Scott Wittet for editorial revision of the manuscript. This publication is based on research funded by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of their organizations or the Bill & Melinda Gates Foundation. NR 47 TC 29 Z9 29 U1 0 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD NOV 4 PY 2013 VL 12 AR 391 DI 10.1186/1475-2875-12-391 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 281LQ UT WOS:000329103400003 PM 24188096 ER PT J AU Peasah, SK Azziz-Baumgartner, E Breese, J Meltzer, MI Widdowson, MA AF Peasah, Samuel K. Azziz-Baumgartner, Eduardo Breese, Joseph Meltzer, Martin I. Widdowson, Marc-Alain TI Influenza cost and cost-effectiveness studies globally - A review SO VACCINE LA English DT Review DE Influenza; Cost effectiveness analysis; Vaccination; Global ID SEASONAL INFLUENZA; OF-ILLNESS; MORTALITY; DISEASE; BURDEN; IMPACT AB Every year, approximately 10-20% of the world's population is infected with influenza viruses, resulting in a significant number of outpatient and hospital visits and substantial economic burden both on health care systems and society. With recently updated WHO recommendations on influenza vaccination and broadening vaccine production, policy makers in middle- and low-income countries will need data on the cost of influenza disease and the cost effectiveness of vaccination. We reviewed the published literature to summarize estimates of cost and cost-effectiveness of influenza vaccination. We searched PUBMED (MEDLINE), EMBASE, WEB of KNOWLEDGE, and IGOOGLE using the key words 'influenza', 'economic cost', 'cost effectiveness', and 'economic burden'. We identified 140 studies which estimated either cost associated with seasonal influenza or cost effectiveness/cost-benefit of influenza vaccination. 118 of these studies were conducted in World Bank-defined high income, 22 in upper-middle income, and no studies in low and lower-middle income countries. The per capita cost of a case of influenza illness ranged from $30 to $64. 22 studies reported that influenza vaccination was cost-saving; reported cost-effectiveness ratios were $10,000/outcome in 13 studies, $10,000 to $50,000 in 13 studies, and >$50,000 in 3 studies. There were no studies from low income countries and few studies among pregnant women. Substantial differences in methodology limited the generalization of results. Decision makers in lower income countries lack economic data to support influenza vaccine policy decisions, especially of pregnant women. Standardized cost-effectiveness studies of influenza vaccination of WHO-recommended risk groups' methods are urgently needed. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Peasah, Samuel K.; Azziz-Baumgartner, Eduardo; Breese, Joseph; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, NCIRD, Atlanta, GA 30333 USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, NCEZID, Atlanta, GA USA. RP Peasah, SK (reprint author), Ctr Dis Control & Prevent, NCIRD, Atlanta, GA 30333 USA. EM Skpeasah@gmail.com OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 21 TC 25 Z9 28 U1 1 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 4 PY 2013 VL 31 IS 46 BP 5339 EP 5348 DI 10.1016/j.vaccine.2013.09.013 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 254NS UT WOS:000327173000006 PM 24055351 ER PT J AU Yucesoy, B Talzhanov, Y Johnson, VJ Wilson, NW Biagini, RE Wang, W Frye, B Weissman, DN Germolec, DR Luster, MI Barmada, MM AF Yucesoy, Berran Talzhanov, Yerkebulan Johnson, Victor J. Wilson, Nevin W. Biagini, Raymond E. Wang, Wei Frye, Bonnie Weissman, David N. Germolec, Dori R. Luster, Michael I. Barmada, Michael M. TI Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations SO VACCINE LA English DT Article DE Major histocompatibility complex; Genetic polymorphism; Childhood vaccine; Immune response ID HUMAN-LEUKOCYTE ANTIGEN; HEPATITIS-B-VACCINE; MEASLES-VACCINE; HLA-G; ANTIBODY-RESPONSE; SURFACE-ANTIGEN; NONRESPONSIVENESS; POLYMORPHISMS; HAPLOTYPES; VIRUS AB The influence of genetic variability within the major histocompatibility complex (MHC) region on variations in immune responses to childhood vaccination was investigated. The study group consisted of 135 healthy infants who had been immunized with hepatitis B (HBV), 7-valent pneumococcal conjugate (PCV7), and diphtheria, tetanus, acellular pertussis (DTaP) vaccines according to standard childhood immunization schedules. Genotype analysis was performed on genomic DNA using Illumina Goldengate MHC panels (Mapping and Exon Centric). At the 1 year post vaccination check-up total, isotypic, and antigen-specific serum antibody levels were measured using multiplex immunoassays. A number of single nucleotide polymorphisms (SNPs) within MHC Class I and II genes were found to be associated with variations in the vaccine specific antibody responses and serum levels of immunoglobulins (IgG, IgM) and IgG isotypes (IgG1, IgG4) (all at p <0.001). Linkage disequilibrium patterns and functional annotations showed that significant SNPs were strongly correlated with other functional regulatory SNPs. These SNPs were found to regulate the expression of a group of genes involved in antigen processing and presentation including HLA-A, HLA-C, HLA-G, HLA-H, HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DOB, and TAP-2. The results suggest that genetic variations within particular MHC genes can influence immune response to common childhood vaccinations, which in turn may influence vaccine efficacy. Published by Elsevier Ltd. C1 [Yucesoy, Berran; Wang, Wei; Frye, Bonnie] NIOSH, Toxicol & Mol Biol Branch, CDC, Morgantown, WV 26505 USA. [Talzhanov, Yerkebulan; Barmada, Michael M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Johnson, Victor J.] BRT, Morrisville, NC USA. [Wilson, Nevin W.] Univ Nevada, Sch Med, Dept Pediat, Reno, NV 89557 USA. [Biagini, Raymond E.] NIOSH, Biomonitoring & Hlth Assessment Branch, CDC, Cincinnati, OH 45226 USA. [Weissman, David N.] NIOSH, Div Resp Dis Studies, CDC, Morgantown, WV 26505 USA. [Germolec, Dori R.] NIEHS, Toxicol Branch, DNTP, Res Triangle Pk, NC 27709 USA. [Luster, Michael I.] W Virginia Univ, Sch Publ Hlth, Morgantown, WV 26506 USA. RP Yucesoy, B (reprint author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM byucesoy@cdc.gov; yet5@pitt.edu; vjohnson@brt-labs.com; nwilson@medicine.nevada.edu; RBiagini@cdc.gov; WWang1@cdc.gov; BFrye@cdc.gov; DWeissman@cdc.gov; germolec@niehs.nih.gov; miklus22@comcast.net; barmada@pitt.edu OI Barmada, M Michael/0000-0002-3604-6460 FU NIEHS [Y1-ES-0001] FX This work was supported in part by an Interagency Agreement with the Intramural Research Program of the NIEHS (Y1-ES-0001). NR 46 TC 11 Z9 12 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 4 PY 2013 VL 31 IS 46 BP 5381 EP 5391 DI 10.1016/j.vaccine.2013.09.026 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 254NS UT WOS:000327173000011 PM 24075919 ER PT J AU Chang, WC Yen, C Chi, CL Wu, FT Huang, YC Lin, JS Huang, FC Tate, JE Wu, HS Hsiung, CA AF Chang, Wan-Chi Yen, Catherine Chi, Cheng-Liang Wu, Fang-Tzy Huang, Yhu-Chering Lin, Jen-Shiou Huang, Fu-Chen Tate, Jacqueline E. Wu, Ho-Sheng Hsiung, Chao A. TI Cost-effectiveness of rotavirus vaccination programs in Taiwan SO VACCINE LA English DT Article DE Gastroenteritis; Rotavirus; Rotavirus vaccine; Cost-effectiveness ID UNITED-STATES; DISEASE BURDEN; GASTROENTERITIS HOSPITALIZATIONS; MOLECULAR EPIDEMIOLOGY; ECONOMIC BURDEN; CHILDREN; DIARRHEA; SURVEILLANCE; PREVENTION; REDUCTION AB Background: In Taiwan, two rotavirus vaccines are available on the private market, but are not included in the National Immunization Program (NIP). To help assess whether to include rotavirus vaccines in the NIP, we examined the potential impact and cost-effectiveness of vaccination, from the health care system perspective alone. Methods: We used a Microsoft Excel-based model to assess rotavirus vaccination impact on rotavirus disease burden and the cost-effectiveness of 2-dose and 3-dose vaccination programs among a birth cohort of Taiwanese children followed for 5 years. Principal model inputs included data on rotavirus disease burden and related healthcare costs, vaccination cost and coverage rates, and vaccine efficacy. Principal model outputs included the number of health-related events and costs averted and incremental cost per disability-adjusted life year averted. Results: A national rotavirus vaccination program, regardless of number of doses per course, would prevent 4 deaths, >10,500 hospitalizations, and >64,000 outpatient visits due to rotavirus infection among children <5 years annually, resulting in similar to 80%, 90%, and 70% declines in these outcomes, respectively, and a similar to$7 million decline in annual medical costs. A national 2- or 3-dose vaccination program would be cost-saving up to $13.30/dose ($26.60/course) or $7.98/dose ($23.94/course), respectively; very cost-effective up to $24.08 per dose ($48.16/course) or $15.18/dose ($45.54/course), respectively; and cost-effective up to $45.65/dose ($9130/course) or $29.59/dose ($88.77/course), respectively. Conclusions: A national rotavirus vaccination program could substantially reduce rotavirus disease burden among Taiwanese children and be potentially cost-effective, depending on the vaccine price. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Chang, Wan-Chi; Chi, Cheng-Liang; Hsiung, Chao A.] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan. [Yen, Catherine; Tate, Jacqueline E.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Wu, Fang-Tzy; Wu, Ho-Sheng] Ctr Dis Control, Res & Diagnost Ctr, Dept Hlth, Atlanta, GA 30333 USA. [Huang, Yhu-Chering] Chang Gung Mem Hosp Linkou, Div Pediat Infect Dis, Tao Yuan, Taiwan. [Huang, Yhu-Chering] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan. [Lin, Jen-Shiou] Changhua Christian Hosp, Dept Lab Med, Changhua, Taiwan. [Huang, Fu-Chen] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan. [Huang, Fu-Chen] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan. [Wu, Ho-Sheng] Taipei Med Univ, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan. RP Hsiung, CA (reprint author), Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan. EM cyen@cdc.gov; hsiung@nhri.org.tw RI Hsiung, Chao Agnes/E-3994-2010 FU "Technology Project for Surveillance and Prevalence of Gastroenteritis in Taiwan" from Centers for Disease Control, Department of Health, Execute Yuan, Taiwan [DOH98-DC-1005] FX Funding: This study was financially supported by the following research grant: "Technology Project for Surveillance and Prevalence of Gastroenteritis in Taiwan" from Centers for Disease Control, Department of Health, Execute Yuan, Taiwan (supported grant: DOH98-DC-1005). NR 31 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 4 PY 2013 VL 31 IS 46 BP 5458 EP 5465 DI 10.1016/j.vaccine.2013.08.103 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 254NS UT WOS:000327173000021 PM 24060569 ER PT J AU Catumbela, E Freitas, A Serrano, D Furtado, ML Gomes, M Shiraishi, RW Young, P Naffga, N Hall, DL Mendoza, MCT Costa, C Sarmento, A Costa-Pereira, A AF Catumbela, E. Freitas, A. Serrano, D. Furtado, M. L. Gomes, M. Shiraishi, R. W. Young, P. Naffga, N. Hall, D. Love Mendoza, M. C. T. Costa, C. Sarmento, A. Costa-Pereira, A. TI The Angola HIV epidemic, 2004-11: a case of change or stability? SO LANCET LA English DT Meeting Abstract CT Translational Medicine Conference on HIV Research - What will it Take to Achieve an AIDS-Free World CY NOV 03-05, 2013 CL San Francisco, CA C1 [Catumbela, E.; Freitas, A.; Costa-Pereira, A.] Univ Porto, Fac Med, Dept Hlth Informat & Decis Sci, P-4200450 Oporto, Portugal. [Catumbela, E.; Freitas, A.; Costa-Pereira, A.] Univ Porto, Ctr Res Hlth Technol & Informat Syst CINTESIS, P-4200450 Oporto, Portugal. [Catumbela, E.; Freitas, A.; Costa-Pereira, A.] Univ Agostinho Neto, Fac Med, Dept Pathol, Luanda, Angola. [Serrano, D.; Furtado, M. L.; Gomes, M.] Inst Nacl Luta SIDA, Luanda, Angola. [Shiraishi, R. W.] US Ctr Dis Control & Prevent, Epidemiol & Strateg Informat Branch, Div Global HIV AIDS, Atlanta, GA USA. [Young, P.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Maputo, Mozambique. [Naffga, N.; Hall, D. Love; Mendoza, M. C. T.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Luanda, Angola. [Costa, C.] Univ Nova Lisboa, Natl Sch Publ Hlth, P-1200 Lisbon, Portugal. [Sarmento, A.] Univ Porto, Fac Med, Dept Infect Dis, P-4100 Oporto, Portugal. EM ecassoco@gmail.com RI FMUP, CINTESIS/C-6631-2014; Freitas, Alberto/C-1972-2012; Costa-Pereira, Altamiro/I-5987-2012 OI FMUP, CINTESIS/0000-0001-7248-2086; Freitas, Alberto/0000-0003-2113-9653; Costa-Pereira, Altamiro/0000-0001-8467-6398 NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD NOV 3 PY 2013 VL 382 SU 2 BP 17 EP 17 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 300HD UT WOS:000330454100018 ER PT J AU Whitney, EAS Massung, RF Kersh, GJ Fitzpatrick, KA Mook, DM Taylor, DK Huerkamp, MJ Vakili, JC Sullivan, PJ Berkelman, RL AF Whitney, Ellen A. Spotts Massung, Robert F. Kersh, Gilbert J. Fitzpatrick, Kelly A. Mook, Deborah M. Taylor, Douglas K. Huerkamp, Michael J. Vakili, Jessica C. Sullivan, Patrick J. Berkelman, Ruth L. TI Survey of Laboratory Animal Technicians in the United States for Coxiella burnetii Antibodies and Exploration of Risk Factors for Exposure SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Article ID Q-FEVER; DAIRY-COWS; SHEEP; VACCINATION; DIAGNOSIS; OUTBREAK; RECOMMENDATIONS; ENVIRONMENT; INFECTIONS; MANAGEMENT AB Little is known about the prevalence of zoonotic infections among laboratory animal care technicians (LAT). Q fever, a disease caused by Coxiella burnetii, is a known occupational hazard for persons caring for livestock. We sought to determine the seroprevalence of C. burnetii antibodies among LAT and to identify risk factors associated with C. burnetii seropositivity. A survey was administered and serum samples collected from a convenience sample of 97 LAT. Samples were screened by using a Q fever IgG ELISA. Immunofluorescent antibody assays for phase I and phase II IgG were used to confirm the status of samples that were positive or equivocal by ELISA; positive samples were titered to endpoint. Antibodies against C. burnetii were detected in 6 (6%) of the 97 respondents. In our sample of LAT, seropositivity to C. burnetii was therefore twice as high in LAT as compared with the general population. Age, sex, and working with sheep regularly were not associated with seropositivity. Risk factors associated with seropositivity included breeding cattle within respondent's research facility, any current job contact with waste from beef cattle or goats, and exposure to animal waste during previous jobs or outside of current job duties. Only 15% of responding LAT reported being aware that sheep, goats, and cattle can transmit Q fever. Research facilities that use cattle or goats should evaluate their waste-management practices and educational programs in light of these findings. Additional efforts are needed to increase awareness among LAT regarding Q fever and heightened risk of exposure to infectious materials. Physicians should consider the risk of infection with C. burnetii when treating LAT with potential occupational exposures. C1 [Whitney, Ellen A. Spotts; Berkelman, Ruth L.] Emory Univ, Ctr Publ Hlth Preparedness & Res, Atlanta, GA 30322 USA. [Whitney, Ellen A. Spotts; Sullivan, Patrick J.; Berkelman, Ruth L.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. [Vakili, Jessica C.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. [Mook, Deborah M.; Taylor, Douglas K.; Huerkamp, Michael J.] Emory Univ, Div Anim Resources Pathol & Lab Med, Atlanta, GA 30322 USA. [Massung, Robert F.; Kersh, Gilbert J.; Fitzpatrick, Kelly A.] Ctr Dis Control & Prevent, NCEZID, Div Vector Borne Dis, Rickettsial Zoonoses Branch, Atlanta, GA USA. RP Whitney, EAS (reprint author), Emory Univ, Ctr Publ Hlth Preparedness & Res, Atlanta, GA 30322 USA. EM ewhitn2@emory.edu FU Elizabeth R Griffin Research Foundation FX We thank Colleen Spellen for her assistance with data entry and Ann Tourigny Turner and Betty R Cartwright for facilitating the study at the AALAS meeting. Financial support for this research was provided by a grant from The Elizabeth R Griffin Research Foundation to the Center for Public Health Preparedness and Research, Rollins School of Public Health. NR 53 TC 2 Z9 2 U1 1 U2 3 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD NOV PY 2013 VL 52 IS 6 BP 725 EP 731 PG 7 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA AN7WB UT WOS:000340810600003 PM 24351760 ER PT J AU Kobau, R Zack, MM AF Kobau, Rosemarie Zack, Matthew M. TI Attitudes Toward Mental Illness in Adults by Mental Illness-Related Factors and Chronic Disease Status: 2007 and 2009 Behavioral Risk Factor Surveillance System SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID DEPRESSION AB Objectives. We examined how attitudes toward mental illness treatment and its course differ by serious psychological distress, mental illness treatment, chronic disease, and sociodemographic factors using representative state-based data. Methods. Using data from jurisdictions supporting the Behavioral Risk Factor Surveillance System's Mental Illness and Stigma Module (35 states, the District of Columbia, and Puerto Rico), we compared adjusted proportions of adults agreeing that "Treatment can help people with mental illness lead normal lives" (treatment effectiveness) and that "People are generally caring and sympathetic to people with mental illness" (supportive environment), by demographic characteristics, serious psychological distress, chronic disease status, and mental illness treatment. Results. Attitudes regarding treatment effectiveness and a supportive environment for people with mental illness varied within and between groups. Most adults receiving mental illness treatment agreed that treatment is effective. Fewer adults with serious psychological distress than those without such distress agreed that treatment is effective. Fewer of those receiving treatment, those with psychological distress, and those with chronic disease perceived the environment as supportive. Conclusions. These data can be used to target interventions for population subgroups with less favorable attitudes and for surveillance. C1 [Kobau, Rosemarie; Zack, Matthew M.] Ctr Dis Control & Prevent, Div Populat Hlth, Arthrit Epilepsy & Well Being Branch, Atlanta, GA 30341 USA. RP Kobau, R (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Hwy NE,MS K-78, Atlanta, GA 30341 USA. EM rmk4@cdc.gov FU Centers for Disease Control and Prevention; Substance Abuse and Mental Health Services Administration; Carter Center FX This article was prepared for the May 2013 theme issue on Stigma and Mental Health. External funding for the May 2013 issue was provided by the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and The Carter Center. NR 25 TC 2 Z9 2 U1 1 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2013 VL 103 IS 11 BP 2078 EP 2089 DI 10.2105/AJPH.2013.301321 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4BG UT WOS:000331038500050 PM 24028243 ER PT J AU Bogart, LM Elliott, MN Kanouse, DE Klein, DJ Davies, SL Cuccaro, PM Banspach, SW Peskin, MF Schuster, MA AF Bogart, Laura M. Elliott, Marc N. Kanouse, David E. Klein, David J. Davies, Susan L. Cuccaro, Paula M. Banspach, Stephen W. Peskin, Melissa F. Schuster, Mark A. TI PERCEIVED DISCRIMINATION AND RACIAL/ETHNIC DISPARITIES IN YOUTH PROBLEM BEHAVIORS RESPONSE SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID HEALTH; CARE C1 [Bogart, Laura M.; Klein, David J.; Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Dept Med, Boston, MA 02115 USA. [Bogart, Laura M.; Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Elliott, Marc N.; Kanouse, David E.] RAND Corp, Santa Monica, CA USA. [Davies, Susan L.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL USA. [Cuccaro, Paula M.; Peskin, Melissa F.] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA USA. RP Bogart, LM (reprint author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. EM laura.bogart@childrens.harvard.edu FU NCCDPHP CDC HHS [U19 DP002664, U48 DP000046, U48 DP000056, U48 DP000057] NR 6 TC 1 Z9 1 U1 2 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2013 VL 103 IS 11 BP E1 EP E2 DI 10.2105/AJPH.2013.301570 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4BG UT WOS:000331038500002 PM 24028223 ER PT J AU Miller, KS Lasswell, SM Riley, DB Poulsen, MN AF Miller, Kim S. Lasswell, Sarah M. Riley, Drewallyn B. Poulsen, Melissa N. TI Families Matter! Presexual Risk Prevention Intervention SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID RURAL WESTERN KENYA; PARENTING INTERVENTION AB Parent-based HIV prevention programming may play an important role in reaching youths early to help establish lifelong patterns of safe and healthy sexual behaviors. Families Matter! is a 5-session, evidence-based behavioral intervention designed for primary caregivers of children aged 9 to 12 years to promote positive parenting and effective parent-child communication about sexuality and sexual risk reduction. The program's 5-step capacity-building model was implemented with local government, community, and faith-based partners in 8 sub-Saharan African countries with good intervention fidelity and high levels of participant retention. Families Matter! may be useful in other resource-constrained settings. C1 [Miller, Kim S.; Lasswell, Sarah M.; Riley, Drewallyn B.; Poulsen, Melissa N.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Miller, KS (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, 1600 Clifton Rd,Mailstop E-04, Atlanta, GA 30333 USA. EM kmiller@cdc.gov FU Centers for Disease Control and Prevention FX This research was supported by the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention. NR 12 TC 3 Z9 3 U1 2 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2013 VL 103 IS 11 BP E16 EP E20 DI 10.2105/AJPH.2013.301417 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4BG UT WOS:000331038500014 PM 24028229 ER PT J AU Cohen, C Moyes, J Tempia, S Groom, M Walaza, S Pretorius, M Dawood, H Chhagan, M Haffejee, S Variava, E Kahn, K Tshangela, A von Gottberg, A Wolter, N Cohen, AL Kgokong, B Venter, M Madhi, SA AF Cohen, Cheryl Moyes, Jocelyn Tempia, Stefano Groom, Michelle Walaza, Sibongile Pretorius, Marthi Dawood, Halima Chhagan, Meera Haffejee, Summaya Variava, Ebrahim Kahn, Kathleen Tshangela, Akhona von Gottberg, Anne Wolter, Nicole Cohen, Adam L. Kgokong, Babatyi Venter, Marietjie Madhi, Shabir A. TI Severe Influenza-associated Respiratory Infection in High HIV Prevalence Setting, South Africa, 2009-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL DNA; TRACT INFECTIONS; UNITED-STATES; DOUBLE-BLIND; CHILDREN; ADULTS; TIME; EFFICACY; VACCINE AB Data on influenza epidemiology in HIV-infected persons are limited, particularly for sub-Saharan Africa, where HIV infection is widespread. We tested respiratory and blood samples from patients with acute lower respiratory tract infections hospitalized in South Africa during 2009-2011 for viral and pneumococcal infections. Influenza was identified in 9% (1,056/11,925) of patients enrolled; among influenza case-patients, 358 (44%) of the 819 who were tested were infected with HIV. Influenza-associated acute lower respiratory tract infection incidence was 4-8 times greater for HIV-infected (186-228/100,000) than for HIV-uninfected persons (26-54/100,000). Furthermore, multivariable analysis showed HIV-infected patients were more likely to have pneumococcal co-infection; to be infected with influenza type B compared with type A; to be hospitalized for 2-7 days or >7 days; and to die from their illness. These findings indicate that HIV-infected persons are at greater risk for severe illnesses related to influenza and thus should be prioritized for influenza vaccination. C1 [Cohen, Cheryl; Moyes, Jocelyn; Walaza, Sibongile; Pretorius, Marthi; Tshangela, Akhona; von Gottberg, Anne; Wolter, Nicole; Kgokong, Babatyi; Venter, Marietjie; Madhi, Shabir A.] Natl Hlth Lab Serv, Johannesburg, South Africa. [Cohen, Cheryl; Moyes, Jocelyn; Groom, Michelle; Variava, Ebrahim; Kahn, Kathleen; von Gottberg, Anne; Wolter, Nicole; Madhi, Shabir A.] Univ Witwatersrand, Johannesburg, South Africa. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tempia, Stefano; Cohen, Adam L.] Ctr Dis Control & Prevent South Africa, Pretoria, South Africa. [Dawood, Halima; Chhagan, Meera; Haffejee, Summaya] Univ KwaZulu Natal, Durban, South Africa. [Dawood, Halima] Pietermaritzburg Metropolitan Hosp, Pietermaritzburg, South Africa. [Variava, Ebrahim] Klerksdorp Tshepong Hosp, Klerksdorp, South Africa. [Kahn, Kathleen] Umea Univ, Umea, Sweden. [Kahn, Kathleen] INDEPTH Network, Accra, Ghana. [Venter, Marietjie] Univ Pretoria, ZA-0002 Pretoria, South Africa. RP Cohen, C (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Gauteng, South Africa. EM cherylc@nicd.ac.za RI Venter, Marietjie/P-9604-2016 OI Venter, Marietjie/0000-0003-2696-824X FU National Institute for Communicable Diseases of the National Health Laboratory Services; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA [U51/IP000155-04] FX This study received funding from the National Institute for Communicable Diseases of the National Health Laboratory Services and was supported in part by Preparedness and Response to Avian and Pandemic Influenza in South Africa funds from the US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (Cooperative Agreement No. U51/IP000155-04). NR 39 TC 39 Z9 39 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2013 VL 19 IS 11 BP 1766 EP 1774 DI 10.3201/eid1911.130546 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AA4JE UT WOS:000331061100006 PM 24209781 ER PT J AU Xiang, NJ Havers, F Chen, T Song, Y Tu, WX Li, LL Cao, Y Liu, B Zhou, L Meng, L Hong, ZH Wang, R Niu, Y Yao, JY Liao, KJ Jin, LM Zhang, YP Li, Q Widdowson, MA Feng, ZJ AF Xiang, Nijuan Havers, Fiona Chen, Tao Song, Ying Tu, Wenxiao Li, Leilei Cao, Yang Liu, Bo Zhou, Lei Meng, Ling Hong, Zhiheng Wang, Rui Niu, Yan Yao, Jianyi Liao, Kaiju Jin, Lianmei Zhang, Yanping Li, Qun Widdowson, Marc-Alain Feng, Zijian TI Use of National Pneumonia Surveillance to Describe Influenza A(H7N9) Virus Epidemiology, China, 2004-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H7N9 VIRUS; HUMAN INFECTIONS; POULTRY AB In mainland China, most avian influenza A(H7N9) cases in the spring of 2013 were reported through the pneumonia of unknown etiology (PUE) surveillance system. To understand the role of possible underreporting and surveillance bias in assessing the epidemiology of subtype H7N9 cases and the effect of live-poultry market closures, we examined all PUE cases reported from 2004 through May 3, 2013. Historically, the PUE system was underused, reporting was inconsistent, and PUE reporting was biased toward A(H7N9)-affected provinces, with sparse data from unaffected provinces; however, we found no evidence that the older ages of persons with A(H7N9) resulted from surveillance bias. The absolute number and the proportion of PUE cases confirmed to be A(H7N9) declined after live-poultry market closures (p<0.001), indicating that market closures might have positively affected outbreak control. In China, PUE surveillance needs to be improved. C1 [Xiang, Nijuan; Chen, Tao; Tu, Wenxiao; Li, Leilei; Cao, Yang; Liu, Bo; Zhou, Lei; Meng, Ling; Hong, Zhiheng; Wang, Rui; Niu, Yan; Yao, Jianyi; Liao, Kaiju; Jin, Lianmei; Zhang, Yanping; Li, Qun; Feng, Zijian] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Havers, Fiona; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA USA. [Song, Ying] Ctr Dis Control & Prevent, Beijing, Peoples R China. RP Feng, ZJ (reprint author), 155 Changbai Rd, Beijing 102206, Peoples R China. EM fengzj@chinacdc.cn FU China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases; National Ministry of Science and Technology Emergency Research Project on human infection with avian influenza A(H7N9) virus (Epidemiology Research Project) [KJYJ-2013-01-02] FX This work was supported by the China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases and a grant from National Ministry of Science and Technology Emergency Research Project on human infection with avian influenza A(H7N9) virus (Epidemiology Research Project) (KJYJ-2013-01-02). NR 12 TC 11 Z9 12 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2013 VL 19 IS 11 BP 1784 EP 1790 DI 10.3201/eid1911.130865 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AA4JE UT WOS:000331061100008 PM 24206646 ER PT J AU Eberhard, ML AF Eberhard, Mark L. TI Subcutaneous Infection with Dirofilaria spp. Nematode in Human, France SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D65, Atlanta, GA 30333 USA. EM meberhard@cdc.gov NR 1 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2013 VL 19 IS 11 BP 1904 EP 1905 DI 10.3201/eid1911.130606 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AA4JE UT WOS:000331061100038 PM 24188526 ER PT J AU Potter, P AF Potter, Polyxeni TI My Name Is Nobody SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2013 VL 19 IS 11 BP 1908 EP 1909 DI 10.3201/eid1911.AC1911 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AA4JE UT WOS:000331061100040 PM 24350352 ER PT J AU Lohiniva, AL Dueger, E Talaat, M Refaey, S Zaki, A Horton, KC Kandeel, A AF Lohiniva, Anna-Leena Dueger, Erica Talaat, Maha Refaey, Samir Zaki, Amal Horton, Katherine Chisholm Kandeel, Amr TI Poultry rearing and slaughtering practices in rural Egypt: an exploration of risk factors for H5N1 virus human transmission SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Backyard poultry; human H5N1 risk factors; socio-cultural ID INFLUENZA; INFECTION AB Background Highly pathogenic avian influenza (H5N1) virus continues to cause infections in Egypt. This study describes the practices associated with raising and slaughtering household poultry to identify risk factors for H5N1 infection and reasons for non-compliance with preventive measures. Methods An investigation was conducted of 56 households with household flocks (19 households with human H5N1 cases, 19 with poultry H5N1 cases, and 18 with no reported poultry or human H5N1 cases). Data were collected via structured observations and in-depth interviews. Results Half of the households kept at least some free-range poultry and mixed at least some different species of poultry as it was considered beneficial for the poultry. Feeding and cleaning practices exposed children to contact with poultry; slaughtering contaminated homes; use of personal protective barriers was not a norm; waste management exposed the communities to slaughtering waste and dead chickens; and reporting of sick and dead poultry was not a practice. Only minor changes in poultry-handling took place following H5N1 virus outbreaks. Discussion H5N1 virus prevention in Egypt represents both an epidemiological and socio-cultural challenge. Traditional poultry-rearing practices that likely increase exposures to H5N1-infected poultry are common throughout Egypt. Despite education campaigns following sporadic H5N1 outbreaks, no differences in these practices could be detected between households with previous H5N1 human or poultry cases and those households with any previous experience with H5N1. Development of H5N1 infection-related education campaign strategies should focus on perceptions underlying traditional practices in order to tailor public awareness messages that are meaningful for communities. C1 [Lohiniva, Anna-Leena; Dueger, Erica; Talaat, Maha; Horton, Katherine Chisholm] US Naval Med Res Unit 3, Global Dis Detect & Response Program, Cairo, Egypt. [Dueger, Erica] Ctr Dis Control & Prevent, Atlanta, GA USA. [Refaey, Samir; Zaki, Amal] Minist Hlth & Populat Egypt, Prevent Sect, Cairo, Egypt. RP Lohiniva, AL (reprint author), US Naval Med Res Unit, Global Dis Detect & Response Program, 3,PSC 452,POB 5000, FPO, AE 09835 USA. EM anna.lohiniva.ctr.fi@med.navy.mil RI Mashamba-Thompson, Tivani /B-6087-2014 FU Centers for Disease Control and Prevention (CDC) Influenza Division; CDC Division of Global Disease Detection & Emergency Response; military funding at US Naval Medical Research Unit FX Funding for this study was provided by the Centers for Disease Control and Prevention (CDC) Influenza Division and the CDC Division of Global Disease Detection & Emergency Response.; Some authors are contractors supported by military funding at US Naval Medical Research Unit No.3. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that "Copyright protection under this title is not available for any work of the United States Government." Title 17 U.S.C. 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties. NR 22 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1251 EP 1259 DI 10.1111/irv.12023 PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400052 PM 23145955 ER PT J AU Basurto-Davila, R Garza, R Meltzer, MI Carlino, OL Albalak, R Orellano, PW Uez, O Shay, DK Santandrea, C Weis, MD Averhoff, F Widdowson, MA AF Basurto-Davila, Ricardo Garza, Roberto Meltzer, Martin I. Carlino, Oreste L. Albalak, Rachel Orellano, Pablo W. Uez, Osvaldo Shay, David K. Santandrea, Cora del Carmen Weis, Maria Averhoff, Francisco Widdowson, Marc-Alain TI Household economic impact and attitudes toward school closures in two cities in Argentina during the 2009 influenza A (H1N1) pandemic SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Costs and cost analysis; healthcare economics; human; influenza; pandemics; prevention and control ID OUTBREAK; CHILDREN; TRANSMISSION; NETWORKS; DISEASES; SPREAD AB Background School closures were widely implemented in Argentina during the 2009 H1N1 influenza virus pandemic. Objectives To assess the economic impact of school closures on households, their effectiveness in preventing children from engaging in social group activities, and parental attitudes toward them. Methods Three schools that closed for 2 weeks in response to the pandemic were identified in two socioeconomically distinct cities in Argentina. All households with children enrolled in these schools were surveyed. Direct and indirect costs attributable to closures were estimated from the household perspective. Other information collected included children activities during the closures and parental attitudes toward the intervention. Results Completed questionnaires were returned by 45% of surveyed households. Direct and indirect costs due to closures represented 11% of imputed monthly household income in the city with lower socioeconomic status, and 3% in the other city (P=0.01). Non-childcare expenses and loss of workdays were more common in the city with lower socioeconomic status. Childcare expenses were less common and were experienced by a similar percentage of households in both cities. About three-quarters of respondents in both cities agreed with the closures. The main concern among those who disagreed with closures was their negative impact on education. Children in more than two-thirds of affected households left their home at least once during the closures to spend time in public places. Conclusion School closures may more significantly impact low-income households. Authorities should consider the range of economic impacts of school closures among families when planning their implementation. C1 [Basurto-Davila, Ricardo] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Garza, Roberto; Meltzer, Martin I.; Albalak, Rachel; Shay, David K.; Averhoff, Francisco; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Carlino, Oreste L.; Orellano, Pablo W.; Santandrea, Cora] Minist Salud Nac, Buenos Aires, DF, Argentina. [Uez, Osvaldo] Inst Nacl Epidemiol, Mar Del Plata, Buenos Aires, Argentina. [del Carmen Weis, Maria] Direcc Epidemiol & Inmunizac, Olavarria, Argentina. RP Basurto-Davila, R (reprint author), 313 N Figueroa St,Room 121, Los Angeles, CA 90012 USA. EM ribasurto-davila@ph.lacounty.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933; Shay, David/0000-0001-9619-4820; Orellano, Pablo/0000-0001-8911-663X FU U.S. Centers for Disease Control and Prevention; Pan American Health Organization FX We would like to thank study participants for providing data and school administrators and staff for collaborating in our data collection efforts. We also thank provincial health and education authorities in Jujuy and Tierra del Fuego for their assistance and advice in the planning and implementation of the project. Finally, we thank officials from the Pan American Health Organization for their assistance with the logistics of this project. This work was supported by the U.S. Centers for Disease Control and Prevention and the Pan American Health Organization. NR 26 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1308 EP 1315 DI 10.1111/irv.12054 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400058 PM 23176127 ER PT J AU Storms, AD Van Kerkhove, MD Azziz-Baumgartner, E Lee, WK Widdowson, MA Ferguson, NM Mounts, AW AF Storms, Aaron D. Van Kerkhove, Maria D. Azziz-Baumgartner, Eduardo Lee, Wing-Kei Widdowson, Marc-Alain Ferguson, Neil M. Mounts, Anthony W. TI Worldwide transmission and seasonal variation of pandemic influenza A(H1N1)2009 virus activity during the 2009-2010 pandemic SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE 2009 influenza A (H1N1); pandemic influenza; seasonality ID EPIDEMIOLOGY AB Background Seasonal influenza activity varies with geography and time of year. Objective To describe how pandemic influenza A(H1N1) 2009 [A (H1N1)pdm09] activity varied during the 2009-2010 pandemic. Methods We analyzed influenza virological data compiled by the World Health Organization from June 2009-August 2010. We calculated weekly proportions of A(H1N1) pdm09-positive specimens out of all A(H1N1) pdm09-positive specimens detected during the study period for each country. We compared parameters of pandemic activity (e. g., peak A[H1N1] pdm09 weekly proportion [peak activity], number of weeks between the 5th and 95th percentiles of A(H1N1) pdm09 cumulative weekly proportion [duration of activity]) between countries in temperate and tropical-subtropical regions. We quantified the proportion of A (H1N1) pdm09 out of all influenza A specimens by country and correlated it with countries' central latitudes. Results We analyzed data from 80 countries (47 temperate, 33 tropical-subtropical). The median proportion of cases identified during the peak week was higher in temperate (0.12) than in tropical-subtropical (0.09) regions (P < 0.01). The median duration of activity was longer in tropical-subtropical (27 weeks) than in temperate countries (20 weeks) (P < 0.01). In most temperate countries (98%), peak pandemic activity occurred during the fall-winter period. There was a positive correlation between country central latitude and proportion of A(H1N1)pdm09 out of all influenza A specimens (r: 0.76; P < 0.01). Conclusions The transmission of A(H1N1) pdm09 exhibited similarities with seasonal influenza transmission in that activity varied between temperate and tropical-subtropical countries and by time of year. Our findings suggest the potential utility of accounting for these factors during future pandemic planning. C1 [Storms, Aaron D.; Azziz-Baumgartner, Eduardo; Widdowson, Marc-Alain; Mounts, Anthony W.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Storms, Aaron D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Van Kerkhove, Maria D.; Lee, Wing-Kei; Mounts, Anthony W.] WHO, Global Influenza Programme, CH-1211 Geneva, Switzerland. [Van Kerkhove, Maria D.; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modeling, London, England. RP Storms, AD (reprint author), 1600 Clifton Rd NE,MS A-04, Atlanta, GA 30333 USA. EM adstorms@cdc.gov RI Ferguson, Neil/B-8578-2008; OI Ferguson, Neil/0000-0002-1154-8093; Widdowson, Marc-Alain/0000-0002-0682-6933 FU Centers for Disease Control and Prevention; World Health Organization; Imperial College of London FX The authors would like to recognize all of the National Influenza Centers, the WHO Global Influenza Surveillance and Response System and other laboratories who reported their data on FluNet or otherwise made it available to the global community. The free and transparent sharing of data is critical to improving our corporate understanding of influenza transmission dynamics and our ability to appropriately and effectively respond to future pandemics. This work was supported by the Centers for Disease Control and Prevention, the World Health Organization, and Imperial College of London. NR 19 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1328 EP 1335 DI 10.1111/irv.12106 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400060 PM 23551904 ER PT J AU Mortensen, E Louie, J Pertowski, C Cadwell, BL Weiss, E Acosta, M Matyas, BT AF Mortensen, Eva Louie, Janice Pertowski, Carol Cadwell, Betsy L. Weiss, Edward Acosta, Meileen Matyas, Bela T. TI Epidemiology and outcomes of adults with asthma who were hospitalized or died with 2009 pandemic influenza A (H1N1) - California, 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE pandemic H1N1; adults with asthma; death; hospitalizations ID CLINICAL-PRACTICE; UNITED-STATES; SOCIETY AB Background Asthma was the most common chronic condition among adults hospitalized for 2009 pandemic influenza A (H1N1) (pH1N1). Objectives We describe the epidemiology and factors for severe outcomes among adults with asthma who were hospitalized or died from pH1N1 in California. Methods We reviewed California Department of Public Health pH1N1 reports from April 23, 2009 through August 11, 2009. Reports were included if the patient had pH1N1 (or non-subtypeable influenza A) infection by polymerase chain reaction in an adult (age >= 18 years) with asthma who was hospitalized or died. Patients were classified as having intermittent or persistent asthma on the basis of regular medications. Risk factors associated with severe outcomes (i.e., intensive care unit admission or death) vs those with less severe outcomes were assessed by chi-square tests and logistic regression. Results Among 744 identified patients, 170 (23%) had asthma (61% intermittent, 39% persistent). 132 of 142 (93%) patients had other chronic medical conditions. Severe outcomes occurred in 54 of 162 (33%), more commonly among those with renal disease (64% versus 31%; P = 0.04) and chest radiograph infiltrates (54% versus 11%; P < 0.01), less commonly among those who received antivirals within 48 hours of symptom onset (22% versus 44%; P = 0.02). In multivariable analysis, chest radiograph infiltrates were associated with severe outcomes (adjusted odds ratio 9.38, 95% confidence interval 3.05-28.90). Conclusions One third of adults with asthma who died or were hospitalized with pH1N1 experienced severe outcomes. Early empiric antiviral therapy should be encouraged, especially among asthma patients. C1 [Mortensen, Eva] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Mortensen, Eva; Louie, Janice; Pertowski, Carol; Acosta, Meileen; Matyas, Bela T.] Calif Dept Publ Hlth, Richmond, CA USA. [Pertowski, Carol] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Cadwell, Betsy L.; Weiss, Edward] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. RP Mortensen, E (reprint author), Off Publ Hlth Surveillance & Res, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA. EM eva.mortensen@va.gov NR 17 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1343 EP 1349 DI 10.1111/irv.12120 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400062 PM 23848363 ER PT J AU Yu, HJ Feng, LZ Viboud, CG Shay, DK Jiang, Y Zhou, H Zhou, MG Xu, Z Hu, N Yang, WZ Nie, SF AF Yu, Hongjie Feng, Luzhao Viboud, Cecile G. Shay, David K. Jiang, Yong Zhou, Hong Zhou, Maigeng Xu, Zhen Hu, Nan Yang, Weizhong Nie, Shaofa TI Regional variation in mortality impact of the 2009 A (H1N1) influenza pandemic in China SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE A(H1N1) pandemic; China; influenza; mortality; negative binomial model; regional variation ID RESPIRATORY SYNCYTIAL VIRUS; A H1N1; UNITED-STATES; SEASONAL INFLUENZA; GLOBAL MORTALITY; RISK-FACTORS; HONG-KONG; DEATHS; POPULATION; INFECTION AB Background Laboratory-confirmed deaths grossly underestimate influenza mortality burden, so that reliable burden estimates are derived from indirect statistical studies, which are scarce in low- and middle-income settings. Objectives Here, we used statistical excess mortality models to estimate the burden of seasonal and pandemic influenza in China. Methods We modeled data from a nationally representative population-based death registration system, combined with influenza virological surveillance data, to estimate influenza-associated excess mortality for the 2004-2005 through 2009-2010 seasons, by age and region. Results The A(H1N1) pandemic was associated with 11.4-12.1 excess respiratory and circulatory (R&C) deaths per 100 000 population in rural sites of northern and southern China during 2009-2010; these rates were 2.2-2.8 times higher than those of urban sites (P < 0.01). Influenza B accounted for a larger proportion of deaths than pandemic A(H1N1) in 2009-2010 in some regions. Nationally, we attribute 126 200 (95% CI, 61 000-248 400) excess R&C deaths (rate of 9.4/100 000) and 2 323 000 (1 166 000-4 533 000) years of life lost (YLL) to the first year of A (H1N1) pdm circulation. Conclusions The A(H1N1) pandemic posed a mortality and YLL burden comparable to that of interpandemic influenza in China. Our high burden estimates in rural areas highlight the need to enhance epidemiological surveillance and healthcare services, in underdeveloped and remote areas. C1 [Yu, Hongjie; Nie, Shaofa] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Stat, Wuhan 430030, Peoples R China. [Yu, Hongjie; Feng, Luzhao; Xu, Zhen; Yang, Weizhong] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China. [Viboud, Cecile G.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Jiang, Yong; Hu, Nan] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Zhou, Hong] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Zhou, Maigeng] Chinese Ctr Dis Control & Prevent, Ctr Publ Hlth Surveillance & Informat Serv, Beijing, Peoples R China. RP Nie, SF (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Stat, 13 Hangkong Rd, Wuhan 430030, Peoples R China. EM sf_nie@mails.tjmu.edu.cn OI Shay, David/0000-0001-9619-4820 FU China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases; Ministry of Science and Technology, China [2012 ZX10004-201] FX We thank the local Centers for Disease Control and Prevention in the Disease Surveillance Points sites and National Influenza Surveillance Network. The views expressed are those of the authors and do not necessarily represent the policy of the China CDC or the U.S. Centers for Disease Control and Prevention. This study was supported by the China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases and the Grants of the Ministry of Science and Technology, China (2012 ZX10004-201). NR 36 TC 10 Z9 15 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1350 EP 1360 DI 10.1111/irv.12121 PG 11 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400063 PM 23668477 ER PT J AU Suryaprasad, A Redd, JT Hancock, K Branch, A Steward-Clark, E Katz, JM Fry, AM Cheek, JE AF Suryaprasad, Anil Redd, John T. Hancock, Kathy Branch, Alicia Steward-Clark, Evelene Katz, Jacqueline M. Fry, Alicia M. Cheek, James E. CA Influenza Serology Working Grp Amer Indian Alaska Native Pandemic TI Severe acute respiratory infections caused by 2009 pandemic influenza A (H1N1) among American Indians-southwestern United States, May 1-July 21, 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE American Indians; H1N1 subtype; hospitalizations; influenza viruses ID DISEASE HOSPITALIZATIONS; VIRUS-INFECTIONS; RISK-FACTOR; OBESITY; DISPARITIES; CHILDREN; PEOPLE; ADULTS; DEATH AB Background During April-July 2009, U. S. hospitalization rates for 2009 pandemic influenza A (H1N1) virus (H1N1pdm09) infection were estimated at 4.5/100 000 persons. We describe rates and risk factors for H1N1pdm09 infection among American Indians (AIs) in four isolated southwestern U. S. communities served by the Indian Health Service (IHS). Methods We reviewed clinical and demographic information from medical records of AIs hospitalized during May 1-July 21, 2009 with severe acute respiratory infection (SARI). Hospitalization rates were determined using denominator data provided by IHS. H1N1pdm09 infection was confirmed with polymerase chain reaction, rapid tests, or convalescent serology. Risk factors for more severe (SARI) versus milder [influenza-like illness (ILI)] illness were determined by comparing confirmed SARI patients with outpatients with ILI. Results Among 168 SARI-hospitalized patients, 52% had confirmed H1N1pdm09 infection and 93% had > 1 high-risk condition for influenza complications. The H1N1pdm09 SARI hospitalization rate was 131/100 000 persons [95% confidence interval (CI), 102-160] and was highest among ages 0-4 years (353/100 000; 95% CI, 215-492). Among children, asthma (adjusted odds ratio [aOR] 3.2; 95% CI, 1.2-8.4) and age < 2 years (aOR 3.8; 95% CI, 1.4-10.0) were associated with H1N1pdm09 SARI-associated hospitalization, compared with outpatient ILI. Among adults, diabetes (aOR 3.1; 95% CI, 1.5-6.4) was associated with hospitalization after controlling for obesity. Conclusions H1N1pdm09 hospitalization rates among this isolated AI population were higher than reported for other U. S. populations. Almost all case patients had high-risk health conditions. Prevention strategies for future pandemics should prioritize AIs, particularly in isolated rural areas. C1 [Suryaprasad, Anil] Ctr Res Dis Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Suryaprasad, Anil; Redd, John T.; Cheek, James E.] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. [Hancock, Kathy; Branch, Alicia; Steward-Clark, Evelene; Katz, Jacqueline M.; Fry, Alicia M.; Influenza Serology Working Grp] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. Tuba City Reg Healthcare Corp, Tuba City, AZ USA. Winslow Indian Hlth Care Ctr, Winslow, AZ USA. Whiteriver Indian Hlth Serv Hosp, Whiteriver, AZ USA. Sells Indian Hlth Serv Hosp, Sells, AZ USA. Phoenix Indian Med Ctr, Phoenix, AZ USA. [Amer Indian Alaska Native Pandemic] Flagstaff Med Ctr, Flagstaff, AZ USA. RP Suryaprasad, A (reprint author), Epidem Intelligence Serv, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30333 USA. EM asuryaprasad@cdc.gov RI Mashamba-Thompson, Tivani /B-6087-2014 FU Centers for Disease Control and Prevention, Indian Health Service FX This study was financially supported by the Centers for Disease Control and Prevention, Indian Health Service. NR 37 TC 4 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2013 VL 7 IS 6 BP 1361 EP 1369 DI 10.1111/irv.12123 PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA AA3OG UT WOS:000331001400064 PM 23721100 ER PT J AU Nelson, EAS de Quadros, CA Santosham, M Parashar, UD Steele, D AF Nelson, E. Anthony S. de Quadros, Ciro A. Santosham, Mathuram Parashar, Umesh D. Steele, Duncan TI Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE rotavirus vaccine; immunization financing; immunization policy; policy recommendations; advisory committee; National Immunization Technical Advisory Group; evidence-based decision making ID TECHNICAL ADVISORY GROUPS; SURVEILLANCE NETWORK; LESS-THAN-5 YEARS; UNITED-STATES; HOSPITALIZATIONS; CHILDREN; DIARRHEA; GASTROENTERITIS; REDUCTION; EFFICACY AB Despite a WHO recommendation in 2009, reaffirmed in 2013, that all countries should consider introducing rotavirus vaccines into their National Immunization Programs, as of June 2013 only 45 have done so. One major consideration appears to have been the costs of the vaccine to countries. Of concern is that Asian countries have been slow to introduce rotavirus vaccines despite having robust data that could inform the decision-making process. Although decisions on new vaccine introduction are very complex and vary by country and region, economic evaluations are often pivotal once vaccine efficacy and safety has been established, and disease burden documented and communicated. Unfortunately, with private sector list prices of vaccines often used in economic evaluations, rather than a potential public health sector pricing structure, policy-makers may defer decisions on rotavirus vaccine introduction based on the belief that "the vaccine price is too high," even though this might be based on erroneous data. The Pan American Health Organization's Revolving Fund provides one example of how vaccine price can be made more competitive and transparent through a regional tendering process. Other mechanisms, such as tiered pricing and UNICEF procurement, also exist that could help Asian and other countries move forward more quickly with rotavirus vaccine introduction. C1 [Nelson, E. Anthony S.] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China. [de Quadros, Ciro A.] Sabin Vaccine Inst, Washington, DC USA. [Santosham, Mathuram] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Parashar, Umesh D.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Steele, Duncan] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Nelson, EAS (reprint author), Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China. EM tony-nelson@cuhk.edu.hk FU Baxter; GlaxoSmithKline; MedImmune; Wyeth; Merck; Pfizer; Intercell FX EASN has participated in a vaccine studies funded by Baxter, GlaxoSmithKline, MedImmune, and Wyeth, has received funding to conduct disease surveillance studies from Merck and Pfizer, and lecture fees and travel support from GlaxoSmithKline, Merck, Intercell, and Pfizer. The other authors have declared that no competing interests exist NR 46 TC 6 Z9 6 U1 0 U2 2 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD NOV PY 2013 VL 9 IS 11 BP 2418 EP 2426 DI 10.4161/hv.26107 PG 9 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 299FW UT WOS:000330382300026 PM 23955246 ER PT J AU Greenberg, AE Purcell, DW Gordon, CM Flores, S Grossman, C Fisher, HH Barasky, RJ AF Greenberg, Alan E. Purcell, David W. Gordon, Christopher M. Flores, Stephen Grossman, Cynthia Fisher, Holly H. Barasky, Rebecca J. TI NIH Support of Centers for AIDS Research and Department of Health Collaborative Public Health Research: Advancing CDC's Enhanced Comprehensive HIV Prevention Planning Project SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE Centers for AIDS Research; Enhanced Comprehensive HIV Prevention Planning; National HIV/AIDS Strategy; HIV care continuum; HIV treatment cascade ID CARE; RECOMMENDATIONS C1 [Greenberg, Alan E.; Barasky, Rebecca J.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Epidemiol & Biostat, Washington, DC 20037 USA. [Greenberg, Alan E.; Barasky, Rebecca J.] Dist Columbia Dev Ctr AIDS Res, Washington, DC USA. [Purcell, David W.; Flores, Stephen; Fisher, Holly H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gordon, Christopher M.; Grossman, Cynthia] NIMH, Bethesda, MD 20892 USA. RP Greenberg, AE (reprint author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Epidemiol & Biostat, 2100-W Penn Ave NW,8th Floor, Washington, DC 20037 USA. EM aeg1@gwu.edu FU National Institutes of Health [5P30AI087714] FX Supported by supplemental funds to the National Institutes of Health funded District of Columbia Developmental Center for AIDS Research (CFAR) grant (5P30AI087714) for the CFAR Enhanced Comprehensive HIV Prevention Planning initiative. NR 28 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2013 VL 64 SU 1 BP S1 EP S6 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300JW UT WOS:000330461200001 PM 23982663 ER PT J AU Charles, LE Gu, JK Fekedulegn, D Andrew, ME Violanti, JM Burchfiel, CM AF Charles, Luenda E. Gu, Ja K. Fekedulegn, Desta Andrew, Michael E. Violanti, John M. Burchfiel, Cecil M. TI Association Between Shiftwork and Glomerular Filtration Rate in Police Officers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CHRONIC KIDNEY-DISEASE; METABOLIC SYNDROME; SLEEP DURATION; CARDIOVASCULAR-DISEASE; UNITED-STATES; CIRCADIAN CLOCK; BLOOD-PRESSURE; HEART-DISEASE; RENAL-DISEASE; RISK-FACTORS AB Objective: To investigate associations between shiftwork and glomerular filtration rate among white/Hispanic (n = 273) and African American (n = 81) police officers. Methods: Analysis of variance/analysis of variance was utilized to compare mean values of estimated glomerular filtration rate (eGFR) across shiftwork categories. Results: Shiftwork was significantly associated with eGFR among white/Hispanic officers only: day (88.6 +/- 2.8), afternoon (90.6 +/- 2.9), and night shift (83.1 +/- 3.1 mL/min/1.73 m(2)); afternoon versus night, P = 0.007. Percentage of hours worked on the night shift was inversely associated with mean levels of eGFR, trend P = 0.001. Body mass index modified the association between shiftwork and eGFR (interaction P = 0.038). Among officers with body mass index 25 kg/m(2) or higher, those who worked the night shift had the lowest mean eGFR (afternoon vs night, P = 0.012; day vs night, P = 0.029). Conclusions: Night-shift work was associated with decreased kidney function among white/Hispanic officers. Longitudinal studies are warranted among all races. C1 [Charles, Luenda E.; Gu, Ja K.; Fekedulegn, Desta; Andrew, Michael E.; Burchfiel, Cecil M.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Violanti, John M.] SUNY Albany, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY USA. RP Charles, LE (reprint author), NIOSH, HELD, BEB, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM lcharles@cdc.gov FU National Institute for Occupational Safety and Health [200-2003-01580] FX Supported by the National Institute for Occupational Safety and Health, contract no. 200-2003-01580. NR 50 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2013 VL 55 IS 11 BP 1323 EP 1328 DI 10.1097/JOM.0b013e3182a299c9 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300FE UT WOS:000330449000012 PM 24164760 ER PT J AU Gase, LN Pennotti, R Smith, KD AF Gase, Lauren N. Pennotti, Radha Smith, Kenneth D. TI "Health in All Policies": Taking Stock of Emerging Practices to Incorporate Health in Decision Making in the United States SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE Health in All Policies; healthy public policy; intersectoral action on health ID IMPACT ASSESSMENT; PUBLIC-HEALTH; FOCUS AB Objective: Policies affecting the determinants of health lie largely outside the control of the health care and public health sectors. Ensuring health considerations in the formation and implementation of policies, programs, projects, and plans from all sectors, though lofty, is the overall aim of Health in All Policies. The purpose of this article was to identify categories of strategies that illustrate how Health in All Policies had been implemented in the United States. Design: We used a 3-phased process: (1) review of the published and gray literature; (2) analysis of case examples to identify a draft framework, which included tactics and strategies for implementing Health in All Policies; and (3) vetting the draft framework through individual and group consultation. Results: We identify 7 interrelated strategies for incorporating health considerations into decisions and systems: (1) developing and structuring cross-sector relationships; (2) incorporating health into decision-making processes; (3) enhancing workforce capacity; (4) coordinating funding and investments; (5) integrating research, evaluation and data systems; (6) synchronizing communications and messaging; and (7) implementing accountability structures. For each strategy, we provide illustrative examples from the United States to help public health leaders identify effective tactics for Health in All Policies implementation. Conclusions: Through our review, we offer a starting point for categorizing and describing the emerging practices used to work across sectors and address the determinants of health. By delineating the different types of strategies and tactics to achieve Health in All Policies, we provide public health practitioners with a "menu" of options for incorporating Health in All Policies into their work. C1 [Gase, Lauren N.] Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, Los Angeles, CA 90010 USA. [Pennotti, Radha] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Smith, Kenneth D.] Natl Assoc Cty & City Hlth Officials, Washington, DC USA. RP Gase, LN (reprint author), Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, 3530 Wilshire Blvd,8th Floor, Los Angeles, CA 90010 USA. EM lgase@ph.lacounty.gov NR 62 TC 12 Z9 12 U1 4 U2 26 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2013 VL 19 IS 6 BP 529 EP 540 DI 10.1097/PHH.0b013e3182980c6e PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300ED UT WOS:000330446300011 PM 24080816 ER PT J AU Fleischhacker, SE Flournoy, R Moore, LV AF Fleischhacker, Sheila E. Flournoy, Rebecca Moore, Latetia V. TI Meaningful, Measurable, and Manageable Approaches to Evaluating Healthy Food Financing Initiatives: An Overview of Resources and Approaches SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE community and economic development; food access; healthy food financing initiatives; healthy food retail; policy evaluation ID COMMUNITY-DEVELOPMENT; PHYSICAL-ACTIVITY; UNITED-STATES; ENVIRONMENTS; OBESITY; POLICY; ADOLESCENTS; RESTAURANTS; VALIDATION; ACCESS AB More than 23 million Americans have limited access to grocery stores. Healthy food financing initiatives have been emerging at local, state, and federal levels to address grocery gaps. Through public-private partnerships, retailers have been awarded funding to open or renovate a variety of food outlets. Preliminary findings have reported increased access to healthy foods, as well as improved community and economic development. As policy makers continue to consider enacting or expanding these initiatives and as all program stakeholders increasingly seek information on program impacts, this article provides guidance on using meaningful, measurable, and manageable methods to evaluate program's multifaceted outcomes. C1 [Fleischhacker, Sheila E.] NIH, NIH Div Nutr Res Coordinat, US Dept HHS, Bethesda, MD 20892 USA. [Flournoy, Rebecca] Alameda Cty Publ Hlth Dept, Oakland, CA USA. [Moore, Latetia V.] Ctr Dis Control & Prevent, Nutr Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Fleischhacker, SE (reprint author), NIH, NIH Div Nutr Res Coordinat, US Dept HHS, Two Democracy Plaza,Room 635,6707 Democracy Blvd, Bethesda, MD 20892 USA. EM sheila.fleischhacker@nih.gov NR 43 TC 6 Z9 6 U1 4 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2013 VL 19 IS 6 BP 541 EP 549 DI 10.1097/PHH.0b013e318271c6eb PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300ED UT WOS:000330446300012 PM 23073081 ER PT J AU Dolen, V Talkington, K Bhatt, A Rodewald, L AF Dolen, Virginia Talkington, Kathy Bhatt, Achal Rodewald, Lance TI Structures, Roles, and Procedures of State Advisory Committees on Immunization SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE advisory committee; immunization; immunization policy; public health; school and childcare vaccination requirements; state health agencies AB Context: Advisory committees have the potential to play a critical role in decision making and implementation at the state level. Many states have advisory committees for their immunization programs to assist in decision making on topics such as implementing new vaccines in their states, school and childcare requirements and exemptions and addressing concerns about vaccine safety. Objective: This article describes how immunization advisory committees work; their roles, formation, organization, and structure; membership; the issues they address; and their benefit to state immunization programs. Design: In 2011, the Association of State and Territorial Health Officials, in collaboration with the Centers for Disease Control and Prevention, conducted an online survey of immunization program managers to determine which states have immunization advisory committees, how these committees function, and the perceived benefits of the committees to state immunization programs. Follow-up half-hour telephone interviews were conducted with 5 states to gain in-depth information on specific advisory committees. Results: One hundred percent of states and 3 territories responded, giving an overall response rate of 91%. Thirty-four of the 53 respondents (64%) reported having an advisory committee for immunization issues. Membership is composed of physicians, public health representatives, and nurses as well as public advocates and members of the public. States reported a variety of issues their committee has worked on; the most frequently mentioned issue was school and childcare vaccination requirements. Others included immunization information systems and vaccination of health care personnel. Conclusions: Overall, states with immunization advisory committees reported that the committees were helpful on issues faced by the program and worth the time and monetary commitment. Given the reported benefits of state immunization advisory committees and the complex program and policy decisions that states face in the dynamic immunization environment, additional states may want to consider establishing immunization advisory committees. C1 [Dolen, Virginia; Talkington, Kathy] Assoc State & Terr Hlth Officials, Arlington, VA 22202 USA. [Bhatt, Achal; Rodewald, Lance] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Dolen, V (reprint author), Assoc State & Terr Hlth Officials, 2231 Crystal Dr,Ste 450, Arlington, VA 22202 USA. EM vdolen@astho.org OI Rodewald, Lance/0000-0003-2593-542X FU NCIRD CDC HHS [U38IP000456] NR 3 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2013 VL 19 IS 6 BP 582 EP 588 DI 10.1097/PHH.0b013e318271c738 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300ED UT WOS:000330446300017 PM 23449124 ER PT J AU Lavinghouze, R Snyder, K Rieker, P Ottoson, J AF Lavinghouze, Rene Snyder, Kimberly Rieker, Patricia Ottoson, Judith TI Consideration of an Applied Model of Public Health Program Infrastructure SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE infrastructure; intervention; program evaluation; program sustainability; public health ID COMMUNITY CAPACITY; SYSTEM; NETWORK; PARTNERSHIPS; COALITIONS; LESSONS; FLORIDA AB Systemic infrastructure is key to public health achievements. Individual public health program infrastructure feeds into this larger system. Although program infrastructure is rarely defined, it needs to be operationalized for effective implementation and evaluation. The Ecological Model of Infrastructure (EMI) is one approach to defining program infrastructure. The EMI consists of 5 core (Leadership, Partnerships, State Plans, Engaged Data, and Managed Resources) and 2 supporting (Strategic Understanding and Tactical Action) elements that are enveloped in a program's context. We conducted a literature search across public health programs to determine support for the EMI. Four of the core elements were consistently addressed, and the other EMI elements were intermittently addressed. The EMI provides an initial and partial model for understanding program infrastructure, but additional work is needed to identify evidence-based indicators of infrastructure elements that can be used to measure success and link infrastructure to public health outcomes, capacity, and sustainability. C1 [Lavinghouze, Rene] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Snyder, Kimberly] ICF Int, Atlanta, GA USA. [Rieker, Patricia] Boston Univ, Boston, MA 02215 USA. [Rieker, Patricia] Harvard Univ, Sch Med, Boston, MA USA. [Ottoson, Judith] San Francisco State Univ, San Francisco, CA 94132 USA. RP Lavinghouze, R (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Hwy F-79, Atlanta, GA 30341 USA. EM shl3@cdc.gov FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [DP09-901]; PHS HHS [PUB L 111-5] NR 48 TC 2 Z9 2 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD NOV-DEC PY 2013 VL 19 IS 6 BP E28 EP E37 DI 10.1097/PHH.0b013e31828554c8 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300ED UT WOS:000330446300004 PM 23411417 ER PT J AU Nacher, M Adenis, A Mc Donald, S Gomes, MDM Singh, S Lima, IL Leite, RM Hermelijn, S Wongsokarijo, M Van Eer, M Da Silva, SM Da Costa, MM Silva, M Calvacante, M Leitao, TDJS Gomez, BL Restrepo, A Tobon, A Canteros, CE Aznar, C Blanchet, D Vantilcke, V Vautrin, C Boukhari, R Chiller, T Scheel, C Ahlquist, A Roy, M Lortholary, O Carme, B Couppie, P Vreden, S AF Nacher, Mathieu Adenis, Antoine Mc Donald, Sigrid Gomes, Margarete Do Socorro Mendonca Singh, Shanti Lima, Ivina Lopes Leite, Rosilene Malcher Hermelijn, Sandra Wongsokarijo, Merril Van Eer, Marja Da Silva, Silvia Marques Da Costa, Maurimelia Mesquita Silva, Marizette Calvacante, Maria Leitao, Terezinha do Menino Jesus Silva Gomez, Beatriz L. Restrepo, Angela Tobon, Angela Canteros, Cristina E. Aznar, Christine Blanchet, Denis Vantilcke, Vincent Vautrin, Cyrille Boukhari, Rachida Chiller, Tom Scheel, Christina Ahlquist, Angela Roy, Monika Lortholary, Olivier Carme, Bernard Couppie, Pierre Vreden, Stephen TI Disseminated Histoplasmosis in HIV-Infected Patients in South America: A Neglected Killer Continues on Its Rampage SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Editorial Material ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POSITIVE PATIENTS; AIDS; DIAGNOSIS; BRAZIL; CEARA C1 [Nacher, Mathieu; Adenis, Antoine; Carme, Bernard] Ctr Hosp Cayenne, Ctr Invest Clin Epidemiol Clin Antilles Guyane In, Cayenne, French Guiana. [Nacher, Mathieu; Adenis, Antoine; Aznar, Christine; Blanchet, Denis; Carme, Bernard; Couppie, Pierre] Univ Antilles Guyane, EA 3593, Cayenne, French Guiana. [Mc Donald, Sigrid; Hermelijn, Sandra; Vreden, Stephen] Acad Ziekenhuis Paramaribo Hosp, Paramaribo, Surinam. [Gomes, Margarete Do Socorro Mendonca; Lima, Ivina Lopes; Leite, Rosilene Malcher] Lab Cent Saude Publ Amapa, Macapa, Brazil. [Singh, Shanti] Natl AIDS Program, Georgetown, Guyana. [Wongsokarijo, Merril] Publ Hlth Cent Lab Suriname, Paramaribo, Surinam. [Van Eer, Marja] Diakonessenhuis Hosp, Paramaribo, Surinam. [Da Silva, Silvia Marques; Da Costa, Maurimelia Mesquita] Inst Evandro Chagas, Belem, Para, Brazil. [Silva, Marizette; Calvacante, Maria] Hosp Clin Dr Alberto Lima, Macapa, Brazil. [Leitao, Terezinha do Menino Jesus Silva] Univ Fed Ceara, Fac Med, Dept Saude Comunitaria, Fortaleza, Ceara, Brazil. [Gomez, Beatriz L.; Restrepo, Angela; Tobon, Angela] Corp Invest Biol, Medellin, Colombia. [Canteros, Cristina E.] INEI ANLIS Dr Carlos G Malbran, Buenos Aires, DF, Argentina. [Vantilcke, Vincent; Vautrin, Cyrille; Boukhari, Rachida] Ctr Hosp Ouest Guyanais, St Laurent Du Maroni, French Guiana. [Chiller, Tom; Scheel, Christina; Ahlquist, Angela; Roy, Monika] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Lortholary, Olivier] Inst Pasteur, Natl Reference Ctr Mycoses & Antifungals, Mol Mycol Unit, Paris, France. [Lortholary, Olivier] CNRS URA3012, Paris, France. RP Nacher, M (reprint author), Ctr Hosp Cayenne, Ctr Invest Clin Epidemiol Clin Antilles Guyane In, Cayenne, French Guiana. EM mathieu.nacher@ch-cayenne.fr OI Couppie, Pierre/0000-0002-4213-2867 NR 24 TC 14 Z9 15 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD NOV PY 2013 VL 7 IS 11 AR e2319 DI 10.1371/journal.pntd.0002319 PG 3 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 299EM UT WOS:000330378400001 PM 24278485 ER PT J AU Bonilla, DL Durden, LA Eremeeva, ME Dasch, GA AF Bonilla, Denise L. Durden, Lance A. Eremeeva, Marina E. Dasch, Gregory A. TI The Biology and Taxonomy of Head and Body Lice-Implications for Louse-Borne Disease Prevention SO PLOS PATHOGENS LA English DT Article ID PEDICULUS-HUMANUS-CAPITIS; BARTONELLA-QUINTANA; PRIMARY ENDOSYMBIONT; PERMETHRIN; RESISTANCE; DISTRIBUTIONS; PHTHIRAPTERA; IVERMECTIN; EVOLUTION; MACAQUES C1 [Bonilla, Denise L.] Calif Dept Publ Hlth, Vector Borne Dis Sect, Richmond, CA 94804 USA. [Durden, Lance A.] Georgia So Univ, Dept Biol, Statesboro, GA 30460 USA. [Eremeeva, Marina E.] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Statesboro, GA 30460 USA. [Dasch, Gregory A.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA USA. RP Bonilla, DL (reprint author), Calif Dept Publ Hlth, Vector Borne Dis Sect, Richmond, CA 94804 USA. EM Denise.Bonilla@cdph.ca.gov OI Dasch, Gregory/0000-0001-6090-1810 FU Georgia Southern University; Jiann-Ping Hsu College of Public Health FX This work was partially supported by a Georgia Southern University Faculty Research Award (MEE and LAD) and Faculty Research Grant from the Jiann-Ping Hsu College of Public Health (MEE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 5 Z9 5 U1 1 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD NOV PY 2013 VL 9 IS 11 AR e1003724 DI 10.1371/journal.ppat.1003724 PG 5 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299HN UT WOS:000330386900007 PM 24244157 ER PT J AU Qvarnstrom, Y Nerad, TA Visvesvara, GS AF Qvarnstrom, Yvonne Nerad, Thomas A. Visvesvara, Govinda S. TI Characterization of a New Pathogenic Acanthamoeba Species, A. byersi n. sp., Isolated from a Human with Fatal Amoebic Encephalitis SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE Group 1 Acanthamoeba; human isolate; nuclear small subunit ribosomal RNA gene; ribosomal secondary structure; sequence type T18; 18S rRNA gene ID FREE-LIVING AMEBAS; RIBOSOMAL-RNA; GENUS ACANTHAMOEBA; SEQUENCE TYPES; IDENTIFICATION; GENOTYPE; KERATITIS; SPP.; DNA AB Acanthamoeba spp. are free-living amoebae that are ubiquitous in natural environments. They can cause cutaneous, nasopharyngeal, and disseminated infection, leading to granulomatous amebic encephalitis (GAE) in immunocompromised individuals. In addition, they can cause amoebic keratitis in contact lens wearers. Acanthamoeba GAE is almost always fatal because of difficulty and delay in diagnosis and lack of optimal antimicrobial therapy. Here, we report the description of an unusual strain isolated from skin and brain of a GAE patient. The amoebae displayed large trophozoites and star-shaped cysts, characteristics for acanthamoebas belonging to morphology Group 1. However, its unique morphology and growth characteristics differentiated this new strain from other Group 1 species. DNA sequence analysis, secondary structure prediction, and phylogenetic analysis of the 18S rRNA gene confirmed that this new strain belonged to Group 1, but that it was distinct from the other sequence types within that group. Thus, we hereby propose the establishment of a new species, Acanthamoeba byersi n. sp. as well as a new sequence type, T18, for this new strain. To our knowledge, this is the first report of a Group 1 Acanthamoeba that is indisputably pathogenic in humans. C1 [Qvarnstrom, Yvonne] CDC, Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Nerad, Thomas A.] George Mason Univ, Manassas, VA 20110 USA. [Visvesvara, Govinda S.] CDC, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Qvarnstrom, Y (reprint author), CDC, Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, MS D64,1600 Clifton Rd, Atlanta, GA 30329 USA. EM bvp2@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 51 Z9 51 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 EI 1550-7408 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD NOV PY 2013 VL 60 IS 6 BP 626 EP 633 DI 10.1111/jeu.12069 PG 8 WC Microbiology SC Microbiology GA 295MX UT WOS:000330121300008 PM 23879685 ER PT J AU Tharp, AT Carter, M Fasula, AM Hatfield-Timajchy, K Jayne, PE Latzman, NE Kinsey, J AF Tharp, Andra Teten Carter, Marion Fasula, Amy M. Hatfield-Timajchy, Kendra Jayne, Paula E. Latzman, Natasha E. Kinsey, Jennine TI Advancing Adolescent Sexual and Reproductive Health by Promoting Healthy Relationships SO JOURNAL OF WOMENS HEALTH LA English DT Article ID DATING VIOLENCE; CONDOM USE; UNITED-STATES; ROMANTIC RELATIONSHIPS; FEMALES; PREGNANCY; CONTEXT; GIRLS AB The field of public health faces a challenge in preventing adverse sexual and reproductive health outcomes such as sexually transmitted diseases, unintended pregnancy, and dating and sexual violence among adolescents. Innovative approaches are needed to better address these issues. Focusing on healthy relationships is an emerging approach that may be used to promote adolescent sexual and reproductive health. In this report, we discuss the need for innovative and efficient strategies for adolescent sexual and reproductive health, the benefits of a healthy relationships approach, describe the need for a science-based conceptual framework on healthy relationships, and provide some considerations for developing a conceptual framework of healthy relationships in order to move the field of public health forward. C1 [Tharp, Andra Teten; Latzman, Natasha E.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Carter, Marion; Kinsey, Jennine] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Fasula, Amy M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Hatfield-Timajchy, Kendra] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth, Atlanta, GA 30341 USA. [Jayne, Paula E.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. RP Tharp, AT (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F-64, Atlanta, GA 30341 USA. EM atharp@cdc.gov NR 28 TC 5 Z9 5 U1 0 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD NOV 1 PY 2013 VL 22 IS 11 BP 911 EP 914 DI 10.1089/jwh.2013.4534 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 295PA UT WOS:000330126800002 PM 24116967 ER PT J AU Dinh, TH Kamb, ML Msimang, V Likibi, M Molebatsi, T Goldman, T Lewis, DA AF Thu-Ha Dinh Kamb, Mary L. Msimang, Veerle Likibi, Muptal Molebatsi, Thabo Goldman, Thurma Lewis, David A. TI Integration of Preventing Mother-To-Child Transmission of HIV and Syphilis Testing and Treatment in Antenatal Care Services in the Northern Cape and Gauteng Provinces, South Africa SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID GENITAL ULCER DISEASE; MATERNAL SYPHILIS; PREGNANCY; MEN AB Background: South Africa recommends universal syphilis and HIV testing in pregnancy, with prompt antiretroviral therapy or penicillin treatment for women testing positive. Methods: We used a multistage, purposeful sampling strategy to retrospectively identify clinical records from a sample (7.3%) of 32,518 women delivering from January 2005 to June 2006 at 6 public clinics in the Northern Cape and Gauteng. Descriptive analyses and logistic regression were used to assess coverage and factors related to testing and treatment of HIV and syphilis. Results: Of 2379 women sampled, 93% accessed antenatal care (ANC) services during pregnancy and 71% before the third pregnancy trimester. Testing during pregnancy or delivery was 74% for HIV and 84% for syphilis; testing at the first ANC visit was 41% and 71%; and infection prevalence at delivery was 14% and 5%, respectively. Of 243 women with reactive HIV tests, 104 (43%) had treatment documented (single-dose nevirapine) before delivery. Of 98 women with reactive syphilis tests, 73% had documented receipt of 1 penicillin injection and 36% had all 3 recommended injections. Multivariable analysis found women tested for syphilis were almost 4 times more likely to have had no HIV test compared with those without syphilis testing (adjusted odds ratios, 3.9; 95% confidence interval, 1.7-5.5). Conclusions: Integration and provision of a package of HIV and syphilis testing at the first ANC visit and decentralizing treatments of both infections to primary care settings could increase the coverage of testing and treatment services, thus enhancing the effectiveness of current programs eliminating mother-to-child transmission of HIV and syphilis. C1 [Thu-Ha Dinh; Goldman, Thurma] Ctr Dis Control & Prevent, Div Global HIV AIDS CDC DGHA, Atlanta, GA USA. [Thu-Ha Dinh; Kamb, Mary L.; Msimang, Veerle] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent CDC DSTDP, Atlanta, GA USA. [Lewis, David A.] NHLS, NICD, Johannesburg, South Africa. [Likibi, Muptal] Gauteng Dept Hlth, Johannesburg, South Africa. [Molebatsi, Thabo] Northern Cape Dept Hlth, Kimberley, South Africa. Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa. RP Dinh, TH (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM dvt1@cdc.gov NR 17 TC 7 Z9 7 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 846 EP 851 DI 10.1097/OLQ.0000000000000042 PG 6 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900005 PM 24113405 ER PT J AU Fanfair, RN Zaidi, A Taylor, LD Xu, FJ Gottlieb, S Markowitz, L AF Fanfair, Robyn Neblett Zaidi, Akbar Taylor, LaShan D. Xu, Fujie Gottlieb, Sami Markowitz, Lauri TI Trends in Seroprevalence of Herpes Simplex Virus Type 2 Among Non-Hispanic Blacks and Non-Hispanic Whites Aged 14 to 49 Years-United States, 1988 to 2010 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; GENITAL HERPES; TRANSMISSION; ACQUISITION; DISPARITIES; WOMEN; MEN; HERPES-SIMPLEX-VIRUS-2; METAANALYSIS; CONDOMS AB Objectives: Genital herpes simplex virus type 2 (HSV-2) is one of the most prevalent sexually transmitted infections in the United States. We sought to assess differences in HSV-2 seroprevalence among non-Hispanic blacks and non-Hispanic whites and describe trends over time from 1988 to 2010. Methods: Data from National Health and Nutrition Examination Surveys (NHANES) were used to determine national HSV-2 seroprevalence estimates from National Health and Nutrition Examination Surveys 1988 to 1994, 1999 to 2002, 2003 to 2006, and 2007 to 2010. Persons aged 14 to 49 years were included in the analyses. Race/Ethnicity was defined by self-report as non-Hispanic white or non-Hispanic black. Purified glycoprotein specific for HSV-2 was used to detect type-specific antibodies using an immunodot assay. The same assay was used in all surveys. History of diagnosed genital herpes was self-reported. Results: Overall, HSV-2 seroprevalence decreased in the United States between 1988 to 1994 and 2007 to 2010, from 21.2% to 15.5%. Among non-Hispanic white females, HSV-2 seroprevalence decreased from 19.5% (1988-1994) to 15.3% (2007-2010; P < 0.001); HSV-2 seroprevalence remained stable among non-Hispanic black females, 52.5% (1988-1994) to 49.9% (2007-2010; P = 0.1). The female black/white prevalence ratio was 2.7 (95% confidence interval [CI], 2.4-3.0) in 1988 to 1994 increasing to 3.3 (95% CI, 2.9-3.7) in 2007 to 2010 (P = 0.01). Among males, the black/white prevalence ratio was 2.4 (95% CI, 1.9-2.9) in 1988 to 1994 increasing to 4.4 (95% CI, 3.3-5.8) in 2007 to 2010 (P = 0.001). The overall percentage of HSV-2-seropositive survey participants who reported never being told by a doctor or health care professional that they had genital herpes did not change significantly between 1988 to 1994 and 2007 to 2010 and remained high (90.7% and 87.4%, respectively). Conclusions: Although HSV-2 seroprevalence decreased overall, the decrease was most marked among non-Hispanic whites, and racial disparities significantly increased over time. These persistent disparities demonstrate the need for innovative prevention strategies among this at-risk population. C1 [Fanfair, Robyn Neblett; Zaidi, Akbar; Taylor, LaShan D.; Xu, Fujie; Gottlieb, Sami; Markowitz, Lauri] US Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Fanfair, RN (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E02, Atlanta, GA 30333 USA. EM iyo5@cdc.gov NR 30 TC 11 Z9 11 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 860 EP 864 DI 10.1097/OLQ.0000000000000043 PG 5 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900008 PM 24113408 ER PT J AU Meites, E Llata, E Braxton, J Schwebke, JR Bernstein, KT Pathela, P Asbel, LE Kerani, RP Mettenbrink, CJ Weinstock, HS AF Meites, Elissa Llata, Eloisa Braxton, Jim Schwebke, Jane R. Bernstein, Kyle T. Pathela, Preeti Asbel, Lenore E. Kerani, Roxanne P. Mettenbrink, Christie J. Weinstock, Hillard S. TI Trichomonas vaginalis in Selected US Sexually Transmitted Disease Clinics: Testing, Screening, and Prevalence SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; PELVIC-INFLAMMATORY-DISEASE; STD SURVEILLANCE NETWORK; UNITED-STATES; CHLAMYDIA-TRACHOMATIS; AMPLIFICATION ASSAY; AFRICAN WOMEN; INFECTION; ACQUISITION; RISK AB Background: Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection in the United States, affecting 3.1% of women of reproductive age. Infection is associated with HIV acquisition and pelvic inflammatory disease. In the United States, Centers for Disease Control and Prevention guidelines recommend testing all women with vaginal discharge for T. vaginalis, but except for HIV-infected women, there are no national guidelines for screening asymptomatic persons. The objective of this analysis is to assess testing and screening practices for T. vaginalis among symptomatic and asymptomatic women in the sexually transmitted disease (STD) clinic setting. Methods: We analyzed data on demographics, clinical presentation, and laboratory testing for all women visiting a clinician in 2010 to 2011 at any of 15 STD clinics participating in the STD Surveillance Network. Prevalence of laboratory-confirmed T. vaginalis infection was calculated among symptomatic women tested and among asymptomatic women screened. Results: A total of 59,176 women visited STD clinicians: 39,979 were considered symptomatic and 19,197 were considered asymptomatic for T. vaginalis infection, whereas 211 were HIV-infected. Diagnostic practices varied by jurisdiction: 4.0% to 96.1% of women were tested or screened for T. vaginalis using any laboratory test. Among 17,952 symptomatic women tested, prevalence was 26.2%. Among 3909 asymptomatic women screened, prevalence was 6.5%. Among 92 HIV-infected women tested/screened, prevalence was 29.3%. Conclusions: Trichomoniasis is common among STD clinic patients. In this analysis, most STD clinics tested symptomatic women seeking care, in accordance with national guidelines. All HIV-infected women should be screened annually. Additional evidence and national guidance are needed regarding potential benefits of T. vaginalis screening in other asymptomatic women. C1 [Meites, Elissa; Llata, Eloisa; Braxton, Jim; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Schwebke, Jane R.] Univ Alabama Birmingham, Birmingham, AL USA. [Bernstein, Kyle T.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Pathela, Preeti] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Asbel, Lenore E.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Kerani, Roxanne P.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Kerani, Roxanne P.] Univ Washington, Seattle, WA 98195 USA. [Mettenbrink, Christie J.] Denver Publ Hlth Dept, Denver, CO USA. RP Meites, E (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM emeites@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 FU Centers for Disease Control and Prevention FX The Centers for Disease Control and Prevention provided funding support for this work. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 31 TC 13 Z9 13 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 865 EP 869 DI 10.1097/OLQ.0000000000000038 PG 5 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900009 PM 24113409 ER PT J AU Castro, AR Jost, HA AF Castro, Arnold R. Jost, Heather A. TI Effect of Multiple Freeze and Thaw Cycles on the Sensitivity of IgG and IgM Immunoglobulins in the Sera of Patients With Syphilis SO SEXUALLY TRANSMITTED DISEASES LA English DT Article AB We describe the effects of multiple freeze and thaw cycles on the sensitivity of the immunoglobulins IgG and IgM measured by enzyme-linked immunoassays in the sera of patients with syphilis. Stored frozen sera can withstand repeated freezing and thawing cycles with a minimal detrimental effect on the sensitivity of the sera. C1 [Castro, Arnold R.; Jost, Heather A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Castro, AR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ajc5@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 870 EP 871 DI 10.1097/OLQ.0000000000000036 PG 2 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900010 PM 24113410 ER PT J AU Introcaso, CE Rogers, ME Abbott, SA Gorwitz, RJ Markowitz, LE Schillinger, JA AF Introcaso, Camille E. Rogers, Meighan E. Abbott, Sharon A. Gorwitz, Rachel J. Markowitz, Lauri E. Schillinger, Julia A. TI Expedited Partner Therapy in Federally Qualified Health Centers-New York City, 2012 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID INFECTION; CARE AB Background: Management of patients' sex partners is a critical element of sexually transmitted disease (STD) control. Expedited partner therapy (EPT), a practice in which patients deliver medication or a prescription directly to their partners, is one option for partner management. As of 2009, New York State law specifically allows EPT for chlamydial infection. Federally qualified health centers (FQHCs) in New York City (NYC) care for patients at risk for STDs. We describe the policies and practices surrounding EPT and other STD management in NYC FQHCs. Methods: In 2012, we surveyed medical directors at all NYC FQHC parent entities and clinicians at a sample of their corresponding clinical sites about written policies and actual practices regarding EPT for chlamydial infection and other STD management. Results: Twenty-two entities (22/29; 76%) and 51 sites (51/72; 70%) responded to the survey. More than half of entities have a written policy permitting EPT, and 80% of sites provide EPT. Most entity policies allow EPT for, and most sites provide EPT to, adolescents and adults with both opposite-sex and/or same-sex partners. Most sites use electronic health records and provide EPT by prescriptions, and one third of sites do not provide educational materials with EPT. Conclusions: Our results indicate widespread EPT provision by NYC FQHCs; however, areas for improvement exist, specifically in following guidelines that recommend providing educational materials with EPT and do not recommend EPT for men with male partners. The use of prescriptions for EPT and electronic health records were identified as potential barriers to EPT provision. C1 [Introcaso, Camille E.; Gorwitz, Rachel J.; Markowitz, Lauri E.; Schillinger, Julia A.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Rogers, Meighan E.; Schillinger, Julia A.] Bur Sexually Transmitted Dis Control, New York City Dept Hlth & Mental Hyg, New York, NY USA. [Abbott, Sharon A.] Cicatelli Associates Inc, New York, NY USA. RP Introcaso, CE (reprint author), Ctr Dis Control & Prevent, Corp Sq Bldg 10,MS E-02, Atlanta, GA 30333 USA. EM camille.introcaso@gmail.com NR 12 TC 6 Z9 6 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 881 EP 885 DI 10.1097/OLQ.0000000000000045 PG 5 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900014 PM 24113414 ER PT J AU Glanz, JM Narwaney, KJ Newcomer, SR Daley, MF Hambidge, SJ Rowhani-Rahbar, A Lee, GM Nelson, JC Naleway, AL Nordin, JD Lugg, MM Weintraub, ES AF Glanz, Jason M. Narwaney, Komal J. Newcomer, Sophia R. Daley, Matthew F. Hambidge, Simon J. Rowhani-Rahbar, Ali Lee, Grace M. Nelson, Jennifer C. Naleway, Allison L. Nordin, James D. Lugg, Marlene M. Weintraub, Eric S. TI Association Between Undervaccination With Diphtheria, Tetanus Toxoids, and Acellular Pertussis (DTaP) Vaccine and Risk of Pertussis Infection in Children 3 to 36 Months of Age SO JAMA PEDIATRICS LA English DT Article ID YOUNG-CHILDREN; EPIDEMIC; INFANTS; SAFETY AB IMPORTANCE Undervaccination is an increasing trend that potentially places children and their communities at an increased risk for serious infectious diseases. OBJECTIVE To examine the association between undervaccination and pertussis in children 3 to 36 months of age. DESIGN Matched case-control study with conditional logistic regression analysis. SETTING Eight managed care organizations of the Vaccine Safety Datalink between 2004 and 2010. PARTICIPANTS Each laboratory-confirmed case of pertussis (72 patients) was matched to 4 randomly selected controls (for a total of 288 controls). The case patients were matched to controls by managed care organization site, sex, and age at the index date. The index date was defined as the date of pertussis diagnosis for the case patients. EXPOSURE Undervaccination for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine. Undervaccination was defined as the number of doses of DTaP vaccine that was either missing or delayed by the index date. Case patients and controls could be undervaccinated by 0, 1, 2, 3, or 4 doses of DTaP vaccine. Children undervaccinated by 0 doses were considered age-appropriately vaccinated by the index date. MAIN OUTCOME AND MEASURE Pertussis. RESULTS Of the 72 case patients with pertussis, 12 (16.67%) were hospitalized, and 34 (47.22%) were undervaccinated for DTaP vaccine by the date of pertussis diagnosis. Of the 288 matched controls, 64 (22.22%) were undervaccinated for DTaP vaccine. Undervaccination was strongly associated with pertussis. Children undervaccinated for 3 or 4 doses of DTaP vaccine were 18.56 (95% Cl, 4.92-69.95) and 28.38 (95% Cl, 3.19-252.63) times more likely, respectively, to have received a diagnosis of pertussis than children who were age-appropriately vaccinated. CONCLUSIONS AND RELEVANCE Undervaccination with DTaP vaccine increases the risk of pertussis among children 3 to 36 months of age. C1 [Glanz, Jason M.; Narwaney, Komal J.; Newcomer, Sophia R.; Daley, Matthew F.; Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80237 USA. [Glanz, Jason M.; Hambidge, Simon J.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Daley, Matthew F.; Hambidge, Simon J.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Rowhani-Rahbar, Ali] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Ctr Child Hlth Care Studies, Dept Populat Med, Boston, MA USA. [Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA. [Nelson, Jennifer C.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Naleway, Allison L.] Kaiser Permanente Northwest, Portland, OR USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Lugg, Marlene M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA. RP Glanz, JM (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, POB 378066, Denver, CO 80237 USA. EM jason.m.glanz@kp.org OI Naleway, Allison/0000-0001-5747-4643 FU America's Health Insurance Plans under from the Centers for Disease Control and Prevention [200-2002-00732] FX This study was funded through a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the Centers for Disease Control and Prevention. NR 18 TC 22 Z9 22 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD NOV PY 2013 VL 167 IS 11 BP 1060 EP 1064 DI 10.1001/jamapediatrics.2013.2353 PG 5 WC Pediatrics SC Pediatrics GA 291PX UT WOS:000329842300019 PM 24019039 ER PT J AU Haines, J McDonald, J O'Brien, A Sherry, B Bottino, CJ Schmidt, ME Taveras, EM AF Haines, Jess McDonald, Julia O'Brien, Ashley Sherry, Bettylou Bottino, Clement J. Schmidt, Marie Evans Taveras, Elsie M. TI Healthy Habits, Happy Homes Randomized Trial to Improve Household Routines for Obesity Prevention Among Preschool-Aged Children SO JAMA PEDIATRICS LA English DT Article ID BODY-MASS INDEX; CHILDHOOD OBESITY; SLEEP DURATION; US CHILDREN; FAMILY DINNER; RISK-FACTORS; EARLY-LIFE; OVERWEIGHT; INTERVENTION; TELEVISION AB IMPORTANCE Racial/ethnic and socioeconomic disparities exist across risk factors for childhood obesity. OBJECTIVE To examine the effectiveness of a home-based intervention to improve household routines known to be associated with childhood obesity among a sample of low-income, racial/ethnic minority families with young children. DESIGN Randomized trial. SETTING The intervention was delivered in the families' homes. PARTICIPANTS The study involved 121 families with children aged 2 to 5 years who had a television (TV) in the room where he or she slept; 111 (92%) had 6-month outcome data (55 intervention and 56 control). The mean (SD) age of the children was 4.0 (1.1) years; 45% were overweight/obese. Fifty-two percent of the children were Hispanic, 34% were black, and 14% were white/other. Nearly 60% of the families had household incomes of $20 000 or less. INTERVENTIONS The 6-month intervention promoted 4 household routines, family meals, adequate sleep, limiting TV time, and removing the TV from the child's bedroom, using (1) motivational coaching at home and by phone, (2) mailed educational materials, and (3) text messages. Control subjects were mailed materials focused on child development. MAIN OUTCOMES AND MEASURES Change in parent report of frequency of family meals (times/wk), child sleep duration (hours/d), child weekday and weekend day TV viewing (hours/d), and the presence of a TV in the room where the child slept from baseline to 6 months. A secondary outcome was change in age- and sex-adjusted body mass index (calculated as weight in kilograms divided by height in meters squared). RESULTS Compared with control subjects, intervention participants had increased sleep duration (0.75 hours/d; 95% CI, 0.06 to 1.44; P =.03), greater decreases in TV viewing on weekend days (-1.06 hours/d; 95% CI, -1.97 to -0.15; P =.02), and decreased body mass index (-0.40; 95% CI, -0.79 to 0.00; P =.05). No significant intervention effect was found for the presence of a TV in the room where the child slept or family meal frequency. CONCLUSIONS AND RELEVANCE Our results suggest that promoting household routines, particularly increasing sleep duration and reducing TV viewing, may be an effective approach to reduce body mass index among low-income, racial/ethnic minority children. Longer-term studies are needed to determine maintenance of behavior change. C1 [McDonald, Julia; O'Brien, Ashley; Taveras, Elsie M.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA. [McDonald, Julia; O'Brien, Ashley; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Taveras, Elsie M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Haines, Jess] Univ Guelph, Dept Family Relat & Appl Nutr, Guelph, ON N1G 2W1, Canada. [Sherry, Bettylou] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Bottino, Clement J.; Schmidt, Marie Evans] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Schmidt, Marie Evans] Childrens Hosp Boston, Ctr Media & Child Hlth, Boston, MA USA. RP Taveras, EM (reprint author), Massachusetts Gen Hosp Children, Div Gen Pediat, Dept Pediat, 100 Cambridge St,15th Fl,Mail Code M100C1570, Boston, MA 02114 USA. EM etaveras@partners.org FU Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion (Prevention Research Centers) [1U48DP00194] FX This work was supported by the Centers for Disease Control and Prevention and the National Center for Chronic Disease Prevention and Health Promotion (Prevention Research Centers grant 1U48DP00194). NR 45 TC 49 Z9 49 U1 7 U2 49 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD NOV PY 2013 VL 167 IS 11 BP 1072 EP 1079 DI 10.1001/jamapediatrics.2013.2356 PG 8 WC Pediatrics SC Pediatrics GA 291PX UT WOS:000329842300021 PM 24019074 ER PT J AU Studnicki, J Ekezue, BF Tsulukidze, M Honore, P Moonesinghe, R Fisher, J AF Studnicki, James Ekezue, Bola F. Tsulukidze, Maka Honore, Peggy Moonesinghe, Ramal Fisher, John TI Disparity in Race-Specific Comorbidities Associated With Central Venous Catheter-Related Bloodstream Infection (AHRQ-PSI7) SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE racial disparity; patient safety; comorbidities ID PATIENT SAFETY INDICATORS; LENGTH-OF-STAY; ADVERSE EVENTS; HEART-FAILURE; ADMINISTRATIVE DATA; RACIAL DISPARITIES; WEIGHT-LOSS; HOSPITALS; LESSONS; TIME AB Studies of racial disparities in hospital-level patient safety outcomes typically apply a race-common approach to risk adjustment. Risk factors specific to a minority population may not be identified in a race-common analysis if they represent only a small percentage of total cases. This study identified patient comorbidities and characteristics associated with the likelihood of a venous catheter-related bloodstream infection (Agency for Healthcare Research and Quality Patient Safety Indicator 7 [PSI7]) separately for blacks and whites using race-specific logistic regression models. Hospitals were ranked by the racial disparity in PSI7 and segmented into 4 groups. The analysis identified both black- and white-specific risk factors associated with PSI7. Age showed race-specific reverse association, with younger blacks and older whites more likely to have a PSI7 event. These findings suggest the need for race-specific covariate adjustments in patient outcomes and provide a new context for examining racial disparities. C1 [Studnicki, James; Ekezue, Bola F.; Tsulukidze, Maka; Fisher, John] Univ N Carolina, Charlotte, NC 28223 USA. [Honore, Peggy] US Dept HHS, Rockville, MD USA. [Moonesinghe, Ramal] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ekezue, BF (reprint author), Univ N Carolina, Dept Publ Hlth Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA. EM bekezue@uncc.edu FU Office of the Secretary, US Department of Health and Human Services, Offices of Healthcare Quality and Minority Health [OS58124] FX The authors received the following financial support for the research, authorship, and/or publication of this article: This study was partially supported by the Office of the Secretary, US Department of Health and Human Services, Offices of Healthcare Quality and Minority Health (Agreement # OS58124). NR 28 TC 2 Z9 2 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 EI 1555-824X J9 AM J MED QUAL JI Am. J. Med. Qual. PD NOV PY 2013 VL 28 IS 6 BP 525 EP 532 DI 10.1177/1062860613480826 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 286SX UT WOS:000329490100002 PM 23526359 ER PT J AU Voramongkol, N Naiwatanakul, T Punsuwan, N Kullerk, N Lolekha, R Sarika, P Pattarakulwanich, S McConnell, MS AF Voramongkol, Nipunporn Naiwatanakul, Thananda Punsuwan, Niramon Kullerk, Nareeluck Lolekha, Rangsima Sarika, Pattanasin Pattarakulwanich, Somsak McConnell, Michelle S. TI COMPLIANCE WITH AND OUTCOMES OF CD4-BASED NATIONAL GUIDELINES FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV FOR THAILAND, 2006-2007 SO SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH LA English DT Article DE PMTCT; HAART; early infant diagnosis; policy compliance; Thailand ID PROGRAM; WOMEN AB The 2006 Thailand national prevention of mother-to-child transmission of HIV (PMTCT) guidelines recommended antiretroviral (ARV) regimen use during antenatal care (ANC) be based on CD4 results: highly active antiretroviral therapy (HAART) should be used for a CD4 <200 cells/mm(3) and zidovudine/single-dose nevirapine should be used for a CD4 count 200 cell/mm(3). We evaluated compliance with and outcomes of these guidelines. We conducted a retrospective chart review of HIV-infected women and their infants born during October 2006 - December 2007 at 27 hospitals in 11 provinces of Thailand. The infant HIV-infection status was determined using laboratory test results and death reports. Mother-infant pairs were classified as fully, partially, or non-compliant with PMTCT guidelines based on CD4 testing history and ARV received. Factors associated with compliance were analyzed using univariate and multivariate generalized estimating equations (GEE). Among 875 mother-infant pairs reviewed, 387 mothers (44%) had ANC CD4 testing done, of whom 75 (19%) had a CD4 count <200 cells/mm(3). Proportions of pairs fully, partially and non-compliant with guidelines were 38, 34 and 28%, respectively. A definitive infant HIV-infection status was determined in 578 infants (66%). The overall mother-to-child transmission (MTCT) rate was 5.1% [95% confidence interval (95% (CI): 3.8-6.9] and the MTCT rates for the fully, partially and non-compliant groups were 1.2% (95% CI: 0.43.3), 6.0% (95%CI: 3.7-9.5) and 9.5% (95% CI: 6.2-14.0; p<0.001). Factors associated with compliance were: having ANC, awareness of the mothers' HIV status before delivery, and having first ANC prior to 24 weeks gestation. Compliance with the 2006 national PMTCT guidelines was low, and the MTCT rates were high among non-and partially compliant mother-infant pairs. The simplified PMTCT guidelines introduced in 2010, might increase compliance with and improve outcomes for Thailand's PMTCT program. C1 [Voramongkol, Nipunporn; Kullerk, Nareeluck; Pattarakulwanich, Somsak] Minist Publ Hlth, Dept Hlth, Nonthaburi, Thailand. [Naiwatanakul, Thananda; Lolekha, Rangsima; Sarika, Pattanasin; McConnell, Michelle S.] Thailand Minist Publ Hlth US CD Collaborat, Global AIDS Program, Thailand Asia Reg Off, Nonthaburi, Thailand. [Naiwatanakul, Thananda; Lolekha, Rangsima; Sarika, Pattanasin; McConnell, Michelle S.] CDC Southeast Asia Reg Off, Nonthaburi, Thailand. [Punsuwan, Niramon] Minist Publ Hlth, Dept Dis Control, Bur Epidemiol, Nonthaburi, Thailand. [McConnell, Michelle S.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. RP Naiwatanakul, T (reprint author), Thailand Minist Publ Hlth US CD Collaborat, Global AIDS Program, Thailand Asia Reg Off, Nonthaburi, Thailand. EM job8018@yahoo.com; tdm6@th.cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through CDC/DGHA under Thai Ministry of Public Health [1U2G GH000616] FX The authors gratefully thank Dr Sompong Sakulisapiyaporn, Department of Health for his leadership and support. We also thank Dr Kenneth Katz and Dr Mitch Wolfe, GAP Thailand/Asia Regional Office and the US CDC for their review and input for this manuscript. Special thanks to the evaluation teams and hospitals that participated in this program evaluation. This research was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC/DGHA under the terms of Cooperative Agreement with the Thai Ministry of Public Health #1U2G GH000616. NR 19 TC 2 Z9 2 U1 0 U2 0 PU SOUTHEAST ASIAN MINISTERS EDUC ORGANIZATION PI BANGKOK PA SEAMEO-TROPMED, 420-6 RAJVITHI RD,, BANGKOK 10400, THAILAND SN 0125-1562 J9 SE ASIAN J TROP MED JI Southeast Asian J. Trop. Med. Public Health PD NOV PY 2013 VL 44 IS 6 BP 997 EP 1009 PG 13 WC Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine SC Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine GA 286NN UT WOS:000329476100008 PM 24450237 ER PT J AU Freedman, AM Kuester, SA Jernigan, J AF Freedman, Ariela M. Kuester, Sarah A. Jernigan, Jan TI Evaluating Public Health Resources: What Happens When Funding Disappears? SO PREVENTING CHRONIC DISEASE LA English DT Article ID SUSTAINABILITY; PROGRAM; CONSEQUENCES; PREVENTION; FLORIDA; STATES; CUTS AB Introduction Although various factors affect the sustainability of public health programs, funding levels can influence many aspects of program continuity. Program evaluation in public health typically does not assess the progress of initiatives after discontinuation of funding. The objective of this study was to describe the effect of funding loss following expiration of a 5-year federal grant awarded to state health departments for development of statewide obesity prevention partnerships. Methods The study used qualitative methods involving semistructured key informant interviews with state health departments. Data were analyzed using thematic analysis for effect of funding loss on staffing, programs, partnerships, and implementation of state plans. Results Many of the programs that continued to run after the grant expired operated at reduced capacity, either reaching fewer people or conducting fewer program activities for the same population. Although many states were able to leverage funding from other sources, this shift in funding source often resulted in priorities changing to meet new funding requirements. Evaluation capacity suffered in all states. Nearly all states reported losing infrastructure and capacity to communicate widely with partners. All states reported a severe or complete loss of their ability to provide training and technical assistance to partners. Despite these reduced capacities, states reported several key resources that facilitated continued work on the state plan. Conclusions Decisions regarding continuation of funding are often dependent on budget constraints, evidence of success, and perceived ability to succeed in the future. Evaluating public health funding decisions may help guide development of best practice strategies for supporting long-term program success. C1 [Kuester, Sarah A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Freedman, Ariela M.] Teach Amer, Atlanta, GA USA. [Jernigan, Jan] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Kuester, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS-F77, Atlanta, GA 30341 USA. EM skuester@cdc.gov FU CDC's Division of Nutrition, Physical Activity, and Obesity FX CDC's Division of Nutrition, Physical Activity, and Obesity provided funding for this study. NR 23 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2013 VL 10 AR 130130 DI 10.5888/pcd10.130130 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285LK UT WOS:000329395300009 ER PT J AU Moore, LV AF Moore, Latetia V. TI Supporting Healthful Eating Through Retail Environmental Change: Communities Putting Prevention to Work SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material ID FOOD ENVIRONMENT; AVAILABILITY C1 Ctr Dis Control & Prevent, Nutr Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Moore, LV (reprint author), Ctr Dis Control & Prevent, Nutr Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F77, Atlanta, GA 30341 USA. EM lvmoore@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2013 VL 10 AR 130166 DI 10.5888/pcd10.130166 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285LK UT WOS:000329395300008 ER PT J AU Wang, BH He, MF Wang, LM Engelgau, MM Zhao, WH Wang, LH AF Wang, Baohua He, Minfu Wang, Limin Engelgau, Michael M. Zhao, Wenhua Wang, Linhong TI Breast Cancer Screening Among Adult Women in China, 2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID SERVICES TASK-FORCE; RURAL CHINA; HEALTH; COUNTRIES; TRIAL AB Introduction Breast cancer is the most frequently diagnosed type of cancer among women in China. However, China does not have a national screening program or national screening guidelines. Little information on participation in breast cancer screening among Chinese women is available. Methods We used data from the 2010 China Chronic Disease and Risk Factor Surveillance System that included 53,513 women aged 18 years or older. Women were asked about breast cancer screening participation (any type of screening method), and we examined screening participation rates. We adjusted estimates and performed multivariable logistic regression to adjust for potential confounders. Results Overall, 21.7% (95% confidence interval [CI], 19.2%-24.2%) of respondents reported previous breast cancer screening. The participation rates were highest among women aged 30 to 39 years (30.7%; 95% CI, 26.9%-34.4%) and lowest among women 70 years or older (6.3%; 95% CI, 5.1%-7.6%). Compared with women living in the western region, women in the eastern region were 1.5 times more likely to be screened (adjusted odds ratio [On 1.5; 95% CI, 1.2-2.0). Compared with women without insurance, women with urban insurance were more likely to be screened (prevalence ratio = 2.6; 95% CI, 2.3-3.0) and be screened within the last 2 years (OR = 1.3; 95% CI, 1.0-1.7; P = .04). Conclusion Breast cancer screening participation rates among Chinese women were low and varied greatly by age, region, and insurance status. Comprehensive and prioritized strategies are needed to improve breast cancer screening participation among older women, those without medical insurance, and those living in the west. C1 [Wang, Baohua; He, Minfu; Wang, Limin; Zhao, Wenhua] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Engelgau, Michael M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Wang, LH (reprint author), 27 Nanwei Rd, Beijing 100050, Peoples R China. EM linhong@chinawch.org.cn FU Ministry of Health of the People's Republic of China FX This study was funded by Ministry of Health of the People's Republic of China. We thank all of the participants for taking part in this study. We are grateful to all related provincial and local health administrative departments, the US Centers for Disease Control and Prevention (CDC), and more than 2,000 field interviewers for their support and hard work. We are grateful for important suggestions for the article from Saraiya Mona and Li Jun from US CDC, as well as Ann Chao from the US National Cancer Institute, as well to Cai Ying, US CDC, for assistance with final manuscript preparation. There are no conflicts of interest relevant to this article. This article is not intended to provide medical advice, diagnosis, or treatment. NR 30 TC 2 Z9 2 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2013 VL 10 AR 130136 DI 10.5888/pcd10.130136 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285LK UT WOS:000329395300002 ER PT J AU Hsiang, MS Hwang, J Tao, AR Liu, YB Bennett, A Shanks, GD Cao, J Kachur, SP Feachem, RGA Gosling, RD Gao, Q AF Hsiang, Michelle S. Hwang, Jimee Tao, Amy R. Liu, Yaobao Bennett, Adam Shanks, George Dennis Cao, Jun Kachur, Stephen Patrick Feachem, Richard G. A. Gosling, Roly D. Gao, Qi TI Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China SO MALARIA JOURNAL LA English DT Article DE Malaria elimination; Mass drug administration; Primaquine; Plasmodium vivax; China ID ANTIMALARIAL-DRUGS; HENAN PROVINCE; RADICAL CURE; TRANSMISSION; PRIMAQUINE; AREAS; PYRIMETHAMINE; POPULATION; STRATEGIES; VENEZUELA AB Background: Recent progress in malaria control has caused renewed interest in mass drug administration (MDA) as a potential elimination strategy but the evidence base is limited. China has extensive experience with MDA, but it is not well documented. Methods: An ecological study was conducted to describe the use of MDA for the control and elimination of Plasmodium vivax in Jiangsu Province and explore the association between MDA and malaria incidence. Two periods were focused on: 1973 to 1983 when malaria burden was high and MDA administered to highly endemic counties province-wide, and 2000 to 2009, when malaria burden was low and a focal approach was used in two counties. All available data about the strategies implemented, MDA coverage, co-interventions, incidence, and adverse events were collected and described. Joinpoint analysis was used to describe trends in incidence and the relationship between MDA coverage and incidence was explored in negative binomial regression models. Results: From 1973 to 1983, MDA with pyrimethamine and primaquine was used on a large scale, with up to 30 million people in target counties covered in a peak year (50% of the total population). Joinpoint analyses identified declines in annual incidence, -56.7% (95% CI -75.5 to -23.7%) from 1973-1976 and -12.4% (95% CI -24.7 to 2.0%) from 1976-1983. Population average negative binomial models identified a relationship between higher total population MDA coverage and lower monthly incidence from 1973-1976, IRR 0.98 (95% CI 0.97 to 1.00), while co-interventions, rainfall and GDP were not associated. From 2000-2009, incidence in two counties declined (annual change -43.7 to -14.0%) during a time when focal MDA using chloroquine and primaquine was targeted to villages and/or individuals residing near passively detected index cases (median 0.04% of total population). Although safety data were not collected systematically, there were rare reports of serious but non-fatal events. Conclusions: In Jiangsu Province, China, large-scale MDA was implemented and associated with declines in high P. vivax malaria transmission; a more recent focal approach may have contributed to interruption of transmission. MDA should be considered a potential key strategy for malaria control and elimination. C1 [Hsiang, Michelle S.; Hwang, Jimee; Feachem, Richard G. A.; Gosling, Roly D.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Hsiang, Michelle S.] Univ Calif San Francisco, Dept Pediat, UCSF Benioff Childrens Hosp, San Francisco, CA USA. [Hwang, Jimee; Kachur, Stephen Patrick] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Tao, Amy R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Liu, Yaobao; Cao, Jun; Gao, Qi] Jiangsu Inst Parasit Dis, Key Lab Parasit Dis Control & Prevent, Jiangsu Prov Key Lab Parasite Mol Biol, Minist Hlth, Wuxi, Peoples R China. [Bennett, Adam] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Syst & Dev, New Orleans, LA USA. [Shanks, George Dennis] Australian Army Inst, Enoggera, Qld, Australia. RP Hsiang, MS (reprint author), Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. EM hsiangm@peds.ucsf.edu; gaoqi54@hotmail.com RI Shanks, George Dennis/F-4056-2014 OI Shanks, George Dennis/0000-0001-5763-8660 FU Bill and Melinda Gates Foundation; UCSF Pathways Funding Committee Research Fellowship program; National Institutes of Health/National Institute of Allergy and Infectious Diseases [P0045532]; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Fellowship Award [P0049395]; Centers for Diseases Control and Prevention; Jiangsu Province's Medical High Tech Platform [ZX201108]; Jiangsu Science and Technology Department [BM2009902]; President's Malaria Initiative; Australian Defence Force FX This work has been an output of the Asia Pacific Malaria Elimination Network (APMEN) as well as the Malaria Elimination Group (MEG). Funding for the work was provided through a grant from the Bill and Melinda Gates Foundation to the UCSF Global Heath Group (MSH, RGAF, RG) as well as a grant from the UCSF Pathways Funding Committee Research Fellowship program (ART). MSH is additionally funded by a National Institutes of Health/National Institute of Allergy and Infectious Diseases K23 grant (P0045532) and a Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Fellowship Award (P0049395). JH and SPK are funded by the Centers for Diseases Control and Prevention. YL, JC, and QG are funded by Jiangsu Province's Medical High Tech Platform (ZX201108) and Jiangsu Science and Technology Department (BM2009902). AB is funded by a grant from the President's Malaria Initiative. GDS is funded by the Australian Defence Force. The paper represents the views of the authors and not the opinion or policy of their organization or the funders. NR 55 TC 21 Z9 21 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD NOV 1 PY 2013 VL 12 AR 383 DI 10.1186/1475-2875-12-383 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 281LL UT WOS:000329102900001 PM 24175930 ER PT J AU Rivailler, P Moisy, D Naffakh, N AF Rivailler, Pierre Moisy, Dorothee Naffakh, Nadia TI Multiple hosts and Influenza A viruses genetic mixing SO VIROLOGIE LA French DT Review DE influenza viruses; interspecies transmission; genetic mixing ID AVIAN INFLUENZA; SWINE INFLUENZA; RESPIRATORY-DISEASE; UNITED-STATES; TRANSMISSION; H5N1; NEURAMINIDASE; HUMANS; INFECTION; DOGS AB Influenza A viruses have a segmented, negative-stranded RNA genome. These viruses are classified according to the antigenic properties of the two glycoproteins, expressed on the surface of the virus particles, the hemagglutinin (HA or H) and the neuraminidase (NA or N). To date, 17 H and 10N have been described and 116 HxNy combinations or subtypes reported. Except for the H17N10 subtype recently identified in bats, all identified subtypes have been identified in wild aquatic birds. These birds are considered to be the natural reservoir of influenza A viruses, from which some subtypes can be transmitted to other bird and mammal species, including humans. Interspecies transmissions seem to occur regularly, and can occasionally lead to the adaptation and stable establishment of a new viral lineage in a given species. This review recalls the genetic diversity of avian, swine and human influenza viruses and focuses on lesser-known influenza A viruses, identified in horses, dogs and very recently in bats. It discusses the genetic mixing that may result from interspecies transmission, and the associated risks of epizootics, zoonosis and pandemics. C1 [Rivailler, Pierre] Univ S Carolina, Dept Biol Sci, Columbia, SC 29205 USA. [Moisy, Dorothee; Naffakh, Nadia] Inst Pasteur, Unite Genet Mol Virus ARN, Dept Virol, F-75015 Paris, France. [Moisy, Dorothee; Naffakh, Nadia] CNRS, UMR 3569, F-75015 Paris, France. [Moisy, Dorothee; Naffakh, Nadia] Univ Paris Diderot, Sorbonne Paris Cite, Unite Genet Mol Virus ARN, EA302, F-75015 Paris, France. RP Rivailler, P (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM nadia.naffakh@pasteur.fr NR 56 TC 0 Z9 0 U1 1 U2 20 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 1267-8694 J9 VIROLOGIE JI Virologie PD NOV-DEC PY 2013 VL 17 IS 6 BP 387 EP 400 DI 10.1684/vir.2013.0540 PG 14 WC Virology SC Virology GA 280PX UT WOS:000329044300002 ER PT J AU Gounder, P Beers, R Bornschlegel, K Hinterland, K Batter, S AF Gounder, Prabhu Beers, Richard Bornschlegel, Katherine Hinterland, Kinjia Batter, Sharon TI Medication injection safety knowledge and practices among anesthesiologists: New York State, 2011 SO JOURNAL OF CLINICAL ANESTHESIA LA English DT Article DE Anesthesiologists: bloodbome pathogens; Drug injection practices; Infection control; Injection contamination; Medication injeotion safety; Patient safety ID HEALTH-CARE SETTINGS; HEPATITIS-C VIRUS; UNITED-STATES; NOSOCOMIAL TRANSMISSION AB Study Objective: To survey anesthesiologists to assess medication injection safety knowledge and practices, and to improve infection control programs of the New York City Department of Health and Mental Hygiene and the New York State Society of Anesthesiologists (NYSSA). Design: Survey instrument. Setting: Scientific Educational and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA. Measurements: A confidential, 23-question survey was emailed to a total of 2,310 NYSSA members. Data from the survey were culled from the responses of NYSSA members who practiced in New York State only. Main Results: Of the 607 survey respondents, 595 met inclusion criteria (response rate 26%). Of these, 94% to 99% correctly answered 4 categories of questions about injection-contamination mechanisms. Respondents reported unacceptable practices (eg, not using a new needle and syringe for each new patient [3%]; not using a new needle and syringe to access medication vials [28%]; and combining vial content leftovers [11%]). Resident physicians reported these unacceptable practices more often than attending physicians. Use of medication vials for multiple patients (permitted for multi-dose vials but a potentially high-risk practice) was reported by 49% of respondents and was more common among those who worked in outpatient settings. Reported barriers to using a new medication vial for each new patient were medication shortages (44%), reduction of waste (44%), and cost (27%). Unacceptable or potentially high-risk practices were more common among respondents who reported >= one barrier. Conclusions: Although they were not necessarily representative of all anesthesiologists in New York State, unacceptable or high-risk injection practices were common among respondents despite widespread knowledge regarding injection-contamination mechanisms. System barriers contribute to the use of medication vials for multiple patients. Published by Elsevier Inc. C1 [Gounder, Prabhu] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Gounder, Prabhu; Bornschlegel, Katherine; Batter, Sharon] New York City Dept Hlth & Mental Hyg, Bur Communicable Dis, Queens, NY 11101 USA. [Beers, Richard] Vet Adm Med Ctr, Dept Anesthesiol, Syracuse, NY 13210 USA. [Beers, Richard] SUNY Upstate Med Univ, Dept Anesthesiol, Syracuse, NY 13210 USA. [Hinterland, Kinjia] New York City Dept Hlth & Mental Hyg, Bur Epidemiol Serv, Queens, NY 11101 USA. RP Gounder, P (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM iym4@cdc.gov FU New York City Department of Health and Mental Hygiene; New York State Society of Anesthesiologists FX Supported by grants from the New York City Department of Health and Mental Hygiene and the New York State Society of Anesthesiologists. NR 17 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0952-8180 EI 1873-4529 J9 J CLIN ANESTH JI J. Clin. Anesth. PD NOV PY 2013 VL 25 IS 7 BP 521 EP 528 DI 10.1016/j.jclinane.2013.04.013 PG 8 WC Anesthesiology SC Anesthesiology GA 275EK UT WOS:000328658900002 PM 24008193 ER PT J AU Wirth, JP Nichols, E Mas'd, H Barham, R Johnson, QW Serdula, M AF Wirth, James P. Nichols, Erin Mas'd, Hanan Barham, Rawhieh Johnson, Quentin W. Serdula, Mary TI External Mill Monitoring of Wheat Flour Fortification Programs: An Approach for Program Managers Using Experiences from Jordan SO NUTRIENTS LA English DT Article DE fortification; external monitoring; wheat flour; compliance; micronutrients AB The fortification of wheat flour with micronutrients is a common strategy to increase vitamin and mineral intake. While wheat flour mills are often inspected by agencies affiliated with national ministries to ensure compliance with national fortification standards, few countries use data derived from these inspections to construct an external monitoring system for use in program management and evaluation. The primary objective of this paper is to assess the performance of the external monitoring system utilized in Jordan according to the US Centers for Disease Control and Prevention's Updated Guidelines for Evaluating Public Health Surveillance Systems. A secondary objective is to present mill monitoring results from 2009 to 2010 in order to demonstrate the data generated by the system. The review concludes that the data required for the system is representative, simple to collect, and can be collected in a flexible manner. The external monitoring system is acceptable to participating agencies and millers and is stable due to mandatory fortification legislation which provides the legal framework for external monitoring. Data on production of fortified flour and utilization of premix can be provided in a timely manner, but on-site mill monitoring and flour sample collection are more challenging due to resource constraints. The frequent collection of a small number of indicators can provide fortification program managers with timely information with which to base decisions. Jordan's external monitoring system successfully documented the performance of each mill and the entire flour fortification program, and can serve as a model for other national fortification programs considering external monitoring approaches. C1 [Wirth, James P.] GroundWork LLC, CH-1299 Crans Pres Celigny, Switzerland. [Wirth, James P.] Global Alliance Improved Nutr, CH-1211 Geneva, Switzerland. [Nichols, Erin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Nutr Phys Act & Obes, US Publ Hlth Serv, Atlanta, GA 30333 USA. [Mas'd, Hanan; Barham, Rawhieh] Minist Hlth, Dept Noncommunicable Dis, Div Nutr, Amman 11118, Jordan. [Johnson, Quentin W.] Flour Fortificat Initiat, Training & Tech Support Grp, Atlanta, GA 30322 USA. [Serdula, Mary] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Wirth, JP (reprint author), GroundWork LLC, 40B Les Landes, CH-1299 Crans Pres Celigny, Switzerland. EM james@groundworkhealth.org; igd1@cdc.gov; Hanan-MoH@live.com; majeda_barham@hotmail.com; quentin@quican.com; mks1@cdc.gov FU Global Alliance for Improved Nutrition; Jordanian Ministry of Health FX The authors would like to acknowledge Nicolas Tsikhlakis for providing regular feedback on the performance of the system from a miller's perspective, to Barbara Macdonald for support during the collection of mill monitoring data, and to Svenja Jungjohann for comments on draft versions of this manuscript. Financial support to refine Jordan's mill monitoring system was provided by the Global Alliance for Improved Nutrition. Financial support for the implementation of the mill monitoring system is provided by the Jordanian Ministry of Health. NR 18 TC 2 Z9 2 U1 3 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6643 J9 NUTRIENTS JI Nutrients PD NOV PY 2013 VL 5 IS 11 BP 4741 EP 4759 DI 10.3390/nu5114741 PG 19 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 274TH UT WOS:000328628600030 PM 24284616 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI DEVELOPING A NEW, NATIONAL APPROACH TO SURVEILLANCE FOR VENTILATOR-ASSOCIATED EVENTS SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article AB This article is an executive summary of a report from the Centers for Disease Control and Prevention Ventilator-Associated Pneumonia Surveillance Definition Working Group, entitled "Developing a New, National Approach to Surveillance for Ventilator-Associatied Events," C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY 12237 USA. [VanAntwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov FU Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; CDC; US Food and Drug Administration; Office of the National Coordinator for Health Information Technology; National Institute of General Medical Sciences; Merck; Cerexa; bioMeriuex; PurThread Technologies; Pfizer; Society of Healthcare Epidemiologists of America; Elsevier; McGraw-Hill; Up-To-Date; Jones and Bartlett FX This work was supported by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. Dr Klompas received grant support from the CDC, US Food and Drug Administration, and the Office of the National Coordinator for Health Information Technology. Dr Balk received grant support from the CDC and bioMerieux for participation in the EPIC CAP study (CDC) and the Procalcitonin in ICU antibiotic stewardship study (CDC and bioMerieux). Dr Deutschman received grant support from the National Institute of General Medical Sciences. Dr Diekema received grant support from Merck, Cerexa, bioMeriuex, PurThread Technologies, and Pfizer. Ms Greene consults for INC. Dr. Hess consulted for Philips Respironics, ResMed, Pari, and Breathe and received honoraria from Covidien and Maquet. Ms Greene lectured for Premier, Advanced Sterilization Products, and APIC. Dr Burns lectured for AACN. Ms Greene presented speeches for Covidien and Maquet. Dr Septimus received an honorarium for a lecture. Dr. Klompas received support from the Society of Healthcare Epidemiologists of America for the development of educational presentations. Dr Deutschman received royalties from Elsevier for the textbook, Evidence-based Practice of Critical Care Medicine. Dr Burns receives royalties from McGraw-Hill for books endorsed by AACN. Ms Greene receives royalties from Up-To-Date, Jones and Bartlett, and McGraw-Hill. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 2 TC 10 Z9 10 U1 1 U2 3 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 EI 1937-710X J9 AM J CRIT CARE JI Am. J. Crit. Care PD NOV 1 PY 2013 VL 22 IS 6 BP 469 EP 473 DI 10.4037/ajcc2013893 PG 5 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 268KB UT WOS:000328167700007 PM 24186816 ER PT J AU Anderson, L Vandenberg, AE Hunter, RH Hooker, SP Bryant, LL Satariano, W AF Anderson, L. Vandenberg, A. E. Hunter, R. H. Hooker, S. P. Bryant, L. L. Satariano, W. TI A CONCEPTUAL FRAMEWORK FOR COMMUNITY WAYFINDING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Anderson, L.; Vandenberg, A. E.; Hunter, R. H.; Hooker, S. P.; Bryant, L. L.; Satariano, W.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 105 EP 105 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102015 ER PT J AU Vandenberg, AE Hunter, R Anderson, L Bryant, LL Hooker, SP Satariano, W Toyoji, M AF Vandenberg, A. E. Hunter, R. Anderson, L. Bryant, L. L. Hooker, S. P. Satariano, W. Toyoji, M. TI CROSS-DISCIPLINARY RESEARCH PERSPECTIVES ON COMMUNITY WAYFINDING AND OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Vandenberg, A. E.] Emory Univ, Dept Med, Div Gen Med & Geriatr, Atlanta, GA 30322 USA. [Hunter, R.] Univ N Carolina, Chapel Hill, NC USA. [Anderson, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bryant, L. L.] Univ Colorado, Denver, CO 80202 USA. [Hooker, S. P.] Arizona State Univ, Phoenix, AZ USA. [Satariano, W.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Toyoji, M.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 106 EP 106 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102016 ER PT J AU Sengupta, M Park-Lee, E Harris-Kojetin, L AF Sengupta, M. Park-Lee, E. Harris-Kojetin, L. TI THE SUPPLY AND USE OF PAID, REGULATED LONG-TERM CARE SERVICES: UNITED STATES, 2012 SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sengupta, M.; Park-Lee, E.; Harris-Kojetin, L.] CDC, NCHS, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 215 EP 216 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103064 ER PT J AU Stevens, J Rudd, RA AF Stevens, J. Rudd, R. A. TI THE IMPACT OF A DECREASING TREND IN US HIP FRACTURE RATES ON FUTURE HIP FRACTURE ESTIMATES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stevens, J.; Rudd, R. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 366 EP 366 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104316 ER PT J AU Espeland, MA Brancati, FL Evans, M Gregg, E Kahn, SE Lewis, CE Pi-Sunyer, X Wing, R AF Espeland, M. A. Brancati, F. L. Evans, M. Gregg, E. Kahn, S. E. Lewis, C. E. Pi-Sunyer, X. Wing, R. TI DESIGN AND PRIMARY FINDINGS OF THE ACTION FOR HEALTH IN DIABETES TRIAL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Espeland, M. A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Brancati, F. L.] Johns Hopkins Sch Med, Baltimore, MD USA. [Evans, M.] NIDDK, Bethesda, MD 20892 USA. [Gregg, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. [Lewis, C. E.] Univ Alabama Birmingham, Birmingham, AL USA. [Pi-Sunyer, X.] Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY USA. [Wing, R.] Miriam Hosp, Providence, RI 02906 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 388 EP 388 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104429 ER PT J AU Hazuda, HP Gaussoin, SA Peters, AL Van Dorsten, B Wadden, TA Yanovski, SZ Zhang, P Rubin, R AF Hazuda, H. P. Gaussoin, S. A. Peters, A. L. Van Dorsten, B. Wadden, T. A. Yanovski, S. Z. Zhang, P. Rubin, R. TI BENEFITS OF INTENSIVE LIFESTYLE INTERVENTION ON DEPRESSION AND HEALTH RELATED QUALITY OF LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gaussoin, S. A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Peters, A. L.] Roybal Comprehens Hlth Ctr, Los Angeles, CA USA. [Van Dorsten, B.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA. [Wadden, T. A.] Univ Penn, Philadelphia, PA 19104 USA. [Yanovski, S. Z.] NIDDK, Bethesda, MD 20892 USA. [Zhang, P.] Ctr Dis Control, Atlanta, GA 30333 USA. [Rubin, R.] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 389 EP 389 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104431 ER PT J AU Albert, M McCaig, LF AF Albert, M. McCaig, L. F. TI INJURY-RELATED EMERGENCY DEPARTMENT VISITS BY OLDER ADULTS; UNITED STATES, 2009-2010 SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Albert, M.; McCaig, L. F.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 434 EP 434 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105137 ER PT J AU Chari, KA Levant, S DeFrances, C AF Chari, K. A. Levant, S. DeFrances, C. TI HOSPITAL CARE FOR PATIENTS AGED 85 YEARS AND OLDER, 2000-2010 SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chari, K. A.; Levant, S.; DeFrances, C.] CDC, Div Hlth Care Stat, NCHS, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 434 EP 434 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105135 ER PT J AU McCaig, LF AF McCaig, L. F. TI OVERVIEW OF THE NATIONAL HOSPITAL AMBULATORY MEDICAL CARE SURVEY (NHAMCS) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McCaig, L. F.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 434 EP 434 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105136 ER PT J AU Vuong, J Wang, X Theodore, JM Whitmon, J de Leon, PG Mayer, LW Carlone, GM Romero-Steiner, S AF Vuong, Jeni Wang, Xin Theodore, Jordan M. Whitmon, Jennifer Gomez de Leon, Patricia Mayer, Leonard W. Carlone, George M. Romero-Steiner, Sandra TI Absence of high molecular weight proteins 1 and/or 2 is associated with decreased adherence among non-typeable Haemophilus influenzae clinical isolates SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID EPITHELIAL-CELLS; UNITED-STATES; HIA GENES; EXPRESSION; ADHESINS; DISEASE; PREVALENCE; ANTIBODIES; PROMOTES; CHILDREN AB High molecular weight (Hmw) proteins 1 and 2, type IV pilin protein (PilA), outer-membrane protein P5 (OmpP5), Haemophilus protein D (Hpd) and Haemophilus adhesive protein (Hap) are surface proteins involved in the adherence of non-typeable Haemophilus influenzae. One hundred clinical isolates were evaluated for the presence of the genes encoding these proteins by PCR and for their adherence capacity (AC) to Detroit 562 nasopharyngeal cells (D562). The majority of isolates were from blood (77/100); other sites were also represented. Confluent D562 monolayers (1.2x10(5) cells per well) were inoculated with standardized minimal infective doses (m.o.i.) of 10(2), 10(3) or 10(4) c.f.u. per well. The AC was categorized as low (<10%) or high (>= 10%) depending on the percentage of c.f.u. adhering per well. All the isolates evaluated showed adherence: 69/100 (69%) demonstrated high adherence, while 31/100 (31%) showed low adherence. Of all the genes evaluated, hmw1A and/or hmw2A were detected in 69/100 (69%) of isolates. The presence of hmw1A and/or hmw2A was associated with increased adherence to D562 cells (P <= 0.001). Dot immunoblots were performed to detect protein expression using mAbs 3D6, AD6 and 10C5. Among the high-adherence isolates (n=69), 72% reacted with 3D6 and 21% with 10C5. Our data indicate that the absence of Hmw1 and/or Hmw2 was associated with decreased adherence to D562 cells. C1 [Vuong, Jeni; Wang, Xin; Theodore, Jordan M.; Whitmon, Jennifer; Mayer, Leonard W.; Carlone, George M.; Romero-Steiner, Sandra] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Atlanta, GA 30333 USA. [Gomez de Leon, Patricia] Univ Nacl Autonoma Mexico, Fac Med, Dept Saude Publ, Mexico City 04510, DF, Mexico. RP Romero-Steiner, S (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Atlanta, GA 30333 USA. EM Ssteiner@cdc.gov OI Romero-Steiner, Sandra/0000-0003-4128-7768 FU Centers for Disease Control and Prevention FX We would like to thank the ABCs team for permission to use their isolates for this study; Dr Amanda Cohn, Dr Elizabeth Briere and Mrs Jessica MacNeil, Centers for Disease Contol and Prevention/Meningitis and Vaccine Preventable Diseases Branch, for assistance with obtaining and selecting ABC isolates and surveillance data; Jim Gathany for his photographic services; and Dr Stephen Barenkamp, St Louis University, St Louis, MO, USA, for donating the mAbs used. This research was supported in part by an appointment to the Emerging Infectious Diseases (EID) Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by the Centers for Disease Control and Prevention. This research was presented in part at the International Conference for Emerging Infectious Diseases, Atlanta, GA, USA, July 11-14, 2010 in a poster format (poster 166). NR 28 TC 3 Z9 3 U1 0 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 EI 1473-5644 J9 J MED MICROBIOL JI J. Med. Microbiol. PD NOV PY 2013 VL 62 BP 1649 EP 1656 DI 10.1099/jmm.0.058222-0 PN 11 PG 8 WC Microbiology SC Microbiology GA 270GG UT WOS:000328306300003 PM 23988628 ER PT J AU Ahmed, S Kim, MH Sugandhi, N Phelps, BR Sabelli, R Diallo, MO Young, P Duncan, D Kellerman, SE AF Ahmed, Saeed Kim, Maria H. Sugandhi, Nandita Phelps, B. Ryan Sabelli, Rachael Diallo, Mamadou O. Young, Paul Duncan, Dana Kellerman, Scott E. CA Interagcy Task Team Prevention & T TI Beyond early infant diagnosis: case finding strategies for identification of HIV-infected infants and children SO AIDS LA English DT Article DE case finding; HIV testing; pediatric HIV; PITC ID SUB-SAHARAN AFRICA; COMMUNITY-HEALTH WORKERS; CLUSTER-RANDOMIZED-TRIAL; THAN 18 MONTHS; ANTIRETROVIRAL THERAPY; PEDIATRIC HIV; COST-EFFECTIVENESS; WESTERN KENYA; UNITED-STATES; IMMUNIZATION CLINICS AB There are 3.4 million children infected with HIV worldwide, with up to 2.6 million eligible for treatment under current guidelines. However, roughly 70% of infected children are not receiving live-saving HIV care and treatment. Strengthening case finding through improved diagnosis strategies, and actively linking identified HIV-infected children to care and treatment is essential to ensuring that these children benefit from the care and treatment available to them. Without attention or advocacy, the majority of these children will remain undiagnosed and die from complications of HIV. In this article, we summarize the challenges of identifying HIV-infected infants and children, review currently available evidence and guidance, describe promising new strategies for case finding, and make recommendations for future research and interventions to improve identification of HIV-infected infants and children. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Ahmed, Saeed; Kim, Maria H.; Sabelli, Rachael] Baylor Coll Med, Clin Ctr Excellence, Lilongwe, Malawi. [Sugandhi, Nandita] Clinton Hlth Access Initiat, New York, NY USA. [Phelps, B. Ryan] United States Agcy Int Dev, Washington, DC USA. [Diallo, Mamadou O.; Young, Paul; Duncan, Dana] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kellerman, Scott E.] Management Sci Hlth, Washington, DC USA. RP Ahmed, S (reprint author), Baylor Coll Med Childrens Fdn Malawi, Tingathe Outreach Program, Private Bag B-397,100 Mzimba Rd,Kamuzu Cent Hosp, Lilongwe 3, Malawi. EM saeeda@bcm.edu FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 106 TC 17 Z9 17 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S235 EP S245 DI 10.1097/QAD.0000000000000099 PG 11 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200012 PM 24361633 ER PT J AU Essajee, SM Arpadi, SM Dziuban, EJ Gonzalez-Montero, R Heidari, S Jamieson, DG Kellerman, SE Koumans, E Ojoo, A Rivadeneira, E Spector, SA Walkowiak, H AF Essajee, Shaffiq M. Arpadi, Stephen M. Dziuban, Eric J. Gonzalez-Montero, Raul Heidari, Shirin Jamieson, David G. Kellerman, Scott E. Koumans, Emilia Ojoo, Atieno Rivadeneira, Emilia Spector, Stephen A. Walkowiak, Helena CA Interagcy Task Team Prevention Tre TI Pediatric treatment 2.0: ensuring a holistic response to caring for HIV-exposed and infected children SO AIDS LA English DT Article ID DRIED BLOOD SPOTS; CLINICAL-OUTCOMES; CARE; DIAGNOSIS; SERVICES; PROGRAM; TRANSMISSION; PREVENTION; INFANTS; TIME AB Treatment 2.0 is an initiative launched by UNAIDS and WHO in 2011 to catalyze the next phase of treatment scale-up for HIV. The initiative defines strategic activities in 5 key areas, drugs, diagnostics, commodity costs, service delivery and community engagement in an effort to simplify treatment, expand access and maximize program efficiency. For adults, many of these activities have already been turned into treatment policies. The recent WHO recommendation to use a universal first line regimen regardless of gender, pregnancy and TB status is a treatment simplification very much in line with Treatment 2.0. But despite that fact that Treatment 2.0 encompasses all people living with HIV, we have not seen the same evolution in policy development for children. In this paper we discuss how Treatment 2.0 principles can be adapted for the pediatric population. There are several intrinsic challenges. The need for distinct treatment regimens in children of different ages makes it hard to define a one size fits all approach. In addition, the fact that many providers are reluctant to treat children without the advice of specialists can hamper decentralization of service delivery. But at the same time, there are opportunities that can be availed now and in the future to scale up pediatric treatment along the lines of Treatment 2.0. We examine each of the five pillars of Treatment 2.0 from a pediatric perspective and present eight specific action points that would result in simplification of pediatric treatment and scale up of HIV services for children. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Essajee, Shaffiq M.] Clinton Hlth Access Initiat, Boston, MA USA. [Arpadi, Stephen M.] Columbia Univ, ICAP, New York, NY USA. [Dziuban, Eric J.; Koumans, Emilia; Rivadeneira, Emilia] CDC, Atlanta, GA 30333 USA. [Gonzalez-Montero, Raul] WHO, CH-1211 Geneva, Switzerland. [Heidari, Shirin] Int AIDS Soc, Geneva, Switzerland. [Jamieson, David G.] Partnership Supply Chain Management, Washington, DC USA. [Kellerman, Scott E.; Walkowiak, Helena] Management Sci Hlth, Washington, DC USA. [Ojoo, Atieno] UNICEF, Copenhagen, Denmark. [Spector, Stephen A.] Univ Calif San Diego, San Diego, CA 92103 USA. RP Essajee, SM (reprint author), Clinton Hlth Access Initiat, Boston, MA USA. EM sessajee@clintonhealthaccess.org FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 50 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S215 EP S224 DI 10.1097/QAD.0000000000000091 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200010 PM 24361631 ER PT J AU Ghadrshenas, A Amor, YB Chang, J Dale, H Sherman, G Vojnov, L Young, P Yogev, R AF Ghadrshenas, Anisa Amor, Yanis B. Chang, Joy Dale, Helen Sherman, Gayle Vojnov, Lara Young, Paul Yogev, Ram CA Interagcy Task Team Prevention & T TI Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda SO AIDS LA English DT Article DE case-finding; early infant diagnosis; PCR; pediatrics; prevention of mother-to-child transmission intervention; vertical transmission ID RESOURCE-LIMITED SETTINGS; HIV-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY; EXPOSED INFANTS; POOLED ANALYSIS; SOUTH-AFRICA; TESTS; MORTALITY; PERFORMANCE; COUNTRIES AB Background:Prevention-of-mother-to-child-transmission (PMTCT) programs have made it possible to achieve dramatic reductions in the rate of vertical HIV transmission. However, high attrition, particularly after delivery, has limited the impact of these interventions for HIV-exposed infants who remain at risk through the end of breastfeeding.Design and methods:A review of current literature on early infant diagnosis (EID) testing and country experience in low-and middle-income countries.Results:While PMTCT programs report reduced rates of infection among infants tested at 2 months of age, too few services are focused on retention of HIV-exposed infants in care. An unacceptably large proportion of HIV-exposed and HIV-infected infants remain unidentified. While the complexities of EID have been simplified with the development of optimized commodities and tools to improve service delivery, the inaccessibility and inadequate uptake of EID services has resulted in lag of care for the millions of HIV-exposed infants who remain unidentified. Coverage of EID testing remains low and there are many HIV- infected infants or at risk of infection who may not enter the health system through PMTCT programs. Waiting for HIV-infected children to present sick is not an adequate strategy for identifying and linking infants to treatment. Several interventions suggest a potential to expand access to EID testing, while more aggressive testing strategies may ensure children can be captured at any point of contact with the health system.Conclusions:Programs focused on preventing vertical transmission need to increase their commitment to child-centric interventions and broaden their measure of success to reflect infants who test negative at the end of the exposure period. This paper argues that EID is a key strategy to retaining HIV-exposed infants through the end of the exposure period, as it provides an opportunity to offer early clinical care and continuous follow up. It is imperative that maternal and child survival programs become sensitized to the urgency of early identification of HIV in infants and their retention in care. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Ghadrshenas, Anisa; Vojnov, Lara] Clinton Hlth Access Initiat, Boston, MA 02127 USA. [Amor, Yanis B.] Columbia Univ, Earth Inst, New York, NY USA. [Chang, Joy; Dale, Helen; Young, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sherman, Gayle] Natl Hlth Lab Serv, Johannesburg, South Africa. [Yogev, Ram] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. RP Ghadrshenas, A (reprint author), Clinton Hlth Access Initiat, 383 Dorchester Ave,Suite 400, Boston, MA 02127 USA. EM AGhadrshenas@clintonhealthaccess.org FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 44 TC 16 Z9 16 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S197 EP S205 DI 10.1097/QAD.0000000000000104 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200008 PM 24361629 ER PT J AU Modi, S Chiu, A Ng'eno, B Kellerman, SE Sugandhi, N Muhe, L AF Modi, Surbhi Chiu, Alex Ng'eno, Bernadette Kellerman, Scott E. Sugandhi, Nandita Muhe, Lulu CA Child Survival Working Grp Interag TI Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings SO AIDS LA English DT Article DE children; HIV; mortality; opportunistic infections ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PNEUMOCOCCAL CONJUGATE VACCINE; XPERT MTB/RIF ASSAY; PULMONARY TUBERCULOSIS; SOUTH-AFRICA; COTRIMOXAZOLE PROPHYLAXIS; INTEGRATED MANAGEMENT; UNITED-STATES; HIV-1-INFECTED CHILDREN AB Objective:Although antiretroviral treatment (ART) has reduced the incidence of HIV-related opportunistic infections among children living with HIV, access to ART remains limited for children, especially in resource-limited settings. This paper reviews current knowledge on the contribution of opportunistic infections and common childhood illnesses to morbidity and mortality in children living with HIV, highlights interventions known to improve the health of children, and identifies research gaps for further exploration.Design and Methods:Literature review of peer-reviewed articles and abstracts combined with expert opinion and operational experience.Results:Morbidity and mortality due to opportunistic infections has decreased in both developed and resource-limited countries. However, the burden of HIV-related infections remains high, especially in sub-Saharan Africa, where the majority of HIV-infected children live. Limitations in diagnostic capacity in resource-limited settings have resulted in a relative paucity of data on opportunistic infections in children. Additionally, the reliance on clinical diagnosis means that opportunistic infections are often confused with common childhood illnesseswhich also contribute to excess morbidity and mortality in these children. Although several preventive interventions have been shown to decrease opportunistic infection-related mortality, implementation of many of these interventions remains inconsistent.Conclusions:In order to reduce opportunistic infection-related mortality, early ART must be expanded, training for front-line clinicians must be improved, and additional research is needed to improve screening and diagnostic algorithms. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Modi, Surbhi; Chiu, Alex] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Chiu, Alex] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, CDC Experience Appl Epidemiol Fellowship, Atlanta, GA 30333 USA. [Ng'eno, Bernadette] Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi, Kenya. [Kellerman, Scott E.] Management Sci Hlth, Arlington, VA USA. [Sugandhi, Nandita] Clinton Hlth Access Initiat, New York, NY USA. [Muhe, Lulu] WHO, CH-1211 Geneva, Switzerland. RP Modi, S (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Pediat HIV Care & Treatment Team, 1600 Clifton Rd NE,MS-E04, Atlanta, GA 30333 USA. EM smodi@cdc.gov FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 87 TC 4 Z9 4 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S159 EP S167 DI 10.1097/QAD.0000000000000080 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200004 PM 24361625 ER PT J AU Phelps, BR Ahmed, S Amzel, A Diallo, MO Jacobs, T Kellerman, SE Kim, MH Sugandhi, N Tam, M Wilson-Jones, M AF Phelps, B. Ryan Ahmed, Saeed Amzel, Anouk Diallo, Mamadou O. Jacobs, Troy Kellerman, Scott E. Kim, Maria H. Sugandhi, Nandita Tam, Melanie Wilson-Jones, Megan CA Interagcy Task Team Prevention Tre TI Linkage, initiation and retention of children in the antiretroviral therapy cascade: an overview SO AIDS LA English DT Article DE antiretroviral therapy; barriers; diagnosis; linkage; loss to follow-up; monitoring; pediatric HIV; retention ID HIV-INFECTED CHILDREN; FOLLOW-UP; EXPOSED CHILDREN; SOUTH-AFRICA; WESTERN KENYA; CARE; MORTALITY; PROGRAM; MALAWI; BARRIERS AB In 2012, there were an estimated 2 million children in need of antiretroviral therapy (ART) in the world, but ART is still reaching fewer than 3 in 10 children in need of treatment. [1, 7] As more HIV-infected children are identified early and universal treatment is initiated in children under 5 regardless of CD4, the success of pediatric HIV programs will depend on our ability to link children into care and treatment programs, and retain them in those services over time. In this review, we summarize key individual, institutional, and systems barriers to diagnosing children with HIV, linking them to care and treatment, and reducing loss to follow-up (LTFU). We also explore how linkage and retention can be optimally measured so as to maximize the impact of available pediatric HIV care and treatment services. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Phelps, B. Ryan; Amzel, Anouk; Jacobs, Troy; Tam, Melanie] United States Agcy Int Dev, Off HIV AIDS, Washington, DC USA. [Ahmed, Saeed; Kim, Maria H.] Baylor Coll Med, Houston, TX 77030 USA. [Diallo, Mamadou O.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kellerman, Scott E.] Management Sci Hlth, Washington, DC USA. [Sugandhi, Nandita] Clinton Hlth Access Initiat, New York, NY USA. [Wilson-Jones, Megan] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England. RP Phelps, BR (reprint author), United States Agcy Int Dev, Off HIV AIDS, Washington, DC USA. EM bphelps@usaid.gov FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 51 TC 15 Z9 15 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S207 EP S213 DI 10.1097/QAD.0000000000000095 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200009 PM 24361630 ER PT J AU Sint, TT Lovich, R Hammond, W Kim, M Melillo, S Lu, L Ching, P Marcy, J Rollins, N Koumans, EH Heap, AN Brewinski-Isaacs, M AF Sint, Tin Tin Lovich, Ronnie Hammond, Wendy Kim, Maria Melillo, Sara Lu, Lydia Ching, Pamela Marcy, Jennifer Rollins, Nigel Koumans, Emilia H. Heap, Amie N. Brewinski-Isaacs, Margaret CA Child Survival Working Grp Interag TI Challenges in infant and young child nutrition in the context of HIV SO AIDS LA English DT Article DE antiretroviral drugs; breastfeeding; HIV; infant feeding options; prevention of mother-to-child transmission; resource-limited settings ID ACTIVE ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; VIRAL LOAD; MORTALITY; TRANSMISSION; GROWTH; MILK; INFECTION; WEIGHT; IMMUNE AB There is consensus on the benefits for all infants of exclusive breastfeeding for 6 months and introduction of appropriate complementary foods at 6 months, followed by continued breastfeeding. However, guidelines on infant and young child feeding (IYCF) for HIV-positive mothers have changed continually since 2000. This article explores issues and evidence related to IYCF for the prevention and care of paediatric HIV in resource-limited settings in light of new HIV treatment guidelines, implementation challenges and knowledge gaps.In 2010 the impact of antiretroviral drugs (ARVs) on reducing the risk of mother-to-child transmission of HIV moved WHO to urge countries to endorse either avoidance of all breastfeeding or exclusive breastfeeding for the first 6 months while taking ARVs, depending on which strategy could give their infants the greatest chance of HIV-free survival. Implementation of the 2010 recommendations is challenged by lack of healthcare provider training, weak clinic-community linkages to support mother/infant pairs and lack of national monitoring and reporting on infant feeding indicators.More evidence is needed to inform prevention and treatment of malnutrition among HIV-exposed and HIV-infected children. Knowledge gaps include the effects of prolonged ARV exposure, the cause of HIV-associated growth faltering, the effects of early infant testing on continuation of breastfeeding and specific nutrition interventions needed for HIV-infected children.Significant progress has been made toward keeping mothers alive and reducing paediatric HIV infection, but sustained political, financial and scientific commitment are required to ensure meaningful interventions to eliminate postnatal transmission and meet the nutritional needs of HIV-exposed and HIV-infected children. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Sint, Tin Tin] UNICEF, Program Div, Nutr Sect, New York, NY 10017 USA. [Lu, Lydia; Ching, Pamela; Koumans, Emilia H.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Rollins, Nigel] WHO, Newborn Child & Adolescent Hlth, Dept Maternal, Geneva, Switzerland. [Heap, Amie N.] USAID, Off HIV AIDS, Rockville, MD USA. [Brewinski-Isaacs, Margaret] HRSA, Global AIDS Program, Rockville, MD USA. RP Sint, TT (reprint author), UNICEF, Program Div, Nutr Sect, 3 United Nations Plaza, New York, NY 10017 USA. EM ttsint@unicef.org FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 39 TC 2 Z9 2 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S169 EP S177 DI 10.1097/QAD.0000000000000089 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200005 PM 24361626 ER PT J AU Sugandhi, N Rodrigues, J Kim, M Ahmed, S Amzel, A Tolle, M Dziuban, EJ Kellerman, SE Rivadeneira, E AF Sugandhi, Nandita Rodrigues, Jessica Kim, Maria Ahmed, Saeed Amzel, Anouk Tolle, Mike Dziuban, Eric J. Kellerman, Scott E. Rivadeneira, Emilia CA Interagcy Task Team Prevention Tre TI HIV-exposed infants: rethinking care for a lifelong condition SO AIDS LA English DT Article DE HIV-exposed infant; HIV-exposed uninfected; mother-infant pair ID UNINFECTED CHILDREN BORN; TENOFOVIR DISOPROXIL FUMARATE; INFECTED MOTHERS; SOUTH-AFRICA; FOLLOW-UP; OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY; PERINATAL EXPOSURE; HEALTH OUTCOMES; PREGNANCY AB Each year over a million infants are born to HIV-infected mothers. With scale up of prevention of mother-to-child transmission (PMTCT) interventions, only 210000 of the 1.3 million infants born to mothers with HIV/AIDS in 2012 became infected. Current programmatic efforts directed at infants born to HIV-infected mothers are primarily focused on decreasing their risk of infection, but an emphasis on maternal interventions has meant follow-up of exposed infants has been poor. Programs are struggling to retain this population in care until the end of exposure, typically at the cessation of breastfeeding, between 12 and 24 months of age. But HIV exposure is a life-long condition that continues to impact the health and well being of a child long after exposure has ended. A better understanding of the impact of HIV on exposed infants is needed and new programs and interventions must take into consideration the long-term health needs of this growing population. The introduction of lifelong treatment for all HIV-infected pregnant women is an opportunity to rethink how we provide services adapted for the long-term retention of mother-infant pairs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Sugandhi, Nandita] Clinton Hlth Access Initiat, New York, NY USA. [Rodrigues, Jessica] UNICEF New York, New York, NY USA. [Rodrigues, Jessica] IATT Secretariat New York, New York, NY USA. [Kim, Maria; Ahmed, Saeed; Tolle, Mike] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA. [Amzel, Anouk] USAID, Washington, DC USA. [Dziuban, Eric J.; Rivadeneira, Emilia] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Kellerman, Scott E.] Management Sci Hlth, Arlington, VA USA. RP Sugandhi, N (reprint author), Clinton Hlth Access Initiat, 383 Dorchester Suite 400, Boston, MA 02127 USA. EM nsugandhi@clintonhealthaccess.org FU UNICEF; Canadian International Development Agency (CIDA) FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the World Health Organization or the U.S. government including the U.S. Centers for Disease Control and Prevention and Agency for Toxic Substances Disease Registry and the United States Agency for International Development. The authors acknowledge the support of UNICEF and the Canadian International Development Agency (CIDA) whose financial assistance made this series possible and the U.S. President's Emergency Plan for AIDS Relief for support of contributing staff time. NR 60 TC 6 Z9 6 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD NOV PY 2013 VL 27 SU 2 BP S187 EP S195 DI 10.1097/QAD.0000000000000090 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 266CY UT WOS:000328001200007 PM 24361628 ER PT J AU Lang, JE AF Lang, Jason E. TI CDC-FUNDED WORKSITE HEALTH PROMOTION AND PROTECTION PROGRAMS SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Editorial Material C1 Natl Ctr Chron Dis Prevent & Hlth Promot, Workplace Hlth Programs, Atlanta, GA 30341 USA. RP Lang, JE (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Workplace Hlth Programs, Atlanta, GA 30341 USA. NR 11 TC 0 Z9 0 U1 1 U2 1 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2013 VL 28 IS 2 BP THAP8 EP THAP12 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 268UP UT WOS:000328196400005 ER PT J AU Smith, KW Souter, I Dimitriadis, I Ehrlich, S Williams, PL Calafat, AM Hauser, R AF Smith, Kristen W. Souter, Irene Dimitriadis, Irene Ehrlich, Shelley Williams, Paige L. Calafat, Antonia M. Hauser, Russ TI Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID IN-VITRO FERTILIZATION; ESTROGENIC ACTIVITY; REPRODUCTIVE DISORDERS; HUMAN HEALTH; PREGNANCY; EXPOSURE; RESERVE; HUMANS; PRESERVATIVES; EXPRESSION AB BACKGROUND: Parabens are preservatives commonly used in personal care products, pharmaceuticals, and foods. There is documented widespread human exposure to parabens, and some experimental data suggest that they act as estrogenic endocrine disruptors. As far as we are aware, no epidemiologic studies have assessed female reproductive health effects in relation to paraben exposure. OBJECTIVE: We examined the association of urinary paraben concentrations with markers of ovarian reserve in a prospective cohort study of women seeking fertility treatment at Massachusetts General Hospital, Boston, Massachusetts. METHODS: Measures of ovarian reserve were day-3 follicle-stimulating hormone (FSH), antral follicle count (AFC), and ovarian volume. Paraben concentrations [methyl-paraben (MP), propylparaben (PP), and butyl-paraben (BP)] were measured in spot urine samples collected prior to the assessment of outcome measures. We used linear and Poisson regression models to estimate associations of urinary paraben concentrations (in tertiles) with ovarian reserve measures. RESULTS: Of the women enrolled in 2004-2010, 192 had at least one ovarian reserve outcome measured (mean age +/- SD, 36.1 +/- 4.5 years; range, 21.0-46.7 years). MP and PP were detected in > 99% of urine samples and BP in > 75%. We found a suggestive trend of lower AFC with increasing urinary PP tertiles [mean percent change (95% CI) for tertiles 2 and 3 compared with tertile 1, respectively, were -5.0% (-23.7, 18.4) and -16.3% (-30.8, 1.3); trend p-value (p(trend)) = 0.07] as well as higher day-3 FSH with higher urinary PP tertiles [mean change (95% CI) for tertiles 2 and 3 compared with tertile 1 were 1.16 IU/L (-0.26, 2.57) and 1.02 IU/L (-0.40, 2.43); p(trend) = 0.16]. We found no consistent evidence of associations between urinary MP or BP and day-3 FSH or AFC, or between urinary MP, PP, or BP and ovarian volume. CONCLUSIONS: PP may be associated with diminished ovarian reserve. However, our results require confirmation in further studies. C1 [Smith, Kristen W.; Dimitriadis, Irene; Ehrlich, Shelley; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Souter, Irene; Dimitriadis, Irene; Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Fertil Ctr,Div Reprod Endoc, Boston, MA USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hauser, R (reprint author), 665 Huntington Ave,Bldg 1,14th Floor, Boston, MA 02115 USA. EM rhauser@hsph.harvard.edu RI Ehrlich , Shelley/L-6991-2015 FU National Institute of Environmental Health Sciences, National Institutes of Health [ES009718, ES000002, T32ES007069] FX This work was supported by grants ES009718, ES000002, and T32ES007069 from the National Institute of Environmental Health Sciences, National Institutes of Health. NR 41 TC 15 Z9 16 U1 2 U2 27 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV-DEC PY 2013 VL 121 IS 11-12 BP 1299 EP 1305 DI 10.1289/ehp.1205350 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 266ZA UT WOS:000328061900018 PM 23912598 ER PT J AU McKelvey, W Jacobson, JB Kass, D Barr, DB Davis, M Calafat, AM Aldous, KM AF McKelvey, Wendy Jacobson, J. Bryan Kass, Daniel Barr, Dana Boyd Davis, Mark Calafat, Antonia M. Aldous, Kenneth M. TI Population-Based Biomonitoring of Exposure to Organophosphate and Pyrethroid Pesticides in New York City SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID US POPULATION; URINE SPECIMENS; QUALITY-CONTROL; INSECTICIDES; METABOLITES; HEALTH; URBAN; CHILDREN AB BACKGROUND: Organophosphates and pyrethroids are the most common classes of insecticides used in the United States. Widespread use of these compounds to control building infestations in New York City (NYC) may have caused higher exposure than in less-urban settings. OBJECTIVES: The objectives of our study were to estimate pesticide exposure reference values for NYC and identify demographic and behavioral characteristics that predict exposures. METHODS: The NYC Health and Nutrition Examination Survey was a population-based, cross-sectional study conducted in 2004 among adults >= 20 years of age. It measured urinary concentrations of organo-phosphate metabolites [dimethylphosphate (DMP), dimethylthio-phosphate (DMTP), dimethyl-dithio-phosphate, diethylphosphate, diethylthiophosphate, and diethyldithiophosphate] in 883 participants, and pyrethroid metabolites [3-phenoxybenzoic acid (3-PBA), trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carboxylic acid (trans-DCCA), 4-fluoro3-phenoxybenzoic acid, and cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane-1-carboxylic acid] in 1,452 participants. We used multi-variable linear regression to estimate least-squares geometric mean total dialkyl-phospate (Sigma DAP) and 3-PBA concentrations across categories of predictors. RESULTS: The dimethyl organo-phosphate metabolites had the highest 95th percentile concentrations (87.4 mu g/L and 74.7 mu g/L for DMP and DMTP, respectively). The highest 95th percentiles among pyrethroid metabolites were measured for 3-PBA and trans-DCCA (5.23 mu g/L and 5.94 mu g/L, respectively). Concentrations of Sigma DAP increased with increasing age, non-Hispanic white or black compared with Hispanic race/ethnicity, professional pesticide use, and increasing frequency of fruit consumption; they decreased with non-green vegetable consumption. Absolute differences in geometric mean urinary 3-PBA concentrations across categories of predictors were too small to be meaningful. CONCLUSION: Estimates of exposure to pyrethroids and dimethyl organo-phosphates were higher in NYC than in the United States overall, underscoring the importance of considering pest and pesticide burdens in cities when formulating pesticide use regulations. C1 [McKelvey, Wendy; Jacobson, J. Bryan; Kass, Daniel] New York City Dept Hlth & Mental Hyg, Div Environm Hlth, New York, NY 10013 USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Davis, Mark; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Aldous, Kenneth M.] New York State Dept Hlth, Wadsworth Ctr, Div Environm Hlth Sci, Lab Organ Analyt Chem, Albany, NY USA. RP McKelvey, W (reprint author), New York City Dept Hlth & Mental Hyg, Bur Environm Surveillance & Policy, 125 Worth St,3rd Floor,CN 34E, New York, NY 10013 USA. EM wmckelve@health.nyc.gov FU National Center for Environmental Health, CDC [U50CCJU222455, U50CCU223290, U59EH223392-05, U38EH000464-01] FX This study was supported by grants from the National Center for Environmental Health, CDC (grants U50CCJU222455 and U50CCU223290 to the NYC DOHMH; grants U59EH223392-05 and U38EH000464-01 to the Wadsworth Center). NR 41 TC 16 Z9 16 U1 6 U2 25 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV-DEC PY 2013 VL 121 IS 11-12 BP 1349 EP 1356 DI 10.1289/ehp.1206015 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 266ZA UT WOS:000328061900025 PM 24076605 ER PT J AU Lam, T Williams, PL Burns, JS Sergeyev, O Korrick, SA Lee, MM Birnbaum, LS Revich, B Altshul, LM Patterson, DG Turner, WE Hauser, R AF Lam, Thuy Williams, Paige L. Burns, Jane S. Sergeyev, Oleg Korrick, Susan A. Lee, Mary M. Birnbaum, Linda S. Revich, Boris Altshul, Larisa M. Patterson, Donald G., Jr. Turner, Wayman E. Hauser, Russ TI Predictors of Serum Chlorinated Pesticide Concentrations among Prepubertal Russian Boys SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID PERSISTENT ORGANIC POLLUTANTS; SCHOOL-AGED CHILDREN; POLYCHLORINATED-BIPHENYLS; ORGANOCHLORINE PESTICIDES; DIOXIN EXPOSURE; ADIPOSE-TISSUE; DIETARY-INTAKE; LIFE-STYLE; HEXACHLOROBENZENE; HEXACHLOROCYCLOHEXANE AB BACKGROUND: Few studies have evaluated predictors of childhood exposure to organochlorine pesticides (OCPs), a class of lipophilic persistent chemicals. Objectives: Our goal was to identify predictors of serum OCP concentrations-hexachlorobenzene (HCB), beta-hexachlorocyclohexane (beta-HCH), and p,p-dichlorodiphenyldichloroethylene (p,p'-DDE)-among boys in Chapaevsk, Russia. METHODS: Between 2003 and 2005, 499 boys 8-9 years of age were recruited in a prospective cohort. The initial study visit included a physical examination; blood collection; health, lifestyle, and food-frequency questionnaires; and determination of residential distance from a local factory complex that produced HCB and beta-HCH. Fasting serum samples were analyzed for OCPs at the U.S. Centers for Disease Control and Prevention. General linear regression models were used to identify predictors of the boys' serum HCB, beta-HCH, and p,p'-DDE concentrations. RESULTS: Among 355 boys with OCP measurements, median serum HCB, beta-HCH, and p,p'-DDE concentrations were 158, 167, and 284 ng/g lipid, respectively. Lower body mass index, longer breastfeeding duration, and local dairy consumption were associated with higher concentrations of OCPs. Boys who lived < 2 km from the factory complex had 64% (95% CI: 37, 96) and 57% (95% CI: 32, 87) higher mean HCB and beta-HCH concentrations, respectively, than boys who lived >= 5 km away. Living > 3 years in Chapaevsk predicted higher beta-HCH concentrations, and having parents who lacked a high school education predicted higher p,p'-DDE concentrations. CONCLUSIONS: Among this cohort of prepubertal Russian boys, predictors of serum OCPs included consumption of local dairy products, longer local residence, and residential proximity to the local factory complex. C1 [Lam, Thuy; Burns, Jane S.; Korrick, Susan A.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sergeyev, Oleg] Samara State Med Univ, Dept Phys Educ & Hlth, Samara, Russia. [Sergeyev, Oleg] Chapaevsk Med Assoc, Chapaevsk, Samara Region, Russia. [Korrick, Susan A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA. [Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Pediat & Cell Biol, Pediat Endocrine Div, Worcester, MA USA. [Birnbaum, Linda S.] NCI, Res Triangle Pk, NC USA. [Birnbaum, Linda S.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Revich, Boris] Russian Acad Sci, Inst Forecasting, Moscow, Russia. [Altshul, Larisa M.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA. [Altshul, Larisa M.] Environm Hlth & Engn Inc, Needham, MA USA. [Patterson, Donald G., Jr.] EnviroSolut Consulting Inc, Auburn, GA USA. [Patterson, Donald G., Jr.] Axys Analyt Solut, Sidney, BC, Canada. [Patterson, Donald G., Jr.] Exponent Inc, Maynard, MA USA. [Turner, Wayman E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lam, T (reprint author), Environm & Occupat Med & Epidemiol Program, 665 Huntington Ave,Bldg 1,Room 1406N, Boston, MA 02115 USA. EM tlam@mail.harvard.edu; rhauser@hsph.harvard.edu RI Sergeyev, Oleg/H-8854-2013 OI Sergeyev, Oleg/0000-0002-5745-3348 FU U.S. Environmental Protection Agency [R82943701]; National Institute of Environmental Health Sciences [ES014370, ES000002, ES017117]; National Institute for Occupational Safety and Health [T42-OH008416-04] FX This work was funded by the U.S. Environmental Protection Agency (R82943701) and the National Institute of Environmental Health Sciences (ES014370, ES000002, and ES017117). T. L. is supported by National Institute for Occupational Safety and Health training grant T42-OH008416-04. NR 45 TC 6 Z9 6 U1 3 U2 12 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV-DEC PY 2013 VL 121 IS 11-12 BP 1372 EP 1377 DI 10.1289/ehp.1306480 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 266ZA UT WOS:000328061900028 PM 23955839 ER PT J AU Akinbami, LJ Kit, BK Simon, AE AF Akinbami, Lara J. Kit, Brian K. Simon, Alan E. TI Impact of Environmental Tobacco Smoke on Children With Asthma, United States, 2003-2010 SO ACADEMIC PEDIATRICS LA English DT Article DE asthma; environmental tobacco smoke ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; EXPOSURE; ADOLESCENTS; TRENDS; DISPARITIES; PREVALENCE; ABSENCE; CARE AB OBJECTIVE: Given widespread interventions to reduce environmental tobacco smoke (ETS) exposure and improve asthma control, we sought to assess the current impact of ETS exposure on children with asthma. METHODS: We analyzed 2003-2010 data for nonsmoking children aged 6 to 19 years with asthma from the National Health and Nutrition Examination Survey. Outcomes (sleep disturbance, missed school days, health care visits, activity limitation, and wheezing with exercise) were compared between ETS exposed children (serum cotinine levels 0.05 to 10 ng/mL) and unexposed children (<0.05 ng/mL) using ordinal regression adjusted for demographic characteristics. We also assessed whether associations were observable with low ETS exposure levels (0.05 to 1.0 ng/mL). RESULTS: Overall, 53.3% of children aged 6 to 19 years with asthma were ETS exposed. Age-stratified models showed associations between ETS exposure and most adverse outcomes among 6- to 11-year-olds, but not 12- to 19-year-olds. Even ETS exposure associated with low serum cotinine levels was associated with adverse outcomes for 6- to 11-year-olds. Race-stratified models for children aged 6 to 19 years showed an association between ETS exposure and missing school, health care visits, and activity limitation due to wheezing among non-Hispanic white children, and disturbed sleep among non-Hispanic white and Mexican children. Among non-Hispanic black children, there was no elevated risk between ETS exposure and the assessed outcomes: non-Hispanic black children had high rates of adverse outcomes regardless of ETS exposure. CONCLUSIONS: Among children with asthma 6 to 11 years of age, ETS exposure was associated with most adverse outcomes. Even ETS exposure resulting in low serum cotinine levels was associated with risks for young children with asthma. C1 [Akinbami, Lara J.; Simon, Alan E.] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Kit, Brian K.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Akinbami, Lara J.; Kit, Brian K.] US PHS, Rockville, MD USA. RP Akinbami, LJ (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM lakinbami@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 16 Z9 16 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD NOV-DEC PY 2013 VL 13 IS 6 BP 508 EP 516 PG 9 WC Pediatrics SC Pediatrics GA 261TX UT WOS:000327688600006 PM 24021528 ER PT J AU Gler, MT Guilatco, R Caoili, JC Ershova, J Cegielski, P Johnson, JL AF Tarcela Gler, Ma Guilatco, Ruffy Caoili, Janice C. Ershova, Julia Cegielski, Peter Johnson, John L. TI Weight Gain and Response to Treatment for Multidrug-Resistant Tuberculosis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PULMONARY TUBERCULOSIS; NUTRITIONAL-STATUS; RISK-FACTORS; OUTCOMES; ADULTS; PERU AB Alternatives to culture are needed in high burden countries to assess whether response to treatment of multidrug-resistant-tuberculosis (MDR-TB) is satisfactory. The objective was to assess the association of weight gain and treatment outcome. The methods included analysis of clinical, bacteriologic, and weight from 439 MDR-TB patients in the Philippines. Odds ratios (ORs) were calculated to determine whether 5% weight gain during the first 6 months of treatment was associated with outcome. Three hundred and ten (71%) patients were cured and 129 (29%) had poor outcomes (death, defaulted, or failed treatment). Fifty-three percent were underweight (body mass index [BMI] < 18.5 kg/m(2)) before treatment. Five percent weight gain after completing 3 months of treatment was associated with good outcome among patients who were underweight before treatment (OR 2.1; 95% confidence interval [CI], 1.05 to 4.4). Baseline weight and degree of weight change during the first 6 months of treatment can help identify persons who are more likely to have poor outcomes and require other interventions. C1 Trop Dis Fdn, Makati, Philippines. [Ershova, Julia; Cegielski, Peter] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Johnson, John L.] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA. [Tarcela Gler, Ma; Guilatco, Ruffy; Caoili, Janice C.] Trop Dis Fdn, PMDT, Makati, Philippines. RP Gler, MT (reprint author), Makati Med Ctr, Rm 336B,2 Amorsolo St, Makati 1229, Philippines. EM tarcelasg@yahoo.com; rsguilatco@gmail.com; janice.caoili@gmail.com; jhe3@cdc.gov; gzc2@cdc.gov; jlj@case.edu NR 26 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2013 VL 89 IS 5 BP 943 EP 949 DI 10.4269/ajtmh.13-0011 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 251BZ UT WOS:000326904100021 PM 24019430 ER PT J AU Kading, RC Gilbert, AT Mossel, EC Crabtree, MB Kuzmin, IV Niezgoda, M Agwanda, B Markotter, W Weil, MR Montgomery, JM Rupprecht, CE Miller, BR AF Kading, Rebekah C. Gilbert, Amy T. Mossel, Eric C. Crabtree, Mary B. Kuzmin, Ivan V. Niezgoda, Michael Agwanda, Bernard Markotter, Wanda Weil, M. Ryan Montgomery, Joel M. Rupprecht, Charles E. Miller, Barry R. TI Isolation and molecular characterization of Fikirini rhabdovirus, a novel virus from a Kenyan bat SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID FAMILY RHABDOVIRIDAE; AFRICAN BAT; SARS-LIKE; CORONAVIRUSES; LYSSAVIRUS; RESERVOIRS; RABIES; MEMBER AB Zoonotic and vector-borne pathogens have comprised a significant component of emerging human infections in recent decades, and bats are increasingly recognized as reservoirs for many of these disease agents. To identify novel pathogens associated with bats, we screened tissues of bats collected in Kenya. Virus isolates were identified by next generation sequencing of viral nucleic acid preparations from the infected cell culture supernatant and characterized. Here we report the identification of Fikirini rhabdovirus, a novel rhabdovirus isolated from a bat, Hipposideros vittatus, captured along the Kenyan coast. C1 [Kading, Rebekah C.; Mossel, Eric C.; Crabtree, Mary B.; Miller, Barry R.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. [Gilbert, Amy T.; Kuzmin, Ivan V.; Niezgoda, Michael; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA USA. [Agwanda, Bernard] Natl Museums Kenya, Nairobi, Kenya. [Markotter, Wanda] Univ Pretoria, Dept Microbiol & Plant Pathol, ZA-0002 Pretoria, South Africa. [Weil, M. Ryan] SRA Int, Atlanta, GA USA. [Weil, M. Ryan] Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Montgomery, Joel M.] Ctr Dis Control & Prevent, Global Dis Detect Program, Nairobi, Kenya. RP Kading, RC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. EM fxk7@cdc.gov RI Kading, Rebekah/E-5633-2017; OI Kading, Rebekah/0000-0002-4996-915X; Markotter, Wanda/0000-0002-7550-0080 FU Global Disease Detection Program of the Centers for Disease Control and Prevention (Atlanta, GA); United States Agency for International Development Emerging Pandemic Threats Program; United States Centers for Disease Control and Prevention FX We acknowledge Sergio Recuenco of the CDC Rabies program for generation of the map. This project was funded through Technical Support Corps funds from the Global Disease Detection Program of the Centers for Disease Control and Prevention (Atlanta, GA), and by an Interagency Agreement between the United States Agency for International Development Emerging Pandemic Threats Program and the United States Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors only, and do not necessarily reflect the views of their respective institutions. NR 38 TC 11 Z9 12 U1 0 U2 16 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD NOV PY 2013 VL 94 BP 2393 EP 2398 DI 10.1099/vir.0.053983-0 PN 11 PG 6 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 264VW UT WOS:000327910100002 PM 23939976 ER PT J AU Tilburt, JC Koller, K Tiesinga, JJ Wilson, RT Trinh, AC Hill, K Hall, IJ Smith, JL Ekwueme, DU Petersen, WO AF Tilburt, Jon C. Koller, Kathryn Tiesinga, James J. Wilson, Robin T. Trinh, Anne C. Hill, Kristin Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Petersen, Wesley O. TI Patterns of Clinical Response to PSA Elevation in American Indian/Alaska Native Men: A Multi-center Pilot Study SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE American Indian; Alaska Native; prostate specific antigen; prostate cancer ID PROSTATE-SPECIFIC ANTIGEN; ALASKA-NATIVES; CANCER-MORTALITY; REFERENCE RANGES; INDIANS; US; HEALTH; CARE AB Objective. To assess clinical treatment patterns and response times among American Indian/Alaska Native men with a newly elevated PSA. Methods. We retrospectively identified men ages 50-80 receiving care in one of three tribally-operated clinics in Northern Minnesota, one medical center in Alaska, and who had an incident PSA elevation (>= 4 ng/ml) in a specified time period. A clinical response was considered timely if it was documented as occurring within 90 days of the incident PSA elevation. Results. Among 82 AI/AN men identified from medical records with an incident PSA elevation, 49 (60%) received a timely clinical response, while 18 (22%) had no documented clinical response. Conclusions. One in five AI/AN men in our study had no documented clinical action following an incident PSA elevation. Although a pilot study, these findings suggest the need to improve the documentation, notification, and care following an elevated PSA at clinics serving AI/AN men. C1 [Tilburt, Jon C.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. [Tilburt, Jon C.] Mayo Clin, Biomed Eth Res Unit, Rochester, MN USA. [Tilburt, Jon C.] Mayo Clin, Ctr Sci Healthcare Delivery, Healthcare Delivery Res Program, Rochester, MN USA. [Koller, Kathryn] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Anchorage, AK USA. [Tiesinga, James J.] Alaska Native Tribal Hlth Consortium, Dept Lab & Pathol, Anchorage, AK USA. [Wilson, Robin T.] Penn State Hershey Canc Inst, Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA. [Trinh, Anne C.] Dept Publ Hlth, Columbus, OH USA. [Hill, Kristin] Great Lakes Intertribal Epidemiol Ctr, Lac Du Flambeau, WI USA. [Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Petersen, Wesley O.] Mayo Clin, Ctr Comprehens Canc, Behav Hlth Res Program, Rochester, MN USA. RP Tilburt, JC (reprint author), Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. FU Intramural CDC HHS [CC999999] NR 24 TC 0 Z9 0 U1 0 U2 2 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2013 VL 24 IS 4 BP 1676 EP 1685 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 251CG UT WOS:000326904800024 PM 24185163 ER PT J AU Cullen, KA Arguin, PM AF Cullen, Karen A. Arguin, Paul M. TI Malaria Surveillance - United States, 2011 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID PLASMODIUM-FALCIPARUM; HAITI AB Problem/Condition: Malaria in humans is caused by intraerythrocytic protozoa of the genus Plasmodium. These parasites are transmitted by the bite of an infective female Anopheles mosquito. The majority of malaria infections in the United States occur among persons who have traveled to regions with ongoing malaria transmission. However, malaria is also occasionally acquired by persons who have not traveled out of the country, through exposure to infected blood products, congenital transmission, laboratory exposure, or local mosquitoborne transmission. Malaria surveillance in the United States is conducted to identify episodes of local transmission and to guide prevention recommendations for travelers. Period Covered:, This report summarizes cases in persons with onset of illness in 2011 and summarizes trends during previous years. Description of System: Malaria cases diagnosed by blood film, polymerase chain reaction, or rapid diagnostic tests are mandated to be reported to local and state health departments by health-care providers or laboratory staff. Case investigations are conducted by local and state health departments, and reports are transmitted to CDC through the National Malaria Surveillance System, National Notifiable Diseases Surveillance System, or direct CDC consults. Data from these reporting systems serve as the basis for this report. Results: CDC received 1,925 reported cases of malaria with an onset of symptoms in 2011 among persons in the United States, including 1,920 cases classified as imported, one laboratory-acquired case, one transfusion-related case, two congenital cases, and one cryptic case. The total number of cases represents an increase of 14% from the 1,691 cases reported for 2010 and the largest number of reported cases since 1971. Plasmodium falciparum, P vivax, P malariae, and P ovale were identified in 49%, 22%, 3%, and 3% of cases, respectively. Twenty-one (1%) patients were infected by two species. The infecting species was unreported or undetermined in 23% of cases, an increase of 5 percentage points from 2010. Of the 871 patients who reported purpose of travel, 607 (70%) were visiting friends or relatives (VFR). Among the 929 cases in U.S. civilians for whom information on chemoprophylaxis use and travel region was known, 57 (6%) patients reported that they had followed and adhered to a chemoprophylactic drug regimen recommended by CDC for the regions to which they had traveled. Thirty-seven cases were reported in pregnant women, among whom only one adhered to chemoprophylaxis. Among all reported cases, significantly more cases (n=275 [14%]) were classified as severe infections in 2011 compared with 2010 (n=183 [11%]; p=0.0018; chi square). Five persons with malaria died in 2011. After 2 years of improvement in completion of data elements on the malaria case form, higher percentages of incomplete data in 2011 for residential status (from 11% in 2010 to 19% in 2011) and species (from 18% in 2010 to 22% in 2011) were noted. Interpretation: The number of cases reported in 2011 marked the largest number of cases since 1971 (N = 3,180). Despite progress in reducing the global burden of malaria, the disease remains endemic in many regions, and the use of appropriate prevention measures by travelers is still inadequate. Public Health Actions: Completion of data elements on the malaria case report form decreased in 2011 compared with 2010. This incomplete reporting compromises efforts to examine trends in malaria cases and prevent infections. VFR travelers continue to be a difficult population to reach with effective malaria prevention strategies. Evidence-based prevention strategies that effectively target VFR travelers need to be developed and implemented to have a substantial impact on the numbers of imported malaria cases in the United States. Although more persons with cases reported taking chemoprophylaxis to prevent malaria, the majority reported not taking it, and adherence was poor among those who did take chemoprophylaxis. Proper use of malaria chemoprophylaxis will prevent the majority of malaria illness and reduce the risk for severe disease (http://www.cdc.gov/malaria/travelers/drugs.html). Malaria infections can be fatal if not diagnosed and treated promptly with antimalarial medications appropriate for the patient's age and medical history, the likely country of malaria acquisition, and previous use of antimalarial chemoprophylaxis. Clinicians should consult the CDC Guidelines for Treatment of Malaria and contact the CDC's Malaria Hotline for case management advice, when needed. Malaria treatment recommendations can be obtained online (http://www.cdc.gov/malaria/diagnosis_treatment) or by calling the Malaria Hotline (770-488-7788 or toll-free at 855-856-4713). C1 [Cullen, Karen A.; Arguin, Paul M.] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Cullen, KA (reprint author), CDC, Ctr Global Hlth, Div Parasit Dis, Atlanta, GA 30333 USA. EM kcullen@cdc.gov NR 35 TC 26 Z9 26 U1 1 U2 15 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD NOV 1 PY 2013 VL 62 IS 5 BP 1 EP 17 PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 263LO UT WOS:000327810300001 PM 24172939 ER PT J AU Amer, S Zidan, S Adamu, H Ye, JB Roellig, D Xiao, LH Feng, YY AF Amer, Said Zidan, Shereif Adamu, Haileeyesus Ye, Jianbin Roellig, Dawn Xiao, Lihua Feng, Yaoyu TI Prevalence and characterization of Cryptosporidium spp. in dairy cattle in Nile River delta provinces, Egypt SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Cryptosporidium; Cryptosporidiosis; Genotype; Subtype; Cattle; Zoonosis; Molecular epidemiology; Egypt ID EASTERN UNITED-STATES; DEER-LIKE GENOTYPE; MOLECULAR CHARACTERIZATION; SUBTYPE ANALYSIS; PARVUM SUBTYPES; BUFFALO CALVES; PUBLIC-HEALTH; BEEF-CALVES; ANDERSONI; CHILDREN AB Molecular characterizations of Cryptosporidium spp. in dairy cattle in industrialized nations have mostly shown a dominance of Cryptosporidium parvum, especially its Ha subtypes in pre-weaned calves. Few studies, however, have been conducted on the distribution of Cryptosporidium species and C parvum subtypes in various age groups of dairy cattle in developing countries. In this study, we examined the prevalence and molecular characteristics of Cryptosporidium in dairy cattle in four Nile River delta provinces in Egypt. Modified Ziehl-Neelsen acid-fast microscopy was used to screen for Cryptosporidium oocysts in 1974 fecal specimens from animals of different ages on 12 farms. Positive fecal specimens were identified from all studied farms with an overall prevalence of 13.6%. By age group, the infection rates were 12.5% in pre-weaned calves, 10.4% in post-weaned calves, 22.1% in heifers, and 10.7% in adults. PCR-RFLP and DNA sequence analyses of microscopy-positive fecal specimens revealed the presence of four major Cryptosporidium species. In pre-weaned calves, C parvum was most common (30/69 or 43.5%), but Cryptosporidium ryanae (13/69 or 18.8%), Cryptosporidium bovis (7/69 or 10.2%), and Cryptosporidium andersoni (7/69 or 10.2%) were also present at much higher frequencies seen in most industrialized nations. Mixed infections were seen in 12/69 (17.4%) of genotyped specimens. In contrast, C andersoni was the dominant species (193/195 or 99.0%) in post-weaned calves and older animals. Subtyping of C parvum based on sequence analysis of the 60 kDa glycoprotein gene showed the presence of subtypes IIdA20G1 in nine specimens, HaA15G1R1 in 27 specimens, and a rare subtype IIaA14G1R1r1b in one specimen. The common occurrence of non-C parvum species and lid subtypes in pre-weaned calves is a distinct feature of cryptosporidiosis transmission in dairy cattle in Egypt. The finding of the same two dominant Ha and lid C parvum subtypes recently found in humans in Egypt suggests calves can be potential reservoirs of zoonotic cryptosporidiosis. Published by Elsevier Inc. C1 [Amer, Said; Adamu, Haileeyesus; Ye, Jianbin; Roellig, Dawn; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Amer, Said] Kafr El Sheikh Univ, Fac Sci, Dept Zool, Kafr Al Sheikh 33516, Egypt. [Zidan, Shereif] Menoufia Univ, Sadat Branch, Fac Vet Med, Dept Anim Hyg & Zoonoses, Al Menoufia, Egypt. [Adamu, Haileeyesus] Univ Addis Ababa, Addis Ababa, Ethiopia. [Ye, Jianbin; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; OI Xiao, Lihua/0000-0001-8532-2727; Adamu, Haileeyesus/0000-0003-2998-5977 FU Arab Fund for Economic & Social Development (Zamalat Program); National Natural Science Foundation of China [31229005, 31110103901]; Centers for Disease Control and Prevention FX This research was supported by the Arab Fund for Economic & Social Development (Zamalat Program), National Natural Science Foundation of China (Project Nos. 31229005 and 31110103901), and Centers for Disease Control and Prevention. NR 62 TC 13 Z9 16 U1 0 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD NOV PY 2013 VL 135 IS 3 BP 518 EP 523 DI 10.1016/j.exppara.2013.09.002 PG 6 WC Parasitology SC Parasitology GA 256BA UT WOS:000327283500007 PM 24036320 ER PT J AU Pohl, TJ Kolor, K Fangman, WL Brewer, BJ Raghuraman, MK AF Pohl, Thomas J. Kolor, Katherine Fangman, Walton L. Brewer, Bonita J. Raghuraman, M. K. TI A DNA Sequence Element That Advances Replication Origin Activation Time in Saccharomyces cerevisiae SO G3-GENES GENOMES GENETICS LA English DT Article DE DNA replication; origins of replication; Saccharomyces cerevisiae; ARS; temporal regulation ID S-PHASE; TEMPORAL PROGRAM; YEAST ORIGIN; TRANSCRIPTION; INITIATION; KU AB Eukaryotic origins of DNA replication undergo activation at various times in S-phase, allowing the genome to be duplicated in a temporally staggered fashion. In the budding yeast Saccharomyces cerevisiae, the activation times of individual origins are not intrinsic to those origins but are instead governed by surrounding sequences. Currently, there are two examples of DNA sequences that are known to advance origin activation time, centromeres and forkhead transcription factor binding sites. By combining deletion and linker scanning mutational analysis with two-dimensional gel electrophoresis to measure fork direction in the context of a two-origin plasmid, we have identified and characterized a 19- to 23-bp and a larger 584-bp DNA sequence that are capable of advancing origin activation time. C1 [Pohl, Thomas J.; Brewer, Bonita J.] Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA. [Pohl, Thomas J.; Kolor, Katherine; Fangman, Walton L.; Brewer, Bonita J.; Raghuraman, M. K.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Kolor, Katherine] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30329 USA. RP Raghuraman, MK (reprint author), Univ Washington, Dept Genome Sci, Box 355065 Foege Bldg,Room S-041,3720 15th Ave NE, Seattle, WA 98195 USA. EM raghu@u.washington.edu FU National Institute of General Medical Sciences [18926] FX We thank past and present members of the Brewer/Raghuraman lab along with members of the Dunham lab for thoughtful discussions and comments on this manuscript. This research was supported by a National Institute of General Medical Sciences grant (18926) to W. L. F., B.J.B., and M. K. R. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work conducted by Katherine Kolor was performed in her private capacity. No official support or endorsement by the Centers for Disease Control and Prevention, Department of Health and Human Services is intended, nor should it be inferred. NR 29 TC 4 Z9 4 U1 0 U2 5 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD NOV PY 2013 VL 3 IS 11 BP 1955 EP 1963 DI 10.1534/g3.113.008250 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 255LY UT WOS:000327241900006 PM 24022751 ER PT J AU Laskay, UA Breci, L Vilcins, IME Dietrich, G Barbour, AG Piesman, J Wysocki, VH AF Laskay, Uenige A. Breci, Linda Vilcins, Inger-Marie E. Dietrich, Gabrielle Barbour, Alan G. Piesman, Joseph Wysocki, Vicki H. TI Survival of Host Blood Proteins in Ixodes scapularis (Acari: Ixodidae) Ticks: A Time Course Study SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE LC-MS/MS; mouse; hemoglobin; vector-borne disease; reservoir ID MASS-SPECTROMETRY; AMBLYOMMA-AMERICANUM; BORRELIA-BURGDORFERI; BOOPHILUS-MICROPLUS; 12S RDNA; IDENTIFICATION; PROTEOMICS; RICINUS; DISEASE; PATHOGENS AB Ixodes scapularis Say, 1821 larvae were fed on mice and allowed to molt under laboratory conditions. A liquid chromatography-tandem mass spectrometry-based proteomic study was conducted to identify the type of mammalian proteins present in the derived nymphal ticks at different time intervals after molting. Albumin was present for 85 d; transferrin was present for 29 d; and, more importantly, hemoglobin remained detectable for up to 309 d postmolting. Peptides of actin, keratin, and tubulin are highly similar between mouse and tick, and therefore, unambiguous assignment of these proteins to different species was not possible. Establishing a time line for the persistence of hemoglobin, one of the most abundant blood proteins, at detectable levels in ticks after the bloodmeal and molting advances our efforts to use this protein to identify the host species. C1 [Laskay, Uenige A.; Breci, Linda; Wysocki, Vicki H.] Univ Arizona, Dept Chem & Biochem, Tucson, AZ 85721 USA. [Vilcins, Inger-Marie E.; Barbour, Alan G.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Sch Med, Irvine, CA 92697 USA. [Dietrich, Gabrielle; Piesman, Joseph] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Wysocki, VH (reprint author), Ohio State Univ, Dept Chem & Biochem, 100 West 18th Ave, Columbus, OH 43210 USA. EM wysocki.11@osu.edu FU U.S. Public Health Service [(AI)-065359]; CDC; National Institutes of Health/National Center for Research Resources [1 S10 RR028868] FX We thank Chengsi Huang, Erin Kaleta, and Neil Patel for assistance with the tick sampling and Michael Riehle for the use of the insectary. The research was partially supported by U.S. Public Health Service grant (AI)-065359 to A. G. B. and V. H. W. and by intramural funds of the CDC. Financial support for the Orbitrap Velos was provided by National Institutes of Health/National Center for Research Resources 1 S10 RR028868 to University of Arizona. NR 28 TC 1 Z9 1 U1 1 U2 18 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2013 VL 50 IS 6 BP 1282 EP 1290 DI 10.1603/ME12125 PG 9 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 258GZ UT WOS:000327448700013 PM 24843933 ER PT J AU Hochberg, NS Barnett, ED Chen, LH Wilson, ME Iyer, H MacLeod, WB Yanni, E Jentes, ES Karchmer, AW Ooi, W Kogelman, L Benoit, C Hamer, DH AF Hochberg, Natasha S. Barnett, Elizabeth D. Chen, Lin H. Wilson, Mary E. Iyer, Hari MacLeod, William B. Yanni, Emad Jentes, Emily S. Karchmer, Adolf W. Ooi, Winnie Kogelman, Laura Benoit, Christine Hamer, Davidson H. TI International Travel by Persons With Medical Comorbidities: Understanding Risks and Providing Advice SO MAYO CLINIC PROCEEDINGS LA English DT Article ID GEOSENTINEL SURVEILLANCE NETWORK; ORGAN TRANSPLANT RECIPIENTS; YELLOW-FEVER VACCINE; INFECTIOUS-DISEASES; RETURNED TRAVELERS; UNITED-STATES; HEALTH; IMMUNIZATION; ILLNESS; PREGNANCY AB Objective: To describe the medical conditions, travel plans, counseling, and medications prescribed for high-risk international travelers. Patients and Methods: This cross-sectional study was conducted from March 1, 2008, through July 31, 2010, in 5 clinics in the greater Boston area. We assessed all travelers seen for pretravel care and compared demographic characteristics, travel plans, pretravel counseling, and interventions for healthy and high-risk travelers (as defined by medical history or pregnancy). Results: Of 15,440 travelers, 2769 (17.9%) were high-risk; 644 of 2769 (23.3%) were immunocompromised travelers, 2056 (74.3%) had medical comorbidities, and 69 (2.5%) were pregnant women. The median age of high-risk travelers was 47 years compared with 32 years for healthy travelers (P=.0001). High-risk travelers visited the clinic a median of 25 days (range, 10-44 days) before departure. Overall, 2562 (93.9%) of high-risk travelers visited countries with medium or high risk of typhoid fever, 2340 (85.7%) visited malaria-risk countries, and 624 (22.8%) visited yellow fever-endemic countries. Of travelers to yellow fever-endemic countries, 8 of 23 (34.8%) pregnant women and 64 of 144 (44.4%) immunocompromised travelers received yellow fever vaccine. Of eligible high-risk travelers, 11 of 76 (14.5%) received a pneumococcal vaccine, 213 of 640 (33.3%) influenza vaccine, and 956 of 2681 (35.7%) either tetanus-diphtheria or tetanus-diphtheria-pertussis vaccine. Conclusion: High-risk travelers made up nearly 20% of patients in these travel clinics, and they mostly traveled to destinations with malaria and typhoid risk. For health care professionals caring for travelers with underlying medical problems, providing appropriate travel counseling and making vaccine decisions, such as for yellow fever, are complex. Travelers with complicated medical histories may warrant evaluation by an experienced travel medicine specialist. (C) 2013 Mayo Foundation for Medical Education and Research C1 [Hochberg, Natasha S.] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02118 USA. [Hochberg, Natasha S.; Hamer, Davidson H.] Boston Univ, Dept Med, Sch Med, Boston, MA 02118 USA. [MacLeod, William B.; Hamer, Davidson H.] Boston Univ, Dept Int Hlth, Sch Publ Hlth, Boston, MA 02118 USA. [Barnett, Elizabeth D.; Benoit, Christine] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. [Wilson, Mary E.] Harvard Univ, Dept Global Hlth & Populat, Sch Publ Hlth, Boston, MA USA. [Iyer, Hari; MacLeod, William B.; Hamer, Davidson H.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [Yanni, Emad; Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Ooi, Winnie] Lahey Clin Fdn, Travel & Trop Med Clin, Burlington, MA USA. [Kogelman, Laura] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA. RP Hochberg, NS (reprint author), Boston Univ, Dept Epidemiol, Sch Publ Hlth, 715 Albany St,Talbot 420E, Boston, MA 02118 USA. EM nhoch@bu.edu FU CDC; Boston Medical Center [U19C100508-01] FX This study was funded by a cooperative agreement between the CDC and Boston Medical Center (U19C100508-01). NR 44 TC 20 Z9 21 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD NOV PY 2013 VL 88 IS 11 BP 1231 EP 1240 DI 10.1016/j.mayocp.2013.07.018 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 258TA UT WOS:000327480400013 PM 24120073 ER PT J AU Cardozo, BL Sivilli, TI Crawford, C Scholte, WF Petit, P Ghitis, F Ager, A Eriksson, C AF Cardozo, Barbara Lopes Sivilli, Teresa I. Crawford, Carol Scholte, Willem F. Petit, Pilar Ghitis, Frida Ager, Alastair Eriksson, Cynthia TI Factors Affecting Mental Health of Local Staff Working in the Vanni Region, Sri Lanka SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE national staff; humanitarian aid workers; depression; PTSD; Sri Lanka ID SOCIAL SUPPORT; WORKERS; TRAUMA; SYMPTOMS; WAR; REFUGEES; EVENTS; RELIEF AB In the aftermath of the civil war that extended from 1983-2009, humanitarian organizations provided aid to the conflict-affected population of the Vanni region in northern Sri Lanka. In August, 2010, a needs assessment was conducted to determine the mental-health status of Sri Lankan national humanitarian aid staff working in conditions of stress and hardship, and consider contextual and organizational characteristics influencing such status. A total of 398 staff members from nine organizations working in the Vanni area participated in the survey, which assessed stress, work characteristics, social support, coping styles, and symptoms of psychological distress. Exposure to traumatic, chronic, and secondary stressors was common. Nineteen percent of the population met criteria for posttraumatic stress disorder (PTSD), 53% of participants reported elevated anxiety symptoms, and 58% reported elevated depression symptoms. Those reporting high levels of support from their organizations were less likely to suffer depression and PTSD symptoms than those reporting lower levels of staff support (OR = 0.23, p < .001) and (OR = 0.26, p < .001), respectively. Participants who were age 55 or older were significantly less likely to suffer anxiety symptoms than those who were between 15 and 34 years of age (OR = 0.13, p = .011). Having experienced travel difficulties was significantly associated with more anxiety symptoms (OR = 3.35, p < .001). It was recommended that organizations provide stress-management training and increase support to their staff. C1 [Cardozo, Barbara Lopes; Sivilli, Teresa I.] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Ctr Global Hlth, Atlanta, GA 30341 USA. [Sivilli, Teresa I.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Crawford, Carol] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. [Scholte, Willem F.; Petit, Pilar; Ghitis, Frida] Antares Fdn, Amsterdam, Netherlands. [Scholte, Willem F.] Equator Fdn, Diemen, Netherlands. [Ager, Alastair] Columbia Univ, Mailman Sch Publ Hlth, Dept Clin Populat & Family, New York, NY 10027 USA. RP Cardozo, BL (reprint author), Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Ctr Global Hlth, 4770 Buford Hwy NE,Mailstop F-60, Atlanta, GA 30341 USA. EM bhc8@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 3 Z9 3 U1 4 U2 16 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2013 VL 5 IS 6 BP 581 EP 590 DI 10.1037/a0030969 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 259UR UT WOS:000327552300010 PM 27099648 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Friclkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E Van Antwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Friclkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward Van Antwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary SO RESPIRATORY CARE LA English DT Article DE ventilator-associated pneumonia; ICU; epidemiology; public health; critical care; mechanicalventilation C1 [Magill, Shelley S.; Friclkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Div Pulm Crit Care & Sleep, Warren Alpert Med Sch, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [Van Antwerpen, Carole] New York State Dept Hlth, Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [Van Antwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The work described herein was supported by the Centers for Disease Control and Prevention (CDC). NR 2 TC 2 Z9 2 U1 0 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD NOV PY 2013 VL 58 IS 11 BP 1985 EP 1989 DI 10.4187/respcare.02759 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 252JZ UT WOS:000327002300021 ER PT J AU Ometto, T Durigon, EL de Araujo, J Aprelon, R de Aguiar, DM Cavalcante, GT Melo, RM Levi, JE de Azevedo, SM Petry, MV Neto, IS Serafini, P Villalobos, E Cunha, EMS Lara, MDCSH Nava, AFD Nardi, MS Hurtado, R Rodrigues, R Sherer, AL Sherer, JDM Geraldi, MP de Seixas, MMM Peterka, C Bandeira, DD Pradel, J Vachiery, N Labruna, MB de Camargo, LMA Lanciotti, R Lefrancois, T AF Ometto, Tatiana Durigon, Edison Luiz de Araujo, Jansen Aprelon, Rosalie de Aguiar, Daniel Moura Cavalcante, Guacyara Tenorio Melo, Rosane Marini Levi, Jose Eduardo de Azevedo Junior, Severino Mendes Petry, Maria Virginia Neto, Isaac Simao Serafini, Patricia Villalobos, Eliana Sequetin Cunha, Elenice Maria Lara, Maria do Carmo Custodio S. H. Dales Nava, Alessandra Ferreira Nardi, Marcello Schiavo Hurtado, Renata Rodrigues, Roberta Sherer, Angelo Luis Martins Sherer, Janete de Fatima Geraldi, Marcelo Plaisant Moraes de Seixas, Marina Maria Peterka, Cassio Bandeira, Debora de Souza Pradel, Jennifer Vachiery, Nathalie Labruna, Marcelo Bahia Aranha de Camargo, Luiz Marcelo Lanciotti, Robert Lefrancois, Thierry TI West Nile virus surveillance, Brazil, 2008-2010 SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE West Nile virus; Serology; Molecular biology; Brazil; Equids; Migratory birds ID LINKED IMMUNOSORBENT ASSAYS; SEROLOGIC EVIDENCE; HORSES; ANTIBODIES; MEXICO; INFECTION; STATE; ARGENTINA; EVOLUTION; AMERICA AB Background: West Nile virus (WNV) is an emergent pathogen that is widely distributed in North and Central America. The recent introduction in South America has focused attention on the spread of WNV across Southern American countries. The transmission network involves mosquitoes, birds, horses and humans. Methods: The serological evaluation of sera from 678 equids and 478 birds was performed using a WNV-specific blocking ELISA, and only the positive results were confirmed by plaque reduction neutralisation tests (PRNTs). Molecular analysis was performed on sera from 992 healthy equids and on 63 macerates of brains from equids that died of encephalitis and had previously tested negative for other pathogens. We also tested swabs from 928 birds. The samples analysed were collected in different biomes of Brazil. Results: We identified WNV antibodies by ELISA in thirteen equids and five birds, and PRNT90 confirmed WNV positivity in four equid samples collected in 2009 in an area between the Amazon and the Pantanal. None of the ELISA positive bird samples were confirmed by PRNT90, and all samples tested by RT-PCR were negative. Conclusion: WNV circulation is confirmed by this large scale survey even in the absence of detection of clinical cases. C1 [Ometto, Tatiana; Durigon, Edison Luiz; de Araujo, Jansen; Hurtado, Renata; Moraes de Seixas, Marina Maria] Univ Sao Paulo, Lab Virol Clin & Mol BSL3, ICB, BR-05508900 Sao Paulo, Brazil. [Aprelon, Rosalie; Pradel, Jennifer; Vachiery, Nathalie; Lefrancois, Thierry] CIRAD UMR CMAEE CIRAD INRA, Petit Bourg 97170, Guadeloupe. [de Aguiar, Daniel Moura] Univ Fed Mato Grosso UFMT, Dept Clin Med Vet, BR-78060900 Cuiaba, Brazil. [Cavalcante, Guacyara Tenorio] Univ Sao Paulo, Inst Fis, BR-05508090 Sao Paulo, Brazil. [Melo, Rosane Marini] Inst Defesa Agr Estado Mato Gross INDEA, BR-78050970 Cuiaba, Brazil. [Levi, Jose Eduardo; Geraldi, Marcelo Plaisant] Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil. [de Azevedo Junior, Severino Mendes; Rodrigues, Roberta] Univ Fed Rural Pernambuco UFRPE, BR-52171900 Recife, PE, Brazil. [Petry, Maria Virginia; Sherer, Angelo Luis; Martins Sherer, Janete de Fatima] Univ Vale Rio Sinos UNISINOS, BR-93022000 Sao Leopoldo, Brazil. [Neto, Isaac Simao; Serafini, Patricia] Ctr Nacl Pesquisa & Conservacao Aves Silvestre CE, BR-88053700 Florianopolis, SC, Brazil. [Villalobos, Eliana; Sequetin Cunha, Elenice Maria; Lara, Maria do Carmo Custodio S. H.] Inst Biol, Ctr Pesquisa & Desenvolvimento Sanidade Anim, BR-04014002 Sao Paulo, Brazil. [Dales Nava, Alessandra Ferreira] EcoHlth Alliance, BR-05508270 Sao Paulo, Brazil. [Nardi, Marcello Schiavo; Peterka, Cassio; Bandeira, Debora de Souza] IPE, BR-19280000 Teodoro Sampaio, Brazil. [Hurtado, Renata; Labruna, Marcelo Bahia] Univ Sao Paulo, Fac Med Vet & Zootecnia, BR-05508270 Sao Paulo, Brazil. [Aranha de Camargo, Luiz Marcelo] Univ Sao Paulo, Inst Ciencias Biomed 5, BR-78965300 Monte Negro, Brazil. [Lanciotti, Robert] Ctr Dis Control & Prevent CDC, Ft Collins, CO 80521 USA. RP Ometto, T (reprint author), Univ Sao Paulo, Lab Virol Clin & Mol BSL3, ICB, BR-05508900 Sao Paulo, Brazil. EM tatiometto@usp.br RI Aguiar, Daniel/F-1268-2013; lefrancois, thierry/C-5070-2011; OI Aguiar, Daniel/0000-0001-8631-522X; lefrancois, thierry/0000-0001-8793-5228; Durigon, Edison/0000-0003-4898-6553 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2009/05994-9]; Interreg IV Caraibe 'CaribVET' (Europe Project); FEDER FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2009/05994-9); Interreg IV Caraibe 'CaribVET' (Europe Project) and FEDER 2007-2013 'Risque en sante animale et vegetale'. NR 33 TC 16 Z9 16 U1 1 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0035-9203 EI 1878-3503 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD NOV PY 2013 VL 107 IS 11 BP 723 EP 730 DI 10.1093/trstmh/trt081 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 258LN UT WOS:000327460900008 PM 24008895 ER PT J AU Rollinson, D Knopp, S Levitz, S Stothard, JR Tchuente, LAT Garba, A Mohammed, KA Schur, N Person, B Colley, DG Utzinger, J AF Rollinson, David Knopp, Stefanie Levitz, Sarah Stothard, J. Russell Tchuente, Louis-Albert Tchuem Garba, Amadou Mohammed, Khalfan A. Schur, Nadine Person, Bobbie Colley, Daniel G. Utzinger, Juerg TI Time to set the agenda for schistosomiasis elimination SO ACTA TROPICA LA English DT Article DE Schistosomiasis; Schistosoma haematobium; Schistosoma japonicum; Schistosoma mansoni; Morbidity control; Transmission control; Elimination ID NEGLECTED TROPICAL DISEASES; POLYMERASE-CHAIN-REACTION; SUB-SAHARAN AFRICA; INTESTINAL PARASITIC INFECTIONS; SOIL-TRANSMITTED HELMINTHIASIS; URINARY SCHISTOSOMIASIS; HEALTH-EDUCATION; PRAZIQUANTEL TREATMENT; HAEMATOBIUM INFECTION; TRANSMISSION SITES AB It is time to raise global awareness to the possibility of schistosomiasis elimination and to support endemic countries in their quest to determine the most appropriate approaches to eliminate this persistent and debilitating disease. The main interventions for schistosomiasis control are reviewed, including preventive chemotherapy using praziquantel, snail control, sanitation, safe water supplies, and behaviour change strategies supported by information, education and communication (IEC) materials. Differences in the biology and transmission of the three main Schistosoma species (i.e. Schistosoma haematobium, S. mansoni and S. japonicum), which impact on control interventions, are considered. Sensitive diagnostic procedures to ensure adequate surveillance in areas attaining low endemicity are required. The importance of capacity building is highlighted. To achieve elimination, an intersectoral approach is necessary, with advocacy and action from local communities and the health community to foster cooperative ventures with engineers, the private sector, governments and non-governmental organizations specialized in water supply and sanitation. Examples of successful schistosomiasis control programmes are reviewed to highlight what has been learnt in terms of strategy for control and elimination. These include St. Lucia and other Caribbean islands, Brazil and Venezuela for S. mansoni; Saudi Arabia and Egypt for both S. mansoni and S. haematobium; Morocco, Tunisia, Algeria, Mauritius and the Islamic Republic of Iran for S. haematobium; Japan and the People's Republic of China for S. japonicum. Additional targets for elimination or even eradication could be the two minor human schistosome species S. guineenisis and S. intercalatum, which have a restricted distribution in West and Central Africa. The examples show that elimination of schistosomiasis is an achievable and desirable goal requiring full integration of preventive chemotherapy with the tools of transmission control. An agenda for the elimination of schistosomiasis would aim to identify the gaps in knowledge, and define the tools, strategies and guidelines that will help national control programmes move towards elimination, including an internationally accepted mechanism that allows verification/confirmation of elimination. (C) 2012 Elsevier B.V. All rights reserved. C1 [Rollinson, David; Levitz, Sarah] Nat Hist Museum, Dept Zool, Wolfson Wellcome Biomed Labs, London SW7 5BD, England. [Knopp, Stefanie; Garba, Amadou; Schur, Nadine; Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland. [Knopp, Stefanie; Garba, Amadou; Schur, Nadine; Utzinger, Juerg] Univ Basel, CH-4003 Basel, Switzerland. [Stothard, J. Russell] Univ Liverpool, Liverpool Sch Trop Med, Ctr Trop & Infect Dis, Liverpool L3 5QA, Merseyside, England. [Tchuente, Louis-Albert Tchuem] Minist Publ Hlth, Natl Programme Control Schistosomiasis & Intestin, Yaounde, Cameroon. [Tchuente, Louis-Albert Tchuem] Univ Yaounde, Lab Parasitol & Ecol, Yaounde, Cameroon. [Tchuente, Louis-Albert Tchuem] Ctr Schistosomiasis & Parasitol, Yaounde, Cameroon. [Garba, Amadou] Minist Sante Publ & Lutte Contre Endemies, Programme Natl Lutte Contre Bilharziose & Geohelm, Niamey, Niger. [Mohammed, Khalfan A.] Minist Hlth, Helminth Control Lab Unguja, Zanzibar, Tanzania. [Person, Bobbie] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Colley, Daniel G.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Colley, Daniel G.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. RP Rollinson, D (reprint author), Nat Hist Museum, Dept Zool, Wolfson Wellcome Biomed Labs, Cromwell Rd, London SW7 5BD, England. EM d.rollinson@nhm.ac.uk RI Rollinson, David/C-7406-2009 FU European Union (EU) [FP6-2004-DEV-3/PL032203]; Schistosomiasis Consortium for Operational Research and Evaluation through the University of Georgia Research Foundation; Forschungsfonds der Universitat Basel; University of Georgia [RR374-053/4787996]; Bill & Melinda Gates Foundation [50816] FX Many of the ideas presented here arose thanks to funding from the European Union (EU)-funded Specific Targeted Research Project FP6-2004-DEV-3/PL032203 (CONTRAST: http://www.eu-contrast.eu) programme and the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE: http://score.uga.edu) funded through the University of Georgia Research Foundation. S. Knopp was supported by the "Forschungsfonds der Universitat Basel" and by a sub-award (no. RR374-053/4787996) from the University of Georgia, which is awarded by the Bill & Melinda Gates Foundation (prime award no. 50816). We are grateful to Dr. Lester Chitsulo from WHO and three anonymous referees for a series of helpful comments and suggestions. NR 151 TC 135 Z9 142 U1 12 U2 65 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD NOV PY 2013 VL 128 IS 2 SI SI BP 423 EP 440 DI 10.1016/j.actatropica.2012.04.013 PG 18 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 249IW UT WOS:000326771900027 PM 22580511 ER PT J AU Di, YP Tkach, AV Yanamala, N Stanley, S Gao, SL Shurin, MR Kisin, ER Kagan, VE Shvedova, A AF Di, Y. Peter Tkach, Alexey V. Yanamala, Naveena Stanley, Shyla Gao, Shengli Shurin, Michael R. Kisin, Elena R. Kagan, Valerian E. Shvedova, Anna TI Dual Acute Proinflammatory and Antifibrotic Pulmonary Effects of Short Palate, Lung, and Nasal Epithelium Clone-1 after Exposure to Carbon Nanotubes SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE SPLUNC1; BPIFA1; carbon nanotube; fibrosis; inflammation ID PROTEIN-NANOPARTICLE INTERACTIONS; PSEUDOMONAS-AERUGINOSA INFECTION; HOST-DEFENSE; LAVAGE FLUID; PLUNC; MICE; IDENTIFICATION; SPLUNC1; GENE; INFLAMMATION AB Carbon nanotubes (CNTs; allotropes of carbon with a cylindrical nanostructure) have emerged as one of the most commonly used types of nanomaterials, with numerous applications in industry and biomedicine. However, the inhalation of CNTs has been shown to elicit pulmonary toxicity, accompanied by a robust inflammatory response with an early-onset fibrotic phase. Epithelial host-defense proteins represent an important component of the pulmonary innate immune response to foreign inhalants such as particles and bacteria. The short palate, lung, and nasal epithelium clone-1 (SPLUNC1) protein, a member of the bactericidal/permeability-increasing-fold (BPIF)-containing protein family, is a 25-kD secretory protein that is expressed in nasal, oropharyngeal, and lung epithelia, and has been shown to have multiple functions, including antimicrobial and chemotactic activities, as well as surfactant properties. This study sought to assess the importance of SPLUNC1-mediated pulmonary responses in airway epithelial secretions, and to explore the biological relevance of SPLUNC1 to inhaled particles in a single-walled carbon nanotube (SWCNT) model. Using Scgb1a1-hSPLUNC1 transgenic mice, we observed that SPLUNC1 significantly modified host inflammatory responses by increasing leukocyte recruitment and enhancing phagocytic activity. Furthermore, we found that transgenic mice were more susceptible to SWCNT exposure at the acute phase, but showed resistance against lung fibrogenesis through pathological changes in the long term. The binding of SPLUNC1 also attenuated SWCNT-induced TNF-alpha secretion by RAW 264.7 macrophages. Taken together, our data indicate that SPLUNC1 is an important component of mucosal innate immune defense against pulmonary inhaled particles. C1 [Di, Y. Peter; Gao, Shengli; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA. [Tkach, Alexey V.; Yanamala, Naveena; Stanley, Shyla; Kisin, Elena R.; Shvedova, Anna] NIOSH, Pathol & Physiol Res Branch, Ctr Dis Control & Prevent, Morgantown, WV USA. [Stanley, Shyla; Shvedova, Anna] W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA. [Shurin, Michael R.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. RP Di, YP (reprint author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 100 Technol Dr,Suite 322, Pittsburgh, PA 15219 USA. EM peterdi@pitt.edu; peterdi@pitt.edu RI Di, Yuanpu Peter/H-4191-2016 OI Di, Yuanpu Peter/0000-0003-2028-2087 FU National Institute of Occupational and Safety Health grants (NIOSH) [3927ZKNL, 2927ZKCY]; National Institutes of Health [R01 HL-091938, ES-019304, HL-070755, U19 AI-068021]; University of Pittsburgh Central Research Development Fund FX This work was supported by National Institute of Occupational and Safety Health grants (NIOSH) - 3927ZKNL & 2927ZKCY (A. S.), National Institutes of Health grants R01 HL-091938 (Y.P.D.), ES-019304, HL-070755, and U19 AI-068021 (V. E. K.), and by the University of Pittsburgh Central Research Development Fund (Y.P.D.). NR 48 TC 9 Z9 9 U1 0 U2 11 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD NOV PY 2013 VL 49 IS 5 BP 759 EP 767 DI 10.1165/rcmb.2012-0435OC PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 251WV UT WOS:000326964800009 PM 23721177 ER PT J AU McCaig, LF Burt, CW Schappert, SM Albert, M Uddin, S Brown, C Madans, J AF McCaig, Linda F. Burt, Catharine W. Schappert, Susan M. Albert, Michael Uddin, Sayeedha Brown, Clarice Madans, Jennifer TI NHAMCS: Does It Hold Up to Scrutiny? SO ANNALS OF EMERGENCY MEDICINE LA English DT Letter ID EMERGENCY-DEPARTMENT C1 [McCaig, Linda F.; Burt, Catharine W.; Schappert, Susan M.; Albert, Michael; Uddin, Sayeedha; Brown, Clarice] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Madans, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP McCaig, LF (reprint author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 15 TC 6 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD NOV PY 2013 VL 62 IS 5 BP 549 EP 551 DI 10.1016/j.annemergmed.2013.04.028 PG 3 WC Emergency Medicine SC Emergency Medicine GA 251CU UT WOS:000326906200026 PM 24161117 ER PT J AU Brueck, SE Panaccio, MP Stancescu, D Woskie, S Estill, C Waters, M AF Brueck, Scott E. Panaccio, Mary Prince Stancescu, Daniel Woskie, Susan Estill, Cheryl Waters, Martha TI Noise Exposure Reconstruction and Evaluation of Exposure Trends in Two Large Automotive Plants SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE automobile industry; noise; retrospective exposure assessment; task-based exposure ID INDUCED HEARING-LOSS; WORKERS; COHORT AB This study used a task-based approach to reconstruct employee noise exposures at two large automotive manufacturing plants for the period 19701989, utilizing historic noise measurement data, work history records, documented changes in plant operations, focus group discussions, structured interviews with long-tenure employees, and task-based job profiles. Task-based job noise exposure profiles were developed in the 1990s when the plants conducted task-based noise monitoring. Under the assumption that tasks and time-at-task profile within jobs did not change over time, these profiles were applied to historic jobs. By linking historic noise exposure measurements to job tasks, this approach allowed task-based reconstructed noise exposure profiles to capture variability of daily noise exposures. Reconstructed noise exposures, along with task-based noise exposure measurements collected at each plant during the 1990s, were analyzed to examine time trends in workplace noise levels and worker noise exposure. Our analysis of noise exposure trends revealed that noise levels for many jobs declined by 3 dBA from 1970 to 1998 as operational and equipment changes occurred in the plants and some noise control measures were implemented, but for some jobs, noise levels increased in the mid- to late 1990s, most likely because of an increase in production at that time. Overall, the percentage of workers exposed to noise levels > 90 dBA decreased from 95% in 1970 to 54% in 1998 at one of the plants and decreased from 36% in 1970 to similar to 5% in 1999 at the other plant. These reductions indicate a degree of success for the hearing conservation program. However, the actual number of employees with noise exposure > 90 dBA increased because of a substantial increase in the number of production employees, particularly in jobs with high noise levels, which shows a hearing conservation program challenge that companies face during periods of increased production. Future analysis of hearing levels in these plant populations will help determine whether noise level reduction translates into decreased hearing loss at these plants. C1 [Brueck, Scott E.] NIOSH, Hazard Evaluat & Tech Assistance Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Panaccio, Mary Prince; Estill, Cheryl] NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Stancescu, Daniel] NIOSH, Div Compensat Anal & Support, Cincinnati, OH 45226 USA. [Woskie, Susan] Univ Massachusetts, Dept Work Environm, Lowell, MA 01854 USA. [Waters, Martha] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Brueck, SE (reprint author), NIOSH, Hazard Evaluat & Tech Assistance Branch, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS R-11, Cincinnati, OH 45226 USA. EM sbrueck@cdc.gov FU National Occupational Research Agenda of the National Institute for Occupational Safety and Health FX National Occupational Research Agenda of the National Institute for Occupational Safety and Health. NR 31 TC 2 Z9 2 U1 3 U2 19 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD NOV PY 2013 VL 57 IS 9 BP 1091 EP 1104 DI 10.1093/annhyg/met035 PG 14 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 251WX UT WOS:000326965200001 PM 23852046 ER PT J AU Birch, ME Ruda-Eberenz, TA Chai, M Andrews, R Hatfield, RL AF Birch, M. Eileen Ruda-Eberenz, Toni A. Chai, Ming Andrews, Ronnee Hatfield, Randal L. TI Properties that Influence the Specific Surface Areas of Carbon Nanotubes and Nanofibers SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE BET-specific surface area; carbon nanotube; nanofiber; nanomaterial ID MOBILITY-BASED METHODS; OXIDATIVE STRESS; PORE STRUCTURE; STRUCTURAL-CHARACTERIZATION; INHALATION EXPOSURE; PULMONARY TOXICITY; TITANIUM-DIOXIDE; EPITHELIAL-CELLS; AQUEOUS-SOLUTION; GAS-ADSORPTION AB Commercially available carbon nanotubes and nanofibers were analyzed to examine possible relationships between their BrunauerEmmettTeller specific surface areas (SSAs) and their physical and chemical properties. Properties found to influence surface area were number of walls/diameter, impurities, and surface functionalization with hydroxyl and carboxyl groups. Characterization by electron microscopy, energy-dispersive X-ray spectrometry, thermogravimetric analysis, and elemental analysis indicates that SSA can provide insight on carbon nanomaterials properties, which can differ vastly depending on synthesis parameters and post-production treatments. In this study, how different properties may influence surface area is discussed. The materials examined have a wide range of surface areas. The measured surface areas differed from product specifications, to varying degrees, and between similar products. Findings emphasize the multiple factors that influence surface area and mark its utility in carbon nanomaterial characterization, a prerequisite to understanding their potential applications and toxicities. Implications for occupational monitoring are discussed. C1 [Birch, M. Eileen; Andrews, Ronnee] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Hatfield, Randal L.] Pacific Surface Sci Inc, Oxnard, CA 93033 USA. RP Birch, ME (reprint author), NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, MS-R7 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM mib2@cdc.gov FU Intramural CDC HHS [CC999999] NR 78 TC 9 Z9 9 U1 2 U2 30 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD NOV PY 2013 VL 57 IS 9 BP 1148 EP 1166 DI 10.1093/annhyg/met042 PG 19 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 251WX UT WOS:000326965200006 PM 24029925 ER PT J AU Mai, CT Kucik, JE Isenburg, J Feldkamp, ML Marengo, LK Bugenske, EM Thorpe, PG Jackson, JM Correa, A Rickard, R Alverson, CJ Kirby, RS AF Mai, Cara T. Kucik, James E. Isenburg, Jennifer Feldkamp, Marcia L. Marengo, Lisa K. Bugenske, Erin M. Thorpe, Phoebe G. Jackson, Jodi M. Correa, Adolfo Rickard, Russel Alverson, C. J. Kirby, Russell S. CA Natl Birth Defects Prevention TI Selected Birth Defects Data from Population-Based Birth Defects Surveillance Programs in the United States, 2006 to 2010: Featuring Trisomy Conditions SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE Trisomies; Birth; Defects; Prevalence; Down Syndrome ID DOWN-SYNDROME; METROPOLITAN ATLANTA; PRENATAL-DIAGNOSIS; MATERNAL AGE; 10 REGIONS; PREVALENCE; EPIDEMIOLOGY; SURVIVAL; TRENDS; PREDICTORS C1 [Mai, Cara T.; Kucik, James E.; Thorpe, Phoebe G.; Jackson, Jodi M.; Alverson, C. J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Kucik, James E.; Bugenske, Erin M.] Carter Consulting, Atlanta, GA USA. [Feldkamp, Marcia L.] Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. [Marengo, Lisa K.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Rickard, Russel] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. RP Mai, CT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM CWM7@cdc.gov FU Intramural CDC HHS [CC999999] NR 41 TC 21 Z9 21 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2013 VL 97 IS 11 BP 709 EP 725 DI 10.1002/bdra.23198 PG 17 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 255DK UT WOS:000327219400001 PM 24265125 ER PT J AU Jackson, JM Druschel, CM Shapira, SK AF Jackson, Jodi M. Druschel, Charlotte M. Shapira, Stuart K. TI Expanding Diagnostic Testing beyond Cytogenetics: Implications for Birth Defects Research and Surveillance SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Editorial Material ID PRENATAL-DIAGNOSIS; DOWN-SYNDROME; CHROMOSOMAL MICROARRAY; MATERNAL PLASMA; FETAL DNA; POPULATION; HAWAII; ABNORMALITIES; PREVALENCE; TRISOMY-18 C1 [Jackson, Jodi M.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Druschel, Charlotte M.] New York State Dept Hlth, New York State Congenital Malformat Registry, Troy, NY USA. [Shapira, Stuart K.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Off Director, Atlanta, GA USA. RP Jackson, JM (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 44 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2013 VL 97 IS 11 BP 726 EP 729 DI 10.1002/bdra.23195 PG 4 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 255DK UT WOS:000327219400002 PM 24265126 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events Executive Summary SO CHEST LA English DT Article C1 [Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Balk, Robert; Burns, Suzanne M.; Deutschman, Clifford S.; Gutterman, David; Hammer, Beth; Hill, Nicholas S.; Kollef, Marin; Levy, Mitchell; Lipsett, Pamela] Amer Thorac Soc, Soc Crit Care Med, Crit Care Soc Collaborat Amer Assoc Crit Care Nur, Amer Coll Chest Phys, Philadelphia, PA USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Surveillance Working Grp, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Professionals Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [VanAntwerpen, Carole] Council State & Territorial Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept Hlth & Human Serv, Off Dis Prevent & Hlth Promot, Washington, DC USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov OI Diekema, Daniel/0000-0003-1273-0724 NR 2 TC 6 Z9 6 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2013 VL 144 IS 5 BP 1448 EP 1452 DI 10.1378/chest.13-1640 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 254DI UT WOS:000327143700010 PM 24189858 ER PT J AU Burke, W Antommaria, AHM Bennett, R Botkin, J Clayton, EW Henderson, GE Holm, IA Jarvik, GP Khoury, MJ Knoppers, BM Press, NA Ross, LF Rothstein, MA Saal, H Uhlmann, WR Wilfond, B Wolf, SM Zimmern, R AF Burke, Wylie Antommaria, Armand H. Matheny Bennett, Robin Botkin, Jeffrey Clayton, Ellen Wright Henderson, Gail E. Holm, Ingrid A. Jarvik, Gail P. Khoury, Muin J. Knoppers, Bartha Maria Press, Nancy A. Ross, Lainie Friedman Rothstein, Mark A. Saal, Howard Uhlmann, Wendy R. Wilfond, Benjamin Wolf, Susan M. Zimmern, Ron TI Recommendations for returning genomic incidental findings? We need to talk! SO GENETICS IN MEDICINE LA English DT Article ID BLOOD-PRESSURE; MANAGEMENT; PROGRAM; DISEASE AB The American College of Medical Genetics and Genomics recently issued recommendations for reporting incidental findings from clinical whole-genome sequencing and whole-exome sequencing. The recommendations call for evaluating a specific set of genes as part of all whole-genome sequencing/whole-exome sequencing and reporting all pathogenic variants irrespective of patient age. The genes are associated with highly penetrant disorders for which treatment or prevention is available. The effort to generate a list of genes with actionable findings is commendable, but the recommendations raise several concerns. They constitute a call for opportunistic screening, through intentional effort to identify pathogenic variants in specified genes unrelated to the clinical concern that prompted testing. Yet for most of the genes, we lack evidence about the predictive value of testing, genotype penetrance, spectrum of phenotypes, and efficacy of interventions in unselected populations. Furthermore, the recommendations do not allow patients to decline the additional findings, a position inconsistent with established norms. Finally, the recommendation to return adult,onset disease findings when children are tested is inconsistent with current professional consensus, including other policy statements of the American College of Medical Genetics and Genomics. Instead of premature practice recommendations, we call for robust dialogue among stakeholders to define a pathway to normatively sound, evidence-based guidelines. C1 [Burke, Wylie] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98195 USA. [Antommaria, Armand H. Matheny] Cincinnati Childrens Hosp Med Ctr, Eth Ctr, Cincinnati, OH 45229 USA. [Bennett, Robin; Jarvik, Gail P.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Botkin, Jeffrey] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Clayton, Ellen Wright] Vanderbilt Univ, Ctr Biomed Eth & Soc, Nashville, TN 37235 USA. [Clayton, Ellen Wright] Vanderbilt Univ, Sch Law, Nashville, TN 37240 USA. [Henderson, Gail E.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. [Holm, Ingrid A.] Boston Childrens Hosp, Div Genet, Boston, MA USA. [Holm, Ingrid A.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA. [Holm, Ingrid A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Knoppers, Bartha Maria] McGill Univ, Ctr Genom & Policy, Montreal, PQ, Canada. [Press, Nancy A.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Press, Nancy A.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Ross, Lainie Friedman] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA. [Ross, Lainie Friedman] Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA. [Rothstein, Mark A.] Univ Louisville, Sch Med, Inst Bioeth, Louisville, KY 40292 USA. [Saal, Howard] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA. [Uhlmann, Wendy R.] Univ Michigan, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA. [Uhlmann, Wendy R.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. [Wilfond, Benjamin] Univ Washington, Treuman Katz Ctr Pediat Bioeth, Seattle Childrens Res Inst, Seattle, WA 98195 USA. [Wilfond, Benjamin] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Wolf, Susan M.] Univ Minnesota, Sch Med, Sch Law, Minneapolis, MN 55455 USA. [Wolf, Susan M.] Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA. [Zimmern, Ron] Fdn Genom & Populat Hlth, Cambridge, England. RP Burke, W (reprint author), Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98195 USA. EM wburke@u.washington.edu RI Jarvik, Gail/N-6476-2014; OI Jarvik, Gail/0000-0002-6710-8708; Clayton, Ellen/0000-0002-0308-4110 FU National Institutes of Health [P50HG003374, 1R21HG00612, P50HG004488, 1R01HG006615, HG005491, U01HG006507, U01HG006375, R01HG005092, R01HG002213, 1R01CA154517]; Genome Canada/Genome Quebec; Robert Wood Johnson Foundation [69763] FX This work was supported in part by National Institutes of Health grants P50HG003374 (W.B., G.P.J., B.W.), 1R21HG00612 (E.W.C, B.M.K., L.F.R.), P50HG004488 (G.E.H.), 1R01HG006615 (I.A.H.), HG005491 (I.A.H.), U01HG006507 (G.RJ., W.B.), U01HG006375 (G.P.J.), R01HG005092 (W.R.U.), R01HG002213 (W.R.U.), and 1R01CA154517 (S.M.W.), Genome Canada/Genome Quebec (B.M.K.), and Robert Wood Johnson Foundation grant 69763 (S.M.W.). NR 26 TC 118 Z9 118 U1 4 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2013 VL 15 IS 11 BP 854 EP 859 DI 10.1038/gim.2013.113 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 250LB UT WOS:000326853200003 PM 23907645 ER PT J AU Mueller, PW Lyons, J Kerr, G Haase, CP Isett, RB AF Mueller, Patricia W. Lyons, Justine Kerr, Gregory Haase, Chad P. Isett, R. Benjamin TI Standard enrichment methods for targeted next-generation sequencing in high-repeat genomic regions SO GENETICS IN MEDICINE LA English DT Letter C1 [Mueller, Patricia W.; Lyons, Justine; Kerr, Gregory] Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Newborn Screening & Mol Biol Branch, Atlanta, GA 30333 USA. [Haase, Chad P.] Emory Univ, Dept Human Genet, Emory GRA Genom Core, Atlanta, GA 30322 USA. [Isett, R. Benjamin] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. RP Mueller, PW (reprint author), Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Newborn Screening & Mol Biol Branch, Atlanta, GA 30333 USA. EM pwm2@cdc.gov NR 3 TC 3 Z9 3 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2013 VL 15 IS 11 BP 910 EP 911 DI 10.1038/gim.2013.119 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA 250LB UT WOS:000326853200012 PM 24196000 ER PT J AU Heimburg-Molinaro, J Priest, JW Live, D Boons, GJ Song, XZ Cummings, RD Mead, JR AF Heimburg-Molinaro, Jamie Priest, Jeffery W. Live, David Boons, Geert-Jan Song, Xuezheng Cummings, Richard D. Mead, Jan R. TI Microarray Analysis of the Response of Human Antibodies to Synthetic Cryptosporidium Glycopeptides SO GLYCOBIOLOGY LA English DT Meeting Abstract CT Annual Conference of the Society-for-Glycobiology CY NOV 17-20, 2013 CL St Petersburg, FL SP Soc Glycobiol C1 [Heimburg-Molinaro, Jamie; Song, Xuezheng; Cummings, Richard D.; Mead, Jan R.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Priest, Jeffery W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Live, David; Boons, Geert-Jan] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0959-6658 EI 1460-2423 J9 GLYCOBIOLOGY JI Glycobiology PD NOV PY 2013 VL 23 IS 11 MA 185 BP 1394 EP 1395 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 251YY UT WOS:000326972400195 ER PT J AU Gould, LH Rosenblum, I Nicholas, D Phan, Q Jones, TF AF Gould, L. Hannah Rosenblum, Ida Nicholas, David Phan, Quyen Jones, Timothy F. TI Contributing Factors in Restaurant- Associated Foodborne Disease Outbreaks, FoodNet Sites, 2006 and 2007 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID UNITED-STATES; PATHOGENS; SURVEILLANCE; LIMITATIONS; INFECTION; MINNESOTA; ILLNESS; WORKERS AB An estimated 48 million cases of foodborne illness occur each year in the United States, resulting in approximately 128,000 hospitalizations and 3,000 deaths. Over half of all foodborne disease outbreaks reported to the Centers for Disease Control and Prevention are associated with eating in restaurants or delicatessens. We reviewed data from restaurant-associated foodborne disease outbreaks to better understand the factors that contribute to these outbreaks. Data on restaurant-associated foodborne disease outbreaks reported by sites participating in the Foodborne Diseases Active Surveillance Network (FoodNet) were analyzed to characterize contributing factors reported in foodborne disease outbreaks and the levels of evidence used to identify these factors. Of 457 foodborne disease outbreaks reported in 2006 and 2007 by FoodNet sites, 300 (66%) were restaurant associated, and of these 295 (98%) had at least one reported contributing factor. One to nine (with a median of two) contributing factors were reported per outbreak. Of the 257 outbreaks with a single etiology reported, contributing factors associated with food worker health and hygiene were reported for 165 outbreaks (64%), factors associated with food preparation practices within the establishment were reported for 88 outbreaks (34%), and factors associated with contamination introduced before reaching the restaurant were reported for 56 outbreaks (22%). The pronounced role of food workers in propagating outbreaks makes it clear that more work is needed to address prevention at the local level. Food workers should be instructed not to prepare food while ill to prevent the risk of transmitting pathogens. C1 [Gould, L. Hannah; Rosenblum, Ida] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30330 USA. [Nicholas, David] New York State Dept Hlth, Albany, NY 12237 USA. [Phan, Quyen] Connecticut Dept Publ Hlth, Hartford, CT 06106 USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN 37243 USA. RP Gould, LH (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30330 USA. EM lgould@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 9 Z9 9 U1 1 U2 14 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD NOV PY 2013 VL 76 IS 11 BP 1824 EP 1828 DI 10.4315/0362-028X.JFP-13-037 PG 5 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 253NV UT WOS:000327096000001 PM 24215683 ER PT J AU Dulko, D Pace, CM Dittus, KL Sprague, BL Pollack, LA Hawkins, NA Geller, BM AF Dulko, Dorothy Pace, Claire M. Dittus, Kim L. Sprague, Brian L. Pollack, Lori A. Hawkins, Nikki A. Geller, Berta M. TI Barriers and Facilitators to Implementing Cancer Survivorship Care Plans SO ONCOLOGY NURSING FORUM LA English DT Article AB Purpose/Objectives: To evaluate the process of survivorship care plan (SCP) completion and to survey oncology staff and primary care physicians (PCPs) regarding challenges of implementing SCPs. Design: Descriptive pilot study. Setting: Two facilities in Vermont, an urban academic medical center and a rural community academic cancer center. Sample: 17 oncology clinical staff created SCPs, 39 PCPs completed surveys, and 58 patients (breast or colorectal cancer) participated in a telephone survey. Methods; Using Journey Forward tools, SCPs were created and presented to patients. PCPs received the SCP with a survey assessing its usefulness and barriers to delivery Oncology staff were interviewed to assess perceived challenges and benefits of SCPs. Qualitative and quantitative data were used to identify challenges to the development and implementation process as well as patient perceptions of the SCP visit. Main Research Variables: SCP, healthcare provider perception of barriers to completion and implementation, and patient perception of SCP visit. Findings: Oncology staff cited the time required to obtain information for SCPs as a challenge. Completing SCPs 3-6 months after treatment ended was optimal. All participants felt advanced practice professionals should complete and review SCPs with patients. The most common challenge for PCPs to implement SCP recommendations was insufficient knowledge of cancer survivor issues. Most patients found the care plan visit very useful, particularly within six months of diagnosis. Conclusions: Creation time may be a barrier to widespread SCP implementation. Cancer survivors find SCPs useful, but PCPs feel insufficient knowledge of cancer survivor issues is a barrier to providing best follow-up care. Incorporating SCPs in electronic medical records may facilitate patient identification, appropriate staff scheduling, and timely SCP creation. Implications for Nursing: Oncology nurse practitioners are well positioned to create and deliver SCPs, transitioning patients from oncology care to a PCP in a shared-care model of optimal wellness. Institution support for the time needed for SCP creation and review is imperative for sustaining this initiative. Knowledge Translation: Accessing complete medical records is an obstacle for completing SCPs. A 3-6 month window to develop and deliver SCPs may be ideal. PCPs perceive insufficient knowledge of cancer survivor issues as a barrier to providing appropriate follow-up care. C1 [Dulko, Dorothy] Univ Miami, Miami Beach, FL USA. [Pace, Claire M.] Dartmouth Hitchcock Med Ctr, Dept Radiat Oncol, Lebanon, NH 03766 USA. [Dittus, Kim L.] Univ Vermont, Dept Med, Burlington, VT 05405 USA. [Sprague, Brian L.] Univ Vermont, Dept Surg, Burlington, VT 05405 USA. [Pollack, Lori A.; Hawkins, Nikki A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Geller, Berta M.] Univ Vermont, Dept Family Med, Burlington, VT 05405 USA. [Geller, Berta M.] Univ Vermont, Dept Radiol, Burlington, VT 05405 USA. RP Dulko, D (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. EM dorothydulko@gmail.com RI Mashamba-Thompson, Tivani /B-6087-2014 FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [5U48DP001935-02, U48 DP001935] NR 11 TC 33 Z9 33 U1 6 U2 19 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD NOV PY 2013 VL 40 IS 6 BP 575 EP 580 DI 10.1188/13.ONF.575-580 PG 6 WC Oncology; Nursing SC Oncology; Nursing GA 250IT UT WOS:000326847100010 PM 24161636 ER PT J AU Wong, KK Jain, S Blanton, L Dhara, R Brammer, L Fry, AM Finelli, L AF Wong, Karen K. Jain, Seema Blanton, Lenee Dhara, Rosaline Brammer, Lynnette Fry, Alicia M. Finelli, Lyn TI Influenza-Associated Pediatric Deaths in the United States, 2004-2012 SO PEDIATRICS LA English DT Article DE influenza; mortality; pediatric; surveillance ID IMMUNIZATION PRACTICES ACIP; RANDOMIZED CONTROLLED-TRIAL; 2009 PANDEMIC INFLUENZA; LABORATORY-CONFIRMED INFLUENZA; H1N1 VIRUS-INFECTION; ADVISORY-COMMITTEE; STAPHYLOCOCCUS-AUREUS; VACCINES RECOMMENDATIONS; HOSPITALIZED CHILDREN; OSELTAMIVIR TREATMENT AB BACKGROUND: Influenza-associated deaths in children occur annually. We describe the epidemiology of influenza-associated pediatric deaths from the 2004-2005 through the 2011-2012 influenza seasons. METHODS: Deaths in children <18 years of age with laboratory-confirmed influenza virus infection were reported to the Centers for Disease Control and Prevention by using a standard case report form to collect data on demographic characteristics, medical conditions, clinical course, and laboratory results. Characteristics of children with no high-risk medical conditions were compared with those of children with high-risk medical conditions. RESULTS: From October 2004 through September 2012, 830 pediatric influenza-associated deaths were reported. The median age was 7 years (interquartile range: 1-12 years). Thirty-five percent of children died before hospital admission. Of 794 children with a known medical history, 43% had no high-risk medical conditions, 33% had neurologic disorders, and 12% had genetic or chromosomal disorders. Children without high-risk medical conditions were more likely to die before hospital admission (relative risk: 1.9; 95% confidence interval: 1.6-2.4) and within 3 days of symptom onset (relative risk: 1.6; 95% confidence interval: 1.3-2.0) than those with high-risk medical conditions. CONCLUSIONS: Influenza can be fatal in children with and without high-risk medical conditions. These findings highlight the importance of recommendations that all children should receive annual influenza vaccination to prevent influenza, and children who are hospitalized, who have severe illness, or who are at high risk of complications (age <2 years or with medical conditions) should receive antiviral treatment as early as possible. C1 [Wong, Karen K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Influenza Div, Atlanta, GA USA. [Jain, Seema; Blanton, Lenee; Dhara, Rosaline; Brammer, Lynnette; Fry, Alicia M.; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Wong, KK (reprint author), 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30329 USA. EM vij4@cdc.gov NR 55 TC 33 Z9 36 U1 1 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2013 VL 132 IS 5 BP 796 EP 804 DI 10.1542/peds.2013-1493 PG 9 WC Pediatrics SC Pediatrics GA 245PE UT WOS:000326475000046 PM 24167165 ER PT J AU Pickering, LK Peter, G Shulman, ST AF Pickering, Larry K. Peter, Georges Shulman, Stanford T. TI The Red Book Through the Ages SO PEDIATRICS LA English DT Article DE history; Red Book; pediatrics; American Academy of Pediatrics; vaccine development ID INFECTIOUS-DISEASES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS; PEDIATRICS; DIAGNOSIS; VACCINES; AMERICA; WEB AB The first edition of the Red Book was published in 1938. Since then, there have been numerous advances in the fields of infectious diseases and public health that have decreased morbidity and mortality of infants, children, and adolescents. Over the years, emerging pathogens and disease complexes have been described, sophisticated diagnostic techniques developed, advances in antimicrobial therapy have occurred, and immunizations have been implemented to prevent previously deadly diseases. Of the 18 diseases or organisms in the 1938 edition, 13 are now vaccine-preventable. Since inception of the Red Book, the aims of the editors have been to keep pace with these innovations and to continue to inform the medical community. These goals have made the Red Book a fundamental resource for pediatricians and other health care professionals in terms of guiding diagnosis, therapy, and prevention of infectious diseases. The list of 18 diseases or organisms originally described in the 1938 Red Book has expanded to include over 160 diseases or organisms in the 2012 edition. The pace of biomedical discovery, as well as the amount of information available and the number of methods for its delivery, will continue to accelerate in the future. Integration of information into future editions of the Red Book will ensure that practitioners continue to rely on the Red Book in its various electronic formats for clinical guidance and support. C1 [Pickering, Larry K.] Emory Univ, Sch Med, Atlanta, GA USA. [Pickering, Larry K.] Ctr Dis Control & Prevent, Advisory Comm Immunizat Practices, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Peter, Georges] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02912 USA. [Shulman, Stanford T.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Infect Dis, Chicago, IL USA. [Shulman, Stanford T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Pickering, LK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-27, Atlanta, GA 30333 USA. EM lpickering@cdc.gov NR 19 TC 1 Z9 1 U1 2 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2013 VL 132 IS 5 BP 898 EP 906 DI 10.1542/peds.2013-2538 PG 9 WC Pediatrics SC Pediatrics GA 245PE UT WOS:000326475000059 PM 24127477 ER PT J AU Bialek, SR Perella, D Zhang, J Mascola, L Viner, K Jackson, C Lopez, AS Watson, B Civen, R AF Bialek, Stephanie R. Perella, Dana Zhang, John Mascola, Laurene Viner, Kendra Jackson, Christina Lopez, Adriana S. Watson, Barbara Civen, Rachel TI Impact of a Routine Two-Dose Varicella Vaccination Program on Varicella Epidemiology SO PEDIATRICS LA English DT Article DE varicella/epidemiology; varicella vaccination; chickenpox/epidemiology; chickenpox vaccine; population surveillance; United States/epidemiology ID AGED 19-35 MONTHS; UNITED-STATES; CHILDREN; HOSPITALIZATIONS; IMPLEMENTATION; CHALLENGES; PREVENTION; MORTALITY; OUTBREAK; COVERAGE AB OBJECTIVE: One-dose varicella vaccination for children was introduced in the United States in 1995. In 2006, a second dose was recommended to further decrease varicella disease and outbreaks. We describe the impact of the 2-dose vaccination program on varicella incidence, severity, and outbreaks in 2 varicella active surveillance areas. METHODS: We examined varicella incidence rates and disease characteristics in Antelope Valley (AV), CA, and West Philadelphia, PA, and varicella outbreak characteristics in AV during 1995-2010. RESULTS: In 2010, varicella incidence was 0.3 cases per 1000 population in AV and 0.1 cases per 1000 population in West Philadelphia: 76% and 67% declines, respectively, since 2006 and 98% declines in both sites since 1995; incidence declined in all age groups during 2006-2010. From 2006-2010, 61.7% of case patients in both surveillance areas had been vaccinated with 1 dose of varicella vaccine and 7.5% with 2 doses. Most vaccinated case patients had <50 lesions with no statistically significant differences among 1- and 2-dose cases (62.8% and 70.3%, respectively). Varicella-related hospitalizations during 2006-2010 declined >40% compared with 2002-2005 and >85% compared with 1995-1998. Twelve varicella outbreaks occurred in AV during 2007-2010, compared with 47 during 2003-2006 and 236 during 1995-1998 (P < .01). CONCLUSIONS: Varicella incidence, hospitalizations, and outbreaks in 2 active surveillance areas declined substantially during the first 5 years of the 2-dose varicella vaccination program. Declines in incidence across all ages, including infants who are not eligible for varicella vaccination, and adults, in whom vaccination levels are low, provide evidence of the benefit of high levels of immunity in the population. C1 [Bialek, Stephanie R.; Zhang, John; Lopez, Adriana S.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Perella, Dana; Viner, Kendra; Watson, Barbara] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Mascola, Laurene; Jackson, Christina; Civen, Rachel] Cty Los Angeles Dept Publ Hlth, Los Angeles, CA USA. RP Bialek, SR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM sbialek@cdc.gov FU Centers for Disease Control and Prevention FX Funded through a cooperative agreement with the Centers for Disease Control and Prevention. NR 30 TC 40 Z9 43 U1 1 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2013 VL 132 IS 5 BP E1134 EP E1140 DI 10.1542/peds.2013-0863 PG 7 WC Pediatrics SC Pediatrics GA 245PE UT WOS:000326475000003 PM 24101763 ER PT J AU Filene, JH Kaminski, JW Valle, LA Cachat, P AF Filene, Jill H. Kaminski, Jennifer W. Valle, Linda Anne Cachat, Patrice TI Components Associated With Home Visiting Program Outcomes: A Meta-analysis SO PEDIATRICS LA English DT Article DE birth outcomes; child cognitive development; child maltreatment; child physical health; early childhood; effectiveness; home visiting; infancy; maternal life course; meta-analysis; parenting behavior ID VISITATION; SURVEILLANCE AB BACKGROUND: Although several systematic reviews have concluded that home visiting has strong evidence of effectiveness, individual evaluations have produced inconsistent results. We used a component-based, domain-specific approach to determine which characteristics most strongly predict outcomes. METHODS: Medline and PsycINFO searches were used to identify evaluations of universal and selective home visiting programs implemented in the United States. Coders trained to the study criterion coded characteristics of research design, program content, and service delivery. We conducted random-effects, inverse-variance-weighted linear regressions by using program characteristics to predict effect sizes on 6 outcome domains (birth outcomes, parenting behavior and skills, maternal life course, child cognitive outcomes, child physical health, and child maltreatment). RESULTS: Aggregated to a single effect size per study (k = 51), the mean effect size was 0.20 (95% confidence interval: 0.14 to 0.27), with a range of -0.68 to 3.95. Mean effect sizes were significant and positive for 3 of the 6 outcome domains (maternal life course outcomes, child cognitive outcomes, and parent behaviors and skills), with heterogeneity of effect sizes in all 6 outcome domains. Research design characteristics generally did not predict effect sizes. No consistent pattern of effective components emerged across all outcome domains. CONCLUSIONS: Home visiting programs demonstrated small but significant overall effects, with wide variability in the size of domain-specific effects and in the components that significantly predicted domain-specific effects. Communities may need complementary or alternative strategies to home visiting programs to ensure widespread impact on these 6 important public health outcomes. C1 [Filene, Jill H.; Cachat, Patrice] James Bell Associates, Arlington, VA 22201 USA. [Kaminski, Jennifer W.; Valle, Linda Anne] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Filene, JH (reprint author), James Bell Associates, 3033 Wilson Blvd,Suite 650, Arlington, VA 22201 USA. EM filene@jbassoc.com FU Pew Center on the States FX FUNDING: This study was supported by The Pew Center on the States. The views expressed are those of the authors and do not necessarily reflect the views of the Pew Center on the States or The Pew Charitable Trusts. NR 24 TC 18 Z9 18 U1 2 U2 22 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD NOV PY 2013 VL 132 SU 2 BP S100 EP S109 DI 10.1542/peds.2013-1021H PG 10 WC Pediatrics SC Pediatrics GA 252QF UT WOS:000327022300007 PM 24187111 ER PT J AU Brody, DJ Zhang, XL Kit, BK Dillon, CF AF Brody, Debra J. Zhang, Xinli Kit, Brian K. Dillon, Charles F. TI Reference values and factors associated with exhaled nitric oxide: US youth and adults SO RESPIRATORY MEDICINE LA English DT Article DE Exhaled nitric oxide; Reference values; National Health and Nutrition Examination Survey ID GENERAL-POPULATION; CLINICAL REMISSION; HEALTHY-CHILDREN; ATOPIC ASTHMA; HEIGHT; SAMPLE; AGE; SCHOOLCHILDREN; DETERMINANTS; COMMUNITY AB Background: Normative values for fractional exhaled nitric oxide (FeNO) and the associated co-factors are important in understanding the role of FeNO as a biomarker in airway disease. The objective of this study is to establish reference FeNO values for youth and adult asymptomatic, lifetime nonsmokers in the United States, and to describe the factors affecting these levels. Methods: Cross-sectional analyses of the National Health and Nutrition Examination Survey from 2007 to 2010. The analytic sample consisted of 4718 youth and adults, ages 6-79 years, who were lifelong nonsmokers, and free of asthma, and other respiratory conditions and symptoms. Log(e) FeNO values were used as dependent variables to test associations of demographic and health related-covariates. Multivariable regression models were used to assess the independent effect and covariate-adjusted contribution of the factors. Results: The geometric mean FeNO level was 8.3, 12.1, and 16.2 ppb for males 6-11, 12-19, and 20-79 years, and 8.4, 10.9, and 12.6 ppb for females in the corresponding age groups. Overall, FeNO levels increased with increasing age (p < 0.001), and height (p < 0.001). In all age groups, FeNO levels were positively associated with eosinophil counts, and with testing in the morning. Among youths 6-11 and 12-19 years, non-Hispanics whites had lower FeNO values than non-Hispanic blacks and Hispanic youths. No race-ethnic difference in FeNO levels was evident for adults 20-79 years. Among adolescents and adults, FeNO levels were higher for mates than for females, controlling for all other factors. Conclusions: These reference values and associated attributes in youths and adults are useful in evaluating the role of FeNO in airway diseases. Published by Elsevier Ltd. C1 [Brody, Debra J.; Zhang, Xinli; Kit, Brian K.; Dillon, Charles F.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD 20782 USA. RP Brody, DJ (reprint author), 3311 Toledo Rd,Room 4213, Hyattsville, MD 20782 USA. EM djb4@cdc.gov; fqw1@cdc.gov; igd0@cdc.gov; cid2@cdc.gov NR 55 TC 16 Z9 16 U1 0 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD NOV PY 2013 VL 107 IS 11 BP 1682 EP 1691 DI 10.1016/j.rmed.2013.07.006 PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 255HU UT WOS:000327230800006 PM 24041745 ER PT J AU Paulino, RD Benega, MA Santos, KCD da Silva, DBB Pereira, JC Sasaki, NA Silva, PE Curti, SP Oliveira, MI Carvalhanas, TRMP Peret, T Erdman, D de Paiva, TM AF Paulino, Renato de Souza Benega, Margarete Aparecida de Oliveira Santos, Katia Correa Borges da Silva, Daniela Bernardes Pereira, Juliana Cristina Sasaki, Norio Augusto Silva, Patricia Evelin Curti, Suely Pires Oliveira, Maria Isabel Carvalhanas, Telma R. M. P. Peret, Teresa Erdman, Dean de Paiva, Terezinha Maria TI DIFFERENTIAL DIAGNOSIS OF RESPIRATORY VIRUSES BY USING REAL TIME RT-PCR METHODOLOGY SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO LA English DT Letter ID CORONAVIRUS C1 [Paulino, Renato de Souza; Benega, Margarete Aparecida; de Oliveira Santos, Katia Correa; Borges da Silva, Daniela Bernardes; Pereira, Juliana Cristina; Sasaki, Norio Augusto; Silva, Patricia Evelin; Curti, Suely Pires; Oliveira, Maria Isabel; de Paiva, Terezinha Maria] Adolfo Lutz Inst, Ctr Virol, Nucleo Doencas Resp, BR-01246902 Sao Paulo, Brazil. [Carvalhanas, Telma R. M. P.] Epidemiol Surveillance Ctr State Sao Paulo, Sao Paulo, Brazil. [Peret, Teresa; Erdman, Dean] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP de Paiva, TM (reprint author), Adolfo Lutz Inst, Ctr Virol, Nucleo Doencas Resp, Av Dr Arnaldo 355, BR-01246902 Sao Paulo, Brazil. EM tterezinha@uol.com.br NR 4 TC 0 Z9 0 U1 0 U2 0 PU INST MEDICINA TROPICAL SAO PAULO PI SAO PAULO PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000, BRAZIL SN 0036-4665 EI 1678-9946 J9 REV INST MED TROP SP JI Rev. Inst. Med. Trop. Sao Paulo PD NOV-DEC PY 2013 VL 55 IS 6 BP 432 EP 432 DI 10.1590/S0036-46652013000600012 PG 1 WC Tropical Medicine SC Tropical Medicine GA 251ZT UT WOS:000326974700012 ER PT J AU Ritter, JM Sanchez, S Jones, TL Zaki, SR Drew, CP AF Ritter, J. M. Sanchez, S. Jones, T. L. Zaki, S. R. Drew, C. P. TI Neurologic Melioidosis in an Imported Pigtail Macaque (Macaca nemestrina) SO VETERINARY PATHOLOGY LA English DT Article DE Burkholderia pseudomallei; immunohistochemistry; macaque; melioidosis; meningoencephalomyelitis; neurologic; PCR ID BURKHOLDERIA-PSEUDOMALLEI; IDENTIFICATION; OSTEOMYELITIS; EPIDEMIOLOGY AB Burkholderia pseudomallei is the cause of melioidosis in humans and other animals. Disease occurs predominately in Asia and Australia. It is rare in North America, and affected people and animals typically have a history of travel to (in human cases) or importation from (in animal cases) endemic areas. We describe the gross and histopathologic features and the microbiologic, molecular, and immunohistochemical diagnoses of a case of acute meningoencephalomyelitis and focal pneumonia caused by B. pseudomallei infection in a pigtail macaque that was imported from Indonesia to the United States for research purposes. This bacterium has been classified as a Tier 1 overlap select agent and toxin; therefore, recognition of pathologic features, along with accurate and timely confirmatory diagnostic testing, in naturally infected research animals is imperative to protect animals and personnel in the laboratory animal setting. C1 [Ritter, J. M.; Jones, T. L.; Zaki, S. R.; Drew, C. P.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Sanchez, S.] Univ Georgia, Georgia Lab Anim Diagnost Serv, Athens, GA 30602 USA. RP Ritter, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G 32, Atlanta, GA 30333 USA. EM jritter@cdc.gov NR 28 TC 1 Z9 1 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0300-9858 EI 1544-2217 J9 VET PATHOL JI Vet. Pathol. PD NOV PY 2013 VL 50 IS 6 BP 1139 EP 1144 DI 10.1177/0300985813485249 PG 6 WC Pathology; Veterinary Sciences SC Pathology; Veterinary Sciences GA 252BX UT WOS:000326980600032 PM 23576240 ER PT J AU Liu, YW Steenland, K Rong, Y Hnizdo, E Huang, XJ Zhang, H Shi, TM Sun, Y Wu, TC Chen, WH AF Liu, Yuewei Steenland, Kyle Rong, Yi Hnizdo, Eva Huang, Xiji Zhang, Hai Shi, Tingming Sun, Yi Wu, Tangchun Chen, Weihong TI Exposure-Response Analysis and Risk Assessment for Lung Cancer in Relationship to Silica Exposure: A 44-Year Cohort Study of 34,018 Workers SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE cohort; exposure-response analysis; lung cancer; risk assessment; silica; silicosis ID NESTED CASE-CONTROL; CRYSTALLINE SILICA; OCCUPATIONAL-EXPOSURE; POTTERY WORKERS; MINERS; MORTALITY; DUST; EPIDEMIOLOGY; METAANALYSIS; SMOKING AB Crystalline silica has been classified as a human carcinogen by the International Agency for Research on Cancer (Lyon, France); however, few previous studies have provided quantitative data on silica exposure, silicosis, and/or smoking. We investigated a cohort in China (in 19602003) of 34,018 workers without exposure to carcinogenic confounders. Cumulative silica exposure was estimated by linking a job-exposure matrix to work history. Cox proportional hazards model was used to conduct exposure-response analysis and risk assessment. During a mean 34.5-year follow-up, 546 lung cancer deaths were identified. Categorical analyses by quartiles of cumulative silica exposure (using a 25-year lag) yielded hazard ratios of 1.26, 1.54, 1.68, and 1.70, respectively, compared with the unexposed group. Monotonic exposure-response trends were observed among nonsilicotics (P for trend 0.001). Analyses using splines showed similar trends. The joint effect of silica and smoking was more than additive and close to multiplicative. For workers exposed from ages 20 to 65 years at 0.1 mg/m(3) of silica exposure, the estimated excess lifetime risk (through age 75 years) was 0.51. These findings confirm silica as a human carcinogen and suggest that current exposure limits in many countries might be insufficient to protect workers from lung cancer. They also indicate that smoking cessation could help reduce lung cancer risk for silica-exposed individuals. C1 [Liu, Yuewei; Rong, Yi; Huang, Xiji; Zhang, Hai; Wu, Tangchun; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430030, Hubei, Peoples R China. [Liu, Yuewei; Rong, Yi; Huang, Xiji; Zhang, Hai; Wu, Tangchun; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan 430030, Hubei, Peoples R China. [Liu, Yuewei; Rong, Yi; Huang, Xiji; Zhang, Hai; Wu, Tangchun; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Environm Protect, Wuhan 430030, Hubei, Peoples R China. [Liu, Yuewei; Rong, Yi; Huang, Xiji; Zhang, Hai; Wu, Tangchun; Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, State Key Lab Environm Hlth Incubating, Wuhan 430030, Hubei, Peoples R China. [Liu, Yuewei; Shi, Tingming] Hubei Ctr Dis Control & Prevent, Inst Hlth Surveillance Anal & Protect, Wuhan, Hubei, Peoples R China. [Steenland, Kyle] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol & Environm Hlth, Atlanta, GA 30322 USA. [Hnizdo, Eva] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Sun, Yi] German Social Accid Insurance, Inst Occupat Safety & Hlth, Dept Appl Epidemiol, St Augustin, Germany. RP Chen, WH (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China. EM wchen@mails.tjmu.edu.cn RI Chen, Weihong/D-2177-2011 OI Chen, Weihong/0000-0001-8689-7311 FU National Basic Research Program of China [2011CB503804] FX This study was supported by the National Basic Research Program of China (grant 2011CB503804). NR 41 TC 18 Z9 20 U1 3 U2 22 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 1 PY 2013 VL 178 IS 9 BP 1424 EP 1433 DI 10.1093/aje/kwt139 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247SZ UT WOS:000326642300010 PM 24043436 ER PT J AU Lu, PJ Singleton, JA Euler, GL Williams, W Bridges, CB AF Lu, Peng-Jun Singleton, James A. Euler, Gary L. Williams, WalterW. Bridges, Carolyn B. TI Seasonal Influenza Vaccination Coverage Among Adult Populations in the United States, 20052011 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE adults; high-risk conditions; influenza; influenza vaccine; vaccination; vaccination coverage ID IMMUNIZATION PRACTICES ACIP; HIGH-RISK ADULTS; RANDOMIZED CONTROLLED-TRIAL; PNEUMOCOCCAL VACCINATION; ADVISORY-COMMITTEE; RACIAL/ETHNIC DIFFERENCES; VACCINES RECOMMENDATIONS; H1N1 INFLUENZA; SELF-REPORT; CARE AB The most effective strategy for preventing influenza is annual vaccination. We analyzed 20052011 data from the National Health Interview Survey (NHIS), using Kaplan-Meier survival analysis to estimate cumulative proportions of persons reporting influenza vaccination in the 20042005 through 20102011 seasons for persons aged 18, 1849, 5064, and 65 years, persons with high-risk conditions, and health-care personnel. We compared vaccination coverage by race/ethnicity within each age and high-risk group. Vaccination coverage among adults aged 18 years increased from 27.4 during the 20052006 influenza season to 38.1 during the 20102011 season, with an average increase of 2.2 annually. From the 20052006 season to the 20102011 season, coverage increased by 1012 percentage points for all groups except adults aged 65 years. Coverage for the 20102011 season was 70.2 for adults aged 65 years, 43.7 for adults aged 5064 years, 36.7 for persons aged 1849 years with high-risk conditions, and 55.8 for health-care personnel. In most subgroups, coverage during the 20102011 season was significantly lower among non-Hispanic blacks and Hispanics than among non-Hispanic whites. Vaccination coverage among adults under age 65 years increased from 20052006 through 20102011, but substantial racial/ethnic disparities remained in most age groups. Targeted efforts are needed to improve influenza vaccination coverage and reduce disparities. C1 [Lu, Peng-Jun; Singleton, James A.; Euler, Gary L.; Williams, WalterW.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM plu@cdc.gov NR 58 TC 22 Z9 22 U1 2 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 1 PY 2013 VL 178 IS 9 BP 1478 EP 1487 DI 10.1093/aje/kwt158 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247SZ UT WOS:000326642300016 PM 24008912 ER PT J AU Weinberger, DM Bruden, DT Grant, LR Lipsitch, M O'Brien, KL Pelton, SI Sanders, EAM Feikin, DR AF Weinberger, Daniel M. Bruden, Dana T. Grant, Lindsay R. Lipsitch, Marc O'Brien, Katherine L. Pelton, Stephen I. Sanders, Elisabeth A. M. Feikin, Daniel R. TI Using Pneumococcal Carriage Data to Monitor Postvaccination Changes in Invasive Disease SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE carriage; conjugate vaccine; pneumococcal; pneumococcus; surveillance; vaccine effectiveness; vaccines ID CONJUGATE VACCINE USE; STREPTOCOCCUS-PNEUMONIAE; SEROTYPE REPLACEMENT; ALASKAN CHILDREN; IMPACT; COLONIZATION; TRANSMISSION; DECADE AB Pneumococcal conjugate vaccines (PCVs) have been introduced worldwide. However, few developing countries have high-quality surveillance systems available for monitoring vaccine impact. We evaluated whether data from nasopharyngeal carriage studies can be used to accurately monitor post-PCV changes in the incidence of invasive pneumococcal disease (IPD) among children under 5 years of age. For various dates during 19912010, data on nasopharyngeal pneumococcal carriage and on IPD before and after administration of 7-valent PCV (PCV7) were available from England and Wales, the Netherlands, the Navajo and White Mountain Apache American Indian populations, and the US states of Massachusetts and Alaska. We estimated the change in carriage prevalence for each serotype in each study and then either calculated the average change (inverse variance-weighted) among vaccine and nonvaccine serotypes (model 1) or used mixed-effects models to estimate the change for each serotype individually, pooling serotype data within or between studies (models 2 and 3). We then multiplied these values by the proportion of IPD caused by each serotype during the pre-PCV7 period to obtain an estimate of post-PCV7 disease incidence. Model 1 accurately captured overall changes in IPD incidence following PCV7 introduction for most studies, while the more detailed models, models 2 and 3, were less accurate. Carriage data can be used in this simple model to estimate post-PCV changes in IPD incidence. C1 [Weinberger, Daniel M.] NIH, Div Int Epidemiol & Populat Studies, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Weinberger, Daniel M.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Bruden, Dana T.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Grant, Lindsay R.; O'Brien, Katherine L.] Johns Hopkins Univ, Ctr Amer Indian Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [O'Brien, Katherine L.; Feikin, Daniel R.] Johns Hopkins Univ, Int Vaccine Access Ctr, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Pelton, Stephen I.] Boston Univ, Sch Med, Dept Pediat, Boston Med Ctr, Boston, MA 02118 USA. [Pelton, Stephen I.] Boston Univ, Sch Med, Sect Pediat Infect Dis, Boston Med Ctr, Boston, MA 02118 USA. [Pelton, Stephen I.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Weinberger, DM (reprint author), Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, POB 208034, New Haven, CT 06520 USA. EM Daniel.weinberger@yale.edu OI Pelton, Stephen/0000-0003-4862-5344; Lipsitch, Marc/0000-0003-1504-9213 FU Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health; National Institutes of Health [2R01AI048935]; Bill and Melinda Gates Foundation [37875]; Native American Research Centers for Health [U26IHS300013/03, U269400012-01]; Centers for Disease Control and Prevention National Vaccine Program Office; Thrasher Research Fund [02820-9]; Wyeth Vaccines (Pfizer Inc.); US Agency for International Development; World Health Organization; Pfizer Inc. [WS950636]; Pfizer Inc. (New York, New York); GlaxoSmithKline (GSK; London); GlaxoSmithKline (GSK; United Kingdom); Pfizer; Wyeth (Overland Park, Kansas)/Pfizer; GSK; Novartis FX D.M.W. was supported by the Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health. M.L. was supported by National Institutes of Health grant 2R01AI048935. Support for the Navajo/WMA studies came from the Bill and Melinda Gates Foundation (grant 37875), The Native American Research Centers for Health (grants U26IHS300013/03 and U269400012-01), the Centers for Disease Control and Prevention National Vaccine Program Office, the Thrasher Research Fund (grant 02820-9), Wyeth Vaccines (Pfizer Inc.), the US Agency for International Development, and the World Health Organization. Support for the Alaskan postvaccine carriage study was provided, in part, by a grant from Pfizer Inc. (grant WS950636).; D.M.W. has received research funding from Pfizer Inc. (New York, New York). K.O.B. and L.R.G. have received research grant support related to pneumococcal vaccines from GlaxoSmithKline (GSK; London, United Kingdom) and Pfizer. K.O.B. has received honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by Merck & Company (Whitehouse Station, New Jersey), Sanofi-Pasteur (Swiftwater, Pennsylvania), and GSK. E.A.M.S. has been given research grant support related to pneumococcal vaccines from Wyeth (Overland Park, Kansas)/Pfizer and GSK and has received honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by Pfizer and GSK. S.I.P. has received honoraria for participation in advisory board activities related to pneumococcal vaccine or pneumococcal disease from Pfizer, Merck Vaccines, Novartis (Basel, Switzerland), and GSKbio. M.L. has accepted honoraria or consulting fees from Pfizer and Novartis. NR 29 TC 23 Z9 23 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 1 PY 2013 VL 178 IS 9 BP 1488 EP 1495 DI 10.1093/aje/kwt156 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247SZ UT WOS:000326642300017 PM 24013204 ER PT J AU Bamrah, S Woodruff, RSY Powell, K Ghosh, S Kammerer, JS Haddad, MB AF Bamrah, S. Woodruff, R. S. Yelk Powell, K. Ghosh, S. Kammerer, J. S. Haddad, M. B. TI Tuberculosis among the homeless, United States, 1994-2010 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE genotyping; housing; latent tuberculous infection ID FOREIGN-BORN PERSONS; MYCOBACTERIUM-TUBERCULOSIS; OUTBREAK; TRANSMISSION; HEALTH; COUNTY; CARE AB OBJECTIVES: 1) To describe homeless persons diagnosed with tuberculosis (TB) during the period 19942010, and 2) to estimate a TB incidence rate among homeless persons in the United States. METHODS: TB cases reported to the National Tuberculosis Surveillance System were analyzed by origin of birth. Incidence rates were calculated using the US Department of Housing and Urban Development homeless population estimates. Analysis of genotyping results identified clustering as a marker for transmission among homeless TB patients. RESULTS: Of 270 948 reported TB cases, 16 527 (6%) were homeless. The TB incidence rate among homeless persons ranged from 36 to 47 cases per 100 000 population SUMMARY in 2006-2010. Homeless TB patients had over twice the odds of not completing treatment and of belonging to a genotype cluster. US- and foreign-born homeless TB patients had respectively 8 and 12 times the odds of substance abuse. CONCLUSIONS: Compared to the general population, homeless persons had an approximately 10-fold increase in TB incidence, were less likely to complete treatment and more likely to abuse substances. Public health out-reach should target homeless populations to reduce the excess burden of TB in this population. C1 [Bamrah, S.; Woodruff, R. S. Yelk; Powell, K.; Ghosh, S.; Kammerer, J. S.; Haddad, M. B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bamrah, S (reprint author), 1600 Clifton Rd MS E-10, Atlanta, GA 30333 USA. EM feu3@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 17 Z9 17 U1 0 U2 10 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2013 VL 17 IS 11 BP 1414 EP 1419 DI 10.5588/ijtld.13.0270 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 244YK UT WOS:000326425900010 PM 24125444 ER PT J AU Demissie, Z Lowry, R Eaton, DK Park, S Kann, L AF Demissie, Zewditu Lowry, Richard Eaton, Danice K. Park, Sohyun Kann, Laura TI Electronic Media and Beverage Intake Among United States High School Students-2010 SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article DE adolescent; beverages; mass media ID PHYSICAL-ACTIVITY; ADOLESCENTS; CHILDREN; DIETARY; CONSUMPTION; TELEVISION; BEHAVIOR; OBESITY; ADULTS; TIME AB Objective: To describe electronic media exposure and its associations with beverage intake among United States high school students. Methods: School-based survey data from a nationally representative sample of 9th-through 12th-grade students from the National Youth Physical Activity and Nutrition Study were analyzed using chi-square and multivariate logistic analyses. Results: Onan average school day, 23.5% of students used a computer or played video/computer games >= 3 h/d, 28.3% watched television (TV) >= 3 h/d, 79.9% had >= 3 TVs in the home, 70.2% had a TV in their bedroom, and 41.0% most of the time or always had a TV on while eating dinner at home. Students with high media exposure were more likely to drink sugar-sweetened beverages >= 3 times per day and less likely to drink water >= 3 times per day and drink >= 2 glasses of milk per day. Conclusions and Implications: Efforts to reduce sugar-sweetened beverage intake among adolescents may include limiting exposure to electronic media. C1 [Demissie, Zewditu] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Demissie, Zewditu; Lowry, Richard; Eaton, Danice K.; Kann, Laura] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Promot, Atlanta, GA 30341 USA. RP Demissie, Z (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Hwy NE,MS K-33, Atlanta, GA 30341 USA. EM izj5@cdc.gov NR 28 TC 6 Z9 6 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 EI 1878-2620 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD NOV-DEC PY 2013 VL 45 IS 6 BP 756 EP 760 DI 10.1016/j.jneb.2013.03.017 PG 5 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA 247EA UT WOS:000326596800040 PM 23791899 ER PT J AU Weyant, RJ Tracy, SL Anselmo, T Beltran-Aguilar, ED Donly, KJ Frese, WA Hujoel, PP Iafolla, T Kohn, W Kumar, J Levy, SM Tinanoff, N Wright, JT Zero, D Aravamudhan, K Frantsve-Hawley, J Meyer, DM AF Weyant, Robert J. Tracy, Sharon L. Anselmo, Theresa (Tracy) Beltran-Aguilar, Eugenio D. Donly, Kevin J. Frese, William A. Hujoel, Philippe P. Iafolla, Timothy Kohn, William Kumar, Jayanth Levy, Steven M. Tinanoff, Norman Wright, J. Timothy Zero, Domenick Aravamudhan, Krishna Frantsve-Hawley, Julie Meyer, Daniel M. CA Amer Dent Assoc Council Sci TI Topical fluoride for caries prevention Executive summary of the updated clinical recommendations and supporting systematic review SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Caries prevention; caries; evidence-based dentistry; fluoride; practice guidelines; preventive dentistry ID ACIDULATED PHOSPHATE-FLUORIDE; RANDOMIZED CONTROLLED-TRIAL; DENTAL-CARIES; VARNISH DURAPHAT; PRESCHOOL-CHILDREN; APPROXIMAL CARIES; PRIMARY TEETH; ROOT CARIES; PROFESSIONAL APPLICATION; PROPHYLACTIC PASTE AB Background. A panel of experts convened by the American Dental Association (ADA) Council on Scientific Affairs presents evidence-based clinical recommendations regarding professionally applied and prescription-strength, home-use topical fluoride agents for caries prevention. These recommendations are an update of the 2006 ADA recommendations regarding professionally applied topical fluoride and were developed by using a new process that includes conducting a systematic review of primary studies. Types of Studies Reviewed. The authors conducted a search of MEDLINE and the Cochrane Library for clinical trials of professionally applied and prescription-strength topical fluoride agents-including mouthrinses, varnishes, gels, foams and pastes-with caries increment outcomes published in English through October 2012. Results. The panel included 71 trials from 82 articles in its review and assessed the efficacy of various topical fluoride caries-preventive agents. The panel makes recommendations for further research. Practical Implications. The panel recommends the following for people at risk of developing dental caries: 2.26 percent fluoride varnish or 1.23 percent fluoride (acidulated phosphate fluoride) gel, or a prescription-strength, home-use 0.05 percent fluoride gel or paste or 0.09 percent fluoride mouthrinse for patients 6 years or older. Only 2.26 percent fluoride varnish is recommended for children younger than 6 years. The strengths of the recommendations for the recommended products varied from "in favor" to "expert opinion for." As part of the evidence-based approach to care, these clinical recommendations should be integrated with the practitioner's professional judgment and the patient's needs and preferences. C1 [Weyant, Robert J.] Univ Pittsburgh, Dept Dent Publ Hlth, Sch Dent Med, Pittsburgh, PA 15260 USA. [Tracy, Sharon L.] Amer Dent Assoc, Div Sci, Ctr Evidence Based Dent, Chicago, IL 60611 USA. [Anselmo, Theresa (Tracy)] San Luis Obispo Hlth Agcy, Oral Hlth Program, San Luis Obispo, CA USA. [Beltran-Aguilar, Eugenio D.] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA USA. [Donly, Kevin J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Frese, William A.] Univ Illinois, Dept Pediat, Chicago, IL USA. [Hujoel, Philippe P.] Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA. [Iafolla, Timothy] Natl Inst Dent & Craniofacial Res, Off Sci Policy & Anal, NIH, Bethesda, MD USA. [Kohn, William] Delta Dent Plans Assoc, Oak Brook, IL USA. [Kumar, Jayanth] New York State Dept Hlth, Bur Dent Hlth, Albany, NY 12237 USA. [Kumar, Jayanth] SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA. [Levy, Steven M.] Univ Iowa, Coll Dent, Dept Prevent & Community Dent, Iowa City, IA 52242 USA. [Levy, Steven M.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Tinanoff, Norman] Univ Maryland, Sch Dent, Baltimore, MD 21201 USA. [Wright, J. Timothy] Univ N Carolina, Sch Dent, Dept Pediat Dent, Chapel Hill, NC USA. [Zero, Domenick] Indiana Univ Sch Dent, Dept Prevent & Community Dent, Indianapolis, IN USA. [Zero, Domenick] Indiana Univ Sch Dent, Oral Hlth Res Inst, Indianapolis, IN USA. [Zero, Domenick] Indiana Univ Sch Dent, Indianapolis, IN USA. [Aravamudhan, Krishna] Amer Dent Assoc, Div Dent Practice, Off Qual Assessment & Improvement, Chicago, IL USA. [Frantsve-Hawley, Julie] Amer Dent Assoc, Div Sci, Ctr Evidence Based Dent, Chicago, IL USA. [Meyer, Daniel M.] Amer Dent Assoc, Chicago, IL USA. RP Tracy, SL (reprint author), Amer Dent Assoc, Div Sci, Ctr Evidence Based Dent, 211 E Chicago Ave, Chicago, IL 60611 USA. EM tracys@ada.org FU Centers for Disease Control and Prevention, Atlanta FX The American Dental Association Council on Scientific Affairs Expert Panel on Topical Fluoride Agents commissioned this study, which was supported in part by the Centers for Disease Control and Prevention, Atlanta. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 96 TC 55 Z9 58 U1 3 U2 16 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD NOV PY 2013 VL 144 IS 11 BP 1279 EP 1291 PG 13 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 246DF UT WOS:000326516600012 PM 24177407 ER PT J AU Dean, HD Williams, KM Fenton, KA AF Dean, Hazel D. Williams, Kim M. Fenton, Kevin A. TI FROM THEORY TO ACTION: APPLYING SOCIAL DETERMINANTS OF HEALTH TO PUBLIC HEALTH PRACTICE SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID RACIAL DISPARITIES RP Dean, HD (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, MS-E-07, Atlanta, GA 30333 USA. EM hdean@cdc.gov NR 21 TC 3 Z9 3 U1 0 U2 7 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 SU 3 BP 1 EP 4 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IR UT WOS:000326611600001 PM 24179272 ER PT J AU Dean, HD Fenton, KA AF Dean, Hazel D. Fenton, Kevin A. TI Integrating a Social Determinants of Health Approach into Public Health Practice: A Five-Year Perspective of Actions Implemented by CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention SO PUBLIC HEALTH REPORTS LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; DATA SYSTEMS; TUBERCULOSIS; POLICY; RATES C1 [Dean, Hazel D.; Fenton, Kevin A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Dean, HD (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, MS-E-07, Atlanta, GA 30333 USA. EM hdean@cdc.gov NR 32 TC 2 Z9 2 U1 0 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 SU 3 BP 5 EP 11 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IR UT WOS:000326611600002 PM 24179273 ER PT J AU Penman-Aguilar, A Harrison, KM Dean, HD AF Penman-Aguilar, Ana Harrison, Kathleen McDavid Dean, Hazel D. TI Identifying the Root Causes of Health Inequities: Reflections on the 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Health Equity Symposium SO PUBLIC HEALTH REPORTS LA English DT Article ID SOCIAL DETERMINANTS C1 [Penman-Aguilar, Ana; Harrison, Kathleen McDavid; Dean, Hazel D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Penman-Aguilar, A (reprint author), Ctr Dis Control & Prevent, Off Director, Off Minor Hlth & Hlth Equ, 4770 Buford Hwy NE,MS-K77, Atlanta, GA 30333 USA. EM bpv4@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 SU 3 BP 29 EP 32 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IR UT WOS:000326611600005 PM 24179276 ER PT J AU Flynn, MA Check, P Eggerth, DE Tonda, J AF Flynn, Michael A. Check, Pietra Eggerth, Donald E. Tonda, Josana TI Improving Occupational Safety and Health Among Mexican Immigrant Workers: A Binational Collaboration SO PUBLIC HEALTH REPORTS LA English DT Article ID INJURY AB Latino immigrants are 50% more likely than all workers in the United States to experience a fatal injury at work. Occupational safety and health (OSH) organizations often find that the approaches and networks they successfully use to promote OSH among U.S.-born workers are ineffective at reaching Latino immigrants. This article describes the collaboration between the National Institute for Occupational Safety and Health (NIOSH) and the Mexican Ministry of Foreign Affairs (Secretaria de Relaciones Exteriores) to promote OSH among Mexican immigrant workers. The Ministry of Foreign Affairs operates 50 consulates throughout the U.S. that provide four million discrete service contacts with Mexican citizens annually. The focus of this ongoing collaboration is to develop the internal capacity of Mexican institutions to promote OSH among Mexican immigrants while simultaneously developing NIOSH's internal capacity to create effective and sustainable initiatives to better document and reduce occupational health disparities for Mexican immigrants in the U.S. C1 [Flynn, Michael A.; Check, Pietra; Eggerth, Donald E.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Flynn, Michael A.; Eggerth, Donald E.] Michigan State Univ, Consortium Multicultural Psychol Res, E Lansing, MI 48824 USA. [Tonda, Josana] Inst Mexicans Abroad, Minist Foreign Affairs, Mexico City, DF, Mexico. RP Flynn, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS C-10, Cincinnati, OH 45226 USA. EM mflynn@cdc.gov NR 29 TC 3 Z9 3 U1 1 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 SU 3 BP 33 EP 38 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IR UT WOS:000326611600006 PM 24179277 ER PT J AU Avey, H Fuller, E Branscomb, J Cheung, K Jackson, P Wong, N Henderson, M Williams, S AF Avey, Holly Fuller, Elizabeth Branscomb, Jane Cheung, Karen Jackson, Phillip Wong, Naima Henderson, Michael Williams, Samantha TI Using a Health in All Policies Approach to Address Social Determinants of Sexually Transmitted Disease Inequities in the Context of Community Change and Redevelopment SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; GONORRHEA; NEIGHBORHOOD; SYPHILIS; RATES; INEQUALITIES; DISPARITIES; PREVALENCE; RACE AB Objectives. We used a Health in All Policies (HiAP) framework to determine what data, policy, and community efficacy opportunities exist for improving sexual health and reducing sexually transmitted diseases (STDs) in an area surrounding an Army base undergoing redevelopment in Atlanta, Georgia. Methods. We conducted a literature review, consulted with experts, mapped social determinants in the community, conducted key informant interviews with community leaders to explore policy solutions, used Photovoice with community members to identify neighborhood assets, and shared data with all stakeholder groups to solicit engagement for next steps. Results. We identified the following HiAP-relevant determinants of STD inequities in the literature: education, employment, male incarceration, drug and alcohol marketing, and social capital. Quantitative data confirmed challenges in education, employment, and male incarceration in the area. Interviews identified policy opportunities such as educational funding ratios, Community Hire Agreements, code and law enforcement, addiction and mental health resources, lighting for safety, and a nonemergency public safety number. Photovoice participants identified community assets to protect including family-owned businesses, green spaces, gathering places, public transportation resources, historical sites, and architectural elements. Stakeholder feedback provided numerous opportunities for next steps. Conclusions. This study contributes to the HiAP literature by providing an innovative mixed-methods design that locates social determinants of STDs within a geographic context, identifies policy solutions from local leaders, highlights community assets through the lens of place attachment, and engages stake-holders in identifying next steps. Findings from this study could inform other redevelopments, community-based studies of STDs, and HiAP efforts. C1 [Avey, Holly] Human Impact Partners, Oakland, CA 94607 USA. [Fuller, Elizabeth; Branscomb, Jane; Cheung, Karen; Wong, Naima] Georgia State Univ, Georgia Hlth Policy Ctr, Atlanta, GA 30303 USA. [Cheung, Karen] ICE Int, Seattle, WA USA. [Jackson, Phillip] Georgia State Univ, Dept Geosci, Atlanta, GA 30303 USA. [Henderson, Michael] Georgia State Univ, Dept Publ Management & Policy, Atlanta, GA 30303 USA. [Williams, Samantha] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis Prevent, Social & Behav Res & Evaluat Branch, Atlanta, GA USA. RP Avey, H (reprint author), Human Impact Partners, 304 12th St,Ste 3B, Oakland, CA 94607 USA. EM havey@humanimpact.org NR 29 TC 2 Z9 2 U1 2 U2 22 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 SU 3 BP 77 EP 86 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IR UT WOS:000326611600012 PM 24179283 ER PT J AU Gowda, C Dong, SM Potter, RC Dombkowski, KJ Stokley, S Dempsey, AF AF Gowda, Charitha Dong, Shiming Potter, Rachel C. Dombkowski, Kevin J. Stokley, Shannon Dempsey, Amanda F. TI A Systematic Evaluation of Different Methods for Calculating Adolescent Vaccination Levels Using Immunization Information System Data SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; PROGRESS AB Objective. Immunization information systems (IISs) are valuable surveillance tools; however, population relocation may introduce bias when determining immunization coverage. We explored-alternative methods for estimating the vaccine-eligible population when calculating adolescent immunization levels Using a statewide IIS. Methods. We performed a retrospective analysis of the Michigan State Care Improvement Registry (MCIR) for all adolescents aged 11-18 years registered in the MCIR as of October 2010. We explored four methods for determining denominators: (1) including all adolescents with MCIR records, (2) excluding adolescents with out-of-state residence, (3) further excluding those Without MCIR activity 10 years prior to the evaluation date, and (4) using a denominator based on U.S. Census data. We estimated state- and county-specific coverage levels for four adolescent vaccines. Results. We found a 20% difference in estimated vaccination coverage between the most inclusive and restrictive denominator populations. Although there was some variability among the four methods in vaccination at the state level (2%-11%), greater variation occurred at the county level (up to 21%). This variation was substantial enough to potentially impact public health assessments of immunization programs. Generally, vaccines with higher coverage levels had greater absolute variation, as did counties with smaller populations. Conclusion. At the county level, using the four denominator calculation methods resulted in substantial differences in estimated adolescent immunization rates that were less apparent when aggregated at the state level. Further research is needed to ascertain the most appropriate method for estimating vaccine coverage levels using IIS data. C1 [Gowda, Charitha; Dong, Shiming; Dombkowski, Kevin J.] Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA. [Potter, Rachel C.] Michigan Dept Community Hlth, Lansing, MI USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Dempsey, Amanda F.] Univ Colorado, Dept Pediat, Childrens Outcomes Res Grp, Aurora, CO 80045 USA. RP Dempsey, AF (reprint author), Univ Colorado, Dept Pediat, Childrens Outcomes Res Grp, 13199 East Montview Blvd,Ste 300, Aurora, CO 80045 USA. EM amanda.dempsey@ucdenver.edu FU Centers for Disease Control and Prevention (CDC) [U01 IP000414 IP10-002] FX This research was supported by award #U01 IP000414 IP10-002 from the Centers for Disease Control and Prevention (CDC). The findings and conclusions expressed in this article are those of the authors and do not necessarily represent the views of CDC. NR 14 TC 3 Z9 3 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 IS 6 BP 489 EP 497 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IP UT WOS:000326611400008 PM 24179260 ER PT J AU Byrd, KK Lu, PJ Murphy, TV AF Byrd, Kathy K. Lu, Peng-Jun Murphy, Trudy V. TI Hepatitis B Vaccination Coverage Among Health-Care Personnel in the United States SO PUBLIC HEALTH REPORTS LA English DT Article ID INFLUENZA VACCINATION; PNEUMOCOCCAL VACCINATION; IMMUNIZATION PRACTICES; BLOODBORNE PATHOGENS; HOSPITAL PERSONNEL; WORKERS; ACCEPTANCE; RISK; REQUIREMENTS; PREVALENCE AB Objectives. We compared self-reported hepatitis B (HepB) vaccine coverage among health-care personnel (HCP) with HepB vaccine coverage among the general-population-and determined trends in vaccination coverage among HCP. Methods. We used the 2010 National Health Interview Survey (NHIS) to determine the weighted proportion of self-reported >= 1 and >= 3-dose HepB vaccine coverage among HCP aged >= 18 years. We used logistic regression to determine independent predictors of vaccination and performed a trend analysis to determine changes in coverage from 2004 to 2010 using data from the 2004-2010 NHIS. Results. Overall, 69.5% (95% confidence interval [Cl] 67.2, 71.8) and 63.4% (95% Cl 60.8, 65.9) of HCP reported receiving >= 1 and >= 3 doses of HepB vaccine, respectively, compared with 27.1% (95% Cl 26.1, 28.1%) and 23.0% (95% Cl 22.1, 24.0) among non-HCP. Among HCP with direct patient contact, 80.7% (95% Cl 78.2, 83.1) and 74.0% (95% Cl 71.2, 76.8) received >= 1 and >= 3 HepB vaccine doses, respectively. Independent predictors of vaccination included direct patient contact, having more than a high school education, influenza vaccination in the past year, and ever having been tested for HIV There was no significant change in reported coverage from 2004 through 2010. Conclusion. The 2010 HepB vaccine coverage estimate among HCP remained well below the Healthy People 2010 goal of 90%. Efforts to target unvaccinated HCP for preexposure HepB protection should be encouraged. C1 [Byrd, Kathy K.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Lu, Peng-Jun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Byrd, KK (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30333 USA. EM gdn8@cdc.gov NR 49 TC 8 Z9 9 U1 0 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 IS 6 BP 498 EP 509 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IP UT WOS:000326611400009 PM 24179261 ER PT J AU Ahluwalia, IB Helms, K Morrow, B AF Ahluwalia, Indu B. Helms, Kristen Morrow, Brian TI Assessing the Validity and Reliability of Three Indicators Self-Reported on the Pregnancy Risk Assessment Monitoring System Survey SO PUBLIC HEALTH REPORTS LA English DT Article ID HOSPITAL DISCHARGE DATA; BIRTH CERTIFICATE DATA; VITAL-STATISTICS; MEDICAL CONDITIONS; MATERNAL RECALL; NORTH-CAROLINA; VALIDATION; INFORMATION; AGREEMENT; INSURANCE AB Objectives. We investigated the reliability and validity of three self-reported indicators from the Pregnancy Risk Assessment Monitoring System (PRAMS) survey. Methods. We used 2008 PRAMS (n=15,646) data from 12 states that had implemented the 2003 revised U.S. Certificate of Live Birth. We estimated reliability by kappa coefficient and validity by sensitivity and specificity using the birth certificate data as the reference for the following: prenatal participation in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC); Medicaid payment for delivery; and breastfeeding initiation. These indicators were examined across several demographic subgroups. Results. The reliability was high for all three measures: 0.81 for WIC participation, 0.67 for Medicaid payment of delivery, and 0.72 for breastfeeding initiation. The validity of PRAMS indicators was also high: WIC participation (sensitivity = 90.8%, specificity = 90.6%), Medicaid payment for delivery (sensitivity = 82.4%, specificity = 85.6%);and breastfeeding initiation (sensitivity = 94.3%, specificity = 76.0%). The prevalence estimates were higher on PRAMS than the birth certificate for each of the indicators except Medicaid-paid delivery among non-Hispanic black women. Kappa values within most subgroups remained in the moderate range (0.40-0.80). Sensitivity and specificity values were lower for Hispanic women who responded to the PRAMS survey in Spanish and for breastfeeding initiation among women who delivered very low birthweight and very preterm infants. Conclusion. The validity and reliability of the PRAMS data for measures assessed were high. Our findings support the use of PRAMS data for epidemiological surveillance, research, and planning. C1 [Ahluwalia, Indu B.; Morrow, Brian] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [Helms, Kristen] DB Consulting Grp Inc, Atlanta, GA USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-22, Atlanta, GA 30341 USA. EM Iahluwalia@cdc.gov NR 30 TC 2 Z9 2 U1 0 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2013 VL 128 IS 6 BP 527 EP 536 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 247IP UT WOS:000326611400012 PM 24179264 ER PT J AU Beckman, S Materna, B Goldmacher, S Zipprich, J D'Alessandro, M Novak, D Harrison, R AF Beckman, Stella Materna, Barbara Goldmacher, Suzi Zipprich, Jennifer D'Alessandro, Maryann Novak, Debra Harrison, Robert TI Evaluation of respiratory protection programs and practices in California hospitals during the 2009-2010 H1N1 influenza pandemic SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE N95 respirator; Aerosol transmissible disease; Hospital; Health care; Preparedness ID HEALTH-CARE WORKERS; UNITED-STATES; TRANSMISSION; SARS; EQUIPMENT; PERSONNEL; NURSES; VIRUS AB Background: Emergence of the novel 2009 influenza A H1N1 virus in California led to an evaluation of hospital respiratory protection programs (RPPs) and practices by the California Department of Public Health during the 2009-2010 influenza season. Methods: Onsite evaluation of 16 hospitals consisted of interviews with managers and health care workers about RPPs and practices, review of written RPPs, and limited observations of personnel using respirators. Data were analyzed using descriptive statistics. Results: All hospitals had implemented policies requiring the minimum use of N95 filtering facepiece respirators when working with patients with H1N1 virus infection; 95.5% of health care workers (n = 199) reported they would wear at least this level of protection when in close contact with a patient with confirmed or suspected H1N1 virus infection. However, evaluation of written RPPs indicated deficiencies in required areas, most commonly in recordkeeping, designation of a program administrator, program evaluation, employee training, and fit testing procedures. Conclusions: Health care workers were aware of respiratory protection required when providing care for patients with confirmed or suspected H1N1 virus infection. Hospitals should improve written RPPs, fully implement written procedures, and conduct periodic program evaluation to ensure effectiveness of respirator use for health care worker protection. Increased accessibility of resources tailored for hospital respirator program administrators may be helpful. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Beckman, Stella] Council State & Terr Epidemiologists, Epidemiol Fellowship Program, Atlanta, GA USA. [Beckman, Stella; Materna, Barbara; Goldmacher, Suzi; Zipprich, Jennifer; Harrison, Robert] Calif Dept Publ Hlth, Occupat Hlth Branch, Richmond, CA 94804 USA. [Goldmacher, Suzi] Inst Publ Hlth, Oakland, CA USA. [Zipprich, Jennifer] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA. [D'Alessandro, Maryann; Novak, Debra] NIOSH, Ctr Dis Control & Prevent, Natl Personal Protect Technol Lab, Pittsburgh, PA USA. RP Materna, B (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy,P-3, Richmond, CA 94804 USA. EM barbara.materna@cdph.ca.gov FU National Institute for Occupational Safety and Health, National Personal Protection Technology Laboratory [254-2009-31321] FX Funding support for this work was provided by the National Institute for Occupational Safety and Health, National Personal Protection Technology Laboratory, through contract No. 254-2009-31321 awarded to the Public Health Institute and California Department of Public Health. NR 19 TC 16 Z9 16 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2013 VL 41 IS 11 BP 1024 EP 1031 DI 10.1016/j.ajic.2013.05.006 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 242KY UT WOS:000326241700016 PM 23932825 ER PT J AU Ellingson, K AF Ellingson, Katherine TI Breaking down P values and 95% confidence intervals: What infection preventionists should know about statistical certainty SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Ellingson, K (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM KEllingson@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2013 VL 41 IS 11 BP 1083 EP 1084 DI 10.1016/j.ajic.2013.03.298 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 242KY UT WOS:000326241700027 PM 23768440 ER PT J AU Allen-Bridson, K Gross, C Hebden, JN Morrell, GC Wright, MO Horan, T AF Allen-Bridson, Katherine Gross, Cindy Hebden, Joan N. Morrell, Gloria C. Wright, Marc-Oliver Horan, Teresa TI Healthcare-associated infections studies project: An American Journal of Infection Control and National Healthcare Safety Network data quality collaboration-Ventilator-associated event 1, 2013 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article AB This is the second case study published in a series in AJIC since the Centers for Disease Control and Prevention/National Healthcare Safety Network (NHSN) surveillance definition update of 2013. These cases reflect some of the complex patient scenarios Infection Preventionists (IP) have encountered in their daily surveillance of health care-associated infections (HAI) using NHSN definitions. This is the first case utilizing the new NHSN Ventilator-associated Events (VAE) module and criteria. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Allen-Bridson, Katherine; Morrell, Gloria C.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Healthcare Safety Network, Atlanta, GA USA. [Gross, Cindy] Emergint Technol Inc, CACI, Atlanta, GA USA. [Hebden, Joan N.] Wolters Kluwer Hlth Sentri7, Bellevue, WA USA. [Wright, Marc-Oliver] North Shore Univ Hlth Syst, Dept Infect Control, Evanston, IL USA. [Horan, Teresa] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Allen-Bridson, K (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM fsa6@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2013 VL 41 IS 11 BP 1085 EP 1086 DI 10.1016/j.ajic.2013.05.010 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 242KY UT WOS:000326241700028 PM 23972519 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a new national approach to surveillance for ventilator-associated events: Executive summary SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Ventilator-associated pneumonia; Intensive care unit; Epidemiology; Public health; Critical care; Mechanical ventilation AB In September 2011, the Centers for Disease Control and Prevention (CDC) convened a Ventilator-Associated Pneumonia (VAP) Surveillance Definition Working Group to organize a formal process for leaders and experts of key stakeholder organizations to discuss the challenges of VAP surveillance definitions and to propose new approaches to VAP surveillance in adult patients (Table 1). The charges to the Working Group were to (1) critically review a draft, streamlined VAP surveillance definition developed for use in adult patients; (2) suggest modifications to enhance the reliability and credibility of the surveillance definition within the critical care and infection prevention communities; and (3) propose a final adult surveillance definition algorithm to be implemented in the CDC's National Healthcare Safety Network (NHSN), taking into consideration the potential future use of the definition algorithm in public reporting, interfacility comparisons, and pay-for-reporting and pay-for-performance programs. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Div Infect Dis, Carver Coll Med, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Surveillance Working Grp, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [VanAntwerpen, Carole] Council State & Territorial Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov OI Diekema, Daniel/0000-0003-1273-0724 FU Centers for Disease Control and Prevention (CDC) FX Supported by the Centers for Disease Control and Prevention (CDC). NR 2 TC 3 Z9 4 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2013 VL 41 IS 11 BP 1096 EP 1099 DI 10.1016/j.ajic.2013.07.001 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 242KY UT WOS:000326241700031 PM 24176770 ER PT J AU Ghaji, N Boulet, SL Tepper, N Hooper, WC AF Ghaji, Nafisa Boulet, Sheree L. Tepper, Naomi Hooper, William C. TI Trends in venous thromboembolism among pregnancy-related hospitalizations, United States, 1994-2009 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE pregnancy; pulmonary embolism; venous thromboembolism; venous thrombosis ID PULMONARY-EMBOLISM; POSTPARTUM PERIOD; RISK-FACTORS; POPULATION; US; MORTALITY; DISEASE AB OBJECTIVE: The purpose of this study was to evaluate national trends in the rate of pregnancy-related hospitalizations for venous thromboembolism (VTE) from 1994-2009 and to estimate the prevalence of comorbid conditions among these hospitalizations. STUDY DESIGN: An estimated 64,413,973 pregnancy-related hospitalizations among women 15-44 years old were identified in the 1994-2009 Nationwide Inpatient Sample. Trends in VTE-associated pregnancy hospitalizations were evaluated with the use of variance-weighted least squares regression. Chi-square tests were used to assess changes in prevalence of demographics and comorbid conditions, and multivariable logistic regression was used to evaluate the likelihood of VTE during the study period after adjustment for comorbid conditions. Antepartum, delivery, and postpartum hospitalizations were evaluated separately and reported in 4-year increments. RESULTS: From 1994-2009, there was a 14% increase in the rate of overall VTE-associated pregnancy hospitalizations; antepartum and postpartum hospitalizations with VTE increased by 17% and 47%, respectively. Between 1994-1997 and 2006-2009, the prevalence of hypertension and obesity doubled among all VTE-associated pregnancy hospitalizations; significant increases in diabetes mellitus and heart disease were also noted. A temporal increase in the likelihood of a VTE diagnosis in pregnancy was observed for antepartum hospitalizations from 2006-2009 when compared with 1994-1997 (adjusted odds ratio, 1.62; 95% confidence interval, 1.48-1.78). CONCLUSION: There has been an upward trend in VTE-associated pregnancy hospitalizations from 1994-2009 with concomitant increases in comorbid conditions. Clinicians should have a heightened awareness of the risk of VTE among pregnant women, particularly among those with comorbid conditions, and should have a low threshold for evaluation in women with symptoms or signs of VTE. C1 [Ghaji, Nafisa; Hooper, William C.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30341 USA. [Boulet, Sheree L.; Tepper, Naomi] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K-34, Atlanta, GA 30341 USA. EM sboulet@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 10 Z9 10 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2013 VL 209 IS 5 AR 433.e1 DI 10.1016/j.ajog.2013.06.039 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 242LP UT WOS:000326243700012 PM 23810274 ER PT J AU Kramer, MS Berg, C Abenhaim, H Dahhou, M Rouleau, J Mehrabadi, A Joseph, KS AF Kramer, Michael S. Berg, Cynthia Abenhaim, Haim Dahhou, Mourad Rouleau, Jocelyn Mehrabadi, Azar Joseph, K. S. TI Incidence, risk factors, and temporal trends in severe postpartum hemorrhage SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE hysterectomy; maternal mortality; maternal morbidity; postpartum hemorrhage; stillbirth AB OBJECTIVE: Because the diagnosis of postpartum hemorrhage (PPH) depends on the accoucheur's subjective estimate of blood loss and varies according to mode of delivery, we examined temporal trends in severe PPH, defined as PPH plus receipt of a blood transfusion, hysterectomy, and/or surgical repair of the uterus. STUDY DESIGN: We analyzed 8.5 million hospital deliveries in the US Nationwide Inpatient Sample from 1999 to 2008 for temporal trends in, and risk factors for, severe PPH, based on International Classification of Diseases, 9th revision, clinical modification diagnosis and procedure codes. Sequential logistic regression models that account for the stratified random sampling design were used to assess the extent to which changes in risk factors explain the trend in severe PPH. RESULTS: Of the total 8,571,209 deliveries, 25,906 (3.0 per 1000) were complicated by severe PPH. The rate rose from 1.9 to 4.2 per 1000 from 1999 to 2008 (P for yearly trend <.0001), with increases in severe atonic and nonatonic PPH, due especially to PPH with transfusion, but also PPH with hysterectomy. Significant risk factors included maternal age >= 35 years (adjusted odds ratio [aOR], 1.5; 95% confidence interval [CI], 1.5-1.6), multiple pregnancy (aOR, 2.8; 95% CI, 2.6-3.0), fibroids (aOR, 2.0; 95% CI, 1.8-2.2), pre-eclampsia (aOR, 3.1; 95% CI, 2.9-3.3), amnionitis (aOR, 2.9; 95% CI, 2.5-3.4), placenta previa or abruption (aOR, 7.0; 95% CI, 6.6-7.3), cervical laceration (aOR, 94.0; 95% CI, 87.3-101.2), uterine rupture (aOR, 11.6; 95% CI, 9.7-13.8), instrumental vaginal delivery (aOR, 1.5; 95% CI, 1.4-1.6), and cesarean delivery (aOR, 1.4; 95% CI, 1.3-1.5). Changes in risk factors, however, accounted for only 5.6% of the increase in severe PPH. CONCLUSION: A doubling in incidence of severe PPH over 10 years was not explained by contemporaneous changes in studied risk factors. C1 [Kramer, Michael S.; Dahhou, Mourad] McGill Univ, Dept Pediat, Fac Med, Montreal, PQ H3A 2T5, Canada. [Kramer, Michael S.] McGill Univ, Epidemiol Biostat & Occupat Hlth, Fac Med, Montreal, PQ H3A 2T5, Canada. [Abenhaim, Haim] McGill Univ, Dept Obstet & Gynecol, Fac Med, Montreal, PQ H3A 2T5, Canada. [Rouleau, Jocelyn] Publ Hlth Agcy Canada, Div Surveillance & Epidemiol, Maternal & Infant Hlth Sect, Ottawa, ON, Canada. [Mehrabadi, Azar; Joseph, K. S.] Univ British Columbia, Fac Med, Dept Obstet & Gynecol, Vancouver, BC, Canada. [Berg, Cynthia] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Kramer, MS (reprint author), McGill Univ, Dept Pediat, Fac Med, Montreal, PQ H3A 2T5, Canada. OI Joseph, K.S./0000-0003-2317-5607 FU Canadian Institutes of Health Research FX Supported by a grant from the Canadian Institutes of Health Research. NR 20 TC 25 Z9 26 U1 1 U2 19 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2013 VL 209 IS 5 AR 449.e1 DI 10.1016/j.ajog.2013.07.007 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 242LP UT WOS:000326243700018 PM 23871950 ER PT J AU Hannon, PA Maxwell, AE Escoffery, C Vu, T Kohn, M Leeman, J Carvalho, ML Pfeiffer, DJ Dwyer, A Fernandez, ME Vernon, SW Liang, L DeGroff, A AF Hannon, Peggy A. Maxwell, Annette E. Escoffery, Cam Thuy Vu Kohn, Marlana Leeman, Jennifer Carvalho, Michelle L. Pfeiffer, Debbie J. Dwyer, Andrea Fernandez, Maria E. Vernon, Sally W. Liang, Lily DeGroff, Amy TI Colorectal Cancer Control Program Grantees' Use of Evidence-Based Interventions SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID CLIENT-DIRECTED INTERVENTIONS; HEALTH-CARE PROVIDERS; SCREENING SIGMOIDOSCOPY; INCREASE RECOMMENDATION; SYSTEMATIC REVIEWS; BREAST; MORTALITY; DELIVERY; IMPACT AB Background: Colorectal cancer (CRC) screening is recommended for adults aged 50-75 years, yet screening rates are low, especially among the uninsured. The CDC initiated the Colorectal Cancer Control Program (CRCCP) in 2009 with the goal of increasing CRC screening rates to 80% by 2014. A total of 29 grantees (states and tribal organizations) receive CRCCP funding to (1) screen uninsured adults and (2) promote CRC screening at the population level. Purpose: CRCCP encourages grantees to use one or more of five evidence-based interventions (EBIs) recommended by the Guide to Community Preventive Services. The purpose of the study was to evaluate grantees' EBI use. Methods: A web-based survey was conducted in 2011 measuring grantees' use of CRC screening EBIs and identifying their implementation partners. Data were analyzed in 2012. Results: Twenty-eight grantees (97%) completed the survey. Most respondents (96%) used small media. Fewer used client reminders (75%); reduction of structural barriers (50%); provider reminders (32%); or provider assessment and feedback (50%). Provider-oriented EBIs were rated as harder to implement than client-oriented EBIs. Grantees partnered with several types of organizations to implement EBIs, many with county- or state-wide reach. Conclusions: Almost all grantees implement EBIs to promote CRC screening, but the EBIs that may have the greatest impact with CRC screening are implemented by fewer grantees in the first 2 years of the CRCCP. (C) 2013 American Journal of Preventive Medicine. All rights reserved. C1 [Hannon, Peggy A.; Thuy Vu; Kohn, Marlana] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Hlth Promot Res Ctr, Seattle, WA 98195 USA. [Maxwell, Annette E.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Escoffery, Cam; Carvalho, Michelle L.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [DeGroff, Amy] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Leeman, Jennifer] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA. [Pfeiffer, Debbie J.] Washington Univ, Hlth Commun Res Lab, St Louis, MO USA. [Dwyer, Andrea] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Fernandez, Maria E.; Vernon, Sally W.; Liang, Lily] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Hlth Promot & Behav Sci, Houston, TX 77030 USA. RP Hannon, PA (reprint author), 1107 NE 45th St,Ste 200, Seattle, WA 98105 USA. EM peggyh@uw.edu FU CDC; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Washington) [U48DP001911]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of California at Los Angeles) [U48 DP001934]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Emory University) [U48DP001909]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of North Carolina) [U48DP000059]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (Washington University at St. Louis) [U48DP001903]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Colorado) [U48DP001938]; National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Texas at Houston) [U48DP001949] FX The authors thank the CRCCP grantees for their participation in the survey. This publication was supported by the CDC and the National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (University of Washington, U48DP001911; University of California at Los Angeles, U48 DP001934; Emory University, U48DP001909; University of North Carolina, U48DP000059; Washington University at St. Louis, U48DP001903; University of Colorado, U48DP001938; and University of Texas at Houston, U48DP001949). NR 16 TC 11 Z9 11 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2013 VL 45 IS 5 BP 644 EP 648 DI 10.1016/j.amepre.2013.06.010 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 237ZS UT WOS:000325910800015 PM 24139779 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, D Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events SO CRITICAL CARE MEDICINE LA English DT Article DE ventilator-associated pneumonia; intensive care unit; epidemiology; public health; critical care; mechanical ventilation ID DIAGNOSTIC-TECHNIQUES; RANDOMIZED-TRIAL; PNEUMONIA RATES; INFECTIONS; VALIDATION; CRITERIA; DEFINITIONS AB Objective: To develop and implement an objective, reliable approach to surveillance for ventilator-associated events in adult patients. Design: The Centers for Disease Control and Prevention (CDC) convened a Ventilator-Associated Pneumonia (VAP) Surveillance Definition Working Group in September 2011. Working Group members included representatives of stakeholder societies and organizations and federal partners. Main results: The Working Group finalized a three-tier, adult surveillance definition algorithm for ventilator-associated events. The algorithm uses objective, readily available data elements and can identify a broad range of conditions and complications occurring in mechanically ventilated adult patients, including but not limited to VAP. The first tier definition, ventilator-associated condition (VAC), identifies patients with a period of sustained respiratory deterioration following a sustained period of stability or improvement on the ventilator, defined by changes in the daily minimum fraction of inspired oxygen or positive end-expiratory pressure. The second tier definition, infection-related ventilator-associated complication (IVAC), requires that patients with VAC also have an abnormal temperature or white blood cell count, and be started on a new antimicrobial agent. The third tier definitions, possible and probable VAP, require that patients with IVAC also have laboratory and/or microbiological evidence of respiratory infection. Conclusions: Ventilator-associated events surveillance was implemented in January 2013 in the CDC's National Healthcare Safety Network. Modifications to improve surveillance may be made as additional data become available and users gain experience with the new definitions. C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Balk, Robert; Burns, Suzanne M.; Deutschman, Clifford S.; Gutterman, David; Hammer, Beth; Hill, Nicholas S.; Kollef, Marin; Levy, Mitchell; Lipsett, Pamela] Amer Thorac Soc, Amer Coll Chest Phys, Soc Crit Care Med, Crit Care Soc Collaborat Amer Assoc Crit Care Nur, New York, NY USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemi, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Med Coll Wisconsin, Zablocki Vet Adm Med Ctr, Dept Cardiol, Milwaukee, WI 53226 USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean] Massachusetts Gen Hosp, Dept Res Care, Boston, MA 02114 USA. [Hess, Dean] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Divis Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Univ, Ctr Sci, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [VanAntwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM smagill@cdc.gov OI Diekema, Daniel/0000-0003-1273-0724 FU Centers for Disease Control and Prevention (CDC); Centers for Disease Control (CDC); U.S. Food and Drug Administration; Office of the National Co-ordinator for Health IT; CDC; bioMerieux; National Institute of General Medical Sciences; Merck; Cerexa; bioMeriuex; PurThread Technologies; Pfizer; Society of Critical Care Medicine FX The work described herein was supported by the Centers for Disease Control and Prevention (CDC).; Dr. Klompas received grant support from the Centers for Disease Control (CDC), U.S. Food and Drug Administration, and the Office of the National Co-ordinator for Health IT. Dr. Balk received grant support from the CDC and bioMerieux for participation in the EPIC CAP study (CDC) and the Procalcitonin in ICU antibiotic stewardship study (CDC and bioMerieux). Dr. Deutschman received grant support from the National Institute of General Medical Sciences. Dr. Diekema received grant support from Merck, Cerexa, bioMeriuex, PurThread Technologies, and Pfizer.; Ms. Greene is employed by the Rochester General Hospital. Dr. Lipsett has board membership with the Society of Critical Care Medicine. Dr. Deutschman received a stipend for his Presidency with the Society of Critical Care Medicine. NR 37 TC 71 Z9 71 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD NOV PY 2013 VL 41 IS 11 BP 2467 EP 2475 DI 10.1097/CCM.0b013e3182a262db PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 243BO UT WOS:000326291600032 PM 24162674 ER PT J AU Mottl, AK Lauer, A Dabelea, D Maahs, DM D'Agostino, RB Dolan, LM Gilliam, LK Lawrence, JM Rodriguez, B Marcovina, SM Imperatore, G Shankar, RK Afkarian, M Reynolds, K Liese, AD Mauer, M Mayer-Davis, EJ AF Mottl, Amy K. Lauer, Abigail Dabelea, Dana Maahs, David M. D'Agostino, Ralph B., Jr. Dolan, Larry M. Gilliam, Lisa K. Lawrence, Jean M. Rodriguez, Beatriz Marcovina, Santica M. Imperatore, Giuseppina Shankar, Roopa Kanakatti Afkarian, Maryam Reynolds, Kristi Liese, Angela D. Mauer, Michael Mayer-Davis, Elizabeth J. CA SEARCH Diabet Youth Study Grp TI Albuminuria According to Status of Autoimmunity and Insulin Sensitivity Among Youth With Type 1 and Type 2 Diabetes SO DIABETES CARE LA English DT Article ID GLUCOSE DISPOSAL RATE; METABOLIC SYNDROME; NONDIABETIC SUBJECTS; COMPLICATIONS TRIAL; RENAL-INSUFFICIENCY; WAIST CIRCUMFERENCE; PREVALENCE; RESISTANCE; MELLITUS; MICROALBUMINURIA AB OBJECTIVETo evaluate whether etiologic diabetes type is associated with the degree of albuminuria in children with diabetes.RESEARCH DESIGN AND METHODSSEARCH is an observational, longitudinal study of children with diabetes. Youth with newly diagnosed diabetes were classified according to diabetes autoantibody (DAA) status and presence of insulin resistance. We defined insulin resistance as an insulin sensitivity score <25th percentile for the United States general youth population. DAA status was based on positivity for the 65-kD isoform of glutamate decarboxylase and insulinoma-associated protein 2 antigens. The four etiologic diabetes type groups were as follows: DAA(+)/insulin-sensitive (IS) (n = 1,351); DAA(+)/insulin-resistant (IR) (n = 438); DAA(-)/IR (n = 379); and DAA(-)/IS (n = 233). Urinary albumin:creatinine ratio (UACR) was measured from a random urine specimen. Multivariable regression analyses assessed the independent relationship between the four diabetes type groups and magnitude of UACR.RESULTSAdjusted UACR means across the four groups were as follows: DAA(+)/IS = 154 g/mg; DAA(+)/IR = 137 g/mg; DAA(-)/IR = 257 g/mg; and DAA(-)/IS = 131 g/mg (P < 0.005). Only DAA(-)/IR was significantly different. We performed post hoc multivariable regression analysis restricted to the two IR groups to explore the contribution of DAA status and insulin sensitivity (continuous) to the difference in UACR between the IR groups. Only insulin sensitivity was significantly associated with UACR ( = -0.54; P < 0.0001).CONCLUSIONSIn youth with diabetes, the DAA(-)/IR group had a greater UACR than all other groups, possibly because of the greater magnitude of insulin resistance. Further exploration of the relationships between severity of insulin resistance, autoimmunity, and albuminuria in youth with diabetes is warranted. C1 [Mottl, Amy K.] Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27515 USA. [Lauer, Abigail; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Dabelea, Dana] Univ Colorado Denver, Dept Epidemiol, Sch Publ Hlth, Aurora, CO USA. [Maahs, David M.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO USA. [Dolan, Larry M.; Shankar, Roopa Kanakatti] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA. [Gilliam, Lisa K.] Univ Washington, Dept Med, Seattle, WA USA. [Lawrence, Jean M.; Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Rodriguez, Beatriz] Kuakini Med Ctr, Honolulu, HI USA. [Marcovina, Santica M.] Univ Washington, Dept Med, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Afkarian, Maryam] Univ Washington, Renal Res Inst, Seattle, WA 98195 USA. [Liese, Angela D.] Univ S Carolina, Dept Epidemiol & Biostat, Ctr Res Nutr & Hlth Dispar, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Mauer, Michael] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA. [Mauer, Michael] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Publ Hlth, Dept Med, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA. RP Mottl, AK (reprint author), Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27515 USA. EM amy_mottl@med.unc.edu RI Dagostino Jr, Ralph/C-4060-2017; OI Dagostino Jr, Ralph/0000-0002-3550-8395; Mottl, Amy/0000-0002-4258-1726 FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center, Cincinnati [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical and Translational Research (SCTR) Institute at the Medical University of South Carolina (National Institutes of Health/National Center for Research Resources) [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver (DERC National Institutes of Health) [P30 DK57516]; Institutional Clinical and Translational Science Award (CTSA); National Institutes of Health/National Center for Research Resources at the University of Cincinnati [1UL1RR026314-01] FX SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site contract numbers for the study are as follows: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714); University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1); Kuakini Medical Center (U58CCU919256 and U01 DP000245); Children's Hospital Medical Center, Cincinnati (U48/CCU519239, U01 DP000248, and 1U18DP002709); University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01); University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01); and Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171). The authors also received support from involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical and Translational Research (SCTR) Institute at the Medical University of South Carolina (National Institutes of Health/National Center for Research Resources grant number UL1RR029882); Children's Hospital and Regional Medical Center (grant number M01RR00037); Colorado Pediatric General Clinical Research Center (grant number M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC National Institutes of Health P30 DK57516); and the Institutional Clinical and Translational Science Award (CTSA) and National Institutes of Health/National Center for Research Resources at the University of Cincinnati (grant number 1UL1RR026314-01). NR 38 TC 7 Z9 7 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2013 VL 36 IS 11 BP 3633 EP 3638 DI 10.2337/dc13-0568 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 242VZ UT WOS:000326274100045 PM 23846811 ER PT J AU Schaefer, MK Kossover, RA Perz, JF AF Schaefer, Melissa K. Kossover, Rachel A. Perz, Joseph F. TI Sharing Insulin Pens: Are You Putting Patients at Risk? SO DIABETES CARE LA English DT Letter C1 [Schaefer, Melissa K.; Kossover, Rachel A.; Perz, Joseph F.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Schaefer, MK (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM mschaefer@cdc.gov NR 4 TC 5 Z9 5 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2013 VL 36 IS 11 BP E188 EP E189 DI 10.2337/dc13-1522 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 242VZ UT WOS:000326274100002 PM 24159184 ER PT J AU Kalman, L Tarleton, J Percy, A Aradhya, S Bale, S Bayrak-Toydemir, P Bridges, C Buller-Burckle, A Dag, S Iyer, R Vo, T Zvereff, V Toji, L AF Kalman, L. Tarleton, J. Percy, A. Aradhya, S. Bale, S. Bayrak-Toydemir, P. Bridges, C. Buller-Burckle, A. Das, S. Iyer, R. Vo, T. Zvereff, V. Toji, L. TI Development of a Genomic DNA Reference Material Panel for Rett Syndrome Genetic Testing SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Molecular-Pathology (AMP) CY NOV 14-16, 2013 CL Phoenix, AZ SP Assoc Mol Pathol C1 [Kalman, L.; Toji, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tarleton, J.; Bridges, C.] Mission Hlth Syst, Fullerton Genet Ctr, Asheville, NC USA. [Percy, A.] Univ Alabama Birmingham, Birmingham, AL USA. [Aradhya, S.; Bale, S.] GeneDx, Gaithersburg, MD USA. [Bayrak-Toydemir, P.] ARUP Labs, Salt Lake City, UT USA. [Buller-Burckle, A.] Quest Diagnost, San Juan Capistrano, CA USA. [Das, S.] Univ Chicago, Chicago, IL 60637 USA. [Iyer, R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Vo, T.] Ambry Genet, Also Viejo, CA USA. [Zvereff, V.] LabCorp, Res Triangle Pk, NC USA. [Toji, L.] Coriell Cell Repositories, Camden, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2013 VL 15 IS 6 BP 845 EP 846 PG 2 WC Pathology SC Pathology GA 248BF UT WOS:000326668000026 ER PT J AU Church, D Funke, B Hegde, M Chao, C Trow, J Slotta, D Halavi, M Meric, PA Ananiev, V Frishberg, D Rubinstein, W da Silva, C Gowrisankar, S Ajay, S Chapman, B Compton, J Dames, S Das, S Feng, Y Hambuch, T Kulkarni, S Mao, R O'Fallon, BD Shrivastava, S Toji, L Zhang, V Zook, J Kalman, L AF Church, D. Funke, B. Hegde, M. Chao, C. Trow, J. Slotta, D. Halavi, M. Meric, P. A. Ananiev, V. Frishberg, D. Rubinstein, W. da Silva, C. Gowrisankar, S. Ajay, S. Chapman, B. Compton, J. Dames, S. Das, S. Feng, Y. Hambuch, T. Kulkarni, S. Mao, R. O'Fallon, B. D. Shrivastava, S. Toji, L. Zhang, V. Zook, J. Kalman, L. TI Development of Consensus Reference Material Tools for Clinical Next-Generation Sequencing Tests SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Molecular-Pathology (AMP) CY NOV 14-16, 2013 CL Phoenix, AZ SP Assoc Mol Pathol C1 [Church, D.] NIH, Bethesda, MD 20892 USA. [Funke, B.] Massachusetts Gen Hosp, Cambridge, MA USA. [Funke, B.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Hegde, M.; da Silva, C.] Emory Univ, Sch Med, Atlanta, GA USA. [Chao, C.; Trow, J.; Slotta, D.; Halavi, M.; Meric, P. A.; Ananiev, V.; Frishberg, D.; Rubinstein, W.] NIH, Bethesda, MD 20892 USA. [Gowrisankar, S.] Partners Healthcare Ctr Personalized Genet Med, Cambridge, MA USA. [Ajay, S.; Hambuch, T.] Illumina, San Diego, CA USA. [Chapman, B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Compton, J.] GeneDx Inc, Gaithersburg, MD USA. [Dames, S.; Mao, R.; O'Fallon, B. D.] ARUP Labs, Salt Lake City, UT USA. [Das, S.] Univ Chicago, Chicago, IL 60637 USA. [Feng, Y.; Zhang, V.] Baylor Coll Med, Houston, TX 77030 USA. [Kulkarni, S.; Shrivastava, S.] Washington Univ, Sch Med, St Louis, MO USA. [Toji, L.] Coriell Inst Med Res, Camden, NJ USA. [Zook, J.] NIST, Gaithersburg, MD 20899 USA. [Kalman, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2013 VL 15 IS 6 BP 847 EP 847 PG 1 WC Pathology SC Pathology GA 248BF UT WOS:000326668000032 ER PT J AU Floyd, RL Ebrahim, S Tsai, J O'Connor, M Sokol, R AF Floyd, R. Louise Ebrahim, Shahul Tsai, James O'Connor, Mary Sokol, Robert TI Strategies to Reduce Alcohol-Exposed Pregnancies (vol 10, pg S149, 2006) SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Correction C1 [Floyd, R. Louise; Ebrahim, Shahul; Tsai, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Connor, Mary] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Sokol, Robert] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA. [Ebrahim, Shahul] Ctr Dis Control & Prevent E86, Atlanta, GA 30333 USA. RP Ebrahim, S (reprint author), Ctr Dis Control & Prevent E86, Atlanta, GA 30333 USA. EM sebrahim@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2013 VL 17 IS 9 BP 1735 EP 1735 DI 10.1007/s10995-007-0203-6 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 243EJ UT WOS:000326299300025 ER PT J AU desVignes-Kendrick, M Reynolds, K Lee, T Gaul, L Klein, K Irvin, K Wellman, A Hardin, A Williams, I Wiegand, R Harris, J Parise, M Abanyie, F Harvey, RR AF desVignes-Kendrick, M. Reynolds, Kaye Lee, Teresa Gaul, Linda Klein, Kate Irvin, Kari Wellman, Allison Hardin, Angela Williams, Ian Wiegand, Ryan Harris, Julie Parise, Monica Abanyie, Francisca Harvey, R. Reid TI Outbreaks of Cyclosporiasis - United States, June-August 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Irvin, Kari; Wellman, Allison; Hardin, Angela] US FDA, Coordinated Outbreak Response & Evaluat Network, Off Foods & Vet Med, Rockville, MD 20857 USA. [Abanyie, Francisca; Harvey, R. Reid] CDC, Atlanta, GA 30333 USA. RP Harvey, RR (reprint author), CDC, Atlanta, GA 30333 USA. EM rharvey@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 1 PY 2013 VL 62 IS 43 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GU UT WOS:000326451500004 ER PT J AU Kadima, NT Kobau, R Zack, MM Helmers, S AF Kadima, Norbert T. Kobau, Rosemarie Zack, Matthew M. Helmers, Sandra TI National Epilepsy Month - November 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POPULATION; LIFE C1 [Kadima, Norbert T.] SciMetrika, Res Triangle Pk, NC USA. [Kobau, Rosemarie; Zack, Matthew M.; Helmers, Sandra] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Kobau, R (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM rkobau@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 1 PY 2013 VL 62 IS 43 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GU UT WOS:000326451500001 ER PT J AU Sodha, S AF Sodha, Samir TI Global Routine Vaccination Coverage-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Sodha, Samir] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Sodha, Samir] United Nations Childrens Fund UNICEF, New York, NY USA. [Sodha, Samir] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Sodha, S (reprint author), WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. EM ssodha@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD NOV 1 PY 2013 VL 62 IS 43 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GU UT WOS:000326451500003 ER PT J AU Albarino, CG Uebelhoer, LS Vincent, JP Khristova, ML Chakrabarti, AK McElroy, A Nichol, ST Towner, JS AF Albarino, Cesar G. Uebelhoer, Luke S. Vincent, Joel P. Khristova, Marina L. Chakrabarti, Ayan K. McElroy, Anita Nichol, Stuart T. Towner, Jonathan S. TI Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate SO VIROLOGY LA English DT Article DE Filovirus; Marburgvirus; Marburg virus; Bat isolate; Minigenome; Recombinant; Full-length; GFP; Macrophages; Cytokines ID HEMORRHAGIC-FEVER; EBOLA-VIRUS; CYNOMOLGUS MACAQUES; REPLICATION; TRANSCRIPTION; INFECTION; GLYCOPROTEIN; PATHOGENESIS; MINIGENOMES; CULTURE AB Recent investigations have shown the Egyptian fruit bat (Rousettus aegyptiacus) to be a natural reservoir for marburgviruses. To better understand the life cycle of these viruses in the natural host, a new reverse genetics system was developed for the reliable rescue of a Marburg virus (MARV) originally isolated directly from a R. aegyptiacus bat (371 Bat). To develop this system, the exact terminal sequences were first determined by 5' and 3' RACE, followed by the cloning of viral proteins NP, VP35, VP30 and L into expression plasmids. Novel conditions were then developed to efficiently replicate virus mini-genomes followed by the construction of full-length genomic clones from which recombinant wild type and GFP-containing MARVs were rescued. Surprisingly, when these recombinant MARVs were propagated in primary human macrophages, a dramatic difference was found in their ability to grow and to elicit antiviral cytokine responses. Published by Elsevier Inc. C1 [Albarino, Cesar G.; Uebelhoer, Luke S.; Vincent, Joel P.; Khristova, Marina L.; Chakrabarti, Ayan K.; McElroy, Anita; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jit88@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX We thank K. Conzelmann for providing BSRT7/5 cells and Christina Spiropoulou for excellent advice and criticism for this work. Dr. Luke Uebelhoer holds a fellowship supported by the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and CDC NR 28 TC 13 Z9 15 U1 0 U2 44 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV PY 2013 VL 446 IS 1-2 BP 230 EP 237 DI 10.1016/j.virol.2013.07.038 PG 8 WC Virology SC Virology GA 236ZX UT WOS:000325839100026 PM 24074586 ER PT J AU Abdul-Quader, AS Feelemyer, J Modi, S Stein, ES Briceno, A Semaan, S Horvath, T Kennedy, GE Des Jarlais, DC AF Abdul-Quader, Abu S. Feelemyer, Jonathan Modi, Shilpa Stein, Ellen S. Briceno, Alya Semaan, Salaam Horvath, Tara Kennedy, Gail E. Des Jarlais, Don C. TI Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review SO AIDS AND BEHAVIOR LA English DT Review DE Structural-level interventions; Needle-exchange programs; HIV; Hepatitis C; People who inject drugs (PWID) ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; USERS; PREVALENCE; RISK; PREVENTION; INTERVENTIONS; COVERAGE; IMPACT; TRANSMISSION AB Needle-syringe programs (NSP) have been effective in reducing HIV and hepatitis C (HCV) infection among people who inject drugs (PWID). Achieving sustainable reductions in these blood-borne infections requires addressing structural factors so PWID can legally access NSP services. Systematic literature searches collected information on NSP coverage and changes in HIV or HCV infection prevalence or incidence at the population level. Included studies had to document biomarkers (HIV or HCV) coupled with structural-level NSP, defined by a minimum 50 % coverage of PWID and distribution of 10 or more needles/syringe per PWID per year. Fifteen studies reported structural-level NSP and changes in HIV or HCV infection prevalence/incidence. Nine reported decreases in HIV prevalence, six in HCV infection prevalence, and three reported decreases in HIV incidence. The results support NSP as a structural-level intervention to reduce population-level infection and implementation of NSP for prevention and treatment of HIV and HCV infection. C1 [Abdul-Quader, Abu S.; Semaan, Salaam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Epidemiol & Strateg Informat Branch, Atlanta, GA 30329 USA. [Feelemyer, Jonathan; Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, Inst Chem Dependency, New York, NY 10003 USA. [Modi, Shilpa] George Washington Univ, Elliott Sch Int Affairs, Washington, DC 20052 USA. [Stein, Ellen S.; Briceno, Alya; Horvath, Tara; Kennedy, Gail E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Abdul-Quader, AS (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Epidemiol & Strateg Informat Branch, CORP Bldg 1 Rm 2308-02,MS E30, Atlanta, GA 30329 USA. EM afa3@cdc.gov FU NIAID NIH HHS [R01 AI 083035] NR 43 TC 29 Z9 30 U1 5 U2 22 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD NOV PY 2013 VL 17 IS 9 BP 2878 EP 2892 DI 10.1007/s10461-013-0593-y PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 240QW UT WOS:000326113100004 PM 23975473 ER PT J AU Paz-Bailey, G Miller, W Shiraishi, RW Jacobson, JO Abimbola, TO Chen, SY AF Paz-Bailey, Gabriela Miller, William Shiraishi, Ray W. Jacobson, Jerry O. Abimbola, Taiwo O. Chen, Sanny Y. TI Reaching Men Who Have Sex with Men: A Comparison of Respondent-Driven Sampling and Time-Location Sampling in Guatemala City SO AIDS AND BEHAVIOR LA English DT Article DE HIV surveillance; MSM; RDS; TLS; Hidden populations ID HARD-TO-REACH; BEHAVIORAL SURVEILLANCE; HIDDEN POPULATIONS; LATIN-AMERICA; HIV RISK; COUNTRIES; METHODOLOGY; PREVENTION; EPIDEMIC; WORKERS AB We present a comparison of respondent-driven sampling (RDS) and time-location sampling (TLS) for behavioral surveillance studies among men who have sex with men (MSM). In 2010, we conducted two simultaneous studies using TLS (N = 609) and RDS (N = 507) in Guatemala city. Differences in characteristics of the population reached based on weighted estimates as well as the time and cost of recruitment are presented. RDS MSM were marginally more likely to self-report as heterosexual, less likely to disclose sexual orientation to family members and more likely to report sex with women than TLS MSM. Although RDS MSM were less likely than TLS MSM to report a parts per thousand yen2 non-commercial male partners, they were more likely to report selling sex in the past 12 months. The cost per participant was $89 and $121 for RDS and TLS, respectively. Our results suggest that RDS reached a more hidden sub-population of non-gay-identifying MSM than TLS and had a lower implementation cost. C1 [Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB, Atlanta, GA 30333 USA. [Miller, William] Univ Chapel Hill, Dept Publ Hlth, Chapel Hill, NC USA. [Shiraishi, Ray W.; Abimbola, Taiwo O.; Chen, Sanny Y.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Paz-Bailey, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM gmb5@cdc.gov OI Miller, William/0000-0002-4140-1797 FU CGH CDC HHS [6D43GH000014-05]; NIAID NIH HHS [P30 AI50410, P30 AI050410] NR 44 TC 15 Z9 15 U1 2 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD NOV PY 2013 VL 17 IS 9 BP 3081 EP 3090 DI 10.1007/s10461-013-0589-7 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 240QW UT WOS:000326113100022 PM 23963498 ER PT J AU Crider, KS Cordero, AM Qi, YP Mulinare, J Dowling, NF Berry, RJ AF Crider, Krista S. Cordero, Amy M. Qi, Yan Ping Mulinare, Joseph Dowling, Nicole F. Berry, Robert J. TI Prenatal folic acid and risk of asthma in children: a systematic review and meta-analysis SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Review ID CHILDHOOD RESPIRATORY HEALTH; NEURAL-TUBE DEFECTS; LUNG-FUNCTION; FOLATE LEVELS; BIRTH COHORT; PREGNANCY; ATOPY; SUPPLEMENTATION; VITAMIN-B-12; PREVENTION AB Background: Childhood asthma has become a critical public health problem because of its high morbidity and increasing prevalence. The impact of nutrition and other exposures during pregnancy on long-term health and development of children has been of increasing interest. Objective: We performed a systematic review and meta-analysis of the association of folate and folic acid intake during pregnancy and risk of asthma and other allergic outcomes in children. Design: We performed a systematic search of 8 electronic databases for articles that examined the association between prenatal folate or folic acid exposure and risk of asthma and other allergic outcomes (eg, allergy, eczema, and atopic dermatitis) in childhood. We performed a meta-analysis by using a random-effects model to derive a summary risk estimate of studies with similar exposure timing, exposure assessment, and outcomes. Results: Our meta-analysis provided no evidence of an association between maternal folic acid supplement use (compared with no use) in the prepregnancy period through the first trimester and asthma in childhood (summary risk estimate: 1.01; 95% CI: 0.78, 1.30). Because of substantial heterogeneity in exposures and outcomes, it was not possible to generate summary measures for other folate indicators (eg, blood folate concentrations) and asthma or allergy-related outcomes; however, the preponderance of primary risk estimates was not elevated. Conclusions: Our findings do not support an association between periconceptional folic acid supplementation and increased risk of asthma in children. However, because of the limited number and types of studies in the literature, additional research is needed. C1 [Crider, Krista S.; Cordero, Amy M.; Qi, Yan Ping; Dowling, Nicole F.; Berry, Robert J.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Mulinare, Joseph] Carter Consulting Inc, Atlanta, GA USA. RP Crider, KS (reprint author), 1600 Clifton RD,Mail Stop E86, Atlanta, GA 30333 USA. EM krider@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU CDC; US Department of Energy FX Supported by the CDC and in part by an appointment to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. NR 37 TC 32 Z9 33 U1 3 U2 17 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2013 VL 98 IS 5 BP 1272 EP 1281 DI 10.3945/ajcn.113.065623 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 239XJ UT WOS:000326059000016 PM 24004895 ER PT J AU Rascoe, LN Santamaria, C Handali, S Dangoudoubiyam, S Kazacos, KR Wilkins, PP Ndao, M AF Rascoe, Lisa N. Santamaria, Cynthia Handali, Sukwan Dangoudoubiyam, Sriveny Kazacos, Kevin R. Wilkins, Patricia P. Ndao, Momar TI Interlaboratory Optimization and Evaluation of a Serological Assay for Diagnosis of Human Baylisascariasis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID PROCYONIS AB A Western blot assay using a recombinant protein, recombinant Baylisascaris procyonis RAG1 protein (rBpRAG1), was developed for the diagnosis of human baylisascariasis concurrently by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, and the National Reference Centre for Parasitology (NRCP) in Montreal, Canada. Assay performance was assessed by testing 275 specimens at the CDC and 405 specimens at the NRCP. Twenty specimens from 16 cases of baylisascariasis were evaluated. Eighteen were positive, with the assay correctly identifying 14 of 16 patients. The rBpRAG1 Western blot assay showed no cross-reactivity with Toxocara-positive serum and had an overall sensitivity of 88% and a specificity of 98%. C1 [Rascoe, Lisa N.; Handali, Sukwan; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Santamaria, Cynthia; Ndao, Momar] McGill Univ, Ctr Hlth, Res Inst, Natl Reference Ctr Parasitol, Montreal, PQ, Canada. [Dangoudoubiyam, Sriveny; Kazacos, Kevin R.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. RP Wilkins, PP (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM pwilkins@cdc.gov; momar.ndao@mcgill.ca FU Public Health Agency of Canada/National Microbiology Laboratory [HT070-010033] FX Work performed at the NRCP was supported by the Public Health Agency of Canada/National Microbiology Laboratory (grant HT070-010033). NR 10 TC 4 Z9 5 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD NOV PY 2013 VL 20 IS 11 BP 1758 EP 1763 DI 10.1128/CVI.00387-13 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 241KI UT WOS:000326165300014 PM 24049107 ER PT J AU Violanti, JM Charles, LE Gu, JK Burchfiel, CM Andrew, ME Joseph, PN Dorn, JM AF Violanti, John M. Charles, Luenda E. Gu, Ja K. Burchfiel, Cecil M. Andrew, Michael E. Joseph, P. Nedra Dorn, Joan M. TI Depressive symptoms and carotid artery intima-media thickness in police officers SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Cardiovascular disease; Depression; Risk factors; Police ID NUTRITION EXAMINATION SURVEY; SLEEP QUALITY INDEX; RISK-FACTORS; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; SUBCLINICAL ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; NATIONAL-HEALTH; NEGATIVE AFFECT AB Police work is a stressful occupation. Depressive symptoms, which may occur as a result of exposure to stressors in police work, have been known to be associated with an increased risk of cardiovascular disease. This cross-sectional study investigated the association between depressive symptoms and carotid artery intima-media thickness (CIMT) among police officers. CIMT was measured with B-mode carotid ultrasonography. Depressive symptoms were measured using the Center for Epidemiological Studies Depression (CES-D) scale. Analyses of variance and covariance were utilized to examine the mean values of common CIMT (CCA IMT) and maximum CIMT (MMXIMT) across quintiles of depressive symptoms. Participants included 412 officers (mean age = 41 years). Hypertension status significantly modified the association between CES-D score and CIMT. The association between CES-D score and CCA IMT was statistically significant (adjusted P = 0.030) but only among officers without hypertension. The associations between CES-D score and MMXIMT were not significant among officers with or without hypertension. Our results also showed that among officers who reported poor sleep quality, mean levels of CCA IMT, and MMXIMT tended to increase as depressive symptoms increased. Depressive symptoms may be therefore be independently associated with CIMT, yet masked by hypertension. Even though sleep quality did not significantly modify the main association, our results also suggest that poor sleep quality may act synergistically with depressive symptoms to increase CIMT. Future prospective work would help to clarify these associations. C1 [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14214 USA. [Charles, Luenda E.; Gu, Ja K.; Burchfiel, Cecil M.; Andrew, Michael E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Joseph, P. Nedra] Univ Chicago, Ctr Comprehens Canc, Epidemiol & Res Recruitment Core, Chicago, IL 60637 USA. [Dorn, Joan M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Exercise & Nutr Sci, Buffalo, NY 14214 USA. RP Violanti, JM (reprint author), SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, 270 Farber Hall, Buffalo, NY 14214 USA. EM violanti@buffalo.edu FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 51 TC 3 Z9 3 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 EI 1432-1246 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD NOV PY 2013 VL 86 IS 8 BP 931 EP 942 DI 10.1007/s00420-012-0829-6 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 240DA UT WOS:000326073700009 PM 23184119 ER PT J AU Benoit, CM MacLeod, WB Hamer, DH Sanchez-Vegas, C Chen, LH Wilson, ME Karchmer, AW Yanni, E Hochberg, NS Ooi, WW Kogelman, L Barnett, ED AF Benoit, Christine M. MacLeod, William B. Hamer, Davidson H. Sanchez-Vegas, Carolina Chen, Lin H. Wilson, Mary E. Karchmer, Adolf W. Yanni, Emad Hochberg, Natasha S. Ooi, Winnie W. Kogelman, Laura Barnett, Elizabeth D. TI Acceptability of Hypothetical Dengue Vaccines Among Travelers SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID HEMORRHAGIC-FEVER; UNITED-STATES; IMMUNIZATION; ACCEPTANCE; COUNTRIES AB BackgroundDengue viruses have spread widely in recent decades and cause tens of millions of infections mostly in tropical and subtropical areas. Vaccine candidates are being studied aggressively and may be ready for licensure soon. MethodsWe surveyed patients with past or upcoming travel to dengue-endemic countries to assess rates and determinants of acceptance for four hypothetical dengue vaccines with variable efficacy and adverse event (AE) profiles. Acceptance ratios were calculated for vaccines with varied efficacy and AE risk. ResultsAcceptance of the four hypothetical vaccines ranged from 54% for the vaccine with lower efficacy and serious AE risk to 95% for the vaccine with higher efficacy and minor AE risk. Given equal efficacy, vaccines with lower AE risk were better accepted than those with higher AE risk; given equivalent AE risk, vaccines with higher efficacy were better accepted than those with lower efficacy. History of Japanese encephalitis vaccination was associated with lower vaccine acceptance for one of the hypothetical vaccines. US-born travelers were more likely than non-US born travelers to accept a vaccine with 75% efficacy and a risk of minor AEs (p=0.003). Compared with North American-born travelers, Asian- and African-born travelers were less likely to accept both vaccines with 75% efficacy. ConclusionsMost travelers would accept a safe and efficacious dengue vaccine if one were available. Travelers valued fewer potential AEs over increased vaccine efficacy. C1 [Benoit, Christine M.; Sanchez-Vegas, Carolina; Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA. [MacLeod, William B.; Hamer, Davidson H.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [MacLeod, William B.; Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA. [Hamer, Davidson H.; Hochberg, Natasha S.] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. [Chen, Lin H.] Mt Auburn Hosp, Travel Med Ctr, Div Infect Dis, Cambridge, MA USA. [Chen, Lin H.; Karchmer, Adolf W.] Harvard Univ, Sch Med, Boston, MA USA. [Wilson, Mary E.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Yanni, Emad] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Hochberg, Natasha S.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Ooi, Winnie W.] Lahey Clin Fdn, Travel & Trop Med Clin, Burlington, MA USA. [Kogelman, Laura] Tufts Med Ctr, Infect Dis Clin, Boston, MA USA. RP Barnett, ED (reprint author), Boston Med Ctr, Maxwell Finland Lab Infect Dis, 670 Albany St Room 625, Boston, MA 02118 USA. EM ebarnett@bu.edu FU Centers for Disease Control and Prevention [1U19CI000508-01]; Boston Medical Center [1U19CI000508-01]; Sanofi-Pasteur, Inc. FX This research was funded by a cooperative agreement (1U19CI000508-01) between the Centers for Disease Control and Prevention and Boston Medical Center and was supported in part by a research grant from Sanofi-Pasteur, Inc. The opinions are those of the authors and do not necessarily represent those of the CDC or Sanofi-Pasteur. NR 29 TC 2 Z9 2 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD NOV PY 2013 VL 20 IS 6 BP 346 EP 351 DI 10.1111/jtm.12056 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 239ML UT WOS:000326029200021 PM 24165380 ER PT J AU Sanchez-Vegas, C Hamer, DH Chen, LH Wilson, ME Benoit, C Hunsperger, E MacLeod, WB Jentes, ES Ooi, WW Karchmer, AW Kogelman, L Yanni, E Marano, N Barnett, ED AF Sanchez-Vegas, Carolina Hamer, Davidson H. Chen, Lin H. Wilson, Mary E. Benoit, Christine Hunsperger, Elizabeth MacLeod, William B. Jentes, Emily S. Ooi, Winnie W. Karchmer, Adolf W. Kogelman, Laura Yanni, Emad Marano, Nina Barnett, Elizabeth D. TI Prevalence of Dengue Virus Infection in US Travelers Who Have Lived in or Traveled to Dengue-Endemic Countries SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID RISK-FACTORS; RETURNED TRAVELERS; IMMUNOGLOBULIN-M; PUBLIC-HEALTH; UNITED-STATES; FEVER; SURVEILLANCE; DIAGNOSIS AB BackgroundDengue virus (DENV) infections may occur in travelers. ObjectivesTo determine prevalence of anti-DENV IgG antibody in travelers who lived in or visited dengue-endemic countries and to describe risk factors and characteristics associated with infection and subsequent anti-DENV IgG antibody presence. MethodsParticipants were enrolled from travel clinics of the Boston Area Travel Medicine Network from August 2008 through June 2009. Demographic information, trip duration, travel history, and a blood sample were collected. Serum samples were tested for anti-DENV IgG antibody by indirect IgG enzyme-linked immunosorbent assay (ELISA), and antibody-mediated virus neutralization by plaque reduction neutralization test (PRNT) for anti-DENV IgG antibody-positive and selected negative samples. Participants were stratified into group 1: born in dengue-endemic countries; group 2: born in nonendemic countries but lived continuously for 1year in a dengue-endemic country; group 3: born in nonendemic countries and traveled to a dengue-endemic country for 2weeks but <1year. ResultsSix hundred travelers were enrolled. Anti-DENV IgG antibody was identified in 113 (19%) when tested by ELISA (51% in group 1, 40% in group 2, and 6.9% in group 3) and in 71 (12%) by PRNT (42% primary monotypic and 58% heterotypic reactive responses). Sensitivity and specificity of the ELISA based on PRNT results were 85% to 100% and 79% to 94%, assuming up to 15% misclassification of ELISA negative results. Presence of anti-DENV IgG antibody by ELISA was associated with years lived in dengue-endemic countries and birthplace in the Caribbean for group 1, receipt of Japanese encephalitis vaccine in group 3, and self-reported history of dengue in all three groups. ConclusionsNineteen percent of participants who were born, lived in, or traveled to dengue-endemic countries had anti-DENV IgG antibody by ELISA; 12% had antibodies by PRNT, 85% of whom had no history of dengue. Presence of DENV antibodies was associated with years lived in dengue-endemic countries and self-reported history of dengue. C1 [Sanchez-Vegas, Carolina; Benoit, Christine; Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA. [Hamer, Davidson H.; MacLeod, William B.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [Hamer, Davidson H.; MacLeod, William B.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA. [Hamer, Davidson H.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA. [Chen, Lin H.] Mt Auburn Hosp, Travel Med Ctr, Div Infect Dis, Cambridge, MA USA. [Chen, Lin H.; Karchmer, Adolf W.] Harvard Univ, Sch Med, Boston, MA USA. [Wilson, Mary E.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Hunsperger, Elizabeth] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Dengue Branch, San Juan, PR USA. [Jentes, Emily S.; Yanni, Emad; Marano, Nina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Ooi, Winnie W.] Lahey Clin Med Ctr, Travel & Trop Med Clin, Burlington, MA USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Kogelman, Laura] Tufts Med Ctr, Infect Dis Clin, Boston, MA USA. RP Barnett, ED (reprint author), Boston Med Ctr, Maxwell Finland Lab Infect Dis, 670 Albany St Room 625, Boston, MA 02118 USA. EM ebarnett@bu.edu FU Centers for Disease Control and Prevention (CDC) [U19CI000508-01]; Sanofi Pasteur FX This study was supported by Cooperative Agreement U19CI000508-01 from the Centers for Disease Control and Prevention (CDC) to Boston Medical Center and by a research grant from Sanofi Pasteur. NR 29 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD NOV PY 2013 VL 20 IS 6 BP 352 EP 360 DI 10.1111/jtm.12057 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 239ML UT WOS:000326029200022 PM 24165381 ER PT J AU Nordin, JD Parker, ED Vazquez-Benitez, G Kharbanda, EO Naleway, A Marcy, SM Molitor, B Kuckler, L Baggs, J AF Nordin, James D. Parker, Emily D. Vazquez-Benitez, Gabriela Kharbanda, Elyse O. Naleway, Allison Marcy, S. Michael Molitor, Beth Kuckler, Leslie Baggs, James TI Safety of the Yellow Fever Vaccine: A Retrospective Study SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID SERIOUS ADVERSE EVENTS; VISCEROTROPIC DISEASE; IMMUNIZATION SAFETY; YOUNG-ADULTS; ADVANCED AGE; RISK-FACTOR; DATALINK; 17D; ADOLESCENTS; IMMUNOGENICITY AB BackgroundYellow fever (YF) vaccine is considered safe; however, severe illness and death following vaccination have been reported. MethodsVaccine Safety Datalink (VSD) and US Department of Defense (DoD) data were used to identify adverse reactions following YF vaccination. Within the VSD, YF-vaccine-exposed subjects were compared to age-, site-, and gender-matched unexposed subjects. YF-vaccine-exposed DoD subjects were studied using a risk-interval design. For both cohorts, ICD-9 codes were analyzed for allergic and local reactions, mild systemic reactions, and possible visceral and neurologic adverse events (AEs). ResultsThe VSD cohort received 47,159 doses from 1991 through 2006. The DoD cohort received 1.12 million doses from 1999 through 2007. Most subjects received other vaccines simultaneously. In the VSD cohort, rates of allergic, local, and mild systemic reactions were not statistically different between YF-vaccine-exposed and -unexposed subjects. In the DoD, there was an increased risk for outpatient allergic events in the period following vaccination with YF and other vaccines rate ratios [RR 3.85, 95% confidence interval (CI) 3.35-4.41] but with no increased risk for inpatient allergic reactions. In both cohorts, inpatient ICD-9 codes for visceral events were significantly less common following vaccination; inpatient codes for neurologic events were less common in the VSD YF-vaccine-exposed adult cohort, but did not differ between exposed and unexposed periods in the DoD. In the DoD, one fatal case of YF-vaccine-associated viscerotropic disease (YF-vaccine-AVD) was detected. The estimated death rate was 0.89 for 1,000,000 YF vaccine doses (95% CI 0.12-6.31/1,000,000 doses). No YF vaccine-associated deaths occurred in the VSD. ConclusionsIn these closed cohorts we did not detect increased risk for visceral or neurologic events following YF vaccination. The death rate following YF vaccine was consistent with previous reports. These data support current recommendations for use of YF vaccine in young healthy individuals. These data are inadequate to judge safety of YF vaccines in elderly patients. C1 [Nordin, James D.; Parker, Emily D.; Vazquez-Benitez, Gabriela; Kharbanda, Elyse O.; Molitor, Beth; Kuckler, Leslie] HealthPartners Inst Educ & Res, Minneapolis, MN 55420 USA. [Naleway, Allison] Northwest Kaiser Permanente, Portland, OR USA. [Marcy, S. Michael] So Calif Permanente Med Grp, Los Angeles, CA USA. [Baggs, James] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Nordin, JD (reprint author), HealthPartners Inst Educ & Res, MS 21111R,POB 1524, Minneapolis, MN 55420 USA. EM james.d.nordin@healthpartners.com OI Baggs, James/0000-0003-0757-4683; Naleway, Allison/0000-0001-5747-4643 FU America's Health Insurance Plans (AHIP) under Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). NR 32 TC 4 Z9 4 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD NOV PY 2013 VL 20 IS 6 BP 368 EP 373 DI 10.1111/jtm.12070 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 239ML UT WOS:000326029200024 PM 24118538 ER PT J AU Reidy, DE Wilson, LF Sloan, CA Cohn, AM Smart, LM Zeichner, A AF Reidy, Dennis E. Wilson, Lauren F. Sloan, Colleen A. Cohn, Amy M. Smart, Laura M. Zeichner, Amos TI Psychopathic traits and men's anger response to interpersonal conflict: A pilot study SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Psychopathy; Anger; Frustration; Emotion-dysfunction ID REACTIVE AGGRESSION; COLLEGE-STUDENTS; SELF-REPORT; BEHAVIOR; PERSONALITY; FRUSTRATION; SUSCEPTIBILITY; DYSFUNCTION; DIRECTIONS; CONSTRUCT AB Psychopathy is associated with emotional dysfunction that impedes the experience of emotions such as fear and sadness and has been purported to facilitate violent behavior. However, findings relative to the association between psychopathy and anger have not been reliably substantiated. Theorists have proposed that psychopathy predisposes one to experience greater frustration and anger, whereas other experts have suggested that there is no convincing evidence for this assertion. In the present study, we tested the relationship between psychopathy subfactors and anger subsequent to conflict or non-conflict interactions. Sixty-eight collegiate-men completed the Self-Report Psychopathy Scale and read vignettes depicting either a conflict or non-conflict scenario and were asked to imagine themselves in the situation. Following presentation of the vignettes, participants completed a lexical-decision-task assessing affective states. Results indicated that the psychopathy subfactors demonstrated strong differential associations, where Factor 1 showed negative and Factor 2 showed positive association with anger activation in response to interpersonal conflict. Findings are discussed in terms of the importance of anger as a facilitator of violence in some psychopathic individuals. Published by Elsevier Ltd. C1 [Reidy, Dennis E.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Reidy, Dennis E.; Wilson, Lauren F.; Smart, Laura M.; Zeichner, Amos] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. [Sloan, Colleen A.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. [Cohn, Amy M.] Univ S Florida, Dept Mental Hlth & Law Policy, Tampa, FL 33620 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov NR 48 TC 2 Z9 2 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD NOV PY 2013 VL 55 IS 8 BP 957 EP 961 DI 10.1016/j.paid.2013.07.473 PG 5 WC Psychology, Social SC Psychology GA 237YD UT WOS:000325906700017 ER PT J AU Roland, KB Benard, VB Greek, A Hawkins, NA Manninen, D Saraiya, M AF Roland, K. B. Benard, V. B. Greek, A. Hawkins, N. A. Manninen, D. Saraiya, M. TI Primary care provider practices and beliefs related to cervical cancer screening with the HPV test in Federally Qualified Health Centers SO PREVENTIVE MEDICINE LA English DT Article DE Cervical cancer screening; Screening guidelines; HPV testing ID HUMAN-PAPILLOMAVIRUS; UNITED-STATES; PHYSICIANS; GUIDELINES; BREAST; WOMEN; PREVENTION; EXPERIENCE; NEOPLASIA; COUNTRIES AB Objective. Cervical cancer screening using the human papillomavirus (HPV) test and Pap test together (co-testing) is an option for average-risk women years of age. With normal co-test results, screening intervals can be extended. The study objective is to assess primary care provider practices, beliefs, facilitators and barriers to using the co-test and extending screening intervals among low-income women. Method. Data were collected from 98 providers in 15 Federally Qualified Health Center (FQHC) clinics in Illinois between August 2009 and March 2010 using a cross-sectional survey. Results. 39% of providers reported using the co-test, and 25% would recommend a three-year screening interval for women with normal co-test results. Providers perceived greater encouragement for co-testing than for extending screening intervals with a normal co-test result. Barriers to extending screening intervals included concerns about patients not returning annually for other screening tests (77%), patient concerns about missing cancer (62%), and liability (52%). Conclusion. Among FQHC providers in Illinois, few administered the co-test for screening and recommended appropriate intervals, possibly due to concerns over loss to follow-up and liability. Education regarding harms of too-frequent screening and false positives may be necessary to balance barriers to extending screening intervals. Published by Elsevier Inc. C1 [Roland, K. B.; Benard, V. B.; Hawkins, N. A.; Saraiya, M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Greek, A.; Manninen, D.] Battelle Mem Inst, Hlth & Analyt, Seattle, WA 98109 USA. RP Roland, KB (reprint author), 4770 Buford Hwy NE,MS K-55, Atlanta, GA 30341 USA. EM kroland@cdc.gov FU Centers for Disease Control and Prevention [0006] FX Centers for Disease Control and Prevention, 200-2002-00573, Task Order No. 0006. NR 42 TC 13 Z9 13 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV PY 2013 VL 57 IS 5 BP 419 EP 425 DI 10.1016/j.ypmed.2013.04.012 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 239WV UT WOS:000326057600004 PM 23628517 ER PT J AU Saraiya, M Steben, M Watson, M Markowitz, L AF Saraiya, M. Steben, M. Watson, M. Markowitz, L. TI Evolution of cervical cancer screening and prevention in United States and Canada: Implications for public health practitioners and clinicians SO PREVENTIVE MEDICINE LA English DT Article DE HPV; Screening; Vaccination; North America; US and Canada ID HUMAN-PAPILLOMAVIRUS VACCINATION; INTRAEPITHELIAL NEOPLASIA; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; ASYMPTOMATIC WOMEN; INTERVENTIONS; SERVICES; METAANALYSIS; GUIDELINES; MANAGEMENT AB Objective. Declines in cervical cancer incidence and mortality in Canada and in the United States have been widely attributed to the introduction of the Papanicolaou (Pap) test. This article reviews changes in screening and introduction of HPV vaccination. Method. Sentinel events in cervical cancer screening and primary prevention through HPV vaccination in the US and Canada are described. Results. Despite commonalities, cervical cancer screening and prevention differ between the two countries. Canada has a combination of opportunistic and organized programs at the provincial and territorial level, while the US has opportunistic screening and vaccination systems. In the US, the HPV test along with the Pap test (co-testing) is part of national recommendations for routine cervical cancer screening for women age 30 and older. Co-testing is not being considered anywhere in Canada, but primary HPV testing is currently recommended (but not implemented) in one province in Canada. Conclusion. Many prevention strategies are available for cervical cancer. Continued public health efforts should focus on increasing vaccine coverage in the target age groups and cervical cancer screening for women at appropriate intervals. Ongoing evaluation will be needed to ensure appropriate use of health resources, as vaccinated women become eligible for screening. Published by Elsevier Inc. C1 [Saraiya, M.; Watson, M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Steben, M.] Inst Natl Sante Publ Quebec, STI Unit, Quebec City, PQ, Canada. [Steben, M.] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ H3C 3J7, Canada. [Markowitz, L.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div STD Prevent, Epidemiol Branch, Atlanta, GA USA. RP Saraiya, M (reprint author), 4770 Buford Hwy NE,MS K-55, Atlanta, GA 30341 USA. EM yzs2@cdc.gov FU Abbott Molecular; Becicton-Dickinson; Copan; Digene-Qiagen; Genomica; Gen-Probe; Greiner Bio-One; GSK/GSK biologicals; Graceway pharma/Medicis; Hologic; IncellDx; Innogenetics NV; Laboratoire Biron; Marubeni; Merck/Merck Sharp Dohme; MTM laboratories; NeoDiagnostix; Roche molecular systems; Warnex FX Marc Steben personally or through his affiliations has received research, travel grants, lecture honorarium and advisory honorarium from Abbott Molecular, Becicton-Dickinson, Copan, Digene-Qiagen, Genomica, Gen-Probe, Greiner Bio-One, GSK/GSK biologicals, Graceway pharma/Medicis,Hologic, IncellDx, Innogenetics NV, Laboratoire Biron, Marubeni, Merck/Merck Sharp Dohme, MTM laboratories, NeoDiagnostix, Roche molecular systems and Warnex. NR 69 TC 11 Z9 11 U1 0 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV PY 2013 VL 57 IS 5 BP 426 EP 433 DI 10.1016/j.ypmed.2013.01.020 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 239WV UT WOS:000326057600005 PM 23402963 ER PT J AU Zhao, Z Murphy, TV AF Zhao, Zhen Murphy, Trudy V. TI Which newborns missed the hepatitis B birth dose vaccination among US children? SO PREVENTIVE MEDICINE LA English DT Article DE Hepatitis B vaccine; Non-receipt of the birth dose; Risk factors; Universal supply policy; ACIP recommendations ID AGED 19-35 MONTHS; UNITED-STATES; COVERAGE; VACCINES; THIMEROSAL; PROGRESS; IMPACT; RISK AB Objectives. Hepatitis Hepatitis B birth dose vaccination is a critical step in preventing perinatal hepatitis B virus infection. This study assesses the prevalence of children who missed the birth dose of hepatitis B vaccination and identifies socio-demographic factors associated with non-receipt of the birth dose among children in the United States. Methods. A survey observation study was conducted with the national representative sample of 17,053 U.S. children aged 19-35 months obtained from the 2009 National Immunization Survey. Categorical data analysis and multivariable logistic regression in the context of complex sample survey were applied to evaluate the prevalence and determine the independent risk factors. Results. 39.2% of children missed the birth dose of hepatitis B vaccination. Children who reside in states without a universal hepatitis B vaccine supply policy, are not covered by health insurance, and have only 1 vaccination provider are significantly associated with non-receipt of the birth dose hepatitis B vaccination. Conclusions. Children who reside in states without a universal hepatitis B vaccine supply policy, and who are not covered by health insurance are two important modifiable risk factors for not receiving the birth dose hepatitis B vaccination. Future intervention studies could be needed to help control those modifiable risk factors. Published by Elsevier Inc. C1 [Zhao, Zhen] Natl Ctr Immunizat & Resp Dis, Centers Dis Control & Prevent, Atlanta, GA 30333 USA. [Murphy, Trudy V.] Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Centers Dis Control & Prevent, Atlanta, GA 30333 USA. RP Zhao, Z (reprint author), Natl Ctr Immunizat & Resp Dis, Centers Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30333 USA. EM zaz0@cdc.gov NR 23 TC 1 Z9 1 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV PY 2013 VL 57 IS 5 BP 613 EP 617 DI 10.1016/j.ypmed.2013.08.012 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 239WV UT WOS:000326057600037 PM 23988497 ER PT J AU Hawkins, NA Benard, VB Greek, A Roland, KB Manninen, D Saraiya, M AF Hawkins, Nikki A. Benard, Vicki B. Greek, April Roland, Katherine B. Manninen, Diane Saraiya, Mona TI Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers SO PREVENTIVE MEDICINE LA English DT Article DE Cervical cancer screening; Early detection of cancer; Patient acceptance of health care; Patient compliance; Healthcare disparities ID UNITED-STATES; PAP TEST; WOMEN; PHYSICIANS; NEOPLASIA; SOCIETY; LESS; US AB Objective. Despite guidelines recommending cervical cancer screening intervals be extended beyond one year, clinical practice has been slow to change. Patient preferences are a potential barrier. In the Centers for Disease Control's Cervical Cancer (Cx3) Study at Federally Qualified Health Centers (FQHCs) across Illinois, we surveyed patients about screening practices, and assessed beliefs regarding lengthening screening intervals. Method. We analyzed data from 984 low income women in the Cx3 Study (2009-2011). Participants completed a survey assessing health history, knowledge about Pap testing, beliefs and intentions about extending screening intervals, and demographics. Results. The majority reported annual Pap testing (61%), while only 24% reported a 2-3 year screening interval (recommendation at time of survey). Misunderstandings about the Pap test were prevalent, with over half believing it screened for vaginal, yeast, and sexually transmitted infections (58%-72%). Unfavorable beliefs about extending screening intervals were common. The majority (57%) indicated that they would not wait 3 years to be screened if their physician recommended it, and intentions were associated with knowledge about Pap testing. Conclusion. Most women reported annual cervical cancer screening, and intended to resist longer screening intervals. Patients' lack of knowledge and unfavorable beliefs may serve as barriers to extending screening intervals. Published by Elsevier Inc. C1 [Hawkins, Nikki A.; Benard, Vicki B.; Roland, Katherine B.; Saraiya, Mona] CDC, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30333 USA. [Greek, April; Manninen, Diane] Battelle Mem Inst, Seattle, WA USA. RP Hawkins, NA (reprint author), 4770 Buford Hwy NE,MS F-75, Atlanta, GA 30341 USA. EM nhawkins@cdc.gov FU Centers for Disease Control Prevention [200-2002-00573, 0006] FX Centers for Disease Control & Prevention, Contract 200-2002-00573, Task Order No. 0006. NR 18 TC 12 Z9 12 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV PY 2013 VL 57 IS 5 BP 641 EP 645 DI 10.1016/j.ypmed.2013.08.021 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 239WV UT WOS:000326057600042 PM 24012831 ER PT J AU King, BA Dube, SR Babb, SD McAfee, TA AF King, Brian A. Dube, Shanta R. Babb, Stephen D. McAfee, Timothy A. TI Patient-reported recall of smoking cessation interventions from a health professional SO PREVENTIVE MEDICINE LA English DT Article DE Tobacco use cessation; Smoking cessation; Counseling; Adult; Questionnaires ID TOBACCO-CESSATION; HMOS AB Objective. To determine the prevalence and characteristics of current cigarette smokers who report receiving health care provider interventions ('5A's': ask, advise, assess, assist, arrange) for smoking cessation. Methods. Data came from the 2009-2010 National Adult Tobacco Survey, a telephone survey of United States adults aged >= 18 years. Among current cigarette smokers who reported visiting a health professional in the past year (n = 16,542), estimates were calculated overall and by sex, age, race/ethnicity, education, income, health insurance coverage, and sexual orientation. Results. Among smokers who visited a health professional (75.2%), 87.9% were asked if they used tobacco, 65.8% were advised to quit, and 42.6% were asked if they wanted to quit. Among those wanting to quit, 78.2% were offered assistance and 17.5% had follow-up arranged. Receipt of the 'ask' component was lower among males and uninsured individuals. Receipt of the 'advise' and 'assess' components was lower among those aged 18-24 and uninsured individuals. Receipt of the 'assist' component was lower among non-Hispanic blacks. No differences were observed for the 'arrange' component. Conclusions. Many current smokers report receiving health care provider interventions for smoking cessation. Continued efforts to educate, encourage, and support all health professionals to provide effective, comprehensive tobacco cessation interventions to their patients may be beneficial. Published by Elsevier Inc. C1 [King, Brian A.; Dube, Shanta R.; Babb, Stephen D.; McAfee, Timothy A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [King, Brian A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM baking@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 12 Z9 14 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD NOV PY 2013 VL 57 IS 5 BP 715 EP 717 DI 10.1016/j.ypmed.2013.07.010 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 239WV UT WOS:000326057600055 PM 23872172 ER PT J AU Roland, KB Rodriguez, JL Patterson, JR Trivers, KF AF Roland, Katherine B. Rodriguez, Juan L. Patterson, Jennifer Rees Trivers, Katrina F. TI A literature review of the social and psychological needs of ovarian cancer survivors SO PSYCHO-ONCOLOGY LA English DT Review DE cancer; ovarian cancer; survivorship; psychosocial needs; oncology ID QUALITY-OF-LIFE; GYNECOLOGIC-ONCOLOGY-GROUP; LONG-TERM SURVIVORS; CELL TUMOR SURVIVORS; FUNCTIONAL-ASSESSMENT; CLINICAL-TRIALS; PSYCHOMETRIC PROPERTIES; UNITED-STATES; SELF-ESTEEM; DISTRESS AB ObjectiveTo identify and comprehensively present the psychosocial needs of ovarian cancer (OvCa) survivors, including young survivors <45 years of age. MethodsA literature review was conducted using keywords specific to psychosocial health and OvCa survivorship to identify peer-reviewed, original research articles published in English between January 2000 and December 2010; 28 articles were identified as relevant. Articles were abstracted and results categorized according to six psychosocial domains: quality of life (QoL), social support and relationships, self-image and sexual functioning, psychological distress and functioning, fear of death/recurrence, and personal growth and coping. Findings unique to young survivors are presented when applicable. Psychosocial measurement tools used in relevant studies are also presented. ResultsPhysical complications and side effects have significant impact on OvCa survivors' psychosocial health. Access to social support services and relational support is critical, as feelings of isolation are common. Survivors report low levels of sexual activity and satisfaction, potentially causing strain on personal relationships, and survivors experience high levels of distress, depression, and anxiety. However, QoL can improve after diagnosis for some OvCa survivors, many of whom report spiritual growth and strengthened personal relationships. Younger survivors are likely to have greater distress and lower QoL compared with older survivors. ConclusionsOvCa is the deadliest of all gynecologic cancers, greatly impacting the psychosocial health of survivors. Increased awareness of psychosocial health among OvCa survivors themselves, their social support system, and their health care providers is necessary to adequately address their unique needs. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Roland, Katherine B.; Rodriguez, Juan L.; Trivers, Katrina F.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Patterson, Jennifer Rees] SciMetrika LLC, Durham, NC USA. RP Roland, KB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Hwy,NE,MS F-76, Atlanta, GA 30341 USA. EM kroland@cdc.gov FU Centers for Disease Control and Prevention FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This work was funded by Centers for Disease Control and Prevention funds. NR 96 TC 21 Z9 21 U1 4 U2 32 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD NOV PY 2013 VL 22 IS 11 BP 2408 EP 2418 DI 10.1002/pon.3322 PG 11 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 239MS UT WOS:000326030300002 PM 23760742 ER PT J AU Sheikh, S Chang, A Kieszak, S Law, R Bennett, HKW Ernst, E Bond, GR Spiller, HA Schurz-Rogers, H Chu, A Bronstein, AC Schier, JG AF Sheikh, S. Chang, A. Kieszak, S. Law, R. Bennett, H. K. W. Ernst, E. Bond, G. R. Spiller, H. A. Schurz-Rogers, H. Chu, A. Bronstein, A. C. Schier, J. G. TI Characterizing risk factors for pediatric lamp oil product exposures SO CLINICAL TOXICOLOGY LA English DT Article DE Lamp oil; Lamp oil products; Hydrocarbons ID ASPIRATION AB Poisonings from lamp oil ingestion continue to occur worldwide among the pediatric population despite preventive measures such as restricted sale of colored and scented lamp oils. This suggests that optimal prevention practices for unintentional pediatric exposures to lamp oil have yet to be identified and/or properly implemented. Objective. To characterize demographic, health data, and potential risk factors associated with reported exposures to lamp oil by callers to poison centers (PCs) in the US and discuss their public health implications. Study design. This was a two part study in which the first part included characterizing all exposures to a lamp oil product reported to the National Poison Data System (NPDS) with regard to demographics, exposure, health, and outcome data from 1/1/2000 to 12/31/2010. Regional penetrance was calculated using NPDS data by grouping states into four regions and dividing the number of exposure calls by pediatric population per region (from the 2000 US census). Temporal analyses were performed on NPDS data by comparing number of exposures by season and around the July 4th holiday. Poisson regression was used to model the count of exposures for these analyses. In the second part of this project, in order to identify risk factors we conducted a telephone-based survey to the parents of children from five PCs in five different states. The 10 most recent lamp oil product exposure calls for each poison center were systematically selected for inclusion. Calls in which a parent or guardian witnessed a pediatric lamp oil product ingestion were eligible for inclusion. Data on demographics, exposure information, behavioral traits, and health were collected. A descriptive analysis was performed and Fisher's exact test was used to evaluate associations between variables. All analyses were conducted using SAS v9.3. Results. Among NPDS data, 2 years was the most common patient age reported and states in the Midwestern region had the highest numbers of exposure calls compared to other regions. Exposure calls differed by season (p < 0.0001) and were higher around the July 4th holiday compared to the rest of the days in July (2.09 vs. 1.89 calls/day, p < 0.002). Most exposures occurred inside a house, were managed on-site and also had a "no effect" medical outcome. Of the 50 PC-administered surveys to parents or guardians, 39 (78%) met inclusion criteria for analysis. The majority of ingestions occurred in children that were 2 years of age, that were not alone, involved tiki torch fuel products located on a table or shelf, and occurred inside the home. The amount of lamp oil ingested did not appear to be associated with either the smell (p = 0.19) or the color of the oil (p = 1.00) in this small sample. Approximately half were asymptomatic (n = 18; 46%), and of those that reported symptoms, cough was the most common (n = 20, 95%) complaint. Conclusions. Lamp oil product exposures are most common among young children (around 2 years of age) while at home, not alone and likely as a result of the product being in a child-accessible location. Increasing parental awareness about potential health risks to children from these products and teaching safe storage and handling practices may help prevent both exposures and associated illness. These activities may be of greater benefit in Midwestern states and during summer months (including the period around the July 4th holiday). C1 [Sheikh, S.; Chang, A.; Kieszak, S.; Law, R.; Schurz-Rogers, H.; Schier, J. G.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Hlth Studies Branch, Atlanta, GA 30333 USA. [Bennett, H. K. W.] Utah Poison Control Ctr, Salt Lake City, UT USA. [Ernst, E.] Wisconsin Poison Ctr, Milwaukee, WI USA. [Bond, G. R.] Cincinnati Drug & Poison Informat Ctr, Cincinnati, OH USA. [Spiller, H. A.] Kentucky Reg Poison Ctr, Louisville, KY USA. [Chu, A.] New Jersey Poison Informat & Educ Syst, Newark, NJ USA. [Bronstein, A. C.] Amer Assoc Poison Control Ctr, Alexandria, VA USA. RP Chang, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM ctn7@cdc.gov RI Sheikh, Sophia/F-9746-2015 FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 0 U2 2 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 EI 1556-9519 J9 CLIN TOXICOL JI Clin. Toxicol. PD NOV PY 2013 VL 51 IS 9 BP 871 EP 878 DI 10.3109/15563650.2013.839028 PG 8 WC Toxicology SC Toxicology GA 238JF UT WOS:000325941600009 PM 24066734 ER PT J AU Gallo, MF Walldorf, J Kolesar, R Agarwal, A Kourtis, AP Jamieson, DJ Finlay, A AF Gallo, Maria F. Walldorf, Jenny Kolesar, Robert Agarwal, Aarti Kourtis, Athena P. Jamieson, Denise J. Finlay, Alyssa TI Evaluation of a volunteer community-based health worker program for providing contraceptive services in Madagascar SO CONTRACEPTION LA English DT Article DE Community health workers; Contraception; Evaluation; Multivariable linear regression ID RURAL BANGLADESH; DISCONTINUATION; PROVISION; PAKISTAN; QUALITY; AFRICA AB Background: Madagascar recently scaled up their volunteer community health worker (CHW) program in maternal health and family planning to reach remote and underserved communities. Study design: We conducted a cross-sectional evaluation using a systematic sample of 100 CHWs trained to provide contraceptive counseling and short-acting contraceptive services at the community level. CHWs were interviewed on demographics, recruitment, training, supervision, commodity supply, and other measures of program functionality; tested on knowledge of injectable contraception; and observed by an expert while completing five simulated client encounters with uninstructed volunteers. We developed a CHW performance score (0-100%) based on the number of counseling activities adequately met during the client encounters and used multivariable linear regression to identify correlates of the score. Results: CHWs had a mean performance score of 73.9% (95% confidence interval [CI]: 70.3-77.6%). More education, more weekly volunteer hours, and receiving a refresher training correlated with a higher performance score. We found no other associations between measures of the components previously identified as essential for effective CHW programs and performance score. Conclusions: Although areas of deficiency were identified, CHWs proved capable of providing high-quality contraception services. Published by Elsevier Inc. C1 [Gallo, Maria F.; Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Walldorf, Jenny] Univ Maryland, Dept Pediat & Trop Med, Baltimore, MD 21201 USA. [Agarwal, Aarti; Finlay, Alyssa] Ctr Dis Control & Prevent, Ctr Global Hlth, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Gallo, MF (reprint author), Div Reprod Hlth, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov RI Mashamba-Thompson, Tivani /B-6087-2014 FU USAID FX Funding for this evaluation was provided by the USAID. The author Robert Kolesar is employed by USAID; however, his role in the manuscript preparation was limited to the literature review and programmatic context and he was not involved in the data collection or analysis. The remaining authors have no potential conflicts of interest. NR 36 TC 5 Z9 5 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD NOV PY 2013 VL 88 IS 5 BP 657 EP 665 DI 10.1016/j.contraception.2013.06.008 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 238AI UT WOS:000325912400013 PM 23850074 ER PT J AU Kersh, GJ AF Kersh, Gilbert J. TI Antimicrobial therapies for Q fever SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Review DE antibacterial agents; Coxiella burnetii; disease management; doxycycline; pregnancy; Q fever ID COXIELLA-BURNETII INFECTION; IN-VITRO SUSCEPTIBILITY; ANTIBIOTIC-TREATMENT; PREGNANCY; DOXYCYCLINE; ENDOCARDITIS; CLARITHROMYCIN; CIPROFLOXACIN; ERYTHROMYCIN; NETHERLANDS AB Q fever is caused by the bacterium Coxiella burnetii and has both acute and chronic forms. The acute disease is a febrile illness often with headache and myalgia that can be self-limiting, whereas the chronic disease typically presents as endocarditis and can be life threatening. The normal therapy for the acute disease is a 2 week course of doxycycline, whereas chronic disease requires 18-24 months of doxycycline in combination with hydroxychloroquine. Alternative treatments are used for pregnant women, young children and those who cannot tolerate doxycycline. Doxycycline resistance is rare, but has been reported. Co-trimoxazole is a currently recommended alternative treatment, but quinolones, rifampin and newer macrolides may also provide some benefit. C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Kersh, GJ (reprint author), Ctr Dis Control & Prevent, Mailstop G13,1600 Clifton Rd, Atlanta, GA 30333 USA. EM gkersh@cdc.gov FU Intramural CDC HHS [CC999999] NR 65 TC 7 Z9 7 U1 0 U2 8 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 EI 1744-8336 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD NOV PY 2013 VL 11 IS 11 BP 1207 EP 1214 DI 10.1586/14787210.2013.840534 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 239MI UT WOS:000326028800013 PM 24073941 ER PT J AU Zhang, GQ Cai, FP Zhou, ZY Devos, J Wagar, N Diallo, K Zulu, I Wadonda-Kabondo, N Stringer, JSA Weidle, PJ Ndongmo, CB Sikazwe, I Sarr, A Kagoli, M Nkengasong, J Gao, F Yang, CF AF Zhang, Guoqing Cai, Fangping Zhou, Zhiyong Devos, Joshua Wagar, Nick Diallo, Karidia Zulu, Isaac Wadonda-Kabondo, Nellie Stringer, Jeffrey S. A. Weidle, Paul J. Ndongmo, Clement B. Sikazwe, Izukanji Sarr, Abdoulaye Kagoli, Matthew Nkengasong, John Gao, Feng Yang, Chunfu TI Simultaneous Detection of Major Drug Resistance Mutations in the Protease and Reverse Transcriptase Genes for HIV-1 Subtype C by Use of a Multiplex Allele-Specific Assay SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIRETROVIRAL TREATMENT; IMMUNODEFICIENCY-VIRUS; TREATMENT-NAIVE; VARIANTS; POPULATIONS; THERAPY; FAILURE; OPTIMIZATION; SURVEILLANCE; SENSITIVITY AB High-throughput, sensitive, and cost-effective HIV drug resistance (HIVDR) detection assays are needed for large-scale monitoring of the emergence and transmission of HIVDR in resource-limited settings. Using suspension array technology, we have developed a multiplex allele-specific (MAS) assay that can simultaneously detect major HIVDR mutations at 20 loci. Forty-five allele-specific primers tagged with unique 24-base oligonucleotides at the 5' end were designed to detect wild-type and mutant alleles at the 20 loci of HIV-1 subtype C. The MAS assay was first established and optimized with three plasmid templates (C-wt, C-mut1, and C-mut2) and then evaluated using 148 plasma specimens from HIV-1 subtype C-infected individuals. All the wild-type and mutant alleles were unequivocally distinguished with plasmid templates, and the limits of detection were 1.56% for K219Q and K219E, 3.13% for L76V, 6.25% for K65R, K70R, L74V, L100I, K103N, K103R, Q151M, Y181C, and I47V, and 12.5% for M41L, K101P, K101E, V106A, V106M, Y115F, M184V, Y188L, G190A, V32I, I47A, I84V, and L90M. Analyses of 148 plasma specimens revealed that the MAS assay gave 100% concordance with conventional sequencing at eight loci and >95% (range, 95.21% to 99.32%) concordance at the remaining 12 loci. The differences observed were caused mainly by 24 additional low-abundance alleles detected by the MAS assay. Ultradeep sequencing analysis confirmed 15 of the 16 low-abundance alleles. This multiplex, sensitive, and straightforward result-reporting assay represents a new efficient genotyping tool for HIVDR surveillance and monitoring. C1 [Zhang, Guoqing; Zhou, Zhiyong; Devos, Joshua; Wagar, Nick; Diallo, Karidia; Nkengasong, John; Yang, Chunfu] CDC, Int Lab Branch, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. [Weidle, Paul J.] CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Cai, Fangping; Gao, Feng] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Zulu, Isaac; Ndongmo, Clement B.] CDC Zambia, Lusaka, Zambia. [Wadonda-Kabondo, Nellie; Sarr, Abdoulaye] CDC Malawi, Lilongwe, Malawi. [Stringer, Jeffrey S. A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Stringer, Jeffrey S. A.] Ctr Infect Dis Res Zambia, Lusaka, Zambia. [Sikazwe, Izukanji] Minist Hlth, Lusaka, Zambia. [Kagoli, Matthew] Minist Hlth Malawi, Lilongwe, Malawi. RP Yang, CF (reprint author), CDC, Int Lab Branch, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. EM feng.gao@duke.edu; cyang1@cdc.gov RI Yang, Chunfu/G-6890-2013; Zhang, Guoqing/C-9523-2014 FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention; U.S. National Institutes of Health [RO1 GM065057]; International Emerging Infectious Diseases (EID) fellowship program; Association of Public Health Laboratories (APHL); Centers for Disease Control and Prevention FX This project was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention, grants from the U.S. National Institutes of Health (no. RO1 GM065057), and the appointment of Guoqing Zhang to the International Emerging Infectious Diseases (EID) fellowship program sponsored by the Association of Public Health Laboratories (APHL) and the Centers for Disease Control and Prevention. NR 41 TC 12 Z9 13 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2013 VL 51 IS 11 BP 3666 EP 3674 DI 10.1128/JCM.01669-13 PG 9 WC Microbiology SC Microbiology GA 236PT UT WOS:000325812200030 PM 23985909 ER PT J AU Spencer, S Gaglani, M Naleway, A Reynolds, S Ball, S Bozeman, S Henkle, E Meece, J Vandermause, M Clipper, L Thompson, M AF Spencer, Sarah Gaglani, Manjusha Naleway, Allison Reynolds, Sue Ball, Sarah Bozeman, Sam Henkle, Emily Meece, Jennifer Vandermause, Mary Clipper, Lydia Thompson, Mark TI Consistency of Influenza A Virus Detection Test Results across Respiratory Specimen Collection Methods Using Real-Time Reverse Transcription-PCR SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CHILDREN; SEASON AB In our prospective cohort study, we compared the performance of nasopharyngeal, oropharyngeal, and nasal swabs for the detection of influenza virus using real-time reverse transcription-PCR assay. Joint consideration of results from oropharyngeal and nasal swabs was as effective as consideration of results from nasopharyngeal swabs alone, as measured by sensitivity and noninferiority analysis. C1 [Spencer, Sarah; Reynolds, Sue; Thompson, Mark] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, NCIRD, Atlanta, GA 30333 USA. [Gaglani, Manjusha; Clipper, Lydia] Texas A&M Hlth Sci Ctr, Coll Med, Scott & White Healthcare, Div Pediat Infect Dis, Temple, TX USA. [Naleway, Allison; Henkle, Emily] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Ball, Sarah; Bozeman, Sam] ABT Associates Inc, Cambridge, MA 02138 USA. [Vandermause, Mary] Marshfield Clin Res Fdn, Core Lab, Marshfield, WI USA. RP Spencer, S (reprint author), Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, NCIRD, Atlanta, GA 30333 USA. EM vmf5@cdc.gov OI Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2010-F-33396]; appointment to the Research Participation Program at the Centers for Disease Control and Prevention FX Funding for this study was supported by the Centers for Disease Control and Prevention (contract 200-2010-F-33396 to Abt Associates, Inc.). This research was also supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 11 TC 5 Z9 5 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2013 VL 51 IS 11 BP 3880 EP 3882 DI 10.1128/JCM.01873-13 PG 3 WC Microbiology SC Microbiology GA 236PT UT WOS:000325812200070 PM 24108606 ER PT J AU Tsai, V Pritzker, BB Diaz, MH Winchell, JM Hicks, LA Petrone, B Benitez, A Wolff, BJ Soyemi, KL AF Tsai, Victoria Pritzker, Bernard B. Diaz, Maureen H. Winchell, Jonas M. Hicks, Lauri A. Petrone, Brianna Benitez, Alvaro Wolff, Bernard J. Soyemi, Kenneth L. TI Cluster of Macrolide-Resistant Mycoplasma pneumoniae Infections in Illinois in 2012 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID REAL-TIME PCR; RESOLUTION MELT ANALYSIS; TANDEM-REPEAT ANALYSIS; MINOCYCLINE; OUTBREAK; CHILDREN; SCHOOL; CHINA AB Macrolide-resistant Mycoplasma pneumoniae is an increasing problem worldwide but is not well documented in the United States. We report a cluster of macrolide-resistant M. pneumoniae cases among a mother and two daughters. C1 [Tsai, Victoria; Soyemi, Kenneth L.] Illinois Dept Publ Hlth, Chicago, IL USA. [Pritzker, Bernard B.] Lake Forest Pediat Associates Ltd, Lake Forest, IL USA. [Diaz, Maureen H.; Winchell, Jonas M.; Hicks, Lauri A.; Petrone, Brianna; Benitez, Alvaro; Wolff, Bernard J.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. RP Tsai, V (reprint author), Illinois Dept Publ Hlth, Chicago, IL USA. EM Victoria.Tsai@illinois.gov FU Centers for Disease Control and Prevention (CDC) [5U38HM000414-5] FX This report was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by Centers for Disease Control and Prevention (CDC) Cooperative Agreement 5U38HM000414-5. NR 27 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2013 VL 51 IS 11 BP 3889 EP 3892 DI 10.1128/JCM.01613-13 PG 4 WC Microbiology SC Microbiology GA 236PT UT WOS:000325812200073 PM 23966493 ER PT J AU Harrington, SM Bell, M Bernard, K Lagace-Wiens, P Schuetz, AN Hartman, B McQuiston, JR Wilson, D LaSalvia, M Ng, B Richter, S Taege, A AF Harrington, S. M. Bell, M. Bernard, K. Lagace-Wiens, P. Schuetz, A. N. Hartman, B. McQuiston, J. R. Wilson, D. LaSalvia, M. Ng, B. Richter, S. Taege, A. TI Novel Fastidious, Partially Acid-Fast, Anaerobic Gram-Positive Bacillus Associated with Abscess Formation and Recovered from Multiple Medical Centers SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DIETZIA-MARIS; RHODOCOCCUS-EQUI; PATIENT; NOV AB We report a novel anaerobe causing abscess in four patients at three hospitals. In the clinical specimen, bacilli were branching, Gram positive, and acid fast. The organism grew slowly and was not identified by 16S rRNA sequencing. Our findings support the description of a new genus and species of the suborder Corynebacterineae. C1 [Harrington, S. M.; Wilson, D.; LaSalvia, M.; Richter, S.] Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44106 USA. [Taege, A.] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA. [Bell, M.; McQuiston, J. R.] Ctr Dis Control & Prevent, Special Bacteriol Reference Lab, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Bernard, K.; Ng, B.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Bernard, K.; Lagace-Wiens, P.] Univ Manitoba, Fac Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada. [Schuetz, A. N.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pathol & Lab Med, New York, NY USA. [Hartman, B.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Infect Dis, New York, NY USA. RP Harrington, SM (reprint author), Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44106 USA. EM harrins2@ccf.org NR 10 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2013 VL 51 IS 11 BP 3903 EP 3907 DI 10.1128/JCM.01497-13 PG 5 WC Microbiology SC Microbiology GA 236PT UT WOS:000325812200077 PM 24025902 ER PT J AU Date, K Person, B Nygren, B Were, V Kola, S Ayers, T Quick, R AF Date, Kashmira Person, Bobbie Nygren, Benjamin Were, Vincent Kola, Steve Ayers, Tracy Quick, Robert TI Evaluation of a Rapid Cholera Response Activity-Nyanza Province, Kenya, 2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE attitudes and practices; cholera; cholera response; hand-washing; impact; knowledge; water treatment ID ORAL REHYDRATION THERAPY; CHILDHOOD DIARRHEA; WESTERN KENYA; EPIDEMIC; OUTBREAK; AFRICA; WATER AB Background. In response to recurrent cholera outbreaks in Nyanza Province, Kenya, a local nongovernmental organization assisted the Ministry of Health by providing cholera education activities to some cholera-affected communities. We evaluated the impact on cholera prevention knowledge and practices. Methods. In November-December 2008, we conducted a cross-sectional household survey and tested stored water for chlorine in 6 cholera-affected enumeration areas (intervention-EAs) where response activities had occurred between March-September 2008, and 6 comparison-EAs with no known reports of cholera outbreaks or response activities. Results. We enrolled 358 individuals from intervention-EAs and 365 from comparison-EAs. Overall, > 80% knew cholera symptoms and over 60% knew that water treatment prevented diarrhea; < 20% had chlorine residual in stored water. More intervention-EA respondents than comparison-EA respondents recalled a cholera outbreak in their community (52% vs 19%, P < .0001), and of those, 51% versus 39%, respectively, had attended a cholera response event. Detectable chlorine residuals in stored water were found in a higher percentage of intervention-EA and comparison-EA event attendees (21% and 25%, respectively) than nonattendees (17% and 8%, respectively). Conclusions. There was a gap between knowledge and practice of water treatment as a cholera preventive measure. Cholera event attendance may have modestly motivated increased household water treatment. C1 [Date, Kashmira] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Person, Bobbie] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA. [Date, Kashmira; Nygren, Benjamin; Ayers, Tracy; Quick, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Were, Vincent; Kola, Steve] Safe Water & AIDS Project, Kisumu, Kenya. RP Quick, R (reprint author), CDC, Waterborne Dis Prevent Branch, 1600 Clifton Rd,MS C09, Atlanta, GA 30307 USA. EM rquick@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU Integrated Disease Surveillance and Response program at the Centers for Disease Control and Prevention; United States Agency for International Development FX This work was supported by the Integrated Disease Surveillance and Response program at the Centers for Disease Control and Prevention and the United States Agency for International Development. NR 17 TC 3 Z9 3 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S62 EP S68 DI 10.1093/infdis/jit198 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800010 PM 24101647 ER PT J AU Keddy, KH Sooka, A Parsons, MB Njanpop-Lafourcade, BM Fitchet, K Smith, AM AF Keddy, Karen H. Sooka, Arvinda Parsons, Michele B. Njanpop-Lafourcade, Berthe-Marie Fitchet, Kaye Smith, Anthony M. TI Diagnosis of Vibrio cholerae O1 Infection in Africa SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cholera; Africa; Vibrio cholerae O1; rapid diagnostic tests; diagnostics; antimicrobial susceptibility testing; molecular diagnostics; quality management ID POLYMERASE-CHAIN-REACTION; TIME PCR ASSAY; RAPID DETECTION; TRANSPORT MEDIUM; FIELD-EVALUATION; STOOL SAMPLES; DIPSTICK TEST; OUTBREAK; EPIDEMIC; SPECIMENS AB Isolation of Vibrio cholerae O1 is necessary for cholera outbreak confirmation. Rapid diagnostic testing of fecal specimens, based on lipopolysaccharide detection of V. cholerae O1 or O139, may assist in early outbreak detection and surveillance. Cary-Blair transport medium is recommended for specimen transport. Filter paper, although used in epidemics, needs evaluation against rectal swab specimens. Fecal specimens are subcultured onto selective and nonselective media, including 5% blood agar and TCBS agar, for detection of V. cholerae O1 or O139. Suspicious, oxidase-positive isolates are serotyped in monovalent antisera. Antimicrobial-susceptibility testing is performed to detect resistance. Molecular characterization supports phenotypic identification and outbreak investigations. The presence of genes encoding cholera toxin, lipopolysaccharide, and El Tor biotype traits can be confirmed. Standardized pulsed-field gel electrophoresis analysis facilitates strain comparison. Quality management ensures reliability of results through validation and verification of functional laboratory equipment; quality control of testing procedures, laboratory reagents, and consumables; and participation in proficiency-testing schemes. C1 [Keddy, Karen H.; Sooka, Arvinda; Smith, Anthony M.] Natl Hlth Lab Serv, Ctr Enter Dis, Natl Inst Communicable Dis, Johannesburg, South Africa. [Fitchet, Kaye] Natl Hlth Lab Serv, Qual Assurance Unit, Natl Inst Communicable Dis, Johannesburg, South Africa. [Keddy, Karen H.; Smith, Anthony M.] Univ Witwatersrand, ZA-2050 Johannesburg, South Africa. [Parsons, Michele B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Njanpop-Lafourcade, Berthe-Marie] Agence Med Prevent, Paris, France. RP Keddy, KH (reprint author), Natl Inst Communicable Dis, Ctr Enter Dis, P Bag X4 2131, Johannesburg, South Africa. EM karenk@nicd.ac.za FU Africhol; Bill and Melinda Gates Foundation FX This work was supported by Africhol, a project funded by the Bill and Melinda Gates Foundation. NR 50 TC 2 Z9 2 U1 0 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S23 EP S31 DI 10.1093/infdis/jit196 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800005 PM 24101641 ER PT J AU Loharikar, A Briere, E Ope, M Langat, D Njeru, I Gathigi, L Makayotto, L Ismail, AM Thuranira, M Abade, A Amwayi, S Omolo, J Oundo, J De Cock, KM Breiman, RF Ayers, T Mintz, E O'Reilly, CE AF Loharikar, Anagha Briere, Elizabeth Ope, Maurice Langat, Daniel Njeru, Ian Gathigi, Lucy Makayotto, Lyndah Ismail, Abdirizak M. Thuranira, Martin Abade, Ahmed Amwayi, Samuel Omolo, Jared Oundo, Joe De Cock, Kevin M. Breiman, Robert F. Ayers, Tracy Mintz, Eric O'Reilly, Ciara E. TI A National Cholera Epidemic With High Case Fatality Rates-Kenya 2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cholera; Kenya; outbreak; water; sanitation; nomadic; semi-pastoral ID AFRICA; PREVENTION; OUTBREAK; WORLDWIDE; REFUGEES; THERAPY; HEALTH; WATER; RISK AB Background. Cholera remains endemic in sub-Saharan Africa. We characterized the 2009 cholera outbreaks in Kenya and evaluated the response. Methods. We analyzed surveillance data and estimated case fatality rates (CFRs). Households in 2 districts, East Pokot (224 cases; CFR = 11.7%) and Turkana South (1493 cases; CFR = 1.0%), were surveyed. We randomly selected 15 villages and 8 households per village in each district. Healthcare workers at 27 health facilities (HFs) were surveyed in both districts. Results. In 2009, cholera outbreaks caused a reported 11 425 cases and 264 deaths in Kenya. Data were available from 44 districts for 6893 (60%) cases. District CFRs ranged from 0% to 14.3%. Surveyed household respondents (n = 240) were aware of cholera (97.5%) and oral rehydration solution (ORS) (87.9%). Cholera deaths were reported more frequently from East Pokot (n = 120) than Turkana South (n = 120) households (20.7% vs. 12.3%). The average travel time to a HF was 31 hours in East Pokot compared with 2 hours in Turkana South. Fewer respondents in East Pokot (9.8%) than in Turkana South (33.9%) stated that ORS was available in their village. ORS or intravenous fluid shortages occurred in 20 (76.9%) surveyed HFs. Conclusions. High CFRs in Kenya are related to healthcare access disparities, including availability of rehydration supplies. C1 [Loharikar, Anagha; Briere, Elizabeth] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Loharikar, Anagha; Briere, Elizabeth; Ayers, Tracy; Mintz, Eric; O'Reilly, Ciara E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Ope, Maurice; Langat, Daniel; Njeru, Ian] Minist Publ Hlth & Sanitat, Div Dis Surveillance & Response, Nairobi, Kenya. [Gathigi, Lucy; Makayotto, Lyndah; Ismail, Abdirizak M.; Thuranira, Martin; Abade, Ahmed; Amwayi, Samuel; Omolo, Jared; Oundo, Joe] Minist Publ Hlth & Sanitat, Kenya Field Epidemiol & Lab Training Program, Nairobi, Kenya. [Oundo, Joe; De Cock, Kevin M.; Breiman, Robert F.] CDC Kenya, Nairobi, Kenya. RP Loharikar, A (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Waterborne Dis Prevent Branch, 1600 Clifton Rd NE,MS C-O9, Atlanta, GA 30333 USA. EM anagha.loharikar@gmail.com OI Ayers, Tracy/0000-0003-4140-3263 FU US government or the Kenya Ministry of Public Health and Sanitation FX At the time of this investigation, the authors were all either employees of the US government or the Kenya Ministry of Public Health and Sanitation. No outside funds were used to support these investigations or the writing of this manuscript. NR 44 TC 2 Z9 2 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S69 EP S77 DI 10.1093/infdis/jit220 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800011 PM 24101648 ER PT J AU Maskery, B DeRoeck, D Levin, A Kim, YE Wierzba, TF Clemens, JD AF Maskery, Brian DeRoeck, Denise Levin, Ann Kim, Young Eun Wierzba, Thomas F. Clemens, John D. TI Strategy, Demand, Management, and Costs of an International Cholera Vaccine Stockpile SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cholera; vaccine; stockpile; health policy ID MASS VACCINATION; SPATIAL-ANALYSIS; REFUGEE CAMP; EPIDEMIC; HAITI; OUTBREAK; RISK; EMERGENCIES; ZIMBABWE; ILLNESS AB In this article, we review the feasibility of mass vaccination against cholera and estimate the global population at risk for epidemic cholera. We then examine the cost of establishing and managing a cholera vaccine stockpile and summarize published mathematical models of the estimated impact of reactive vaccination campaigns developed for the current Haitian outbreak and a recent outbreak in Zimbabwe. On the basis of these evaluations, we recommend a stockpile that starts at 2 million doses, with an estimated annual cost of $5.5-$13.9 million in 2013, and grows to 10 million doses per year by 2017, with an annual cost of $27-$51 million. We believe that the stockpile can enhance efforts to mitigate future cholera outbreaks by guaranteeing the availability of cholera vaccines and, through use of the stockpile, by revealing knowledge about the efficient use of cholera vaccines during and after crises. C1 [Maskery, Brian; Kim, Young Eun; Wierzba, Thomas F.; Clemens, John D.] Int Vaccine Inst, Seoul, South Korea. RP Maskery, B (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM bmaskery@gmail.com FU Bill and Melinda Gates Foundation through the Cholera Vaccine Initiative program [38 590]; government of Kuwait [75 000 433]; government of Republic of Korea [75 000 433]; government of Sweden [75 000 433] FX This work was supported by the Bill and Melinda Gates Foundation through the Cholera Vaccine Initiative program (grant 38 590), administered by the International Vaccine Institute (IVI), Seoul, Republic of Korea; and by the governments of Kuwait, Republic of Korea, and Sweden (grant 75 000 433 to the IVI). NR 43 TC 5 Z9 5 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S15 EP S22 DI 10.1093/infdis/jit233 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800004 PM 24101640 ER PT J AU Mengel, M Mintz, E Nair, GB Gessner, BD AF Mengel, Martin Mintz, Eric Nair, Gopinath Balakrish Gessner, Bradford D. TI CHOLERA IN AFRICA: MICROBIOLOGY, EPIDEMIOLOGY, PREVENTION AND CONTROL Editorial Committee Introduction SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material C1 [Mengel, Martin; Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Mintz, Eric] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Nair, Gopinath Balakrish] Natl Inst Cholera & Enter Dis, Kolkata, India. RP Gessner, BD (reprint author), Bur Liaison Immeuble JB Say, AMP, 13 Chemin Levant, F-01210 Ferney Voltaire, France. EM bgessner@aamp.org NR 14 TC 0 Z9 0 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S1 EP S3 DI 10.1093/infdis/jit403 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800001 PM 24101637 ER PT J AU Mintz, ED Tauxe, RV AF Mintz, Eric D. Tauxe, Robert V. TI Cholera in Africa: A Closer Look and a Time for Action SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cholera; Africa; surveillance; prevention ID EPIDEMIC; HAITI C1 [Mintz, Eric D.; Tauxe, Robert V.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Mintz, ED (reprint author), Ctr Dis Control & Prevent, Mailstop C-09,1600 Clifton Rd, Atlanta, GA 30333 USA. EM emintz@cdc.gov FU Africhol; Bill and Melinda Gates Foundation FX This work was supported by Africhol, a project funded by the Bill and Melinda Gates Foundation. NR 33 TC 5 Z9 5 U1 1 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 SU 1 BP S4 EP S7 DI 10.1093/infdis/jit205 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 236AV UT WOS:000325766800002 PM 24101644 ER PT J AU Yang, H Carney, PJ Chang, JC Villanueva, JM Stevens, J AF Yang, Hua Carney, Paul J. Chang, Jessie C. Villanueva, Julie M. Stevens, James TI Structural Analysis of the Hemagglutinin from the Recent 2013 H7N9 Influenza Virus SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN RECEPTOR SPECIFICITY; A VIRUS; BRITISH-COLUMBIA; HUMAN INFECTION; H5N1 VIRUSES; HUMAN-BEINGS; BINDING; CONJUNCTIVITIS; HUMANS; ORIGIN AB In March 2013, the Chinese Center for Disease Control and Prevention reported human infections with an H7N9 influenza virus, and by 20 July 2013, the numbers of laboratory-confirmed cases had climbed to 134, including 43 fatalities and 127 hospitalizations. The newly emerging H7N9 viruses constitute an obvious public health concern because of the apparent severity of this outbreak. Here we focus on the hemagglutinins (HAs) of these viruses and assess their receptor binding phenotype in relation to previous HAs studied. Glycan microarray and kinetic analyses of recombinant A(H7N9) HAs were performed to compare the receptor binding profile of wild-type receptor binding site variants at position 217, a residue analogous to one of two positions known to switch avian to human receptor preference in H2N2 and H3N2 viruses. Two recombinant A(H7N9) HAs were structurally characterized, and a mutational study of the receptor binding site was performed to analyze important residues that can affect receptor preference and affinity. Results highlight a weak human receptor preference of the H7N9 HAs, suggesting that these viruses require further adaptation in order to adapt fully to humans. C1 [Yang, Hua; Carney, Paul J.; Chang, Jessie C.; Villanueva, Julie M.; Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM fwb4@cdc.gov FU Centers for Disease Control and Prevention. Creation of the cDNA; BARDA [HHSO100201000061C]; Novartis Vaccines and Diagnostics; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; National Institute of General Medical Sciences [GM62116] FX This work was funded by the Centers for Disease Control and Prevention. Creation of the cDNA for this work was supported in part by BARDA contract HHSO100201000061C with Novartis Vaccines and Diagnostics. Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract DE-AC02-06CH11357. Glycan microarray slides were produced under contract for the Centers for Disease Control and Prevention using a glycan library generously provided by the Consortium for Functional Glycomics (CFG) (www.functionalglycomics.org) funded by National Institute of General Medical Sciences grant GM62116. NR 62 TC 39 Z9 40 U1 3 U2 40 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD NOV PY 2013 VL 87 IS 22 BP 12433 EP 12446 DI 10.1128/JVI.01854-13 PG 14 WC Virology SC Virology GA 237JJ UT WOS:000325865400043 PM 24027325 ER PT J AU Caspers, KM Romitti, PA Lin, S Olney, RS Holmes, LB Werler, MM AF Caspers, Kristin M. Romitti, Paul A. Lin, Shao Olney, Richard S. Holmes, Lewis B. Werler, Martha M. CA Natl Birth Defects Prevention TI Maternal Periconceptional Exposure to Cigarette Smoking and Congenital Limb Deficiencies SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE case-control studies; limb deficiencies; congenital; maternal exposure; musculoskeletal abnormalities; pregnancy; smoking; folic acid ID NONSMOKING PREGNANT-WOMEN; BIRTH-DEFECTS PREVENTION; RED-BLOOD-CELLS; FOLIC-ACID; REDUCTION DEFECTS; PASSIVE SMOKING; TOBACCO-SMOKE; NEURAL-TUBE; HOMOCYSTEINE; GROWTH AB BackgroundCongenital limb deficiencies (LD)s are characterised by the failure or disruption in formation of limbs or digits. Epidemiological research on maternal exposure to cigarette smoke and LDs is inconclusive. MethodsData from the National Birth Defects Prevention Study were used to examine LDs and maternal exposure to active or passive cigarette smoke. Mothers of LD case (n=906) and unaffected control (n=8352) pregnancies from October 1997 through December 2007 reported on exposure type and quantity. Logistic regression was used to estimate adjusted odds ratio (OR) and 95% confidence interval [95% CI]; interactions with folic acid (FA) intake were tested. ResultsFor any LD, ORs were elevated for active (1.24 [95% CI 1.01, 1.53]), passive (home) (1.28 [95% CI 1.03, 1.59]), and active and passive' (1.34 [95% CI 1.05, 1.70]) exposures. The ORs for longitudinal LDs were elevated for passive (home) (1.62 [95% CI 1.14, 2.31]) and active and passive' (1.62 [95% CI 1.09, 2.41]) exposures. The OR for pre-axial LDs were elevated for any (1.39 [95% CI 1.01, 1.90]), active (1.53 [95% CI 1.03, 2.29]), passive (home) (1.82 [95% CI 1.23, 2.69]), and active and passive' (1.87 [95% CI 1.20, 2.92]) exposures. For lower limbs, ORs were elevated for passive (home) (1.44 [95% CI 1.01, 2.04]) and smoking 15 or more cigarettes/day (2.25 [95% CI 1.27, 3.97]). Interactions showed that ORs for any passive smoke exposure were 0.43 and 0.59 higher in the absence of FA intake for any and terminal transverse LDs. ConclusionsMaternal active smoking and exposure to passive cigarette smoke emerged as a potential teratogen that affects limb and digit formation. FA was not found to mitigate the impact. C1 [Caspers, Kristin M.; Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA 52242 USA. [Lin, Shao] New York State Dept Hlth, Albany, NY USA. [Olney, Richard S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Holmes, Lewis B.] Massachusetts Gen Hosp, Genet & Teratol Unit, Boston, MA 02114 USA. [Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Romitti, PA (reprint author), Univ Iowa, Dept Epidemiol, Coll Publ Hlth, S416 CPHB,105 River St, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu OI Lin, Shao/0000-0002-5535-7504 FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001] FX This work was supported by cooperative agreements under Program Announcements (PA) PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study (NBDPS) (U01DD000492). Coding of drug information in NBDPS used the Slone Drug Dictionary, under license from the Slone Epidemiology Center at Boston University, Boston, MA. We would also like to acknowledge Drs Charlotte Hobbs, Gary Shaw, Marlene Anderka, Charlotte Druschel, Andrew Olshan, Robert Meyer, Mark Canfield, Peter Langlois, and Marcia Feldkamp. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. There are no stated conflicts of interest. NR 32 TC 5 Z9 5 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD NOV PY 2013 VL 27 IS 6 BP 509 EP 520 DI 10.1111/ppe.12075 PG 12 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 238WZ UT WOS:000325983800002 PM 24134526 ER PT J AU Miller, JE Pedersen, LH Streja, E Bech, BH Yeargin-Allsopp, M Braun, KV Schendel, DE Christensen, D Uldall, P Olsen, J AF Miller, Jessica E. Pedersen, Lars Henning Streja, Elani Bech, Bodil H. Yeargin-Allsopp, Marshalyn Braun, Kim Van Naarden Schendel, Diana E. Christensen, Deborah Uldall, Peter Olsen, Jorn TI Maternal Infections during Pregnancy and Cerebral Palsy: A Population-based Cohort Study SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE maternal infections; bacterial infections; pregnancy; congenital cerebral palsy ID URINARY-TRACT-INFECTIONS; PERIVENTRICULAR LEUKOMALACIA; BIRTH-WEIGHT; WHITE-MATTER; RISK; CHORIOAMNIONITIS; INFLAMMATION; CHILDHOOD; EPILEPSY; REGISTRY AB BackgroundCerebral palsy (CP) is a common motor disability in childhood. We examined the association between maternal infections during pregnancy and the risk of congenital CP in the child. MethodsLiveborn singletons in Denmark between 1997 and 2003 were identified from the Danish National Birth Registry and followed from 1 year of life until 2008. Redemption of antibiotics from the National Register of Medicinal Product Statistics and maternal infections reported by the National Hospital Register were used as markers of maternal infection during pregnancy. CP diagnoses were obtained from the Danish Cerebral Palsy Registry. Adjusted hazard ratio (HR) and 95% confidence interval (CI) were estimated by Cox proportional hazard models. ResultsOf the 440564 singletons with follow-up data, 840 were diagnosed with congenital CP. Maternal genito-urinary tract infections (HR 2.1, 95% CI 1.4, 3.2) were associated with CP in all births, in term births (HR 1.9, 95% CI 1.1, 3.2), in children with spastic CP (HR 2.1, 95% CI 1.4, 3.3), and among first-born children (HR 1.9, 95% CI 1.4, 3.3). Overall, we found associations between redeemed nitrofurantoin (HR 1.7, 95% CI 1.1, 2.8) and CP. Among trimester-specific exposures, CP risk was associated with prescriptions redeemed in the first trimester for any antibacterials, beta-lactam antibacterials, and nitrofurantoin, an antibiotic commonly used to treat lower urinary tract infection, and genito-urinary tract infections in the third trimester. ConclusionGenito-urinary tract infections and antibiotic use during pregnancy were associated with increased risks of CP, indicating that some maternal infections or causes of maternal infections present in prenatal life may be part of a causal pathway leading to CP. C1 [Miller, Jessica E.; Streja, Elani; Olsen, Jorn] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Yeargin-Allsopp, Marshalyn; Braun, Kim Van Naarden; Schendel, Diana E.; Christensen, Deborah] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Pedersen, Lars Henning] Aarhus Univ, Inst Clin Med, Dept Obstet & Gynecol, Aarhus, Denmark. [Pedersen, Lars Henning; Bech, Bodil H.; Olsen, Jorn] Aarhus Univ, Epidemiol Sect, Dept Publ Hlth, Aarhus, Denmark. [Uldall, Peter] Univ Southern Denmark, Natl Inst Publ Hlth, Danish Cerebral Palsy Registry, Copenhagen, Denmark. [Uldall, Peter] Univ Copenhagen, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark. RP Miller, JE (reprint author), UCLA Fielding Sch Publ Hlth, Dept Epidemiol, 650 Charles E Young Dr South, Los Angeles, CA 90095 USA. EM jemille@ucla.edu RI Olsen, Jorn/F-8801-2015; Bech, Bodil Hammer/B-9646-2016; Miller, Jessica/I-2255-2016 OI Olsen, Jorn/0000-0001-7462-5140; FU National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia; University of Aarhus, Denmark FX This study was supported by a grant from the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, and the University of Aarhus, Denmark. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 36 TC 5 Z9 6 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD NOV PY 2013 VL 27 IS 6 BP 542 EP 552 DI 10.1111/ppe.12082 PG 11 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 238WZ UT WOS:000325983800005 PM 24117888 ER PT J AU Smith, SM Dart, RC Katz, NP Paillard, F Adams, EH Comer, SD Degroot, A Edwards, RR Haddox, JD Jaffe, JH Jones, CM Kleber, HD Kopecky, EA Markman, JD Montoya, ID O'Brien, C Roland, CL Stanton, M Strain, EC Vorsanger, G Wasan, AD Weiss, RD Turk, DC Dworkin, RH AF Smith, Shannon M. Dart, Richard C. Katz, Nathaniel P. Paillard, Florence Adams, Edgar H. Comer, Sandra D. Degroot, Aldemar Edwards, Robert R. Haddox, J. David Jaffe, Jerome H. Jones, Christopher M. Kleber, Herbert D. Kopecky, Ernest A. Markman, John D. Montoya, Ivan D. O'Brien, Charles Roland, Carl L. Stanton, Marsha Strain, Eric C. Vorsanger, Gary Wasan, Ajay D. Weiss, Roger D. Turk, Dennis C. Dworkin, Robert H. TI Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations SO PAIN LA English DT Review DE Classification; Clinical trials; Prescription drug abuse; Prescription drug misuse; Systematic review ID AMERICAN ASSOCIATION; ADVERSE EVENTS; OPIOID THERAPY; CHRONIC PAIN; ADDICTION; DEPENDENCE; DIVERSION; ADOLESCENTS AB As the nontherapeutic use of prescription medications escalates, serious associated consequences have also increased. This makes it essential to estimate misuse, abuse, and related events (MAREs) in the development and postmarketing adverse event surveillance and monitoring of prescription drugs accurately. However, classifications and definitions to describe prescription drug MAREs differ depending on the purpose of the classification system, may apply to single events or ongoing patterns of inappropriate use, and are not standardized or systematically employed, thereby complicating the ability to assess MARE occurrence adequately. In a systematic review of existing prescription drug MARE terminology and definitions from consensus efforts, review articles, and major institutions and agencies, MARE terms were often defined inconsistently or idiosyncratically, or had definitions that overlapped with other MARE terms. The Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership convened an expert panel to develop mutually exclusive and exhaustive consensus classifications and definitions of MAREs occurring in clinical trials of analgesic medications to increase accuracy and consistency in characterizing their occurrence and prevalence in clinical trials. The proposed ACTTION classifications and definitions are designed as a first step in a system to adjudicate MAREs that occur in analgesic clinical trials and postmarketing adverse event surveillance and monitoring, which can be used in conjunction with other methods of assessing a treatment's abuse potential. (C) 2013 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved. C1 [Smith, Shannon M.; Dworkin, Robert H.] Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14627 USA. [Dart, Richard C.] Univ Colorado, Sch Med, Denver, CO USA. [Dart, Richard C.] Denver Hlth, Rocky Mt Poison & Drug Ctr, Denver, CO USA. [Katz, Nathaniel P.] Analges Solut, Natick, MA USA. [Katz, Nathaniel P.; Haddox, J. David] Tufts Univ, Boston, MA 02111 USA. [Paillard, Florence] Focus Biocom, Durango, CO USA. [Adams, Edgar H.] Covance Market Access, Gaithersburg, MD USA. [Comer, Sandra D.; Kleber, Herbert D.] Columbia Univ, New York State Psychiat Inst, New York, NY USA. [Degroot, Aldemar] Astellas Pharma Inc, Northbrook, IL USA. [Edwards, Robert R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Haddox, J. David] Purdue Pharma LP, Stamford, CT USA. [Jaffe, Jerome H.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Jones, Christopher M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kopecky, Ernest A.] Collegium Pharmaceut Inc, Canton, MA USA. [Markman, John D.] Univ Rochester, Dept Neurosurg, Rochester, NY USA. [Montoya, Ivan D.] NIDA, Bethesda, MD 20892 USA. [O'Brien, Charles] Univ Penn, Philadelphia, PA 19104 USA. [Roland, Carl L.] Pfizer Inc, Cary, NC USA. [Stanton, Marsha] Horizon Pharma Inc, Deerfield, IL USA. [Strain, Eric C.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Vorsanger, Gary] Janssen Sci Affairs LLC, Raritan, NJ USA. [Wasan, Ajay D.] Harvard Univ, Sch Med, Chestnut Hill, MA USA. [Weiss, Roger D.] Harvard Univ, Sch Med, Boston, MA USA. [Weiss, Roger D.] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02178 USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Dworkin, Robert H.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [Dworkin, Robert H.] Univ Rochester, Sch Med & Dent, Ctr Human Expt Therapeut, Rochester, NY USA. RP Smith, SM (reprint author), Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14627 USA. EM shannon1_smith@urmc.rochester.edu RI bebarta, vikhyat/K-3476-2015 FU U.S. Food and Drug Administration, the Centers for Disease Control and Prevention; ACTTION; U.S. Food and Drug Administration; National Institute on Drug Abuse [DA09236, DA031022, DA16759, K23 DA020681] FX The findings, conclusions, and recommendations contained in this report are those of the authors. No official endorsement by the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, or the pharmaceutical companies that provided unrestricted grants to support the activities of ACTTION should be inferred. Financial support for this study was provided by ACTTION, which has received research contracts, grants, or other revenue from the U.S. Food and Drug Administration, various pharmaceutical companies, and other sources. This work was also supported by Grants DA09236, DA031022, and DA16759 (to Sandra D. Comer), Grant K23 DA020681 (to Ajay D. Wasan), and Grant K24 DA022288 (to Roger D. Weiss) from the National Institute on Drug Abuse. NR 43 TC 54 Z9 54 U1 0 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD NOV PY 2013 VL 154 IS 11 BP 2287 EP 2296 DI 10.1016/j.pain.2013.05.053 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 238FG UT WOS:000325927500010 PM 23792283 ER PT J AU Marjuki, H Mishin, VP Sleeman, K Okomo-Adhiambo, M Sheu, TG Guo, LZ Xu, XY Gubareva, LV AF Marjuki, Henju Mishin, Vasiliy P. Sleeman, Katrina Okomo-Adhiambo, Margaret Sheu, Tiffany G. Guo, Lizheng Xu, Xiyan Gubareva, Larisa V. TI Bioluminescence-Based Neuraminidase Inhibition Assay for Monitoring Influenza Virus Drug Susceptibility in Clinical Specimens SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID B VIRUSES; UNITED-STATES; OSELTAMIVIR; RESISTANCE; H1N1; SURVEILLANCE; CHILDREN; INFECTIONS; CHALLENGES; MUTATIONS AB The QFlu prototype bioluminescence-based neuraminidase (NA) inhibition (NI) assay kit was designed to detect NA inhibitor (NAI)-resistant influenza viruses at point of care. Here, we evaluated its suitability for drug susceptibility assessment at a surveillance laboratory. A comprehensive panel of reference viruses (n = 14) and a set of 90 seasonal influenza virus A and B isolates were included for testing with oseltamivir and/or zanamivir in the QFlu assay using the manufacturer-recommended protocol and a modified version attuned to surveillance requirements. The 50% inhibitory concentrations (IC(50)s) generated were compared with those of NI assays currently used for monitoring influenza drug susceptibility, the fluorescent (FL) and chemiluminescent (CL) assays. To provide proof of principle, clinical specimens (n = 235) confirmed by real-time reverse transcription (RT)-PCR to contain influenza virus A(H1N1) pdm09 and prescreened for the oseltamivir resistance marker H275Y using pyrosequencing were subsequently tested in the QFlu assay. All three NI assays were able to discriminate the reference NA variants and their matching wild-type viruses based on the difference in their IC(50)s. Unless the antigenic types were first identified, certain NA variants (e.g., H3N2 with E119V) could be detected among seasonal viruses using the FL assays only. Notably, the QFlu assay identified oseltamivir-resistant A(H1N1) pdm09 viruses carrying the H275Y marker directly in clinical specimens, which is not feasible with the other two phenotypic assays, which required prior virus culturing in cells. Furthermore, The QFlu assay allows detection of the influenza virus A and B isolates carrying established and potential NA inhibitor resistance markers and may become a useful tool for monitoring drug resistance in clinical specimens. C1 [Marjuki, Henju; Mishin, Vasiliy P.; Sleeman, Katrina; Okomo-Adhiambo, Margaret; Sheu, Tiffany G.; Guo, Lizheng; Xu, Xiyan; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM lgubareva@cdc.gov NR 37 TC 4 Z9 4 U1 0 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2013 VL 57 IS 11 BP 5209 EP 5215 DI 10.1128/AAC.01086-13 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 235ZY UT WOS:000325764000003 PM 23917311 ER PT J AU Rudolph, K Bulkow, L Bruce, M Zulz, T Reasonover, A Harker-Jones, M Hurlburt, D Hennessy, T AF Rudolph, Karen Bulkow, Lisa Bruce, Michael Zulz, Tammy Reasonover, Alisa Harker-Jones, Marcella Hurlburt, Debby Hennessy, Thomas TI Molecular Resistance Mechanisms of Macrolide-Resistant Invasive Streptococcus pneumoniae Isolates from Alaska, 1986 to 2010 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; UNITED-STATES; SEROTYPE 19A; ANTIMICROBIAL RESISTANCE; ANTIBACTERIAL SUSCEPTIBILITY; MULTICENTER SURVEILLANCE; GENETIC ELEMENTS; PROTEKT US; PYOGENES; MEF(A) AB The rapid emergence of antibiotic-resistant pneumococcal strains has reduced treatment options. The aim of this study was to determine antimicrobial susceptibilities, serotype distributions, and molecular resistance mechanisms among macrolide-resistant invasive pneumococcal isolates in Alaska from 1986 to 2010. We identified cases of invasive pneumococcal disease in Alaska from 1986 to 2010 through statewide population-based laboratory surveillance. All invasive pneumococcal isolates submitted to the Arctic Investigations Program laboratory were confirmed by standard microbiological methods and serotyped by slide agglutination and the Quellung reaction. MICs were determined by the broth microdilution method, and macrolide-resistant genotypes were determined by multiplex PCR. Among 2,923 invasive pneumococcal isolates recovered from 1986 to 2010, 270 (9.2%) were nonsusceptible to erythromycin; 177 (66%) erythromycin-nonsusceptible isolates demonstrated coresistance to penicillin, and 167 (62%) were multidrug resistant. The most frequent serotypes among the macrolide-resistant isolates were serotypes 6B (23.3%), 14 (20.7%), 19A (16.7%), 9V (8.9%), 19F (6.3%), 6A (5.6%), and 23F (4.8%). mef and erm(B) genes were detected in 207 (77%) and 32 (12%) of the isolates, respectively. Nineteen (7%) of the erythromycin-nonsusceptible isolates contained both mef and erm(B) genotypes; 15 were of serotype 19A. There was significant year-to-year variation in the proportion of isolates that were nonsusceptible to erythromycin (P < 0.001). Macrolide resistance among pneumococcal isolates from Alaska is mediated predominantly by mef genes, and this has not changed significantly over time. However, there was a statistically significant increase in the proportion of isolates that possess both erm(B) and mef, primarily due to serotype 19A isolates. C1 [Rudolph, Karen; Bulkow, Lisa; Bruce, Michael; Zulz, Tammy; Reasonover, Alisa; Harker-Jones, Marcella; Hurlburt, Debby; Hennessy, Thomas] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. RP Rudolph, K (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. EM krudolph@cdc.gov NR 50 TC 7 Z9 7 U1 0 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2013 VL 57 IS 11 BP 5415 EP 5422 DI 10.1128/AAC.00319-13 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 235ZY UT WOS:000325764000028 PM 23959308 ER PT J AU Gould, CV Edwards, JR Cohen, J Bamberg, WM Clark, LA Farley, MM Johnston, H Nadle, J Winston, L Gerding, DN McDonald, LC Lessa, FC AF Gould, Carolyn V. Edwards, Jonathan R. Cohen, Jessica Bamberg, Wendy M. Clark, Leigh Ann Farley, Monica M. Johnston, Helen Nadle, Joelle Winston, Lisa Gerding, Dale N. McDonald, L. Clifford Lessa, Fernanda C. CA Clostridium Difficile Infect Ctr Dis Control Prevention TI Effect of Nucleic Acid Amplification Testing on Population-Based Incidence Rates of Clostridium difficile Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Clostridium difficile; clinical laboratory techniques; nucleic acid amplification techniques; incidence; surveillance ID REAL-TIME PCR; ENZYME-IMMUNOASSAY; DIAGNOSIS; IMPACT; TOXIN; ASSAY AB Nucleic acid amplification testing (NAAT) is increasingly being adopted for diagnosis of Clostridium difficile infection (CDI). Data from 3 states conducting population-based CDI surveillance showed increases ranging from 43% to 67% in CDI incidence attributable to changing from toxin enzyme immunoassays to NAAT. CDI surveillance requires adjustment for testing methods. C1 [Gould, Carolyn V.; Edwards, Jonathan R.; Cohen, Jessica; McDonald, L. Clifford; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Bamberg, Wendy M.; Johnston, Helen] Colorado Dept Hlth, Denver, CO 80220 USA. [Clark, Leigh Ann; Farley, Monica M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Farley, Monica M.] Emory Univ, Div Infect Dis, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta VA Med Ctr, Atlanta, GA USA. [Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA. [Winston, Lisa] Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA. [Gerding, Dale N.] Hines VA Hosp, Maywood, IL USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. RP Gould, CV (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS A-31, Atlanta, GA 30333 USA. EM cgould@cdc.gov FU GOJO FX D. N. G. holds patents for treatment of CDI licensed to ViroPharma; is a consultant for Merck, ViroPharma, GSK, Roche, Novartis, Optimer, Cubist, Cangene, Sanofi Pasteur, and Actelion; and holds research grants from GOJO. All other authors report no potential conflicts. NR 17 TC 24 Z9 24 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2013 VL 57 IS 9 BP 1304 EP 1307 DI 10.1093/cid/cit492 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 235ZM UT WOS:000325762500018 PM 23899677 ER PT J AU Luther, VP Ohl, CA Hicks, LA AF Luther, Vera P. Ohl, Christopher A. Hicks, Lauri A. TI Antimicrobial Stewardship Education for Medical Students SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Luther, Vera P.; Ohl, Christopher A.] Wake Forest Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA. [Hicks, Lauri A.] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Luther, VP (reprint author), Wake Forest Sch Med, Dept Internal Med, Infect Dis Sect, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA. EM vluther@wakehealth.edu NR 1 TC 5 Z9 5 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2013 VL 57 IS 9 BP 1366 EP U167 DI 10.1093/cid/cit480 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 235ZM UT WOS:000325762500030 PM 23893971 ER PT J AU Hartley, DM Nelson, NP Arthur, RR Barboza, P Collier, N Lightfoot, N Linge, JP van der Goot, E Mawudeku, A Madoff, LC Vaillant, L Walters, R Yangarber, R Mantero, J Corley, CD Brownstein, JS AF Hartley, D. M. Nelson, N. P. Arthur, R. R. Barboza, P. Collier, N. Lightfoot, N. Linge, J. P. van der Goot, E. Mawudeku, A. Madoff, L. C. Vaillant, L. Walters, R. Yangarber, R. Mantero, J. Corley, C. D. Brownstein, J. S. TI An overview of Internet biosurveillance SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Review DE Digital disease detection; digital epidemiology; electronic surveillance; epidemic intelligence; event-based surveillance; Internet-based surveillance; participatory epidemiology; web-based text mining ID INFECTIOUS-DISEASE DETECTION; PUBLIC-HEALTH SURVEILLANCE; OUTBREAK; CLASSIFICATION; INTELLIGENCE; SYSTEM; DENGUE; MEDIA; WEB AB Internet biosurveillance utilizes unstructured data from diverse web-based sources to provide early warning and situational awareness of public health threats. The scope of source coverage ranges from local media in the vernacular to international media in widely read languages. Internet biosurveillance is a timely modality that is available to government and public health officials, healthcare workers, and the public and private sector, serving as a real-time complementary approach to traditional indicator-based public health disease surveillance methods. Internet biosurveillance also supports the broader activity of epidemic intelligence. This overview covers the current state of the field of Internet biosurveillance, and provides a perspective on the future of the field. C1 [Hartley, D. M.] Georgetown Univ, Sch Med, Imaging Sci & Informat Syst Ctr, Washington, DC 20057 USA. [Hartley, D. M.] Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20057 USA. [Nelson, N. P.] Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20057 USA. [Arthur, R. R.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Barboza, P.; Vaillant, L.] French Inst Publ Hlth Surveillance InVS, Int Dept, St Maurice, France. [Collier, N.] Natl Inst Informat, Tokyo, Japan. [Collier, N.] European Bioinformat Inst, Cambridge, England. [Lightfoot, N.] CORDS, Lyon, France. [Linge, J. P.; van der Goot, E.] Commiss European Communities, Joint Res Ctr, I-21020 Ispra, Italy. [Mawudeku, A.] PHAC, Ottawa, ON, Canada. [Madoff, L. C.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Walters, R.; Corley, C. D.] Pacific NW Natl Lab, Richland, WA 99352 USA. [Yangarber, R.] Univ Helsinki, Dept Comp Sci, SF-00510 Helsinki, Finland. [Mantero, J.] European Ctr Dis Prevent & Control, Surveillance & Response Support Unit, Stockholm, Sweden. [Brownstein, J. S.] Harvard Univ, Harvard Mit Div Hlth Sci & Technol, Childrens Hosp Boston, Sch Med, Boston, MA USA. RP Hartley, DM (reprint author), Georgetown Univ, Med Ctr, Imaging Sci & Informat Syst Ctr, 2115 Wisconsin Ave NW,Suite 603, Washington, DC 20057 USA. EM hartley@isis.georgetown.edu RI Yangarber, Roman/H-4762-2016; OI , David/0000-0003-2589-2538 NR 48 TC 19 Z9 19 U1 6 U2 34 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1198-743X EI 1469-0691 J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD NOV PY 2013 VL 19 IS 11 BP 1006 EP 1013 DI 10.1111/1469-0691.12273 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 233JK UT WOS:000325564400012 PM 23789639 ER PT J AU Sauber-Schatz, EK Mack, KA Diekman, ST Paulozzi, LJ AF Sauber-Schatz, Erin K. Mack, Karin A. Diekman, Shane T. Paulozzi, Leonard J. TI Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Pain clinic; Pill mill; Drug overdose death; Drug-related hospitalization; Neonatal abstinence syndrome; Florida ID UNITED-STATES; DIVERSION; ABUSE; RATES; TEXAS AB Background: Community-level associations between pain clinics and drug-related outcomes have not been empirically demonstrated. Methods: To explore these associations we correlated overdose death rates, hospital-discharge rates for drug-related hospitalizations including neonatal abstinence syndrome, and emergency department rates for drug-related visits with registered pain clinic density and rate of opioid pills dispensed per person at the county-level Florida in 2009. Negative binomial regression was used to model the crude associations and associations adjusted for exposure measures and county demographic characteristics. Results: An estimated 732 pain clinics operated in Florida in 2009, a rate of 3.9/100,000 people. Among the 67 counties in Florida, 23(34.3%) had no pain clinics, and three had 90 or more. Adjusted negative binomial regression determined no significant association between pain clinic rate and drug-related outcomes. However, rates of drug-caused, opioid-caused, and oxycodone-caused death correlated significantly with rates of opioid and oxycodone pills dispensed per person in adjusted analyses. For every increase of one pill in the rate of oxycodone pills per person, there was a 6% increase in the rate of oxycodone-related overdose death. Conclusions: Although pain clinics, some of which are "pill mills," are clearly a source of drugs used nonmedically, their impact on health outcomes might be difficult to quantify because the pills they prescribe might be consumed in other counties or states. The impact of "pill mill" laws might be better measured by more proximal measures such as the number of such facilities. Published by Elsevier Ireland Ltd. C1 [Sauber-Schatz, Erin K.; Mack, Karin A.; Diekman, Shane T.; Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Div Unint Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Sauber-Schatz, EK (reprint author), Ctr Dis Control & Prevent, Div Unint Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F62, Atlanta, GA 30341 USA. EM ige7@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 NR 34 TC 15 Z9 15 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD NOV 1 PY 2013 VL 133 IS 1 BP 161 EP 166 DI 10.1016/j.drugalcdep.2013.05.017 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 236GH UT WOS:000325783000020 PM 23769424 ER PT J AU Dittus, PJ AF Dittus, Patricia J. TI The Promise of Worksite Parent-Based HIV Prevention for Youth SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID INTERVENTIONS; HEALTH; ADOLESCENTS; PROGRAM C1 Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Dittus, PJ (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. NR 13 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD NOV PY 2013 VL 53 IS 5 BP 557 EP 558 DI 10.1016/j.jadohealth.2013.08.016 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 235WI UT WOS:000325751800002 PM 24138762 ER PT J AU Schmidt, MA Gold, R Kurosky, SK Daley, MF Irving, SA Gee, J Naleway, AL AF Schmidt, Mark A. Gold, Rachel Kurosky, Samantha K. Daley, Matthew F. Irving, Stephanie A. Gee, Julianne Naleway, Allison L. TI Uptake, Coverage, and Completion of Quadrivalent Human Papillomavirus Vaccine in the Vaccine Safety Datalink, July 2006-June 2011 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Papillomavirus vaccines; Vaccination; HPV vaccines; Gardasil ID AGED 13-17 YEARS; UNITED-STATES; CERVICAL-CANCER; ADOLESCENT GIRLS; YOUNG-WOMEN; HPV; US; PREVENTION; PHYSICIANS; INITIATION AB Purpose: The Advisory Committee on Immunization Practices recommended quadrivalent human papillomavirus vaccine (HPV4) for use in females in June 2006 and in males in October 2009. The objective of our study was to describe HPV4 uptake, single-dose coverage, and completion of the three-dose series among those 9-26 years of age, after the respective female and male vaccine licensures through June 2011. Methods: The study population included members of eight managed care organizations participating in the Vaccine Safety Datalink; we abstracted demographic and comprehensive vaccine information from electronic health records. Results: We found one-dose coverage increasing throughout the study period, to a high of 37.7% among females and 1.3% among males in June 2011. Among those receiving at least one HPV4 dose, three-dose series completion was 42% for females and 30.2% for males. Conclusions: Our results demonstrate low initiation and completion of the HPV4 series among those recommended to receive the vaccine. Although consistent with previous studies, these results highlight the continued need to develop, implement, and monitor strategies to increase HPV4 vaccine initiation and completion in younger adolescents to achieve maximum impact in reducing the burden of cervical cancer and other HPV-related diseases. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Schmidt, Mark A.; Gold, Rachel; Kurosky, Samantha K.; Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Irving, Stephanie A.] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI USA. [Gee, Julianne] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA USA. RP Schmidt, MA (reprint author), Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Mark.A.Schmidt@kpchr.org OI Irving, Stephanie/0000-0001-7437-6797; Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention , through America's Health Insurance Plans [200-2002-00732] FX Financial support for this study was provided in full by the Centers for Disease Control and Prevention (200-2002-00732), through America's Health Insurance Plans. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 38 TC 9 Z9 9 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD NOV PY 2013 VL 53 IS 5 BP 637 EP 641 DI 10.1016/j.jadohealth.2013.08.002 PG 5 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 235WI UT WOS:000325751800015 PM 24138765 ER PT J AU Liddon, N Michael, SL Dittus, P Markowitz, LE AF Liddon, Nicole Michael, Shannon L. Dittus, Patricia Markowitz, Lauri E. TI Maternal Underestimation of Child's Sexual Experience: Suggested Implications for HPV Vaccine Uptake at Recommended Ages SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE HPV vaccine; Adolescents; Sexual behavior ID ADOLESCENTS; TEEN AB Purpose: Despite official recommendation for routine HPV vaccination of boys and girls at age 11-12 years, parents and providers are more likely to vaccinate their children/patients at older ages. Preferences for vaccinating older adolescents may be related to beliefs about an adolescent's sexual experience or perceived parental resistance to vaccinating children who are assumed to be sexually inexperienced. Methods: Using data from the 1995 wave of the National Longitudinal Study of Adolescent Health (ADD Health), a subset of a nationally representative sample of adolescents in grades 7 through 12 and their parents (n=13,461), we investigated maternal underestimation of adolescent sexual experience. Results: About one third (34.8%) of adolescents reported being sexually experienced and of these, 46.8% of their mothers inaccurately reported that their child was not sexually experienced. Underestimation varied by adolescent age with 78.1% of mothers of sexually active 11-13-year-olds reporting their child was not sexually active, compared with 56.4% of mothers of sexually active 14-16-year-olds and only 34.4% of mothers of 17-18-year-olds. Conclusions: Although most adolescents are not sexually active at age 11 or 12 years, waiting until a parent thinks a child is sexually active could result in missed opportunities for prevention. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Liddon, Nicole; Michael, Shannon L.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Dittus, Patricia; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30341 USA. RP Liddon, N (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Hwy,MS K-12, Atlanta, GA 30341 USA. EM nel6@cdc.gov NR 10 TC 11 Z9 11 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD NOV PY 2013 VL 53 IS 5 BP 674 EP 676 DI 10.1016/j.jadohealth.2013.07.026 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 235WI UT WOS:000325751800021 PM 24035133 ER PT J AU White, GE Mazurek, JM Moorman, JE AF White, Gretchen E. Mazurek, Jacek M. Moorman, Jeanne E. TI Work-related asthma and employment status-38 states and District of Columbia, 2006-2009 SO JOURNAL OF ASTHMA LA English DT Article DE Asthma; behavioral risk factor surveillance system; employment; occupational health ID CALL-BACK-SURVEY; OCCUPATIONAL ASTHMA; EXACERBATED ASTHMA; ADULTS; HEALTH; SYMPTOMS; EXPOSURE; OUTCOMES AB Objectives: To examine differences in current employment status between persons with health professional-diagnosed work-related asthma and non-work-related asthma and to examine factors associated with unemployment in these groups. Methods: We analyzed the 2006-2009 Behavioral Risk Factor Surveillance System Asthma Call-back Survey for ever-employed adults (excluding those who were retired, homemakers and students at the time of the interview) with current asthma in 38 states and District of Columbia (N = 25 680). We calculated prevalence ratios (PRs) adjusted for age, sex, race/ethnicity, education and income. Results: Among adults with current asthma, individuals with work-related asthma were less likely to be currently employed for wages (PR = 0.89; 95% confidence interval [CI] 0.84-0.95) and more likely to be unable to work (PR = 1.44; 95% CI = 1.24-1.67) than those with non-work-related asthma. Among adults with current asthma who were unemployed at the time of the interview, adults with work-related asthma did not differ from those with non-work-related asthma in naming disability as reason for unemployment (PR = 1.09; 95% CI = 0.94-1.26). However, those with work-related asthma were more likely to be unable to work for health reasons other than disability (PR = 1.46; 95% CI = 1.01-2.12) than adults with non-work-related asthma. Conclusions: Additional studies are needed to determine what health reasons prevent individuals with work-related asthma from working and if the health reasons are asthma-related. C1 [White, Gretchen E.; Mazurek, Jacek M.] NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Moorman, Jeanne E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. RP White, GE (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, 1095 Willowdale Rd,MS HG900, Morgantown, WV 26505 USA. EM ipb8@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 4 Z9 4 U1 0 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 EI 1532-4303 J9 J ASTHMA JI J. Asthma PD NOV PY 2013 VL 50 IS 9 BP 954 EP 959 DI 10.3109/02770903.2013.829491 PG 6 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 236AS UT WOS:000325766500006 PM 23889492 ER PT J AU Petticrew, M Anderson, L Elder, R Grimshaw, J Hopkins, D Hahn, R Krause, L Kristjansson, E Mercer, S Sipe, T Tugwell, P Ueffing, E Waters, E Welch, V AF Petticrew, Mark Anderson, Laurie Elder, Randy Grimshaw, Jeremy Hopkins, David Hahn, Robert Krause, Lauren Kristjansson, Elizabeth Mercer, Shawna Sipe, Teresa Tugwell, Peter Ueffing, Erin Waters, Elizabeth Welch, Vivian TI Complex interventions and their implications for systematic reviews: a pragmatic approach SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE Systematic reviews; Evaluation; Complex interventions; Complexity; Evidence synthesis; Qualitative research ID HEALTH; EFFICACY; TRIALS AB Complex interventions present unique challenges for systematic reviews. Current debates tend to center around describing complexity, rather than providing guidance on what to do about it. At a series of meetings during 2009-2012, we met to review the challenges and practical steps reviewer could take to incorporate a complexity perspective into systematic reviews. Based on this, we outline a pragmatic approach to dealing with complexity, beginning, as for any review, with clearly defining the research question(s). We argue that reviews of complex interventions can themselves be simple or complex, depending on the question to be answered. In systematic reviews and evaluations of complex interventions, it will be helpful to start by identifying the sources of complexity, then mapping aspects of complexity in the intervention onto the appropriate sources of evidence (such as specific types of quantitative or qualitative study). Although we focus on systematic reviews, the general approach is also applicable to primary research that is aimed at evaluating complex interventions. Although the examples are drawn from health care, the approach may also be applied to other sectors (e.g., social policy or international development). We end by concluding that systematic reviews should follow the principle of Occam's razor: explanations should be as complex as they need to be and no more. (c) 2013 Elsevier Inc. All rights reserved. C1 [Petticrew, Mark] London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1H 9SH, England. [Anderson, Laurie] Washington State Inst Publ Policy, Olympia, WA USA. [Elder, Randy; Hopkins, David; Hahn, Robert; Mercer, Shawna; Sipe, Teresa] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Grimshaw, Jeremy; Kristjansson, Elizabeth; Tugwell, Peter; Welch, Vivian] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. [Krause, Lauren] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Ueffing, Erin] Ottawa Hosp Res Inst, Canadian Cochrane Ctr, Ottawa, ON, Canada. [Waters, Elizabeth] Univ Melbourne, Melbourne Sch Populat Hlth, McCaughey Ctr, Melbourne, Vic, Australia. RP Petticrew, M (reprint author), London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1H 9SH, England. EM Mark.Petticrew@lshtm.ac.uk OI Tugwell, Peter/0000-0001-5062-0556 FU CIHR FX No relevant conflicts relating to this article. M.P. receives funding from the CIHR funded International Collaboration on Complex Interventions, which supported some of the work reported in this article. NR 27 TC 34 Z9 34 U1 1 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD NOV PY 2013 VL 66 IS 11 BP 1209 EP 1214 DI 10.1016/j.jclinepi.2013.06.004 PG 6 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 235PP UT WOS:000325733500007 PM 23953085 ER PT J AU Eke, PI Dye, BA Wei, L Slade, GD Thornton-Evans, GO Beck, JD Taylor, GW Borgnakke, WS Page, RC Genco, RJ AF Eke, P. I. Dye, B. A. Wei, L. Slade, G. D. Thornton-Evans, G. O. Beck, J. D. Taylor, G. W. Borgnakke, W. S. Page, R. C. Genco, R. J. TI Self-reported Measures for Surveillance of Periodontitis SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE Centers for Disease Control and Prevention (CDC); dental health surveys; epidemiologic methods; epidemiology; health status indicators; NHANES ID UNITED-STATES; CASE DEFINITIONS; DISEASE; POPULATION; PREVALENCE; VALIDITY; ADULTS; PREDICTION; QUESTIONS; PROTOCOLS AB The purpose of this study was to evaluate the performance of self-reported measures in predicting periodontitis in a representative US adult population, based on 2009-2010 National Health and Nutrition Examination Survey (NHANES) data. Self-reported gum health and treatment history, loose teeth, bone loss around teeth, tooth not looking right, and use of dental floss and mouthwash were obtained during in-home interviews and validated against full-mouth clinically assessed periodontitis in 3,743 US adults 30 years and older. All self-reported measures (> 95% item response rates) were associated with periodontitis, and bivariate correlations between responses to these questions were weak, indicating low redundancy. In multivariable logistic regression modeling, the combined effects of demographic measures and responses to 5 self-reported questions in predicting periodontitis of mild or greater severity were 85% sensitive and 58% specific and produced an area under the receiver operator characteristic curve' (AUROCC) of 0.81. Four questions were 95% sensitive and 30% specific, with an AUROCC of 0.82 in predicting prevalence of clinical attachment loss 3 mm at one or more sites. In conclusion, self-reported measures performed well in predicting periodontitis in US adults. Where preferred clinically based surveillance is unattainable, locally adapted variations of these self-reported measures may be a promising alternative for surveillance of periodontitis. C1 [Eke, P. I.] Ctr Dis Control & Prevent CDC, Div Populat Hlth, Atlanta, GA 30333 USA. [Dye, B. A.] Ctr Dis Control & Prevent CDC, Div Hlth & Nutr Examinat Surveys, Atlanta, GA USA. [Dye, B. A.; Thornton-Evans, G. O.] Ctr Dis Control & Prevent CDC, Div Oral Hlth, Atlanta, GA USA. [Wei, L.] DB Consulting Grp Inc, Atlanta, GA USA. [Slade, G. D.; Beck, J. D.] Univ N Carolina, Sch Dent, Chapel Hill, NC USA. [Taylor, G. W.] Univ Calif San Francisco, Dept Prevent & Restorat Dent Sci, San Francisco, CA 94143 USA. [Borgnakke, W. S.] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA. [Page, R. C.] Univ Washington, Sch Dent, Seattle, WA 98195 USA. [Genco, R. J.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Oral Biol & Microbiol, Buffalo, NY 14260 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent CDC, Div Populat Hlth, Atlanta, GA 30333 USA. EM peke@cdc.gov FU CDC FX The authors acknowledge the contributions by members of the CDC Periodontal Disease Surveillance initiative (Eke and Genco, 2007). This work was supported by CDC as part of an internal project and was not supported by any external funding or institution. The findings and conclusion in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The author(s) received no financial support and declare no potential conflicts of interest with respect to the authorship and/or publication of this article. NR 23 TC 24 Z9 26 U1 0 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 EI 1544-0591 J9 J DENT RES JI J. Dent. Res. PD NOV PY 2013 VL 92 IS 11 BP 1041 EP 1047 DI 10.1177/0022034513505621 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 235AC UT WOS:000325685300017 PM 24065636 ER PT J AU Wilkes, M Srinivasan, M Cole, G Tardif, R Richardson, LC Plescia, M AF Wilkes, Michael Srinivasan, Malathi Cole, Galen Tardif, Richard Richardson, Lisa C. Plescia, Marcus TI Discussing Uncertainty and Risk in Primary Care: Recommendations of a Multi-Disciplinary Panel Regarding Communication Around Prostate Cancer Screening SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE prostate cancer screening; men's health; shared decision-making; communication; funding priorities; risk ID CONTINUING MEDICAL-EDUCATION; SHARED DECISION-MAKING; SERVICES TASK-FORCE; GENERAL-PRACTICE; HEALTH; AIDS; INTERVENTIONS; STRATEGIES; FRAMEWORK; BENEFITS AB Shared decision making improves value-concordant decision-making around prostate cancer screening (PrCS). Yet, PrCS discussions remain complex, challenging and often emotional for physicians and average-risk men. In July 2011, the Centers for Disease Control and Prevention convened a multidisciplinary expert panel to identify priorities for funding agencies and development groups to promote evidence-based, value-concordant decisions between men at average risk for prostate cancer and their physicians. Two-day multidisciplinary expert panel in Atlanta, Georgia, with structured discussions and formal consensus processes. Sixteen panelists represented diverse specialties (primary care, medical oncology, urology), disciplines (sociology, communication, medical education, clinical epidemiology) and market sectors (patient advocacy groups, Federal funding agencies, guideline-development organizations). Panelists used guiding interactional and evaluation models to identify and rate strategies that might improve PrCS discussions and decisions for physicians, patients and health systems/society. Efficacy was defined as the likelihood of each strategy to impact outcomes. Effort was defined as the relative amount of effort to develop, implement and sustain the strategy. Each strategy was rated (1-7 scale; 7 = maximum) using group process software (ThinkTank(TM)). For each group, intervention strategies were grouped as financial/regulatory, educational, communication or attitudinal levers. For each strategy, barriers were identified. Highly ranked strategies to improve value-concordant shared decision-making (SDM) included: changing outpatient clinic visit reimbursement to reward SDM; development of evidence-based, technology-assisted, point-of-service tools for physicians and patients; reframing confusing prostate cancer screening messages; providing pre-visit decision support interventions; utilizing electronic health records to promote benchmarking/best practices; providing additional training for physicians around value-concordant decision-making; and using re-accreditation to promote training. Conference outcomes present an expert consensus of strategies likely to improve value-concordant prostate cancer screening decisions. In addition, the methodology used to obtain agreement provides a model of successful collaboration around this and future controversial cancer screening issues, which may be of interest to funding agencies, educators and policy makers. C1 [Wilkes, Michael; Srinivasan, Malathi] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Cole, Galen; Richardson, Lisa C.; Plescia, Marcus] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Tardif, Richard] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Wilkes, M (reprint author), Univ Calif Davis, Sch Med, 1 Shield Ave, Sacramento, CA 95817 USA. EM mswilkes@ucdavis.edu FU Oak Ridge Institute for Science and Education (ORISE) under Centers for Disease Control and Prevention FX Funding for and coordination of the workgroup was provided by the Oak Ridge Institute for Science and Education (ORISE) under contract with the Centers for Disease Control and Prevention. NR 52 TC 4 Z9 4 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2013 VL 28 IS 11 BP 1410 EP 1419 DI 10.1007/s11606-013-2419-z PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 236DQ UT WOS:000325774800011 PM 23649782 ER PT J AU Chen, DS Locarnini, S Wait, S Bae, SH Chen, PJ Fung, JYY Kim, HS Lu, SN Sung, J Tanaka, J Wakita, T Ward, J Wallace, J AF Chen, Ding-Shinn Locarnini, Stephen Wait, Suzanne Bae, Si-Hyun Chen, Pei-Jer Fung, James Y. Y. Kim, Hong Soo Lu, Sheng-Nan Sung, Joseph Tanaka, Junko Wakita, Takaji Ward, John Wallace, Jack CA CEVHAP North Asia Workshop Viral TI Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia SO JOURNAL OF HEPATOLOGY LA English DT Article DE Hepatitis B; Hepatitis C; Asia; Policy ID C VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; B-VIRUS; CONSENSUS STATEMENTS; VACCINATION PROGRAM; TAIWAN; MANAGEMENT; DIAGNOSIS; EPIDEMIOLOGY; ERADICATION AB Background & Aims: The World Health Organisation (WHO) Prevention & Control of Viral Hepatitis Infection: Framework for Global Action offers a global vision for the prevention and control of viral hepatitis. In October 2012, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) organised the North Asia Workshop on Viral Hepatitis in Taipei to discuss how to implement the WHO Framework in the North Asia region. This paper presents outcomes from this workshop. Methods: Twenty-eight representatives from local liver associations, patient organisations, and centres of excellence in Hong Kong, Japan, Korea, and Taiwan participated in the workshop. Findings: Priority areas for action were described along the four axes of the WHO Framework: (1) awareness, advocacy and resources; (2) evidence and data; (3) prevention of transmission; and (4) screening and treatment. Priorities included: axis 1: greater public and professional awareness, particularly among primary care physicians and local advocacy networks. Axis 2: better economic data and identifying barriers to screening and treatment uptake. Axis 3: monitoring of vaccination outcomes and targeted harm reduction strategies. Axis 4: strengthening links between hospitals and primary care providers, and secure funding of screening and treatment, including for hepatocellular carcinoma. Conclusions: The WHO Framework provides an opportunity to develop comprehensive and cohesive policies in North Asia and the broader region. A partnership between clinical special-ists, primary care physicians, policy makers, and people with or at risk of viral hepatitis is essential in shaping future policies. C1 [Chen, Ding-Shinn] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Locarnini, Stephen] Victorian Infect Dis Reference Lab, North Melbourne, Australia. [Wait, Suzanne] SHW Hlth Ltd, London, England. [Bae, Si-Hyun] Catholic Univ, Coll Med, Seoul St Mary Hosp, Dept Internal Med, Seoul, South Korea. [Chen, Pei-Jer] Natl Taiwan Univ & Hosp, Hepatitis Res Ctr, Taipei, Taiwan. [Fung, James Y. Y.] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. [Kim, Hong Soo] SoonChunHyang Univ Hosp, Dept Internal Med, Div Gastroenterol, Cheonan, South Korea. [Lu, Sheng-Nan] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan. [Sung, Joseph] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. [Tanaka, Junko] Hiroshima Univ, Dept Epidemiol Infect Dis Control & Prevent, Inst Biomed & Hlth Sci, Hiroshima, Japan. [Wakita, Takaji] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan. [Ward, John] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Wallace, Jack] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Vic, Australia. RP Locarnini, S (reprint author), WHO Reg Reference Lab Hepatitis B, 10 Wreckyn St, North Melbourne, Vic 3051, Australia. EM Stephen.Locarnini@mh.org.au RI Ruan, YL/B-9813-2009; Li, Lien/I-9223-2014; OI CHEN, DING-SHINN/0000-0001-7791-6154 FU Bristol-Myers Squibb; Merck; Gilead; Janssen; CEVHAP FX The CEVHAP North Asia Forum was made possible through unrestricted grants and core funding from Bristol-Myers Squibb, Merck, Gilead, and Janssen. This publication was funded by CEVHAP as part of this workshop. NR 37 TC 11 Z9 11 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD NOV PY 2013 VL 59 IS 5 BP 1073 EP 1080 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 235WZ UT WOS:000325754200025 PM 23850942 ER PT J AU Lott, JP Liu, K Landry, ML Nix, WA Oberste, MS Bolognia, J King, B AF Lott, Jason P. Liu, Kristina Landry, Marie-Louise Nix, W. Allan Oberste, M. Steven Bolognia, Jean King, Brett TI Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE atypical; coxsackievirus A6; diagnosis; enterovirus; evaluation; exanthem; hand-foot-and-mouth disease ID CLINICAL SPECIMENS; ENTEROVIRUS 71; SURVEILLANCE; OUTBREAK; FEATURES; TAIWAN; PCR AB Background: Hand-foot-and-mouth disease (HFMD) is an acute viral illness commonly caused by coxsackievirus (CV)-A16 and enterovirus 71 infections. Recently, atypical HFMD has been reported in association with CV-A6, an uncommon enterovirus strain. Objective: We sought to describe the clinical features of atypical HFMD associated with CV-A6 infection and its diagnostic laboratory evaluation. Methods: Patients presenting to our institution with history and examination suggestive of atypical HFMD from January 2012 to July 2012 were identified. Morphology and distribution of mucocutaneous lesions were recorded. Enterovirus infection was assessed by reverse transcriptase polymerase chain reaction of biologic specimens. Enterovirus type was determined by viral capsid protein 1 gene sequencing. Results: Two adults and 3 children with atypical HFMD were identified. Four of 5 patients exhibited widespread cutaneous lesions. In 2 patients with a history of atopic dermatitis, accentuation in areas of dermatitis was noted. Associated systemic symptoms prompted 4 of 5 patients to seek emergency care, and both adults were hospitalized for diagnostic evaluation. Infection with CV-A6 was confirmed in all patients. Limitations: This study is a case series from a single institution. Conclusion: Consideration of the expanded range of cutaneous findings in atypical HFMD caused by CV-A6 infection may assist clinicians in diagnosis and management. C1 [Lott, Jason P.; Liu, Kristina; Bolognia, Jean; King, Brett] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA. [Landry, Marie-Louise] Yale Univ, Sch Med, Lab Med, New Haven, CT 06520 USA. [Landry, Marie-Louise] Yale Univ, Sch Med, Internal Med, New Haven, CT 06520 USA. [Lott, Jason P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA. [Nix, W. Allan; Oberste, M. Steven] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Atlanta, GA USA. RP King, B (reprint author), Yale Univ, Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06520 USA. EM brett.king@yale.edu OI Lott, Jason/0000-0002-4097-7225 NR 26 TC 25 Z9 31 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD NOV PY 2013 VL 69 IS 5 BP 736 EP 741 DI 10.1016/j.jaad.2013.07.024 PG 6 WC Dermatology SC Dermatology GA 235WN UT WOS:000325752500042 PM 24035209 ER PT J AU Hogben, M Hood, J Collins, D McFarlane, M AF Hogben, Matthew Hood, Julia Collins, Dayne McFarlane, Mary TI Assessing the role of prevention partnerships in STD prevention: a review of comprehensive STD prevention systems progress reports SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article DE Service Delivery; Programme Science; Public Health AB Systematic analysis of STD programme data contributes to a national portrait of sexually transmitted disease (STD) prevention activities, including research and evaluation specifically designed to optimise programme efficiency and impact. We analysed the narrative of the 2009 annual progress reports of the US Comprehensive STD Prevention Systems cooperative agreement for 58 STD programmes, concentrating on programme characteristics and partnerships. Programmes described 516 unique partnerships with a median of seven organisations cited per STD programme. Non-profit organisations (including service providers) were most frequently cited. Higher gonorrhoea morbidity was associated with reporting more partnerships; budget problems were associated with reporting fewer. Challenges to engaging in partnerships included budget constraints, staff turnover and low interest. Data provide a source of information for judging progress in programme collaboration and for informing a sustained programme-focused research and evaluation agenda. C1 [Hogben, Matthew; Collins, Dayne; McFarlane, Mary] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Hood, Julia] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Hogben, M (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM mhogben@cdc.gov NR 6 TC 3 Z9 3 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD NOV PY 2013 VL 89 IS 7 BP 590 EP 594 DI 10.1136/sextrans-2012-050944 PG 5 WC Infectious Diseases SC Infectious Diseases GA 233CM UT WOS:000325542900015 PM 23825304 ER PT J AU Wang, G Yan, L Ayala, C George, MG Fang, J AF Wang, Guijing Yan, Lili Ayala, Carma George, Mary G. Fang, Jing TI Hypertension-Associated Expenditures for Medication Among US Adults SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; drug cost; economics; high blood pressure; hypertension ID HEALTH-CARE EXPENDITURES; UNITED-STATES; BLOOD-PRESSURE; RISK-FACTORS; PREVALENCE; OUTCOMES; COSTS; DISEASE; CANADA; BURDEN AB We sought to estimate how much the presence of hypertension adds to annual per capita and total expenditures for medication among US adults. The sample included 21,782 civilian noninstitutionalized adults aged 18 years who participated in the 2007 Medical Expenditure Panel Survey. Hypertension was defined as having a diagnosis of high blood pressure (except during pregnancy) or taking a blood pressure medication. We used a 2-part model to examine all-cause medication expenditure associated with hypertension. The prevalence of hypertension was 32.2%. Overall, 66.7% of adults purchased prescribed medications, with this proportion higher among hypertensive (93.0%) than normotensive (54.4%) adults (P < 0.001). Hypertensive adults were more likely to have medication expenditures than were normotensive adults (odds ratio (OR) 6.42; P < 0.001). Among hypertensive adults, those aged 45 years were more likely to incur medication expenditure than those aged 1844 years (OR 3.00, P < 0.001 for those aged 4564 years; OR 5.95, P < 0.001 for those aged 65 years), whereas women were 2.91 times as likely as men to have medication spending (P < 0.001). Hispanics were less likely than non-Hispanic whites to have such spending (OR 0.51; P < 0.001). Among those purchasing medications, the average cost was $1,510 higher among hypertensive persons ($2,337) than normotensive persons ($827). Hypertension-associated expenditures for medication were estimated at $68 billion in the US civilian non-institutionalized population in 2007. The presence of hypertension among US adults is associated with an increase of all-cause expenditures for medication, with this increase varying across groups by age and sex. C1 [Wang, Guijing; Yan, Lili; Ayala, Carma; George, Mary G.; Fang, Jing] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30329 USA. RP Wang, G (reprint author), Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30329 USA. EM gbw9@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 5 Z9 5 U1 1 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD NOV PY 2013 VL 26 IS 11 BP 1295 EP 1302 DI 10.1093/ajh/hpt079 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 232HW UT WOS:000325484800007 PM 23727748 ER PT J AU Henn, SA Bell, JL Sussell, AL Konda, S AF Henn, Scott A. Bell, Jennifer L. Sussell, Aaron L. Konda, Srinivas TI Occupational Carbon Monoxide Fatalities in the US From Unintentional Non-Fire Related Exposures, 1992-2008 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE carbon monoxide; fatalities; occupational; surveillance; CFOI ID WAREHOUSE WORKERS HEADACHE; UNITED-STATES; HYDROGEN-SULFIDE; DEATHS; SURVEILLANCE; INHALATION; SAFETY AB ObjectiveTo analyze characteristics of, and trends in, work-related carbon monoxide (CO) fatalities in the US. MethodsRecords of unintentional, non-fire related fatalities from CO exposure were extracted from the Bureau of Labor Statistics' Census of Fatal Occupational Injuries and the Occupational Safety and Health Administration's Integrated Management Information System for years 1992-2008 and analyzed separately. ResultsThe average number of annual CO fatalities was 22 (standard deviation=8). Fatality rates were highest among workers aged 65, males, Hispanics, winter months, the Midwest, and the Fishing, Hunting, and Trapping industry subsector. Self-employed workers accounted for 28% of all fatalities. Motor vehicles were the most frequent source of fatal CO exposure, followed by heating systems and generators. ConclusionsCO has been the most frequent cause of occupational fatality due to acute inhalation, and has shown no significant decreasing trend since 1992. The high number of fatalities from motor vehicles warrants further investigation. Am. J. Ind. Med. 56:1280-1289, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Henn, Scott A.; Sussell, Aaron L.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Bell, Jennifer L.; Konda, Srinivas] NIOSH, Div Safety Res, Morgantown, WV 26505 USA. RP Henn, SA (reprint author), NIOSH, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM shenn@cdc.gov RI Konda, Srinivas/G-2747-2015 OI Konda, Srinivas/0000-0002-8934-4111 FU Intramural CDC HHS [CC999999] NR 39 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2013 VL 56 IS 11 BP 1280 EP 1289 DI 10.1002/ajim.22226 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 230QH UT WOS:000325356700004 PM 23868822 ER PT J AU Ma, CC Burchfiel, CM Charles, LE Dorn, JM Andrew, ME Gu, JK Joseph, PN Fekedulegn, D Slaven, JE Hartley, TA Mnatsakanova, A Violanti, JM AF Ma, Claudia C. Burchfiel, Cecil M. Charles, Luenda E. Dorn, Joan M. Andrew, Michael E. Gu, Ja Kook Joseph, Parveen Nedra Fekedulegn, Desta Slaven, James E. Hartley, Tara A. Mnatsakanova, Anna Violanti, John M. TI Associations of Objectively Measured and Self-Reported Sleep Duration With Carotid Artery Intima Media Thickness Among Police Officers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE carotid artery intima media thickness; occupational epidemiology; sleep duration; actigraphy ID CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; RISK-FACTORS; PHYSICAL-ACTIVITY; NATIONAL-HEALTH; SHIFT WORK; STRESS; COHORT; ADULTS; METAANALYSIS AB BackgroundWe aimed to examine the association of objectively measured and self-reported sleep duration with carotid artery intima media thickness (IMT) among 257 police officers, a group at high risk for cardiovascular disease (CVD). MethodsSleep duration was estimated using actigraphic data and through self-reports. The mean maximum IMT was the average of the largest 12 values scanned bilaterally from three angles of the near and far wall of the common carotid, bulb, and internal carotid artery. Linear and quadratic regression models were used to assess the association of sleep duration with IMT. ResultsOfficers who had fewer than 5 or 8hr or more of objectively measured sleep duration had significantly higher maximum IMT values, independent of age. Self-reported sleep duration was not associated with either IMT measure. ConclusionAttainment of sufficient sleep duration may be considered as a possible strategy for atherosclerosis prevention among police officers. Am. J. Ind. Med. 56:1341-1351, 2013. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Ma, Claudia C.; Burchfiel, Cecil M.; Charles, Luenda E.; Andrew, Michael E.; Gu, Ja Kook; Joseph, Parveen Nedra; Fekedulegn, Desta; Slaven, James E.; Hartley, Tara A.; Mnatsakanova, Anna] NIOSH, HELD, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Dorn, Joan M.; Violanti, John M.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Dorn, Joan M.] Ctr Dis Control & Prevent, Off Noncommunicable Dis, Natl Ctr Chron Dis Prevent & Hlth Promot Injury &, Atlanta, GA USA. [Joseph, Parveen Nedra] Univ Chicago, Ctr Comprehens Canc, Epidemiol & Res Recruitment Core, Chicago, IL 60637 USA. [Slaven, James E.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. RP Ma, CC (reprint author), NIOSH, HELD, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM iia4@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX Contract grant sponsor: National Institute for Occupational Safety and Health (NIOSH); Contract grant number: 200-2003-01580. NR 60 TC 5 Z9 5 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2013 VL 56 IS 11 BP 1341 EP 1351 DI 10.1002/ajim.22236 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 230QH UT WOS:000325356700010 PM 24038303 ER PT J AU Mulloy, KB Sumner, SA Rose, C Conway, GA Reynolds, SJ Davidson, ME Heidel, DS Layde, PM AF Mulloy, Karen B. Sumner, Steven A. Rose, Cecile Conway, George A. Reynolds, Stephen J. Davidson, Margaret E. Heidel, Donna S. Layde, Peter M. TI Renewable Energy and Occupational Health and Safety Research Directions: A White Paper from the Energy Summit, Denver Colorado, April 11-13, 2011 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Review DE occupational health and safety; renewable energy industry; extractive energy industry; Hazards ID LIFE-CYCLE ASSESSMENT; WORK-RELATED SYMPTOMS; BIODIESEL PRODUCTION; LUNG-FUNCTION; RESPIRATORY SYMPTOMS; SAWMILL WORKERS; PULMONARY-FUNCTION; URANIUM MINERS; EXPOSURE ASSESSMENT; PERSONAL EXPOSURES AB Renewable energy production may offer advantages to human health by way of less pollution and fewer climate-change associated ill-health effects. Limited data suggests that renewable energy will also offer benefits to workers in the form of reduced occupational injury, illness and deaths. However, studies of worker safety and health in the industry are limited. The Mountain and Plains Education and Research Center (MAP ERC) Energy Summit held in April 2011 explored issues concerning worker health and safety in the renewable energy industry. The limited information on hazards of working in the renewable energy industry emphasizes the need for further research. Two basic approaches to guiding both prevention and future research should include: (1) applying lessons learned from other fields of occupational safety and health, particularly the extractive energy industry; and (2) utilizing knowledge of occupational hazards of specific materials and processes used in the renewable energy industry. Am. J. Ind. Med. 56:1359-1370, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Mulloy, Karen B.] Colorado Sch Publ Hlth, Dept Environm & Occupat Hlth, Aurora, CO 80045 USA. [Sumner, Steven A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Rose, Cecile] Natl Jewish Hlth, Div Environm & Occupat Hlth, Denver, CO USA. [Conway, George A.] NIOSH, Agr Forestry & Fishing Program, Alaska Pacific Reg Off, Ctr Dis Control & Prevent, Anchorage, AK USA. [Reynolds, Stephen J.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Davidson, Margaret E.] Colorado State Univ, High Plains Intermt Ctr Agr Hlth & Safety, Ft Collins, CO 80523 USA. [Heidel, Donna S.] NIOSH, Educ & Informat Div, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Layde, Peter M.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA. [Layde, Peter M.] Med Coll Wisconsin, Injury Res Ctr, Milwaukee, WI 53226 USA. RP Mulloy, KB (reprint author), Colorado Sch Publ Hlth, Dept Environm & Occupat Hlth, 13001 E 17th Pl,B119, Aurora, CO 80045 USA. EM kbmulloydo@gmail.com FU Mountain and Plains Education and Research Center; NIOSH [T42 OH009229-05] FX The 1st Annual Energy Summit was sponsored by the Mountain and Plains Education and Research Center with the Grant sponsor: NIOSH; Grant number: T42 OH009229-05. NR 124 TC 4 Z9 5 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2013 VL 56 IS 11 BP 1359 EP 1370 DI 10.1002/ajim.22184 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 230QH UT WOS:000325356700012 PM 23996832 ER PT J AU Hartley, S Valley, S Kuhn, L Washer, LL Gandhi, T Meddings, J Chenoweth, C Malani, AN Saint, S Srinivasan, A Flanders, SA AF Hartley, Sarah Valley, Staci Kuhn, Latoya Washer, Laraine L. Gandhi, Tejal Meddings, Jennifer Chenoweth, Carol Malani, Anurag N. Saint, Sanjay Srinivasan, Arjun Flanders, Scott A. TI Inappropriate Testing for Urinary Tract Infection in Hospitalized Patients: An Opportunity for Improvement SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; DISEASES-SOCIETY; AMERICA; DIAGNOSIS; BACTERIURIA; ADULTS AB Urine cultures are frequently obtained for hospitalized patients. We reviewed documented indications for culture and compared these with professional society guidelines. Lack of documentation and important clinical scenarios (before orthopedic procedures and when the patient has altered mental status without a urinary catheter) are highlighted as areas of use outside of current guidelines. C1 [Hartley, Sarah; Valley, Staci; Washer, Laraine L.; Gandhi, Tejal; Meddings, Jennifer; Chenoweth, Carol; Saint, Sanjay; Flanders, Scott A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Kuhn, Latoya; Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. [Kuhn, Latoya; Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Hosp Outcomes Program Excellence, Ann Arbor, MI USA. [Washer, Laraine L.] Univ Michigan, Dept Infect Control & Epidemiol, Ann Arbor, MI 48109 USA. [Malani, Anurag N.] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA. [Srinivasan, Arjun] Ctr Dis Control & Prevent, Healthcare Associated Infect Prevent Programs, Div Healthcare Qual Promot, Atlanta, GA USA. RP Hartley, S (reprint author), Univ Michigan Hlth Syst, 1500 East Med Ctr Dr,SPC 5736, Ann Arbor, MI 48109 USA. EM hartsara@med.umich.edu FU Centers for Disease Control and Prevention (CDC) Foundation [N011987] FX This project was funded by the Centers for Disease Control and Prevention (CDC) Foundation (grant N011987 to S. A. F.). Other than initial scientific review and approval for funding, the CDC Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 10 TC 12 Z9 12 U1 0 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV 1 PY 2013 VL 34 IS 11 BP 1204 EP 1207 DI 10.1086/673449 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 232KB UT WOS:000325491500012 PM 24113606 ER PT J AU Kuhar, DT Henderson, DK Struble, KA Heneine, W Thomas, V Cheever, LW Gomaa, A Panlilio, AL AF Kuhar, D. T. Henderson, D. K. Struble, K. A. Heneine, W. Thomas, V Cheever, L. W. Gomaa, A. Panlilio, A. L. CA US Public Hlth Serv Working Grp TI Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis (vol 34, pg 875, 2013) SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Correction C1 [Gomaa, A.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Atlanta, GA USA. NR 1 TC 3 Z9 3 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV 1 PY 2013 VL 34 IS 11 BP 1238 EP 1238 DI 10.1086/673726 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 232KB UT WOS:000325491500023 ER PT J AU Afdhal, NH Zeuzem, S Schooley, RT Thomas, DL Ward, JW Litwin, AH Razavi, H Castera, L Poynard, T Muir, A Mehta, SH Dee, L Graham, C Church, DR Talal, AH Sulkowski, MS Jacobson, IM AF Afdhal, N. H. Zeuzem, S. Schooley, R. T. Thomas, D. L. Ward, J. W. Litwin, A. H. Razavi, H. Castera, L. Poynard, T. Muir, A. Mehta, S. H. Dee, L. Graham, C. Church, D. R. Talal, A. H. Sulkowski, M. S. Jacobson, I. M. CA New Paradigm HCV Therapy Meeting TI The new paradigm of hepatitis C therapy: integration of oral therapies into best practices SO JOURNAL OF VIRAL HEPATITIS LA English DT Review DE diagnosis; directly acting antiviral agents; health services; hepatitis C; pharmacoeconomics ID GENOTYPE 1 INFECTION; SUSTAINED VIROLOGICAL RESPONSE; RANDOMIZED CONTROLLED-TRIAL; SOFOSBUVIR PLUS RIBAVIRIN; VIRUS-ANTIBODY ASSAYS; UNITED-STATES; INJECT DRUGS; ANTIVIRAL TREATMENT; TRANSIENT ELASTOGRAPHY; COST-EFFECTIVENESS AB Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels. C1 [Afdhal, N. H.] Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02215 USA. [Afdhal, N. H.] Harvard Univ, Sch Med, Boston, MA USA. [Zeuzem, S.] JW Goethe Univ Hosp, Dept Med, Frankfurt, Germany. [Schooley, R. T.] Univ Calif, San Diego Sch Med, Div Infect Dis, La Jolla, CA USA. [Thomas, D. L.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Ward, J. W.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Litwin, A. H.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Litwin, A. H.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA. [Razavi, H.] Ctr Dis Anal, Louisville, CO USA. [Castera, L.] Hop Beaujon, AP HP, Serv Hepatol, Clichy, France. [Poynard, T.] Grp Hosp Pitie Salpetriere, Serv Hepatol, F-75634 Paris, France. [Muir, A.] Duke Clin Res Inst, Gastroenterol & Hepatol Res Grp, Durham, NC USA. [Mehta, S. H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Dee, L.] Fair Pricing Coalit & AIDS Act Baltimore, Baltimore, MD USA. [Graham, C.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Church, D. R.] Bur Infect Dis, Massachusetts Dept Publ Hlth, Boston, MA USA. [Talal, A. H.] SUNY Buffalo, Dept Internal Med, Div Gastroenterol & Hepatol, Buffalo, NY 14260 USA. [Sulkowski, M. S.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Jacobson, I. M.] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY USA. RP Afdhal, NH (reprint author), Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, 110 Francis St, Boston, MA 02215 USA. EM nafdhal@caregroup.harvard.edu FU Abbott Laboratories; Bristol-Myers Squibb; Gilead Sciences, Inc.; GlaxoSmithKline; Merck Co, Inc.; Vertex Pharmaceuticals, Inc.; Achillion Pharmaceuticals, Inc.; Boehringer Ingelheim; Idenix Pharmaceuticals; Janssen Therapeutics; Merck Co.; Novartis Pharmaceutical Corporation; Roche; Presidio Pharmaceuticals, Inc.; Santaris Pharma A/S; Achillion Pharmaceuticals; GlobeImmune Inc.; Medtronic, Inc.; Merck Co., Inc.; Pfizer, Inc.; Scynexis, Inc.; Tibotec Pharmaceuticals, Ltd.; AbbVie Pharmaceuticals; Vertex Pharmaceuticals FX The following authors disclose financial relationships with one or more meeting sponsors. Nezam H. Afdhal: research support from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Merck & Co, Inc., and Vertex Pharmaceuticals, Inc.; consultant or advisory arrangements with Boehringer Ingelheim, Echosens, Gilead Sciences, Inc., GlaxoSmithKline, Kadmon Corporation, Ligand Pharmaceuticals, Inc., Medgenics Inc., Merck & Co., Inc., Novartis Pharmaceutical Corporation, Spring Bank Pharmaceuticals, Inc., Quest Diagnostics, and Vertex Pharmaceuticals, Inc.; and stock ownership in Medgenics, Inc. and Spring Bank Pharmaceuticals, Inc. Ira M. Jacobson: advisor for AbbVie Pharmaceuticals, Achillion Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Enanta Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Idenix Pharmaceuticals, Kadmon Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Genentech, Inc., Janssen Therapeutics, and Vertex Pharmaceuticals, Inc.; consultant for Abbott Laboratories, Achillion Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Enanta Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Idenix Pharmaceuticals, Kadmon Corporation, Merck & Co., Inc., Novartis Pharmaceutical Corporation, Genentech, Inc., Janssen Therapeutics, and Vertex Pharmaceuticals, Inc.; grant support from Abbott Laboratories, Achillion Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Novartis Pharmaceutical Corporation, Pfizer Inc., Genentech, Inc., Janssen Therapeutics, and Vertex Pharmaceuticals, Inc.; and speakers bureau for Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Genentech, Inc., and Vertex Pharmaceuticals, Inc. Stefan Zeuzem: honoraria and consultant fees from Abbott Laboratories, Achillion Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc., Idenix Pharmaceuticals, Janssen Therapeutics, Merck & Co., Novartis Pharmaceutical Corporation, Roche, Presidio Pharmaceuticals, Inc., Santaris Pharma A/S, and Vertex Pharmaceuticals, Inc.; and speakers bureau for Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Therapeutics, Merck & Co., and Vertex Pharmaceuticals, Inc. Robert Schooley: grant support from Boehringer Ingelheim and Bristol-Myers Squibb; consultant for Johnson & Johnson, Merck & Co., and Santaris Pharma A/S; board member for Gilead Sciences, Inc., GlobeImmune Inc., and Monogram Biosciences; stock ownership in GlobeImmune Inc. and Achillion Pharmaceuticals. David L. Thomas: grant support from Merck & Co., Inc.; consultant for Gilead Sciences, Inc., Janssen Therapeutics, and Merck & Co.; provisions of medicines, equipment, or administrative support from Gilead Sciences, Inc.; medications for Nitt Study from Merck & Co., Inc. Alain Litwin: consultant for Boehringer Ingelheim, Janssen Therapeutics, Kadmon Corporation, and Gilead Sciences, Inc.; grant support from Vertex Pharmaceuticals, Inc. Homie Razavi: consultant for Abbott Laboratories, Boehringer Ingelheim, Gilead Sciences, Inc., Merck & Co., Inc., Novartis Pharmaceutical Corporation, and Vertex Pharmaceuticals, Inc. Laurent Castera: speakers bureau for Gilead Sciences, Inc., Janssen Therapeutics, and Merck & Co. Inc.; board member for Merck & Co., Inc., Bristol-Myers Squibb, and Gilead Sciences, Inc. Thierry Poynard: speakers bureau and consultant for Merck & Co., Inc.; stock ownership in BioPredictive.; Andrew Muir: grant support from Abbott Laboratories, Achillion Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, GlobeImmune Inc., Medtronic, Inc., Merck & Co., Inc., Pfizer, Inc., Roche, Scynexis, Inc., and Vertex Pharmaceuticals, Inc.; consultant for Achillion Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Profectus Biosciences, Inc., Scynexis, Inc., and Vertex Pharmaceuticals, Inc. Camilla Graham, former employee of Vertex Pharmaceuticals (left 9/28/12), Andrew Talal: grant support from Abbott Laboratories, Bristol-Myers Squibb, Boehinger Ingelheim, Roche, Gilead Sciences, Inc., Merck & Co., Inc., Tibotec Pharmaceuticals, Ltd., and Vertex Pharmaceuticals, Inc.; advisor for Abbott Diagnostics, Boehringer Ingelheim, Merck & Co., and Pfizer, Inc.; developed educational presentations for Medscape and Merck & Co., Inc. Mark Sulkowski: advisor and consultant for AbbVie Pharmaceuticals, Boehinger Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc., Idenix Pharmaceuticals, Janssen Therapeutics, Merck & Co., Inc., Roche, and Vertex Pharmaceuticals; grants from AbbVie Pharmaceuticals, Boehinger Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen Therapeutics, Merck & Co., Inc., Roche, and Vertex Pharmaceuticals. Daniel Church, Lynda Dee, and Shruti Mehta have no potential conflicts to disclose. John Ward has no potential conflicts of interest to disclose; the findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 112 TC 42 Z9 46 U1 2 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD NOV PY 2013 VL 20 IS 11 BP 745 EP 760 DI 10.1111/jvh.12173 PG 16 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 231ZA UT WOS:000325455700001 ER PT J AU Kis, Z Jones, J Creanga, A Ferdinand, K Inui, K Gerloff, N Davis, CT Nguyen, T Donis, RO AF Kis, Z. Jones, J. Creanga, A. Ferdinand, K. Inui, K. Gerloff, N. Davis, C. T. Nguyen, T. Donis, R. O. TI Real-time RT-PCR assay to differentiate clades of H5N1 avian influenza viruses circulating in Vietnam SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Highly pathogenic avian influenza; H5N1; Real-time RT-PCR; Cade-differentiation; Vietnam ID LIVE POULTRY MARKETS; CONTINUED EVOLUTION; SUBTYPE H5N1; WILD BIRDS; CHINA; NOMENCLATURE; SPREAD; EGYPT; FARMS AB Continued circulation and geographical expansion of highly pathogenic avian influenza H5N1 virus have led to the emergence of numerous clades in Vietnam. Although viral RNA sequencing and phylogenetic analysis are the gold standard for H5N1 HA clade designation, limited sequencing capacity in many laboratories precludes rapid H5N1 clade identification and detection of novel viruses. Therefore, a Taqman real-time RT-PCR assay for rapid differentiation of the four major H5N1 clades detected in Vietnam was developed. Using HA sequence alignments of clades 1.1, 2.3.2.1, 2.3.4, and 7 viruses, primers and FAM-labeled probes were designed to target conserved regions characteristic of each clade. The assay was optimized and evaluated using circulating clades of H5N1 collected in Vietnam from 2007 to 2012 and shown to be both sensitive and specific for the differentiation of the four H5N1 clades. The assay provides a useful tool for screening of large specimen collections for HA gene sequencing and phylogenetic analysis and for the rapid identification of molecular clade signatures to support outbreak investigations and surveillance activities. Finally, this assay may be useful to monitor for the emergence of novel or variant clades of H5N1 in Vietnam in the future or in other countries where these particular clades may circulate. (C) 2013 Elsevier B.V. All rights reserved. C1 [Kis, Z.; Jones, J.; Creanga, A.; Ferdinand, K.; Gerloff, N.; Davis, C. T.; Donis, R. O.] CDC, Influenza Div, Atlanta, GA 30333 USA. [Kis, Z.] Natl Ctr Epidemiol, Budapest, Hungary. [Inui, K.] Food & Agr Org Vietnam, Hanoi, Vietnam. [Nguyen, T.] Hanoi Univ Agr, Grad Sch, Hanoi, Vietnam. [Nguyen, T.] Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam. RP Donis, RO (reprint author), Ctr Dis Control & Prevent, NCIRD, Influenza Div, 1600 Clifton Rd NE,MS G16, Atlanta, GA 30333 USA. EM rvd6@cdc.gov RI Gerloff, Nancy/C-8955-2015 OI Gerloff, Nancy/0000-0001-5696-8318 NR 28 TC 6 Z9 6 U1 0 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2013 VL 193 IS 2 BP 452 EP 458 DI 10.1016/j.jviromet.2013.06.023 PG 7 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 228MH UT WOS:000325190400032 PM 23850699 ER PT J AU Kodani, M Martin, A Mixson-Hayden, T Drobeniuc, J Gish, RR Kamili, S AF Kodani, Maja Martin, Alyssa Mixson-Hayden, Tonya Drobeniuc, Jan Gish, Robert R. Kamili, Saleem TI One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Hepatitis D virus; qRT-PCR; One-step; Detection; Quantitation ID REVERSE TRANSCRIPTION-PCR; DELTA-VIRUS; SERUM; QUANTIFICATION; REPLICATION; POLYMERASE; KINETICS; GENOME AB Hepatitis D virus (HDV) is a defective virus which requires hepatitis B virus (HBV) surface antigen (HBsAg) for its assembly. Hepatitis B infected individuals co-infected or superinfected with HDV often present with more severe hepatitis, progress faster to liver disease, and have a higher mortality rate than individuals infected with HBV alone. Currently, there are no commercially available clinical tests for the detection and quantitation of HDV RNA in the United States. A one-step TaqMan quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was developed for detection of HDV RNA, designing primers located in the region just downstream from the HDV antigen gene. The assay has the potential to detect all eight HDV genotypes. A quantifiable synthetic RNA control was also developed for use in the determination of HDV RNA titers in clinical samples. The limit of detection of this assay is 7.5 x 10(2) HDV RNA copies/ml with a dynamic range of six logs. Most clinical specimens tested (40/41) fell within the linear range of the assay. The median HDV RNA titer of the tested specimens was 6.24 x 10(6) copies/ml, with a range of 8.52 x 10(3)-1.79 x 10(9) copies/ml. Out of 132 anti-HDV-positive specimens 41 (31.1%) were positive for HDV RNA. Published by Elsevier B.V. C1 [Kodani, Maja; Martin, Alyssa; Mixson-Hayden, Tonya; Drobeniuc, Jan; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Gish, Robert R.] UC San Diego Hlth Syst, Dept Med, San Diego, CA 92103 USA. RP Kamili, S (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MailStop A33, Atlanta, GA 30333 USA. EM skamili@cdc.gov NR 21 TC 8 Z9 8 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2013 VL 193 IS 2 BP 531 EP 535 DI 10.1016/j.jviromet.2013.07.033 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 228MH UT WOS:000325190400046 PM 23896020 ER PT J AU Bousse, T Shore, DA Goldsmith, CS Hossain, MJ Jang, Y Davis, CT Donis, RO Stevens, J AF Bousse, Tatiana Shore, David A. Goldsmith, Cynthia S. Hossain, M. Jaber Jang, Yunho Davis, Charles T. Donis, Ruben O. Stevens, James TI Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Influenza virus; Vaccine; Field flow fractionation; Multiangle light scattering ID VACCINE PRODUCTION; MDCK CELLS; PROTEIN; RECOMBINANTS; GENERATION; MORPHOLOGY; GROWTH; LIVE; DNA AB Recent advances in instrumentation and data analysis in field flow fractionation and multi-angle light scattering (FFF-MALS) have enabled greater use of this technique to characterize and quantitate viruses. In this study, the FFF-MALS technique was applied to the characterization and quantitation of type A influenza virus particles to assess its usefulness for vaccine preparation. The use of FFF-MALS for quantitation and measurement of control particles provided data accurate to within 5% of known values, reproducible with a coefficient of variation of 1.9%. The methods, sensitivity and limit of detection were established by analyzing different volumes of purified virus, which produced a linear regression with fitting value R-2 of 0.99. FFF-MALS was further applied to detect and quantitate influenza virus in the supernatant of infected MDCK cells and allantoic fluids of infected eggs. FFF fractograms of the virus present in these different fluids revealed similar distribution of monomeric and oligomeric virions. However, the monomer fraction of cell grown virus had greater size variety. Notably, beta-propialactone (BPL) inactivation of influenza viruses did not influence any of the FFF-MALS measurements. Quantitation analysis by FFF-MALS was compared to infectivity assays and real-time RT-PCR (qRT-PCR) and the limitations of each assay were discussed. Published by Elsevier B.V. C1 [Bousse, Tatiana; Shore, David A.; Hossain, M. Jaber; Jang, Yunho; Davis, Charles T.; Donis, Ruben O.; Stevens, James] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, CCID, NCIRD, Influenza Div, 1600 Clifton Rd,Mail Stop D-30, Atlanta, GA 30333 USA. EM fwb4@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. We would like to thank Michelle Chen and the technical scientists at the Wyatt Technology Corporation for their careful reading of the manuscript and helpful advice. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR 41 TC 10 Z9 10 U1 0 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2013 VL 193 IS 2 BP 589 EP 596 DI 10.1016/j.jviromet.2013.07.026 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 228MH UT WOS:000325190400056 PM 23916678 ER PT J AU Hofstetter, AR De La Cruz, JA Patel, JR McCoy, JW Cao, WP Kim, JH Diebold, BA Belser, JA Tumpey, TM Katz, JM Sambhara, S Gangappa, S Lambeth, JD AF Hofstetter, Amelia Ruth De La Cruz, Juan A. Patel, Jenish R. McCoy, James W. Cao, Weiping Kim, Jin H. Diebold, Becky A. Belser, Jessica A. Tumpey, Terrence M. Katz, Jacqueline M. Sambhara, Suryaprakash Gangappa, Shivaprakash Lambeth, J. David TI Nox1 as a Therapeutic Target to Improve Survival in Influenza a Infection SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract C1 [Hofstetter, Amelia Ruth; McCoy, James W.; Diebold, Becky A.; Lambeth, J. David] Emory Univ, Atlanta, GA 30322 USA. [Hofstetter, Amelia Ruth; De La Cruz, Juan A.; Patel, Jenish R.; Cao, Weiping; Kim, Jin H.; Belser, Jessica A.; Tumpey, Terrence M.; Katz, Jacqueline M.; Sambhara, Suryaprakash; Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Atlanta, GA USA. OI Hofstetter, Amelia/0000-0003-4113-5473 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD NOV 1 PY 2013 VL 65 SU 2 MA 282 BP S125 EP S125 DI 10.1016/j.freeradbiomed.2013.10.706 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA V40JU UT WOS:000209475700300 ER PT J AU Honein, MA Moore, CA AF Honein, Margaret A. Moore, Cynthia A. TI The Safety or Risk of Antihistamine Use in Pregnancy: Reassuring Data Are Helpful but Not Sufficient SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Editorial Material C1 [Honein, Margaret A.; Moore, Cynthia A.] Ctr Dis Control, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Honein, MA (reprint author), Ctr Dis Control, Birth Defects Branch, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM mrh7@cdc.gov FU Intramural CDC HHS [CC999999] NR 12 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD NOV-DEC PY 2013 VL 1 IS 6 BP 675 EP 676 DI 10.1016/j.jaip.2013.08.005 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA V38WY UT WOS:000209374700017 PM 24565716 ER PT J AU Sandt, CH Fedorka-Cray, PJ Tewari, D Ostroff, S Joyce, K M'ikanatha, NM AF Sandt, Carol H. Fedorka-Cray, Paula J. Tewari, Deepanker Ostroff, Stephen Joyce, Kevin M'ikanatha, Nkuchia M. TI A Comparison of Non-Typhoidal Salmonella from Humans and Food Animals Using Pulsed-Field Gel Electrophoresis and Antimicrobial Susceptibility Patterns SO PLOS ONE LA English DT Article ID SEROTYPE ENTERITIDIS INFECTIONS; UNITED-STATES; FOODBORNE ILLNESS; RISK-FACTORS; DIVERSITY; SITES AB Salmonellosis is one of the most important foodborne diseases affecting humans. To characterize the relationship between Salmonella causing human infections and their food animal reservoirs, we compared pulsed-field gel electrophoresis (PFGE) and antimicrobial susceptibility patterns of non-typhoidal Salmonella isolated from ill humans in Pennsylvania and from food animals before retail. Human clinical isolates were received from 2005 through 2011 during routine public health operations in Pennsylvania. Isolates from cattle, chickens, swine and turkeys were recovered during the same period from federally inspected slaughter and processing facilities in the northeastern United States. We found that subtyping Salmonella isolates by PFGE revealed differences in antimicrobial susceptibility patterns and, for human Salmonella, differences in sources and invasiveness that were not evident from serotyping alone. Sixteen of the 20 most common human Salmonella PFGE patterns were identified in Salmonella recovered from food animals. The most common human Salmonella PFGE pattern, Enteritidis pattern JEGX01.0004 (JEGX01.0003ARS), was associated with more cases of invasive salmonellosis than all other patterns. In food animals, this pattern was almost exclusively (99%) found in Salmonella recovered from chickens and was present in poultry meat in every year of the study. Enteritidis pattern JEGX01.0004 (JEGX01.0003ARS) was associated with susceptibility to all antimicrobial agents tested in 94.7% of human and 97.2% of food animal Salmonella isolates. In contrast, multidrug resistance (resistance to three or more classes of antimicrobial agents) was observed in five PFGE patterns. Typhimurium patterns JPXX01.0003 (JPXX01.0003 ARS) and JPXX01.0018 (JPXX01.0002 ARS), considered together, were associated with resistance to five or more classes of antimicrobial agents: ampicillin, chloramphenicol, streptomycin, sulfonamides and tetracycline (ACSSuT), in 92% of human and 80% of food animal Salmonella isolates. The information from our study can assist in source attribution, outbreak investigations, and tailoring of interventions to maximize their impact on prevention. C1 [Sandt, Carol H.] Penn Dept Hlth, Bur Labs, Exton, PA USA. [Fedorka-Cray, Paula J.] ARS, USDA, Athens, GA USA. [Ostroff, Stephen; M'ikanatha, Nkuchia M.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. [Tewari, Deepanker] Penn Dept Agr, Penn Vet Lab, Harrisburg, PA USA. [Joyce, Kevin] Ctr Dis Control & Prevent, Natl Antimicrobial Resistance Monitoring Syst, Atlanta, GA USA. RP Sandt, CH (reprint author), Penn Dept Hlth, Bur Labs, Exton, PA USA. EM csandt@pa.gov FU Pennsylvania Department of Health through Centers for Disease Control and Prevention grant for National Antimicrobial Resistance Monitoring [ELC-04040] FX This study was supported in part by the Pennsylvania Department of Health through Centers for Disease Control and Prevention grant (ELC-04040) for National Antimicrobial Resistance Monitoring. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 10 Z9 10 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 30 PY 2013 VL 8 IS 10 AR e77836 DI 10.1371/journal.pone.0077836 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 243RL UT WOS:000326334500067 PM 24204990 ER PT J AU Sejvar, JJ AF Sejvar, James J. TI Influenza vaccines and Guillain-Barre syndrome The continuing question SO NEUROLOGY LA English DT Editorial Material ID SYNDROME FOLLOWING VACCINATION; IMMUNIZATION C1 Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. EM zea3@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD OCT 29 PY 2013 VL 81 IS 18 BP 1562 EP 1563 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AA0FB UT WOS:000330769800007 PM 24166961 ER PT J AU Fonjungo, PN Kebede, Y Arneson, W Tefera, D Yimer, K Kinde, S Alem, M Cheneke, W Mitiku, H Tadesse, E Tsegaye, A Kenyon, T AF Fonjungo, Peter N. Kebede, Yenew Arneson, Wendy Tefera, Derese Yimer, Kedir Kinde, Samuel Alem, Meseret Cheneke, Waqtola Mitiku, Habtamu Tadesse, Endale Tsegaye, Aster Kenyon, Thomas TI Preservice laboratory education strengthening enhances sustainable laboratory workforce in Ethiopia SO HUMAN RESOURCES FOR HEALTH LA English DT Article DE Preservice education; PEPFAR; Curriculum; Standardization; Laboratory workforce strengthening; Training; Sustainability ID SUB-SAHARAN AFRICA; ANTIRETROVIRAL TREATMENT; HEALTH SYSTEMS; HIV/AIDS CARE; DELIVERY AB Background: There is a severe healthcare workforce shortage in sub Saharan Africa, which threatens achieving the Millennium Development Goals and attaining an AIDS-free generation. The strength of a healthcare system depends on the skills, competencies, values and availability of its workforce. A well-trained and competent laboratory technologist ensures accurate and reliable results for use in prevention, diagnosis, care and treatment of diseases. Methods: An assessment of existing preservice education of five medical laboratory schools, followed by remedial intervention and monitoring was conducted. The remedial interventions included 1) standardizing curriculum and implementation; 2) training faculty staff on pedagogical methods and quality management systems; 3) providing teaching materials; and 4) procuring equipment for teaching laboratories to provide practical skills to complement didactic education. Results: A total of 2,230 undergraduate students from the five universities benefitted from the standardized curriculum. University of Gondar accounted for 252 of 2,230 (11.3%) of the students, Addis Ababa University for 663 (29.7%), Jimma University for 649 (29.1%), Haramaya University for 429 (19.2%) and Hawassa University for 237 (10.6%) of the students. Together the universities graduated 388 and 312 laboratory technologists in 2010/2011 and 2011/2012 academic year, respectively. Practical hands-on training and experience with well-equipped laboratories enhanced and ensured skilled, confident and competent laboratory technologists upon graduation. Conclusions: Strengthening preservice laboratory education is feasible in resource-limited settings, and emphasizing its merits (ample local capacity, country ownership and sustainability) provides a valuable source of competent laboratory technologists to relieve an overstretched healthcare system. C1 [Fonjungo, Peter N.; Kebede, Yenew; Tefera, Derese; Yimer, Kedir; Kenyon, Thomas] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Addis Ababa, Ethiopia. [Arneson, Wendy] Amer Soc Clin Pathologists, Chicago, IL USA. [Kinde, Samuel; Tsegaye, Aster] Univ Addis Ababa, Sch Allied Hlth Sci, Coll Hlth Sci, Dept Med Lab Sci, Addis Ababa, Ethiopia. [Alem, Meseret] Univ Gondar, Sch Biomed & Lab Sci, Coll Med & Hlth Sci, Gondar, Ethiopia. [Cheneke, Waqtola] Jimma Univ, Dept Med Lab Sci & Pathol, Coll Publ Hlth & Med Sci, Jimma, Ethiopia. [Mitiku, Habtamu] Haramaya Univ, Dept Med Lab Sci, Coll Hlth & Med Sci, Harar, Ethiopia. [Tadesse, Endale] Hawassa Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Hawassa, Ethiopia. [Fonjungo, Peter N.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Fonjungo, PN (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Addis Ababa, Ethiopia. EM pdf4@cdc.gov OI Tsegaye, Aster/0000-0002-9026-4629 FU PEPFAR; PHS HHS [5U2GPS1285] NR 22 TC 1 Z9 1 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-4491 J9 HUM RESOUR HEALTH JI Hum. Resour. Health PD OCT 28 PY 2013 VL 11 AR 56 DI 10.1186/1478-4491-11-56 PG 7 WC Health Policy & Services; Industrial Relations & Labor SC Health Care Sciences & Services; Business & Economics GA 260MV UT WOS:000327599900001 PM 24164781 ER PT J AU Lu, PJ Santibanez, TA Williams, WW Zhang, J Ding, HL Bryan, L O'Halloran, A Greby, SM Bridges, CB Graitcer, SB Kennedy, ED Lindley, MC Ahluwalia, IB LaVail, K Pabst, LJ Harris, L Vogt, T Town, M Singleton, JA AF Lu, Peng-jun Santibanez, Tammy A. Williams, Walter W. Zhang, Jun Ding, Helen Bryan, Leah O'Halloran, Alissa Greby, Stacie M. Bridges, Carolyn B. Graitcer, Samuel B. Kennedy, Erin D. Lindley, Megan C. Ahluwalia, Indu B. LaVail, Katherine Pabst, Laura J. Harris, LaTreace Vogt, Tara Town, Machell Singleton, James A. TI Surveillance of Influenza Vaccination Coverage - United States, 2007-08 Through 2011-12 Influenza Seasons SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID HEALTH-CARE PERSONNEL; H1N1 2009 MONOVALENT; AUGUST 2009-JANUARY 2010; HIGH-RISK ADULTS; CHILDREN AGED 6; PREGNANT-WOMEN; PNEUMOCOCCAL VACCINATION; PANDEMIC INFLUENZA; SELF-REPORT; RACIAL/ETHNIC DIFFERENCES AB Problem/Condition: Substantial improvement in annual influenza vaccination of recommended groups is needed to reduce the health effects of influenza and reach Healthy People 2020 targets. No single data source provides season-specific estimates of influenza vaccination coverage and related information on place of influenza vaccination and concerns related to influenza and influenza vaccination. Reporting Period: 2007-08 through 2011-12 influenza seasons. Description of Systems: CDC uses multiple data sources to obtain estimates of vaccination coverage and related data that can guide program and policy decisions to improve coverage. These data sources include the National Health Interview Survey (NHIS), the Behavioral Risk Factor Surveillance System (BRFSS), the National Flu Survey (NFS), the National Immunization Survey (NIS), the Immunization Information Systems (IIS) eight sentinel sites, Internet panel surveys of health-care personnel and pregnant women, and the Pregnancy Risk Assessment and Monitoring System (PRAMS). Results: National influenza vaccination coverage among children aged 6 months-17 years increased from 31.1% during 2007-08 to 56.7% during the 2011-12 influenza season as measured by NHIS. Vaccination coverage among children aged 6 months-17 years varied by state as measured by NIS. Changes from season to season differed as measured by NIS and NHIS. According to IIS sentinel site data, full vaccination (having either one or two seasonal influenza vaccinations, as recommended by the Advisory Committee on Immunization Practices for each influenza season, based on the child's influenza vaccination history) with up to two recommended doses for the 2011-12 season was 27.1% among children aged 6 months-8 years and was 44.3% for the youngest children (aged 6-23 months). Influenza vaccination coverage among adults aged = 18 years increased from 33.0% during 2007-08 to 38.3% during the 2011-12 influenza season as measured by NHIS. Vaccination coverage by age group for the 2011-12 season as measured by BRFSS was < 5 percentage points different from NHIS estimates, whereas NFS estimates were 6-8 percentage points higher than BRFSS estimates. Vaccination coverage among persons aged = 18 years varied by state as measured by BRFSS. For adults aged = 18 years, a doctor's office was the most common place for receipt of influenza vaccination (38.4%, BRFSS; 32.5%, NFS) followed by a pharmacy (20.1%, BRFSS; 19.7%, NFS). Overall, 66.9% of health-care personnel (HCP) reported having been vaccinated during the 2011-12 season, as measured by an Internet panel survey of HCP, compared with 62.4%, as estimated through NHIS. Vaccination coverage among pregnant women was 47.0%, as measured by an Internet panel survey of women pregnant during the influenza season, and 43.0%, as measured by BRFSS during the 2011-12 influenza season. Overall, as measured by NFS, 86.8% of adults aged = 18 years rated the influenza vaccine as very or somewhat effective, and 46.5% of adults aged = 18 years believed their risk for getting sick with influenza if unvaccinated was high or somewhat high. Interpretation: During the 2011-12 season, influenza vaccination coverage varied by state, age group, and selected populations (e.g., HCP and pregnant women), with coverage estimates well below the Healthy People 2020 goal of 70% for children aged 6 months-17 years, 70% for adults aged = 18 years, and 90% for HCP. Public Health Actions: Continued efforts are needed to encourage health-care providers to offer influenza vaccination and to promote public health education efforts among various populations to improve vaccination coverage. Ongoing surveillance to obtain coverage estimates and information regarding other issues related to influenza vaccination (e.g., knowledge, attitudes, and beliefs) is needed to guide program and policy improvements to reduce morbidity and mortality associated with influenza by increasing vaccination rates. Ongoing comparisons of telephone and Internet panel surveys with in-person surveys such as NHIS are needed for appropriate interpretation of data and resulting public health actions. Examination of results from all data sources is necessary to fully assess the various components of influenza vaccination coverage among different populations in the United States. RP Lu, PJ (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 99 TC 57 Z9 58 U1 1 U2 16 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD OCT 25 PY 2013 VL 62 IS 4 BP 1 EP 28 PG 28 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 242JI UT WOS:000326235700001 PM 24157710 ER PT J AU Keckler, MS Reynolds, MG Damon, IK Karem, KL AF Keckler, M. Shannon Reynolds, Mary G. Damon, Inger K. Karem, Kevin L. TI The effects of post-exposure smallpox vaccination on clinical disease presentation: Addressing the data gaps between historical epidemiology and modern surrogate model data SO VACCINE LA English DT Review DE Smallpox vaccination; Prophylactic vaccination; Animal models; Post-exposure vaccination; Orthopoxviruses; Variola virus; Epidemiology; Smallpox; Monkeypox; Vaccinia ID MONKEYPOX VIRUS-INFECTION; VACCINIA VIRUS; INTRAFAMILIAL TRANSMISSION; ORTHOPOXVIRUS INFECTION; ANTIVIRAL TREATMENT; ANTIBODY-RESPONSES; POXVIRUS INFECTION; VARIOLA VIRUS; ANIMAL-MODELS; PRAIRIE DOGS AB Decades after public health interventions - including pre- and post-exposure vaccination - were used to eradicate smallpox, zoonotic orthopoxvirus outbreaks and the potential threat of a release of variola virus remain public health concerns. Routine prophylactic smallpox vaccination of the public ceased worldwide in 1980, and the adverse event rate associated with the currently licensed live vaccinia virus vaccine makes reinstatement of policies recommending routine pre-exposure vaccination unlikely in the absence of an orthopoxvirus outbreak. Consequently, licensing of safer vaccines and therapeutics that can be used post-orthopoxvirus exposure is necessary to protect the global population from these threats. Variola virus is a solely human pathogen that does not naturally infect any other known animal species. Therefore, the use of surrogate viruses in animal models of orthopoxvirus infection is important for the development of novel vaccines and therapeutics. Major complications involved with the use of surrogate models include both the absence of a model that accurately mimics all aspects of human smallpox disease and a lack of reproducibility across model species. These complications limit our ability to model post-exposure vaccination with newer vaccines for application to human orthopoxvirus outbreaks. This review seeks to (1) summarize conclusions about the efficacy of post-exposure smallpox vaccination from historic epidemiological reports and modern animal studies; (2) identify data gaps in these studies; and (3) summarize the clinical features of orthopoxvirus-associated infections in various animal models to identify those models that are most useful for post-exposure vaccination studies. The ultimate purpose of this review is to provide observations and comments regarding available model systems and data gaps for use in improving post-exposure medical countermeasures against orthopoxviruses. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Keckler, M. Shannon; Reynolds, Mary G.; Damon, Inger K.; Karem, Kevin L.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. RP Keckler, MS (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, 1600 Clifton Rd,Mailstop G-06, Atlanta, GA 30333 USA. EM hbq0@cdc.gov FU Intramural CDC HHS [CC999999] NR 97 TC 3 Z9 3 U1 3 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 25 PY 2013 VL 31 IS 45 BP 5192 EP 5201 DI 10.1016/j.vaccine.2013.08.039 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 252HR UT WOS:000326996300006 PM 23994378 ER PT J AU Hopkins, DR Ruiz-Tiben, E Eberhard, ML Roy, SL AF Hopkins, Donald R. Ruiz-Tiben, Ernesto Eberhard, Mark L. Roy, Sharon L. TI Progress Toward Global Eradication of Dracunculiasis - January 2012-June 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Hopkins, Donald R.; Ruiz-Tiben, Ernesto] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Eberhard, Mark L.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, World Hlth Org Collaborating Ctr Res Training & E, Atlanta, GA 30333 USA. RP Roy, SL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM slroy@cdc.gov NR 6 TC 4 Z9 4 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 25 PY 2013 VL 62 IS 42 BP 829 EP 833 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GS UT WOS:000326451200001 ER PT J AU Skillman, D Riek, L Davis, B Harris, JR Nett, RJ AF Skillman, Donald Riek, Laurel Davis, Brian Harris, Julie R. Nett, Randall J. TI Histoplasmosis in a State Where It Is Not Known to Be Endemic - Montana, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FUNGAL-INFECTIONS; UNITED-STATES; DIAGNOSIS; UPDATE C1 [Skillman, Donald] St Peters Med Grp, Helena, MT USA. [Riek, Laurel] Lewis & Clark City Cty Hlth Dept, Helena, MT USA. [Davis, Brian] Billings Clin, Billings, MT USA. [Harris, Julie R.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. [Nett, Randall J.] CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Atlanta, GA 30333 USA. RP Nett, RJ (reprint author), CDC, Career Epidemiol Field Officer Program, Div State & Local Readiness, Atlanta, GA 30333 USA. EM gge5@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 25 PY 2013 VL 62 IS 42 BP 834 EP 837 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GS UT WOS:000326451200002 ER PT J AU Epperson, S Brammer, L Blanton, L Mustaquim, D Kniss, K Steffens, C Abd Elal, AI Gubareva, L Wallis, T Katz, J Villanueva, J Xu, XY Bresee, J Cox, N Finelli, L Oboho, I AF Epperson, Scott Brammer, Lynnette Blanton, Lenee Mustaquim, Desiree Kniss, Krista Steffens, Craig Abd Elal, Anwar Isa Gubareva, Larisa Wallis, Teresa Katz, Jackie Villanueva, Julie Xu, Xiyan Bresee, Joseph Cox, Nancy Finelli, Lyn Oboho, Ikwo CA World Hlth Org Collaborating Ctr TI Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VIRUS; VACCINE; VARIANT C1 [Oboho, Ikwo] CDC, EIS, Atlanta, GA 30333 USA. RP Oboho, I (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM ioboho@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 25 PY 2013 VL 62 IS 42 BP 838 EP 842 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GS UT WOS:000326451200003 ER PT J AU Davis, S Bosserman, E Montgomery, S Woodhall, D Russell, ES AF Davis, Stephanie Bosserman, Elizabeth Montgomery, Susan Woodhall, Dana Russell, Elizabeth S. TI Strongyloidiasis in a Rural Setting - Southeastern Kentucky, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Davis, Stephanie; Bosserman, Elizabeth; Montgomery, Susan; Woodhall, Dana] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Russell, Elizabeth S.] CDC, EIS, Atlanta, GA 30333 USA. RP Davis, S (reprint author), CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM smdavis@cdc.gov NR 4 TC 8 Z9 8 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 25 PY 2013 VL 62 IS 42 BP 843 EP 843 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GS UT WOS:000326451200004 ER PT J AU Leapley, A Cruze, A Mejia-Echeverry, A Stanek, D Quaye, E Vento, S McAuliffe, I Montgomery, SP Samuels, AM AF Leapley, Andrea Cruze, Alazandria Mejia-Echeverry, Alvaro Stanek, Danielle Quaye, Elesi Vento, Stephany McAuliffe, Isabel Montgomery, Susan P. Samuels, Aaron M. TI Strongyloides Infection Among Patients at a Long-Term Care Facility - Florida, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Leapley, Andrea] Florida Int Univ, Miami, FL 33199 USA. [Quaye, Elesi] Florida Dept Health, Bur Publ Hlth Labs Miami, Miami, FL USA. [Vento, Stephany] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [McAuliffe, Isabel; Montgomery, Susan P.; Samuels, Aaron M.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Samuels, AM (reprint author), CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM amsamuels@cdc.gov NR 0 TC 3 Z9 3 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 25 PY 2013 VL 62 IS 42 BP 844 EP 844 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GS UT WOS:000326451200005 ER PT J AU Mase, S Chorba, T Lobue, P Castro, K AF Mase, Sundari Chorba, Terence Lobue, Philip Castro, Kenneth TI Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID TMC207 AB Multidrug-resistant tuberculosis (MDR TB) is caused by Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampin, the two most effective of the four first-line TB drugs (the other two drugs being ethambutol and pyrazinamide). MDR TB includes the subcategory of extensively drug-resistant TB (XDR TB), which is MDR TB with additional resistance to any fluoroquinolone and to at least one of three injectable anti-TB drugs (i.e., kanamycin, capreomycin, or amikacin). MDR TB is difficult to cure, requiring 18-24 months of treatment after sputum culture conversion with a regimen that consists of four to six medications with toxic side effects, and carries a mortality risk greater than that of drug-susceptible TB. Bedaquiline fumarate (Sirturo or bedaquiline) is an oral diarylquinoline. On December 28, 2012, on the basis of data from two Phase IIb trials (i.e., well-controlled trials to evaluate the efficacy and safety of drugs in patients with a disease or condition to be treated, diagnosed, or prevented), the Food and Drug Administration (FDA) approved use of bedaquiline under the provisions of the accelerated approval regulations for "serious or life-threatening illnesses" (21CFR314.500) (Cox EM. FDA accelerated approval letter to Janssen Research and Development. Available at http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384Orig1s000ltr.pdf). This report provides provisional CDC guidelines for FDA-approved and unapproved, or off-label, uses of bedaquiline in certain populations, such as children, pregnant women, or persons with extrapulmonary MDR TB who were not included in the clinical trials for the drug. CDC's Division of TB Elimination developed these guidelines on the basis of expert opinion informed by data from systematic reviews and literature searches. This approach is different from the statutory standards that FDA uses when approving drugs and drug labeling. These guidelines are intended for health-care professionals who might use bedaquiline for the treatment of MDR TB for indicated and off-label uses. Aspects of these guidelines are not identical to current FDA-approved labeling for bedaquiline. Bedaquiline should be used with clinical expert consultation as part of combination therapy (minimum four-drug treatment regimen) and administered by direct observation to adults aged >= 18 years with a diagnosis of pulmonary MDR TB (Food and Drug Administration. SIRTURO [ bedaquiline] tablets label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf). Use of the drug also can be considered for individual patients in other categories (e.g., persons with extrapulmonary TB, children, pregnant women, or persons with HIV or other comorbid conditions) when treatment options are limited. However, further study is required before routine use of bedaquiline can be recommended in these populations. A registry for persons treated with bedaquiline is being implemented by Janssen Therapeutics to track patient outcomes, adverse reactions, laboratory testing results (e.g., diagnosis, drug susceptibility, and development of drug resistance), use of concomitant medications, and presence of other comorbid conditions. Suspected adverse reactions (i.e., any adverse event for which there is a reasonable possibility that the drug caused the adverse event) and serious adverse events (i.e., any adverse event that results in an outcome such as death, hospitalization, permanent disability, or a life-threatening situation) should be reported to Janssen Therapeutics at telephone 1-800-526-7736, to FDA at telephone 1-800-332-1088 or at http://www.fda.gov/medwatch, and to CDC's Emergency Operations Center at telephone 1-770-488-7100. C1 [Mase, Sundari; Chorba, Terence; Lobue, Philip; Castro, Kenneth] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. RP Mase, S (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM fyy0@cdc.gov NR 19 TC 12 Z9 12 U1 1 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD OCT 25 PY 2013 VL 62 IS 9 BP 1 EP 12 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 242JN UT WOS:000326236500001 ER PT J AU Ochomo, EO Bayoh, NM Walker, ED Abongo, BO Ombok, MO Ouma, C Githeko, AK Vulule, J Yan, GY Gimnig, JE AF Ochomo, Eric O. Bayoh, Nabie M. Walker, Edward D. Abongo, Bernard O. Ombok, Maurice O. Ouma, Collins Githeko, Andrew K. Vulule, John Yan, Guiyun Gimnig, John E. TI The efficacy of long-lasting nets with declining physical integrity may be compromised in areas with high levels of pyrethroid resistance SO MALARIA JOURNAL LA English DT Article ID INSECTICIDE-TREATED NETS; ANOPHELES-GAMBIAE COMPLEX; POLYMERASE-CHAIN-REACTION; IMPREGNATED BED NETS; WESTERN KENYA; MALARIA VECTORS; CHILD-MORTALITY; SPATIAL-DISTRIBUTION; EXPERIMENTAL HUT; MOSQUITO NET AB Background: Long-lasting insecticide-treated mosquito nets (LLINs) are a primary malaria prevention strategy in sub-Saharan Africa. However, emergence of insecticide resistance threatens the effectiveness of LLINs. Methods: Cross-sectional surveys of LLINs were conducted in houses of seven and four villages in Gem and Bungoma Districts in western Kenya, respectively. Condition (number and area of holes in the nets), number and species of mosquitoes resting inside them, and insecticidal activity of nets were quantified. Mosquitoes collected inside nets were allowed to lay eggs and progeny tested for susceptibility to deltamethrin and permethrin, pyrethoids commonly deployed in LLINs in western Kenya. Results: In Gem, 83.3% of nets were less than three years old and 32.4% had at least one hole of any size; while in Bungoma, 92% were less than three years old and 48% had at least one hole. No anopheline and five Culex spp. mosquitoes were found resting inside nets in Gem regardless of the number and size of holes, while 552 Anopheles gambiae s.l., five Anopheles funestus s.l. and 137 Culex spp. were in nets in Bungoma. The number of mosquitoes resting inside nets increased with hole areas > 50 cm in Bungoma. In WHO resistance assays, f1 offspring of samples collected in nets in Bungoma were 94 and 65% resistant to deltamethrin and permethrin, respectively. Nets from Bungoma retained strong activity against a susceptible laboratory strain, but not against f1 offspring of field-collected An. gambiae s.s. All An. gambiae s. s. samples collected in nets were homozygous for the kdr genotype L1014S. Conclusions: In areas with pyrethroid resistant vectors, LLINs with modest hole areas permit mosquito entry and feeding, providing little protection against the vectors. LLIN formulations develop large holes within three years of use, diminishing their presupposed lifetime effectiveness. C1 [Ochomo, Eric O.; Bayoh, Nabie M.; Abongo, Bernard O.; Ombok, Maurice O.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu 40100, Kenya. [Ochomo, Eric O.; Ouma, Collins] Maseno Univ, Sch Publ Hlth & Community Dev, Dept Biomed Sci & Technol, Maseno, Kenya. [Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. [Githeko, Andrew K.; Vulule, John] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Yan, Guiyun] Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Sch Biol Sci, Irvine, CA 92717 USA. [Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Ochomo, EO (reprint author), KEMRI CDC Res & Publ Hlth Collaborat, POB 1578, Kisumu 40100, Kenya. EM ericochomo@yahoo.com FU National Science Foundation (NSF) [EF-072377] FX We are grateful to the team of community interviewers and mosquito samplers in Bungoma and Gem, the dedicated KEMRI/CDC entomology team, specifically Celestine Wekesa, Judith Wandera, Brigid Kemei, Joseph Nduati, Diana Omoke, Duncan Ayata and Dan Juma and the KEMRI Climate and Human Health research team: Silas Agumba, Enock Onyango, Paul Omondi, Joseph Maritim, Amos Ouko, Maxwel Gesuge and Amos Wabwale for their support and dedication during the fieldwork and lab analysis of the collected samples. We thank the director KEMRI for the permission to publish this data. This study was supported by resources from the National Science Foundation (NSF grant EF-072377) and the Forgatory grant, USA, the National Council for Science and Technology (NCST), Division of Malaria Control (DOMC) and Population Services International (PSI), Kenya. NR 63 TC 20 Z9 20 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD OCT 24 PY 2013 VL 12 AR 368 DI 10.1186/1475-2875-12-368 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 281KG UT WOS:000329099400002 PM 24156715 ER PT J AU Mesquita, PMM Srinivasan, P Johnson, TJ Rastogi, R Evans-Strickfaden, T Kay, MS Buckheit, KW Buckheit, RW Smith, JM Kiser, PF Herold, BC AF Mesquita, Pedro M. M. Srinivasan, Priya Johnson, Todd J. Rastogi, Rachna Evans-Strickfaden, Tammy Kay, Michael S. Buckheit, Karen W. Buckheit, Robert W., Jr. Smith, James M. Kiser, Patrick F. Herold, Betsy C. TI Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties SO RETROVIROLOGY LA English DT Article DE HIV; Pre-Exposure Prophylaxis; Intravaginal ring; Microbicide; Preclinical models ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-NEGATIVE WOMEN; PREEXPOSURE PROPHYLAXIS; INTRAVAGINAL RING; INFECTION; MICROBICIDES; PREVENTION; DELIVERY; DAPIVIRINE; HERPES AB Background: The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels. Results: Cells exposed to TDF were equally protected from HIV whether or not the drug-treated cells were washed with medium or seminal plasma prior to challenge. In contrast, several-fold higher concentrations of NNRTIs and entry inhibitors were needed to attain similar levels of HIV inhibition following a wash with seminal plasma. Conversely, the NNRTIs and PIE12, but not TDF or MVC, were effectively transferred from ex vivo treated explants and protected co-cultured T cells. Biopsies obtained from IQP-0528 ring-treated macaques also protected co-cultured T cells with viral inhibition ranging from 42-72%. Antiviral activity correlated with the concentration of drug recovered. Combinations of TDF with IQP-0528 protected in both in vitro models. Conclusions: Together, these models suggest that intracellularly retained drugs such as TDF may protect resident immune cells following coitus but sustained delivery may be required to protect immune cells subsequently recruited into the genital tract. Sustained delivery may also be critical for NNRTIs, which are rapidly transported out of cells and could be lost following sexual intercourse. An ideal approach may be a combination of drugs with complementary bioavailability profiles formulated for sustained delivery. C1 [Mesquita, Pedro M. M.; Herold, Betsy C.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. [Mesquita, Pedro M. M.; Herold, Betsy C.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Srinivasan, Priya; Evans-Strickfaden, Tammy; Smith, James M.] Ctr Dis Control & Prevent, Lab Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Johnson, Todd J.; Rastogi, Rachna; Kiser, Patrick F.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. [Kay, Michael S.] Univ Utah, Dept Biochem, Salt Lake City, UT USA. [Buckheit, Karen W.; Buckheit, Robert W., Jr.] ImQuest BioSci Inc, Frederick, MD USA. RP Mesquita, PMM (reprint author), Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. EM pedro.mesquita@einstein.yu.edu RI Kiser, Patrick/C-2843-2014; OI Kiser, Patrick/0000-0002-3868-7122; Mesquita, Pedro/0000-0002-6591-4896 FU National Institutes of Health [U19 AI076980, R33 AI079763, U19 AI103461]; National Institute of Allergy and Infectious Diseases; U.S. Department of Health and Human Services [Y1-AI-0681-02] FX We thank Gilead for providing tenofovir disoproxil fumarate, ViiV Healthcare and the International Partnership for Microbicides (IPM) for Maraviroc and IPM for Dapivirine. This work was supported by National Institutes of Health grants U19 AI076980, R33 AI079763 and U19 AI103461, and funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services, under interagency agreement no. Y1-AI-0681-02. We acknowledge the following members of CDC's DHAP-Laboratory Branch/ Pre-clinical Evaluation Team for their contributions to our non-human primate research: James Mitchell, Leecresia Jenkins, Shanon Bachmann, and Frank Deyounks for animal technical assistance, and David Garber, Janet McNicholl and R. Michael Hendry for programmatic and supervisory support. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 33 TC 13 Z9 13 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD OCT 24 PY 2013 VL 10 AR 113 DI 10.1186/1742-4690-10-113 PG 11 WC Virology SC Virology GA 280PP UT WOS:000329043500005 PM 24156604 ER PT J AU Doyle, TJ Goodin, K Hamilton, JJ AF Doyle, Timothy J. Goodin, Kate Hamilton, Janet J. TI Maternal and Neonatal Outcomes among Pregnant Women with 2009 Pandemic Influenza A(H1N1) Illness in Florida, 2009-2010: A Population-Based Cohort Study SO PLOS ONE LA English DT Article ID H1N1 VIRUS-INFECTION; A H1N1; UNITED-STATES; RISK-FACTOR; POSTPARTUM WOMEN; INFANT-DEATH; OBESITY; HOSPITALIZATION; AUSTRALIA; DISEASE AB Introduction: Pregnant women have been identified as a high risk group for severe illness with 2009 pandemic influenza A(H1N1) virus infection (pH1N1). Obesity has also been identified as a risk factor for severe illness, though this has not been thoroughly assessed among pregnant women. The objectives of this study were to provide risk estimates for adverse maternal and neonatal outcomes associated with pH1N1 illness during pregnancy and to assess the role of obesity in these outcomes. Methods: We established a retrospective population-based cohort of all live births occurring in Florida during the first 15 months of the pandemic. Illness with pH1N1 during pregnancy was ascertained through record linkage with the Florida state notifiable disease surveillance database. Data from the birth record, including pre-pregnancy body mass index, were analyzed to assess risk of adverse outcomes associated with pH1N1 illness. Results: A total of 194 women were identified through surveillance with pH1N1 illness during pregnancy. Children born to women with pH1N1 illness during pregnancy were at increased risk for low birth weight [OR (95% CI): 1.78 (1.11-2.860)], premature birth [2.21 (1.47-3.330)], and infant death [4.46 (1.80-11.00)], after adjusting for other factors. Women with pH1N1 illness during pregnancy were at increased risk for severe outcomes including admission to an intensive care unit. Obesity was an observed risk factor, both for the more severe pH1N1 illness detected through surveillance, and for severe maternal outcomes. Conclusions: Case-patients in this analysis likely represent the most severely ill subset of all women infected with pH1N1 during pregnancy, limiting the generalizability of these findings to more severely ill patients rather than influenza infection in general. Nevertheless, these results suggest that more severe pH1N1 illness during pregnancy is associated with adverse neonatal outcomes and that pregnant women should continue to be targeted for appropriate prophylaxis and early treatment. C1 [Doyle, Timothy J.; Goodin, Kate; Hamilton, Janet J.] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Doyle, Timothy J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Doyle, TJ (reprint author), Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. EM tdoyle@cdc.gov NR 47 TC 12 Z9 12 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 24 PY 2013 VL 8 IS 10 AR e79040 DI 10.1371/journal.pone.0079040 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 241FR UT WOS:000326152300089 PM 24205364 ER PT J AU Smith, RM Schaefer, MK Kainer, MA Wise, M Finks, J Duwve, J Fontaine, E Chu, A Carothers, B Reilly, A Fiedler, J Wiese, AD Feaster, C Gibson, L Griese, S Purfield, A Cleveland, AA Benedict, K Harris, JR Brandt, ME Blau, D Jernigan, J Weber, JT Park, BJ AF Smith, Rachel M. Schaefer, Melissa K. Kainer, Marion A. Wise, Matthew Finks, Jennie Duwve, Joan Fontaine, Elizabeth Chu, Alvina Carothers, Barbara Reilly, Amy Fiedler, Jay Wiese, Andrew D. Feaster, Christine Gibson, Lex Griese, Stephanie Purfield, Anne Cleveland, Angela A. Benedict, Kaitlin Harris, Julie R. Brandt, Mary E. Blau, Dianna Jernigan, John Weber, J. Todd Park, Benjamin J. CA Multistate Fungal Infection TI Fungal Infections Associated with Contaminated Methylprednisolone Injections SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID FACET JOINT INJECTION; LOW-BACK-PAIN; ASPERGILLUS MENINGITIS; CLADOSPORIUM-CLADOSPORIOIDES; CORTICOSTEROID INJECTION; MULTISTATE OUTBREAK; STEROID INJECTIONS; EPIDURAL ABSCESS; UNITED-STATES; SRI-LANKA AB BackgroundFungal infections are rare complications of injections for treatment of chronic pain. In September 2012, we initiated an investigation into fungal infections associated with injections of preservative-free methylprednisolone acetate that was purchased from a single compounding pharmacy. MethodsThree lots of methylprednisolone acetate were recalled by the pharmacy; examination of unopened vials later revealed fungus. Notification of all persons potentially exposed to implicated methylprednisolone acetate was conducted by federal, state, and local public health officials and by staff at clinical facilities that administered the drug. We collected clinical data on standardized case-report forms, and we tested for the presence of fungi in isolates and specimens by examining cultures and performing polymerase-chain-reaction assays and histopathological and immunohistochemical testing. ResultsBy October 19, 2012, more than 99% of 13,534 potentially exposed persons had been contacted. As of July 1, 2013, there were 749 reported cases of infection in 20 states, with 61 deaths (8%). Laboratory evidence of Exserohilum rostratum was present in specimens from 153 case patients (20%). Additional data were available for 728 case patients (97%); 229 of these patients (31%) had meningitis with no other documented infection. Case patients had received a median of 1 injection (range, 1 to 6) of implicated methylprednisolone acetate. The median age of the patients was 64 years (range, 15 to 97), and the median incubation period (the number of days from the last injection to the date of the first diagnosis) was 47 days (range, 0 to 249); 40 patients (5%) had a stroke. ConclusionsAnalysis of data from a large, multistate outbreak of fungal infections showed substantial morbidity and mortality. The infections were associated with injection of a contaminated glucocorticoid medication from a single compounding pharmacy. Rapid public health actions included prompt recall of the implicated product, notification of exposed persons, and early outreach to clinicians. C1 [Smith, Rachel M.; Griese, Stephanie; Purfield, Anne] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Smith, Rachel M.; Purfield, Anne; Cleveland, Angela A.; Benedict, Kaitlin; Harris, Julie R.; Brandt, Mary E.; Park, Benjamin J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Schaefer, Melissa K.; Wise, Matthew; Jernigan, John; Weber, J. Todd] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Blau, Dianna] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Kainer, Marion A.; Wiese, Andrew D.] Tennessee Dept Hlth, Nashville, TN USA. [Finks, Jennie; Fiedler, Jay] Bur Epidemiol, Michigan Dept Community Hlth, Lansing, MI USA. [Duwve, Joan; Feaster, Christine] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Fontaine, Elizabeth; Gibson, Lex] Virginia Dept Hlth, Richmond, VA USA. [Chu, Alvina] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Carothers, Barbara] New Jersey Dept Hlth, Trenton, NJ USA. [Reilly, Amy] Florida Dept Hlth, Tallahassee, FL USA. [Griese, Stephanie] North Carolina Div Publ Hlth, Raleigh, NC USA. RP Park, BJ (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. EM bpark1@cdc.gov RI Lankau, Emily/C-8057-2011; OI Lankau, Emily/0000-0002-7094-7780; Wiese, Andrew/0000-0002-0699-4224 NR 39 TC 56 Z9 56 U1 1 U2 17 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 24 PY 2013 VL 369 IS 17 BP 1598 EP 1609 DI 10.1056/NEJMoa1213978 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 239MZ UT WOS:000326031100009 PM 23252499 ER PT J AU Chiller, TM Roy, M Nguyen, D Guh, A Malani, AN Latham, R Peglow, S Kerkering, T Kaufman, D McFadden, J Collins, J Kainer, M Duwve, J Trump, D Blackmore, C Tan, C Cleveland, AA MacCannell, T Muehlenbachs, A Zaki, SR Brandt, ME Jernigan, JA AF Chiller, Tom M. Roy, Monika Duc Nguyen Guh, Alice Malani, Anurag N. Latham, Robert Peglow, Sheree Kerkering, Tom Kaufman, David McFadden, Jevon Collins, Jim Kainer, Marion Duwve, Joan Trump, David Blackmore, Carina Tan, Christina Cleveland, Angela A. MacCannell, Tara Muehlenbachs, Atis Zaki, Sherif R. Brandt, Mary E. Jernigan, John A. CA Multistate Fungal Infection TI Clinical Findings for Fungal Infections Caused by Methylprednisolone Injections SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CONTAMINATED METHYLPREDNISOLONE; STEROID INJECTIONS; EXSEROHILUM; MENINGITIS; TISSUES; STROKE; DNA AB Background Since September 18, 2012, public health officials have been investigating a large outbreak of fungal meningitis and other infections in patients who received epidural, paraspinal, or joint injections with contaminated lots of methylprednisolone acetate. Little is known about infections caused by Exserohilum rostratum, the predominant outbreak-associated pathogen. We describe the early clinical course of outbreak-associated infections. Methods We reviewed medical records for outbreak cases reported to the Centers for Disease Control and Prevention before November 19, 2012, from the six states with the most reported cases (Florida, Indiana, Michigan, New Jersey, Tennessee, and Virginia). Polymerase-chain-reaction assays and immunohistochemical testing were performed on clinical isolates and tissue specimens for pathogen identification. Results Of 328 patients without peripheral-joint infection who were included in this investigation, 265 (81%) had central nervous system (CNS) infection and 63 (19%) had non-CNS infections only. Laboratory evidence of E. rostratum was found in 96 of 268 patients (36%) for whom samples were available. Among patients with CNS infections, strokes were associated with an increased severity of abnormalities in cerebrospinal fluid (P<0.001). Non-CNS infections were more frequent later in the course of the outbreak (median interval from last injection to diagnosis, 39 days for epidural abscess and 21 days for stroke; P<0.001), and such infections developed in patients with and in those without meningitis. Conclusions The initial clinical findings from this outbreak suggest that fungal infections caused by epidural and paraspinal injection of a contaminated glucocorticoid product can result in a broad spectrum of clinical disease, reflecting possible variations in the pathogenic mechanism and in host and exposure risk factors. (Funded by the Centers for Disease Control and Prevention.) C1 [Chiller, Tom M.; Roy, Monika; Cleveland, Angela A.; Brandt, Mary E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Duc Nguyen; Guh, Alice; MacCannell, Tara; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Duc Nguyen] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [McFadden, Jevon] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Career Epidemiol Field Officer Program, Off Sci & Publ Hlth Practice,Off Publ Hlth Prepar, Atlanta, GA 30333 USA. [Muehlenbachs, Atis; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Malani, Anurag N.] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA. [Latham, Robert] St Thomas Hosp, Nashville, TN USA. [Kainer, Marion] Tennessee Dept Hlth, Nashville, TN USA. [Peglow, Sheree] Elkhart Gen Hosp, Elkhart, IN USA. [Kerkering, Tom] Virginia Tech Carilion Sch Med, Roanoke, NJ USA. [Kaufman, David] Cumberland Internal Med, Vineland, NJ USA. [McFadden, Jevon; Collins, Jim] Michigan Dept Community Hlth, Lansing, MI USA. [Duwve, Joan] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Trump, David] Virginia Dept Hlth, Richmond, VA USA. [Blackmore, Carina] Florida Dept Hlth, Tallahassee, FL USA. [Tan, Christina] New Jersey Dept Hlth, Trenton, NJ USA. RP Jernigan, JA (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM jqj9@cdc.gov FU CDC FX Supported by the CDC. NR 18 TC 29 Z9 29 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 24 PY 2013 VL 369 IS 17 BP 1610 EP 1619 DI 10.1056/NEJMoa1304879 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 239MZ UT WOS:000326031100010 PM 24152260 ER PT J AU Stanley, WT Robbins, LW Malekani, JM Mbalitini, SG Migurimu, DA Mukinzi, JC Hulselmans, J Prevot, V Verheyen, E Hutterer, R Doty, JB Monroe, BP Nakazawa, YJ Braden, Z Carroll, D Peterhans, JCK Bates, JM Esselstyn, JA AF Stanley, William T. Robbins, Lynn W. Malekani, Jean M. Mbalitini, Sylvestre Gambalemoke Migurimu, Dudu Akaibe Mukinzi, Jean Claude Hulselmans, Jan Prevot, Vanya Verheyen, Erik Hutterer, Rainer Doty, Jeffrey B. Monroe, Benjamin P. Nakazawa, Yoshinori J. Braden, Zachary Carroll, Darin Peterhans, Julian C. Kerbis Bates, John M. Esselstyn, Jacob A. TI A new hero emerges: another exceptional mammalian spine and its potential adaptive significance SO BIOLOGY LETTERS LA English DT Article DE functional significance; hero shrew; new species; Scutisorex; vertebral column ID SCUTISOREX-SOMERENI; BIOMECHANICAL MODIFICATIONS; SHREW; THOMAS; CONGO AB The hero shrew's (Scutisorex somereni) massive interlocking lumbar vertebrae represent the most extreme modification of the vertebral column known in mammals. No intermediate form of this remarkable morphology is known, nor is there any convincing theory to explain its functional significance. We document a new species in the heretofore monotypic genus Scutisorex; the new species possesses cranial and vertebral features representing intermediate character states between S. somereni and other shrews. Phylogenetic analyses of DNA sequences support a sister relationship between the new species and S. somereni. While the function of the unusual spine in Scutisorex is unknown, it gives these small animals incredible vertebral strength. Based on field observations, we hypothesize that the unique vertebral column is an adaptation allowing these shrews to lever heavy or compressive objects to access concentrated food resources inaccessible to other animals. C1 [Stanley, William T.; Peterhans, Julian C. Kerbis; Bates, John M.] Field Museum Nat Hist, Chicago, IL 60605 USA. [Robbins, Lynn W.] SW Missouri State Univ, Dept Biol, Springfield, MO 65804 USA. [Malekani, Jean M.] Univ Kinshasa, Dept Biol, Kinshasa, Zaire. [Mbalitini, Sylvestre Gambalemoke; Migurimu, Dudu Akaibe; Mukinzi, Jean Claude] Univ Kisangani, Lab Ecol & Anim Resource Management, Kisangani, Zaire. [Hulselmans, Jan; Verheyen, Erik] Univ Antwerp, Dept Biol, B-2020 Antwerp, Belgium. [Prevot, Vanya; Verheyen, Erik] Royal Belgian Inst Nat Sci, Vertebrate Dept, Brussels, Belgium. [Hutterer, Rainer] Zool Forsch Museum Alexander Koenig, Bonn, Germany. [Doty, Jeffrey B.; Monroe, Benjamin P.; Nakazawa, Yoshinori J.; Braden, Zachary; Carroll, Darin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Peterhans, Julian C. Kerbis] Roosevelt Univ, Coll Profess Studies, Chicago, IL 60605 USA. [Esselstyn, Jacob A.] Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA. [Esselstyn, Jacob A.] Louisiana State Univ, Museum Nat Sci, Baton Rouge, LA 70803 USA. RP Stanley, WT (reprint author), Field Museum Nat Hist, Chicago, IL 60605 USA. EM bstanley@fieldmuseum.org FU National Science Foundation [DEB-1145251] FX We thank Rebecca Banasiak, Anna Goldman and Andrea Niedzielski, who provided assistance with specimen preparation and figures. DNA sequencing was conducted in the Pritzker Molecular Laboratory, Field Museum. We are grateful to M. Anderson, R. Bieler, J. P. Brown, S. Carroll, T. Bakambana Luemba, T. Lumbsch, L. Kalemba Ndimba, C. Oliveros, O. Rieppel, M. A. Rogers, E. Sargis, B. Strack, J. Stanley and D. Willard for logistical support and advice. The National Science Foundation (DEB-1145251) provided funding. Three anonymous reviewers provided helpful comments on an earlier draft of this manuscript. NR 16 TC 4 Z9 4 U1 2 U2 16 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1744-9561 EI 1744-957X J9 BIOL LETTERS JI Biol. Lett. PD OCT 23 PY 2013 VL 9 IS 5 AR 20130486 DI 10.1098/rsbl.2013.0486 PG 5 WC Biology; Ecology; Evolutionary Biology SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Evolutionary Biology GA 297XY UT WOS:000330289600030 PM 23883579 ER PT J AU Wejnert, C Le, B Rose, CE Oster, AM Smith, AJ Zhu, JL The, GPBF AF Wejnert, Cyprian Le, Binh Rose, Charles E. Oster, Alexandra M. Smith, Amanda J. Zhu, Julia The, Gabriela Paz-Bailey For CA NHBS Study Grp TI HIV Infection and Awareness among Men Who Have Sex with Men-20 Cities, United States, 2008 and 2011 SO PLOS ONE LA English DT Article ID BEHAVIORAL SURVEILLANCE SYSTEM; PERSONS AWARE; STIGMA; RISK; PREVENTION; PREVALENCE; UNAWARE; PEOPLE; US AB Over half of HIV infections in the United States occur among men who have sex with men (MSM). Awareness of infection is a necessary precursor to antiretroviral treatment and risk reduction among HIV-infected persons. We report data on prevalence and awareness of HIV infection among MSM in 2008 and 2011, using data from 20 cities participating in the 2008 and 2011 National HIV Behavioral Surveillance System (NHBS) among MSM. Venue-based, time-space sampling was used to recruit men for interview and HIV testing. We analyzed data for men who reported >= 1 male sex partner in the past 12 months. Participants who tested positive were considered to be aware of their infection if they reported a prior positive HIV test. We used multivariable analysis to examine differences between results from 2011 vs. 2008. HIV prevalence was 19% in 2008 and 18% in 2011 (p = 0.14). In both years, HIV prevalence was highest among older age groups, blacks, and men with lower education and income. In multivariable analysis, HIV prevalence did not change significantly from 2008 to 2011 overall (p = 0.51) or in any age or racial/ethnic category (p>0.15 in each category). Among those testing positive, a greater proportion was aware of their infection in 2011 (66%) than in 2008 (56%) (p<0.001). In both years, HIV awareness was higher for older age groups, whites, and men with higher education and income. In multivariable analysis, HIV awareness increased from 2008 to 2011 overall (p<0.001) and for all age and racial/ethnic categories (p<0.01 in each category). In both years, black MSM had the highest HIV prevalence and the lowest awareness among racial/ethnic groups. These findings suggest that HIV-positive MSM are increasingly aware of their infections. C1 [Wejnert, Cyprian; Le, Binh; Rose, Charles E.; Oster, Alexandra M.; Smith, Amanda J.; Zhu, Julia; The, Gabriela Paz-Bailey For; NHBS Study Grp] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. RP Wejnert, C (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. EM CWejnert@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The National HIV Behavioral Surveillance System is funded by the Centers for Disease Control and Prevention (CDC). Study design and data collection are conducted by funded sites in accordance with a standardized protocol developed by CDC. Data analysis and preparation of the manuscript were conducted by CDC staff. NR 31 TC 45 Z9 45 U1 1 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 23 PY 2013 VL 8 IS 10 AR e76878 DI 10.1371/journal.pone.0076878 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239PE UT WOS:000326037000027 PM 24194848 ER PT J AU Metsch, LR Feaster, DJ Gooden, L Schackman, BR Matheson, T Das, M Golden, MR Huffaker, S Haynes, LF Tross, S Malotte, CK Douaihy, A Korthuis, PT Duffus, WA Henn, S Bolan, R Philip, SS Castro, JG Castellon, PC McLaughlin, G Mandler, RN Branson, B Colfax, GN AF Metsch, Lisa R. Feaster, Daniel J. Gooden, Lauren Schackman, Bruce R. Matheson, Tim Das, Moupali Golden, Matthew R. Huffaker, Shannon Haynes, Louise F. Tross, Susan Malotte, C. Kevin Douaihy, Antoine Korthuis, P. Todd Duffus, Wayne A. Henn, Sarah Bolan, Robert Philip, Susan S. Castro, Jose G. Castellon, Pedro C. McLaughlin, Gayle Mandler, Raul N. Branson, Bernard Colfax, Grant N. TI Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections The AWARE Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID HEALTH-CARE SETTINGS; SERVICES-TASK-FORCE; MEN; SEX; EFFICACY; ADOLESCENTS; BEHAVIORS; COHORT; ADULTS; VIRUS AB IMPORTANCE To increase human immunodeficiency virus (HIV) testing rates, many institutions and jurisdictions have revised policies to make the testing process rapid, simple, and routine. A major issue for testing scale-up efforts is the effectiveness of HIV risk-reduction counseling, which has historically been an integral part of the HIV testing process. OBJECTIVE To assess the effect of brief patient-centered risk-reduction counseling at the time of a rapid HIV test on the subsequent acquisition of sexually transmitted infections (STIs). DESIGN, SETTING, AND PARTICIPANTS From April to December 2010, Project AWARE randomized 5012 patients from 9 sexually transmitted disease (STD) clinics in the United States to receive either brief patient-centered HIV risk-reduction counseling with a rapid HIV test or the rapid HIV test with information only. Participants were assessed for multiple STIs at both baseline and 6-month follow-up. INTERVENTIONS Participants randomized to counseling received individual patient-centered risk-reduction counseling based on an evidence-based model. The core elements included a focus on the patient's specific HIV/STI risk behavior and negotiation of realistic and achievable risk-reduction steps. All participants received a rapid HIV test. MAIN OUTCOMES AND MEASURES The prespecified outcome was a composite end point of cumulative incidence of any of the measured STIs over 6 months. All participants were tested for Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum (syphilis), herpes simplex virus 2, and HIV. Women were also tested for Trichomonas vaginalis. RESULTS There was no significant difference in 6-month composite STI incidence by study group (adjusted risk ratio, 1.12; 95% CI, 0.94-1.33). There were 250 of 2039 incident cases (12.3%) in the counseling group and 226 of 2032 (11.1%) in the information-only group. CONCLUSION AND RELEVANCE Risk-reduction counseling in conjunction with a rapid HIV test did not significantly affect STI acquisition among STD clinic patients, suggesting no added benefit from brief patient-centered risk-reduction counseling. C1 [Metsch, Lisa R.; Gooden, Lauren; Castellon, Pedro C.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Metsch, Lisa R.; Feaster, Daniel J.; Gooden, Lauren; Castellon, Pedro C.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Schackman, Bruce R.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA. [Matheson, Tim; Das, Moupali; Huffaker, Shannon; Colfax, Grant N.] San Francisco Dept Publ Hlth, HIV Prevent Sect, San Francisco, CA USA. [Das, Moupali; Colfax, Grant N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Golden, Matthew R.] Univ Washington, Ctr AIDS & STD, Seattle, WA 98195 USA. [Golden, Matthew R.] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Haynes, Louise F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Tross, Susan] Columbia Univ, HIV Ctr Clin & Behav Studies, Dept Psychiat, New York, NY 10032 USA. [Tross, Susan] Columbia Univ, Subst Use Res Ctr, Dept Psychiat, New York, NY 10032 USA. [Malotte, C. Kevin] Calif State Univ Long Beach, Dept Hlth Sci, Long Beach, CA 90840 USA. [Douaihy, Antoine] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Duffus, Wayne A.] Univ S Carolina, Div Infect Dis, Dept Med, Sch Med, Columbia, SC 29208 USA. [Henn, Sarah] Whitman Walker Hlth, Elizabeth Taylor Med Ctr, Washington, DC USA. [Bolan, Robert] Los Angeles Gay & Lesbian Ctr, Jeffrey Goodman Special Care Clin, Los Angeles, CA USA. [Philip, Susan S.] San Francisco Dept Publ Hlth, STD Prevent & Control, San Francisco, CA USA. [Castro, Jose G.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA. [McLaughlin, Gayle] Duval Cty Hlth Dept, Jacksonville, FL USA. [Mandler, Raul N.] NIDA, NIH, Bethesda, MD 20892 USA. [Branson, Bernard] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Metsch, LR (reprint author), Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, 722 W 168th St, New York, NY 10032 USA. EM lm2892@cumc.columbia.edu FU National Institute on Drug Abuse [RC2DA028973]; University of Miami Center for AIDS Research (CFAR) [P30 AI073961] FX Funding for this study and analysis was provided by the National Institute on Drug Abuse (RC2DA028973). The infrastructure of the National Drug Abuse Treatment Clinical Trials Network was used as a platform in conducting this trial (U10-DA13720). Support from the University of Miami Center for AIDS Research (CFAR) is also acknowledged (P30 AI073961). NR 32 TC 43 Z9 44 U1 4 U2 20 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 23 PY 2013 VL 310 IS 16 BP 1701 EP 1710 DI 10.1001/jama.2013.280034 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 238LR UT WOS:000325948500026 PM 24150466 ER PT J AU Lauck, M Switzer, WM Sibley, SD Hyeroba, D Tumukunde, A Weny, G Taylor, B Shankar, A Ting, N Chapman, CA Friedrich, TC Goldberg, TL O'Connor, DH AF Lauck, Michael Switzer, William M. Sibley, Samuel D. Hyeroba, David Tumukunde, Alex Weny, Geoffrey Taylor, Bill Shankar, Anupama Ting, Nelson Chapman, Colin A. Friedrich, Thomas C. Goldberg, Tony L. O'Connor, David H. TI Discovery and full genome characterization of two highly divergent simian immunodeficiency viruses infecting black-and-white colobus monkeys (Colobus guereza) in Kibale National Park, Uganda SO RETROVIROLOGY LA English DT Article DE Simian immunodeficiency virus; SIV; Retrovirus; Lentivirus; Old World primate; Colobus guereza; Uganda; Next-generation sequencing; Virus discovery ID CROSS-SPECIES TRANSMISSION; AFRICAN-GREEN MONKEYS; MANDRILLUS-SPHINX; MOLECULAR CHARACTERIZATION; NONHUMAN-PRIMATES; WILD-BORN; SIV; EPIDEMIOLOGY; LENTIVIRUS; PROTEIN AB Background: African non-human primates (NHPs) are natural hosts for simian immunodeficiency viruses (SIV), the zoonotic transmission of which led to the emergence of HIV-1 and HIV-2. However, our understanding of SIV diversity and evolution is limited by incomplete taxonomic and geographic sampling of NHPs, particularly in East Africa. In this study, we screened blood specimens from nine black-and-white colobus monkeys (Colobus guereza occidentalis) from Kibale National Park, Uganda, for novel SIVs using a combination of serology and "unbiased" deep-sequencing, a method that does not rely on genetic similarity to previously characterized viruses. Results: We identified two novel and divergent SIVs, tentatively named SIVkcol-1 and SIVkcol-2, and assembled genomes covering the entire coding region for each virus. SIVkcol-1 and SIVkcol-2 were detected in three and four animals, respectively, but with no animals co-infected. Phylogenetic analyses showed that SIVkcol-1 and SIVkcol-2 form a lineage with SIVcol, previously discovered in black-and-white colobus from Cameroon. Although SIVkcol-1 and SIVkcol-2 were isolated from the same host population in Uganda, SIVkcol-1 is more closely related to SIVcol than to SIVkcol-2. Analysis of functional motifs in the extracellular envelope glycoprotein (gp120) revealed that SIVkcol-2 is unique among primate lentiviruses in containing only 16 conserved cysteine residues instead of the usual 18 or more. Conclusions: Our results demonstrate that the genetic diversity of SIVs infecting black-and-white colobus across equatorial Africa is greater than previously appreciated and that divergent SIVs can co-circulate in the same colobine population. We also show that the use of "unbiased" deep sequencing for the detection of SIV has great advantages over traditional serological approaches, especially for studies of unknown or poorly characterized viruses. Finally, the detection of the first SIV containing only 16 conserved cysteines in the extracellular envelope protein gp120 further expands the range of functional motifs observed among SIVs and highlights the complex evolutionary history of simian retroviruses. C1 [Lauck, Michael; Friedrich, Thomas C.; Goldberg, Tony L.; O'Connor, David H.] Wisconsin Natl Primate Res Ctr, Madison, WI USA. [Switzer, William M.; Shankar, Anupama] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. [Sibley, Samuel D.; Friedrich, Thomas C.; Goldberg, Tony L.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA. [Hyeroba, David; Tumukunde, Alex; Weny, Geoffrey; Chapman, Colin A.; Goldberg, Tony L.] Makerere Univ, Kampala, Uganda. [Taylor, Bill] Univ Wisconsin, Ctr High Throughput Comp, Madison, WI USA. [Ting, Nelson] Univ Oregon, Dept Anthropol, Eugene, OR 97403 USA. [Ting, Nelson] Univ Oregon, Inst Ecol & Evolut, Eugene, OR 97403 USA. [Chapman, Colin A.] McGill Univ, Dept Anthropol, Montreal, PQ, Canada. [Chapman, Colin A.] McGill Univ, Sch Environm, Montreal, PQ, Canada. [Chapman, Colin A.] Wildlife Conservat Soc, Bronx, NY USA. [O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53711 USA. RP O'Connor, DH (reprint author), Wisconsin Natl Primate Res Ctr, Madison, WI USA. EM doconnor@primate.wisc.edu OI Sibley, Samuel/0000-0002-6754-3187; o'connor, david/0000-0003-2139-470X; Friedrich, Thomas/0000-0001-9831-6895 FU NIH [TW009237, R01 AI084787, R01 AI077376-04A1]; UK Economic and Social Research Council; Research Facilities Improvement Program [RR15459-01, RR020141-01]; UW-Madison; Wisconsin Alumni Research Foundation; National Science Foundation; U.S. Department of Energy's Office of Science; National Center for Research Resources [RR000167]; Office of Research Infrastructure Programs (ORIP) [P51OD011106] FX This work was funded by NIH grant TW009237 as part of the joint NIH-NSF Ecology of Infectious Disease program and the UK Economic and Social Research Council and in part by National Institutes of Health grants R01 AI084787 and R01 AI077376-04A1; it was also supported by National Center for Research Resources grant RR000167 and the Office of Research Infrastructure Programs (ORIP) grant P51OD011106. The research was conducted, in part, at a facility constructed with support from Research Facilities Improvement Program grants RR15459-01 and RR020141-01. This research was performed using resources and the computing assistance of the UW-Madison Center for High Throughput Computing (CHTC) in the Department of Computer Sciences. The CHTC is supported by UW-Madison and the Wisconsin Alumni Research Foundation, and is an active member of the Open Science Grid, which is supported by the National Science Foundation and the U.S. Department of Energy's Office of Science. Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 44 TC 6 Z9 6 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD OCT 21 PY 2013 VL 10 AR 107 DI 10.1186/1742-4690-10-107 PG 13 WC Virology SC Virology GA 280PK UT WOS:000329043000001 PM 24139306 ER PT J AU Erdely, A Dahm, M Chen, BT Zeidler-Erdely, PC Fernback, JE Birch, ME Evans, DE Kashon, ML Deddens, JA Hulderman, T Bilgesu, SA Battelli, L Schwegler-Berry, D Leonard, HD McKinney, W Frazer, DG Antonini, JM Porter, DW Castranova, V Schubauer-Berigan, MK AF Erdely, Aaron Dahm, Matthew Chen, Bean T. Zeidler-Erdely, Patti C. Fernback, Joseph E. Birch, M. Eileen Evans, Douglas E. Kashon, Michael L. Deddens, James A. Hulderman, Tracy Bilgesu, Suzan A. Battelli, Lori Schwegler-Berry, Diane Leonard, Howard D. McKinney, Walter Frazer, David G. Antonini, James M. Porter, Dale W. Castranova, Vincent Schubauer-Berigan, Mary K. TI Carbon nanotube dosimetry: from workplace exposure assessment to inhalation toxicology SO PARTICLE AND FIBRE TOXICOLOGY LA English DT Article DE Workplace exposure assessment; Inhalation exposure; Mouse model; MWCNT Dose response and time dependence; Protein; Gene expression ID ASSESSMENT TECHNIQUE NEAT; TRADE-CENTER DUST; TIME-COURSE; SECONDARY MANUFACTURERS; FIBROTIC RESPONSE; NANOFIBER PRIMARY; PULMONARY; TOXICITY; MICE; LUNG AB Background: Dosimetry for toxicology studies involving carbon nanotubes (CNT) is challenging because of a lack of detailed occupational exposure assessments. Therefore, exposure assessment findings, measuring the mass concentration of elemental carbon from personal breathing zone (PBZ) samples, from 8 U.S.-based multi-walled CNT (MWCNT) manufacturers and users were extrapolated to results of an inhalation study in mice. Results: Upon analysis, an inhalable elemental carbon mass concentration arithmetic mean of 10.6 mu g/m(3) (geometric mean 4.21 mu g/m(3)) was found among workers exposed to MWCNT. The concentration equates to a deposited dose of approximately 4.07 mu g/d in a human, equivalent to 2 ng/d in the mouse. For MWCNT inhalation, mice were exposed for 19 d with daily depositions of 1970 ng (equivalent to 1000 d of a human exposure; cumulative 76 yr), 197 ng (100 d; 7.6 yr), and 19.7 ng (10 d; 0.76 yr) and harvested at 0, 3, 28, and 84 d post-exposure to assess pulmonary toxicity. The high dose showed cytotoxicity and inflammation that persisted through 84 d after exposure. The middle dose had no polymorphonuclear cell influx with transient cytotoxicity. The low dose was associated with a low grade inflammatory response measured by changes in mRNA expression. Increased inflammatory proteins were present in the lavage fluid at the high and middle dose through 28 d post-exposure. Pathology, including epithelial hyperplasia and peribronchiolar inflammation, was only noted at the high dose. Conclusion: These findings showed a limited pulmonary inflammatory potential of MWCNT at levels corresponding to the average inhalable elemental carbon concentrations observed in U.S.-based CNT facilities and estimates suggest considerable years of exposure are necessary for significant pathology to occur at that level. C1 [Erdely, Aaron; Chen, Bean T.; Zeidler-Erdely, Patti C.; Kashon, Michael L.; Hulderman, Tracy; Bilgesu, Suzan A.; Battelli, Lori; Schwegler-Berry, Diane; Leonard, Howard D.; McKinney, Walter; Frazer, David G.; Antonini, James M.; Porter, Dale W.; Castranova, Vincent] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Dahm, Matthew; Deddens, James A.; Schubauer-Berigan, Mary K.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH USA. [Fernback, Joseph E.; Birch, M. Eileen; Evans, Douglas E.] NIOSH, Div Appl Res & Technol, Cincinnati, OH USA. [Erdely, Aaron] NIOSH HELD PPRB, Morgantown, WV 26505 USA. RP Erdely, A (reprint author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. EM efi4@cdc.gov RI Schubauer-Berigan, Mary/B-3149-2009 OI Schubauer-Berigan, Mary/0000-0002-5175-924X NR 50 TC 44 Z9 45 U1 4 U2 37 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-8977 J9 PART FIBRE TOXICOL JI Part. Fibre Toxicol. PD OCT 21 PY 2013 VL 10 AR 53 DI 10.1186/1743-8977-10-53 PG 14 WC Toxicology SC Toxicology GA 277KX UT WOS:000328819200001 PM 24144386 ER PT J AU Guy, GP Ekwueme, DU Yabroff, KR Dowling, EC Li, CY Rodriguez, JL de Moor, JS Virgo, KS AF Guy, Gery P., Jr. Ekwueme, Donatus U. Yabroff, K. Robin Dowling, Emily C. Li, Chunyu Rodriguez, Juan L. de Moor, Janet S. Virgo, Katherine S. TI Economic Burden of Cancer Survivorship Among Adults in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID EXPENDITURE PANEL SURVEY; 2ND PRIMARY CANCERS; BREAST-CANCER; PRODUCTIVITY COSTS; LESS-THAN-65 YEARS; MEDICAL-CARE; PREVALENCE; CALIFORNIA; AGE; MORTALITY AB Purpose To present nationally representative estimates of the impact of cancer survivorship on medical expenditures and lost productivity among adults in the United States. Methods Using the 2008 to 2010 Medical Expenditure Panel Survey, we identified 4,960 cancer survivors and 64,431 individuals without a history of cancer age >= 18 years. Direct medical costs were measured using annual health care expenditures and examined by source of payment and service type. Indirect morbidity costs were estimated from lost productivity as a result of employment disability, missed work days, and lost household productivity. We evaluated the economic burden of cancer survivorship by estimating excess costs among cancer survivors, stratified by time since diagnosis (recently diagnosed [<= 1 year] and previously diagnosed [> 1 year]), compared with individuals without a history of cancer using multivariable regression models stratified by age (18 to 64 and >= 65 years), controlling for age, sex, race/ethnicity, education, and comorbidities. Results In 2008 to 2010, the annual excess economic burden of cancer survivorship among recently diagnosed cancer survivors was $16,213 per survivor age 18 to 64 years and $16,441 per survivor age >= 65 years. Among previously diagnosed cancer survivors, the annual excess burden was $4,427 per survivor age 18 to 64 years and $4,519 per survivor age >= 65 years. Excess medical expenditures composed the largest share of the economic burden among cancer survivors, particularly among those recently diagnosed. Conclusion The economic impact of cancer survivorship is considerable and is also high years after a cancer diagnosis. Efforts to reduce the economic burden caused by cancer will be increasingly important given the growing population of cancer survivors. C1 [Guy, Gery P., Jr.; Ekwueme, Donatus U.; Li, Chunyu; Rodriguez, Juan L.] Ctr Res Dis Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Virgo, Katherine S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Yabroff, K. Robin; de Moor, Janet S.] NCI, Bethesda, MD 20892 USA. [Dowling, Emily C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. RP Guy, GP (reprint author), Ctr Res Dis Prevent, Div Canc Prevent & Control, 4770 Buford Highway,NE,F76, Atlanta, GA 30341 USA. EM irm2@cdc.gov OI Yabroff, K. Robin/0000-0003-0644-5572 NR 42 TC 44 Z9 44 U1 1 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 20 PY 2013 VL 31 IS 30 BP 3749 EP 3757 DI 10.1200/JCO.2013.49.1241 PG 9 WC Oncology SC Oncology GA 301OA UT WOS:000330540400011 PM 24043731 ER PT J AU Mogasale, V Levin, A Maskery, B DeRoeck, D Kim, YE Clemens, J Lopez, AL Burgess, C Wierzba, T AF Mogasale, Vittal Levin, Ann Maskery, Brian DeRoeck, Denise Kim, Young Eun Clemens, John Lena Lopez, Anna Burgess, Colleen Wierzba, Thomas TI Oral cholera vaccines to control endemic disease: an economic and epidemiological modelling analysis SO LANCET LA English DT Meeting Abstract C1 [Mogasale, Vittal; Maskery, Brian; Kim, Young Eun; Clemens, John; Lena Lopez, Anna; Wierzba, Thomas] Int Vaccine Inst, Seoul 151919, South Korea. [Maskery, Brian] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kim, Young Eun] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Clemens, John] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Lena Lopez, Anna] Univ Philippines, Manila Natl Inst Hlth, Manila, Philippines. [Burgess, Colleen] MathEcology, Phoenix, AZ USA. EM vmogasale@ivi.int OI Mogasale, Vittal/0000-0003-0596-8072 NR 0 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD OCT 20 PY 2013 VL 382 SU 1 BP 6 EP 6 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 242KG UT WOS:000326238900006 ER PT J AU Iademarco, MF AF Iademarco, Michael F. TI Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Iademarco, MF (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM miademarco@cdc.gov NR 9 TC 33 Z9 33 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 18 PY 2013 VL 62 IS 41 BP 821 EP 824 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GR UT WOS:000326451100001 ER PT J AU Martinez-Urtaza, J Baker-Austin, C Jones, JL Newton, AE Gonzalez-Aviles, GD DePaola, A AF Martinez-Urtaza, Jaime Baker-Austin, Craig Jones, Jessica L. Newton, Anna E. Gonzalez-Aviles, Gladys D. DePaola, Angelo TI Spread of Pacific Northwest Vibrio parahaemolyticus Strain SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter AB In this letter, the virulent Pacific Northwest clone of Vibrio parahaemolyticus was shown to have spread and caused considerable illness in persons on the Atlantic coasts of the United States and Spain.To the Editor: Globally, Vibrio parahaemolyticus is a leading cause of seafood-associated gastroenteritis. Historically, the V. parahaemolyticus serotypes O4:K12 and O4:KUT, which have been shown to be more virulent than other pathogenic V. parahaemolyticus strains, have been unique to the Pacific Northwest region.(1) These strains, which were first identified in the Pacific Northwest in 1988, caused large U.S. outbreaks in 1997 and 2004.(2) The outbreaks were linked to consumption of Pacific shellfish, but these strains have not been linked to illness or isolated outside the Pacific Northwest until recently. During the summer of 2012, outbreaks of V. parahaemolyticus infection caused ... C1 [Martinez-Urtaza, Jaime] European Ctr Dis Prevent & Control, Stockholm, Sweden. [Baker-Austin, Craig] Ctr Environm Fisheries & Aquaculture Sci, Weymouth, England. [Jones, Jessica L.; DePaola, Angelo] US FDA, Dauphin Isl, AL USA. [Newton, Anna E.; Gonzalez-Aviles, Gladys D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Martinez-Urtaza, J (reprint author), European Ctr Dis Prevent & Control, Stockholm, Sweden. EM craig.baker-austin@cefas.co.uk RI Martinez-Urtaza, Jaime/A-5528-2015 FU Intramural CDC HHS [CC999999] NR 5 TC 24 Z9 25 U1 0 U2 13 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 17 PY 2013 VL 369 IS 16 BP 1573 EP 1574 DI 10.1056/NEJMc1305535 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 267MJ UT WOS:000328101700030 PM 24131194 ER PT J AU Curtis, KA Longosz, AF Kennedy, MS Keating, S Heitman, J Laeyendecker, O Owen, SM AF Curtis, Kelly A. Longosz, Andrew F. Kennedy, M. Susan Keating, Sheila Heitman, John Laeyendecker, Oliver Owen, S. Michele TI Inter-Laboratory Assessment of a Prototype Multiplex Kit for Determination of Recent HIV-1 Infection SO PLOS ONE LA English DT Article ID BED-ENZYME-IMMUNOASSAY; PERFORMANCE-CHARACTERISTICS; TYPE-1 SEROCONVERSION; VACCINE PREPAREDNESS; UNITED-STATES; ASSAY; IDENTIFICATION; SEROINCIDENCE; TRIALS AB Background: Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence from cross-sectional samples. We recently described the development of a customized, HIV-1-specific Bio-Plex assay that allows for the measurement of HIV-specific antibody levels and avidity to multiple analytes for improved HIV-1 incidence estimates. Methods: To assess intra-and inter-laboratory assay performance, prototype multiplex kits were developed and evaluated by three distinct laboratories. Longitudinal seroconversion specimens were tested in parallel by each laboratory and kit performance was compared to that of an in-house assay. Additionally, the ability of the kit to distinguish recent from long-term HIV-1 infection, as compared to the in-house assay, was determined by comparing the reactivity of known recent (infected <6 months) and long-term (infected >12 months) drug naive specimens. Results: Although the range of reactivity for each analyte varied between the prototype kit and in-house assay, a measurable distinction in reactivity between recent and long-term specimens was observed with both assays in all three laboratories. Additionally, kit performance was consistent between all three laboratories. The intra-assay coefficient of variation (CV), between sample replicates for all laboratories, ranged from 0.5% to 6.1%. The inter-laboratory CVs ranged from 8.5% to 21.3% for gp160-avidity index (a) and gp120-normalized mean fluorescent intensity (MFI) value (n), respectively. Conclusion: We demonstrate the feasibility of producing a multiplex kit for measuring HIV antibody levels and avidity, with the potential for improved incidence estimates based on multi-analyte algorithms. The availability of a commercial kit will facilitate the transfer of technology among diverse laboratories for widespread assay use. C1 [Curtis, Kelly A.; Kennedy, M. Susan; Owen, S. Michele] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. [Longosz, Andrew F.; Laeyendecker, Oliver] NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Baltimore, MD USA. [Keating, Sheila; Heitman, John] Blood Syst Res Inst, San Francisco, CA USA. [Laeyendecker, Oliver] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. EM czv2@cdc.gov OI Laeyendecker, Oliver/0000-0002-6429-4760 FU Centers for Disease Control; Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); HIV Prevention Trials Network; NIAID, National Institutes of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, Department of Health and Human Services (DHHS) [U01-AI46745, U01-AI48054, UM1-AI068613, R01-AI095068] FX Funding for this research was provided in part through intramural funding from the Centers for Disease Control. Additional funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Additional funders included: The Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); the HIV Prevention Trials Network sponsored by NIAID, National Institutes of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, Department of Health and Human Services (DHHS, U01-AI46745, U01-AI48054, and UM1-AI068613), R01-AI095068. NR 28 TC 5 Z9 5 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 17 PY 2013 VL 8 IS 10 AR e77765 DI 10.1371/journal.pone.0077765 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239KL UT WOS:000326022200073 PM 24147075 ER PT J AU Zheng, DP Rodrigues, M Bile, E Nguyen, DB Diallo, K DeVos, JR Nkengasong, JN Yang, CF AF Zheng, Du-Ping Rodrigues, Margarida Bile, Ebi Nguyen, Duc B. Diallo, Karidia DeVos, Joshua R. Nkengasong, John N. Yang, Chunfu TI Molecular Characterization of Ambiguous Mutations in HIV-1 Polymerase Gene: Implications for Monitoring HIV Infection Status and Drug Resistance SO PLOS ONE LA English DT Article ID BLOOD SPOT SPECIMENS; TRANSMITTED HIV; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL TREATMENT; GENOTYPING ASSAY; TESTING SITES; SURVEILLANCE; VIETNAM; DIVERSITY; ACCURACY AB Detection of recent HIV infections is a prerequisite for reliable estimations of transmitted HIV drug resistance (t-HIVDR) and incidence. However, accurately identifying recent HIV infection is challenging due partially to the limitations of current serological tests. Ambiguous nucleotides are newly emerged mutations in quasispecies, and accumulate by time of viral infection. We utilized ambiguous mutations to establish a measurement for detecting recent HIV infection and monitoring early HIVDR development. Ambiguous nucleotides were extracted from HIV-1 pol-gene sequences in the datasets of recent (HIVDR threshold surveys [HIVDR-TS] in 7 countries; n=416) and established infections (1 HIVDR monitoring survey at baseline; n=271). An ambiguous mutation index of 2.04x10(-3) nts/site was detected in HIV-1 recent infections which is equivalent to the HIV-1 substitution rate (2x10(-3) nts/site/year) reported before. However, significantly higher index (14.41x10(-3) nts/site) was revealed with established infections. Using this substitution rate, 75.2% subjects in HIVDR-TS with the exception of the Vietnam dataset and 3.3% those in HIVDR-baseline were classified as recent infection within one year. We also calculated mutation scores at amino acid level at HIVDR sites based on ambiguous or fitted mutations. The overall mutation scores caused by ambiguous mutations increased (0.54x10(-2)3.48x10(-2)/DR-site) whereas those caused by fitted mutations remained stable (7.50-7.89x10(-2)/DR-site) in both recent and established infections, indicating that t-HIVDR exists in drug-naive populations regardless of infection status in which new HIVDR continues to emerge. Our findings suggest that characterization of ambiguous mutations in HIV may serve as an additional tool to differentiate recent from established infections and to monitor HIVDR emergence. C1 [Zheng, Du-Ping; Diallo, Karidia; DeVos, Joshua R.; Nkengasong, John N.; Yang, Chunfu] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA. [Rodrigues, Margarida] CDC GAP Angola, Luanda, Angola. [Bile, Ebi] CDC GAP Botswana, Gaborone, Botswana. [Nguyen, Duc B.] US CDC, Dept Hlth & Human Serv, Hanoi, Vietnam. RP Yang, CF (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA. EM CYang1@cdc.gov RI Yang, Chunfu/G-6890-2013 FU Centers for Disease Control and Prevention FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 4 Z9 4 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 17 PY 2013 VL 8 IS 10 AR e77649 DI 10.1371/journal.pone.0077649 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239KL UT WOS:000326022200058 PM 24147046 ER PT J AU Ridenhour, BJ Campitelli, MA Kwong, JC Rosella, LC Armstrong, BG Mangtani, P Calzavara, AJ Shay, DK AF Ridenhour, Benjamin J. Campitelli, Michael A. Kwong, Jeffrey C. Rosella, Laura C. Armstrong, Ben G. Mangtani, Punam Calzavara, Andrew J. Shay, David K. TI Effectiveness of Inactivated Influenza Vaccines in Preventing Influenza-Associated Deaths and Hospitalizations among Ontario Residents Aged >= 65 Years: Estimates with Generalized Linear Models Accounting for Healthy Vaccinee Effects SO PLOS ONE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY SYNCYTIAL VIRUS; PLACEBO-CONTROLLED TRIAL; ALL-CAUSE MORTALITY; ELDERLY-PEOPLE; HERD-IMMUNITY; UNITED-STATES; VACCINATION; IMPACT; COHORT AB Background: Estimates of the effectiveness of influenza vaccines in older adults may be biased because of difficulties identifying and adjusting for confounders of the vaccine-outcome association. We estimated vaccine effectiveness for prevention of serious influenza complications among older persons by using methods to account for underlying differences in risk for these complications. Methods: We conducted a retrospective cohort study among Ontario residents aged >= 65 years from September 1993 through September 2008. We linked weekly vaccination, hospitalization, and death records for 1.4 million community-dwelling persons aged >= 65 years. Vaccine effectiveness was estimated by comparing ratios of outcome rates during weeks of high versus low influenza activity (defined by viral surveillance data) among vaccinated and unvaccinated subjects by using log-linear regression models that accounted for temperature and time trends with natural spline functions. Effectiveness was estimated for three influenza-associated outcomes: all-cause deaths, deaths occurring within 30 days of pneumonia/influenza hospitalizations, and pneumonia/influenza hospitalizations. Results: During weeks when 5% of respiratory specimens tested positive for influenza A, vaccine effectiveness among persons aged >= 65 years was 22% (95% confidence interval [CI], -6%-42%) for all influenza-associated deaths, 25% (95% CI, 13%-37%) for deaths occurring within 30 days after an influenza-associated pneumonia/influenza hospitalization, and 19% (95% CI, 4%-31%) for influenza-associated pneumonia/influenza hospitalizations. Because small proportions of deaths, deaths after pneumonia/influenza hospitalizations, and pneumonia/influenza hospitalizations were associated with influenza virus circulation, we estimated that vaccination prevented 1.6%, 4.8%, and 4.1% of these outcomes, respectively. Conclusions: By using confounding-reducing techniques with 15 years of provincial-level data including vaccination and health outcomes, we estimated that influenza vaccination prevented similar to 4% of influenza-associated hospitalizations and deaths occurring after hospitalizations among older adults in Ontario. C1 [Ridenhour, Benjamin J.; Shay, David K.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Ridenhour, Benjamin J.] Univ Notre Dame, Dept Biol Sci, Eck Inst Global Hlth, South Bend, IN USA. [Campitelli, Michael A.; Kwong, Jeffrey C.; Calzavara, Andrew J.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Kwong, Jeffrey C.; Rosella, Laura C.] Ontario Agcy Hlth Protect & Promot, Toronto, ON, Canada. [Kwong, Jeffrey C.; Rosella, Laura C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada. [Armstrong, Ben G.; Mangtani, Punam] Univ London London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1E 7HT, England. [Calzavara, Andrew J.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England. RP Ridenhour, BJ (reprint author), US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. EM ridenhour.1@nd.edu OI Ridenhour, Benjamin/0000-0001-8271-4629; Shay, David/0000-0001-9619-4820 NR 41 TC 14 Z9 15 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 16 PY 2013 VL 8 IS 10 AR e76318 DI 10.1371/journal.pone.0076318 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 239JR UT WOS:000326019400053 PM 24146855 ER PT J AU Bicego, GT Nkambule, R Peterson, I Reed, J Donnell, D Ginindza, H Duong, YT Patel, H Bock, N Philip, N Mao, C Justman, J AF Bicego, George T. Nkambule, Rejoice Peterson, Ingrid Reed, Jason Donnell, Deborah Ginindza, Henry Duong, Yen T. Patel, Hetal Bock, Naomi Philip, Neena Mao, Cherry Justman, Jessica TI Recent Patterns in Population-Based HIV Prevalence in Swaziland SO PLOS ONE LA English DT Article ID MALE CIRCUMCISION; TRIAL AB Background: The 2011 Swaziland HIV Incidence Measurement Survey (SHIMS) was conducted as part of a national study to evaluate the scale up of key HIV prevention programs. Methods: From a randomly selected sample of all Swazi households, all women and men aged 18-49 were considered eligible, and all consenting adults were enrolled and received HIV testing and counseling. In this analysis, population-based measures of HIV prevalence were produced and compared against similarly measured HIV prevalence estimates from the 2006-7 Swaziland Demographic and Health. Also, measures of HIV service utilization in both HIV infected and uninfected populations were documented and discussed. Results: HIV prevalence among adults aged 18-49 has remained unchanged between 2006-2011 at 31-32%, with substantial differences in current prevalence between women (39%) and men (24%). In both men and women, between since 2006-7 and 2011, prevalence has fallen in the young age groups and risen in the older age groups. Over a third (38%) of the HIV-infected population was unaware of their infection status, and this differed markedly between men (50%) and women (31%). Of those aware of their HIV-positive status, a higher percentage of men (63%) than women (49%) reported ART use. Conclusions: While overall HIV prevalence remains roughly constant, age-specific changes strongly suggest both improved survival of the HIV-infected and a reduction in new HIV infections. Awareness of HIV status and entry into ART services has improved in recent years but remains too low. This study identifies opportunities to improve both HIV preventive and care services in Swaziland. C1 [Bicego, George T.] Ctr Dis Control & Prevent CDC, Mbabane, Swaziland. [Nkambule, Rejoice; Ginindza, Henry] Minist Hlth, Mbabane, Swaziland. [Peterson, Ingrid; Ginindza, Henry] Columbia Univ, Int Ctr AIDS Care & Treatment Programs ICAP, Mbabane, Swaziland. [Donnell, Deborah; Mao, Cherry] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Reed, Jason; Duong, Yen T.; Patel, Hetal; Bock, Naomi] CDC Atlanta, Div Global HIV AIDS, Atlanta, GA USA. [Philip, Neena; Justman, Jessica] Columbia Univ, ICAP, New York, NY USA. RP Bicego, GT (reprint author), Ctr Dis Control & Prevent CDC, Mbabane, Swaziland. EM gpb4@cdc.gov OI Donnell, Deborah/0000-0002-0587-7480 FU CDC FX The CDC funded the SHIMS study and participated in the design, data analysis, and preparation of manuscript. NR 11 TC 34 Z9 34 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 15 PY 2013 VL 8 IS 10 AR e77101 DI 10.1371/journal.pone.0077101 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 237TP UT WOS:000325894100040 PM 24143205 ER PT J AU Kent, EE Forsythe, LP Yabroff, KR Weaver, KE de Moor, JS Rodriguez, JL Rowland, JH AF Kent, Erin E. Forsythe, Laura P. Yabroff, K. Robin Weaver, Kathryn E. de Moor, Janet S. Rodriguez, Juan L. Rowland, Julia H. TI Are Survivors Who Report Cancer-Related Financial Problems More Likely to Forgo or Delay Medical Care? SO CANCER LA English DT Article DE cancer; health disparities; survivors; access to care; financial burden ID QUALITY-OF-LIFE; BREAST-CANCER; UNITED-STATES; LOW-INCOME; HEALTH; BURDEN; POPULATION; IMPACT; WOMEN; COST AB BACKGROUNDFinancial problems caused by cancer and its treatment can substantially affect survivors and their families and create barriers to seeking health care. METHODSThe authors identified cancer survivors diagnosed as adults (n=1556) from the nationally representative 2010 National Health Interview Survey. Using multivariable logistic regression analyses, the authors report sociodemographic, clinical, and treatment-related factors associated with perceived cancer-related financial problems and the association between financial problems and forgoing or delaying health care because of cost. Adjusted percentages using the predictive marginals method are presented. RESULTSCancer-related financial problems were reported by 31.8% (95% confidence interval, 29.3%-34.5%) of survivors. Factors found to be significantly associated with cancer-related financial problems in survivors included younger age at diagnosis, minority race/ethnicity, history of chemotherapy or radiation treatment, recurrence or multiple cancers, and shorter time from diagnosis. After adjustment for covariates, respondents who reported financial problems were more likely to report delaying (18.3% vs 7.4%) or forgoing overall medical care (13.8% vs 5.0%), prescription medications (14.2% vs 7.6%), dental care (19.8% vs 8.3%), eyeglasses (13.9% vs 5.8%), and mental health care (3.9% vs 1.6%) than their counterparts without financial problems (all P<.05). CONCLUSIONSCancer-related financial problems are not only disproportionately represented in survivors who are younger, members of a minority group, and have a higher treatment burden, but may also contribute to survivors forgoing or delaying medical care after cancer. Cancer 2013;119:3710-3717. (c) 2013 American Cancer Society. Approximately one-third of individuals with a history of cancer report cancer-related financial problems. Financial problems are disproportionately more common in survivors who are younger, members of a minority group, and report a higher treatment burden history. They are also associated with delaying or forgoing health care because of cost. C1 [Kent, Erin E.] NCI, Outcomes Res Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Forsythe, Laura P.] Patient Ctr Outcomes Res Inst, Washington, DC USA. [Yabroff, K. Robin] NCI, Hlth Serv & Econ Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Weaver, Kathryn E.] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Div Publ Hlth Sci, Winston Salem, NC USA. [de Moor, Janet S.; Rowland, Julia H.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Rodriguez, Juan L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Kent, EE (reprint author), NCI, Outcomes Res Branch, Appl Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr,MSC 9762, Bethesda, MD 20892 USA. EM Erin.Kent@nih.gov OI Yabroff, K. Robin/0000-0003-0644-5572 FU Intramural NIH HHS [Z99 CA999999] NR 42 TC 46 Z9 46 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 15 PY 2013 VL 119 IS 20 BP 3710 EP 3717 DI 10.1002/cncr.28262 PG 8 WC Oncology SC Oncology GA 230WJ UT WOS:000325373700053 PM 23907958 ER PT J AU Yanamala, N Hatfield, MK Farcas, MT Schwegler-Berry, D Hummer, JA Shurin, MR Birch, ME Gutkin, DW Kisin, E Kagan, VE Bugarski, AD Shvedova, AA AF Yanamala, Naveena Hatfield, Meghan K. Farcas, Mariana T. Schwegler-Berry, Diane Hummer, Jon A. Shurin, Michael R. Birch, M. Eileen Gutkin, Dmitriy W. Kisin, Elena Kagan, Valerian E. Bugarski, Aleksandar D. Shvedova, Anna A. TI Biodiesel versus diesel exposure: Enhanced pulmonary inflammation, oxidative stress, and differential morphological changes in the mouse lung SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Aspiration exposure; Cytokine panel; Pulmonary toxicity; Biodiesel particle retention; Inflammation; Lipid droplets ID EXHAUST PARTICULATE MATTER; FATTY-ACIDS; ENGINE EMISSIONS; EPITHELIAL-CELLS; DENDRITIC CELLS; LIPID DROPLETS; VEGETABLE-OIL; AIRWAY CELLS; FOAM CELLS; PARTICLES AB The use of biodiesel (BD) or its blends with petroleum diesel (D) is considered to be a viable approach to reduce occupational and environmental exposures to particulate matter (PM). Due to its lower particulate mass emissions compared to D, use of BD is thought to alleviate adverse health effects. Considering BD fuel is mainly composed of unsaturated fatty acids, we hypothesize that BD exhaust particles could induce pronounced adverse outcomes, due to their ability to readily oxidize. The main objective of this study was to compare the effects of particles generated by engine fueled with neat BD and neat petroleum-based D. Biomarkers of tissue damage and inflammation were significantly elevated in lungs of mice exposed to BD particulates. Additionally, BD particulates caused a significant accumulation of oxidatively modified proteins and an increase in 4-hydroxynonenal. The up-regulation of inflammatory cytokines/chemokines/growth factors was higher in lungs upon BD particulate exposure. Histological evaluation of lung sections indicated presence of lymphocytic infiltrate and impaired clearance with prolonged retention of BD particulate in pigment laden macrophages. Taken together, these results clearly indicate that BD exhaust particles could exert more toxic effects compared to D. Published by Elsevier Inc. C1 [Yanamala, Naveena; Hatfield, Meghan K.; Farcas, Mariana T.; Schwegler-Berry, Diane; Kisin, Elena; Shvedova, Anna A.] CDC, NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA. [Shvedova, Anna A.] WVU, Dept Physiol & Pharmacol, Morgantown, WV 26505 USA. [Hummer, Jon A.; Bugarski, Aleksandar D.] CDC, NIOSH, Off Mine Safety & Hlth Res, Pittsburgh, PA 15236 USA. [Birch, M. Eileen] NIOSH, CDC, Cincinnati, OH 45226 USA. [Shurin, Michael R.; Gutkin, Dmitriy W.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. RP Shvedova, AA (reprint author), Pathol & Physiol Res Branch MS 2015, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM wqu1@cdc.gov; wla4@cdc.gov; woe7@cdc.gov; qzh3@cdc.gov; shurinmr@upmc.edu; mib2@cdc.gov; dwgutkin@hotmail.com; edk8@cdc.gov; kagan@pitt.edu; zjl1@cdc.gov; ats1@cdc.gov FU NIOSH [2927ZKCY, OH008282]; NIH [RO1 ES-019304, HL-070755, U19 AI-068021] FX This work was supported by NIOSH grants - 2927ZKCY (AS.), and OH008282 (V.E.K.), and NIH grants - RO1 ES-019304, HL-070755 and U19 AI-068021 (V.E.K.). NR 83 TC 20 Z9 20 U1 0 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD OCT 15 PY 2013 VL 272 IS 2 BP 373 EP 383 DI 10.1016/j.taap.2013.07.006 PG 11 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 237XS UT WOS:000325905500013 PM 23886933 ER PT J AU Joh, RI Hoekstra, RM Barzilay, EJ Bowen, A Mintz, ED Weiss, H Weitz, JS AF Joh, Richard I. Hoekstra, Robert M. Barzilay, Ezra J. Bowen, Anna Mintz, Eric D. Weiss, Howard Weitz, Joshua S. TI Dynamics of Shigellosis Epidemics: Estimating Individual-Level Transmission and Reporting Rates From National Epidemiologic Data Sets SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE dysentery; Markov chain Monte Carlo methods; nonlinear dynamics; statistics ID UNITED-STATES; FOODBORNE ILLNESS; MEASLES EPIDEMICS; MODEL; INFLUENZA; DISEASE; INTERVENTIONS; INFECTIONS; OUTBREAKS; PATTERNS AB Shigellosis, a diarrheal disease, is endemic worldwide and is responsible for approximately 15,000 laboratory-confirmed cases in the United States every year. However, patients with shigellosis often do not seek medical care. To estimate the burden of shigellosis, we extended time-series susceptible-infected-recovered models to infer epidemiologic parameters from underreported case data. We applied the time-series susceptible-infected-recoveredbased inference schemes to analyze the largest surveillance data set of Shigella sonnei in the United States from 1967 to 2007 with county-level resolution. The dynamics of shigellosis transmission show strong annual and multiyear cycles, as well as seasonality. By using the schemes, we inferred individual-level parameters of shigellosis infection, including seasonal transmissibilities and basic reproductive number (R-0). In addition, this study provides quantitative estimates of the reporting rate, suggesting that the shigellosis burden in the United States may be more than 10 times the number of laboratory-confirmed cases. Although the estimated reporting rate is generally under 20, and R-0 is generally under 1.5, there is a strong negative correlation between estimates of the reporting rate and R-0. Such negative correlations are likely to pose identifiability problems in underreported diseases. We discuss complementary approaches that might further disentangle the true reporting rate and R-0. C1 [Joh, Richard I.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Hoekstra, Robert M.; Barzilay, Ezra J.; Bowen, Anna; Mintz, Eric D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Weiss, Howard] Georgia Inst Technol, Sch Math, Atlanta, GA 30332 USA. [Weitz, Joshua S.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Weitz, Joshua S.] Georgia Inst Technol, Sch Phys, Atlanta, GA 30332 USA. RP Weitz, JS (reprint author), Georgia Inst Technol, Sch Biol, 310 Ferst Dr, Atlanta, GA 30332 USA. EM jsweitz@gatech.edu OI Joh, Richard/0000-0003-0583-8032 FU Scientific Interface from the Burroughs Wellcome Fund FX Joshua S. Weitz holds a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. NR 32 TC 3 Z9 3 U1 3 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 15 PY 2013 VL 178 IS 8 BP 1319 EP 1326 DI 10.1093/aje/kwt122 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235YK UT WOS:000325759000020 PM 24008913 ER PT J AU Jackson, ML Yu, O Nelson, JC Naleway, A Belongia, EA Baxter, R Narwaney, K Jacobsen, SJ Shay, DK Jackson, LA AF Jackson, Michael L. Yu, Onchee Nelson, Jennifer C. Naleway, Allison Belongia, Edward A. Baxter, Roger Narwaney, Komal Jacobsen, Steven J. Shay, David K. Jackson, Lisa A. TI Further Evidence for Bias in Observational Studies of Influenza Vaccine Effectiveness: The 2009 Influenza A(H1N1) Pandemic SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE confounding factors (epidemiology); epidemiologic methods; influenza; influenza; pandemic; vaccine effectiveness; vaccines ID ALL-CAUSE MORTALITY; ELDERLY-PEOPLE; HOSPITALIZATIONS; BENEFITS; SENIORS; CONTROVERSY; POPULATION; REDUCTION; COHORT; RISK AB Preinfluenza periods have been used to test for uncontrolled confounding in studies of influenza vaccine effectiveness, but some authors have claimed that confounding differs in preinfluenza and influenza periods. We tested this claim by comparing estimates of the vaccine-mortality association during the 2009/2010 influenza year, when there was essentially no circulation of seasonal influenza in the United States, and 2007/2008, a typical influenza year. We pooled data on seniors (adults aged 65 years) from 7 US managed care organizations that participated in the Vaccine Safety Datalink Project. We defined influenza vaccination, all-cause mortality, and potential confounders from administrative databases. We quantified the vaccine-mortality association using Cox regression. During 2007/2008, the adjusted hazard ratio was 0.44 prior to influenza season, 0.62 during influenza season, and 0.71 after influenza season. A similar pattern was observed during 2009/2010, when any effect of seasonal influenza vaccine observed during all time periods must have resulted from confounding: 0.65 during the autumn, 0.80 during the winter, and 0.84 during the summer. In a year with minimal seasonal influenza, we found no evidence that confounding in autumn preinfluenza periods is qualitatively different from confounding in winter. This supports the use of preinfluenza periods as control time periods in studies of influenza vaccine effectiveness. C1 [Jackson, Michael L.; Yu, Onchee; Nelson, Jennifer C.; Jackson, Lisa A.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA. [Naleway, Allison] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI USA. [Baxter, Roger] Kaiser Permanente No Calif, Vaccine Study Ctr, Oakland, CA USA. [Narwaney, Komal] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Los Angeles, CA USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Jackson, ML (reprint author), Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM jackson.ml@ghc.org OI Naleway, Allison/0000-0001-5747-4643; Shay, David/0000-0001-9619-4820; Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans from the Centers for Disease Control and Prevention [200-2002-00732] FX This work was supported by a subcontract with America's Health Insurance Plans (grant 200-2002-00732) from the Centers for Disease Control and Prevention. NR 24 TC 10 Z9 10 U1 0 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 15 PY 2013 VL 178 IS 8 BP 1327 EP 1336 DI 10.1093/aje/kwt124 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235YK UT WOS:000325759000021 PM 23978527 ER PT J AU Kurbatova, EV Cavanaugh, JS Dalton, T Click, ES Cegielski, JP AF Kurbatova, Ekaterina V. Cavanaugh, Joseph S. Dalton, Tracy Click, Eleanor S. Cegielski, J. Peter TI Epidemiology of Pyrazinamide-Resistant Tuberculosis in the United States, 1999-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE tuberculosis; drug resistance; epidemiology; pyrazinamide ID MYCOBACTERIUM-TUBERCULOSIS; PNCA MUTATIONS; MURINE MODEL; SUSCEPTIBILITY; COMBINATIONS; LINEAGE; KOREA; DRUGS; BOVIS AB Background. Pyrazinamide (PZA) is essential in tuberculosis treatment. We describe the prevalence, trends, and predictors of PZA resistance in Mycobacterium tuberculosis complex (MTBC) in the United States. Methods. We analyzed culture-positive MTBC cases with reported drug susceptibility tests for PZA in 38 jurisdictions routinely testing for PZA susceptibility from 1999 to 2009. National Tuberculosis Genotyping Service data for 2004-2009 were used to distinguish M. tuberculosis from Mycobacterium bovis and determine phylogenetic lineage. Results. Overall 2.7% (2167/79 321) of MTBC cases had PZA resistance, increasing annually from 2.0% to 3.3% during 1999-2009 (P < .001), largely because of an increase in PZA monoresistance. PZA-monoresistant MTBC (vs drug-susceptible) was associated with an age of 0-24 years (adjusted prevalence ratio [aPR], 1.50; 95% confidence interval [CI], 1.31-1.71), Hispanic ethnicity (aPR, 3.52; 95% CI, 2.96-4.18), human immunodeficiency virus infection (aPR, 1.43; 95% CI, 1.15-1.77), extrapulmonary disease (aPR, 3.02; 95% CI, 2.60-3.52), and normal chest radiograph (aPR, 1.88; 95% CI, 1.63-2.16) and was inversely associated with Asian (aPR, 0.59; 95% CI, .47-.73) and black (aPR, 0.37; 95% CI, .29-.49) race. Among multidrug-resistant (MDR) cases, 38.0% were PZA-resistant; PZA resistance in MDR MTBC was associated with female sex (aPR, 1.25; 95% CI, 1.08-1.46) and previous tuberculosis diagnosis (aPR, 1.37; 95% CI, 1.16-1.62). Of 28 080 cases with genotyping data, 925 (3.3%) had PZA resistance; 465 of 925 (50.3%) were M. bovis. In non-MDR M. tuberculosis cases, PZA resistance was higher in the Indo-Oceanic than the East Asian lineage (2.2% vs 0.9%, respectively; aPR, 2.26; 95% CI, 1.53-3.36), but in MDR cases it was lower in the Indo-Oceanic lineage (22.0% vs 43.4%, respectively; aPR, 0.54; 95% CI, .32-.90). Conclusions. Specific human and mycobacterial characteristics were associated with PZA-resistant MTBC, reflecting both specific subgroups of the population and phylogenetic lineages of the mycobacteria. C1 [Kurbatova, Ekaterina V.; Cavanaugh, Joseph S.; Dalton, Tracy; Click, Eleanor S.; Cegielski, J. Peter] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Kurbatova, EV (reprint author), CDC, Int Res & Programs Branch, Div TB Eliminat, MS E-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ekurbatova@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 18 Z9 19 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP 1081 EP 1093 DI 10.1093/cid/cit452 PG 13 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100007 PM 23840002 ER PT J AU McDonald, LC AF McDonald, L. Clifford TI Looking to the Future: Vertical vs Horizontal Prevention of Clostridium difficile Infections SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID DIARRHEA; COLONIZATION; SURVEILLANCE; REMOVAL; SPORES C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A35, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 16 TC 2 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP 1103 EP 1105 DI 10.1093/cid/cit477 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100009 PM 23881152 ER PT J AU Venkatesan, A Tunkel, AR Bloch, KC Lauring, AS Sejvar, J Bitnun, A Stahl, JP Mailles, A Drebot, M Rupprecht, CE Yoder, J Cope, JR Wilson, MR Whitley, RJ Sullivan, J Granerod, J Jones, C Eastwood, K Ward, KN Durrheim, DN Solbrig, MV Guo-Dong, L Glaser, CA Consortium, IE AF Venkatesan, A. Tunkel, A. R. Bloch, K. C. Lauring, A. S. Sejvar, J. Bitnun, A. Stahl, J-P. Mailles, A. Drebot, M. Rupprecht, C. E. Yoder, J. Cope, J. R. Wilson, M. R. Whitley, R. J. Sullivan, J. Granerod, J. Jones, C. Eastwood, K. Ward, K. N. Durrheim, D. N. Solbrig, M. V. Guo-Dong, L. Glaser, C. A. Consortium, Int Encephalitis TI Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE encephalitis; guidelines; viral; autoimmune; host genetics ID WEST-NILE-VIRUS; HERPES-SIMPLEX ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; CAT-SCRATCH DISEASE; ACUTE CHILDHOOD ENCEPHALITIS; NMDA-RECEPTOR ENCEPHALITIS; IMMUNOGLOBULIN-M IGM; CEREBROSPINAL-FLUID; MYCOPLASMA-PNEUMONIAE; UNITED-STATES AB Background. Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances in diagnosis and management have been limited, in part, by a lack of consensus on case definitions, standardized diagnostic approaches, and priorities for research. Methods. In March 2012, the International Encephalitis Consortium, a committee begun in 2010 with members worldwide, held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. Results. We present a consensus document that proposes a standardized case definition and diagnostic guidelines for evaluation of adults and children with suspected encephalitis. In addition, areas of research priority, including host genetics and selected emerging infections, are discussed. Conclusions. We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephalitis and will identify key areas and approaches to advance our knowledge of encephalitis. C1 [Venkatesan, A.] Johns Hopkins Univ, Sch Med, Johns Hopkins Encephalitis Ctr, Dept Neurol, Baltimore, MD 21287 USA. [Tunkel, A. R.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Bloch, K. C.] Vanderbilt Univ, Sch Med, Dept Med Infect Dis, Nashville, TN 37212 USA. [Bloch, K. C.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Lauring, A. S.] Univ Michigan, Sch Med, Dept Med, Div Infect Dis, Ann Arbor, MI 48104 USA. [Sejvar, J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Bitnun, A.] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, Toronto, ON M5S 1A1, Canada. [Stahl, J-P.] CHU Grenoble, Infect Dis Dept, F-38043 Grenoble, France. [Stahl, J-P.] Univ 1, Grenoble, France. [Mailles, A.] French Inst Publ Hlth Surveillance, Dept Infect Dis, St Maurice, France. [Drebot, M.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Rupprecht, C. E.] Global Alliance Rabies Control, Manhattan, KS USA. [Yoder, J.; Cope, J. R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Waterborne Dis Prevent Branch, Atlanta, GA USA. [Wilson, M. R.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Wilson, M. R.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Whitley, R. J.] Univ Alabama, Dept Pediat, Tuscaloosa, AL 35487 USA. [Whitley, R. J.] Univ Alabama, Dept Microbiol, Tuscaloosa, AL 35487 USA. [Whitley, R. J.] Univ Alabama, Dept Med, Tuscaloosa, AL 35487 USA. [Whitley, R. J.] Univ Alabama, Dept Neurosurg, Tuscaloosa, AL 35487 USA. [Sullivan, J.] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia. [Granerod, J.; Ward, K. N.] Publ Hlth England, Virus Reference Dept, London, England. [Jones, C.] Univ Sydney, Sydney Emerging Infect Dis & Biosecur Inst, Sydney, NSW 2006, Australia. [Jones, C.] Univ Sydney, Childrens Hosp Westmead Clin Sch, Sydney, NSW 2006, Australia. [Eastwood, K.] Hunter New England Populat Hlth, Wallsend, NSW, Australia. [Ward, K. N.] UCL, Div Infect & Immun, London WC1E 6BT, England. [Durrheim, D. N.] Univ Newcastle, Wallsend, NSW, Australia. [Durrheim, D. N.] Hunter Med Res Inst, Wallsend, NSW, Australia. [Solbrig, M. V.] Univ Manitoba, Dept Med Neurol & Med Microbiol, Winnipeg, MB, Canada. [Guo-Dong, L.] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Dept Viral Encephalitis & Arbovirus, Beijing, Peoples R China. [Glaser, C. A.] Calif Dept Publ Hlth, Div Communicable Dis Control, Richmond, CA USA. RP Venkatesan, A (reprint author), Johns Hopkins Univ, Sch Med, 600 N Wolfe St,Meyer 6-113, Baltimore, MD 21287 USA. EM avenkat2@jhmi.edu RI Jones, Cheryl/A-4985-2011 OI Jones, Cheryl/0000-0001-5363-3694 FU Emerging Infectious Diseases Program of the Centers for Disease Control and Prevention [U50/CCU915548-03, U50/CCU416123]; French Institute for Public health Surveillance; National Natural Science Foundation of China [8129034]; Hunter Medical Research Institute; National Institutes of Health [K08 AI081754]; Manitoba Health Research Council; Public Health England; French infectious Diseases Society FX This work was supported by the Emerging Infectious Diseases Program of the Centers for Disease Control and Prevention U50/CCU915548-03 to C. A. G. and U50/CCU416123 to K. C. B.; French Institute for Public health Surveillance and French infectious Diseases Society (A. M. and J.-P. S.); National Natural Science Foundation of China [8129034] (L. G.-D.); Hunter Medical Research Institute (K. E. and D. D.); National Institutes of Health K08 AI081754 (A. S. L.); Manitoba Health Research Council (M. V. S.); Public Health England (J. G.). NR 89 TC 91 Z9 96 U1 1 U2 22 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP 1114 EP 1128 DI 10.1093/cid/cit458 PG 15 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100011 PM 23861361 ER PT J AU Laidler, MR Tourdjman, M Buser, GL Hostetler, T Repp, KK Leman, R Samadpour, M Keene, WE AF Laidler, Matthew R. Tourdjman, Mathieu Buser, Genevieve L. Hostetler, Trevor Repp, Kimberly K. Leman, Richard Samadpour, Mansour Keene, William E. TI Escherichia coli O157:H7 Infections Associated With Consumption of Locally Grown Strawberries Contaminated by Deer SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Escherichia coli O157; STEC; foodborne disease outbreak; Fragaria; deer ID WHITE-TAILED DEER; HEMOLYTIC-UREMIC SYNDROME; O157-H7 INFECTION; WILD DEER; OUTBREAK; CATTLE; SALMONELLA; PREVALENCE; FIELD; MEAT AB Background. An outbreak of Escherichia coli O157:H7 was identified in Oregon through an increase in Shiga toxin-producing E. coli cases with an indistinguishable, novel pulsed-field gel electrophoresis (PFGE) subtyping pattern. Methods. We defined confirmed cases as persons from whom E. coli O157: H7 with the outbreak PFGE pattern was cultured during July-August 2011, and presumptive cases as persons having a household relationship with a case testing positive for E. coli O157: H7 and coincident diarrheal illness. We conducted an investigation that included structured hypothesis-generating interviews, a matched case-control study, and environmental and traceback investigations. Results. We identified 15 cases. Six cases were hospitalized, including 4 with hemolytic uremic syndrome (HUS). Two cases with HUS died. Illness was significantly associated with strawberry consumption from roadside stands or farmers' markets (matched odds ratio, 19.6; 95% confidence interval, 2.9-infinity). A single farm was identified as the source of contaminated strawberries. Ten of 111 (9%) initial environmental samples from farm A were positive for E. coli O157: H7. All samples testing positive for E. coli O157: H7 contained deer feces, and 5 tested farm fields had >= 1 sample positive with the outbreak PFGE pattern. Conclusions. The investigation identified fresh strawberries as a novel vehicle for E. coli O157: H7 infection, implicated deer feces as the source of contamination, and highlights problems concerning produce contamination by wildlife and regulatory exemptions for locally grown produce. A comprehensive hypothesis-generating questionnaire enabled rapid identification of the implicated product. Good agricultural practices are key barriers to wildlife fecal contamination of produce. C1 [Laidler, Matthew R.; Tourdjman, Mathieu; Buser, Genevieve L.; Leman, Richard; Keene, William E.] Oregon Hlth Author, Oregon Publ Hlth Div, Portland, OR USA. [Tourdjman, Mathieu; Buser, Genevieve L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Hostetler, Trevor; Repp, Kimberly K.] Washington Cty Dept Hlth & Human Serv, Hillsboro, OR USA. [Samadpour, Mansour] Inst Environm Hlth, Lake Forest Pk, WA USA. RP Laidler, MR (reprint author), Acute & Communicable Dis Prevent, Oregon Publ Hlth Div, 800 NE Oregon St,Ste 772, Portland, OR 97232 USA. EM matthew.laidler@state.or.us FU Centers for Disease Control and Prevention [5U01CI000306-5] FX This work was supported by the Centers for Disease Control and Prevention Emerging Infections Program Cooperative Agreement (grant number 5U01CI000306-5). NR 36 TC 31 Z9 31 U1 3 U2 31 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP 1129 EP 1134 DI 10.1093/cid/cit468 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100012 PM 23876397 ER PT J AU Pathela, P Braunstein, SL Blank, S Schillinger, JA AF Pathela, Preeti Braunstein, Sarah L. Blank, Susan Schillinger, Julia A. TI HIV Incidence Among Men With and Those Without Sexually Transmitted Rectal Infections: Estimates From Matching Against an HIV Case Registry SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; rectal Chlamydia; rectal gonorrhea; MSM ID GENITAL ULCER DISEASE; NEW-YORK-CITY; COST-EFFECTIVENESS; HOMOSEXUAL-MEN; UNITED-STATES; PREEXPOSURE PROPHYLAXIS; RISK-FACTORS; SEX; TRANSMISSION; PREVENTION AB Background. Sexually transmitted bacterial rectal infections are objective markers of HIV risk behavior. Quantifying HIV risk among men who have sex with men (MSM) who have had these infections can inform prevention efforts. We measured HIV risk among MSM who have and those who have not been diagnosed with rectal Chlamydia trachomatis (CT) and/or rectal Neisseria gonorrhoeae (GC). Methods. HIV incidence among a cohort of 276 HIV-negative MSM diagnosed with rectal CT and/or GC in New York City sexually transmitted disease (STD) clinics was compared to HIV incidence among HIV-negative MSM without these infections. Matches against the citywide HIV/AIDS registry identified HIV diagnoses from STD clinics, and by other providers. Cox proportional hazards models were used to explore factors associated with HIV acquisition among MSM with rectal infections. Results. HIV-negative MSM with rectal infections (>70% of which were asymptomatic) contributed 464.7 person-years of follow-up. Among them, 31 (11.2%) were diagnosed with HIV, of whom 14 (45%) were diagnosed by non-STD clinic providers. The annual HIV incidence was significantly higher among MSM with rectal infections (6.67%; 95% confidence interval [CI], 4.61%-9.35%) than among MSM without rectal infections (2.53%; 95% CI, 1.31%-4.42%). Black race (hazard ratio, 4.98; 95% CI, 1.75-14.17) was associated with incident HIV among MSM with rectal CT/GC. Conclusions. One in 15 MSM with rectal infections was diagnosed with HIV within a year, a higher risk than for MSM without rectal infections. Such data have implications for screening for rectal STD, and may be useful for targeting populations for risk-reduction counseling and other HIV prevention strategies, such as preexposure prophylaxis. C1 [Pathela, Preeti; Blank, Susan; Schillinger, Julia A.] New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, New York, NY USA. [Braunstein, Sarah L.] New York City Dept Hlth & Mental Hyg, Bur HIV AIDS Prevent & Control, New York, NY USA. [Blank, Susan; Schillinger, Julia A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Pathela, P (reprint author), New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, Gotham Ctr, 42-09 28th St, Queens, NY 11101 USA. EM ppathela@health.nyc.gov NR 30 TC 27 Z9 27 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP 1203 EP 1209 DI 10.1093/cid/cit437 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100026 PM 23800942 ER PT J AU Mahamud, A Burton, A Hassan, M Ahmed, JA Wagacha, JB Spiegel, P Haskew, C Eidex, RB Shetty, S Cookson, S Navarro-Colorado, C Goodson, JL AF Mahamud, Abdirahman Burton, Ann Hassan, Mohamed Ahmed, Jamal A. Wagacha, John B. Spiegel, Paul Haskew, Chris Eidex, Rachel B. Shetty, Sharmila Cookson, Susan Navarro-Colorado, Carlos Goodson, James L. TI Risk Factors for Measles Mortality Among Hospitalized Somali Refugees Displaced by Famine, Kenya, 2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE measles; mortality; vaccination; refugees; acute malnutrition ID CAMPS; OUTBREAK; POPULATIONS; COMMUNITY; AFRICA AB Background. Measles among displaced, malnourished populations can result in a high case fatality ratio. In 2011, a large measles outbreak occurred in Dadaab, Kenya, among refugees fleeing famine and conflict in Somalia. The aim of this study was to identify predictors of measles deaths among hospitalized patients during the outbreak. Methods. A retrospective cohort study design was used to investigate measles mortality among hospitalized measles patients with a date of rash onset during 6 June-10 September 2011. Data were abstracted from medical records and a measles case was defined as an illness with fever, maculopapular rash, and either cough, coryza or conjunctivitis. Vaccination status was determined by patient or parental recall. Independent predictors of mortality were identified using logistic regression analysis. Results. Of 388 hospitalized measles patients, 188 (49%) were from hospital X, 70 (18%) from hospital Y, and 130 (34%) from hospital Z; median age was 22 years, 192 (50%) were 15-29 years of age, and 22 (6%) were vaccinated. The mean number of days from rash onset to hospitalization varied by hospital (hospital X = 5, hospital Y = 3, hospital Z = 6; P < .0001). Independent risk factors for measles mortality were neurological complications (odds ratio [OR], 12.8; 95% confidence interval [CI], 3.1-52.4), acute malnutrition (OR, 7.6; 95% CI, 1.3-44.3), and admission to hospital Z (OR, 4.2; 95% CI, 1.3-13.2). Conclusions. Among Somali refugees, in addition to timely vaccination at border crossing points, early detection and treatment of acute malnutrition and proper management of measles cases may reduce measles mortality. C1 [Mahamud, Abdirahman; Shetty, Sharmila; Cookson, Susan; Navarro-Colorado, Carlos; Goodson, James L.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hassan, Mohamed; Ahmed, Jamal A.; Eidex, Rachel B.] US Ctr Dis Control & Prevent, Nairobi, Kenya. [Burton, Ann; Wagacha, John B.] United Nations High Commissioner Refugees, Nairobi, Kenya. [Spiegel, Paul; Haskew, Chris] United Nations High Commissioner Refugees, Geneva, Switzerland. RP Mahamud, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-47, Atlanta, GA 30333 USA. EM amahamud@cdc.gov OI Navarro Colorado, Carlos/0000-0002-2185-0157 FU US Centers for Disease Control and Prevention FX The US Centers for Disease Control and Prevention provided funding and participated in study design, data analysis, report writing, and decisions to submit the paper for publication. NR 33 TC 6 Z9 6 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2013 VL 57 IS 8 BP E160 EP E166 DI 10.1093/cid/cit442 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 228EJ UT WOS:000325168100004 PM 23821730 ER PT J AU Link-Gelles, R Thomas, A Lynfield, R Petit, S Schaffner, W Harrison, L Farley, MM Aragon, D Nicols, M Kirley, PD Zansky, S Jorgensen, J Juni, BA Jackson, D Moore, MR Lipsitch, M AF Link-Gelles, Ruth Thomas, Ann Lynfield, Ruth Petit, Sue Schaffner, William Harrison, Lee Farley, Monica M. Aragon, Deborah Nicols, Megin Kirley, Pam Daily Zansky, Shelley Jorgensen, James Juni, Billie Anne Jackson, Delois Moore, Matthew R. Lipsitch, Marc TI Geographic and Temporal Trends in Antimicrobial Nonsusceptibility in Streptococcus pneumoniae in the Post-vaccine era in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE antimicrobial resistance; erythromycin; invasive pneumococcal disease; penicillin; pneumococcus; Streptococcus pneumoniae ID PNEUMOCOCCAL CONJUGATE VACCINE; MACROLIDE RESISTANCE; ANTIBIOTIC USE; PENICILLIN RESISTANCE; OTITIS-MEDIA; CHILDREN; COEXISTENCE; INFECTIONS; PREVENTION; SEROTYPES AB Background. We examined whether observed increases in antibiotic nonsusceptible nonvaccine serotypes after introduction of pneumococcal conjugate vaccine in the United States in 2000 were driven primarily by vaccine or antibiotic use. Methods. Using active surveillance data, we evaluated geographic and temporal differences in serotype distribution and within-serotype differences during 2000-2009. We compared nonsusceptibility to penicillin and erythromycin by geography after standardizing differences across time, place, and serotype by regressing standardized versus crude proportions. A regression slope (RS) approaching zero indicates greater importance of the standardizing factor. Results. Through 2000-2006, geographic differences in nonsusceptibility were better explained by within-serotype prevalence of nonsusceptibility (RS 0.32, 95% confidence interval [CI], .08-.55 for penicillin) than by geographic differences in serotype distribution (RS 0.71, 95% CI, .44-.97). From 2007-2009, serotype distribution differences became more important for penicillin (within-serotype RS 0.52, 95% CI, .11-.93; serotype distribution RS 0.57, 95% CI, .14-1.0). Conclusions. Differential nonsusceptibility, within individual serotypes, accounts for most geographic variation in nonsusceptibility, suggesting selective pressure from antibiotic use, rather than differences in serotype distribution, mainly determines nonsusceptibility patterns. Recent trends suggest geographic differences in serotype distribution may be affecting the prevalence of nonsusceptibility, possibly due to decreases in the number of nonsusceptible serotypes. C1 [Link-Gelles, Ruth; Jackson, Delois; Moore, Matthew R.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Lynfield, Ruth] Minnesota Dept Hlth, Minneapolis, MN USA. [Petit, Sue] Connecticut Dept Hlth, Hartford, CT USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Harrison, Lee] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Aragon, Deborah] Colorado Dept Hlth, Denver, CO 80220 USA. [Nicols, Megin] New Mexico Dept Hlth, Santa Fe, NM USA. [Kirley, Pam Daily] Calif Emerging Infect Program, Oakland, CA USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA. [Jorgensen, James] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Juni, Billie Anne] Minnesota Dept Hlth, St Paul, MN USA. [Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Ctr Communicable Dis Dynam, Boston, MA 02115 USA. [Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Lipsitch, Marc] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Link-Gelles, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30333 USA. EM hzt7@cdc.gov OI Lipsitch, Marc/0000-0003-1504-9213 FU Centers for Disease Control and Prevention (CDC); CDC; National Institutes of Health [5R01AI048935, 5U54GM088558] FX This work was supported by the Centers for Disease Control and Prevention (CDC), which provides funding for the Active Bacterial Core surveillance (ABCs) system, a collaboration of state health departments, academic institutions, local partners, and the CDC. M. L. was supported by grants from the National Institutes of Health (grant numbers 5R01AI048935, 5U54GM088558). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CDC or the National Institutes of Health. NR 30 TC 15 Z9 15 U1 0 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2013 VL 208 IS 8 BP 1266 EP 1273 DI 10.1093/infdis/jit315 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 223TJ UT WOS:000324832800010 PM 23852588 ER PT J AU Chaves, SS Aragon, D Bennett, N Cooper, T D'Mello, T Farley, M Fowler, B Hancock, E Kirley, PD Lynfield, R Ryan, P Schaffner, W Sharangpani, R Tengelsen, L Thomas, A Thurston, D Williams, J Yousey-Hindes, K Zansky, S Finelli, L AF Chaves, Sandra S. Aragon, Deborah Bennett, Nancy Cooper, Tara D'Mello, Tiffany Farley, Monica Fowler, Brian Hancock, Emily Kirley, Pam Daily Lynfield, Ruth Ryan, Patricia Schaffner, William Sharangpani, Ruta Tengelsen, Leslie Thomas, Ann Thurston, Diana Williams, Jean Yousey-Hindes, Kimberly Zansky, Shelley Finelli, Lyn TI Patients Hospitalized With Laboratory-Confirmed Influenza During the 2010-2011 Influenza Season: Exploring Disease Severity by Virus Type and Subtype SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; influenza A(H1N1) pdm09; severe influenza; influenza hospitalizations; influenza surveillance ID PANDEMIC-UNITED-STATES; A H1N1; ANTIVIRAL TREATMENT; INFECTION; CHILDREN; OUTCOMES; VACCINE AB Background. The 2010-2011 influenza season was dominated by influenza A(H3N2) virus, but influenza A(H1N1) pdm09 (pH1N1) and B viruses cocirculated. This provided an opportunity to explore within-season predictors of severity among hospitalized patients, avoiding biases associated with season-to-season differences in strain virulence, population immunity, and healthcare seeking. Methods. Population-based, laboratory-confirmed influenza hospitalization surveillance data were used to examine the association between virus type/subtype and outcomes in children and adults. Multivariable analysis explored virus type/subtype, prompt antiviral treatment, medical conditions, and age as predictors for severity (intensive care unit admission or death). Results. In children, pH1N1 (adjusted odds ratio [aOR], 2.19; 95% confidence interval [CI], 1.11-4.3), chronic metabolic disease (aOR, 5.23; 95% CI, 1.74-15.69), and neuromuscular disorder (aOR, 4.84; 95% CI, 2.02-11.58) were independently associated with severity. In adults, independent predictors were pH1N1 (aOR, 2.21; 95% CI, 1.66-2.94), chronic lung disease (aOR, 1.46, 95% CI, 1.12-1.89), and neuromuscular disorder (aOR, 1.68; 95% CI, 1.11-2.52). Antiviral treatment reduced the odds of severity among adults (aOR, 0.47; 95% CI, .33-.68). Conclusions. During the 2010-2011 season, pH1N1 caused more severe disease than H3N2 or B in hospitalized patients. Underlying medical conditions increased severity despite virus strain. Antiviral treatment reduced severity among adults. Our findings underscore the importance of influenza prevention. C1 [Chaves, Sandra S.; D'Mello, Tiffany; Finelli, Lyn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Farley, Monica] Emory Univ, Sch Med, Atlanta, GA USA. [Farley, Monica] Atlanta Vet Adm Med Ctr, Atlanta, GA USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Bennett, Nancy] Univ Rochester Sch, Dept Med & Dent, Rochester, NY USA. [Bennett, Nancy] Dept Publ Hlth, Rochester, NY USA. [Cooper, Tara] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Fowler, Brian] Ohio Dept Hlth, Columbus, OH 43266 USA. [Hancock, Emily] New Mexico Dept Hlth, Santa Fe, NM USA. [Kirley, Pam Daily] Calif Emerging Infect Program, Oakland, CA USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Sharangpani, Ruta] Michigan Dept Community Hlth, Lansing, MI USA. [Tengelsen, Leslie] Idaho Dept Hlth & Welf, Boise, ID USA. [Thurston, Diana] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Williams, Jean] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Yousey-Hindes, Kimberly] Yale Univ, Connecticut Emerging Infect Program, New Haven, CT USA. [Zansky, Shelley] New York State Dept Hlth, Emerging Infect Program, Albany, NY 12237 USA. RP Chaves, SS (reprint author), 1600 Clifton Rd NE,MS A-20, Atlanta, GA 30333 USA. EM schaves@cdc.gov OI Yousey-Hindes, Kimberly/0000-0002-9418-575X FU Centers for Disease Control and Prevention (CDC); CDC [CDC-RFA-CK12-1202, 5U38HM000414] FX The Influenza Hospitalizations Surveillance Network (FluSurv-NET) is a collaboration of state health departments, academic institutions, and local partners and is funded by the Centers for Disease Control and Prevention (CDC). This publication was supported in part by Cooperative Agreement number CDC-RFA-CK12-1202 and 5U38HM000414 from the CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. NR 34 TC 25 Z9 25 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2013 VL 208 IS 8 BP 1305 EP 1314 DI 10.1093/infdis/jit316 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 223TJ UT WOS:000324832800015 PM 23863950 ER PT J AU Hughes, CM Damon, IK Reynolds, MG AF Hughes, Christine M. Damon, Inger K. Reynolds, Mary G. TI Understanding US Healthcare Providers' Practices and Experiences with Molluscum Contagiosum SO PLOS ONE LA English DT Article ID PULSED DYE-LASER; GENITAL WARTS; CHILDREN; EPIDEMIOLOGY; INFECTION; IMIQUIMOD AB Introduction: Molluscum contagiosum is a common superficial skin infection caused by the poxvirus, Molluscum Contagiosum virus. The study objective is to obtain a better understanding of physician practices and experiences with molluscum contagiosum in order to focus informational and guidance material. Methods: A cross-sectional survey to assess medical practitioners' knowledge and practices with molluscum contagiosum was conducted using the 2009 DocStyles survey. Questions regarding category and number of molluscum contagiosum patients seen, treatments used and advice given to patients were included in the survey. Results: Dermatologists saw the most cases, with the majority seeing 51-100 molluscum contagiosum cases/year. The most common cases seen were children with multiple lesions and adults with genital lesions. Respondents were most likely to recommend treatment to immunocompromised individuals, HIV patients, adults with genital lesions and children with multiple lesions. Cryotherapy was the top choice for all specialties with the exception of OB/GYNs, whose top choice was curettage. "Avoid intimate contact until lesions resolve'', "Avoid touching lesions to reduce further spread'', and "Don't be concerned, this will go away'' were the top advice choices. Discussion: Most survey respondents have dealt with molluscum contagiosum in their practice during the previous year. Overall, respondents picked appropriate choices for treatment and advice given; however some ineffective or unnecessary treatments were chosen and recommendations to prevent spread were chosen infrequently. Knowledge gaps for appropriate transmission precaution advice might cause unnecessary spread or autoinoculation. This survey has demonstrated that molluscum contagiosum is a common infection seen by many types of practitioners and therefore guidance on treatment considerations and infection control is valuable. C1 [Hughes, Christine M.; Damon, Inger K.; Reynolds, Mary G.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. RP Hughes, CM (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. EM christine.hughes@cdc.hhs.gov FU U.S. federal government - Centers for Disease Control and Prevention (CDC) FX U.S. federal government - Centers for Disease Control and Prevention (CDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 5 Z9 7 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 14 PY 2013 VL 8 IS 10 AR e76948 DI 10.1371/journal.pone.0076948 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 237RD UT WOS:000325887300046 PM 24155912 ER PT J AU Park, SY Viray, M Johnston, D Taylor, E Chang, A Martin, C Schier, JG Lewis, LS Levri, KM Chatham-Stephens, K AF Park, Sarah Y. Viray, Melissa Johnston, David Taylor, Ethel Chang, Arthur Martin, Colleen Schier, Joshua G. Lewis, Lauren S. Levri, Kara M. Chatham-Stephens, Kevin TI Acute Hepatitis and Liver Failure Following the Use of a Dietary Supplement Intended for Weight Loss or Muscle Building - May-October 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEPATOTOXICITY C1 [Levri, Kara M.; Chatham-Stephens, Kevin] CDC, Atlanta, GA 30333 USA. RP Chatham-Stephens, K (reprint author), CDC, Atlanta, GA 30333 USA. EM david.johnston@doh.hawaii.gov; kchathamstephens@cdc.gov NR 3 TC 1 Z9 1 U1 2 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 11 PY 2013 VL 62 IS 40 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245GO UT WOS:000326450800001 ER PT J AU Zhang, HL Zhang, YZ Yang, WH Feng, Y Nasci, RS Yang, J Liu, YH Dong, CL Li, S Zhang, BS Yin, ZL Wang, PY Fu, SH Li, MH Liu, F Zhang, J Sun, J Li, CW Gao, XY Liu, H Wang, HY Petersen, LR Liang, GD AF Zhang, Hai-Lin Zhang, Yu-Zhen Yang, Wei-Hong Feng, Yun Nasci, Roger S. Yang, Jie Liu, Yong-Hua Dong, Chao-Liang Li, Shi Zhang, Bao-Sen Yin, Zheng-Liu Wang, Pi-Yu Fu, Shi-Hong Li, Ming-Hua Liu, Fen Zhang, Juan Sun, Jie Li, Can-Wei Gao, Xiao-Yan Liu, Hong Wang, Huan-Yu Petersen, Lyle R. Liang, Guo-Dong TI Mosquitoes of Western Yunnan Province, China: Seasonal Abundance, Diversity, and Arbovirus Associations SO PLOS ONE LA English DT Article ID JAPANESE-ENCEPHALITIS-VIRUS; SOUTH-EASTERN; GENOTYPE-I; INFECTION; SEQUENCE; ASIA; IDENTIFICATION; DENSOVIRUS; GRADIENT; VIETNAM AB Objective: The western borderland between Yunnan Province, China, and Myanmar is characterized by a climate that facilitates year-round production of mosquitoes. Numerous mosquito-transmitted viruses, including Japanese encephalitis virus circulate in this area. This project was to describe seasonal patterns in mosquito species abundance and arbovirus activity in the mosquito populations. Methods: Mosquitoes were collected in Mangshi and Ruili cities of Dehong Prefecture near the border of China and Burma in Yunnan Province, the Peoples Republic of China in 2010. We monitored mosquito species abundance for a 12-month period using ultraviolet light, carbon dioxide baited CDC light and gravid traps; and tested the captured mosquitoes for the presence of virus to evaluate mosquito-virus associations in rural/agricultural settings in the area. Results: A total of 43 species of mosquitoes from seven genera were collected, including 15 Culex species, 15 Anopheles spp., four Aedes spp., three Armigeres spp., one Mimomyia spp., two Uranotaenia spp. and three Mansonia spp.. Species richness and diversity varied between Mangshi and Ruili. Culex tritaeniorhynchus, Culex quinquefasciatus, Anopheles sinensis and Anopheles peditaeniatus were the most abundant species in both sampling sites. Ultraviolet light traps collected more specimens than CDC light traps baited with dry ice, though both collected the same variety of mosquito species. The CDC gravid trap was the most effective trap for capture of Culex quinquefasciatus, a species underrepresented in light trap collections. A total of 26 virus strains were isolated, which included 13 strains of Japanese encephalitis virus, four strains of Getah virus, one strain of Oya virus, one strain from the orbivirus genus, and seven strains of Culex pipien pallens densovirus. Conclusions: The present study illustrates the value of monitoring mosquito populations and mosquito-transmitted viruses year-round in areas where the climate supports year-round adult mosquito activity. C1 [Zhang, Hai-Lin; Zhang, Yu-Zhen; Yang, Wei-Hong; Feng, Yun; Liu, Fen; Zhang, Juan; Sun, Jie; Li, Can-Wei] Yunnan Prov Ctr Virus & Rickettsia Res, Yunnan Inst Endem Dis Control & Prevent, Dali, Yunnan, Peoples R China. [Nasci, Roger S.; Petersen, Lyle R.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Yang, Jie; Dong, Chao-Liang; Zhang, Bao-Sen] Dehong Prefecture Ctr Dis Control & Prevent, Mangshi, Yunnan, Peoples R China. [Liu, Yong-Hua; Li, Shi; Yin, Zheng-Liu] Ruili City Ctr Dis Control & Prevent, Ruili, Yunnan, Peoples R China. [Wang, Pi-Yu] Yunnan Inst Parasit Dis, Simao, Yunnan, Peoples R China. [Fu, Shi-Hong; Li, Ming-Hua; Gao, Xiao-Yan; Liu, Hong; Wang, Huan-Yu; Liang, Guo-Dong] Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China. RP Liang, GD (reprint author), Chinese Ctr Dis Control & Prevent, Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China. EM gdliang@hotmail.com RI Li, Minghua/M-8776-2016 FU China Centers for Disease Control and Prevention - U.S. Centers for Disease Control and Prevention [U-19-GH000004]; Ministry of Science and Technology, China [2011CB504702]; State Key Laboratory for Infectious Disease Prevention and Control [2008SKLID105] FX This study was supported by from China Centers for Disease Control and Prevention - U.S. Centers for Disease Control and Prevention Cooperative Agreement U-19-GH000004; The Ministry of Science and Technology, China (2011CB504702); and Development grant of the State Key Laboratory for Infectious Disease Prevention and Control (2008SKLID105). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 2 Z9 5 U1 0 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 11 PY 2013 VL 8 IS 10 AR e77017 DI 10.1371/journal.pone.0077017 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 236SL UT WOS:000325819400094 PM 24146951 ER PT J AU Tan, KR Wiegand, RE Arguin, PM AF Tan, Kathrine R. Wiegand, Ryan E. Arguin, Paul M. TI Exchange Transfusion for Severe Malaria: Evidence Base and Literature Review SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE severe malaria; exchange transfusion; malaria treatment ID PLASMODIUM-FALCIPARUM MALARIA; THERAPEUTIC APHERESIS; UNITED-STATES; ADJUNCT THERAPY; ARTESUNATE; ERYTHROCYTAPHERESIS; EXPERIENCE; INFECTION; AUSTRIA; DISEASE AB Background. Exchange transfusion (ET) has biologic plausibility as an adjunct to antimalarial drugs in treating severe malaria and has been used for decades despite limited evidence of its efficacy in improving survival. We examined the efficacy of ET as an adjunct treatment for severe malaria using US surveillance data and reviewed the literature to update recommendations. Methods. Patients with severe malaria reported to the US national malaria surveillance system during 19852010 were matched, and survival outcomes were compared between patients receiving and not receiving ET. The literature review used search terms "severe malaria" and "exchange transfusion." Case reports and series, observational and case-control studies, and meta-analysis were included. Results. One hundred one patients receiving ET were matched to 314 patients not receiving ET. There was no statistically significant association between ET and survival outcome (odds ratio, 0.84; 95% confidence interval, .44-1.60). We found 87 articles, mostly case reports or series, showing successful use of ET, likely reporting bias. There were 12 comparative studies, most of which were retrospective cohort studies, underpowered with no significant differences in survival. A previously published meta-analysis of 8 comparative studies found no significant survival differences. Adverse events were rarely reported but included acute respiratory distress syndrome, ventricular fibrillation, and hypotension. Conclusions. Despite rapid parasite clearance times resulting from ET, there is no evidence for efficacy of ET as adjunctive therapy in severe malaria. Adjunct ET cannot be recommended. When rapidly acting antimalarials, specifically artemisinins, become more widely available, the biologic plausibility argument for ET will become less relevant. C1 [Tan, Kathrine R.; Arguin, Paul M.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. [Wiegand, Ryan E.] Ctr Dis Control & Prevent, Data Management Grp, Atlanta, GA 30333 USA. RP Tan, KR (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 1600 Clifton Rd,MS A-6, Atlanta, GA 30333 USA. EM ktan@cdc.gov NR 31 TC 15 Z9 17 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 10 PY 2013 VL 57 IS 7 BP 923 EP 928 DI 10.1093/cid/cit429 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 239LX UT WOS:000326027400003 PM 23800940 ER PT J AU Moonan, PK Weis, SE AF Moonan, Patrick K. Weis, Stephen E. TI Caveat Emptor? Meta-Analysis of Studies Comparing Self-Observed Therapy and Directly Observed Therapy for Tuberculosis SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID RANDOMIZED CONTROLLED-TRIAL; PULMONARY TUBERCULOSIS; TREATMENT OUTCOMES; THAILAND; REGIMENS; DOTS C1 [Moonan, Patrick K.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Moonan, Patrick K.; Weis, Stephen E.] Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. RP Moonan, PK (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E10, Atlanta, GA 30333 USA. EM pmoonan@cdc.gov RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 10 PY 2013 VL 57 IS 7 BP 1062 EP + DI 10.1093/cid/cit431 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 239LX UT WOS:000326027400026 PM 23811420 ER PT J AU Zhang, ZF Cogswell, ME Gillespie, C Fang, J Loustalot, F Dai, SF Carriquiry, AL Kuklina, EV Hong, YL Merritt, R Yang, QH AF Zhang, Zefeng Cogswell, Mary E. Gillespie, Cathleen Fang, Jing Loustalot, Fleetwood Dai, Shifan Carriquiry, Alicia L. Kuklina, Elena V. Hong, Yuling Merritt, Robert Yang, Quanhe TI Association between Usual Sodium and Potassium Intake and Blood Pressure and Hypertension among US Adults: NHANES 2005-2010 SO PLOS ONE LA English DT Article ID DIETARY-SODIUM; UNITED-STATES; RANDOMIZED-TRIALS; NUTRITIONAL FACTORS; SALT INTAKE; DISEASE; METAANALYSIS; REDUCTION; CALCIUM; HEALTH AB Objectives: Studies indicate high sodium and low potassium intake can increase blood pressure suggesting the ratio of sodium-to-potassium may be informative. Yet, limited studies examine the association of the sodium-to-potassium ratio with blood pressure and hypertension. Methods: We analyzed data on 10,563 participants aged >= 20 years in the 2005-2010 National Health and Nutrition Examination Survey who were neither taking anti-hypertensive medication nor on a low sodium diet. We used measurement error models to estimate usual intakes, multivariable linear regression to assess their associations with blood pressure, and logistic regression to assess their associations with hypertension. Results: The average usual intakes of sodium, potassium and sodium-to-potassium ratio were 3,569 mg/d, 2,745 mg/d, and 1.41, respectively. All three measures were significantly associated with systolic blood pressure, with an increase of 1.04 mmHg (95% CI, 0.27-1.82) and a decrease of 1.24 mmHg (95% CI, 0.31-2.70) per 1,000 mg/d increase in sodium or potassium intake, respectively, and an increase of 1.05 mmHg (95% CI, 0.12-1.98) per 0.5 unit increase in sodium-to-potassium ratio. The adjusted odds ratios for hypertension were 1.40 (95% CI, 1.07-1.83), 0.72 (95% CI, 0.53-0.97) and 1.30 (95% CI, 1.05-1.61), respectively, comparing the highest and lowest quartiles of usual intake of sodium, potassium or sodium-to-potassium ratio. Conclusions: Our results provide population-based evidence that concurrent higher sodium and lower potassium consumption are associated with hypertension. C1 [Zhang, Zefeng; Cogswell, Mary E.; Gillespie, Cathleen; Fang, Jing; Loustalot, Fleetwood; Dai, Shifan; Kuklina, Elena V.; Hong, Yuling; Merritt, Robert; Yang, Quanhe] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA USA. RP Zhang, ZF (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. EM zzhang3@cdc.gov FU Office of Dietary Supplements, National Institutes of Health [3R01HL091024-02S1]; NSF-PGRP from the National Science Foundation [114139] FX Dr. Carriquiry is currently receiving a grant (#3R01HL091024-02S1) from the Office of Dietary Supplements, National Institutes of Health and A GRANT (NSF-PGRP#114139) from the National Science Foundation. For the remaining authors, no funding was declared. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 28 Z9 30 U1 1 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 10 PY 2013 VL 8 IS 10 AR UNSP e75289 DI 10.1371/journal.pone.0075289 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 236QM UT WOS:000325814200008 PM 24130700 ER PT J AU Tilert, T Dillon, C Paulose-Ram, R Hnizdo, E Doney, B AF Tilert, Timothy Dillon, Charles Paulose-Ram, Ryne Hnizdo, Eva Doney, Brent TI Estimating the US prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010 SO RESPIRATORY RESEARCH LA English DT Article DE Spirometry; Bronchodilator; COPD; Prevalence; NHANES ID REFERENCE VALUES; UNITED-STATES; LUNG-FUNCTION; COPD; POPULATION; ADULTS; DIAGNOSIS; PLATINO; BURDEN; SAMPLE AB Background: During 2007-2010, the National Health and Nutrition Examination Survey (NHANES) conducted a spirometry component which obtained pre-bronchodilator pulmonary lung function data on a nationally representative sample of US adults aged 6-79 years and post-bronchodilator pulmonary lung function data for the subset of adults with airflow limitation. The goals of this study were to 1) compute prevalence estimates of chronic obstructive pulmonary disease (COPD) using pre-bronchodilator and post-bronchodilator spirometry measurements and fixed ratio and lower limit of normal (LLN) diagnostic criteria and 2) examine the potential impact of nonresponse on the estimates. Methods: This analysis was limited to those aged 40-79 years who were eligible for NHANES pre-bronchodilator spirometry (n=7,104). Examinees with likely airflow limitation were further eligible for post-bronchodilator testing (n=1,110). Persons were classified as having COPD based on FEV1/FVC < 70% (fixed ratio) or FEV1/FVC < lower limit of normal (LLN) based on person's age, sex, height, and race/ethnicity. Those without spirometry but self-reporting both daytime supplemental oxygen therapy plus emphysema and/or current chronic bronchitis were also classified as having COPD. The final analytic samples for pre-bronchodilator and post-bronchodilator analyses were 77.1% (n=5,477) and 50.8% (n=564) of those eligible, respectively. To account for non-response, NHANES examination weights were adjusted to the eligible pre-bronchodilator and post-bronchodilator subpopulations. Results: In 2007-2010, using the fixed ratio criterion and pre-bronchodilator test results, COPD prevalence was 20.9% (SE 1.1) among US adults aged 40-79 years. Applying the same criterion to post-bronchodilator test results, prevalence was 14.0% (SE 1.0). Using the LLN criterion and pre-bronchodilator test results, the COPD prevalence was 15.4% (SE 0.8), while applying the same criterion to post-bronchodilator test results, prevalence was 10.2% (SE 0.8). Conclusions: The overall COPD prevalence among US adults aged 40-79 years varied from 10.2% to 20.9% based on whether pre- or post-bronchodilator values were used and which diagnostic criterion (fixed ratio or LLN) was applied. The overall prevalence decreased by approximately 33% when airflow limitation was based on post-bronchodilator as compared to pre-bronchodilator spirometry, regardless of which diagnostic criterion was used. C1 [Tilert, Timothy; Dillon, Charles; Paulose-Ram, Ryne] Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Hnizdo, Eva; Doney, Brent] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Morgantown, WV 26505 USA. RP Tilert, T (reprint author), Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM ttilert@cdc.gov NR 30 TC 10 Z9 11 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD OCT 9 PY 2013 VL 14 AR 103 DI 10.1186/1465-9921-14-103 PG 11 WC Respiratory System SC Respiratory System GA 263XZ UT WOS:000327842600001 PM 24107140 ER PT J AU Cha, RM Smith, D Shepherd, E Davis, CT Donis, R Nguyen, T Nguyen, HD Do, HT Inui, K Suarez, DL Swayne, DE Pantin-Jackwood, M AF Cha, Ra Mi Smith, Diane Shepherd, Eric Davis, C. Todd Donis, Ruben Tung Nguyen Hoang Dang Nguyen Do, Hoa Thi Inui, Ken Suarez, David L. Swayne, David E. Pantin-Jackwood, Mary TI Suboptimal protection against H5N1 highly pathogenic avian influenza viruses from Vietnam in ducks vaccinated with commercial poultry vaccines SO VACCINE LA English DT Article DE Ducks; H5N1 highly pathogenic avian influenza; Vaccine; Protection ID DOMESTIC DUCKS; MUSCOVY DUCKS; PEKIN DUCKS; HONG-KONG; PHYLOGENETIC ANALYSIS; ANAS-PLATYRHYNCHOS; HEMAGGLUTININ GENE; REVERSE GENETICS; A VIRUSES; CLADE 2.2 AB Domestic ducks are the second most abundant poultry species in many Asian countries including Vietnam, and play a critical role in the epizootiology of H5N1 highly pathogenic avian influenza (HPAI) [FAO]. In this study, we examined the protective efficacy in ducks of two commercial H5N1 vaccines widely used in Vietnam; Re-1 containing A/goose/Guangdong/1/1996 hemagglutinin (HA) clade 0 antigens, and Re-5 containing A/duck/Anhui/1/2006 HA clade 2.3.4 antigens. Ducks received two doses of either vaccine at 7 and at 14 or 21 days of age followed by challenge at 30 days of age with viruses belonging to the HA clades 1.1, 2.3.4.3, 2.3.2.1.A and 2.3.2.1.B isolated between 2008 and 2011 in Vietnam. Ducks vaccinated with the Re-1 vaccine were protected after infection with the two H5N1 HPAI viruses isolated in 2008 (HA clades 1.1 and 2.3.4.3) showing no mortality and limited virus shedding. The Re-1 and Re-5 vaccines conferred 90-100% protection against mortality after challenge with the 2010 H5N1 HPAI viruses (HA clade 2.3.2.1.A); but vaccinated ducks shed virus for more than 7 days after challenge. Similarly, the Re-1 and Re-5 vaccines only showed partial protection against the 2011 H5N1 HPAI viruses (HA clade 2.3.2.1.A and 2.3.2.1.B), with a high proportion of vaccinated ducks shedding virus for more than 10 days. Furthermore, 50% mortality was observed in ducks vaccinated with Re-1 and challenged with the 2.3.2.1.B virus. The HA proteins of the 2011 challenge viruses had the greatest number of amino acid differences from the two vaccines as compared to the viruses from 2008 and 2009, which correlates with the lesser protection observed with these viruses. These studies demonstrate the suboptimal protection conferred by the Re-1 and Re-5 commercial vaccines in ducks against H5N1 HPAI clade 2.3.2.1 viruses, and underscore the importance of monitoring vaccine efficacy in the control of H5N1 HPAI in ducks. Published by Elsevier Ltd. C1 [Cha, Ra Mi; Smith, Diane; Shepherd, Eric; Suarez, David L.; Swayne, David E.; Pantin-Jackwood, Mary] USDA ARS, Southeast Poultry Res Lab, Exot & Emerging Avian Viral Dis Unit, Athens, GA 30605 USA. [Davis, C. Todd; Donis, Ruben] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Tung Nguyen] Hanoi Univ Agr, Grad Sch, Hanoi, Vietnam. [Tung Nguyen; Hoang Dang Nguyen; Do, Hoa Thi; Inui, Ken] Natl Ctr Vet Diag, Dept Anim Hlth, Hanoi, Vietnam. RP Pantin-Jackwood, M (reprint author), USDA ARS, Southeast Poultry Res Lab, Exot & Emerging Avian Viral Dis Unit, 934 Coll Stn Rd, Athens, GA 30605 USA. EM Mary.Pantin-Jackwood@ars.usda.gov FU Foreign Agriculture Service of the USDA [60-6612-0-024]; Agriculture Research Service CRIS Projects [6612-32000-048, 6612-32000-063] FX The authors would like to thank Drs. Mariana Sa E. Silva and Kateri Bertran for technical assistance. This study was supported by a Specific Cooperative Agreement with the Foreign Agriculture Service of the USDA Project # #60-6612-0-024, and the Agriculture Research Service CRIS Projects 6612-32000-048 and 6612-32000-063. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture. USDA is an equal opportunity provider and employer. NR 59 TC 15 Z9 15 U1 1 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 9 PY 2013 VL 31 IS 43 BP 4953 EP 4960 DI 10.1016/j.vaccine.2013.08.046 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 242PV UT WOS:000326255400005 PM 23994373 ER PT J AU Moro, PL Harrington, T Shimabukuro, T Cano, M Museru, OI Menschik, D Broder, K AF Moro, Pedro L. Harrington, Theresa Shimabukuro, Tom Cano, Maria Museru, Oidda I. Menschik, David Broder, Karen TI Adverse events after Fluzone (R) Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013 SO VACCINE LA English DT Article DE Adverse event; Intradermal; Surveillance; Trivalent inactivated influenza vaccine; Vaccine safety ID IMMUNIZATION PRACTICES ACIP; SEASONAL INFLUENZA; ADVISORY-COMMITTEE; UNITED-STATES; SAFETY; RECOMMENDATIONS; IMMUNOGENICITY; PREVENTION; ADULTS AB Background: In May 2011, the first trivalent inactivated influenza vaccine exclusively for intradermal administration (TIV-ID) was licensed in the US for adults aged 18-64 years. Objective: To characterize adverse events (AEs) after TIV-ID reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. Methods: We searched VAERS for US reports after TIV-ID among persons vaccinated from July 1, 2011-February 28, 2013. Medical records were requested for reports coded as serious (death, hospitalization, prolonged hospitalization, disability, life-threatening-illness), and those suggesting anaphylaxis. Clinicians reviewed available information and assigned a primary clinical category to each report. Empirical Bayesian data mining was used to identify disproportional AE reporting following TIV-ID. Causality was not assessed. Results: VAERS received 466 reports after TIV-ID; 9(1.9%) were serious, including one reported fatality in an 88-year-old vaccinee. Median age was 43 years (range 4-88 years). The most common AE categories were: 218(46.8%) injection site reactions; 89(19.1%) other non-infectious (comprised mainly of constitutional signs and symptoms); and 74 (15.9%) allergy. Eight reports (1.7%) of anaphylaxis were verified by the Brighton criteria or a documented physician diagnosis. Disproportional reporting was identified for three AEs: 'injection site nodule', 'injection site pruritus', and 'drug administered to patient of inappropriate age'. The findings for the first two AEs were expected. Twenty-four reports of vaccinees <18 years or >= 65 years were reported, and 14 of 24 were coded with the AE 'drug administered to patient of inappropriate age'. Conclusions: Review of VAERS reports did not identify any new or unexpected safety concerns after TIV-ID. Injection site reactions were the most commonly reported AEs, similar to the pre-licensure clinical trials. Use of TIV-ID in younger and older individuals outside the approved age range highlights the need for education of healthcare providers regarding approved TIV-ID use. Published by Elsevier Ltd. C1 [Moro, Pedro L.; Harrington, Theresa; Shimabukuro, Tom; Cano, Maria; Museru, Oidda I.; Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30329 USA. [Menschik, David] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30329 USA. EM psm9@cdc.gov FU CDC budget; FDA budget FX The study was implemented by the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA). The only funds used were from CDC and FDA budgets. This study had no external sponsors. NR 21 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 9 PY 2013 VL 31 IS 43 BP 4984 EP 4987 DI 10.1016/j.vaccine.2013.08.001 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 242PV UT WOS:000326255400009 PM 23994022 ER PT J AU Auld, SC Click, ES Heilig, CM Miramontes, R Cain, KP Bisson, GP Mac Kenzie, WR AF Auld, Sara C. Click, Eleanor S. Heilig, Charles M. Miramontes, Roque Cain, Kevin P. Bisson, Gregory P. Mac Kenzie, William R. TI Association between tuberculin skin test result and clinical presentation of tuberculosis disease SO BMC INFECTIOUS DISEASES LA English DT Article DE Tuberculin test; Miliary tuberculosis; Pulmonary tuberculosis ID ACTIVE PULMONARY TUBERCULOSIS; FOREIGN-BORN PERSONS; UNITED-STATES; MYCOBACTERIAL DISEASE; ADULTS; DIAGNOSIS; CHILDREN; IMMUNITY AB Background: The tuberculin skin test (TST) is used to test for latent tuberculosis (TB) infection and support the diagnosis of active TB. However, little is known about the relationship between the TST result and the clinical presentation of TB disease. Methods: We analyzed US TB surveillance data, 1993-2010, and used multinomial logistic regression to calculate the association between TST result (0-4 mm [negative], 5-9 mm, 10-14 mm, and >= 15 mm) and clinical presentation of disease (miliary, combined pulmonary and extrapulmonary, extrapulmonary only, non-cavitary pulmonary, and cavitary pulmonary). For persons with pulmonary disease, multivariate logistic regression was used to calculate the odds of having acid-fast bacilli (AFB) positive sputum. Results: There were 64,238 persons with culture-confirmed TB included in the analysis, which was stratified by HIV status and birthplace (US-vs. foreign-born). Persons with a TST >= 15 mm were less likely to have miliary or combined pulmonary and extrapulmonary disease, but more likely to have cavitary pulmonary disease than noncavitary pulmonary disease. Persons with non-cavitary pulmonary disease with a negative TST were significantly more likely to have AFB positive sputum. Conclusions: Clinical presentation of TB disease differed according to TST result and persons with a negative TST were more likely to have disseminated disease (i.e., miliary or combined pulmonary and extrapulmonary). Further study of the TST result may improve our understanding of the host-pathogen relationship in TB disease. C1 [Auld, Sara C.; Click, Eleanor S.; Heilig, Charles M.; Miramontes, Roque; Mac Kenzie, William R.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Auld, Sara C.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Cain, Kevin P.] US Ctr Dis Control & Prevent, Kisumu, Kenya. [Bisson, Gregory P.] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. RP Auld, SC (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM via1@cdc.gov RI Heilig, Charles/C-2753-2008; OI Heilig, Charles/0000-0003-1075-1310; Miramontes, Roque/0000-0001-9535-460X NR 31 TC 6 Z9 6 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD OCT 4 PY 2013 VL 13 AR 460 DI 10.1186/1471-2334-13-460 PG 8 WC Infectious Diseases SC Infectious Diseases GA 278OI UT WOS:000328899200002 PM 24093965 ER PT J AU Choi, Y Dienes, HP Krawczynski, K AF Choi, Youkyung Dienes, Hans-Peter Krawczynski, Kris TI Kinetics of miR-122 Expression in the Liver during Acute HCV Infection SO PLOS ONE LA English DT Article ID HEPATITIS-C VIRUS; RT-PCR; MICRORNA MIR-122; RNA; IDENTIFICATION; NORMALIZATION; TRANSLATION; INTERFERON; CANCER; STABILIZATION AB The relationships among micro RNA-122 (miR-122) expression in the liver, hepatitis C virus (HCV) replication and hepatic damage were analyzed in three chimpanzees observed for 180 days after inoculation with HCV genotype 1a. Levels of miR-122 in the liver and serum were measured by real-time RT PCR in serial liver biopsies and serum samples. Hepatic miR-122 levels were normalized separately for each of three chimpanzees with small RNAs and microRNAs that are endogenous to the liver and are stably expressed. Two-to 4-fold rise in hepatic miR-122 levels was observed at the onset of HCV infection (the first 4 weeks) when HCV titers in the liver and serum increased rapidly in all three chimpanzees in concordance with in vitro data indicating the miR-122 significance for HCV replication. Between 10 to 14 weeks after inoculation, when hepatic and serum HCV RNA titers exceeded 3 logs and alanine aminotransferase (ALT) activity was elevated, hepatic miR-122 levels were in decline. Cumulative data derived from all three chimpanzees from 180 days of observation documented an inverse (negative) correlation between hepatic miR-122 and HCV RNA in the liver and serum and positive correlation between level of serum miR-122 and HCV replication. Subsequent rise of miR-122 level during HCV clearance and ALT normalization suggested a tri-phasic occurrence of the relationship among hepatic miR-122 expression, HCV replication and hepatic destruction, which was the most apparent in one chimpanzee but less evident in two other animals. In vivo kinetics of hepatic and serum miR-122, HCV replication and hepatic destruction reflects complexities of the virus-host interaction during the acute phase of HCV infection. C1 [Choi, Youkyung; Krawczynski, Kris] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. [Dienes, Hans-Peter] Univ Cologne, Inst Pathol, Cologne, Germany. RP Krawczynski, K (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. EM kzk1@cdc.gov FU Centers for Disease Control budget FX The study was funded from Centers for Disease Control budget. Financial Management Office of CDC had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 10 Z9 10 U1 1 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 4 PY 2013 VL 8 IS 10 AR e76501 DI 10.1371/journal.pone.0076501 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 232JF UT WOS:000325489100126 PM 24124569 ER PT J AU Barg-Man, C Reyes, R Parker, M Belknap, R Bettridge, J Bedell, DT Galvis, ME Ho, CS Jereb, JA AF Barg-Man, Carolyn Reyes, Randall Parker, Matt Belknap, Robert Bettridge, Juli Bedell, Deborah T. Galvis, Maria E. Ho, Christine S. Jereb, John A. TI Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Barg-Man, Carolyn] CDC, Boulder Cty Publ Hlth, Denver Metro TB Clin, Atlanta, GA 30333 USA. [Reyes, Randall; Parker, Matt; Belknap, Robert] CDC, Denver Metro TB Clin, Atlanta, GA 30333 USA. [Bettridge, Juli] CDC, Colorado Dept Publ Hlth & Environm, Atlanta, GA 30333 USA. [Bedell, Deborah T.] CDC, Div Viral Hepatiti, Atlanta, GA 30333 USA. [Galvis, Maria E.; Ho, Christine S.; Jereb, John A.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Jereb, JA (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jjereb@cdc.gov NR 7 TC 1 Z9 1 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 4 PY 2013 VL 62 IS 39 BP 805 EP 809 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WT UT WOS:000326057400001 ER PT J AU Mathiu, JM Wijesinghe, PR Agocs, M Burton, A Sale, J Van Beneden, C Taylor, T Flannery, B AF Mathiu, Jason Mwenda Wijesinghe, Pushpa Ranjan Agocs, Mary Burton, Anthony Sale, James Van Beneden, Chris Taylor, Thomas Flannery, Brendan TI Estimating Meningitis Hospitalization Rates for Sentinel Hospitals Conducting Invasive Bacterial Vaccine-Preventable Diseases Surveillance SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Mathiu, Jason Mwenda] WHO, Reg Off Africa, Brazzaville, Congo. [Wijesinghe, Pushpa Ranjan] WHO, Reg Off Southeast Asia, New Delhi, India. [Agocs, Mary; Burton, Anthony; Sale, James] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Flannery, Brendan] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. RP Agocs, M (reprint author), WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. EM agocsm@who.int NR 5 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD OCT 4 PY 2013 VL 62 IS 39 BP 810 EP 812 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WT UT WOS:000326057400002 ER PT J AU Sievert, JS Morrissey, BF Calvert, GM AF Sievert, Jennifer S. Morrissey, Barbara F. Calvert, Geoffrey M. TI Severe Acute Illness in a Toddler Exposed to Multiple Agricultural Pesticides and an Insect Repellent SO JOURNAL OF AGROMEDICINE LA English DT Article DE Carbaryl; children; farm workers; orchard; pesticides ID DEET; N,N-DIETHYL-M-TOLUAMIDE; CHILDREN; RATS; PERMETHRIN; CARBAMATE; TOXICITY; AGE AB Acute severe pesticide-related illness among farm worker children is rarely reported. The authors report a toddler with acute onset of apnea, cyanosis, somnolence, hypotonia, tachycardia, and miosis who required hospitalization. Health care providers suspected pesticide poisoning, but were unable to determine the causal agent. Investigation by a public health program documented four pesticide exposures that occurred within one-half hour of acute illness. This case illustrates the importance of a thorough environmental/occupational exposure history and obtaining biological samples. It also documents the need to strengthen the Worker Protection Standard for agricultural workers and the importance of reporting and investigating pesticide-related illness. C1 [Sievert, Jennifer S.; Morrissey, Barbara F.] Washington State Dept Hlth, Off Environm Hlth Safety & Toxicol, Olympia, WA 98504 USA. [Calvert, Geoffrey M.] NIOSH, Epidemiol Surveillance Team 1, Cincinnati, OH 45226 USA. RP Morrissey, BF (reprint author), Washington State Dept Hlth, Off Environm Hlth Safety & Toxicol, POB 47846, Olympia, WA 98504 USA. EM barbara.morrissey@doh.wa.gov NR 29 TC 0 Z9 0 U1 0 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1059-924X EI 1545-0813 J9 J AGROMEDICINE JI J. Agromedicine PD OCT 2 PY 2013 VL 18 IS 4 BP 285 EP 292 DI 10.1080/1059924X.2013.826606 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 233XE UT WOS:000325602000001 PM 24125043 ER PT J AU Ahmed, SM Lopman, BA Levy, K AF Ahmed, Sharia M. Lopman, Benjamin A. Levy, Karen TI A Systematic Review and Meta-Analysis of the Global Seasonality of Norovirus SO PLOS ONE LA English DT Review ID TIME-SERIES ANALYSIS; VIRAL GASTROENTERITIS; ROTAVIRUS DIARRHEA; UNITED-STATES; EPIDEMICS; OUTBREAKS; ENGLAND; WALES; SURVEILLANCE; TRANSMISSION AB Background: Noroviruses are the most common cause of acute gastroenteritis across all ages worldwide. These pathogens are generally understood to exhibit a wintertime seasonality, though a systematic assessment of seasonal patterns has not been conducted in the era of modern diagnostics. Methods: We conducted a systematic review of the Pubmed Medline database for articles published between 1997 and 2011 to identify and extract data from articles reporting on monthly counts of norovirus. We conducted a descriptive analysis to document seasonal patterns of norovirus disease, and we also constructed multivariate linear models to identify factors associated with the strength of norovirus seasonality. Results: The searched identified 293 unique articles, yielding 38 case and 29 outbreak data series. Within these data series, 52.7% of cases and 41.2% of outbreaks occurred in winter months, and 78.9% of cases and 71.0% of outbreaks occurred in cool months. Both case and outbreak studies showed an earlier peak in season-year 2002-03, but not in season-year 2006-07, years when new genogroup II type 4 variants emerged. For outbreaks, norovirus season strength was positively associated with average rainfall in the wettest month, and inversely associated with crude birth rate in both bivariate and multivariate analyses. For cases, none of the covariates examined was associated with season strength. When case and outbreaks were combined, average rainfall in the wettest month was positively associated with season strength. Conclusions: Norovirus is a wintertime phenomenon, at least in the temperate northern hemisphere where most data are available. Our results point to possible associations of season strength with rain in the wettest month and crude birth rate. C1 [Ahmed, Sharia M.; Lopman, Benjamin A.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ahmed, Sharia M.; Levy, Karen] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. RP Lopman, BA (reprint author), Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM blopman@cdc.gov FU Fogarty International Center at the National Institutes of Health [FIC R21TW009032]; U.S. Department of Energy; CDC FX Support was received from the Fogarty International Center (http://www.fic.nih.gov/) at the National Institutes of Health [FIC R21TW009032]. This work was also supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 47 Z9 51 U1 4 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 2 PY 2013 VL 8 IS 10 AR e75922 DI 10.1371/journal.pone.0075922 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 231RG UT WOS:000325434500038 PM 24098406 ER PT J AU Rossen, LM Tarasenko, YN Branum, AM Simon, AE Schoendorf, KC AF Rossen, Lauren M. Tarasenko, Yelena N. Branum, Amy M. Simon, Alan E. Schoendorf, Kenneth C. TI Abdominal Adiposity and Caregiver Recall of Healthcare Provider Identification of Child Overweight in the United States, 2001-2010 SO CHILDHOOD OBESITY LA English DT Article ID BODY-MASS INDEX; NATIONALLY REPRESENTATIVE SAMPLES; EXPERT COMMITTEE RECOMMENDATIONS; WAIST CIRCUMFERENCE PERCENTILES; WEIGHT STATUS; ADOLESCENT OVERWEIGHT; PEDIATRIC PRACTICE; US CHILDREN; OBESITY; PREVENTION AB Background: A minority of overweight or obese children are identified as such by a healthcare provider (HCP). The aim of this study was to examine characteristics of caregiver-reported HCP identification of overweight or obesity and whether it is associated with children's waist circumference (WC). Methods: This was an observational study using a nationally representative sample of 14,694 children (2-15 years of age) from the 2001-2010 National Health and Nutrition Examination Survey. Proxy respondents (i.e., caregivers) for 4906 overweight or obese (BMI >= 85th percentile) children reported whether an HCP had ever told them that their child was overweight. Multi-variable logistic regression analyses were used to examine associations between reported HCP identification of overweight and child sociodemographic and anthropometric characteristics. Results: Over 75% of caregivers of overweight or obese children did not recall being notified of their child's weight status by an HCP, though this proportion has decreased over the past decade. A significant WC by weight status interaction indicated abdominal adiposity was positively associated with reported HCP identification for obese children, but not for overweight children. Conclusions: Lower levels of reported HCP identification were observed for overweight children, compared to obese children; among obese children, those with lower levels of abdominal adiposity were less likely to be identified as overweight by an HCP, according to caregivers. Reasons for this finding remain unclear. Providers may be relying on a child's appearance, rather than universally screening all patients for overweight. Additionally, a variety of parent and provider characteristics may influence weight-related communications and caregiver recall of such information. C1 [Rossen, Lauren M.; Tarasenko, Yelena N.; Branum, Amy M.; Simon, Alan E.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Tarasenko, Yelena N.] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Dept Hlth Policy & Management, Statesboro, GA 30460 USA. [Tarasenko, Yelena N.] Georgia So Univ, Jiann Ping Hsu Coll Publ Hlth, Dept Epidemiol, Statesboro, GA 30460 USA. RP Rossen, LM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, 3311 Toledo Rd,Room 6114, Hyattsville, MD 20782 USA. EM lrossen@cdc.gov FU Intramural CDC HHS [CC999999] NR 46 TC 2 Z9 2 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD OCT PY 2013 VL 9 IS 5 BP 418 EP 426 DI 10.1089/chi.2013.0051 PG 9 WC Pediatrics SC Pediatrics GA AI4PQ UT WOS:000336847700008 PM 24028562 ER PT J AU Faith, MS Heo, M Kral, TVE Sherry, B AF Faith, Myles S. Heo, Moonseong Kral, Tanja V. E. Sherry, Bettylou TI Compliant Eating of Maternally Prompted Food Predicts Increased Body Mass Index z-Score Gain in Girls: Results from a Population- Based Sample SO CHILDHOOD OBESITY LA English DT Article ID CALORIC COMPENSATION; CHILDHOOD OVERWEIGHT; FEEDING RELATIONSHIP; YOUNG ADULTHOOD; SELF-REGULATION; WEIGHT STATUS; 7 Y; CHILDREN; OBESITY; RISK AB Background: Poorer "division of responsibility'' (DoR) feeding, characterized by high parental control and reduced child food choice, may promote pediatric obesity, although population-based prospective data are lacking. We tested whether poorer DoR feeding predicts childhood overweight/obesity onset and BMI z-score gain, over 10 years in the National Longitudinal Study of Youth. Methods: We studied 302 girls and 316 boys, with mean ages 52.24 and 52.35 months, respectively, in 1986, who were followed for 10 years. We excluded children who were initially overweight/obese. Mothers completed three DoR feeding questions in 1986: (1) child eating compliance of prompted foods; (2) child eating compliance of initially refused foods; and (3) mother-allotted child food choice. Child BMI (kg/m(2)) was calculated from measured weights and heights in 1986, 1988, 1992, 1994, and 1996. Results: Daughters who complied with maternal food prompts [odds ratio (OR), 2.01] and those who obeyed maternal prompts to consume initially rejected foods (OR, 2.29) "most of the time'' were significantly more likely than daughters who complied less frequently to become overweight/obese after 8 years. Also, more frequent eating compliance (p < 0.001) and more frequent compliance of initially rejected foods (p = 0.003) predicted greater BMI z-score gain in girls. These associations were not found for boys. Maternal obesity consistently predicted overweight/obesity risk in girls (ORs, 2.48-8.63) and boys (ORs, 2.27-4.03). Conclusions: Teaching parents to avoid coercive feeding practices, while encouraging child self-selection of healthier foods, may help their daughters to achieve better energy balance. C1 [Faith, Myles S.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA. [Heo, Moonseong] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Kral, Tanja V. E.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA. [Kral, Tanja V. E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sherry, Bettylou] Ctr Dis Control & Prevent, Res & Surveillance Team, Obes Prevent & Control Branch, Div Nutr Phys Act & Obes,Natl Ctr Chron Dis Preve, Atlanta, GA USA. RP Faith, MS (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, 2204 McGavran Greenberg Hall,CB 7461, Chapel Hill, NC 27599 USA. EM mfaith@unc.edu FU CDC through the ATPM/CDC/ATSDR [TS 318-15/15] FX This work was supported, in part, by the CDC through the ATPM/CDC/ATSDR Cooperative Agreement (TS 318-15/15). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 40 TC 3 Z9 3 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD OCT PY 2013 VL 9 IS 5 BP 427 EP 436 DI 10.1089/chi.2012.0098 PG 10 WC Pediatrics SC Pediatrics GA AI4PQ UT WOS:000336847700009 PM 24094145 ER PT J AU Dooyema, CA Belay, B Foltz, JL Williams, N Blanck, HM AF Dooyema, Carrie A. Belay, Brook Foltz, Jennifer L. Williams, Nancy Blanck, Heidi M. TI The Childhood Obesity Research Demonstration Project: A Comprehensive Community Approach To Reduce Childhood Obesity SO CHILDHOOD OBESITY LA English DT Article ID IMPROVING PRIMARY-CARE; PHYSICAL-ACTIVITY; CHRONIC ILLNESS; HEALTH WORKERS; CHILDREN; INTERVENTION; ADOLESCENTS; OVERWEIGHT; SCHOOL; ENVIRONMENTS C1 [Dooyema, Carrie A.; Belay, Brook; Foltz, Jennifer L.; Williams, Nancy; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Foltz, Jennifer L.; Williams, Nancy; Blanck, Heidi M.] US Publ Hlth Serv Commissioned Corp, Atlanta, GA USA. RP Dooyema, CA (reprint author), Ctr Dis Control & Prevent, Obes Prevent & Control Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-77, Atlanta, GA 30341 USA. EM igb7@cdc.gov NR 28 TC 21 Z9 21 U1 0 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD OCT PY 2013 VL 9 IS 5 BP 454 EP 459 DI 10.1089/chi.2013.0060 PG 6 WC Pediatrics SC Pediatrics GA AI4PQ UT WOS:000336847700012 PM 24094146 ER PT J AU Baker, M Atkins, A McCann, M Regelmann, W Dizikes, G McColley, S Cavanagh, K Nasr, S Lesko, B Howenstine, M Cordovado, S Earley, M Cuthbert, C Farrell, P AF Baker, M. Atkins, A. McCann, M. Regelmann, W. Dizikes, G. McColley, S. Cavanagh, K. Nasr, S. Lesko, B. Howenstine, M. Cordovado, S. Earley, M. Cuthbert, C. Farrell, P. TI IMPROVING NEWBORN SCREENING FOR CYSTIC FIBROSIS TO REDUCE SCREENING FALSE POSITIVES BY 3-TIER IRT/DNA/DNA STRATEGY USING ILLUMINA NEXT GENERATION SEQUENCING TECHNOLOGY SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Baker, M.; Atkins, A.] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. [Baker, M.; Farrell, P.] Univ Wisconsin, Dept Pediat, Madison, WI USA. [McCann, M.; Regelmann, W.] Newborn Screening Program, Minneapolis, MN USA. [McCann, M.; Regelmann, W.] UMN CF Ctr, Minneapolis, MN USA. [McCann, M.; Regelmann, W.] Newborn Screening Program, St Paul, MN USA. [McCann, M.; Regelmann, W.] UMN CF Ctr, St Paul, MN USA. [Dizikes, G.; McColley, S.] Newborn Screening Program, Chicago, IL USA. [Dizikes, G.; McColley, S.] UNW CF Ctr, Chicago, IL USA. [Cavanagh, K.; Nasr, S.] Newborn Screening Program, Lansing, MI USA. [Cavanagh, K.; Nasr, S.] UMI CF Ctr, Lansing, MI USA. [Lesko, B.; Howenstine, M.] Newborn Screening Program, Indianapolis, IN USA. [Lesko, B.; Howenstine, M.] Riley CF Ctr, Indianapolis, IN USA. [Cordovado, S.; Earley, M.; Cuthbert, C.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2013 VL 48 SU 36 BP 370 EP 371 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA AF0FB UT WOS:000334387200531 ER PT J AU Iskander, J Swain, R AF Iskander, John Swain, Robert TI Medication Safety Resources Available through a New Public Access Repository: A Descriptive Analysis SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Iskander, John; Swain, Robert] Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 159 BP 79 EP 80 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100150 ER PT J AU Peterson, SR Frey, MT Gilboa, SM Broussard, CS AF Peterson, Shenita R. Frey, Meghan T. Gilboa, Suzanne M. Broussard, Cheryl S. TI Public Perception of Risk Factors for Birth Defects: HealthStyles, 2010-2011 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Peterson, Shenita R.] Emory Univ, Atlanta, GA 30322 USA. [Frey, Meghan T.; Gilboa, Suzanne M.; Broussard, Cheryl S.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 299 BP 144 EP 145 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100278 ER PT J AU Gliklich, R Dreyer, N Hernandez-Diaz, S Cragan, J Tassinari, M Covington, D Ephross, S Chambers, C Berliner, E Leavy, M Khurana, L AF Gliklich, Richard Dreyer, Nancy Hernandez-Diaz, Sonia Cragan, Janet Tassinari, Melissa Covington, Deborah Ephross, Sara Chambers, Christina Berliner, Elise Leavy, Michelle Khurana, Laura TI Best Practices for Pregnancy Registries SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Gliklich, Richard; Dreyer, Nancy; Leavy, Michelle; Khurana, Laura] Outcome, Cambridge, MA USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Cragan, Janet] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev DIsabil, Atlanta, GA USA. [Tassinari, Melissa] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Covington, Deborah] PPD, Wilmington, NC USA. [Ephross, Sara] GlaxoSmithKline, Res Triangle Pk, NC USA. [Chambers, Christina] Univ Calif San Diego, La Jolla, CA 92093 USA. [Berliner, Elise] Agcy Healthcare Res & Qual, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 310 BP 150 EP 150 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100289 ER PT J AU Duffy, J Weintraub, E Vellozzi, C DeStefano, F AF Duffy, Jonathan Weintraub, Eric Vellozzi, Claudia DeStefano, Frank TI Risk of Febrile Seizure Following Inactivated Influenza Vaccine and Concomitant Vaccines SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Duffy, Jonathan; Weintraub, Eric; Vellozzi, Claudia; DeStefano, Frank] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 363 BP 176 EP 177 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100340 ER PT J AU Vellozzi, C Iqbal, S Stewart, B Tokars, J DeStefano, F AF Vellozzi, Claudia Iqbal, Shahed Stewart, Brock Tokars, Jerry DeStefano, Frank TI Cumulative Risk of Guillain-Barre Syndrome among Vaccinated and Unvaccinated Populations during the 2009 H1N1 Pandemic SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Vellozzi, Claudia; Iqbal, Shahed; Stewart, Brock; Tokars, Jerry; DeStefano, Frank] US Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 416 BP 204 EP 204 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100393 ER PT J AU Haber, P Patel, M Pan, Y Destefano, F Baggs, J Parashar, U AF Haber, Penina Patel, Manish Pan, Yi Destefano, Frank Baggs, James Parashar, Umesh TI Monitoring of Intussusception after Rotavirus Vaccines-United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2012 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Haber, Penina; Patel, Manish; Pan, Yi; Destefano, Frank; Baggs, James; Parashar, Umesh] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 420 BP 206 EP 206 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100397 ER PT J AU Huybrechts, KF Palmsten, K Margulis, AV Swanson, S Reefhuis, J Hernandez-Diaz, S AF Huybrechts, Krista F. Palmsten, Kristin Margulis, Andrea V. Swanson, Sonja Reefhuis, Jennita Hernandez-Diaz, Sonia TI Welcoming Advanced Methods into the World of Pregnancy Research SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Huybrechts, Krista F.] Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA. [Huybrechts, Krista F.] Harvard Univ, Sch Med, Boston, MA USA. [Palmsten, Kristin; Swanson, Sonja; Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Margulis, Andrea V.] RTI Hlth Solut, Barcelona, Spain. [Reefhuis, Jennita] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 428 BP 210 EP 210 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876100405 ER PT J AU Thyagarajan, V Su, S Gee, J Duffy, J McCarthy, NL Chan, KA Weintraub, E Lin, ND AF Thyagarajan, Veena Su, Sue Gee, Julianne Duffy, Jonathan McCarthy, Natalie L. Chan, K. Arnold Weintraub, Eric Lin, Nancy D. TI Identification of Seizures Among Adults and Children Following Influenza Vaccination Using Health Insurance Claims Data SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Thyagarajan, Veena; Su, Sue] Optum, Epidemiol, Ann Arbor, MI USA. [Gee, Julianne; Duffy, Jonathan; McCarthy, Natalie L.; Weintraub, Eric] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Chan, K. Arnold; Lin, Nancy D.] Optum, Epidemiol, Waltham, MA USA. [Chan, K. Arnold] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 617 BP 307 EP 308 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876101185 ER PT J AU Reefhuis, J Bobo, W van Puijenbroek, E Sahin, L AF Reefhuis, Jennita Bobo, William van Puijenbroek, Eugene Sahin, Leyla TI Interpreting and Communicating Risk of Medications in Pregnancy, Using SSRIs as an Example SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Bobo, William] Mayo Clin, Rochester, MN USA. [van Puijenbroek, Eugene] Netherlands Pharmacovigilance Ctr Lareb, Shertogenbosch, Netherlands. [Sahin, Leyla] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 SU 1 SI SI MA 740 BP 371 EP 372 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA AF7EJ UT WOS:000334876101307 ER PT J AU Gregg, EW AF Gregg, Edward W. TI Diabetes-related disability as a target for prevention SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Editorial Material C1 Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Centers Dis Control & Prevent, Atlanta, GA 30341 USA. RP Gregg, EW (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Centers Dis Control & Prevent, Atlanta, GA 30341 USA. EM edg7@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD OCT PY 2013 VL 1 IS 2 BP 81 EP 82 DI 10.1016/S2213-8587(13)70054-8 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AE1YD UT WOS:000333768800003 PM 24622305 ER PT J AU McCree, DH Millett, G Baytop, C Royal, S Ellen, J Halkitis, PN Kupprat, SA Gillen, S AF McCree, Donna H. Millett, Gregorio Baytop, Chanza Royal, Scott Ellen, Jonathan Halkitis, Perry N. Kupprat, Sandra A. Gillen, Sara TI Lessons Learned From Use of Social Network Strategy in HIV Testing Programs Targeting African American Men Who Have Sex With Men SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID INJECTION-DRUG USERS; UNITED-STATES; BLACK-MEN; YOUNG MEN; INFECTION; RISK; INTERVENTION; PREVENTION; METAANALYSIS; DISPARITIES AB Objectives. We report lessons derived from implementation of the Social Network Strategy (SNS) into existing HIV counseling, testing, and referral services targeting 18-to 64-year-old Black gay, bisexual, and other men who have sex with men (MSM). Methods. The SNS procedures used in this study were adapted from a Centers for Disease Control and Prevention-funded, 2-year demonstration project involving 9 community-based organizations (CBOs) in 7 cities. Under the SNS, HIV-positive and HIV-negative men at high risk for HIV (recruiters) were enlisted to identify and recruit persons from their social, sexual, or drug-using networks (network associates) for HIV testing. Sites maintained records of modified study protocols for ascertaining lessons learned. The study was conducted between April 2008 and May 2010 at CBOs in Washington, DC, and New York, New York, and at a health department in Baltimore, Maryland. Results. Several common lessons regarding development of the plan, staffing, training, and use of incentives were identified across the sites. Collectively, these lessons indicate use of SNS is resource-intensive, requiring a detailed plan, dedicated staff, and continual input from clients and staff for successful implementation. Conclusions. SNS may provide a strategy for identifying and targeting clusters of high-risk Black MSM for HIV testing. Given the resources needed to implement the strategy, additional studies using an experimental design are needed to determine the cost-effectiveness of SNS compared with other testing strategies. C1 [McCree, Donna H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Millett, Gregorio] Ctr Dis Control & Prevent, Washington, DC USA. [Baytop, Chanza; Royal, Scott] Abt Associates Inc, Bethesda, MD USA. [Ellen, Jonathan] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Halkitis, Perry N.; Kupprat, Sandra A.] NYU, Ctr Hlth Ident Behav & Prevent Studies, Steinhardt Sch Culture & Human Dev, New York, NY USA. [Gillen, Sara] Harlem United, Community Hlth Serv, New York, NY USA. RP McCree, DH (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE MS D-21, Atlanta, GA 30333 USA. EM zyr1@cdc.gov FU US Centers for Disease Control and Prevention (CDC) [1 UR6 PS000330, 5UR6PS000329, 5UR6PS000368] FX This work was funded by Cooperative Agreements to Abt Associates (1 UR6 PS000330), the Baltimore City Health Department (5UR6PS000329), and Harlem United Center for AIDS Research (5UR6PS000368) from the US Centers for Disease Control and Prevention (CDC). NR 24 TC 6 Z9 6 U1 0 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 IS 10 BP 1851 EP 1856 DI 10.2105/AJPH.2013.301260 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3PK UT WOS:000331004600040 PM 23948017 ER PT J AU Denniston, MM Byrd, KK Klevens, RM Drobeniuc, J Kamili, S Jiles, RB AF Denniston, Maxine M. Byrd, Kathy K. Klevens, R. Monina Drobeniuc, Jan Kamili, Saleem Jiles, Ruth B. TI An Assessment of the Performance of Self-Reported Vaccination Status for Hepatitis B, National Health and Nutrition Examination Survey 1999-2008 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; VIRUS INFECTION; PNEUMOCOCCAL VACCINATION; SURVEILLANCE; STUDENTS AB Objectives. We sought to assess the performance of self-reported vaccination with hepatitis B vaccine (HepB) compared with serological status for hepatitis B markers in the general US civilian population. Methods. Using 1999 through 2008 National Health and Nutrition Examination Survey data, we calculated 3 measures of agreement between self-reported HepB vaccination status and serological status: percent concordance, and positive (PPV) and negative predictive values (NPV) of self-report. Logistic regression was used to identify factors associated with agreement between self-report and serological status. Results. Overall agreement was 83% (95% CI = 82.3, 83.7), NPV of self-report was high (0.95; 95% CI = 0.93, 0.95) and PPV was low (0.53; 95% CI = 0.51, 0.54). Birth year relative to the 1991 recommendation for universal infant HepB vaccination had a strong association with agreement, however, the association was positive for those who reported receiving at least 3 doses and negative for those who reported receiving no doses. Conclusions. Although the low PPV in our study could be attributable in part to waning of vaccine-induced anti-HBs over time, national adult HepB vaccination coverage may be lower than previously estimated because national estimates usually depend on self-report of vaccine receipt. C1 [Denniston, Maxine M.; Klevens, R. Monina; Jiles, Ruth B.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Byrd, Kathy K.] Ctr Dis Control & Prevent, Prevent Branch, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Drobeniuc, Jan; Kamili, Saleem] Ctr Dis Control & Prevent, Branch Lab, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Klevens, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MailStop G37, Atlanta, GA 30329 USA. EM rmk2@cdc.gov NR 17 TC 7 Z9 8 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 IS 10 BP 1865 EP 1873 DI 10.2105/AJPH.2013.301313 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3PK UT WOS:000331004600042 PM 23948014 ER PT J AU Newbern, EC Anschuetz, GL Eberhart, MG Salmon, ME Brady, KA De Los Reyes, A Baker, JM Asbel, LE Johnson, CC Schwarz, DF AF Newbern, E. Claire Anschuetz, Greta L. Eberhart, Michael G. Salmon, Melinda E. Brady, Kathleen A. De Los Reyes, Andrew Baker, Jane M. Asbel, Lenore E. Johnson, Caroline C. Schwarz, Donald F. TI Adolescent Sexually Transmitted Infections and Risk for Subsequent HIV SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-SCHOOL-STUDENTS; UNITED-STATES; YOUNG-ADULTS; EPIDEMIOLOGIC SYNERGY; CHLAMYDIAL INFECTION; DISEASE TREATMENT; HIGH PREVALENCE; RURAL TANZANIA; TRANSMISSION AB Objectives. We estimated the risk of HIV associated with sexually transmitted infection (STI) history during adolescence. Methods. We retrospectively studied a cohort of adolescents (n = 75 273, born in 1985-1993) who participated in the Philadelphia High School STD Screening Program between 2003 and 2010. We matched the cohort to STI and HIV surveillance data sets and death certificates and performed Poisson regression to estimate the association between adolescent STI exposures and subsequent HIV diagnosis. Results. Compared with individuals reporting no STIs during adolescence, adolescents with STIs had an increased risk for subsequent HIV infection (incidence rate ratio [IRR] for adolescent girls = 2.6; 95% confidence interval [CI] = 1.5, 4.7; IRR for adolescent boys = 2.3; 95% CI = 1.7, 3.1). Risk increased with number of STIs. The risk of subsequent HIV infection was more than 3 times as high among those with multiple gonococcal infections during adolescence as among those with none. Conclusions. Effective interventions that reduce adolescent STIs are needed to avert future STI and HIV acquisition. Focusing on adolescents with gonococcal infections or multiple STIs might have the greatest impact on future HIV risk. C1 [Newbern, E. Claire; Anschuetz, Greta L.; Eberhart, Michael G.; Salmon, Melinda E.; Brady, Kathleen A.; De Los Reyes, Andrew; Baker, Jane M.; Asbel, Lenore E.; Johnson, Caroline C.; Schwarz, Donald F.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Salmon, Melinda E.; De Los Reyes, Andrew] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Newbern, EC (reprint author), Div Dis Control, Epidemiol Unit, 2nd Floor,500 S Broad St, Philadelphia, PA 19146 USA. EM claire.newbern@phila.gov FU Centers for Disease Control and Prevention Cooperative Agreements for Comprehensive STD Prevention Systems [5H25PS001351]; Addressing Syndemics Through Program Collaboration and Service Integration [1U38PS003152] FX Partial funding for this study was provided through the Centers for Disease Control and Prevention Cooperative Agreements for Comprehensive STD Prevention Systems (5H25PS001351) and Addressing Syndemics Through Program Collaboration and Service Integration (1U38PS003152). NR 54 TC 8 Z9 8 U1 2 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 IS 10 BP 1874 EP 1881 DI 10.2105/AJPH.2013.301463 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3PK UT WOS:000331004600043 PM 23947325 ER PT J AU Kaminski, JW Perou, R Visser, SN Scott, KG Beckwith, L Howard, J Smith, DC Danielson, ML AF Kaminski, Jennifer W. Perou, Ruth Visser, Susanna N. Scott, Keith G. Beckwith, Leila Howard, Judy Smith, D. Camille Danielson, Melissa L. TI BRIDGING THE GAP BETWEEN IMPLEMENTATION SCIENCE AND PARENTING INTERVENTION RESPOND SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Kaminski, Jennifer W.; Perou, Ruth; Visser, Susanna N.; Smith, D. Camille; Danielson, Melissa L.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Scott, Keith G.] Univ Miami, Linda Ray Intervent Ctr, Miami, FL USA. [Beckwith, Leila; Howard, Judy] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. RP Kaminski, JW (reprint author), Ctr Dis Control & Prevent, Child Dev Studies Team, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E88, Atlanta, GA 30333 USA. EM JKaminski@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 IS 10 BP E12 EP E12 DI 10.2105/AJPH.2013.301528 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3PK UT WOS:000331004600011 PM 23947332 ER PT J AU Kim, SY Saraiva, C Curtis, M Wilson, HG Troyan, J England, L Sharma, AJ AF Kim, Shin Y. Saraiva, Carina Curtis, Michael Wilson, Hoyt G. Troyan, Jennifer England, Lucinda Sharma, Andrea J. TI Fraction of Gestational Diabetes Mellitus Attributable to Overweight and Obesity by Race/Ethnicity, California, 2007-2009 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID RISK-FACTORS; PREGNANCY OUTCOMES; POPULATION; ETHNICITY; WOMEN; PREVALENCE; DIAGNOSIS AB Objectives. We calculated the racial/ethnic-specific percentages of gestational diabetes mellitus (GDM) attributable to overweight and obesity. Methods. We analyzed 1 228 265 records of women aged 20 years or older with a live, singleton birth in California during 2007 to 2009. Using logistic regression, we estimated the magnitude of the association between prepregnancy body mass index and GDM and calculated the percentages of GDM attributable to overweight and obesity overall and by race/ethnicity. Results. The overall estimated GDM prevalence ranged from 5.4% among White women to 11.9% among Asian/Pacific Islander women. The adjusted percentages of GDM deliveries attributable to overweight and obesity were 17.8% among Asians/Pacific Islander, 41.2% among White, 44.2% among Hispanic, 51.2% among Black, and 57.8% among American Indian women. Select Asian subgroups, such as Vietnamese (13.0%), Asian Indian (14.0%), and Filipino (14.2%), had the highest GDM prevalence, but the lowest percentage attributable to obesity. Conclusions. Elevated prepregnancy body mass index contributed to GDM in all racial/ethnic groups, which suggests that decreasing overweight and obesity among women of reproductive age could reduce GDM, associated delivery complications, and future risk of diabetes in both the mother and offspring. C1 [Kim, Shin Y.; Wilson, Hoyt G.; England, Lucinda; Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent, Atlanta, GA USA. [Saraiva, Carina; Curtis, Michael; Troyan, Jennifer] Calif Dept Publ Hlth Surveillance Assessment & Pr, Sacramento, CA USA. RP Kim, SY (reprint author), 4770 Buford Hwy NE,MS F-74, Atlanta, GA 30341 USA. EM skim1@cdc.gov RI Saraiva, Cristina/B-2403-2015; OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 39 TC 22 Z9 22 U1 2 U2 10 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2013 VL 103 IS 10 BP E65 EP E72 DI 10.2105/AJPH.2013.301469 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3PK UT WOS:000331004600019 PM 23947320 ER PT J AU Epstein, JS Jaffe, HW Alter, HJ Klein, HG AF Epstein, Jay S. Jaffe, Harold W. Alter, Harvey J. Klein, Harvey G. TI Blood system changes since recognition of transfusion-associated AIDS SO TRANSFUSION LA English DT Editorial Material ID NON-B-HEPATITIS; WEST-NILE-VIRUS; CHRONIC-FATIGUE-SYNDROME; NON-A-HEPATITIS; UNITED-STATES; TRYPANOSOMA-CRUZI; VIRAL-HEPATITIS; POSTTRANSFUSION HEPATITIS; TRANSMITTED VIRUSES; AUSTRALIA-ANTIGEN C1 [Epstein, Jay S.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA. [Jaffe, Harold W.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. [Alter, Harvey J.; Klein, Harvey G.] NIH, Dept Transfus Med, Bethesda, MD 20892 USA. RP Epstein, JS (reprint author), US FDA, Ctr Biol Evaluat & Res, HFM-300,1401 Rockville Pike, Rockville, MD 20852 USA. EM Jay.Epstein@FDA.HHS.gov NR 71 TC 4 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2013 VL 53 IS 10 SI SI BP 2365 EP 2374 DI 10.1111/trf.12373 PN 2 PG 10 WC Hematology SC Hematology GA 238UY UT WOS:000325978000003 PM 24032622 ER PT J AU Yartel, AK Rein, DB Krauskopf, K Massoud, OI Brown, KA Fallon, MB Smith, BD AF Yartel, Anthony K. Rein, David B. Krauskopf, Katherine Massoud, Omar I. Brown, Kimberly Ann Fallon, Michael B. Smith, Bryce D. TI Hepatitis C Virus (HCV) Antibody Positivity and Predictors among Adult Primary Care Patients: Cross-Sectional Analysis of a Multi-Site Retrospective Cohort Study SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Smith, Bryce D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Yartel, Anthony K.] Ctr Dis Control & Prevent Fdn, Atlanta, GA USA. [Brown, Kimberly Ann] Henry Ford Hosp, Detroit, MI 48202 USA. [Krauskopf, Katherine] Mt Sinai Sch Med, New York, NY USA. [Massoud, Omar I.] Univ Alabama Birmingham, Birmingham, AL USA. [Fallon, Michael B.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Rein, David B.] Univ Chicago, NORC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 24 BP 219A EP 219A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201024 ER PT J AU Bruce, M Bruden, DJ Hurlburt, D Zanis, C Thompson, GC Rea, LD Toomey, M Townshend-Bulson, LJ Rudolph, K Bulkow, L Spradling, P Baum, R Hennessy, TW McMahon, BJ AF Bruce, Michael Bruden, Dana J. Hurlburt, Debby Zanis, Carolyn Thompson, Gail C. Rea, Lisa D. Toomey, Michele Townshend-Bulson, Lisa J. Rudolph, Karen Bulkow, Lisa Spradling, Philip Baum, Richard Hennessy, Thomas W. McMahon, Brian J. TI Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 30 year Follow-up Study and Response to a Booster Dose SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Bruce, Michael; Bruden, Dana J.; Hurlburt, Debby; Zanis, Carolyn; Thompson, Gail C.; Rea, Lisa D.; Toomey, Michele; Rudolph, Karen; Bulkow, Lisa; Baum, Richard; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Townshend-Bulson, Lisa J.; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Spradling, Philip] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 187 BP 300A EP 300A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201187 ER PT J AU Mixson-Hayden, T Lee, D Ganova-Raeva, L Drobeniuc, J Stauffer, W Teshale, EH Kamili, S AF Mixson-Hayden, Tonya Lee, Deborah Ganova-Raeva, Lilia Drobeniuc, Jan Stauffer, William Teshale, Eyasu H. Kamili, Saleem TI Hepatitis A to E Virus Infections in Selected United States-bound Refugee Populations SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Mixson-Hayden, Tonya; Lee, Deborah; Ganova-Raeva, Lilia; Drobeniuc, Jan; Stauffer, William; Teshale, Eyasu H.; Kamili, Saleem] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 214 BP 315A EP 315A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201214 ER PT J AU Suryaprasad, A Byrd, KK Redd, JT Perdue, DG Manos, MM McMahon, BJ AF Suryaprasad, Anil Byrd, Kathy K. Redd, John T. Perdue, David G. Manos, M. Michele McMahon, Brian J. TI Mortality due to Chronic Liver Disease among American Indians and Alaska Natives in the United States, 1999-2009 SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Suryaprasad, Anil; Byrd, Kathy K.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Redd, John T.] Santa Fe Publ Hlth Serv Indian Hosp, Indian Hlth Serv, Santa Fe, NM USA. [Perdue, David G.] Amer Indian Canc Fdn, Minneapolis, MN USA. [Perdue, David G.] Minnesota Gastroenterol PA, Minneapolis, MN USA. [Manos, M. Michele] Kaiser Permanente Div Res, Oakland, CA USA. [McMahon, Brian J.] Alaska Native Med Ctr, Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 269 BP 341A EP 342A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201269 ER PT J AU Gounder, P Bulkow, L Bruce, M Hennessy, TW Snowball, M Spradling, PR McMahon, BJ AF Gounder, Prabhu Bulkow, Lisa Bruce, Michael Hennessy, Thomas W. Snowball, Mary Spradling, Philip R. McMahon, Brian J. TI Comparing the Cost of Screening for Hepatocellular Carcinoma in Persons with Chronic Hepatitis B Virus Infection by Ultrasound Alone Versus a Two-Step Approach Using Alpha-Fetoprotein Followed by Ultrasound SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Gounder, Prabhu; Bulkow, Lisa; Bruce, Michael; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program Off, Anchorage, AK USA. [Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Snowball, Mary; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 370 BP 388A EP 389A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252201370 ER PT J AU Ko, SC Schillie, SF Nelson, N Veselsky, SL Murphy, TV AF Ko, Stephen C. Schillie, Sarah F. Nelson, Noele Veselsky, Steven L. Murphy, Trudy V. TI Hepatitis B Vaccine Response among Infants Born to Hepatitis B Surface Antigen-Positive Women SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Ko, Stephen C.; Schillie, Sarah F.; Nelson, Noele; Veselsky, Steven L.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 845 BP 608A EP 608A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252203013 ER PT J AU Duan, HY Zubkova, I Choi, Y Wells, F Chang, E Pirollo, KF Krawczynski, K Lanford, R Feinstone, S Major, ME AF Duan, Hongying Zubkova, Iryna Choi, Youkyung Wells, Frances Chang, Esther Pirollo, Kathleen F. Krawczynski, Kris Lanford, Robert Feinstone, Stephen Major, Marian E. TI Gene-Expression Profiling to Predict Outcome of Infection in Chimpanzees Vaccinated Against Hepatitis C Virus (HCV) SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Duan, Hongying; Zubkova, Iryna; Wells, Frances; Feinstone, Stephen; Major, Marian E.] US FDA, CBER, Bethesda, MD 20014 USA. [Choi, Youkyung; Krawczynski, Kris] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Chang, Esther; Pirollo, Kathleen F.] Georgetown Univ, Dept Oncol, Washington, DC USA. [Lanford, Robert] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1263 BP 822A EP 823A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204047 ER PT J AU Pereira, TA Syn, WK Choi, SS Voieta, I Resende, V Souza, MM Secor, WE Vidigal, PV Witek, RP Andrade, ZA Pereira, FE Lambertucci, JR Diehl, AM AF Pereira, Thiago A. Syn, Wing-Kin Choi, Steve S. Voieta, Izabela Resende, Vivian Souza, Marcia M. Secor, William E. Vidigal, Paula V. Witek, Rafal P. Andrade, Zilton A. Pereira, Fausto E. Lambertucci, Jose R. Diehl, Anna Mae TI Cholangiocyte proliferation and Osteopontin secretion is induced by Schistosoma mansoni egg antigens and correlates with fibrosis and portal hypertension in human and murine schistosomiasis SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Pereira, Thiago A.; Choi, Steve S.; Diehl, Anna Mae] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA. [Pereira, Thiago A.; Souza, Marcia M.; Andrade, Zilton A.] Ctr Pesquisas Goncalo Moniz FIOCRUZ, Lab Patol Expt, Salvador, BA, Brazil. [Voieta, Izabela; Resende, Vivian; Vidigal, Paula V.; Lambertucci, Jose R.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil. [Syn, Wing-Kin] Fdn Liver Res, Liver Regenerat & Repair Res Grp, Inst Hepatol, London, England. [Secor, William E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pereira, Fausto E.] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Vitoria, Brazil. [Witek, Rafal P.] Life Technol, Carlsbad, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1315 BP 847A EP 847A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204099 ER PT J AU Xu, FJ Li, J Zhang, TL Rupp, LB Lu, M Moorman, AC Gordon, SC Spradling, PR Teshale, EH Boscarino, JA Vijayadeva, V Schmidt, MA Holmberg, SD AF Xu, Fujie Li, Jia Zhang, Talan Rupp, Loralee B. Lu, Mei Moorman, Anne C. Gordon, Stuart C. Spradling, Philip R. Teshale, Eyasu H. Boscarino, Joseph A. Vijayadeva, Vinutha Schmidt, Mark A. Holmberg, Scott D. TI Probabilities of Survival, Liver Transplantation, and Liver Complications by Hepatic Fibrosis Stage among Patients with Chronic Hepatitis C Virus (HCV) Infection from Chronic Hepatitis Cohort Study (CHeCS) SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Xu, Fujie; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.; Holmberg, Scott D.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Li, Jia; Zhang, Talan; Rupp, Loralee B.; Lu, Mei; Gordon, Stuart C.] Henry Ford Hosp, Detroit, MI 48202 USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Honolulu, HI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1433 BP 903A EP 904A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204216 ER PT J AU Moorman, AC Xing, J Rupp, LB Xu, FJ Gordon, SC Lu, M Spradling, PR Teshale, EH Boscarino, JA Vijayadeva, V Schmidt, MA Holmberg, SD AF Moorman, Anne C. Xing, Jian Rupp, Loralee B. Xu, Fujie Gordon, Stuart C. Lu, Mei Spradling, Philip R. Teshale, Eyasu H. Boscarino, Joseph A. Vijayadeva, Vinutha Schmidt, Mark A. Holmberg, Scott D. TI Presence of advanced liver disease concurrent with initial diagnosis of hepatitis C virus (HCV) infection among patients in the Chronic Hepatitis Cohort Study (CHeCS): missed opportunities for intervention SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Moorman, Anne C.; Xing, Jian; Xu, Fujie; Spradling, Philip R.; Teshale, Eyasu H.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Rupp, Loralee B.; Gordon, Stuart C.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1439 BP 906A EP 907A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204222 ER PT J AU Choi, Y Dienes, HP Krawczynski, K AF Choi, Youkyung Dienes, Hans P. Krawczynski, Kris TI Kinetics of miR-122 expression in the liver during acute HCV infection SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Choi, Youkyung; Krawczynski, Kris] Ctr Dis Control & Prevent, Div Viral Hepatitis, NCHHSTP, Atlanta, GA USA. [Dienes, Hans P.] Univ Cologne, Inst Pathol, Cologne, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 1502 BP 936A EP 936A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252204285 ER PT J AU Teshale, EH Xing, J Moorman, AC Rupp, LB Gordon, SC Boscarino, JA Schmidt, MA Vijayadeva, V Spradling, PR Holmberg, SD Xu, FJ AF Teshale, Eyasu H. Xing, Jian Moorman, Anne C. Rupp, Loralee B. Gordon, Stuart C. Boscarino, Joseph A. Schmidt, Mark A. Vijayadeva, Vinutha Spradling, Philip R. Holmberg, Scott D. Xu, Fujie TI Trends in hospital utilization among chronic hepatitis C patients in the US; the Chronic Hepatitis Cohort Study (CHeCS) 2006-2010 SO HEPATOLOGY LA English DT Meeting Abstract CT 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 01-05, 2013 CL Washington, DC SP Amer Assoc Study Liver Dis C1 [Teshale, Eyasu H.; Xing, Jian; Moorman, Anne C.; Spradling, Philip R.; Holmberg, Scott D.; Xu, Fujie] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rupp, Loralee B.; Gordon, Stuart C.] Henry Ford Hlth Syst, Detroit, MI USA. [Schmidt, Mark A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Vijayadeva, Vinutha] Kaiser Permanente, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2013 VL 58 SU 1 SI SI MA 2252 BP 1297A EP 1297A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 297JR UT WOS:000330252206204 ER PT J AU Johnston, B Ligiero, D DeSilva, S Medley, A Nightingale, V Sripipatana, T Bachanas, P Abutu, A Brewinski-Isaacs, M Bathily, F Grillo, M Bertz, L Mani, N AF Johnston, Beverly Ligiero, Daniela DeSilva, Shyami Medley, Amy Nightingale, Vienna Sripipatana, Tabitha Bachanas, Pamela Abutu, Andrew Brewinski-Isaacs, Margaret Bathily, Fatoumata Grillo, Michael Bertz, Lilly Mani, Nithya TI Meeting the family planning needs of women living with HIV in US government global health programs SO AIDS LA English DT Article DE family planning; global health; integration; US government; women living with HIV ID RURAL UGANDA; INFECTION AB The integration of health programs, including HIV and voluntary family planning, is a priority for US government foreign assistance. One critical component of family planning and HIV integration that has significant positive health outcomes is ensuring that all women living with HIV have access to both a full range of contraceptives and safe pregnancy counseling. This article outlines the US government global health strategy to meet the family planning needs of women living with HIV based on three key principles: a focus on reproductive rights through voluntarism and informed choice, quality service provision through evidence-based programming, and development of partnerships. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Johnston, Beverly; Sripipatana, Tabitha] US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20523 USA. [Ligiero, Daniela; Bertz, Lilly] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20037 USA. [DeSilva, Shyami; Mani, Nithya] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA. [Medley, Amy; Bachanas, Pamela; Abutu, Andrew] US Dept HHS, Div Global HIV & AIDS, Ctr Dis Control & Prevent, Washington, DC 20201 USA. [Nightingale, Vienna; Grillo, Michael] US Dept Def, HIV AIDS Prevent Program, Washington, DC 20305 USA. [Brewinski-Isaacs, Margaret] US Dept HHS, Hlth Resources & Serv Adm, Washington, DC 20201 USA. [Bathily, Fatoumata] US Dept HHS, Off Global Affairs, Washington, DC 20201 USA. RP Ligiero, D (reprint author), US Dept State, Off US Global AIDS Coordinator, 2100 Penn Ave,NW Suite 200, Washington, DC 20037 USA. EM LigieroDP@state.gov FU Intramural CDC HHS [CC999999] NR 20 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD OCT PY 2013 VL 27 SU 1 BP S121 EP S125 DI 10.1097/QAD.0000000000000041 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 298UD UT WOS:000330349100014 PM 24088678 ER PT J AU Farnham, PG Gopalappa, C Sansom, SL Hutchinson, AB Brooks, JT Weidle, PJ Marconi, VC Rimland, D AF Farnham, Paul G. Gopalappa, Chaitra Sansom, Stephanie L. Hutchinson, Angela B. Brooks, John T. Weidle, Paul J. Marconi, Vincent C. Rimland, David TI Updates of Lifetime Costs of Care and Quality-of-Life Estimates for HIV-Infected Persons in the United States: Late Versus Early Diagnosis and Entry Into Care SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 34th Annual Meeting of the Society-for-Medical-Decision-Making CY OCT 17-20, 2012 CL Phoenix, AZ SP Soc Med Decis Making DE HIV lifetime costs of care; Timing of diagnosis; entry into care ID ACTIVE ANTIRETROVIRAL THERAPY; MEDICAL-CARE; HEALTH-CARE; HIV-1-INFECTED PATIENTS; PREVENTION; TRANSMISSION; COHORT; ERA; EXPENDITURES; MULTICENTER AB Background: Lifetime costs of care and quality-of-life estimates for HIV-infected persons depend on the disease stage at which these persons are diagnosed, enter care, and start antiretroviral therapy. Updated estimates were used to analyze the effects of late versus early diagnosis/entry on US lifetime care costs, quality-of-life estimates, and HIV transmissions. Methods: The Progression and Transmission of HIV/AIDS model was used to estimate discounted (3%) lifetime treatment costs ($US 2011) and quality-of-life variables from time of infection for cohorts of 10,000 HIV-infected index patients in 4 categories of CD4 count at diagnosis: (I) <= 200 cells/mu L, (II) 201-350 cells/mu L, (III) 351-500 cells/mu L, and (IV) 501-900 cells/mu L. It is assumed that index patient diagnoses were uniformly distributed across the CD4 count range in each category and that patients entered care at the time of diagnosis, remained in care, and were eligible to initiate antiretroviral therapy at a CD4 count of 500 cells/mu L. Lifetime transmissions of the index patients were also estimated. Results: Discounted average lifetime costs varied from $253,000 for category I index patients to $402,000 for category IV patients. Discounted quality-adjusted life years lost decreased from 7.95 to 4.45 across these categories, additional years of life expectancy increased from 30.8 to 38.1, and lifetime transmissions decreased from 1.40 to 0.72. Conclusions: Early diagnosis and treatment of HIV infection increases lifetime costs but improves length and quality of life and reduces the number of new infections transmitted by nearly 50%. C1 [Farnham, Paul G.; Gopalappa, Chaitra; Sansom, Stephanie L.; Hutchinson, Angela B.; Brooks, John T.; Weidle, Paul J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Marconi, Vincent C.; Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Marconi, Vincent C.; Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Marconi, Vincent C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Farnham, PG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,NE,MS E-48, Atlanta, GA 30333 USA. EM pgf1@cdc.gov RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689 NR 44 TC 34 Z9 36 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2013 VL 64 IS 2 BP 183 EP 189 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GP UT WOS:000330452700017 PM 23615000 ER PT J AU Farnham, PG Holtgrave, DR Gopalappa, C Hutchinson, AB Sansom, SL AF Farnham, Paul G. Holtgrave, David R. Gopalappa, Chaitra Hutchinson, Angela B. Sansom, Stephanie L. TI Lifetime Costs and Quality-Adjusted Life Years Saved From HIV Prevention in the Test and Treat Era SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID UNITED-STATES; ANTIRETROVIRAL THERAPY; CARE; INFECTION C1 [Farnham, Paul G.; Hutchinson, Angela B.; Sansom, Stephanie L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Holtgrave, David R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Gopalappa, Chaitra] Futures Inst, Glastonbury, CT USA. RP Farnham, PG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. NR 26 TC 16 Z9 19 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2013 VL 64 IS 2 BP E15 EP E18 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GP UT WOS:000330452700006 PM 24047975 ER PT J AU Steinau, M Unger, ER Hernandez, BY Goodman, MT Copeland, G Hopenhayn, C Cozen, W Saber, MS Huang, YJ Peters, ES Lynch, CF Wilkinson, EJ Rajeevan, MS Lyu, C Saraiya, M AF Steinau, Martin Unger, Elizabeth R. Hernandez, Brenda Y. Goodman, Marc T. Copeland, Glenn Hopenhayn, Claudia Cozen, Wendy Saber, Maria S. Huang, Youjie Peters, Edward S. Lynch, Charles F. Wilkinson, Edward J. Rajeevan, Mangalathu S. Lyu, Christopher Saraiya, Mona TI Human Papillomavirus Prevalence in Invasive Anal Cancers in the United States Before Vaccine Introduction SO JOURNAL OF LOWER GENITAL TRACT DISEASE LA English DT Article DE anal cancer; HPV typing; human papillomavirus; archived tissue; cancer registry ID INTRAEPITHELIAL NEOPLASIA; VARIANTS; INFECTION; CARCINOMA; WOMEN; RISK; US AB Objective. This study aimed to conduct a representative survey of human papillomavirus (HPV) prevalence and its genotype distribution in invasive anal cancer specimens in the United States. Materials and Methods. Population-based archival anal cancer specimens were identified from Florida, Kentucky, Louisiana, and Michigan cancer registries and Surveillance, Epidemiology, and End Results (SEER) tissue repositories in Hawaii, Iowa, and Los Angeles. Sections from 1 representative block per case were used for DNA extraction. All extracts were assayed first by linear array and retested with INNO-LiPA if inadequate or HPV negative. Results. Among 146 unique invasive anal cancer cases, 93 (63.7%) were from women, and 53 (36.3%) were from men. Human papillomavirus (any type) was detected in 133 cases (91.1%) and 129 (88.4%) contained at least 1 high risk-type, most (80.1%) as a single genotype. Human papillomavirus type 16 had the highest prevalence (113 cases, 77.4%); HPV types 6, 11, 18, and 33 were also found multiple times. Among HPV-16-positive cases, 37% were identified as prototype variant Ep, and 63% were nonprototypes: 33% Em, 12% E-G131G, 5% Af1, 4% AA/NA-1, 3% E-C109G, 3% E-G131T, 2% As, and 1% Af2. No significant differences in the distributions of HPV (any), high-risk types, or HPV-16/18 were seen between sex, race, or age group. Conclusions. The establishment of prevaccine HPV prevalence in the United States is critical to the surveillance of vaccine efficacy. Almost80% of anal cancers were positive for the vaccine types HPV-16 or HPV-18, and in 70%, these were the only types detected, suggesting that a high proportion might be preventable by current vaccines. C1 [Steinau, Martin; Unger, Elizabeth R.; Rajeevan, Mangalathu S.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Atlanta, GA 30333 USA. [Hernandez, Brenda Y.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Goodman, Marc T.] Cedars Sinai Med Ctr, Community & Populat Hlth Res Inst, Dept Biomed Sci, Los Angeles, CA 90048 USA. [Copeland, Glenn] Michigan Dept Community Hlth, Michigan Canc Surveillance Program, Lansing, MI USA. [Hopenhayn, Claudia] Univ Kentucky, Dept Epidemiol, Lexington, KY USA. [Cozen, Wendy; Saber, Maria S.] Los Angeles Canc Registry, Los Angeles, CA USA. [Huang, Youjie] Florida Dept Hlth, Tallahassee, FL USA. [Peters, Edward S.] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA USA. [Lynch, Charles F.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Wilkinson, Edward J.] Univ Florida, Coll Med, Gainesville, FL USA. [Lyu, Christopher] Battelle Mem Inst, Durham, NC USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Atlanta, GA 30333 USA. RP Steinau, M (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, 1600 Clifton Rd,MS G41, Atlanta, GA 30333 USA. EM MSteinau@cdc.gov OI /0000-0003-4928-6532; Unger, Elizabeth/0000-0002-2925-5635 FU Centers for Disease Control and Prevention (CDC) intramural funds; Vaccine For Children Funds; CDC (Kentucky) [5U58DP000810-5]; CDC (Florida) [5U58DP000844-5]; CDC (Michigan) [5U58DP000812-5]; CDC (Louisiana) [5U58DP000769-5]; National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services (LosAngeles) [N01-PC-35139]; National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services (Iowa) [N01-PC-35143]; National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services (Hawaii) [N01-PC-35137]; California Department of Health Services [103885]; National Cancer Institute, National Institutes of Health, Department of Health and Human Services from the CDC [N01-PC-2010-00035, 1U58DP000807-3] FX The support for collection of original specimens from nonrepositories (Kentucky, Florida, Michigan, and Louisiana), coordination of genotyping data from both SEER and NPCR registries, and genotyping was largely supported by Centers for Disease Control and Prevention (CDC) intramural funds and Vaccine For Children Funds. This project has been supported in part with Federal funds by the CDC under grant number NO. 5U58DP000810-5 (Kentucky), 5U58DP000844-5 (Florida), 5U58DP000812-5 (Michigan), and 5U58DP000769-5 (Louisiana) and with Federal funds for Residual Tissue Repositories from the National Cancer Institute SEER Population-based Registry Program, National Institutes of Health, Department of Health and Human Services, under contract no. N01-PC-35139 (LosAngeles), N01-PC-35143 (Iowa) and N01-PC-35137 (Hawaii).; The collection of data from California used in this publication was largely supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under contract no. N01-PC-2010-00035; and grant number 1U58DP000807-3 from the CDC. NR 18 TC 22 Z9 23 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1089-2591 EI 1526-0976 J9 J LOW GENIT TRACT DI JI J. Low. Genit. Tract. Dis. PD OCT PY 2013 VL 17 IS 4 BP 397 EP 403 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 299BH UT WOS:000330369100016 PM 23609590 ER PT J AU Yazdy, MM Mitchell, AA Tinker, SC Parker, SE Werler, MM AF Yazdy, Mahsa M. Mitchell, Allen A. Tinker, Sarah C. Parker, Samantha E. Werler, Martha M. TI Periconceptional Use of Opioids and the Risk of Neural Tube Defects SO OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 7th International Conference on Neural Tube Defects CY NOV 06-09, 2011 CL Austin, TX ID BIRTH-DEFECTS; CONGENITAL-MALFORMATIONS; METHADONE; DRUGS; EXPOSURE; BRAIN; RAT; EMBRYOS; ANALGESICS; PREGNANCY AB OBJECTIVE: Opioid medications are among the most effective analgesics. However, the consequences of opioid exposure to the developing human offspring are not known. We assessed whether maternal opioid use in the periconceptional period was associated with the risk of neural tube defects in the offspring. METHODS: We used data from 1998 to 2010 from the Slone Epidemiology Center Birth Defects Study, an ongoing case-control study. Mothers were interviewed by telephone within 6 months of delivery about sociodemographic factors and exposures during pregnancy including detailed questions on type and timing of medication use. Mothers of 305 offsprings with neural tube defect were compared with mothers of 7,125 offsprings in the nonmalformed control group and 13,405 offsprings in the malformed control group. Periconceptional opioid use was defined as any reported use in the 2 months after the lastmenstrual period. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for study center. RESULTS: A higher percentage of mothers of offsprings with neural tube defects (3.9%) reported using an opioid medication than mothers of offsprings in the nonmalformed control group (1.6%) and offsprings in the malformed control group (2.0%) with adjusted ORs of 2.2 (95% CI 1.2-4.2) and 1.9 (95% CI 1.0-3.4), respectively. When offsprings were restricted to those with spina bifida, the adjusted ORs were 2.5 (95% CI 1.3-5.0) and 2.2 (95% CI 1.1-4.1), respectively. CONCLUSION: A 2.2-fold increase in risk would translate to a neural tube defect prevalence of 5.9 per 10,000 live births among women who use opioids. Overall, opioid use in the periconceptional period appeared to be associated with a modest increased risk of neural tube defects. C1 Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Yazdy, MM (reprint author), Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA. EM mahsa@bu.edu OI Yazdy, Mahsa/0000-0002-7415-5350; /0000-0002-7193-077X FU NCBDD CDC HHS [DD000697, U01 DD000697]; NICHD NIH HHS [T32 HD052458] NR 33 TC 24 Z9 24 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2013 VL 122 IS 4 BP 838 EP 844 DI 10.1097/AOG.0b013e3182a6643c PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300EJ UT WOS:000330446900016 PM 24084542 ER PT J AU Meaney-Delman, D Rasmussen, SA Beigi, RH Zotti, ME Hutchings, Y Bower, WA Treadwell, TA Jamieson, DJ AF Meaney-Delman, Dana Rasmussen, Sonja A. Beigi, Richard H. Zotti, Marianne E. Hutchings, Yalonda Bower, William A. Treadwell, Tracee A. Jamieson, Denise J. TI Prophylaxis and Treatment of Anthrax in Pregnant Women SO OBSTETRICS AND GYNECOLOGY LA English DT Review ID GROUP-B STREPTOCOCCUS; BIRTH-DEFECTS-PREVENTION; 1ST-TRIMESTER DRUG-USE; MATERNAL USE; TRANSPLACENTAL PASSAGE; CONGENITAL-ABNORMALITIES; OROFACIAL CLEFTS; AMNIOTIC-FLUID; UNITED-STATES; ORAL CLEFTS AB OBJECTIVE: To review the safety and pharmacokinetics of antimicrobials recommended for anthrax postexposure prophylaxis and treatment in pregnant women. DATA SOURCES: Articles were identified in the PubMed database from inception through December 2012 by searching the keywords (["pregnancy]" and [generic antibiotic drug name]). Additionally, we searched clinicaltrials.gov and conducted hand searches of references from REPROTOX, TERIS, review articles, and Briggs' Drugs in Pregnancy and Lactation. METHODS OF STUDY SELECTION: Articles included in the review contain primary data related to the safety and pharmacokinetics among pregnant women of 14 antimicrobials recommended for anthrax postexposure prophylaxis and treatment (amoxicillin, ampicillin, chloramphenicol, clindamycin, ciprofloxacin, doripenem, doxycycline, levofloxacin, linezolid, meropenem, moxifloxacin, penicillin, rifampin, and vancomycin). TABULATION, INTEGRATION, AND RESULTS: The PubMed search identified 3,850 articles for review. Reference hand searching yielded nine additional articles. In total, 112 articles met the inclusion criteria. CONCLUSIONS: Overall, safety and pharmacokinetic information is limited for these antimicrobials. Although small increases in risks for certain anomalies have been observed with some antimicrobials recommended for prophylaxis and treatment of anthrax, the absolute risk of these antimicrobials appears low. Given the high morbidity and mortality associated with anthrax, antimicrobials should be dosed appropriately to ensure that antibiotic levels can be achieved and sustained. Dosing adjustments may be necessary for the beta-lactam antimicrobials and the fluoroquinolones to achieve therapeutic levels in pregnant women. Data indicate that the b-lactam antimicrobials, the fluoroquinolones, and, to a lesser extent, clindamycin enter the fetal compartment, an important consideration in the treatment of anthrax, because these antimicrobials may provide additional fetal benefit in the second and third trimesters of pregnancy. C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Div Reprod Infect Dis & Obstetr Specialties,Dept, Pittsburgh, PA USA. RP Meaney-Delman, D (reprint author), 1600 Clifton Rd,Mailstop C12, Atlanta, GA 30333 USA. EM vmo0@cdc.gov OI Rasmussen, Sonja/0000-0002-0574-4928 FU Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response FX Supported by funds from the Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response. NR 146 TC 7 Z9 7 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2013 VL 122 IS 4 BP 885 EP 900 DI 10.1097/AOG.0b013e3182a5fdfd PG 16 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300EJ UT WOS:000330446900023 PM 24084549 ER PT J AU Kawwass, JF Boulet, S Kissin, DM Session, DR AF Kawwass, Jennifer F. Boulet, Sheree Kissin, Dmitry M. Session, Donna R. TI Tubal Factor Infertility and Perinatal Risk After Assisted Reproductive Technology Reply SO OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Kawwass, Jennifer F.; Session, Donna R.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA 30322 USA. [Kawwass, Jennifer F.; Boulet, Sheree] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kissin, Dmitry M.] Emory Univ, Sch Med, Dept Gynecol & Obstet,Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot,Div Repr, Atlanta, GA USA. RP Kawwass, JF (reprint author), Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA 30322 USA. FU Intramural CDC HHS [CC999999] NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2013 VL 122 IS 4 BP 909 EP 910 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300EJ UT WOS:000330446900036 PM 24084561 ER PT J AU Nandakumar, S Kannanganat, S Dobos, KM Lucas, M Spencer, JS Fang, SN McDonald, MA Pohl, J Birkness, K Chamcha, V Ramirez, MV Plikaytis, BB Posey, JE Amara, RR Sable, SB AF Nandakumar, Subhadra Kannanganat, Sunil Dobos, Karen M. Lucas, Megan Spencer, John S. Fang, Sunan McDonald, Melissa A. Pohl, Jan Birkness, Kristin Chamcha, Venkateswarlu Ramirez, Melissa V. Plikaytis, Bonnie B. Posey, James E. Amara, Rama Rao Sable, Suraj B. TI O-mannosylation of the Mycobacterium tuberculosis Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection SO PLOS PATHOGENS LA English DT Article ID FIBRONECTIN ATTACHMENT PROTEIN; DENDRITIC CELLS; MANNOSE RECEPTOR; 45-KILODALTON GLYCOPROTEIN; IMMUNE-RESPONSES; PRESENTING CELLS; TRANSGENIC MICE; VACCINE DESIGN; B-CELL; GLYCOSYLATION AB Glycosylation is the most abundant post-translational polypeptide chain modification in nature. Although carbohydrate modification of protein antigens from many microbial pathogens constitutes important components of B cell epitopes, the role in T cell immunity is not completely understood. Here, using ELISPOT and polychromatic flow cytometry, we show that O-mannosylation of the adhesin, Apa, of Mycobacterium tuberculosis (Mtb) is crucial for its T cell antigenicity in humans and mice after infection. However, subunit vaccination with both mannosylated and non-mannosylated Apa induced a comparable magnitude and quality of T cell response and imparted similar levels of protection against Mtb challenge in mice. Both forms equally improved waning BCG vaccine-induced protection in elderly mice after subunit boosting. Thus, O-mannosylation of Apa is required for antigenicity but appears to be dispensable for its immunogenicity and protective efficacy in mice. These results have implications for the development of subunit vaccines using post-translationally modified proteins such as glycoproteins against infectious diseases like tuberculosis. C1 [Nandakumar, Subhadra; Birkness, Kristin; Ramirez, Melissa V.; Plikaytis, Bonnie B.; Posey, James E.; Sable, Suraj B.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. [Kannanganat, Sunil; Chamcha, Venkateswarlu; Amara, Rama Rao] Emory Univ, Yerkes Natl Primate Res Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Kannanganat, Sunil; Chamcha, Venkateswarlu; Amara, Rama Rao] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Dobos, Karen M.; Lucas, Megan; Spencer, John S.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Fang, Sunan; McDonald, Melissa A.; Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. RP Nandakumar, S (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. EM SSable@cdc.gov RI Dobos, Karen/D-1170-2017; OI Dobos, Karen/0000-0001-7115-8524; Sable, Suraj/0000-0001-8440-1693 FU Georgia Research Alliance; National Institute of Health/National Institute of Allergy and Infectious Diseases [HHSN266200400091c]; Centers for Disease Control and Prevention; ORISE; Emerging Infectious Diseases fellowship FX This work was supported by Georgia Research Alliance (to SBS and RRA as principle investigators and JEP and TM Shinnick as co-investigators), National Institute of Health/National Institute of Allergy and Infectious Diseases contract HHSN266200400091c (to KMD), and Centers for Disease Control and Prevention intramural grants. SN and MVR acknowledge the postdoctoral financial assistance from ORISE and Emerging Infectious Diseases fellowship, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 11 Z9 13 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD OCT PY 2013 VL 9 IS 10 AR e1003705 DI 10.1371/journal.ppat.1003705 PG 16 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299GJ UT WOS:000330383800073 PM 24130497 ER PT J AU Tong, SX Zhu, XY Li, Y Shi, M Zhang, J Bourgeois, M Yang, H Chen, XF Recuenco, S Gomez, J Chen, LM Johnson, A Tao, Y Dreyfus, C Yu, WL McBride, R Carney, PJ Gilbert, AT Chang, J Guo, Z Davis, CT Paulson, JC Stevens, J Rupprecht, CE Holmes, EC Wilson, IA Donis, RO AF Tong, Suxiang Zhu, Xueyong Li, Yan Shi, Mang Zhang, Jing Bourgeois, Melissa Yang, Hua Chen, Xianfeng Recuenco, Sergio Gomez, Jorge Chen, Li-Mei Johnson, Adam Tao, Ying Dreyfus, Cyrille Yu, Wenli McBride, Ryan Carney, Paul J. Gilbert, Amy T. Chang, Jessie Guo, Zhu Davis, Charles T. Paulson, James C. Stevens, James Rupprecht, Charles E. Holmes, Edward C. Wilson, Ian A. Donis, Ruben O. TI New World Bats Harbor Diverse Influenza A Viruses SO PLOS PATHOGENS LA English DT Article ID HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; MAXIMUM-LIKELIHOOD; VIRAL POLYMERASE; PB2 PROTEIN; SARS-LIKE; SEGMENT 3; NEURAMINIDASE; BINDING; HOST; CORONAVIRUSES AB Aquatic birds harbor diverse influenza A viruses and are a major viral reservoir in nature. The recent discovery of influenza viruses of a new H17N10 subtype in Central American fruit bats suggests that other New World species may similarly carry divergent influenza viruses. Using consensus degenerate RT-PCR, we identified a novel influenza A virus, designated as H18N11, in a flat-faced fruit bat (Artibeus planirostris) from Peru. Serologic studies with the recombinant H18 protein indicated that several Peruvian bat species were infected by this virus. Phylogenetic analyses demonstrate that, in some gene segments, New World bats harbor more influenza virus genetic diversity than all other mammalian and avian species combined, indicative of a long-standing host-virus association. Structural and functional analyses of the hemagglutinin and neuraminidase indicate that sialic acid is not a ligand for virus attachment nor a substrate for release, suggesting a unique mode of influenza A virus attachment and activation of membrane fusion for entry into host cells. Taken together, these findings indicate that bats constitute a potentially important and likely ancient reservoir for a diverse pool of influenza viruses. C1 [Tong, Suxiang; Li, Yan; Zhang, Jing; Chen, Xianfeng; Tao, Ying] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30332 USA. [Zhu, Xueyong; Dreyfus, Cyrille; Yu, Wenli; Paulson, James C.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [Bourgeois, Melissa; Yang, Hua; Chen, Li-Mei; Johnson, Adam; Carney, Paul J.; Chang, Jessie; Guo, Zhu; Davis, Charles T.; Stevens, James; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Recuenco, Sergio; Gilbert, Amy T.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Gomez, Jorge] Minist Salud MINSA, Direcc Gen Epidemiol, Lima, Peru. [McBride, Ryan; Paulson, James C.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA. [Rupprecht, Charles E.] Scripps Res Inst, Global Alliance Rabies Control, La Jolla, CA 92037 USA. [Holmes, Edward C.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. RP Tong, SX (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30332 USA. EM sot1@cdc.gov; fwb4@cdc.gov; charles_rupprecht@yahoo.com; edward.holmes@sydney.edu.au; wilson@scripps.edu; rvd6@cdc.gov OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411; Holmes, Edward/0000-0001-9596-3552 FU NIH [AI058113, GM062116, GM098791, GM080533-06]; CDC; Skaggs Institute for Chemical Biology; DOE Office of Biological and Environmental Research; NIH, National Center for Research Resources, Biomedical Technology Program [P41RR001209]; National Institute of General Medical Sciences; National Cancer Institute [Y1-CO-1020]; NIGMS [Y1-GM-1104]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357, W-31-109-Eng-38]; Global Disease Detection program TSC funds in the Centers for Disease Control and Prevention, Atlanta, Georgia; collaborative Centers for Disease Control and Prevention-University of Georgia Seed Award FX The work was supported in part by NIH grant AI058113 (IAW and JCP), a contract from the CDC (JCP), and the Skaggs Institute for Chemical Biology. Portions of this research were conducted at SSRL, a national user facility operated by Stanford University on behalf of the U. S. Department of Energy (DOE), Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by NIH, National Center for Research Resources, Biomedical Technology Program (P41RR001209), and the National Institute of General Medical Sciences. The GM/CA CAT 23-ID-D beamline has been funded in whole or in part with federal funds from National Cancer Institute (Y1-CO-1020) and NIGMS (Y1-GM-1104). Supporting institutions for SER-CAT 22-ID may be found at www.ser-cat.org/members.html. Use of the Advanced Photon Source (APS) was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract no. DE-AC02-06CH11357 and contract no. W-31-109-Eng-38. Glycans for the arrays were provided by the Consortium for Functional Glycomics funded by NIH grants GM062116 and GM098791. This is publication 21954 from The Scripps Research Institute. ECH was supported in part by NIH grant GM080533-06. The study was supported in part by the Global Disease Detection program TSC funds in the Centers for Disease Control and Prevention, Atlanta, Georgia (ST) and in part by a collaborative Centers for Disease Control and Prevention-University of Georgia Seed Award (ST). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 314 Z9 345 U1 19 U2 102 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD OCT PY 2013 VL 9 IS 10 AR e1003657 DI 10.1371/journal.ppat.1003657 PG 12 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299GJ UT WOS:000330383800029 PM 24130481 ER PT J AU Tinker, SC Devine, O Mai, C Hamner, HC Reefhuis, J Gilboa, SM Dowling, NF Honein, MA AF Tinker, Sarah C. Devine, Owen Mai, Cara Hamner, Heather C. Reefhuis, Jennita Gilboa, Suzanne M. Dowling, Nicole F. Honein, Margaret A. TI Estimate of the Potential Impact of Folic Acid Fortification of Corn Masa Flour on the Prevention of Neural Tube Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE neural tube defects; folic acid; fortification; prevention ID UNITED-STATES; SPINA-BIFIDA; CONGENITAL-MALFORMATIONS; VITAMIN SUPPLEMENTATION; BIRTH-DEFECTS; FOLATE INTAKE; PREGNANCY; HEALTH; WOMEN; RACE/ETHNICITY AB BACKGROUND: Hispanics in the US have a higher prevalence of neural tube defect (NTD) -affected pregnancies than non-Hispanic whites, and lower median total folic acid (FA) intake. FA fortification of corn masa flour (CMF) is a policy-level intervention for NTD prevention; however, the impact on NTD prevalence has not been estimated. METHODS: We developed a model to estimate the percentage reduction in prevalence of spina bifida and anencephaly (NTDs) that could occur with FA fortification of CMF. Model inputs included estimates of the percentage reduction in United States NTD prevalence attributed to FA fortification of enriched cereal grain products (1995-1996 vs. 1998-2002), the increase in median FA intake after enriched cereal grain product fortification, and the estimated increase in median FA intake that could occur with CMF fortification at the same level as enriched cereal grain products (140 mu g/100 g). We used Monte Carlo simulation to quantify uncertainty. We stratified analyses by racial/ethnic group and rounded results to the nearest 10. RESULTS: We estimated CMF fortification could prevent 30 Hispanic infants from having spina bifida (95% uncertainty interval: 0, 80) and 10 infants from having anencephaly (95% uncertainty interval: 0, 40) annually. The estimated impact among non-Hispanic whites and blacks was smaller. CONCLUSION: CMF fortification with FA could prevent from 0 to 120 infants, with the most likely value of approximately 40, from having spina bifida or anencephaly among Hispanics, the population most likely to benefit from the proposed intervention. While this estimated reduction is unlikely to be discernible using current birth defect surveillance methods, it still suggests an important benefit to the target population. (C) 2013 Wiley Periodicals, Inc. C1 [Tinker, Sarah C.; Devine, Owen; Mai, Cara; Hamner, Heather C.; Reefhuis, Jennita; Gilboa, Suzanne M.; Dowling, Nicole F.; Honein, Margaret A.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Tinker, SC (reprint author), Mail Stop E86,1600 Clifton Rd, Atlanta, GA 30345 USA. EM zzu9@cdc.gov FU Centers for Disease Control and Prevention FX This research was funded by the Centers for Disease Control and Prevention. NR 40 TC 6 Z9 6 U1 2 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2013 VL 97 IS 10 BP 649 EP 657 DI 10.1002/bdra.23158 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 296HW UT WOS:000330176900005 PM 24142499 ER PT J AU Peterson, C Dawson, A Grosse, SD Riehle-Colarusso, T Olney, RS Tanner, JP Kirby, RS Correia, JA Watkins, SM Cassell, CH AF Peterson, Cora Dawson, April Grosse, Scott D. Riehle-Colarusso, Tiffany Olney, Richard S. Tanner, Jean Paul Kirby, Russell S. Correia, Jane A. Watkins, Sharon M. Cassell, Cynthia H. TI Hospitalizations, Costs, and Mortality among Infants with Critical Congenital Heart Disease: How Important Is Timely Detection? SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE heart defects; congenital; pediatrics; costs and cost analysis; birth defects surveillance ID BIRTH-DEFECTS SURVEILLANCE; PULSE OXIMETRY; NEWBORN-INFANTS; SCREENING-TEST; DIAGNOSIS; STRATEGIES; PROGRAMS; FLORIDA; ROLES AB BACKGROUND: Critical congenital heart disease (CCHD) was recently added to the U. S. Recommended Uniform Screening Panel for newborns. States considering screening requirements may want more information about the potential impact of screening. This study examined potentially avoidable mortality among infants with late detected CCHD and assessed whether late detection was associated with increased hospital resource use during infancy. METHODS: This was a state-wide, population-based, observational study of infants with CCHD (n = 3603) born 1998 to 2007 identified by the Florida Birth Defects Registry. We examined 12 CCHD conditions that are targets of newborn screening. Late detection was defined as CCHD diagnosis after the birth hospitalization. Deaths potentially avoidable through screening were defined as those that occurred outside a hospital following birth hospitalization discharge and those that occurred within 3 days of an emergency readmission. RESULTS: For 23% (n = 825) of infants, CCHD was not detected during the birth hospitalization. Death occurred among 20% (n = 568/2,778) of infants with timely detected CCHD and 8% (n = 66/825) of infants with late detected CCHD, unadjusted for clinical characteristics. Potentially preventable deaths occurred in 1.8% (n = 15/825) of infants with late detected CCHD (0.4% of all infants with CCHD). In multivariable models adjusted for selected characteristics, late CCHD detection was significantly associated with 52% more admissions, 18% more hospitalized days, and 35% higher inpatient costs during infancy. CONCLUSION: Increased CCHD detection at birth hospitals through screening may lead to decreased hospital costs and avoid some deaths during infancy. Additional studies conducted after screening implementation are needed to confirm these findings. (C) 2013 Wiley Periodicals, Inc. C1 [Peterson, Cora; Dawson, April; Grosse, Scott D.; Riehle-Colarusso, Tiffany; Olney, Richard S.; Cassell, Cynthia H.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Dawson, April] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Tanner, Jean Paul; Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA. [Correia, Jane A.; Watkins, Sharon M.] Florida Dept Hlth, Florida Birth Defects Registry, Bur Epidemiol, Div Dis Control & Hlth Protect, Tallahassee, FL USA. RP Peterson, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,Mailstop E-86, Atlanta, GA 30329 USA. EM cora.peterson@cdc.hhs.gov OI Peterson, Cora/0000-0001-7955-0977 FU March of Dimes Foundation [5-FY09-533]; Centers for Disease Control and Prevention (CDC); Oak Ridge Institute for Science and Education; U.S. Department of Energy; CDC FX Research Grant No. # 5-FY09-533 from the March of Dimes Foundation supported various aspects of this project, including database development. This study was also supported by appointments to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. Neither funder was involved in decisions regarding design, analysis, or interpretation of study results. NR 30 TC 16 Z9 17 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2013 VL 97 IS 10 BP 664 EP 672 DI 10.1002/bdra.23165 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 296HW UT WOS:000330176900007 PM 24000201 ER PT J AU Delmelle, EM Cassell, CH Dony, C Radcliff, E Tanner, JP Siffel, C Kirby, RS AF Delmelle, Eric M. Cassell, Cynthia H. Dony, Coline Radcliff, Elizabeth Tanner, Jean Paul Siffel, Csaba Kirby, Russell S. TI Modeling Travel Impedance to Medical Care for Children with Birth Defects Using Geographic Information Systems SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; spina bifida; medical care; geocoding; GIS; network modeling; travel distance; travel time ID PUBLIC-HEALTH RESEARCH; FOR-DISEASE-CONTROL; SOCIOECONOMIC-STATUS; OROFACIAL CLEFTS; SPATIAL-ANALYSIS; RURAL RESIDENCE; HEART-DEFECTS; SERVICES; NEEDS; DISTANCE AB BACKGROUND: Children with birth defects may face significant geographic barriers accessing medical care and specialized services. Using a Geographic Information Systems-based approach, one-way travel time and distance to access medical care for children born with spina bifida was estimated. METHODS: Using 2007 road information from the Florida Department of Transportation, we built a topological network of Florida roads. Live-born Florida infants with spina bifida during 1998 to 2007 were identified by the Florida Birth Defects Registry and linked to hospital discharge records. Maternal residence at delivery and hospitalization locations were identified during the first year of life. RESULTS: Of 668 infants with spina bifida, 8.1% (n = 4) could not be linked to inpatient data, resulting in 614 infants. Of those 614 infants, 99.7% (n = 612) of the maternal residential addresses at delivery were successfully geocoded. Infants with spina bifida living in rural areas in Florida experienced travel times almost twice as high compared with those living in urban areas. When aggregated at county levels, one-way network travel times exhibited statistically significant spatial autocorrelation, indicating that families living in some clusters of counties experienced substantially greater travel times compared with families living in other areas of Florida. CONCLUSION: This analysis demonstrates the usefulness of linking birth defects registry and hospital discharge data to examine geographic differences in access to medical care. Geographic Information Systems methods are important in evaluating accessibility and geographic barriers to care and could be used among children with special health care needs, including children with birth defects. (C) 2013 Wiley Periodicals, Inc. C1 [Delmelle, Eric M.; Dony, Coline] Univ N Carolina, Coll Liberal Arts & Sci, Dept Geog & Earth Sci, Charlotte, NC 28223 USA. [Delmelle, Eric M.; Dony, Coline] Univ N Carolina, Coll Liberal Arts & Sci, Ctr Appl GISci, Charlotte, NC 28223 USA. [Cassell, Cynthia H.; Siffel, Csaba] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Radcliff, Elizabeth] Univ N Carolina, Coll Hlth & Human Serv, Dept Publ Hlth Sci, Charlotte, NC 28223 USA. [Tanner, Jean Paul; Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA. RP Delmelle, EM (reprint author), Univ N Carolina, Dept Geog & Earth Sci, 9201 Univ City Blvd, Charlotte, NC 28223 USA. EM eric.delmelle@uncc.edu FU March of Dimes Foundation [5-FY09-533] FX Supported in part by Research Grant No. #5-FY09-533 from the March of Dimes Foundation. NR 64 TC 11 Z9 11 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2013 VL 97 IS 10 BP 673 EP 684 DI 10.1002/bdra.23168 PG 12 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 296HW UT WOS:000330176900008 PM 23996978 ER PT J AU Cassell, CH Krohmer, A Mendez, DD Lee, KA Strauss, RP Meyer, RE AF Cassell, Cynthia H. Krohmer, Anne Mendez, Dara D. Lee, Kyung A. Strauss, Ronald P. Meyer, Robert E. TI Factors Associated with Distance and Time Traveled to Cleft and Craniofacial Care SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE barriers to care; health care accessibility; travel time; travel distance; cleft lip; cleft palate; orofacial clefts ID QUALITY-OF-LIFE; OROFACIAL CLEFTS; BREAST-CANCER; BIRTH-DEFECTS; MEDICAL HOME; CHILDREN; NEEDS; SERVICES; BARRIERS; ACCESS AB BACKGROUND: Information on travel distance and time to care for children with birth defects is lacking. We examined factors associated with travel distance and time to cleft care among children with orofacial clefts. METHODS: In 2006, a mail/ phone survey was administered in English and Spanish to all resident mothers of children with orofacial clefts born 2001 to 2004 and identified by the North Carolina birth defects registry. We analyzed one- way travel distance and time and the extent to which taking a child to care was a problem. We used multivariable logistic regression to examine the association between selected sociodemographic factors and travel distance (<= 60 miles and > 60 miles) and time (<= 60 min and > 60 min) to cleft care. RESULTS: Of 475 eligible participants, 51.6% (n = 245) responded. Of the respondents, 97.1% (n = 238) were the child's biological mother. Approximately 83% (n = 204) of respondents were non- Hispanic White; 33.3% (n = 81) were college educated; and 50.0% (n = 115) had private health insurance. One- way mean and median travel distances were 80 and 50 miles, respectively (range, 0- 1058 miles). One- way mean and median travel times were 92 and 60 min, respectively (range, 5 min to 8 hr). After adjusting for selected sociodemographics, travel distance varied significantly by maternal education, child's age, and cleft type. Travel time varied significantly by child's age. Approximately 67% (n = 162) reported taking their child to receive care was not a problem. CONCLUSION: Approximately 48% of respondents traveled > 1 hr to receive cleft care. Increasing access to care may be important for improving health outcomes among this population (C) 2013 Wiley Periodicals, Inc. C1 [Cassell, Cynthia H.; Krohmer, Anne; Lee, Kyung A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Krohmer, Anne] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Mendez, Dara D.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Lee, Kyung A.] Northrop Grumman Informat Syst, Atlanta, GA USA. [Strauss, Ronald P.] Univ N Carolina, Off Execut Vice Chancellor & Provost, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. [Meyer, Robert E.] State Ctr Hlth Stat, North Carolina Div Publ Hlth, North Carolina Birth Defects Monitoring Program, Raleigh, NC USA. RP Cassell, CH (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM chcassell@cdc.gov OI Mendez, Dara/0000-0003-3999-1991 FU National Center on Birth Defects and Developmental Disabilities [U50/CCU422096]; Centers for Disease Control and Prevention (CDC) FX Supported in part by grant number U50/CCU422096 by the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC). NR 37 TC 8 Z9 8 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2013 VL 97 IS 10 BP 685 EP 695 DI 10.1002/bdra.23173 PG 11 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 296HW UT WOS:000330176900009 PM 24039055 ER PT J AU Gopalappa, C Huang, YLA Gift, TL Owusu-Edusei, K Taylor, M Gales, V AF Gopalappa, Chaitra Huang, Ya-Lin A. Gift, Thomas L. Owusu-Edusei, Kwame Taylor, Melanie Gales, Vincent TI Cost-Effectiveness of Screening Men in Maricopa County Jails for Chlamydia and Gonorrhea to Avert Infections in Women SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; NATIONAL PROBABILITY SAMPLE; ACID AMPLIFICATION TESTS; TREATMENT GUIDELINES; UNITED-STATES; TRACHOMATIS; IMPACT; TRANSMISSION; POSITIVITY; COMMUNITY AB Background: Chlamydia and gonorrhea infections can lead to serious and costly sequelae in women, but sequelae in men are rare. In accordance with the Centers for Disease Control and Prevention guidelines, female jail inmates in Maricopa County (Phoenix area), Arizona, are screened for these infections. Owing to lack of evidence of screening benefits in men, male inmates are tested and treated based on symptoms only. Methods: We developed a probabilistic simulation model to simulate chlamydia and gonorrhea infections in Maricopa County jail male inmates and transmissions to female partners per year. We estimated the cost-effectiveness of screening as the cost per infection averted. Costs were estimated from the perspective of the Maricopa County Department of Public Health and the Correctional Health Services. Results: Compared with symptom-based testing and treating strategy, screening male arrestees of all ages and only those 35 years or younger yielded the following results: averted approximately 556 and 491 cases of infection in women at a cost of approximately US $ 1240 and $ 860 per case averted, respectively, if screened during physical examination (between days 8 and 14 from entry to jail), and averted approximately 1100 and 995 cases of infections averted at a cost of US $ 1030 and $ 710 per infection averted, respectively, if screened early, within 2 to 3 days from entry to jail. Conclusions: Screening of male inmates incurs a modest cost per infection averted in women compared with symptom-based testing. Screening in correctional settings can be used by public health programs to reduce disease burden, sequelae, and associated costs. C1 [Gopalappa, Chaitra; Huang, Ya-Lin A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Gift, Thomas L.; Owusu-Edusei, Kwame; Taylor, Melanie] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, Melanie] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Taylor, Melanie] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. [Gales, Vincent] Maricopa Cty Correct Hlth Serv, Phoenix, AZ USA. RP Gopalappa, C (reprint author), Futures Inst, 41-A New London Tpke, Glastonbury, CT 06033 USA. EM chaitrag@gmail.com OI Gopalappa, Chaitra/0000-0001-8384-6041 FU Intramural CDC HHS [CC999999] NR 29 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2013 VL 40 IS 10 BP 776 EP 783 DI 10.1097/OLQ.0000000000000023 PG 8 WC Infectious Diseases SC Infectious Diseases GA 297FN UT WOS:000330241200004 PM 24275727 ER PT J AU Perez, LG Pratt, M Simoes, EJ de Moura, L Malta, DC AF Perez, Lilian G. Pratt, Michael Simoes, Eduardo J. de Moura, Lenildo Malta, Deborah C. TI Association Between Leisure-Time Physical Activity and Self-Reported Hypertension Among Brazilian Adults, 2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID PREVALENCE; VALIDITY; DISEASE AB Introduction Physical inactivity is a risk factor for hypertension. The objective of this study was to examine the association between self-reported leisure-time physical activity and hypertension among Brazilian adults categorized by sex and body weight. Methods The study used data from adult respondents in 26 capital cities and the Federal District to VIGITEL (N = 54,353), Brazil's 2008 national surveillance system for risk and protective factors for chronic diseases. We conducted a multivariate logistic regression analysis to investigate the association between self-reported leisure-time physical activity and hypertension and examined whether sex or body weight modified this relationship. Results The prevalence of self-reported hypertension was high among women, older people, and people with fewer years of education. Overall, leisure-time physical activity decreased with increasing age, increased with increasing education level, and was higher among men than women. The association for leisure-time physical activity and hypertension was modified by sex but not body weight. Leisure-time physical activity reduced the odds of hypertension in men. Conclusion On the basis of self-reporting, leisure-time physical activity may be protective against hypertension in Brazilian men. Inclusion of other physical activity domains in the analyses may be necessary to fully understand the complex relationship between physical activity and hypertension by sex. In addition, public health priorities in Brazil for improving physical activity can target the entire population and not just those who are overweight or obese. C1 [Pratt, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. [Simoes, Eduardo J.] Univ Missouri, Sch Med, Columbia, MO USA. [de Moura, Lenildo; Malta, Deborah C.] Natl Coordinat Noncommun Dis, Minist Hlth Brazil, Brasilia, DF, Brazil. RP Perez, LG (reprint author), 416 1-2 Mississippi St, San Diego, CA 92140 USA. EM lgperez12@gmail.com RI Malta, Deborah/H-7880-2012; OI Malta, Deborah/0000-0002-8214-5734; Simoes, Eduardo/0000-0003-4371-4305 FU Centers for Disease Control and Prevention (CDC) Foundation [550-10]; Building Global Public Health and Research Capacity for Non-Communicable Disease (NCD) Prevention; CDC Foundation [MOU 550-10] FX This work was supported by the Centers for Disease Control and Prevention (CDC) Foundation, Project 550-10 (2010-2013), Building Global Public Health and Research Capacity for Non-Communicable Disease (NCD) Prevention. Ms Perez carried out the primary analyses for this study while an Association of Schools of Public Health Fellow at CDC with support from the CDC Foundation (MOU 550-10). NR 31 TC 4 Z9 4 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2013 VL 10 AR UNSP 130032 DI 10.5888/pcd10.130032 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285LC UT WOS:000329394500007 ER PT J AU Deitchman, S AF Deitchman, Scott TI Enhancing Crisis Leadership in Public Health Emergencies SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Editorial Material DE crisis leadership; disaster planning; emergency management; leadership; public health ID DISASTER MEDICINE; PREPAREDNESS; MANAGEMENT; DISCIPLINE; TERRORISM; EVOLUTION; MODEL AB Reviews of public health emergency responses have identified a need for crisis leadership skills in health leaders, but these skills are not routinely taught in public health curricula. To develop criteria for crisis leadership in public health, published sources were reviewed to identify attributes of successful crisis leadership in aviation, public safety, military operations, and mining. These sources were abstracted to identify crisis leadership attributes associated with those disciplines and compare those attributes with crisis leadership challenges in public health. Based on this review, the following attributes are proposed for crisis leadership in public health: competence in public health science; decisiveness with flexibility; ability to maintain situational awareness and provide situational assessment; ability to coordinate diverse participants across very different disciplines; communication skills; and the ability to inspire trust. Of these attributes, only competence in public health science is currently a goal of public health education. Strategies to teach the other proposed attributes of crisis leadership will better prepare public health leaders to meet the challenges of public health crises. C1 [Deitchman, Scott] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Deitchman, Scott] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Deitchman, S (reprint author), CDC, NCEH, ATSDR, 4770 Buford Hwy F09, Atlanta, GA 30341 USA. EM sed2@cdc.gov NR 51 TC 0 Z9 0 U1 2 U2 19 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 EI 1938-744X J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2013 VL 7 IS 5 BP 534 EP 540 DI 10.1017/dmp.2013.81 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 273PC UT WOS:000328546700014 PM 24274133 ER PT J AU Eisen, RJ Enscore, RE Atiku, LA Zielinski-Gutierrez, E Mpanga, JT Kajik, E Andama, V Mungujakisa, C Tibo, E MacMillan, K Borchert, JN Gage, KL AF Eisen, Rebecca J. Enscore, Russell E. Atiku, Linda A. Zielinski-Gutierrez, Emily Mpanga, Joseph T. Kajik, Ezekiel Andama, Vincent Mungujakisa, Cyrus Tibo, Emmanuel MacMillan, Katherine Borchert, Jeff N. Gage, Kenneth L. TI Evidence that rodent control strategies ought to be improved to enhance food security and reduce the risk of rodent-borne illnesses within subsistence farming villages in the plague-endemic West Nile region, Uganda SO INTERNATIONAL JOURNAL OF PEST MANAGEMENT LA English DT Article DE food security; food storage; rodent-borne diseases; rodent control; rodent damage; plague; subsistence agriculture AB Rodents pose serious threats to human health and economics, particularly in developing countries where the animals play a dual role as pests: they are reservoirs of human pathogens, and they inflict damage levels to stored products sufficient to cause food shortages. To assess the magnitude of the damage caused by rodents to crops, their level of contact with humans, and to better understand current food storage and rodent control practices, we conducted a survey of 37 households from 17 subsistence farming villages within the West Nile region of Uganda. Our survey revealed that rodents cause both pre- and post-harvest damage to crops. Evidence of rodent access to stored foods was reported in conjunction with each of the reported storage practices. Approximately half of the respondents reported that at least one family member had been bitten by a rat within the previous three months. Approximately two-thirds of respondents practiced some form of rodent control in their homes. The abundance of rodents was similar within homes that practiced or did not practice rodent control. Together, our results show that current efforts are inadequate for effectively reducing rodent abundance in homes. C1 [Eisen, Rebecca J.; Enscore, Russell E.; Zielinski-Gutierrez, Emily; MacMillan, Katherine; Borchert, Jeff N.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80522 USA. [Atiku, Linda A.; Mpanga, Joseph T.; Kajik, Ezekiel; Andama, Vincent; Mungujakisa, Cyrus; Tibo, Emmanuel] Uganda Virus Res Inst, Entebbe, Uganda. RP Eisen, RJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80522 USA. EM dyn2@cdc.gov FU United States Centers for Disease Control and Prevention FX We thank the villagers for their participation in the survey and for allowing us to trap rodents in their homes. The study was funded by the United States Centers for Disease Control and Prevention. NR 25 TC 3 Z9 3 U1 1 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0967-0874 EI 1366-5863 J9 INT J PEST MANAGE JI Int. J. Pest Manage. PD OCT 1 PY 2013 VL 59 IS 4 BP 259 EP 270 DI 10.1080/09670874.2013.845321 PG 12 WC Entomology SC Entomology GA 273KQ UT WOS:000328534100002 PM 26500395 ER PT J AU Dilraj, A Bristow, CC Connolly, C Margot, B Dlamini, S Podewils, LJ AF Dilraj, A. Bristow, C. C. Connolly, C. Margot, B. Dlamini, S. Podewils, L. J. TI Validation of sputum smear results in the Electronic TB Register for the management of tuberculosis, South Africa SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; validation; sputum smear; surveillance ID SYSTEM; COMPLETENESS; BOTSWANA AB BACKGROUND: The accuracy of tuberculosis (TB) surveillance systems is paramount in TB control. In South Africa, information from the laboratory is not directly linked to the Electronic TB Register (ETR). OBJECTIVE: To validate smear results recorded in the ETR with those recorded in the laboratory. METHODS: A retrospective evaluation was conducted among all sputum smear-positive TB patients recorded in the ETR during the fourth quarter of 2009 in KwaZulu-Natal Province. RESULTS: Of 1036 smear-positive patients recorded in the ETR, 683 (65.9%) had positive results recorded in the laboratory register. Only 364 (53.2%) had their smear results recorded in the ETR at the end of the intensive phase of treatment; of 326 (89.6%) recorded as converted to smear-negative, 224 (61.5%) were confirmed as smear-negative in the laboratory. Of 331 patients with end-of-treatment results in the ETR, 302 (91.2%) were recorded as cured, but only 105 (34.8%) were confirmed in the laboratory. CONCLUSIONS: Over a third of TB patients registered as smear-positive in the ETR could not be confirmed based on laboratory results. Many patients did not have a laboratory record, lending to uncertainty as to the validity of the smear results and treatment outcomes recorded in the ETR. C1 [Dilraj, A.; Connolly, C.] South African Med Res Council, ZA-4001 Durban, Kwazulu Natal, South Africa. [Bristow, C. C.] Ctr Dis Control & Prevent, Global AIDS Program, Pretoria, South Africa. [Margot, B.] Republ South Africa KwaZulu Natal Dept Hlth, TB Program, Durban, South Africa. [Dlamini, S.] Republ South Africa Natl Dept Hlth, Pretoria, South Africa. [Podewils, L. J.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Dilraj, A (reprint author), South African Med Res Council, 491 Peter Mokaba Ridge, ZA-4001 Durban, Kwazulu Natal, South Africa. EM atom.dilraj@mrc.ac.za FU Centers for Disease Control and Prevention (CDC); South African Medical Research Council [5 387 U51 PS000729-05, PA PS07-006] FX This project was made possible through the support and collaboration with the Centers for Disease Control and Prevention (CDC) and the South African Medical Research Council (Cooperative Agreement 5 387 U51 PS000729-05, PA PS07-006). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 13 TC 7 Z9 7 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2013 VL 17 IS 10 BP 1317 EP 1321 DI 10.5588/ijtld.12.0904 PG 5 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 275MO UT WOS:000328681500012 PM 24025384 ER PT J AU Franka, R Smith, TG Dyer, JL Wu, XF Niezgoda, M Rupprecht, CE AF Franka, Richard Smith, Todd G. Dyer, Jessie L. Wu, Xianfu Niezgoda, Michael Rupprecht, Charles E. TI Current and future tools for global canine rabies elimination SO ANTIVIRAL RESEARCH LA English DT Review DE Rabies; Elimination; Vaccine; Prevention; Prophylaxis; Education ID MONOCLONAL-ANTIBODY COCKTAIL; POSTEXPOSURE PROPHYLAXIS; INTRATESTICULAR INJECTION; PREEXPOSURE VACCINATION; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; LATIN-AMERICA; UNITED-STATES; STRAY DOGS; PREVENTION AB Even though rabies is almost uniformly fatal, it is readily preventable with currently available tools. Vaccination is highly efficacious for the pre-exposure prophylaxis (PrEP) of rabies in humans and animals, and prompt postexposure prophylaxis (PEP) With vaccine and rabies immune globulin (RIG) can reliably prevent disease in humans. However, access to these tools and knowledge of their proper use are often limited, especially in impoverished, rabies-enzootic countries with the highest disease burden. In the absence of reliable diagnostic capacity and risk assessments, vaccines and RIG are often administered inappropriately, leading to chronic supply shortages and otherwise preventable deaths. Rather than focusing solely on human prophylaxis, it is more cost-effective over the long term to eliminate canine rabies in its natural terrestrial reservoirs. Because more than 99% of human rabies deaths result from dog bites, prevention efforts should focus on dogs. A versatile "One Health" strategy for canine rabies elimination should aim to create sustainable herd immunity in dogs, using proven vaccination strategies at the local level, coupled with community education and humane population management. Such strategies have succeeded in both developed and developing countries, and can be adapted to any locality. Numerous examples in Africa. Asia, and Latin America have shown that community-based, locally guided vaccination and education programs, based on a shared vision and long-term commitment, can eliminate canine rabies. Such programs should have specific goals and measurable outcomes, and should be conducted under the guidance of supportive governments, in collaboration with international partners and nongovernmental organizations. In addition to currently available tools, rabies prevention can be augmented by new dose-sparing human vaccine schedules, alternative routes of vaccine administration, monoclonal antibodies as an alternative to RIG, sensitive and specific point-of-care diagnostics and the development of canine immunocontraceptive methods. Accurate risk assessments of potential human exposures and support for decentralized laboratory capacity will be essential to ensure the most effective utilization of vaccines and RIG until canine rabies has been eliminated. (C) 2013 Published by Elsevier B.V. C1 [Franka, Richard; Smith, Todd G.; Dyer, Jessie L.; Wu, Xianfu; Niezgoda, Michael] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Rupprecht, Charles E.] Global Alliance Rabies Control, Res, Manhattan, KS 66502 USA. RP Franka, R (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Mail Stop G33, Atlanta, GA 30333 USA. EM rfranka@cdc.gov NR 78 TC 15 Z9 16 U1 1 U2 36 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD OCT PY 2013 VL 100 IS 1 BP 220 EP 225 DI 10.1016/j.antiviral.2013.07.004 PG 6 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 268OB UT WOS:000328179300024 PM 23871797 ER PT J AU Li, N Xiao, LH Cama, VA Ortega, Y Gilman, RH Guo, MJ Feng, YY AF Li, Na Xiao, Lihua Cama, Vitaliano A. Ortega, Ynes Gilman, Robert H. Guo, Meijin Feng, Yaoyu TI Genetic Recombination and Cryptosporidium hominis Virulent Subtype IbA10G2 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MOLECULAR CHARACTERIZATION; WATERBORNE OUTBREAK; POPULATION-GENETICS; WASTE-WATER; PARVUM; CHILDREN; EPIDEMIOLOGY; DIVERSITY; AUSTRALIA; CLONING AB Little is known :about the emergence and spread of virulent subtypes of Cryptosporidium hominis, the predominant species responsible for human cryptosporidiosis. We conducted sequence analyses of 32 genetic loci of 53 C. hominis specimens isolated from a longitudinally followed cohort of children living in a small community. We identified by linkage disequilibrium and recombination analyses only limited genetic recombination, which occurred exclusively within the 60-kDa glycoprotein gene subtype IbA10G2, a predominant subtype for outbreaks in industrialized nations and a virulent subtype in the study community. Intensive transmission of virulent subtype IbA10G2 in the study area might have resulted in genetic recombination with other subtypes. Moreover, we identified selection for IbA10G2 at a 129-kb region around the 60-kDa glycoprotein gene in chromosome 6. These findings improve our understanding of the origin and evolution of C. hominis subtypes and the spread of virulent subtypes. C1 [Li, Na; Guo, Meijin; Feng, Yaoyu] E China Univ Sci & Technol, Shanghai 200237, Peoples R China. [Li, Na; Xiao, Lihua; Cama, Vitaliano A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ortega, Ynes] Univ Georgia, Griffin, GA USA. [Gilman, Robert H.] Johns Hopkins Univ, Baltimore, MD USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31110103901, 31229005]; National Basic Research Program of China (973 project) [2011CB200903]; National Institutes of Health [5P01AI051976, 5R21AI059661]; US Department of Agriculture-Cooperative State Research, Education, and Extension Service [2001-51110-11340]; Fundamental Research Funds for the Central Universities, China FX This study was supported in part by the National Natural Science Foundation of China (grants 31110103901 and 31229005), the National Basic Research Program of China (973 project no. 2011CB200903), the National Institutes of Health (grants 5P01AI051976 and 5R21AI059661), the US Department of Agriculture-Cooperative State Research, Education, and Extension Service (grant 2001-51110-11340), and Fundamental Research Funds for the Central Universities, China. NR 39 TC 18 Z9 19 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1573 EP 1582 DI 10.3201/eid1910.121361 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900003 PM 24050210 ER PT J AU Gumede, N Lentsoane, O Burns, CC Pallansch, M de Gourville, E Yogolelo, R Muyembe-Tamfum, JJ Puren, A Schoub, BD Venter, M AF Gumede, Nicksy Lentsoane, Olivia Burns, Cara C. Pallansch, Mark de Gourville, Esther Yogolelo, Riziki Muyembe-Tamfum, Jean Jacques Puren, Adrian Schoub, Barry D. Venter, Marietjie TI Emergence of Vaccine-derived Polloviruses, Democratic Republic of Congo, 2004-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GLOBAL POLIO ERADICATION; DEOXYINOSINE RESIDUES; WIDESPREAD CIRCULATION; CODON DEGENERACY; MIXED-BASE; POLIOVIRUSES; OUTBREAK; IDENTIFICATION; PRIMERS; POLIOMYELITIS AB Polioviruses isolated from 70 acute flaccid paralysis patients from the Democratic Republic of Congo (DRC) during 2004-2011 were characterized and found to be Vaccine-derived type 2 polioviruses (VDPV2s). Partial genomic sequencing of the isolates revealed nucleotide sequence divergence of up to 3.5% in the viral protein 1 capsid region of the viral genome relative to the Sabin vaccine strain. Genetic analysis identified at least 7 circulating lineages localized to specific geographic regions. Multiple independent events of VDPV2 emergence occurred throughout DRC during this 7-year period. During 2010-2011, VDPV2 circulation in eastern DRC occurred in an area distinct from that of wild poliovirus circulation, whereas VDPV2 circulation in the southwestern part of DRC (in Kasai Occidental) occurred within the larger region of wild poliovirus circulation. C1 [Gumede, Nicksy; Lentsoane, Olivia; Puren, Adrian; Schoub, Barry D.; Venter, Marietjie] Natl Inst Communicable Dis, ZA-2131 Johannesburg, South Africa. [Gumede, Nicksy; Schoub, Barry D.] Univ Witwatersrand, Johannesburg, South Africa. [Venter, Marietjie] Univ Pretoria, ZA-0002 Pretoria, South Africa. [Burns, Cara C.; Pallansch, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. [de Gourville, Esther] WHO, CH-1211 Geneva, Switzerland. [Yogolelo, Riziki; Muyembe-Tamfum, Jean Jacques] Natl Inst Biomed Res, Kinshasa, Zaire. RP Gumede, N (reprint author), Natl Inst Communicable Dis, WHO Reg Reference Polio Lab, 1 Modderfontein Rd, ZA-2131 Johannesburg, South Africa. EM nicksyg@nicd.ac.za FU Poliomyelitis Research Fund; WHO FX This work was supported in part by a grant from the Poliomyelitis Research Fund and WHO. NR 39 TC 11 Z9 11 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1583 EP 1589 DI 10.3201/eid1910.130028 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900004 PM 24047933 ER PT J AU Harris, JR Lockhart, SR Sondermeyer, G Vugia, DJ Crist, MB D'Angelo, MT Sellers, B Franco-Paredes, C Makvandi, M Smelser, C Greene, J Stanek, D Signs, K Nett, RJ Chiller, T Park, BJ AF Harris, Julie R. Lockhart, Shawn R. Sondermeyer, Gail Vugia, Duc J. Crist, Matthew B. D'Angelo, Melissa Tobin Sellers, Brenda Franco-Paredes, Carlos Makvandi, Monear Smelser, Chad Greene, John Stanek, Danielle Signs, Kimberly Nett, Randall J. Chiller, Tom Park, Benjamin J. TI Cryptococcus gattii Infections in Multiple States Outside the US Pacific Northwest SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEOFORMANS VAR GATTII; HIV-UNINFECTED PATIENTS; UNITED-STATES; EPIDEMIOLOGIC DIFFERENCES; HIGH PREVALENCE; VARIETY GATTII; MENINGITIS; DISEASE; PATHOGEN; HOST AB Clonal VGII subtypes (outbreak strains) of Cryptococcus gattii have caused an outbreak in the US Pacific North-west since 2004. Outbreak-associated infections occur equally in male and female patients (median age 56 years) and usually cause pulmonary disease in persons with underlying medical conditions. Since 2009, a total of 25 C. gattii infections, 23 (92%) caused by non outbreak strain C. gattii, have been reported from 8 non Pacific Northwest states.-Sixteen (64%) patients were previously healthy, and 21(84%) were male; median age was 43 years (range 15-83 years). Ten patients who provided information reported no past-year travel to areas where C. gattii is known to be endemic. Nineteen (76%) patients had central nervous system infections; 6 (24%) died. C. gattii infection in persons without exposure to known disease-endemic areas suggests possible endemicity in the United States outside the outbreak-affected region; these infections appear to differ in clinical and demographic characteristics from outbreak-associated C. gattii. Clinicians outside the outbreak-affected areas should be aware of locally acquired C. gattii infection and its varied signs and symptoms. C1 [Harris, Julie R.; Lockhart, Shawn R.; Nett, Randall J.; Chiller, Tom; Park, Benjamin J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sondermeyer, Gail; Vugia, Duc J.] Calif Dept Publ Hlth, Richmond, CA USA. [Crist, Matthew B.; D'Angelo, Melissa Tobin] Georgia Dept Publ Hlth, Atlanta, GA USA. [Sellers, Brenda; Franco-Paredes, Carlos] Phoebe Putney Mem Hosp, Albany, GA USA. [Franco-Paredes, Carlos] Hosp Infantil Federico Gomez, Mexico City, DF, Mexico. [Makvandi, Monear; Smelser, Chad] New Mexico Dept Hlth, Santa Fe, NM USA. [Greene, John] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Stanek, Danielle] Florida Dept Hlth, Tallahassee, FL USA. [Signs, Kimberly] Michigan Dept Community Hlth, Lansing, MI USA. [Nett, Randall J.] Montana Dept Publ Hlth & Human Serv, Helena, MT USA. RP Harris, JR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30333 USA. EM ggt5@cdc.gov NR 36 TC 19 Z9 19 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1620 EP 1626 DI 10.3201/eid1910.130441 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900009 PM 24050410 ER PT J AU Mahajan, R Collier, MG Kamili, S Drobeniuc, J Cuevas-Mota, J Garfein, RS Teshale, E AF Mahajan, Reena Collier, Melissa G. Kamili, Saleem Drobeniuc, Jan Cuevas-Mota, Jazmine Garfein, Richard S. Teshale, Eyasu TI Hepatitis E Virus among Persons Who Inject Drugs, San Diego, California, USA, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SHELTERED HOMELESS PERSONS; E ANTIBODIES; PREVALENCE; INFECTION; FRANCE; USERS AB Data about prevalence of hepatitis E virus infection in persons who inject drugs are limited. Among 18-40-year-old persons who inject drugs in California, USA, prevalence of antibodies against hepatitis E virus was 2.7%. This prevalence was associated with age but not with homelessness, incarceration, or high-risk sexual behavior. C1 [Mahajan, Reena] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Mahajan, Reena; Collier, Melissa G.; Kamili, Saleem; Drobeniuc, Jan; Teshale, Eyasu] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cuevas-Mota, Jazmine; Garfein, Richard S.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. RP Mahajan, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G37, Atlanta, GA 30333 USA. EM rmahajan1120@yahoo.com NR 10 TC 3 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1664 EP 1666 DI 10.3201/eid1910.130630 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900020 PM 24047923 ER PT J AU Patrick, ME Gilbert, MJ Blaser, MJ Tauxe, RV Wagenaar, JA Fitzgerald, C AF Patrick, Mary E. Gilbert, Maarten J. Blaser, Martin J. Tauxe, Robert V. Wagenaar, Jaap A. Fitzgerald, Collette TI Human Infections with New Subspecies of Campylobacter fetus SO EMERGING INFECTIOUS DISEASES LA English DT Article ID STRAINS AB Campylobacter fetus subsp. testudinum subsp. nov. is a newly proposed subspecies of C. fetus with markers of reptile origin. We summarize epidemiologic information for 9 humans infected with this bacterium. All cases were in men, most of whom were of Asian origin. Infection might have been related to exposure to Asian foods or reptiles. C1 [Patrick, Mary E.; Tauxe, Robert V.; Fitzgerald, Collette] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Gilbert, Maarten J.; Wagenaar, Jaap A.] Univ Utrecht, Utrecht, Netherlands. [Blaser, Martin J.] NYU, Sch Med, New York, NY USA. [Wagenaar, Jaap A.] Cent Vet Inst, Lelystad, Netherlands. [Gilbert, Maarten J.; Wagenaar, Jaap A.] World Hlth Org Collaborating Ctr Campylobacter, World Org Animal Hlth Reference Lab Campylobacter, Utrecht, Netherlands. RP Patrick, ME (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM mepatrick@cdc.gov NR 14 TC 10 Z9 11 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1678 EP 1680 DI 10.3201/eid1910.130883 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900024 PM 24050521 ER PT J AU Brandt, ME Park, BJ AF Brandt, Mary E. Park, Benjamin J. TI Think Fungus-Prevention and Control of Fungal Infections SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID PUBLIC-HEALTH; COCCIDIOIDOMYCOSIS C1 [Brandt, Mary E.; Park, Benjamin J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Brandt, ME (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G11, Atlanta, GA 30333 USA. EM mbb4@cdc.gov NR 14 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1688 EP 1689 DI 10.3201/eid1910.131092 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900027 PM 24180010 ER PT J AU Wikswo, ME Desai, R Edwards, KM Staat, MA Szilagyi, PG Weinberg, GA Curns, AT Lopman, B Vinje, J Parashar, UD Payne, DC Hall, AJ AF Wikswo, Mary E. Desai, Rishi Edwards, Kathryn M. Staat, Mary Allen Szilagyi, Peter G. Weinberg, Geoffrey A. Curns, Aaron T. Lopman, Benjamin Vinje, Jan Parashar, Umesh D. Payne, Daniel C. Hall, Aron J. TI Clinical Profile of Children with Norovirus Disease in Rotavirus Vaccine Era SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID FINNISH CHILDREN; UNITED-STATES; GASTROENTERITIS C1 [Wikswo, Mary E.; Desai, Rishi; Curns, Aaron T.; Lopman, Benjamin; Vinje, Jan; Parashar, Umesh D.; Payne, Daniel C.; Hall, Aron J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Staat, Mary Allen] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.] Univ Rochester, Sch Med & Dent, New York, NY USA. RP Wikswo, ME (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM ezq1@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 NR 10 TC 10 Z9 10 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1691 EP 1693 DI 10.3201/eid1910.130448 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900029 PM 24047618 ER PT J AU Potter, P AF Potter, Polyxeni TI The Ecology of Wrath SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2013 VL 19 IS 10 BP 1716 EP 1717 DI 10.3201/eid1910.AC1910 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MC UT WOS:000328173900042 ER PT J AU Fraser, AJ Webster, TF Watkins, DJ Strynar, MJ Kato, K Calafat, AM Vieira, VM McClean, MD AF Fraser, Alicia J. Webster, Thomas F. Watkins, Deborah J. Strynar, Mark J. Kato, Kayoko Calafat, Antonia M. Vieira, Veronica M. McClean, Michael D. TI Polyfluorinated compounds in dust from homes, offices, and vehicles as predictors of concentrations in office workers' serum SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Polyfluorinated compounds; PFCs; Dust; Exposure assessment; Offices; Homes ID ATTENTION DEFICIT/HYPERACTIVITY DISORDER; IN-HOUSE DUST; PERFLUOROOCTANE SULFONATE; HUMAN EXPOSURE; INDOOR DUST; PERFLUORINATED CHEMICALS; POLYFLUOROALKYL CHEMICALS; PERFLUOROALKYL COMPOUNDS; NHANES 1999-2000; NATIONAL-HEALTH AB We aimed to characterize levels of polyfluorinated compounds (PFCs) in indoor dust from offices, homes, and vehicles; to investigate factors that may affect PFC levels in dust; and to examine the associations between PFCs in dust and office workers' serum. Dust samples were collected in 2009 from offices, homes, and vehicles of 31 individuals in Boston, MA and analyzed for nineteen PFCs, including perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), fluorotelomer alcohols (FTOHs), and sulfonamidoethanols (FOSEs). Serum was collected from each participant and analyzed for eight PFCs including PFOA and PFOS. Perfluorononanoate, PFOA, perfluoroheptanoate, perfluorohexanoate, PFOS and 8:2 FTOH had detection frequencies >50% in dust from all three microenvironments. The highest geometric mean concentration in office dust was for 8:2 FTOH (309 ng/g), while PFOS was highest in homes (26.9 ng/g) and vehicles (15.8 ng/g). Overall, offices had the highest PFC concentrations, particularly for longer-chain carboxylic acids and FTOHs. Perfluorobutyrate was prevalent in homes and vehicles, but not offices. PFOA serum concentrations were not associated with PFC dust levels after adjusting for PFC concentrations in office air. Dust concentrations of most PFCs are higher in offices than in homes and vehicles. However, indoor dust may not be a significant source of exposure to PFCs for office workers. This finding suggests that our previously published observation of an association between FTOH concentrations in office air and PFOA concentrations in office workers-was not due to confounding by PFCs in dust. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Fraser, Alicia J.; Webster, Thomas F.; Watkins, Deborah J.; Vieira, Veronica M.; McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA. [Watkins, Deborah J.] Brown Univ, Ctr Environm Hlth & Technol, Providence, RI 02912 USA. [Strynar, Mark J.] US EPA, Natl Exposure Res Lab, Human Exposure & Atmospher Sci Div, Res Triangle Pk, NC 27709 USA. [Kato, Kayoko; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Vieira, Veronica M.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Program Publ Hlth, Irvine, CA 92697 USA. RP Fraser, AJ (reprint author), BUSPH Dept Environm Hlth, 715 Albany St,T4W, Boston, MA 02118 USA. EM afraser@bu.edu RI McClean, Michael/J-2934-2015 FU National Institute of Environmental Health Sciences (NIEHS) [R01ES015829, T32ES014562] FX We thank Stephanie Chan, Jessica Nelson, Heather Simpson and Courtney Walker for help with sample collection, and Amal Wanigatunga, Brian Basden, and Tao Jia for technical assistance with analysis of the serum samples. We are grateful to all study participants for enabling this research. This research was supported in part by grants R01ES015829 and T32ES014562 from the National Institute of Environmental Health Sciences (NIEHS). The findings and conclusions, in this report are those of the authors and do not necessarily represent the official position of the CDC, the NIEHS, the U.S. EPA, or the National Institutes of Health. The U.S. EPA, through its Office of Research and Development, collaborated in the research described here; it has been subjected to Agency review and approved for publication. NR 47 TC 20 Z9 24 U1 8 U2 86 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD OCT PY 2013 VL 60 BP 128 EP 136 DI 10.1016/j.envint.2013.08.012 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA 260AH UT WOS:000327566900016 PM 24041736 ER PT J AU Walters, GI Moore, VC McGrath, EE Burge, PS Henneberger, PK AF Walters, G. I. Moore, V. C. McGrath, E. E. Burge, P. S. Henneberger, P. K. TI Agents and trends in health care workers' occupational asthma SO OCCUPATIONAL MEDICINE-OXFORD LA English DT Article DE Cleaning agent; glutaraldehyde; health care; latex; occupational asthma ID PROFESSIONALS; SCHEME AB Background There is a disproportionately high number of cases of work-related asthma occurring in health care occupations due to agents such as glutaraldehyde, latex and cleaning products. Aims To understand the causes and measure trends over time of occupational asthma (OA) in health care workers (HCWs). Methods We reviewed OA notifications from the Midland Thoracic Society's Surveillance Scheme of Occupational Asthma (SHIELD) database in the West Midlands, UK, from 1991 to 2011 and gathered data on occupation, causative agent and annual number of notifications. Results There were 182 cases of OA in HCWs (median annual notifications = 7; interquartile range [IQR] = 5-11), representing 5-19% of annual SHIELD notifications. The modal annual notification was 20 (in 1996); notifications have declined since then, in line with total SHIELD notifications. The majority of cases (136; 75%) occurred in nursing, operating theatre, endoscopy and radiology staff. The most frequently implicated agents were glutaraldehyde (n = 69), latex (n = 47) and cleaning products (n = 27), accounting for 79% of the 182 cases. Cleaning product-related OA was an emerging cause with 22 cases after 2001 and only 5 cases between 1991 and 2000. Conclusions Control measures within the UK National Health Service have seen a decline in OA in HCWs due to latex and glutaraldehyde, though OA remains a problem amongst HCWs exposed to cleaning products. Continuing efforts are required to limit the number of cases in this employment sector. C1 [Walters, G. I.; Moore, V. C.; McGrath, E. E.; Burge, P. S.] Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Birmingham B9 5SS, W Midlands, England. [Henneberger, P. K.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Walters, GI (reprint author), Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Bordesley Green E, Birmingham B9 5SS, W Midlands, England. EM gaxwalters@hotmail.com FU Intramural CDC HHS [CC999999] NR 10 TC 5 Z9 7 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0962-7480 EI 1471-8405 J9 OCCUP MED-OXFORD JI Occup. Med.-Oxf. PD OCT PY 2013 VL 63 IS 7 BP 513 EP 516 DI 10.1093/occmed/kqt093 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 259QZ UT WOS:000327542700013 PM 23933593 ER PT J AU Khetsuriani, N Pallansch, MA Jabirov, S Saparova, N Oberste, MS Wannemuehler, K Ursu, P Wassilak, S Martin, R AF Khetsuriani, Nino Pallansch, Mark A. Jabirov, Shamsiddin Saparova, Nargis Oberste, M. Steven Wannemuehler, Kathleen Ursu, Pavel Wassilak, Steve Martin, Rebecca TI Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010 SO VACCINE LA English DT Article DE Poliomyelitis; Poliomyelitis outbreaks; Polioviruses; Population immunity; Antibodies against polioviruses; Seroprevalence; Tajikistan ID PARALYTIC POLIOMYELITIS; ATTACK RATE AB Background: A serosurvey to evaluate population immunity to polioviruses (PVs) in the context of the importation-related wild PV1 outbreak in Tajikistan in 2010 (461 confirmed cases among children and young adults) was conducted. Methods: Serum specimens from a nationwide sample of 1-24 year-old persons selected through stratified cluster sampling (n=2447) were tested for neutralizing antibodies to all three PV types. Samples with titers <1:8 were considered seronegative. The serosurvey was conducted during the interval after mOPV1 supplementary immunization activities (SIAs) and before tOPV SIAs (targeting ages <= 15 years) implemented to control the outbreak. In the absence of pre-outbreak specimens, results for PV3 were used as a proxy for pre-outbreak PV1 immunity patterns. Results: Overall, PV1 seroprevalence was 98.9%, PV2 seroprevalence was 98.8%, and PV3 seroprevalence was 86.9%. PV1 and PV2 seroprevalence exceeded 95% in all age groups and regions. PV3 seroprevalence was <90% in all age groups and regions, except 15-19 year-olds (91.7%) and Dushanbe (90.0%). PV3 seroprevalence was lowest among 1-4(82.7%) and 5-9 (84.4%) year-olds, particularly among 1-4 year-olds in Kurgan-Tube (76.3%) and RRS (80.0%) regions. Birth cohorts immunized only through routine services (ages, 1-7 years) had lower PV3 seroprevalence than birth cohorts targeted by the SIAs during 1995-2002 (8-19 years): 82.5% versus 89.3%, p<0.001. Conclusions: Suboptimal (<90%) PV3 seroprevalence across wide age range suggests the outbreak resulted from accumulation of susceptibles due to suboptimal coverage over a long time period, particularly in the birth cohorts immunized only through routine services and in areas where the outbreak began (Kurgan-Tube and RRS). High PV1 seroprevalence indicates that mOPV1 SlAs with expanded target age (<= 15 years) succeeded in closing the immunity gap and ongoing WPV1 transmission is unlikely. To accelerate outbreak control in areas which have been polio-free for long time, expanding SIA target age should be considered. (C) 2013 Published by Elsevier Ltd. C1 [Khetsuriani, Nino; Wannemuehler, Kathleen; Wassilak, Steve] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Pallansch, Mark A.; Oberste, M. Steven] CDC, Div Viral Dis, Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jabirov, Shamsiddin] Tajikistan Minist Hlth, Natl Ctr Immunoprophylaxis, Dushanbe, Tajikistan. [Saparova, Nargis; Ursu, Pavel] WHO Tajikistan, Dushanbe, Tajikistan. [Martin, Rebecca] WHO Europe, Copenhagen, Denmark. RP Khetsuriani, N (reprint author), CDC, Dis Eradicat & Eliminat Branch, Global Immunizat Div, Ctr Global Hlth, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA. EM nck7@cdc.gov FU CDC [5 U66 IP000161-03] FX Funding for the serosurvey has been provided by CDC, in part through Cooperative Agreement between CDC and WHO (Cooperative Agreement number: 5 U66 IP000161-03). NR 23 TC 8 Z9 9 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 1 PY 2013 VL 31 IS 42 BP 4911 EP 4916 DI 10.1016/j.vaccine.2013.06.106 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 249IY UT WOS:000326772100036 PM 23891502 ER PT J AU Khetsuriani, N Zakikhany, K Jabirov, S Saparova, N Ursu, P Wannemuehler, K Wassilak, S Efstratiou, A Martin, R AF Khetsuriani, Nino Zakikhany, Katherina Jabirov, Shamsiddin Saparova, Nargis Ursu, Pavel Wannemuehler, Kathleen Wassilak, Steve Efstratiou, Androulla Martin, Rebecca TI Seroepidemiology of diphtheria and tetanus among children and young adults in Tajikistan: Nationwide population-based survey, 2010 SO VACCINE LA English DT Article DE Diphtheria; Tetanus; Population immunity; Susceptibility; Seroprevalence; Tajikistan ID EPIDEMIC DIPHTHERIA; ADVERSE-REACTIONS; IMMUNOGENICITY; IMMUNIZATION; PERTUSSIS; UKRAINE; GEORGIA; TOXOIDS; MEASLES; STATES AB Background: Tajikistan had a major diphtheria outbreak (similar to 10,000 cases) in the 1990s, which was controlled after nationwide immunization campaigns with diphtheria-tetanus toxoid in 1995 and 1996. Since 2000, only 52 diphtheria cases have been reported. However, in coverage surveys conducted in 2000 and 2005, diphtheria-tetanus-pertussis vaccine coverage was lower than administratively reported estimates raising concerns about potential immunity gaps. To further assess population immunity to diphtheria in Tajikistan, diphtheria antibody testing was included in a large-scale nationwide serosurvey for vaccine-preventable diseases conducted in connection with a poliomyelitis outbreak in 2010. In addition, the serosurvey provided an opportunity to assess population immunity to tetanus. Methods: Residents of all regions of Tajikistan aged 1-24 years were included in the serosurvey implemented during September-October 2010. Participants were selected through stratified cluster sampling. Specimens were tested for diphtheria antibodies using a Vero cell neutralization assay and for tetanus antibodies using an anti-tetanus IgG ELISA. Antibody concentrations >= 0.1 IU/mL were considered seropositive. Results: Overall, 51.4% (95% CI, 47.1%-55.6%) of participants were seropositive for diphtheria and 78.9% (95% CI, 74.7%-82.5%) were seropositive for tetanus. The lowest percentages of seropositivity for both diseases were observed among persons aged 10-19 years: diphtheria seropositivity was 37.1% (95% CI, 31.0%-43.7%) among 10-14 year-olds, and 35.3%(95% CI, 29.9%-41.1%) among 15-19 year-olds; tetanus seropositivity in respective age groups was 653% (95% CI, 58.4%-71.6%) and 70.1% (95% CI, 64.5%-75.2%). Conclusions: Population immunity for diphtheria in Tajikistan is low, particularly among 10-19 year-olds. Population immunity to tetanus is generally higher than for diphtheria, but is suboptimal among 10-19 year-olds. These findings highlight the need to improve routine immunization service delivery, and support a one-time supplementary immunization campaign with diphtheria-tetanus toxoid among birth cohorts aged 1-19 years in 2010(3-21 years in 2012) to close immunity gaps and prevent diphtheria outbreaks. Published by Elsevier Ltd. C1 [Khetsuriani, Nino; Wannemuehler, Kathleen; Wassilak, Steve] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. [Zakikhany, Katherina; Efstratiou, Androulla] Hlth Protect Agcy, London, England. [Zakikhany, Katherina] European Ctr Dis Prevent & Control ECDC, European Programme Publ Hlth Microbiol Training E, Stockholm, Sweden. [Jabirov, Shamsiddin] Minist Hlth Tajikistan, Dushanbe, Tajikistan. [Saparova, Nargis; Ursu, Pavel] World Hlth Org WHO Country Off, Dushanbe, Tajikistan. [Martin, Rebecca] WHO Reg Off Europe, Copenhagen, Denmark. RP Khetsuriani, N (reprint author), CDC, Dis Eradicat & Eliminat Branch, Div Immunizat, Ctr Global Hlth, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA. EM nck7@cdc.gov FU CDC [5 U66 IP000161-03] FX Funding for the serosurvey has been provided by CDC, in part through Cooperative Agreement between CDC and WHO (Cooperative Agreement number: 5 U66 IP000161-03). NR 28 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 1 PY 2013 VL 31 IS 42 BP 4917 EP 4922 DI 10.1016/j.vaccine.2013.07.015 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 249IY UT WOS:000326772100037 PM 23859842 ER PT J AU McDonald, R Merrick, MT AF McDonald, Renee Merrick, Melissa T. TI "Above All Things, Be Glad and Young": Advancing Research on Violence in Adolescence INTRODUCTION SO PSYCHOLOGY OF VIOLENCE LA English DT Editorial Material DE youth violence; teen dating violence; bullying; cyber-aggression; sexual violence ID ANOREXIA-NERVOSA; FAMILY-THERAPY; PREVENTION; CHILDHOOD; ABUSE; TERM AB Adolescence is a unique developmental period in which youth are at heightened risk for violence perpetration and victimization, both of which can adversely affect the course of normal psychosocial development and health across the life course. The possible range of violent experiences during adolescence is broad, including physical and relational peer violence, bullying, sexual violence, cyber-aggression, child maltreatment, exposure to parental intimate partner violence, exposure to aggressive media, and more. The 8 articles in this special issue span this wide range of violence experiences. In helping to fill gaps in knowledge about the nature and processes by which violence develops, and how violence experiences affect adolescents, these articles as a group also offer direction for future research. They illustrate the need for research that cuts across the separate bodies of research on violence involving youth, that tackles thorny questions about the conceptualization of violence in its myriad forms, and that considers the ways in which the various forms and dimensions of violence operate together, across levels of the social ecology, to influence outcomes. The findings in this collection of studies also have implications for the development of prevention and intervention programs to address the problem of violence in adolescence. C1 [McDonald, Renee] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA. [Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP McDonald, R (reprint author), So Methodist Univ, Dept Psychol, POB 750442, Dallas, TX 75275 USA. EM rmcdonal@smu.edu NR 30 TC 1 Z9 1 U1 1 U2 24 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD OCT PY 2013 VL 3 IS 4 SI SI BP 289 EP 296 DI 10.1037/a0034275 PG 8 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA 246TV UT WOS:000326562900001 ER PT J AU Knoeller, GE Mazurek, JM Storey, E AF Knoeller, Gretchen E. Mazurek, Jacek M. Storey, Eileen TI Occupation held at the time of asthma symptom development SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE asthma; occupational group; healthy worker effect ID ADULT-ONSET ASTHMA; WORK-RELATED ASTHMA; EXPOSURE; HEALTH; POPULATION; PREVALENCE; RISK AB Background Examining occupations other than those held when asthma symptoms first developed may not correctly identify occupations with higher risk of asthma onset. Methods To determine the occupation held when individuals first developed asthma symptoms, we examined 2010 National Health Interview Survey data for working adults with current asthma. Results Overall 37.1% of working adults with current asthma developed asthma while employed. Of these, the highest proportions of individuals identified office and administrative support (13.3%), sales and related (9.4%), and management (8.5%) as the occupation held when asthma first developed; 37.8% had a different current occupation than at asthma onset, and estimates of a change in occupation were highest for those who developed asthma while working in business and financial operations (49.3%), sales and related (48.6%), and healthcare support (43.8%) occupations. Conclusion Future population-based studies should further examine associations between asthma and occupation held at time of asthma onset. Am. J. Ind. Med. 56:1165-1173, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Knoeller, Gretchen E.; Mazurek, Jacek M.; Storey, Eileen] Ctr Dis Control & Prevent, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA. RP Knoeller, GE (reprint author), 1095 Willowdale Rd,MS H-G 900, Morgantown, WV 26505 USA. EM gknoeller@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH); Centers for Disease Control and Prevention (CDC); National Health Interview Survey Occupational Health Supplement FX Contract grant sponsor: National Institute for Occupational Safety and Health (NIOSH); Contract grant sponsor: Centers for Disease Control and Prevention (CDC); Contract grant sponsor: National Health Interview Survey Occupational Health Supplement. NR 33 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD OCT PY 2013 VL 56 IS 10 BP 1165 EP 1173 DI 10.1002/ajim.22203 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 210JT UT WOS:000323829200005 PM 23794265 ER PT J AU Etienne, CF Tappero, JW Marston, BJ Frieden, TR Kenyon, TA Andrus, JK AF Etienne, Carissa F. Tappero, Jordan W. Marston, Barbara J. Frieden, Thomas R. Kenyon, Thomas A. Andrus, Jon K. TI Cholera Elimination in Hispaniola SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Editorial Material ID EPIDEMIC; HAITI C1 [Andrus, Jon K.] Pan Amer Hlth Org, Washington, DC 20037 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Andrus, JK (reprint author), Pan Amer Hlth Org, 525 23rd St NW, Washington, DC 20037 USA. EM andrusjo@paho.org NR 20 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 615 EP 616 DI 10.4269/ajtmh.13-0510 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100003 PM 24106186 ER PT J AU Fung, ICH Fitter, DL Borse, RH Meltzer, MI Tappero, JW AF Fung, Isaac Chun-Hai Fitter, David L. Borse, Rebekah H. Meltzer, Martin I. Tappero, Jordan W. TI Modeling the Effect of Water, Sanitation, and Hygiene on Oral Cholera Vaccine Implementation in Haiti SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DEVELOPING-COUNTRIES; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; INTERVENTIONS; DIARRHEA; METAANALYSIS; ELIMINATION; COVERAGE; CAMPAIGN; DISEASE AB In 2010, toxigenic Vibrio cholerae was newly introduced to Haiti. Because resources are limited, decision-makers need to understand the effect of different preventive interventions. We built a static model to estimate the potential number of cholera cases averted through improvements in coverage in water, sanitation and hygiene (WASH) (i.e., latrines, point-of-use chlorination, and piped water), oral cholera vaccine (OCV), or a combination of both. We allowed indirect effects and non-linear relationships between effect and population coverage. Because there are limited incidence data for endemic cholera in Haiti, we estimated the incidence of cholera over 20 years in Haiti by using data from Malawi. Over the next two decades, scalable WASH interventions could avert 57,949-78,567 cholera cases, OCV could avert 38,569-77,636 cases, and interventions that combined WASH and OCV could avert 71,586-88,974 cases. Rate of implementation is the most influential variable, and combined approaches maximized the effect. C1 [Fung, Isaac Chun-Hai; Borse, Rebekah H.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Hlth Econ & Modeling Unit, Atlanta, GA 30333 USA. [Fitter, David L.; Tappero, Jordan W.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Tappero, JW (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D69, Atlanta, GA 30333 USA. EM cfung@georgiasouthern.edu; vid3@cdc.gov; rebekahheinzen@gmail.com; qzm4@cdc.gov; jwt0@cdc.gov OI Fung, Isaac Chun-Hai/0000-0001-5496-2529 NR 42 TC 8 Z9 8 U1 4 U2 26 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 633 EP 640 DI 10.4269/ajtmh.13-0201 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100006 PM 24106189 ER PT J AU Steenland, MW Joseph, GA Lucien, MAB Freeman, N Hast, M Nygren, BL Leshem, E Juin, S Parsons, MB Talkington, DF Mintz, ED Vertefeuille, J Balajee, SA Boncy, J Katz, MA AF Steenland, Maria W. Joseph, Gerard A. Lucien, Mentor Ali Ber Freeman, Nicole Hast, Marisa Nygren, Benjamin L. Leshem, Eyal Juin, Stanley Parsons, Michele B. Talkington, Deborah F. Mintz, Eric D. Vertefeuille, John Balajee, S. Arunmozhi Boncy, Jacques Katz, Mark A. TI Laboratory-Confirmed Cholera and Rotavirus among Patients with Acute Diarrhea in Four Hospitals in Haiti, 2012-2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VIBRIO-CHOLERAE; OUTBREAK; SURVEILLANCE; BANGLADESH; EPIDEMIC; STRAINS; UTILITY; O1 AB An outbreak of cholera began in Haiti in October of 2010. To understand the progression of epidemic cholera in Haiti, in April of 2012, we initiated laboratory-enhanced surveillance for diarrheal disease in four Haitian hospitals in three departments. At each site, we sampled up to 10 hospitalized patients each week with acute watery diarrhea. We tested 1,616 specimens collected from April 2, 2012 to March 28, 2013; 1,030 (63.7%) specimens yielded Vibrio cholerae, 13 (0.8%) specimens yielded Shigella, 6 (0.4%) specimens yielded Salmonella, and 63 (3.9%) specimens tested positive for rotavirus. Additionally, 13.5% of children < 5 years old tested positive for rotavirus. Of 1,030 V. cholerae isolates, 1,020 (99.0%) isolates were serotype Ogawa, 9 (0.9%) isolates were serotype Inaba, and 1 isolate was non-toxigenic V. cholerae O139. During 1 year of surveillance, toxigenic cholera continued to be the main cause of acute diarrhea in hospitalized patients, and rotavirus was an important cause of diarrhea-related hospitalizations in children. C1 [Steenland, Maria W.; Nygren, Benjamin L.; Parsons, Michele B.; Talkington, Deborah F.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Joseph, Gerard A.; Lucien, Mentor Ali Ber; Freeman, Nicole; Boncy, Jacques] Natl Publ Hlth Lab, Port Au Prince, Haiti. [Hast, Marisa; Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Hlth Syst Reconstruct Off, Atlanta, GA USA. [Leshem, Eyal] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Juin, Stanley; Vertefeuille, John; Katz, Mark A.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. RP Katz, MA (reprint author), Ctr Dis Control & Prevent, Unit 3400,Box 68, Dpo, AA 34060 USA. EM mws475@mail.harvard.edu; gerardajo944@gmail.com; drmabl@yahoo.com; nicolemfreeman@gmail.com; ium1@cdc.gov; ghz8@cdc.gov; wgp9@cdc.gov; Juins@ht.cdc.gov; zcp9@cdc.gov; dft1@cdc.gov; edm1@cdc.gov; dki4@cdc.gov; fir3@cdc.gov; jacques_boncy@hotmail.com; cfq6@cdc.gov OI Leshem, Eyal/0000-0003-1267-6131 NR 24 TC 10 Z9 10 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 641 EP 646 DI 10.4269/ajtmh.13-0307 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100007 PM 24106190 ER PT J AU Patrick, M Berendes, D Murphy, J Bertrand, F Husain, F Handzel, T AF Patrick, Molly Berendes, David Murphy, Jennifer Bertrand, Fabienne Husain, Farah Handzel, Thomas TI Access to Safe Water in Rural Artibonite, Haiti 16 Months after the Onset of the Cholera Epidemic SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID POINT-OF-USE; DRINKING-WATER; QUALITY; COUNTRIES AB Haiti has the lowest improved water and sanitation coverage in the Western Hemisphere and is suffering from the largest cholera epidemic on record. In May of 2012, an assessment was conducted in rural areas of the Artibonite Department to describe the type and quality of water sources and determine knowledge, access, and use of household water treatment products to inform future programs. It was conducted after emergency response was scaled back but before longer-term water, sanitation, and hygiene activities were initiated. The household survey and source water quality analysis documented low access to safe water, with only 42.3% of households using an improved drinking water source. One-half (50.9%) of the improved water sources tested positive for Escherichia coli. Of households with water to test, 12.7% had positive chlorine residual. The assessment reinforces the identified need for major investments in safe water and sanitation infrastructure and the importance of household water treatment to improve access to safe water in the near term. C1 Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Ctr Global Hlth, Atlanta, GA 30341 USA. [Patrick, Molly; Husain, Farah; Handzel, Thomas] Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, Atlanta, GA 30341 USA. [Berendes, David] Emory Univ, Environm Hlth Sci Program, Rollins Sch Publ Hlth, Laney Grad Sch, Atlanta, GA 30322 USA. [Murphy, Jennifer] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. [Bertrand, Fabienne] Direct Natl Eau Potable & Assainissement, Port Au Prince, Haiti. RP Patrick, M (reprint author), Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, 4770 Buford Highway,MS F57, Atlanta, GA 30341 USA. EM vej7@cdc.gov; dberen2@emory.edu; iod7@cdc.gov; fabienne.bertrand@dinepa.gouv.ht; hgk6@cdc.gov; tnh7@cdc.gov NR 29 TC 12 Z9 12 U1 0 U2 17 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 647 EP 653 DI 10.4269/ajtmh.13-0308 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100008 PM 24106191 ER EF